Immunotherapy

in Translational

Cancer Research





Immunotherapy

in Translational

Cancer Research

EDITED BY

Laurence J. N. Cooper, MD, PhD

Elizabeth A. Mittendorf, MD, PhD

Judy Moyes, MB, BChir, FRCP(C), FRCPCH

Sabitha Prabhakaran, PhD

This edition first published 2018 © 2018 by John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

The right of Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran to be identified as the authors of the editorial in this work has been asserted in accordance with law.

Registered Office(s)

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifical y disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging‐in‐Publication Data

Names: Cooper, Laurence J. N., editor. | Mittendorf, Elizabeth A., editor. | Moyes, Judy, 1953– editor.

| Prabhakaran, Sabitha, editor.

Title: Immunotherapy in translational cancer research / [edited by] Laurence J.N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, Sabitha Prabhakaran.

Description: Hoboken, NJ : Wiley, 2018. | Series: Translational oncology |

Includes bibliographical references and index. |

Identifiers: LCCN 2017056123 (print) | LCCN 2017057426 (ebook) | ISBN 9781118684504 (pdf) |

ISBN 9781118684528 (epub) | ISBN 9781118123225 (hardback)

Subjects: | MESH: Neoplasms–therapy | Translational Medical Research | Immunomodulation |

Clinical Trials as Topic

Classification: LCC RC271.I45 (ebook) | LCC RC271.I45 (print) | NLM QZ 266 |

DDC 616.99/406–dc23

LC record available at https://lccn.loc.gov/2017056123

Cover design: Wiley

Cover images: (Left image) © royaltystockphoto.com/Shutterstock; (Upper right image) © CI Photos/Shutterstock; (Lower right image) © molekuul_be/Shutterstock Set in 9.5/12pt Minion by SPi Global, Pondicherry, India

10 9 8 7 6 5 4 3 2 1





Contents

Editors, vi

11 Repurposing of Drugs for

Contributors, vi

Immunotherapy, 143

Jyothishmathi Swaminathan and Vidya

Introduction, ix

Gopalakrishnan

1 Translation in Immunology: The Role of

12 Immunomodulation with Radiation, 161

Translational Biomarkers to Guide Clinical

Jonathan E. Schoenhals, Taylor R. Cushman,

Use of Immunotherapy for Cancer, 1

Alexandra P. Cadena, Sandra Demaria, and

Saranya Chumsri and Keith L. Knutson

James W. Welsh

2 Monoclonal Antibody Therapy, 12

13 Good Manufacturing Practices Facilities

Elizabeth A. Mittendorf and Sabitha

for Cel ular Therapy, 177

Prabhakaran

Andrew D. Fesnak and Bruce L. Levine

3 Somatic Mutations and Immunotherapy, 24

14 T Cell Receptor Mimic Antibodies, 186

Eric Tran

Gheath Alatrash and Jeffrey J. Mol drem

4 Checkpoint Blockade, 37

15 Stem Cell Transplantation for Treatment

Tracy A. Proverbs‐Singh, Jedd Wolchok, and

of Malignancy, 201

Alexandra Snyder

Lohith S. Bachegowda and

Richard E. Champlin

5 Myeloid Leukemia Vaccines, 54

Paul M. Armistead and Jonathan S. Serody

16 Natural Killer Cell–Based

Immunotherapy, 215

6 Cancer Vaccines for Solid Tumors, 72

Jennifer A. Foltz, Jeffrey S. Mil er, and

Timothy J. Vreeland, Garth S. Herbert, and

Dean A. Lee

George E. Peoples

17 Immunologic Monitoring in Immuno‐

7 Immunotherapy with

Oncology, 228

Non–Genetical y Modified T Cel s, 91

Wil iam R. Gwin and Mary L. Disis

Cassian Yee

18 Cell‐Based Therapies for Canine

8 Immunotherapy with Genetical y Modified

Cancer, 252

T Cel s, 101

Nicola J. Mason and M. Kazim

Liora Schultz and Crystal Mackal

Panjwani

9 Immunomodulation with Adjuvants

19 Interaction between Targeted Therapy

and Cytokines, 115

and Immunotherapy, 268

Dae won Kim and Adi Diab

Peter A. Prieto, Miles C. Andrews,

Alexandria P. Cogdill,

10 Immune Cell Migration in Cancer

and Jennifer A. Wargo

and Immunotherapy, 132

Timothy Murray and Daniel E. Speiser

Index, 286

v





Editors

Laurence J. N. Cooper

Judy Moyes

Department of Pediatrics, University of Texas MD

Pediatrics Research, MD Anderson Cancer Center, Hous-

Anderson Cancer Center, Houston, TX, USA

ton, TX, USA

Elizabeth A. Mittendorf

Sabitha Prabhakaran

Department of Breast Surgical Oncology, The University of

Department of Breast Surgical Oncology, The University of

Texas MD Anderson Cancer Center, Houston, TX, USA

Texas MD Anderson Cancer Center, Houston, TX, USA

vi





Contributors

Gheath Alatrash

Mary L. Disis

Department of Stem Cell Transplantation and Cel ular

Tumor Vaccine Group, Center for Translational Medicine

Therapy, The University of Texas MD Anderson Cancer

in Women’s Health, University of Washington, Seattle, WA,

Center, Houston, TX, USA

USA

Miles C. Andrews

Andrew D. Fesnak

Department of Surgical Oncology, The University of Texas

Department of Pathology and Laboratory Medicine,

MD Anderson Cancer Center, Houston, TX, USA

University of Pennsylvania Perelman School of Medicine,

Philadelphia, PA, USA

Paul M. Armistead

Lineberger Comprehensive Cancer Center, University of

Jennifer A. Foltz

North Carolina, Chapel Hil , NC, USA

Department of Hematology, Oncology, and Bone

Marrow Transplantation, Nationwide Children’s Hospital,

Lohith S. Bachegowda

Columbus, OH, USA

Department of Stem Cell Transplantation and Cel ular

Therapy, The University of Texas, MD Anderson Cancer

Vidya Gopalakrishnan

Center, Houston TX, USA

Departments of Pediatrics and Molecular and Cel ular

Oncology, The University of Texas MD Anderson Cancer

Alexandra P. Cadena

Center, Houston, TX, USA

Department of Radiation Oncology, University of Texas

MD Anderson Cancer Center, Houston, TX, USA

William R. Gwin

Tumor Vaccine Group, Center for Translational Medicine in

Richard E. Champlin

Women’s Health, University of Washington, Seattle, WA, USA

Department of Stem Cell Transplantation and Cel ular

Therapy, The University of Texas, MD Anderson Cancer

Garth S. Herbert

Center, Houston TX, USA

Department of Surgery, San Antonio Military Medical

Center, San Antonio, TX, USA

Alexandria P. Cogdill

Department of Surgical Oncology, The University of Texas

Dae won Kim

MD Anderson Cancer Center, Houston, TX, USA

Department of Gastrointestinal Oncology, Moffitt Cancer

Center, Tampa, FL, USA

Saranya Chumsri

Department of Hematology and Oncology, Mayo Clinic,

Keith L. Knutson

Jacksonville, FL, USA

Department of Immunology, Mayo Clinic, Jacksonville, FL,

USA

Taylor R. Cushman

Department of Radiation Oncology, University of Texas

Dean A. Lee

MD Anderson Cancer Center, Houston, TX, USA

Department of Hematology, Oncology, and Bone Marrow

Transplantation, Nationwide Children’s Hospital, Columbus,

Sandra Demaria

OH, USA

Radiation Oncology and Pathology and Laboratory Medicine,

Weill Cornell Medical College, New York, NY, USA

Bruce L. Levine

Department of Pathology and Laboratory Medicine

Adi Diab

and Center for Cel ular Immunotherapies, University of

Department of Melanoma Medical Oncology, The University Pennsylvania Perelman School of Medicine, Philadelphia, of Texas MD Anderson Cancer Center, Houston, TX, USA

PA, USA

vii

viii Contributors

Crystal Mackall

Liora Schultz

Division of Hematology/Oncology,

Division of Hematology/Oncology, Department of

Department of Pediatrics, Stanford University,

Pediatrics, Stanford University, Stanford, CA, USA

Stanford, CA, USA

Jonathan S. Serody

Nicola J. Mason

Lineberger Comprehensive Cancer Center, University of

School of Veterinary Medicine, University of Pennsylvania,

North Carolina, Chapel Hil , NC, USA

Philadelphia, PA, USA

Alexandra Snyder

Jeffrey S. Miller

Departments of Medicine at Memorial Sloan Kettering

Department of Medicine, University of Minnesota,

Cancer Center and Weill Cornell Medical College, New

Minneapolis, MN, USA

York, NY, USA

Elizabeth A. Mittendorf

Daniel E. Speiser

Department of Breast Surgical Oncology, The University

Ludwig Cancer Research, Department of Oncology,

of Texas MD Anderson Cancer Center, Houston,TX, USA

University of Lausanne, Épalinges, Switzerland

Jeffrey J. Molldrem

Jyothishmathi Swaminathan

Department of Stem Cell Transplantation and Cel ular Ther-

Departments of Pediatrics and Molecular and Cel ular

apy, The University of Texas MD Anderson Cancer Center,

Oncology, The University of Texas MD Anderson Cancer

Houston, TX, USA

Center, Houston, TX, USA

Timothy Murray

Eric Tran

Ludwig Cancer Research, Department of Oncology,

Earle A. Chiles Research Institute, Providence Cancer

University of Lausanne, Épalinges, Switzerland

Center, Portland, OR, USA

M. Kazim Panjwani

Timothy J. Vreeland

School of Veterinary Medicine, University of Pennsylvania,

Department of Surgery, Womack Army Medical Center,

Philadelphia, PA, USA

Fort Bragg, NC, USA

George E. Peoples

Jennifer A. Wargo

Cancer Vaccine Development Program, San Antonio, TX, USA

Departments of Surgical Oncology and Genomic Medicine,

The University of Texas MD Anderson Cancer Center,

Sabitha Prabhakaran

Houston, TX, USA

Department of Breast Surgical Oncology, The Univer-

sity of Texas MD Anderson Cancer Center, Houston, TX, USA

James W. Welsh

Department of Radiation Oncology, University of Texas

Peter A. Prieto

MD Anderson Cancer Center, Houston, TX, USA

Department of Surgery, Oncology, University of Rochester

Medical Center, School of Medicine and Dentistry,

Jedd Wolchok

Rochester, NY, USA

Swim Across America–Ludwig Col aborative Research

Laboratory, Immunology Program, Ludwig Center for

Tracy A. Proverbs‐Singh

Cancer Immunotherapy Department of Medicine at

John Theurer Cancer Center at Hackensack University

Memorial Sloan Kettering Cancer Center and Weill Cornell

Medical Center, Hackensack, NJ, USA

Medical College, New York, NY, USA

Jonathan E. Schoenhals

Cassian Yee

Department of Radiation Oncology, University of

Department of Melanoma Medical Oncology, The

Texas MD Anderson Cancer Center, Houston,

University of Texas MD Anderson Cancer Center,

TX, USA

Houston, TX, USA





Introduction

We live and work in the age of immunotherapy. needed in order to secure long‐term and complete The modality is now firmly affixed to the triad of treatment for the majority of malignancies, espe-chemotherapy, radiation therapy, and surgery. This cial y arising as solid tumors. The coordinated book captures the translation of immunology into response of the endogenous immune system will be therapies. The migration of bench research to mirrored by the corradiated application of immu-bedside experimentation has been largely driven by notherapies. However, that will be the topic of a academia and amplified by industry; however, in future book. What is present and is remarkable, is the current age, there is equipoise between the that monotherapies based on harnessing the not‐for‐profit and for‐profit enterprises regarding immune response have resulted in Lazarus‐type advancements in the human applications of moments, are used to prevent cancer, and have immunotherapies.

provided responses in tumors that were previously

The breadth of treatments reflects the complexity considered untreatable.

of the immune system itself. The coordinated

Immunotherapy as presently wielded is a

response of the multiple components of an endog- relatively blunt tool. Yet the immune system is built enous immune response has generated a portfolio on precision. Academics and industry investigators of immunotherapy options that are reflected in the are only beginning to understand how to sharpen names of the chapters. Not all chapters, though, are the therapeutic edge of an applied immune created equal y. Some immunotherapies are just response. The proving ground is the human experi-beginning their human experimentation and some ence as preclinical models by and large do not yield are seasoned and perhaps even seen as out of vogue. sufficient information regarding efficacy and tox-Nevertheless, as a whole, these components of icity. Thus, immunotherapy practitioners and immune‐based therapies provide patients with patients alike are risk takers. Together, they will therapeutic optimism and some with therapeutic advance the clinical application of the immune impact.

system so that its complexity can be harnessed as

This book is a sum of its chapters and thus an instrument to treat cancer on an individualized individual immunotherapies. What is not yet evi- basis.

dent is how combinations of immune‐based

This is a good time to be studying immunotherapy,

therapies can be harnessed. This is undoubtedly and we hope this book rewards your interest.

ix





CHAPTER 1

1 Translation in Immunology: The

Role of Translational Biomarkers to

Guide Clinical Use of

Immunotherapy for Cancer

Saranya Chumsri1 and Keith L. Knutson2

1 Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA 2 Department of Immunology, Mayo Clinic, Jacksonville, FL, USA Introduction

Despite the long‐standing interest in host

antitumor immunity, it was only recently that

For over a century, the role of the immune system immunotherapy emerged as one of the effective in controlling and eradicating tumors has been a treatment options for cancer. In the past decade, subject of intense debate. Since the 1800s, it has several new immunotherapies, such as immune been recognized that the immune system also checkpoint blockade agents, tumor antigen–

plays an important pathologic protumor role in targeted monoclonal antibodies, and a cell‐based tumor initiation and progression. Virchow com­ dendritic vaccine, were approved by the U.S. Food mented on the interaction between inflammation, and Drug Administration (FDA) for the treatment leukocytes, and cancer in his article from 1863 [1]. of multiple cancer types. In particular, the immune More than a hundred years later, we are still extri­ checkpoint blockade agents, which are treatments cating the complexities of the interaction between that target cytotoxic T‐lymphocyte associated cancers and the host immune system. More protein 4 (CTLA‐4), programmed cell death prorecently, Schreiber, Old, and Smyth described the tein 1 (PD‐1), and programmed cell death ligand process in which cancer and the immune system 1 (PDL‐1), have gained impetus as potent antiinteract with each other, termed “cancer immu­ cancer therapies and have shown promising results noediting” [2]. Cancer immunoediting describes a across several tumor types, leading to a widespread contiguous process that the immune system influ­ revolution in cancer treatments and a massive shift ences and shapes developing tumors. This process in laboratory investigations. Since this form of can result in successful rejection of the tumor or therapy targets the host’s regulatory components of generate a tumor through immunologic evasion, the immune system rather than specific oncogenic the latter of which we now know can occur by mutations or tumor cel s themselves, immune multiple mechanisms and more often than not checkpoint blockade has been shown to be effecthrough any one of a number of immune suppres­ tive across multiple cancer types. Furthermore, sive pathways [3].

given that the immune system has the capacity for

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

1





2 Immunotherapy in Translational Cancer Research long‐term memory, patients who respond to this Biomarkers for anti‐CTLA‐4

form of immunotherapy frequently have durable

responses, which can protect against disease Cytotoxic T‐lymphocyte associated protein 4

progression for months and years [4–6].

(CTLA‐4) is an immune checkpoint that down‐

While the early results of immune checkpoint regulates immune responses. CTLA‐4 functions blockade have been quite promising, only about predominantly early in the cancer‐immunity cycle a third of patients benefit from single agent during T cell activation and enhances the immunotherapy, accounting for both partial and com­ suppressive activity of regulatory T cel s (T cel s) reg

plete responses, defined by the FDA as the [11, 12]. In contrast to PD‐1 or PDL‐1, which is objective response rate (ORR). Not all tumor typical y thought to modulate antigen‐experienced types are equal y responsive to immune check­ effector cel s in inflammatory environments, point blockade, for reasons that as of yet remain CTLA‐4 engages in the priming phase and reguunclear. Emerging studies suggest that combina tion lates the amplitude of early activation of naïve and treatments adding additional immunotherapies or memory T cel s [13]. Ipilimumab was the first other modalities to immune checkpoint blockade immune checkpoint blockade agent approved by results in ORRs that appear to be higher in many FDA, is a humanized monoclonal antibody against cases. However, in most cases the superiority of CTLA‐4, and is indicated for advanced melanoma.

combination therapy over monotherapy is still However, the response rate for single‐agent ipilimnot well proven. Chen and Mellman et al. intro­ umab is merely 10%, and ipilimumab has several duced the concept of the cancer‐immunity cycle, concerning mechanistic‐based toxicities [14].

which describes the intera ctions and processes of Common serious toxicities associated with ipilimhow the immune system recognizes and eradi­ umab are dermatitis, enterocolitis, endocrinopacates cancer cells [7]. To ensure effective thies, liver abnormalities, and uveitis [15].

antitumor activities, a series of stepwise events, Therefore, it is critical to identify biomarkers that including release of cancer cell antigens, antigen can be used to select patients who are more likely to presentation, priming and activation, trafficking benefit from this toxic therapy.

of T cells to tumors, infiltration of T cells into

Several serum biomarkers, such as lactate

tumors, recognition of cancer cells by T cells, dehydrogenase (LDH), C‐reactive protein (CRP), and killing of cancer cells, must be initiated vascular endothelial growth factor (VEGF), and and properly expanded. This cancer‐immunity soluble CD25 (sCD25), have been shown to be cycle hypothesis provides potential opportu­ associated with ipilimumab treatment in patients nities to intervene, and provides rationale for with advanced melanoma [16–19]. Higher baseline combination therapy consisting of multiple levels of LDH and VEGF were associated with immunotherapies to improve clinical responses reduced ipilimumab treatment response in patients

[8]. Additionally, several other combination with metastatic melanoma. However, subsequent approaches, including with chemotherapy, anti­ reductions in LDH, CRP, and T as well as an regs

angiogenic therapy, and hormonal therapy, are increase in absolute lymphocyte count after ipilimbeing considered [5, 9, 10]. In this chapter, umab treatment were significantly associated with potential and established biomarkers that can be improved overall survival (OS) and disease control used as prognostic indicators or as identifiers of rate. sCD25 acts as a decoy receptor for IL‐2. While patients who will benefit more from these recombinant IL‐2 improves efficacy of ipilimumab, immune checkpoint blockade agents are sCD25 inhibits the anticancer effects of ipilimumab, reviewed. Thus, the impressive therapeutic and the high level of baseline sCD25 appears to activity of immune checkpoint blockade, seen in confer resistance to ipilimumab [16]. However, recent years, has solidified the science of transla­ most of these studies were small retrospective datational biomarkers, which enable more rapid, base reviews, and at this time, no confirmatory sensible deployment of novel clinical approaches clinical trials have been done to support the routine for the select groups of patients who are most use of these biomarkers for the selection of patients likely to benefit.

who should receive ipilimumab.





CHAPTER 1 Translation in Immunology 3

Given that ipilimumab exerts its antitumor tumors compared to patients who did not respond.

activity through activation and increasing prolifer­ However, there appeared to be no distinct cutoff ation of T cel s, serial measurements of absolute that can be used to identify patients who would not lymphocyte counts (ALC) in the blood after benefit from ipilimumab therapy [31, 32]. The treatment have also been investigated as a pharma­ inability to establish a cutoff may reflect important codynamic biomarker of ipilimumab [20, 21]. After variations such as HLA allelic variation and immuipilimumab therapy, an ALC ≥ 1000/μL at week nogenicity of the putative neoantigens, both of seven or an increase in ALC from baseline at week which may limit the utility of the mutational load twelve was significantly associated with improved as a response indicator [33].

OS [18, 22, 23]. Besides a simple absolute count of

Despite years of trials and retrospective studies,

lymphocytes, which can be heterogeneous, to date no companion diagnostic test has been CD4+ICOS+ T cel s, an activated T cell subset, have approved by the FDA to identify patients who are been used to track immune response after ipilim­ more likely to benefit from ipilimumab. Thus, umab therapy as a pharmacodynamics marker. additional translational studies of patients under­

Four independent studies demonstrated that going therapy should be designed and implemented patients who had a sustained increase in CD4+ICOS+ to aid in identifying the patients most likely to T cel s over twelve weeks after ipilimumab therapy respond.

had significant improvement in OS [24–28]. This

consistent finding is intriguing because ICOS Biomarkers for anti‐PD‐1/PDL‐1

(inducible T cell costimulatory) costimulation is therapies

associated with Th2 immune responses, suggesting

the possibility that antibodies are involved in the Programmed cell death protein 1 or PD‐1 (also clinical activity of CTLA‐4 blockade [29].

known as PDCD1) and its ligand PD‐1 ligand 1 or

Since T cel s recognize processed peptides PDL‐1 (also known as B7‐H1) are key immune presented by host major histocompatibility com­ checkpoints that down‐regulate antitumor effects of plex molecules, mutations in cancers can produce T cel s in the tumor microenvironment [34, 35].

unique peptides that can be recognized by T cel s, PDL‐1 engages PD‐1 and inhibits proliferation and termed mutated neoantigens [30]. The antigenicity cytokine production of T cel s [36]. Several preclinof these neoantigens may affect the function of the ical studies demonstrated that inhibition of the protein, and a passenger mutation with no PD‐1/PDL‐1 interaction enhances T cell responses functional role may still generate sufficient immune and augments their antitumor activities [34, 37, 38].

responses, although the potential for immune The potential translational biomarkers for anti-escape based on antigen loss is still possible. PD‐1/PDL‐1 can be categorized into either immune-However, a greater mutational load in the tumors related or genomic‐related biomarkers [39].

can potential y produce more neoantigens, which

will result in a larger repertoire of existing tumor‐ Immune‐related biomarkers specific T cel s, and less chances of antigen‐loss PD‐1 and PDL‐1 immune checkpoint blockade variant escape. Given the fact that immune check­ agents are thought to exert their activity mainly by point blockade agents exert their activity by enhancing the antitumor activities of preformed unleashing these preexisting tumor‐specific T cel s, host immune responses [40]. Thus, the amount of it was initial y hypothesized that tumors with preexisting immune infiltrate in the tumor at basehigher mutational loads would respond better to line prior to anti‐PD‐1/PDL‐1 treatment was one this form of therapy [30]. This hypothesis was sub­ of the first translational biomarker candidates to be stantiated based on the early results of studies with explored. In melanoma, higher numbers of preexipilimumab, which has activity in the cancer with isting CD8+ T cel s, particularly at the invasive the highest mutational load, melanoma. In two tumor margin, have been shown to associate with melanoma studies of ipilimumab, patients who tumor regression in patients treated with anti‐PD‐1

responded to ipilimumab had a statistical y therapy (pembrolizumab) [40]. Comparing betsignificant higher median mutation load in their ween responders and nonresponders, responding





4 Immunotherapy in Translational Cancer Research patients had significantly higher numbers of CD8+, respond to anti‐PD‐1 therapy, subsequent studies PD‐1+, and PDL‐1+ cel s at the invasive tumor have shown that objective responses could still be margin and a more clonal T cell antigen receptor observed in some patients with PDL‐1‐negative repertoire. Furthermore, patients who responded tumors [54]. In an analysis of multiple anti‐PD‐1

to therapy had significant increases in CD8+ T cel s trials, the average ORR of anti‐PD‐1 therapy was both inside the tumors and at the invasive margins. approximately 29% across 15 trials in various solid Similar findings, in which an increase in CD8+ malignancies. Among patients with PDL‐1‐positive T cell infiltration after anti‐PD‐1 therapy correlates tumors, the ORR was 48% compared to 15% in with tumor regression, were also observed in PDL‐1‐negative tumors [55]. These findings exemanother study with pembrolizumab in melanoma plified that PDL‐1 negativity cannot be used to and nivolumab in solid tumors in a phase I study exclude patients from anti‐PD‐1 therapies but

[41, 42].

rather to enrich patients who are more likely to

Another immune‐related biomarker that has benefit from this therapy.

received a great deal of attention is tumor cell–

Of note, while PD‐1 is the actual target of anti‐

associated PDL‐1 expression. PDL‐1 is widely PD‐1 therapy, expression of PD‐1 does not appear expressed in the tumor microenvironment not to provide any additional predictive value [50].

only on the tumor cel s but also in subsets of Tumeh et al. demonstrated that more complex immune cel s, particularly macrophages, dendritic parameters, such as close proximity of PD‐1+ cel s cel s, and activated T, B, and NK cel s as well as to PDL‐1+ cel s, proliferation of CD8+ T cel s meaother nonmalignant cel s, including endothelial sured by Ki67 and CD8 costaining, and markers of cel s as part of a physiological process to down‐reg­ IFNγ signaling, provided superior predictive value ulate host immune responses in inflammatory compared to a single marker [40].

microenvironment [43–45]. The distribution of

There are several technical difficulties and limita­

PDL‐1 expression differs among tumor types. In tions of using PDL‐1 expression as a biomarker for certain type of cancers, PDL‐1 is expressed on both anti‐PD‐1/PDL‐1 therapies. First, the expression of tumor cel s and immune infiltrating cel s. These PDL‐1 is variable in multiple tumor biopsies coltypes of cancers include squamous cell carcinoma lected over time and/or from different anatomical of the head and neck (SCCHN), melanoma, breast sites in each individual patient [39]. This variable cancer, and renal cell carcinoma [46–50]. However, expression represents a potential pitfall of develin other forms of cancers such as colorectal (CRC) oping PDL‐1 IHC as an absolute biomarker based and gastric cancer, PDL‐1 is expressed almost on a single biopsied tumor specimen. Moreover, the exclusively on the immune‐infiltrating cel s but tumors used to evaluate PDL‐1 expression were colrarely on the tumor cel s [51, 52].

lected after varied duration of treatment among

In the initial phase I trial of nivolumab, an anti‐ multiple clinical trials. Some of the trials used PD‐1 antibody, in 39 patients with advanced solid tumors collected right before the initiation of malignancies, 9 biopsied samples were available for therapy, and some trials used the tumors from the PDL‐1 assessment by immunohistochemistry. initial diagnosis. The tumors that were collected Among these 9 patients, 3 out of 4 patients with after the initial diagnosis, which could have been membranous expression of PDL‐1 responded to months or years before the initiation of therapy, nivolumab. Objective responses were not observed may not have reflected the PDL‐1 status at the time in the other 5 patients without PDL‐1 expression of therapy. Furthermore, the expression of PDL‐1 is

[42]. Similar findings were subsequently observed not uniform within the tumors. Focal expression of in a larger trial of nivolumab, which demonstrated PDL‐1 could be missed in small core needle biopsy no objective response in patients with PDL‐1‐neg­ specimens, resulting in false negative results [56].

ative tumors. In contrast, patients with PDL‐1

expression of ≥5% of tumor cel s were twice as Genomic‐related biomarkers likely to respond compared to the overall study To date, no specific oncogenic mutations have been population [39, 53]. While PDL‐1 expression can shown to associate with outcome in patients treated be used to identify patients who are more likely to with anti‐PD‐1/PDL‐1 therapy as an independent

CHAPTER 1 Translation in Immunology 5

variable. However, several aberrant oncogenic stem‐cell transplantation and brentuximab vedodrivers and signaling pathways have been shown to tin, showed a remarkable ORR of 87%, including associate with PDL‐1 expression. PTEN mutations 17% with a complete response, 70% partial resulting in constitutive activation of the PI3K‐ response, and 13% with stable disease [63, 64].

AKT pathway have been shown to associate with Similar findings were observed in a subsequent higher PDL‐1 expression in glioma cel s [57]. multi‐center, single arm phase II trial of nivolumab Similar findings were observed with constitutive in 80 patients with classical Hodgkin’s lymphoma ALK signaling activation, which was found to after failure of both autologous stem‐cell transplanassociate with increased PDL‐1 expression via tation and brentuximab vedotin. However, the activation of STAT3 in certain lymphomas and expression of PDL‐1 on Reed‐Sternberg cel s was lung cancers [58]. Additional y, in a subset of lung not required and patients were enrolled regardless adenocarcinomas, KRAS mutations were associ­ of their PDL‐1 expression status. ORR was ated with increased PDL‐1 expression and denser observed in 66.3% of patients, with 9% complete inflammation compared to wild‐type tumors [59]. response, 58% partial response, and 23% stable dis­

Nevertheless, there appeared to be no significant ease [69]. Based on these promising results, the difference in PDL‐1 expression in non‐small‐cell FDA granted the accelerated approval of nivolumab lung cancer (NSCLC) tumors with mutant EGFR for the treatment of patients with Hodgkin’s disease and those with wild‐type EGFR [60]. Furthermore, in this setting.

in melanoma, a previous study also demonstrated

Similar to that reported with ipilimumab, mutano significant difference in PDL‐1 expression bet­ tional burden is another key factor that has been ween BRAF‐V600E mutated vs. wild‐type tumors found to be associated with clinical response to

[61]. Consistent with this finding, the response to anti‐PD‐1/PDL‐1 therapies. Early studies of anti-anti‐PD‐1 therapy appeared to be similar in PD‐1 indicated that these agents appear to have patients with BRAF‐V600E mutation and BRAF activity across all cancers with the highest median wild‐type tumors [6, 62].

mutation loads, namely, melanoma, NSCLC,

Given that genes encoding for both PDL‐1 and SCCHN, bladder cancer, and gastric cancer. The another PD‐1 ligand, PDL‐2, are located on the ORR for anti‐PD‐1 in these cancer types was more 9p24.1 locus, translocations or amplifications of than 15% across the board [53, 70, 71]. In contrast, 9p24.1 locus also have been shown to increase the ORR is relatively low in cancers with low muta­

PDL‐1 and PDL‐2 expression on the surface of tional loads, such as prostate and pancreatic tumors. Amplification of 9p24.1 has been observed cancers. In a small study of patients with lung canin several tumor types, including Hodgkin lym­ cer receiving pembrolizumab, higher mutational phomas [63, 64], mantel cell lymphomas [65], burden was associated with improved response to gastric cancers [66], and breast cancer [67]. Up to this agent [72]. Nevertheless, and much like that 97% of classical Hodgkin’s lymphomas have alter­ observed for ipilimumab, there is no clear cutoff ations of the PDL‐1 and PDL‐2 loci: either for the number of actual mutations that can be polysomy, copy number gain, or amplification used for the purpose of patient selection. Currently, resulting in PDL‐1 overexpression. Furthermore, beyond the number of mutations, there are several consistent with the known capability of virus‐ computational algorithms that can be used to precaused up‐regulation of the PD‐1/PDL‐1 pathway, dict the numbers of potential neoantigens.

Epstein‐Barr virus infection, which is common in However, to date, these algorithms are still highly Hodgkin’s lymphoma, also contributes to overex­ imperfect and at present not suitable for use for pression of PDL‐1. As a result of these two routine clinical management.

mechanisms, a large proportion of classical

Another specific genetic subset that has been

Hodgkin’s lymphoma have increased PDL‐1 shown to associate with higher mutation burden expression [68]. Corresponding to these findings, and better response to anti‐PD‐1/PDL‐1 is tumors the initial phase I study of nivolumab in 23 patients with DNA mismatch repair (MMR) defects. Genes with relapsed or refractory Hodgkin’s lymphoma, in the MMR complex are often found to be mutated, with the majority progressing after autologous deleted, or epigenetical y silenced in several





6 Immunotherapy in Translational Cancer Research cancers, including CRC, gastric, endometrial, effectors [77]. Similar findings were also observed ampul ary, duodenal, and prostate cancers. MMR‐ in hepatocel ular carcinoma, in which the ORR was deficient genotypes account for approximately 4% 36% among hepatitis C infected patients compared of all solid tumors and can be identified by detect­ to 15% in noninfected patients [78].

ing microsatellite instability (MSI) or by

immunohistochemical staining of MMR proteins Approved anti‐PD‐1/PDL‐1 blockade

[39]. These tumors with MMR defect have a 10‐ to agents and biomarkers in clinical use 100‐fold increase in mutational burden compared Since 2014, several agents targeting this particular to MMR‐proficient tumors. Furthermore, colon pathway have been approved or are under cancers with MSI exhibit several other features that consideration by the FDA. Presently, three PD‐1-predict sensitivity to anti‐PD‐1/PDL‐1 therapy. PDL‐1 targeting agents have been approved by the These features include high CD8+ T cell infiltra­ FDA, namely, pembrolizumab, nivolumab, and tion, CD4+ T cel s with the Th1 phenotype, high atezolizumab. Multiple other agents targeting this levels of PD‐1, PDL‐1, CTLA‐4, lymphocyte particular pathway are currently under clinical activation gene (LAG3), and IFNγ‐inducible development. The agents targeting PD‐1 currently immune inhibitory metabolic enzyme (IDO1) [51, in clinical development include pidilizumab, 73]. Despite a general y low rate of response in AMP‐224, and AMP‐514, as well as agents target­

CRC patients, there was a patient with CRC who ing its ligand, PDL‐1, including BMS‐936559, had a durable complete response in the initial phase durvalumab, and avelumab [79].

I trial of nivolumab [42]. Subsequent analysis of

Pembrolizumab, a humanized monoclonal IgG4

this patient’s tumor demonstrated an MSIhi pheno­ antibody against PD‐1, was the first PD‐1/PDL‐1

type [74]. This finding was confirmed in a larger targeting agent approved by the FDA. It was phase II trial of pembrolizumab in patients with approved in September 2014. Pembrolizumab is tumors harboring MMR defects. In this particular currently indicated for the treatment of unresecttrial, patients with MMR‐deficient and ‐proficient able or metastatic melanoma patients, whose CRC were enrolled. The ORR was 40% in MMR‐ tumors express PDL‐1, either as an initial treatment deficient CRC compared to 0% in MMR‐proficient or subsequent treatment after progressing on ipili­

CRC. Similar high response rates were also mumab and/or a BRAF inhibitor, the first or later observed in another cohort of patients with MMR‐ line treatment of patients with metastatic NSCLC, deficient non‐CRC with an ORR of 71% [60].

and the treatment of patients with recurrent or

Besides somatic mutations, integration of onco­ metastatic SCCHN after progressing on platinum-genic viruses in cancer genomes represents another containing chemotherapy [80–83].

form of genetic alterations that can produce neoan­

Similar to pembrolizumab, nivolumab is a

tigens. There are several human cancers that are humanized monoclonal IgG4 antibody against driven by viruses, namely, Epstein‐Barr virus, PD‐1. Currently, nivolumab is indicated as a human papillomavirus, Merkel cell polyomavirus single agent for the first‐line treatment of patients (MCPyV), human T‐lymphotropic virus 1 with BRAFV600 wild‐type unresectable or meta­

(HTLV‐1), Kaposi sarcoma‐associated herpes virus static melanoma, metastatic NSCLC progressing (KSHV), hepatitis B, and hepatitis C viruses. Early after platinum‐based chemotherapy, advanced studies demonstrated that these viral‐associated renal cell carcinoma with prior antiangiogenic cancers might have high response rates to anti‐ therapy [84], relapsed Hodgkin lymphoma after PD‐1/PDL‐1 therapies. Approximately 80% of autologous hematopoietic stem cell transplanta­

Merkel cell carcinomas are associated with MCPyV tion and posttransplantation brentuximab infection, and patients with Merkel cell carcinoma vedotin, and recurrent or metastatic SCCHN prooften produce MCPyV T‐antigen‐specific T cel s gressing after platinum‐based therapy [64, 85–89].

and antibodies [75, 76]. A high ORR of 56% was In addition, nivolumab is also indicated in observed in a phase II trial of pembrolizumab in combination with ipilimumab in unresectable or this group of patients, which might be indicative of metastatic melanoma patients with BRAF wild-activation of latent MCPyV‐specific immune type [90, 91].





CHAPTER 1 Translation in Immunology 7

Table 1.1 Summary of approved biomarkers for anti‐PD‐1/PDL‐1 blockade agents in clinical use.

Assay

Agent

Disease Setting

Cutoff

Reference

PDL‐1 IHC 22C3

PDL‐1 IHC 22C3

1st‐line NCSCLC without EGFR or

TPS ≥ 50%

82

PharmDx assay

PharmDx assay

ALK mutation

For patient selection

≥ 2nd‐line NSCLC

TPS ≥ 1%

60

For patient selection

PDL1 IHC 28‐8

Nivolumab

Nonsquamous NSCLC

TPS ≥ 1%

89

PharmDx assay

For prognostic purpose

Note: TPS = tumor proportion score.

In contrast to pembrolizumab and nivolumab, indication, the cutoff for TPS is lower than the atezolizumab is a humanized monoclonal IgG1 first indication at ≥ 1% rather than ≥ 50%. This antibody against PDL‐1. Atezolizumab is indicated lower cutoff may be due to enhanced sensitivity to for the treatment of patients with local y advanced immune checkpoint blockade agents among or metastatic urothelial carcinoma progressing patients with platinum resistance. In contrast, after platinum‐based chemotherapy [92] and PDL‐1 IHC 28‐8 pharmDx for nivolumab in patients with metastatic NSCLC progressing after NSCLC and melanoma was approved as a compleplatinum‐based chemotherapy [93].

mentary companion diagnostic test rather than a

At present, two established biomarkers are required test for patient selection. In two phase III currently in routine clinical use. They are the trials of nivolumab, NSCLC patients whose PDL‐1 IHC 22C3 pharmDx assay for pembroli­ tumors expressed PDL‐1 ≥ 1% using PDL‐1 IHC

zumab in NSCLC and the PDL‐1 IHC 28‐8 28‐8 pharmDx assay had improved OS, but only in pharmDx assay for nivolumab in nonsquamous the nonsquamous NSCLC group [88, 89]. These NSCLC and melanoma. Upon the approval of assays in current clinical use are summarized in pembrolizumab in NSCLC, the FDA also simulta­ Table 1.1.

neously approved the companion diagnostic test,

PDL‐1 IHC 22C3 pharmDx assay, to guide patient Conclusion

selection. PDL‐1 IHC 22C3 pharmDx is a

qualitative immunohistochemical assay using Immunotherapy, particularly with immune checkmouse monoclonal anti‐PDL‐1 clone 22C3 in for­ point blockade, represents a revolutionary paramalin‐fixed, paraffin‐embedded samples. Tumor digm shift in cancer treatment. By enhancing proportion score (TPS) is used to determine the endogenous host immune responses, rather than expression level of PDL‐1. PDL‐1 is considered specifical y targeting particular aberrant signaling positive if TPS ≥ 1% and high PDL‐1 expression is pathways intrinsic to the tumor cel , this form of defined as TPS ≥ 50%. Currently, pembrolizumab treatment has proven to be effective across multiple has two indications in metastatic NSCLC, tumor types. Nonetheless, the response to immuincluding the first‐line therapy for NSCLC patients notherapy is not universal and specific translawhose tumors have high PDL‐1 expression (TPS ≥ tional biomarkers are needed to identify patients 50%) and no EGFR or ALK genomic aberrations who are more likely to benefit from this therapy.

[82]. This approval was based on a large phase II To date, there are only two PDL‐1 immunohistotrial of pembrolizumab in patients with squamous chemistry assays that are approved by the FDA and and nonsquamous NSCLC, which demonstrated are currently in clinical use. However, as our undersignificantly higher ORR, improved PFS, and OS standing of the interplay between immune system in patients with tumors expressed PDL‐1 ≥ 50% and tumor microenvironment grows, novel mech[60]. The second indication includes the second or anistic‐based biomarkers and combination therapy later line of therapy in NSCLC patients progress­ will emerge to improve patient selection for this ing on platinum‐based chemotherapy. In this form of therapy.





8 Immunotherapy in Translational Cancer Research References

CTLA‐4 blockade: obligatory contribution of IL‐2

receptors and negative prognostic impact of soluble

1. Virchov R. Cel ular pathology as based upon

CD25. Cell Res. 2015;25(2):208–24.

physiological and pathological histology. Philadelphia: J. 17. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, B. Lippincott; 1863.

et al. Pretreatment serum VEGF is associated with

2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoeditclinical response and overall survival in advanced melaing: integrating immunity’s roles in cancer suppression noma patients treated with ipilimumab. Cancer

and promotion. Science. 2011;331(6024):1565–70.

Immunol Res. 2014;2(2):127–32.

3. Motz GT, Coukos G. Deciphering and reversing tumor 18. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, immune suppression. Immunity. 2013;39(1):61–73.

Caraco C, Curvietto M, et al. Immunological and

4. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ,

biological changes during ipilimumab treatment and

Rizvi NA, et al. Overall survival and long‐term safety of

their potential correlation with clinical response and

nivolumab (anti‐programmed death 1 antibody,

survival in patients with advanced melanoma. Cancer

BMS‐936558, ONO‐4538) in patients with previously

Immunol Immunother. 2014;63(7):675–83.

treated advanced non‐small‐cell lung cancer. J Clin 19. Kelderman S, Heemskerk B, van Tinteren H, van den Oncol. 2015;33(18):2004–12.

Brom RR, Hospers GA, van den Eertwegh AJ, et al.

5. Sharma P, Allison JP. The future of immune checkpoint

Lactate dehydrogenase as a selection criterion for ipilimtherapy. Science. 2015;348(6230):56–61.

umab treatment in metastatic melanoma. Cancer

6. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R,

Immunol Immunother. 2014;63(5):449–58.

Neyns B, et al. Nivolumab versus chemotherapy in 20. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, patients with advanced melanoma who progressed after

Thomas L, et al. Ipilimumab monotherapy in patients

anti‐CTLA‐4 treatment (CheckMate 037): a randomised,

with pretreated advanced melanoma: a randomised,

controlled, open‐label, phase 3 trial. Lancet Oncol.

double‐blind, multicentre, phase 2, dose‐ranging study.

2015;16(4):375–84.

Lancet Oncol. 2010;11(2):155–64.

7. Chen DS, Mellman I. Oncology meets immunology: the 21. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten cancer‐immunity cycle. Immunity. 2013;39(1):1–10.

PE, Reijm M, et al. T cell profiling reveals high

8. Mahoney KM, Rennert PD, Freeman GJ. Combination

CD4 + CTLA‐4 + T cell frequency as dominant predictor

cancer immunotherapy and new immunomodulatory

for survival after prostate GVAX/ipilimumab treatment.

targets. Nat Rev Drug Discov. 2015;14(8):561–84.

Cancer Immunol Immunother. 2013;62(2):245–56.

9. Sharma P, Allison JP. Immune checkpoint targeting in 22. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, cancer therapy: toward combination strategies with

Carvajal RD, et al. Single‐institution experience with ipicurative potential. Cel . 2015;161(2):205–14.

limumab in advanced melanoma patients in the com10. Minn AJ, Wherry EJ. Combination Cancer therapies passionate use setting: lymphocyte count after 2 doses

with immune checkpoint blockade: convergence on

correlates with survival. Cancer. 2010;116(7):1767–75.

interferon signaling. Cel . 2016;165(2):272–5.

23. Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H,

11. Chen L, Flies DB. Molecular mechanisms of T cell co‐

Salmon I, Lienard D, et al. Single‐center experience with

stimulation and co‐inhibition. Nat Rev Immunol.

ipilimumab in an expanded access program for patients

2013;13(4):227–42.

with pretreated advanced melanoma. J Immunother.

12. Walker LS. Treg and CTLA‐4: two intertwining path2013;36(3):215–22.

ways to immune tolerance. J Autoimmun. 2013; 24. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso 45:49–57.

P, et al. CTLA‐4 blockade increases IFNgamma‐

13. Topalian SL, Drake CG, Pardoll DM. Targeting the

producing CD4 + ICOShi cel s to shift the ratio of

PD‐1/B7‐H1(PD‐L1) pathway to activate anti‐tumor

effector to regulatory T cel s in cancer patients. Proc Natl

immunity. Curr Opin Immunol. 2012;24(2):207–12.

Acad Sci U S A. 2008;105(39):14987–92.

14. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman 25. Calabro L, Maio M. Immune checkpoint blockade in JA, Haanen JB, et al. Improved survival with ipilimumab

malignant mesothelioma: a novel therapeutic

in patients with metastatic melanoma. N Engl J Med.

strategy against a deadly disease? Oncoimmunology.

2010;363(8):711–23.

2014;3(1):e27482.

15. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab 26. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, and its toxicities: a multidisciplinary approach.

Tarhini AA, et al. Ipilimumab plus sargramostim vs

Oncologist. 2013;18(6):733–43.

ipilimumab alone for treatment of metastatic melanoma:

16. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput

a randomized clinical trial. JAMA. 2014;312(17):

N, Klatzmann D, et al. Anticancer immunotherapy by

1744–53.

CHAPTER 1 Translation in Immunology 9

27. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, 41. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford Sun J, et al. Preoperative CTLA‐4 blockade: tolerability

R, et al. Safety and tumor responses with lambrolizumab

and immune monitoring in the setting of a presurgical

(anti‐PD‐1) in melanoma. N Engl J Med. 2013;369(2):

clinical trial. Clin Cancer Res. 2010;16(10):2861–71.

134–44.

28. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang 42. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, DN, et al. Anti‐CTLA‐4 therapy results in higher

Sharfman WH, et al. Phase I study of single‐agent anti‐

CD4 + ICOShi T cell frequency and IFN‐gamma levels

programmed death‐1 (MDX‐1106) in refractory solid

in both nonmalignant and malignant prostate tissues.

tumors: safety, clinical activity, pharmacodynamics,

Proc Natl Acad Sci U S A. 2009;106(8):2729–34.

and immunologic correlates. J Clin Oncol.

29. Riley JL, June CH. The CD28 family: a T‐cell rheostat for 2010;28(19):3167–75.

therapeutic control of T‐cell activation. Blood. 43. Dong H, Zhu G, Tamada K, Chen L. B7‐H1, a third 2005;105(1):13–21.

member of the B7 family, co‐stimulates T‐cell prolifera30. Schumacher TN, Schreiber RD. Neoantigens in cancer tion and interleukin‐10 secretion. Nat Med.

immunotherapy. Science. 2015;348(6230):69–74.

1999;5(12):1365–9.

31. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, 44. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Desrichard A, et al. Genetic basis for clinical response to

Flies DB, et al. Tumor‐associated B7‐H1 promotes T‐cell

CTLA‐4 blockade in melanoma. N Engl J Med.

apoptosis: a potential mechanism of immune evasion.

2014;371(23):2189–99.

Nat Med. 2002;8(8):793–800.

32. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, 45. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram Zimmer L, et al. Genomic correlates of response to

P, et al. Blockade of B7‐H1 improves myeloid dendritic

CTLA‐4 blockade in metastatic melanoma. Science.

cell‐mediated antitumor immunity. Nat Med.

2015;350(6257):207–11.

2003;9(5):562–7.

33. Schumacher TN, Hacohen N. Neoantigens encoded in the 46. Taube JM, Anders RA, Young GD, Xu H, Sharma R, cancer genome. Curr Opin Immunol. 2016;41:98–103.

McMiller TL, et al. Colocalization of inflammatory

34. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo

response with B7‐H1 expression in human melanocytic

T, et al. PD‐L1/B7H‐1 inhibits the effector phase of

lesions supports an adaptive resistance mechanism of

tumor rejection by T cell receptor (TCR) transgenic

immune escape. Sci Transl Med. 2012;4(127):127ra37.

CD8+ T cel s. Cancer Res. 2004;64(3):1140–5.

47. Cimino‐Mathews A, Thompson E, Taube JM, Ye X, Lu Y,

35. Okazaki T, Honjo T. The PD‐1‐PD‐L pathway in immu­

Meeker A, et al. PD‐L1 (B7‐H1) expression and the

nological tolerance. Trends Immunol. immune tumor microenvironment in primary and 2006;27(4):195–201.

metastatic breast carcinomas. Hum Pathol. 2016;47(1):

36. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T,

52–63.

Nishimura H, et al. Engagement of the PD‐1 immunoin48. Lyford‐Pike S, Peng S, Young GD, Taube JM, Westra hibitory receptor by a novel B7 family member leads to

WH, Akpeng B, et al. Evidence for a role of the PD‐1:PD‐

negative regulation of lymphocyte activation. J Exp Med.

L1 pathway in immune resistance of HPV‐associated

2000;192(7):1027–34.

head and neck squamous cell carcinoma. Cancer Res.

37. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato

2013;73(6):1733–41.

N. Involvement of PD‐L1 on tumor cel s in the escape 49. Thompson RH, Kuntz SM, Leibovich BC, Dong H, from host immune system and tumor immunotherapy

Lohse CM, Webster WS, et al. Tumor B7‐H1 is associated

by PD‐L1 blockade. Proc Natl Acad Sci U S A.

with poor prognosis in renal cell carcinoma patients with

2002;99(19):12293–7.

long‐term follow‐up. Cancer Res. 2006;66(7):3381–5.

38. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, 50. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Ichikawa M, et al. Blockade of B7‐H1 and PD‐1 by

et al. Association of PD‐1, PD‐1 ligands, and other

monoclonal antibodies potentiates cancer therapeutic

features of the tumor immune microenvironment with

immunity. Cancer Res. 2005;65(3):1089–96.

response to anti‐PD‐1 therapy. Clin Cancer Res.

39. Topalian SL, Taube JM, Anders RA, Pardoll DM.

2014;20(19):5064–74.

Mechanism‐driven biomarkers to guide immune check51. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner point blockade in cancer therapy. Nat Rev Cancer.

EM, Taube JM, et al. The vigorous immune microenvi2016;16(5):275–87.

ronment of microsatellite instable colon cancer is

40. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor

balanced by multiple counter‐inhibitory checkpoints.

EJ, Robert L, et al. PD‐1 blockade induces responses

Cancer Discov. 2015;5(1):43–51.

by inhibiting adaptive immune resistance. Nature. 52. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka 2014;515(7528):568–71.

N, Abdelfatah E, et al. Patterns of PD‐L1 expression and

10 Immunotherapy in Translational Cancer Research CD8 T cell infiltration in gastric adenocarcinomas and

relapsed or refractory Hodgkin’s lymphoma. N Engl J

associated immune stroma. Gut. 2017;66(5):794–801.

Med. 2015;372(4):311–9.

53. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith 65. Rubio‐Moscardo F, Climent J, Siebert R, Piris MA, DC, McDermott DF, et al. Safety, activity, and immune

Martin‐Subero JI, Nielander I, et al. Mantle‐cell lymcorrelates of anti‐PD‐1 antibody in cancer. N Engl J

phoma genotypes identified with CGH to BAC microar­

Med. 2012;366(26):2443–54.

rays define a leukemic subgroup of disease and predict

54. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube

patient outcome. Blood. 2005;105(11):4445–54.

JM, Topalian SL. Antagonists of PD‐1 and PD‐L1 in 66. Cancer Genome Atlas Research N. Comprehensive cancer treatment. Semin Oncol. 2015;42(4):587–600.

molecular characterization of gastric adenocarcinoma.

55. Sunshine J, Taube JM. PD‐1/PD‐L1 inhibitors. Curr

Nature. 2014;513(7517):202–9.

Opin Pharmacol. 2015;23:32–8.

67. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M,

56. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S,

Cunliffe HE, Klassen CL, et al. Genomic amplification of

Horinouchi H, et al. Reliability of small biopsy samples

9p24.1 targeting JAK2, PD‐L1, and PD‐L2 is enriched in

compared with resected specimens for the determinahigh‐risk triple negative breast cancer. Oncotarget.

tion of programmed death‐ligand 1 expression in non‐

2015;6(28):26483–93.

small‐cell lung cancer. Clin Lung Cancer. 68. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu 2015;16(5):385–90.

ML, et al. PD‐L1 expression is characteristic of a subset

57. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF,

of aggressive B‐cell lymphomas and virus‐associated

Barry JJ, et al. Loss of tumor suppressor PTEN function

malignancies. Clin Cancer Res. 2013;19(13):3462–73.

increases B7‐H1 expression and immunoresistance in 69. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman glioma. Nat Med. 2007;13(1):84–8.

JM, Ansell S, et al. Nivolumab for classical Hodgkin’s

58. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X,

lymphoma after failure of both autologous stem‐cell

Paessler M, et al. Oncogenic kinase NPM/ALK induces

transplantation and brentuximab vedotin: a multicentre,

through STAT3 expression of immunosuppressive promulticohort, single‐arm phase 2 trial. Lancet Oncol.

tein CD274 (PD‐L1, B7‐H1). Proc Natl Acad Sci U S A.

2016;17(9):1283–94.

2008;105(52):20852–7.

70. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O,

59. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA,

Gordon MS, et al. Predictive correlates of response to the

Tong P, Izzo J, et al. Co‐occurring genomic alterations

anti‐PD‐L1 antibody MPDL3280A in cancer patients.

define major subsets of KRAS‐mutant lung adenocarci­

Nature. 2014;515(7528):563–7.

noma with distinct biology, immune profiles, and 71. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian therapeutic vulnerabilities. Cancer Discov. SL, Hwu P, et al. Safety and activity of anti‐PD‐L1 anti2015;5(8):860–77.

body in patients with advanced cancer. N Engl J Med.

60. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian

2012;366(26):2455–65.

AS, Eder JP, et al. Pembrolizumab for the treatment of 72. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, non‐small‐cell lung cancer. N Engl J Med.

Makarov V, Havel JJ, et al. Cancer immunology: muta2015;372(21):2018–28.

tional landscape determines sensitivity to PD‐1 blockade

61. Rodic N, Anders RA, Eshleman JR, Lin MT, Xu H, Kim

in non‐small cell lung cancer. Science. 2015;348(6230):

JH, et al. PD‐L1 expression in melanocytic lesions does

124–8.

not correlate with the BRAF V600E mutation. Cancer 73. Drescher KM, Sharma P, Watson P, Gatalica Z, Immunol Res. 2015;3(2):110–5.

Thibodeau SN, Lynch HT. Lymphocyte recruitment into

62. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C,

the tumor site is altered in patients with MSI‐H colon

Jiang J, et al. Efficacy and safety of nivolumab in patients

cancer. Fam Cancer. 2009;8(3):231–9.

with BRAF V600 mutant and BRAF wild‐type advanced 74. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube melanoma: a pooled analysis of 4 clinical trials. JAMA

JM, Anders RA, et al. Durable cancer regression off‐

Oncol. 2015;1(4):433–40.

treatment and effective reinduction therapy with an

63. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T,

anti‐PD‐1 antibody. Clin Cancer Res. 2013;19(2):462–8.

O’Donnell E, et al. Integrative analysis reveals selective 75. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase 9p24.1 amplification, increased PD‐1 ligand expression,

K, Jing L, et al. Merkel cell polyomavirus‐specific

and further induction via JAK2 in nodular sclerosing

CD8(+) and CD4(+) T‐cell responses identified in

Hodgkin lymphoma and primary mediastinal large B‐

Merkel cell carcinomas and blood. Clin Cancer Res.

cell lymphoma. Blood. 2010;116(17):3268–77.

2011;17(21):6671–80.

64. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott 76. Afanasiev OK, Yelistratova L, Miller N, Nagase K, EC, Gutierrez M, et al. PD‐1 blockade with nivolumab in

Paulson K, Iyer JG, et al. Merkel polyomavirus‐specific T

CHAPTER 1 Translation in Immunology 11

cel s fluctuate with merkel cell carcinoma burden and

squamous‐cell carcinoma of the head and neck. N Engl

express therapeutical y targetable PD‐1 and Tim‐3

J Med. 2016;375(19):1856–67.

exhaustion markers. Clin Cancer Res. 2013;19(19): 86. Beaver JA, Theoret MR, Mushti S, He K, Libeg M, 5351–60.

Goldberg K, et al. FDA Approval of nivolumab for the

77. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller

first‐line treatment of patients with BRAFV600 wild‐

NJ, Annamalai L, et al. PD‐1 Blockade with pembrolitype unresectable or metastatic melanoma. Clin Cancer zumab in advanced Merkel‐cell carcinoma. N Engl J

Res. 2017.

Med. 2016;374(26):2542–52.

87. Robert C, Long GV, Brady B, Dutriaux C, Maio M,

78. Kudo M. Immune checkpoint blockade in hepatocel ular

Mortier L, et al. Nivolumab in previously untreated melcarcinoma. Liver Cancer. 2015;4(4):201–7.

anoma without BRAF mutation. N Engl J Med.

79. Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba

2015;372(4):320–30.

T, Konishi I. PD‐1/PD‐L1 blockade in cancer treatment: 88. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, perspectives and issues. Int J Clin Oncol. 2016;21(3):

Poddubskaya E, et al. Nivolumab versus docetaxel in

462–73.

advanced squamous‐cell non‐small‐cell lung cancer. N

80. Robert C, Schachter J, Long GV, Arance A, Grob JJ,

Engl J Med. 2015;373(2):123–35.

Mortier L, et al. Pembrolizumab versus ipilimumab in 89. Borghaei H, Paz‐Ares L, Horn L, Spigel DR, Steins M, advanced melanoma. N Engl J Med. 2015;372(26):

Ready NE, et al. Nivolumab versus docetaxel in advanced

2521–32.

nonsquamous non‐small‐cell lung cancer. N Engl J Med.

81. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian

2015;373(17):1627–39.

AS, Eder JP, et al. Pembrolizumab for the treatment of 90. Wolchok JD, Kluger H, Cal ahan MK, Postow MA, Rizvi non‐small‐cell lung cancer. N Engl J Med. 2015;372(21):

NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in

2018–28.

advanced melanoma. N Engl J Med. 2013;369(2):

82. Reck M, Rodriguez‐Abreu D, Robinson AG, Hui R,

122–33.

Csoszi T, Fulop A, et al. Pembrolizumab versus chemo91. Postow MA, Chesney J, Pavlick AC, Robert C, therapy for PD‐L1‐positive non‐small‐cell lung cancer.

Grossmann K, McDermott D, et al. Nivolumab and ipili­

N Engl J Med. 2016;375(19):1823–33.

mumab versus ipilimumab in untreated melanoma. N

83. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder Engl J Med. 2015;372(21):2006–17.

JP, et al. Safety and clinical activity of pembrolizumab for 92. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak treatment of recurrent or metastatic squamous cell car­

DP, Bellmunt J, et al. Atezolizumab as first‐line treatment

cinoma of the head and neck (KEYNOTE‐012): an

in cisplatin‐ineligible patients with local y advanced and

open‐label, multicentre, phase 1b trial. Lancet Oncol.

metastatic urothelial carcinoma: a single‐arm, multicen2016;17(7):956–65.

tre, phase 2 trial. Lancet. 2017;389(10064):67–76.

84. Motzer RJ, Escudier B, McDermott DF, George S, 93. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello Hammers HJ, Srinivas S, et al. Nivolumab versus evero­

F, von Pawel J, et al. Atezolizumab versus docetaxel in

limus in advanced renal‐cell carcinoma. N Engl J Med.

patients with previously treated non‐small‐cell lung

2015;373(19):1803–13.



cancer (OAK): a phase 3, open‐label, multicentre

85. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J,

randomised controlled trial. Lancet. 2017;389(10066):

Colevas AD, Licitra L, et al. Nivolumab for recurrent

255–65.





CHAPTER 2

2 Monoclonal Antibody Therapy

Elizabeth A. Mittendorf and Sabitha Prabhakaran

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Introduction

techniques, and innovative antibody engineering

approaches, as well as the development of large‐

Monoclonal antibody (mAb)–based therapy is one scale production techniques, allowed for the of the most important and successful therapeutic transition of mAb therapy from the laboratory to strategies used for treating patients with solid widespread clinical use [5–8].

tumors and hematologic malignancies. The origins

This chapter summarizes the mechanisms of

of this treatment modality began with the observa­ action of mAbs, characteristics of ideal tumor tion of antigen expression by tumor cel s made antigens to serve as antibody targets, clinical using serological techniques in the 1960s [1]. These development of mAb therapy, and mechanisms of antigens were thought to be “targets” that could be resistance. We focus on mAbs targeting antigens addressed therapeutical y. The development of involved in cancer cell proliferation and survival.

hybridoma technology in 1975, whereby mice were Monoclonal antibodies that have been developed immunized against a specific epitope on an antigen, to either activate or antagonize immunologic pathled to the first generation of murine antibodies tar­ ways are discussed in a subsequent chapter of this geting surface antigens [2]. Subsequently, book. Similarly, mAbs that have been used in the approaches were developed to humanize anti­ construction of chimeric antigen receptor T cel s bodies, which allowed for the creation of mAbs not are the focus of another chapter. Final y, mAbs recognized as foreign by the human immune that target peptide–major histocompatibility system [3, 4]. This represented a critical step in complexes, referred to as TCR mimics, have also advancing mAbs in the clinic. In the following been developed and are the subject of another decades, serologic, genomic, proteomic, and bioin­ chapter.

formatics techniques were used to identify

numerous cell surface antigens that are mutated, Mechanisms of action overexpressed, or selectively expressed in tumor

tissues versus normal tissues. Concomitantly, addi­ Antibodies, which are secreted by B cel s, are key tional technologies to generate human antibodies, components of the adaptive immune system capable including use of transgenic mice, phage display of recognizing antigens with high specificity. They Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

12





CHAPTER 2 Monoclonal Antibody Therapy 13

share similar basic structural units that include two tumors, the addition of cetuximab to chemolarge heavy chains and two small light chains. These therapy or best supportive care resulted in structural units are organized into two distinct improvements in overall survival, progression‐free regions, the Fab variable region, which recognizes survival, and overall response rate. There was no and binds specific antigens, and the Fc region, benefit in patients with KRAS mutant tumors. The which is capable of interacting with specific Fc initial approval in head and neck cancer was for use receptors (Figure 2.1).

in combination with radiation in patients with

The mechanisms by which antibodies can kill local y or regional y advanced squamous cell carcitumor cel s can be categorized broadly as direct noma or as a single agent for patients with recurrent tumor cell killing and immune‐mediated tumor or metastatic disease, for whom prior platinum-cell killing. Direct tumor cell killing can be accom­ based therapy had failed. This approval was based plished by an agonistic mAb binding to a cell on a significant improvement in overall survival surface receptor and inducing apoptosis. In and duration of locoregional disease control when addition, antagonistic mAbs can bind to a cell sur­ cetuximab was added versus radiation therapy face receptor blocking dimerization, kinase alone [14]. It was subsequently approved for use in activation, and downstream signaling. This in turn combination with platinum‐based therapy plus 5-leads to inhibition of cell growth and induction of florouracil for first‐line treatment of patients with apoptosis. Inhibition of cell signaling is one mech­ recurrent locoregional and/or metastatic disease.

anism by which the mAbs cetuximab and This approval was based on the results of a multitrastuzumab work [9, 10]. Cetuximab is a mAb that center study that enrolled patients with metastatic targets the extracel ular domain of the epidermal or local y recurrent head and neck cancer not suitgrowth factor receptor (EGFR). It is approved by able for potential y curative treatment with surgery the U.S. Food and Drug Administration (FDA) for or radiation [15]. The addition of cetuximab to the treatment of KRAS wild‐type, EGFR‐express­ platinum‐based therapy plus 5‐fluorouracil ing metastatic colorectal cancer and recurrent or resulted in significantly improved progression‐free metastatic head and neck cancer. The approval in and overall survival [16].

metastatic colorectal cancer was based on tumor

Trastuzumab is a mAb that targets the extracelsamples from patients enrolled in the CRYSTAL lular portion of HER2. It received initial FDA trial and two supporting studies analyzed retro­ approval in 1998 for the treatment of metastatic spectively [11–13]. In patients with KRAS wild‐type breast cancer that overexpresses the HER2 protein.

Heavy Chain

Light Chain

Disulfide Bond

Fab or Variable Region

Fc or Constant Region

Figure 2.1 General antibody structure. The basic structural chains linked by disulfide bonds. The Fab variable region

units of an antibody are organized into two distinct regions, (green) recognizes and binds specific antigens and the Fc

which include two large heavy chains and two small light

region (orange) interacts with specific Fc receptors.

14 Immunotherapy in Translational Cancer Research Approval was based on data from a phase III trial systemic anaplastic large‐cell lymphoma was based that showed that the addition of trastuzumab to on a single‐arm, phase II, multicenter study that chemotherapy in heavily pretreated patients demonstrated an 86% objective response rate in improved response rates and extended time to patients with CD30‐positive systemic anaplastic disease progression [17]. Trastuzumab is now rou­ large cell lymphoma who had previously received tinely used in the treatment of HER2‐positive multiagent chemotherapy [25].

breast cancer in the metastatic, adjuvant, and neo­

One early ADC used routinely in the clinic is

adjuvant settings.

trastuzumab emtansine (T‐DM1), which includes

In addition to these direct tumor cell killing the mAb trastuzumab linked to emtansine (DM1), mechanisms of action of “naked” mAbs, antibodies a highly potent microtubule polymerase inhibitor.

can be conjugated to cytotoxic drugs and used to T‐DM1 was approved for use in HER2‐postive deliver these drugs directly to the tumor site. The breast cancer based on the results of the EMILIA first antibody drug conjugate (ADC) to receive clinical trial that enrolled women with advanced FDA approval was gemtuzumab ozogamicin, an HER2‐positive breast cancer who were resistant to ADC that links the cytotoxic agent calicheamicin trastuzumab alone [22]. T‐DM1 improved median to an anti‐CD33 antibody. It was approved for use overall survival compared to the combination of in 2000 for patients at least 60 years of age with the HER2 tyrosine kinase inhibitor lapatinib and CD33‐positive acute myeloid leukemia. This was capecitabine. Many additional ADCs are currently based on a single‐arm phase II trial showing an being evaluated in clinical trials.

overall response rate of 26% in these patients [18].

Other mechanisms by which antibodies can kil

This approval was conditioned on completion of a tumor cel s are categorized immune‐mediated subsequent phase III clinical trial; unfortunately, tumor cell killing. Much of immune‐mediated that confirmatory study was negative, leading to tumor cell killing is due to immune cell engagewithdrawal of the approval in 2010 [19]. More ment with the Fc portion of the mAb (Figure 2.2) recently, the results of additional randomized [26]. Specifical y, Fc receptors (FcR) on natural studies adding gemtuzumab ozogamicin to various killer (NK) cel s binding to the Fc portion of a induction regimens have suggested improved mAb engaged with a surface receptor can lead overall survival in specific patients with acute mye­ to antibody‐dependent cel ular cytotoxicity loid leukemia with intermediate cytogenetic (ADCC). ADCC involves the FcR on an NK cel characteristics, leading to renewed interest in this (FcRIII; CD16) recognizing cell‐bound antiagent [20, 21, 22].

bodies and cross‐linking the antibodies, which

The second ADC to receive regulatory approval leads to the release of granzyme and perforin into was brentuximab vedotin, which combines an anti‐ the synapse, promoting apoptosis [27, 28].

CD30 antibody conjugated to monomethyl Although FcR genotypes are not completely preauristatin E, a microtubule disrupting agent. dictive of response to therapy, there is evidence Brentuximab vedotin is approved for use in treat­ that FcR polymorphisms enhance response rates ing patients with relapsed or refractory Hodgkin’s for rituximab in follicular lymphoma, cetuximab lymphoma based on a single‐arm, multicenter in colorectal cancer, and trastuzumab in breast study that enrolled patients who relapsed after cancer [29–31]. ADCC can also be mediated by autologous stem cell transplant [23]. In this study, macrophages. In addition, macrophage binding to brentuximab vedotin showed a 75% objective antibodies coating the cell surface can promote response rate with a median duration of response phagocytosis. Furthermore, tumor antigen–tarof 20.5 months in patients with relapsed or geted mAbs can trigger an antigen‐specific T cel refractory Hodgkin’s lymphoma [23]. A subsequent response via a process known as cross‐presentarandomized phase III trial (AETHERA) showed tion. Briefly, the mAb‐coated tumor antigens that consolidation with brentuximab vedotin after released by dying cel s are taken up by dendritic autologous stem cell transplant improved progression‐ cel s, which process and present the antigen to T

free survival in Hodgkin’s lymphoma patients cel s [32, 33]. These activated T cel s are then able with high‐risk factors for relapse or disease prog­ to recognize the antigen expressed by the tumor ression after transplantation [24]. The approval for cel s complexed with an MHC molecule. Efforts





CHAPTER 2 Monoclonal Antibody Therapy 15

Natural Killer

Cell

A. Antibody-Dependent

Cellular Cytotoxicity

D. Complement-Dependent

Cytotoxicity

C1qC1rC1s

Tumor Cell

Macrophage

T cell

Dendritic Cell

C. Phagocytosis

B. Cross-Presentation and

T Cell Activation

Monoclonal Antibody (mAb)

Granzyme and Perforin

C1q

Tumor Antigen

Fc Receptor (FcR)

Major Histocompatability Complex

Membrane Attack Complex

T Cell Receptor

Figure 2.2 Immune‐mediated mechanisms of action for

tumors cells and coated with mAbs are taken up by

monoclonal antibodies. A. Antibody‐dependent cellular dendritic cells, processed, and presented to T cells. C.

cytotoxicity. Fc gamma receptors on the surface of

Phagocytosis. Macrophage binding to mAb via its FcR

immune effector cells such as natural killer cells bind to

mediates phagocytosis. D. Complement‐dependent

the Fc region of antibodies interacting with tumor cell

cytotoxicity. C1q complement proteins bind to antibodies

surface antigens, leading to the release of granzyme and

interacting with tumor cell surface antigens, triggering

perforin that mediate tumor cell killing. B. Cross‐presentation the complement cascade. Membrane attack complexes

and T cell activation. Tumor antigens released by dying

form on the surface of the cell, leading to cell death.

have been made to modify the Fc region of mAbs glycosylation pattern in a manner that enhances to increase their ability to interact with the interaction with the FcR on effector cel s [34, 35].

immune system. Approaches used include chang­ Obinutuzumab is an example of a glycomodified ing the amino acid sequence or altering the mAb that was shown to be safe and effective,





16 Immunotherapy in Translational Cancer Research leading to FDA approval for the treatment of proteins [45]. In contrast, for mAbs for which cell chronic lymphocytic leukemia [36, 37].

surface receptor internalization is a primary mech­

Final y, mAbs can also induce complement‐ anism of action or for conjugated mAbs that are dependent cytotoxicity (CDC) [38, 39]. The exact designed to deliver a payload into the cancer cel , role of CDC in the clinical response to mAb therapy then rapid, efficient internalization is preferable is unknown, as the effects of CDC are very rapid, [45]. Another consideration, specifical y when whereas the response to mAb‐based therapy occurs considering mAbs for the treatment of solid over weeks. It has been suggested that CDC may tumors, is whether the antigen is secreted. Secreted contribute most to the efficacy of mAbs in hemato­ antigens bind the mAb in the circulation, thereby logic malignancies, where target cel s are exposed limiting the availability of mAb for tumor binding.

to complement proteins in the circulation [40].

Several different categories of tumor antigens

Consistent with this, it is general y accepted that that can be recognized by therapeutic mAbs exist CDC is limited as a mechanism of action for mAb (Table 2.1). Antigens involved in growth and treatment of solid tumors [41]. It has also been sug­ differentiation signaling typical y are growth gested that CDC plays a role in some of the adverse factors or growth factor receptors, including EGFR, effects observed with mAb therapy [42].

HER2, ERBB3, MET, insulin‐like growth factor 1

There is evidence of interactions between var­ receptor (IGF1R), ephrin receptor A3 (EPHA3), ious mechanisms of action of a single mAb. These tumor necrosis factor (TNF)‐related apoptosis-interactions can be synergistic or antagonistic and inducing ligand receptor 1 (TRAILR1), TRAILR2, can impact the antitumor effects of the mAb. For and receptor activator of nuclear factor‐κB ligand example, the effects of complement fixation are (RANKL). Antigens involved in angiogenesis complex [43]. The anti‐CD20 mAb rituximab can include growth factors and proteins that support promote rapid target cell killing via CDC. However, the formation of microvasculature, including complement fixation can also block the interaction vascular endothelial growth factor (VEGF), VEGF

between the mAb and the FcR on NK cel s, thereby receptor (VEGFR), integrin α5β1, and αVβ3.

decreasing ADCC [44]. The mAb, trastuzumab, Stromal and extracel ular matrix antigens are critialso has multiple described mechanisms of action, cal in that they provide structural support for the including inhibition of cell signaling by preventing tumor. Stromal and extracel ular matrix antigens dimerization and promoting receptor internaliza­ that can be targeted include fibroblast activation tion, which inhibits kinase activation [10]. ADCC protein and tenascin. Glycoproteins can be found is another described mechanism of action [32]. on the surface of solid tumor cel s as well as malig­

ADCC requires that the mAb complexed with the nant hematologic cel s. Examples of glycoproteins target antigen remain on the cell surface for recog­ expressed by solid tumors include epithelial cell nition by the FcR of NK cel s. Therefore, the effect adhesion molecule (EPCAM), carcinoembryonic of trastuzumab promoting receptor internalization antigen (CEA), mucins, prostate‐specific memcould decrease the extent of ADCC.

brane antigen (PSMA), and folate‐binding protein

(FBP). Hematopoietic differentiation antigens are

Tumor antigens

typical y associated with cluster of differentiation

(CD) groupings and include CD20, CD30, CD33,

The efficacy and safety of therapeutic mAbs and CD52.

depends on the target antigen. An ideal target

antigen is abundant and has consistent expression Clinical development by malignant cel s [45]. In addition, there should of monoclonal antibodies be limited tendency for antigen‐negative tumor

variants to emerge [41]. If the desired mechanism The initial step in developing mAbs for clinical use of action is ADCC or CDC, then it is preferable involves in vitro and in vivo preclinical studies [8, that the mAb‐antigen complex not be internalized 45, 46]. First, the physical and chemical properties rapidly to allow maximal exposure of the Fc region of the antibody must be characterized. In addition, of the mAb to immune effector cel s or complement detailed analyses must be performed to determine

Table 2.1 Categories of tumor antigens recognized by therapeutic mAbs .

U.S.

Type of Antigen

Target

Tumors Expressing Antigens

Therapeutic Monoclonal Antibody

Type

FDA‐Approved *

Carbohydrate

Lewis‐Y

Breast, colon, lung, and prostate

Hu3S193 and IgN311

Naked antibody

No

Epidermal growth factor

EGFR

Colorectal carcinoma

Panitumumab

Naked antibody

Yes

receptor

Glycolipid

GD2

Neuroblastoma

Dinutuximab

Naked antibody

Yes

GD2

Neuroblastoma and osteosarcoma

Hu3F8 – Y – mAbs[[check]]

Naked antibody

Yes

Glycoproteins expressed

EPCAM

Breast, colon, and lung

Adecatumumab

Naked antibody

No

by solid tumors

CA IX

Renal cell carcinoma

Girentuximab

Naked antibody

Yes

gpA33

Colorectal carcinoma

huA33

Naked antibody

No

PSMA

Prostate carcinoma

J591

Naked antibody

No

CEA

Breast, colon, and lung

Labetuzumab

Naked antibody

No

FBP

Ovarian

MOv18 and MORAb‐003

Naked antibody

No

Growth and differentiation

HER2

Breast, colon, lung, ovarian, and prostate

Ado‐trastuzumab emtansine

Naked antibody

Yes

signaling

VEGF

Lung, colon, and kidney

Bevacizumab

Naked antibody

Yes

EGFR

Glioma, lung, breast, colon, and head and neck

Cetuximab

Naked antibody

Yes

tumors

IGF1R

Breast, colorectal, and pancreatic

Dalotuzumab

Naked antibody

No

CD38

Myeloma

Daratumumab

Naked antibody

Yes

RANKL

Breast and bone

Denosumab

Naked antibody

Yes

MET

Non–small cell lung cancer, acute myeloid

Ficlatuzumab

Naked antibody

No

leukemia, and head and neck cancer

EPHA3

Acute myeloid leukemia, myelodysplastic

Ifabotuzumab

Naked antibody

No

syndromes, and myelofibrosis

TRAILR1

Cervical

Mapatumumab

Naked antibody

No

EGFR

Lung

Necitumumab

Naked antibody

Yes

EGFR

Pancreatic cancer

Nimotuzumab

Naked antibody

Yes

PDGRF α

Sarcoma

Olaratumab

Naked antibody

Yes

HER2

Breast, colon, long, ovarian, and prostate

Pertuzumab

Naked antibody

Yes

ERBB3

Breast, non–small cell lung cancer, and ovarian

Seribantumab

Naked antibody

Yes

ERBB2

Breast, colon, lung, ovarian, and prostate

Trastuzumab

Naked antibody

Yes

( Continued )

Table 2.1 ( Continued)

U.S.

Type of Antigen

Target

Tumors Expressing Antigens

Therapeutic Monoclonal Antibody

Type

FDA‐Approved *

Hematopoietic

CD52

Leukemia

Alemtuzumab

Naked antibody

Yes

differentiation antigen

CD19

Leukemia

Blinatumomab

Bispecific antibody

Yes

CD3

CD30

Hodgkin’s lymphoma

Brentuximab vedotin

Conjugated antibody

Yes

CD33

Leukemia

Gemtuzumab ozogamicin

Conjugated antibody

Yes

CD20

Lymphoma

90 Y‐labeled ibritumomab tiuxetan

Conjugated antibody

Yes

CD20

Leukemia

Obinutuzumab

Naked antibody

Yes

CD20

Leukemia

Ofatumumab

Naked antibody

Yes

VEGFR‐2

Gastric and adenocarcinoma

Ramucirumab

Naked antibody

Yes

CD20

Non‐Hodgkin’s lymphoma

Rituximab

Naked antibody

Yes

CD20

Lymphoma

131 I‐labeled tositumomab

Conjugated antibody

Yes

Immunostimulatory

SLAMF7

Myeloma

Elotuzumab

Naked antibody

Yes

receptor

* As of August 2, 2017.

Note: Monoclonal antibodies targeting immune‐checkpoint inhibitors are discussed in Chapter 4 . Checkpoint blockades are therefore not included in this table.





CHAPTER 2 Monoclonal Antibody Therapy 19

antigen expression in both malignant and normal neoadjuvant trial that demonstrated the addition of tissues. Studies must also be completed to deter­ pertuzumab to trastuzumab and docetaxel led to mine the mAb effects on signaling pathways and significant increases in the pathologic complete immune effector functions. In vivo studies must response rates (i.e., the absence of invasive disease then be completed to determine antibody distribu­ in the breast or axil ary lymph nodes in the pathotion and localization as well as therapeutic activity. logic specimen obtained at the time of surgery) The clinical phase of development requires com­ compared to trastuzumab and docetaxel alone pletion of studies in patients to determine toxicity [56]. This followed prior approval in patients with and confirm therapeutic efficacy. A critical step in HER2‐positive metastatic breast cancer based on clinical evaluation includes determining in vivo the CLEOPATRA trial, a phase III randomized, biodistribution to assess the ratio of mAb uptake in double‐blind, placebo‐controlled trial that showed normal tissues versus the tumor [47]. This a significant improvement in progression‐free information is important for predicting as well as survival (the trial’s primary endpoint) in patients defining dose requirements to achieve optimal receiving pertuzumab versus placebo in plasma and tissue concentration and in establish­ combination with trastuzumab and docetaxel [57].

ing possible effects of antigen‐receptor saturation A secondary endpoint of that trial was overall toxicity [45, 48, 49]. At the Ludwig Institute for survival, and at the time of FDA approval a planned Cancer Research, a clinical trial model has been interim analysis suggested an improvement in Table 2.1 ( Continued)

developed that incorporates toxicity assessment overall survival, but the hazard ratio and p values U.S.

Type of Antigen

Target

Tumors Expressing Antigens

Therapeutic Monoclonal Antibody

Type

FDA‐Approved *

with biodistribution, pharmacokinetic, and phar­ did not cross the stopping boundary. Subsequent Hematopoietic

CD52

Leukemia

Alemtuzumab

Naked antibody

Yes

macodynamics analyses (Reviewed in Scott et al. reports from that trial after longer follow‐up have differentiation antigen

CD19

Leukemia

Blinatumomab

Bispecific antibody

Yes

[45]). Using this design, these investigators have confirmed an overall survival benefit for the CD3

CD30

Hodgkin’s lymphoma

Brentuximab vedotin

Conjugated antibody

Yes

completed first‐in‐human clinical trials of more addition of pertuzumab to trastuzumab and CD33

Leukemia

Gemtuzumab ozogamicin

Conjugated antibody

Yes

CD20

Lymphoma

90 Y‐labeled ibritumomab tiuxetan

Conjugated antibody

Yes

than 15 mAbs in cancer patients. Subsequent phase docetaxel [58].

CD20

Leukemia

Obinutuzumab

Naked antibody

Yes

I to III clinical trials must then be performed to

CD20

Leukemia

Ofatumumab

Naked antibody

Yes

VEGFR‐2

Gastric and adenocarcinoma

Ramucirumab

Naked antibody

Yes

confirm safety and efficacy. In general, most mAbs Mechanisms of resistance CD20

Non‐Hodgkin’s lymphoma

Rituximab

Naked antibody

Yes

have different and usual y milder toxicities than

CD20

Lymphoma

131 I‐labeled tositumomab

Conjugated antibody

Yes

Immunostimulatory

SLAMF7

Myeloma

Elotuzumab

Naked antibody

Yes

standard chemotherapeutics [45, 50, 51]. With While mAb antibody therapy has demonstrated receptor

respect to confirming efficacy, the FDA usual y success in many hematologic malignancies and

* As of August 2, 2017.

bases approval on an agent showing improved solid tumor types, there are a number of mecha­

Note: Monoclonal antibodies targeting immune‐checkpoint inhibitors are discussed in Chapter 4 . Checkpoint blockades are therefore not included in this table.

overall survival compared to standard therapy in a nisms that may limit their clinical effectiveness.

phase III trial. This was the case for rituximab, a For mAbs that work primarily by targeting the mAb targeting CD20. Rituximab was initial y antigen or receptor, heterogeneous target antigen granted FDA approval for use in first‐line treatment expression can limit effectiveness. This heterogeof patients with diffuse large B‐cel , CD20‐positive, neous expression can be present initial y or develop non‐Hodgkin’s lymphoma in combination with during therapy. It may also represent a response to cyclophosphamide, doxorubicin, vincristine, and therapy. In a study evaluating patients with HER2-prednisone, or other anthracycline‐based chemo­ positive breast cancer that received trastuzumab in therapy regimens based on the results of three the neoadjuvant setting, the tumors from approxirandomized trials that demonstrated an improve­ mately one‐third of patients with residual disease ment in overall survival for patients receiving identified at the time of surgery were found to be rituximab [52–54].

HER2‐negative [59]. It was hypothesized that this

There have been instances, however, where represented treatment of the HER2‐positive clones, approval was granted based on surrogate markers. with the remaining tumor cel s being HER2-As an example, in 2013, the FDA granted acceler­ negative. Patients whose residual disease was ated approval to pertuzumab, a mAb targeting HER2‐negative had significantly worse recur­

HER2 for use with trastuzumab and docetaxel in rence‐free survival than patients who retained the neoadjuvant treatment of HER2‐positive breast HER2 positivity. It has also been demonstrated that cancer patients [55]. This approval was based on a expression of the presumed target does not always





20 Immunotherapy in Translational Cancer Research correlate with response to therapy. As an example, responses [32]. CDC can also lead to resistance to evaluation of EGFR expression in archived samples therapy. It has been shown that when anti‐CD20

of metastatic colorectal cancer patients or patients binds to chronic lymphocytic leukemia cel s with recurrent or metastatic squamous cell carci­

followed by complement fixation, the mAb‐

noma of the head and neck treated with the EGFR‐ antigen‐complement complex can be sheared off targeted antibodies cetuximab or panitumumab the surface of the leukemic cell during circulation has shown that expression levels of EGFR is not through the liver and spleen [65]. This results in predictive of response to treatment [60, 61]. In circulating leukemic cel s that lack the target patients with metastatic colorectal cancer, it has antigen and are therefore not susceptible to mAb been shown that KRAS mutational status, not therapy.

EGFR expression, is a reliable marker, with the

benefit of cetuximab being limited to patients with Conclusions KRAS wild‐type tumors [11–13]. In contrast, for

patients with advanced non‐small‐cell lung cancer, The use of mAbs to treat both solid tumors and it is the EGFR expression not KRAS status that pre­ hematologic malignancies represents a great sucdicts for response to cetuximab therapy [62, 63]. cess story in cancer therapy. This success is attrib­

These data suggest that a biomarker that may be utable to advances in our understanding of tumor predictive in one tumor type or setting may not be biology and immunology as well technological predictive in others.

advances enabling target identification and anti­

Other factors related to the engagement of mAb body generation. It is anticipated that continued to the intended antigen receptor can also mediate advances will allow for the development of even decreased effectiveness. These include physical more innovative approaches to capitalize on the properties of the mAb to include size as well as phar­ specificity of mAbs as part of therapeutic strategies macokinetic characteristics such as stability and providing clinical benefit to cancer patients.

half‐life that impact the mAb penetrance into the

tumor [64]. Aspects of the tumor microenviron­ References

ment including vascular permeability and tumor

interstitial pressure can also impact mAb penetrance 1. Rettig WJ, Old LJ. Immunogenetics of human cell surface into the tumor [64]. If there is poor receptor saturadifferentiation. Annu Rev Immunol. 1989;7:481–511.

tion, this may impact the effect of the mAb on 2. Kohler G, Milstein C. Continuous cultures of fused cel s receptor dimerization and downstream signaling. It

secreting antibody of predefined specificity. Nature.

is also possible that the signaling pathway being

1975;256(5517):495–7.

blocked by the mAb is not critical for the tumor’s 3. Riechmann L, Clark M, Waldmann H, Winter G.

Reshaping human antibodies for therapy. Nature. 1988;

growth, or that overactivation of alternative sig332(6162):323–7.

naling pathways may contribute to a lack of response 4. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G.

in the tumor to treatment. Similarly, interactions

Replacing the complementarity‐determining regions in a

between cell surface receptors, which have been

human antibody with those from a mouse. Nature. 1986;

observed for EGFR and MET, can prevent abroga321(6069):522–5.

tion of signaling pathways [64].

5. Chester KA, Begent RH, Robson L, Keep P, Pedley RB,

Final y, the immune‐mediated mechanisms of

Boden JA, et al. Phage libraries for generation of clinical y action can contribute to decreased therapeutic effiuseful antibodies. Lancet. 1994;343(8895):455–6.

cacy. As has been discussed above, mAb binding to 6. Houdebine LM. Production of pharmaceutical proteins the receptor can promote internalization of the

by transgenic animals. Comp Immunol Microbiol Infect

mAb‐receptor complex. This in turn can prohibit

Dis. 2009;32(2):107–21.

7. Nelson AL, Dhimolea E, Reichert JM. Development

FcR binding, limiting ADCC. Furthermore, as was

trends for human monoclonal antibody therapeutics. Nat

also previously discussed, mAb therapy can lead to

Rev Drug Discov. 2010;9(10):767–74.

the induction of antitumor T cell responses via 8. Weiner LM, Surana R, Wang S. Monoclonal antibodies: cross‐presentation. It is also possible that mAb can

versatile platforms for cancer immunotherapy. Nat Rev

lead to the induction of protumor regulatory T cell

Immunol. 2010;10(5):317–27.

CHAPTER 2 Monoclonal Antibody Therapy 21

9. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang

with acute myeloid leukaemia: a meta‐analysis of

Chien CR, Makhson A, et al. Cetuximab and chemoindividual patient data from randomised controlled therapy as initial treatment for metastatic colorectal cantrials. Lancet Oncol. 2014;15(9):986–96.

cer. N Engl J Med. 2009;360(14):1408–17.

21. Lambert JM, Morris CQ. Antibody‐drug conjugates

10. Hudis CA. Trastuzumab: mechanism of action and use

(ADCs) for personalized treatment of solid tumors: a

in clinical practice. N Engl J Med. 2007;357(1):39–51.

review. Adv Ther. 2017;34(5):1015–35.

11. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki 22. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga MP, Cascinu S, et al. Cetuximab plus irinotecan, fluoro­

J, et al. Trastuzumab emtansine for HER2‐positive

uracil, and leucovorin as first‐line treatment for metaadvanced breast cancer. N Engl J Med. 2012;367(19): static colorectal cancer: updated analysis of overall

1783–91.

survival according to tumor KRAS and BRAF mutation 23. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt status. J Clin Oncol. 2011;29(15):2011–9.

JD, Savage KJ, et al. Results of a pivotal phase II study of

12. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F,

brentuximab vedotin for patients with relapsed or

Schuch G, Zubel A, et al. Efficacy according to biorefractory Hodgkin’s lymphoma. J Clin Oncol. 2012; marker status of cetuximab plus FOLFOX‐4 as first‐line

30(18):2183–9.

treatment for metastatic colorectal cancer: the OPUS 24. Moskowitz CH, Nademanee A, Masszi T, Agura E, study. Ann Oncol. 2011;22(7):1535–46.

Holowiecki J, Abidi MH, et al. Brentuximab vedotin as

13. Karapetis CS, Khambata‐Ford S, Jonker DJ, O’Cal aghan

consolidation therapy after autologous stem‐cell trans­

CJ, Tu D, Tebbutt NC, et al. K‐ras mutations and benefit

plantation in patients with Hodgkin’s lymphoma at risk

from cetuximab in advanced colorectal cancer. N Engl J

of relapse or progression (AETHERA): a randomised,

Med. 2008;359(17):1757–65.

double‐blind, placebo‐controlled, phase 3 trial. Lancet.

14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM,

2015;385(9980):1853–62.

Cohen RB, et al. Radiotherapy plus cetuximab for 25. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, squamous‐cell carcinoma of the head and neck. N Engl J

Illidge T, et al. Brentuximab vedotin (SGN‐35) in

Med. 2006;354(6):567–78.

patients with relapsed or refractory systemic anaplastic

15. Kadcyla (ado‐trastuzumab emtansine) for injection, for

large‐cell lymphoma: results of a phase II study. J Clin

intravenous use. Available from https://www.accessdata.

Oncol. 2012;30(18):2190–6.

fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf. July 26. Ravetch J. In vivo veritas: the surprising roles of Fc recep19, 2017.

tors in immunity. Nat Immunol. 2010;11(3):183–5.

16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki 27. Lopez‐Albaitero A, Ferris RL. Immune activation by A, Rottey S, et al. Platinum‐based chemotherapy plus

epidermal growth factor receptor specific monoclonal

cetuximab in head and neck cancer. N Engl J Med.

antibody therapy for head and neck cancer. Arch

2008;359(11):1116–27.

Otolaryngol Head Neck Surg. 2007;133(12):1277–81.

17. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Schol 28. Lopez‐Albaitero A, Lee SC, Morgan S, Grandis JR, S, Fehrenbacher L, et al. Multinational study of the effi­

Gooding WE, Ferrone S, et al. Role of polymorphic Fc

cacy and safety of humanized anti‐HER2 monoclonal

gamma receptor IIIa and EGFR expression level in

antibody in women who have HER2‐overexpressing

cetuximab mediated, NK cell dependent in vitro cytometastatic breast cancer that has progressed after toxicity of head and neck squamous cell carcinoma cel s.

chemotherapy for metastatic disease. J Clin Oncol.

Cancer Immunol Immunother. 2009;58(11):1853–64.

1999;17(9):2639–48.

29. Weng WK, Levy R. Two immunoglobulin G fragment C

18. Sievers EL, Larson RA, Stadtmauer EA, Estey E,

receptor polymorphisms independently predict

Lowenberg B, Dombret H, et al. Efficacy and safety of

response to rituximab in patients with follicular lymgemtuzumab ozogamicin in patients with CD33‐positive phoma. J Clin Oncol. 2003;21(21):3940–7.

acute myeloid leukemia in first relapse. J Clin Oncol. 30. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti 2001;19(13):3244–54.

M, Missale G, et al. Immunoglobulin G fragment C

19. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill

receptor polymorphisms and clinical efficacy of trastu­

T, Brandwein J, et al. A phase 3 study of gemtuzumab

zumab‐based therapy in patients with HER‐2/neu‐

ozogamicin during induction and postconsolidation

positive metastatic breast cancer. J Clin Oncol.

therapy in younger patients with acute myeloid leu2008;26(11):1789–96.

kemia. Blood. 2013;121(24):4854–60.

31. Bibeau F, Lopez‐Crapez E, Di Fiore F, Thezenas S, Ychou

20. Hil s RK, Castaigne S, Appelbaum FR, Delaunay J,

M, Blanchard F, et al. Impact of FcγRIIa‐FcγRIIIa

Petersdorf S, Othus M, et al. Addition of gemtuzumab

polymorphisms and KRAS mutations on the clinical

ozogamicin to induction chemotherapy in adult patients

outcome of patients with metastatic colorectal cancer

22 Immunotherapy in Translational Cancer Research treated with cetuximab plus irinotecan. J Clin Oncol. 44. Wang SY, Racila E, Taylor RP, Weiner GJ. NK‐cell 2009;27(7):1122–9.

activation and antibody‐dependent cel ular cytotoxicity

32. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen‐targeted, induced by rituximab‐coated target cel s is inhibited

monoclonal antibody‐based immunotherapy: clinical

by the C3b component of complement. Blood.

response, cel ular immunity, and immunoescape. J Clin

2008;111(3):1456–63.

Oncol. 2010;28(28):4390–9.

45. Scott AM, Wolchok JD, Old LJ. Antibody therapy of

33. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V,

cancer. Nat Rev Cancer. 2012;12(4):278–87.

Manning EA, et al. Antibody association with HER‐2/

46. Deckert PM. Current constructs and targets in clinical

neu‐targeted vaccine enhances CD8 T cell responses in

development for antibody‐based cancer therapy. Curr

mice through Fc‐mediated activation of DCs. J Clin

Drug Targets. 2009;10(2):158–75.

Invest. 2008;118(5):1700–11.

47. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu

34. Bowles JA, Wang SY, Link BK, Al an B, Beuerlein G,

Z, et al. A phase I clinical trial with monoclonal antibody

Campbell MA, et al. Anti‐CD20 monoclonal antibody

ch806 targeting transitional state and mutant epidermal

with enhanced affinity for CD16 activates NK cel s at

growth factor receptors. Proc Natl Acad Sci U S A.

lower concentrations and more effectively than ritux2007;104(10):4071–6.

imab. Blood. 2006;108(8):2648–54.

48. Cheson BD, Leonard JP. Monoclonal antibody therapy

35. Dalle S, Reslan L, Besseyre de Horts T, Herveau S,

for B‐cell non‐Hodgkin’s lymphoma. N Engl J Med.

Herting F, Plesa A, et al. Preclinical studies on the mech2008;359(6):613–26.

anism of action and the anti‐lymphoma activity of the 49. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, novel anti‐CD20 antibody GA101. Mol Cancer Ther.

Chappell B, Micallef N, et al. Phase I biodistribution and

2011;10(1):178–85.

pharmacokinetic study of Lewis Y‐targeting immuno36. Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, conjugate CMD‐193 in patients with advanced epithelial

Leblond V, Dupuis J, et al. Obinutuzumab (GA101) in

cancers. Clin Cancer Res. 2009;15(21):6709–15.

relapsed/refractory chronic lymphocytic leukemia: final 50. Strevel EL, Siu LL. Cardiovascular toxicity of molecularly data from the phase 1/2 GAUGUIN study. Blood.

targeted agents. Eur J Cancer. 2009;45 Suppl 1:318–31.

2014;124(14):2196–202.

51. Asnacios A, Naveau S, Perlemuter G. Gastrointestinal

37. Gayzva (obinutuzumab) label. Available from https://

toxicities of novel agents in cancer therapy. Eur J Cancer.

w w w. a c c e s s d at a . f d a . g ov / d r u g s at f d a _ d o c s /

2009;45 Suppl 1:332–42.

label/2014/125486_s008lbl.pdf. July 21, 2017.

52. Coiffier B, Lepage E, Briere J, Herbrecht R, Til y H,

38. Dechant M, Weisner W, Berger S, Peipp M, Beyer T,

Bouabdal ah R, et al. CHOP chemotherapy plus ritux­

Schneider‐Merck T, et al. Complement‐dependent

imab compared with CHOP alone in elderly patients

tumor cell lysis triggered by combinations of epidermal

with diffuse large‐B‐cell lymphoma. N Engl J Med.

growth factor receptor antibodies. Cancer Res. 2008;

2002;346(4):235–42.

68(13):4998–5003.

53. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R,

39. Wang SY, Weiner G. Complement and cel ular cytotox­

Trneny M, Imrie K, et al. CHOP‐like chemotherapy plus

icity in antibody therapy of cancer. Expert Opin Biol

rituximab versus CHOP‐like chemotherapy alone in

Ther. 2008;8(6):759–68.

young patients with good‐prognosis diffuse large‐B‐cell

40. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer

lymphoma: a randomised controlled trial by the

MA, van de Winkel JG, Parren PW, et al. Binding of

MabThera International Trial (MInT) Group. Lancet



submaximal C1q promotes complement‐dependent

Oncol. 2006;7(5):379–91.

cytotoxicity (CDC) of B cel s opsonized with anti‐CD20 54. Habermann TM, Weller EA, Morrison VA, Gascoyne mAbs ofatumumab (OFA) or rituximab (RTX): consid­

RD, Cassileth PA, Cohn JB, et al. Rituximab‐CHOP

erably higher levels of CDC are induced by OFA than by

versus CHOP alone or with maintenance rituximab in

RTX. J Immunol. 2009;183(1):749–58.

older patients with diffuse large B‐cell lymphoma. J Clin

41. Weiner GJ. Building better monoclonal antibody‐based

Oncol. 2006;24(19):3121–7.

therapeutics. Nat Rev Cancer. 2015;15(6):361–70.

55. Amiri‐Kordestani L, Wedam S, Zhang L, Tang S, Tilley

42. van der Kolk LE, Grillo‐Lopez AJ, Baars JW, Hack CE,

A, Ibrahim A, et al. First FDA approval of neoadjuvant

van Oers MH. Complement activation plays a key role in

therapy for breast cancer: pertuzumab for the treatment

the side‐effects of rituximab treatment. Br J Haematol.

of patients with HER2‐positive breast cancer. Clin

2001;115(4):807–11.

Cancer Res. 2014;20(21):5359–64.

43. Rogers LM, Veeramani S, Weiner GJ. Complement in 56. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, monoclonal antibody therapy of cancer. Immunol Res.

Liu MC, et al. Efficacy and safety of neoadjuvant pertu2014;59(1–3):203–10.

zumab and trastuzumab in women with local y

CHAPTER 2 Monoclonal Antibody Therapy 23

advanced, inflammatory, or early HER2‐positive breast

colorectal cancer: analysis of data from the EXTREME

cancer (NeoSphere): a randomised multicentre, open‐

and CRYSTAL studies. Eur J Cancer. 2013;49(6):

label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

1161–8.

57. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. 62. Khambata‐Ford S, Harbison CT, Hart LL, Awad M, Xu Pertuzumab plus trastuzumab plus docetaxel for meta­

LA, Horak CE, et al. Analysis of potential predictive

static breast cancer. N Engl J Med. 2012;366(2):109–19.

markers of cetuximab benefit in BMS099, a phase III

58. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V,

study of cetuximab and first‐line taxane/carboplatin in

Campone M, et al. Pertuzumab, trastuzumab, and

advanced non‐small‐cell lung cancer. J Clin Oncol.

docetaxel in HER2‐positive metastatic breast cancer. N

2010;28(6):918–27.

Engl J Med. 2015;372(8):724–34.

63. O’Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C,

59. Mittendorf EA, Wu Y, Scaltriti M, Meric‐Bernstam F,

Eschbach C, Martens UM, et al. Molecular biomarkers

Hunt KK, Dawood S, et al. Loss of HER2 amplification

in non‐small‐cell lung cancer: a retrospective analysis

following trastuzumab‐based neoadjuvant systemic

of data from the phase 3 FLEX study. Lancet Oncol.

therapy and survival outcomes. Clin Cancer Res. 2009;

2011;12(8):795–805.

15(23):7381–8.

64. Pil ay V, Gan HK, Scott AM. Antibodies in oncology.

60. Vectibix (panituumab) label. Available from https://

N Biotechnol. 2011;28(5):518–29.

www.accessdata.fda.gov/drugsatfda_docs/label/2009/ 65. Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, 125147s067lbl.pdf. July 19, 2017.

Engelberts PJ, Parren PW, et al. Loss of CD20 and bound

61. Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R,

CD20 antibody from opsonized B cel s occurs more

Hirsch FR, et al. Predictive value of epidermal growth

rapidly because of trogocytosis mediated by Fc receptor‐

factor receptor expression for first‐line chemotherapy

expressing effector cel s than direct internalization by

plus cetuximab in patients with head and neck and

the B cel s. J Immunol. 2011;187(6):3438–47.





CHAPTER 3

3 Somatic Mutations and

Immunotherapy

Eric Tran

Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA In addition to protecting us from pathogens such may provide insight and clues on how to enhance as viruses and bacteria, it is now clear that the T cell–based immunotherapies against cancer.

immune system can recognize and destroy cancer

Tumor cel s are genetical y and epigenetical y

[1]. Many components of the immune system play different than normal cel s, and these differences a role in antitumor responses, but CD8+ and CD4+ can make them susceptible to immunological T cel s have been perhaps the most well studied. attack. Over the last several decades, different The importance of T cel s in antitumor immunity classes of tumor antigens arising as a consequence has been unequivocal y demonstrated in a plethora of genetic and epigenetic alterations have been of murine studies where genetic or pharma­ described [27]. These classes can be broadly cological perturbation of components of the T cell grouped into “self” and “nonself” tumor antigens.

response impaired or abrogated antitumor Self antigens include cancer germline (CG), tissue responses. In humans, treatment with high doses of differentiation, and overexpressed antigens. The the T cell growth factor interleukin‐2 [2] and the first human tumor antigen characterized was adoptive transfer of ex vivo expanded tumor infil­ MAGE‐A1, a CG antigen [28]. CG antigens are trating T cel s can mediate durable complete normal y expressed in germline cel s (which do not regression in some patients with metastatic solid express human leukocyte antigen [HLA] molecancers [3–11]. Inhibitors to the PD‐1 and CTLA‐4 cules) with limited expression in normal tissues, immune checkpoint pathways have also demon­ but due to DNA demethylation are re‐expressed by strated striking clinical activity in a subset of some cancer cel s. Some well‐studied CG antigens patients with various cancer types [12–26], with include NY‐ESO‐1 and members of the SSX and some of these responses likely mediated by the MAGE families, but a large number of immunoactivation of endogenous antitumor T cel s. genic CG antigens have been described [29] and Although the identity of the tumor rejection some have been targets of immunotherapy. The antigens recognized by T cel s in the vast majority adoptive transfer of T cel s engineered to express T

of reported clinical responders to immunotherapy cell receptors (TCR) targeting an HLA‐A*02:01

will never be known, characterization of the restricted epitope from NY‐ESO‐1 mediated antigens and the T cell response to these antigens objective clinical responses in patients with Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

24

CHAPTER 3 Somatic Mutations and Immunotherapy 25

metastatic melanoma and synovial cell carcinoma expressed in some normal tissues or were expressed with no observed T cell–related toxicities [30, 31]. in normal tissues at some point during human Targeting of the NY‐ESO‐1 CG antigen, however, development. This fact in itself may limit immunois limited by the low frequency of NY‐ESO‐1 therapies that aim to boost the endogenous expression in common tumor types [32]. Although immune response against these antigens, since targeting of the more frequently expressed CG central tolerance may have deleted high‐avidity T

antigen MAGE‐A3 with a recombinant protein cel s targeting these antigens. With the exception of vaccine was not effective in patients with non‐ cell transfer therapy using T cel s engineered with small‐cell lung cancer in the adjuvant setting [33], high‐avidity TCRs against NY‐ESO‐1, other cell transfer immunotherapy using autologous T attempts thus far to target these antigens have cel s engineered to express MAGE‐A3‐specific resulted in either some clinical responses with TCRs resulted in objective tumor regressions in serious toxicities to normal tissues as highlighted five out of nine patients with metastatic cancer; above, or low or unconfirmed response rates with however, serious neurological toxicities were little toxicity. Theoretical y, targeting of these observed in three patients, with two deaths, likely antigens could be a viable strategy if the antigen the consequence of cross‐reactivity of the MAGE‐ were either no longer expressed in targetable A3 TCR with a peptide derived from the highly normal tissues, or expressed on normal but noneshomologous MAGE‐A12 protein, which was sential tissues where col ateral damage would be expressed in a subset of neurons in the brain [34]. acceptable.

Thus, another potential limitation to targeting CG

In contrast to self antigens, “non‐self” tumor

antigens is that some epitopes may be expressed in antigens comprise antigens that are truly tumor normal tissues.

specific; thus, the targeting of these antigens should

Tissue differentiation antigens such as GP100, be safe and not result in normal tissue toxicities.

MART‐1, CEA, and mesothelin are normal y The major classes of these antigens are derived expressed in select healthy tissues but can be from cancer‐causing viruses and neoantigens arisexpressed in some cancers. The targeting of this ing as a consequence of random somatic mutations.

class of antigens should be approached with cau­ Estimates suggest that viruses play a role in tumortion as “on target, off‐tumor” toxicities can occur. igenesis in approximately 10%–15% of human Although some objective tumor regressions were cancers [37, 38]. Thus in these cases, both prophyobserved, the targeting of the melanocyte lactic and therapeutic immunotherapy against viral differentiation antigens GP100 and MART‐1 with epitopes may provide clinical benefit in the absence T cel s genetical y modified to express high avidity of normal tissue toxicities. Indeed, the prophylactic TCRs against these antigens led to toxicities due to vaccination against human papilloma viruses the destruction of normal melanocytes in the skin, (HPV), the causative agent of cervical cancer and eye, and ear [35]. Moreover, the transfer of T cel s some head and neck cancers, among others, can genetical y engineered with high avidity TCRs tar­ prevent the development of these cancers in geting CEA led to severe, transient inflammatory humans (reviewed in Schiller and Lowy [39]).

colitis in patients with colorectal cancer, likely due Synthetic long peptide vaccines against HPV

to recognition of lower levels of CEA expressed in antigens also appeared to be effective in patients normal cel s of the colon [36].

with premalignant disease of the cervix [40] but

Overexpressed proteins, such as HER2/neu not in patients with metastatic gynecological can­

(ERBB2), WT‐1, and p53, represent another major cers [41]. Cell transfer immunotherapy using class of tumor antigens, and some have been targets of tumor‐infiltrating lymphocytes (TILs) containing immunotherapy. However, like tissue differentiation HPV‐reactive T cel s was associated with complete antigens, extreme caution is warranted when target­ tumor regression in two of nine patients with meting this class of antigen since these proteins are also astatic cervical cancer; however, given the found at lower levels in normal tissues.

heterogeneous nature of the infused T cell prod­

The preceding classes of tumor antigens can be ucts, it is possible that T cel s recognizing non‐HPV

considered “self‐antigens” since they are either still antigens were present in the infusion product and

26 Immunotherapy in Translational Cancer Research contributed to tumor regression [10]. Thus, the acid sequencing technologies has greatly facilitated clinical impact of therapeutical y targeting oncovi­ our ability to detect and identify neoantigen-ral epitopes in the metastatic solid cancer setting is reactive T cel s. Some of the main methods that are less clear. Clinical trials for patients with HPV‐ currently being used to detect neoantigen‐reactive associated cancers using TCR‐gene therapy T cel s are shown in Figure 3.1. The process begins targeting an HPV‐16 E6 or E7 viral epitope are with isolation of tumor DNA and RNA, which then ongoing and will provide insight into whether tar­ undergoes next‐generation whole‐exome and/or geting an oncoviral epitope can mediate regression genome, and transcriptome sequencing to identify of metastatic solid tumors. This book chapter somatic mutations expressed by the patient’s autolfocuses on the class of antigens known as mutated ogous cancer. To evaluate T cell reactivity against antigens, hereafter referred to as neoantigens, neoantigens in a relatively unbiased fashion, the which are the protein products of random somatic identified mutations are first encoded in a tandem mutations, and will highlight the evidence in minigene (TMG) construct, which is a genetic conhumans that T cel s targeting this class of antigen struct composed of a variable number of minigenes may be an important component to the success of that each encode for a mutated amino acid flanked many current immunotherapies. Strategies to by approximately 12 amino acids derived from the immunotherapeutical y target neoantigens will wild type protein (Figure 3.1A) [56, 57]. By linking also be discussed.

multiple minigenes together to form a TMG, the

T cel s targeting neoantigens were first described throughput of neoantigen screening is enhanced.

in mice in the late 1980s and early 1990s [42–44], The TMG, either as in vitro transcribed RNA or and shortly after, definitive evidence that a human plasmid DNA, is then introduced into an appro­

T cell could recognize a neoantigen expressed by a priate antigen presenting cell (APC), such as solid cancer was first reported by Coulie and Boon autologous dendritic cel s or B cel s, which can proin 1995 [45]. In this study, peripheral blood T cel s cess and present the neoantigens in the context of from a patient with metastatic melanoma were the patient’s own MHC‐I and MHC‐II molecules.

stimulated in vitro with autologous tumor cell lines T cel s derived from the patient are then cocultured to generate cytotoxic T lymphocyte (CTL) clones, with TMG‐expressing APCs, and T cell reactivity and one clone was found to recognize a point can be assessed by standard immunological assays mutation in an intronic segment encoded by the such as cytokine enzyme‐linked immunosorbent MUM1 gene. However, the initial techniques that assay (ELISA) or enzyme‐linked immunospot used tumor cDNA libraries to identify neoantigen (ELISPOT), and/or flow cytometric analysis of cell T reactive cel s were cumbersome, and over the surface T cell activation markers or intracel ular ensuing two decades the number of patient‐derived cytokine expression. Alternatively, or in addition to neoantigen‐reactive T cel s reported using these TMGs, long peptides containing the mutated techniques was relatively sporadic [46–54]. Thus, it amino acid flanked by amino acids from the wild was uncertain whether T cel s targeting this class of type protein can be synthesized and used to pulse antigen was a rare or common event that would APCs (Figure 3.1B) followed by a coculture as have therapeutic consequences. Despite this, these described above. And analogous to minigenes and techniques have been used to provide some early TMGs, peptides can also be pooled together to correlative evidence that neoantigen‐reactive T generate peptide pools, which increases the cel s may be playing a role in the success of human throughput of neoantigen screening. If reactivity to cancer immunotherapy. For example, neoantigen‐ TMGs or peptide pools is observed, then the idenreactive T cel s were detected in the infusion tity of the recognized neoantigen can be identified product of several patients with melanoma who by performing coculture experiments with the experienced dramatic tumor regressions upon the individual mutated peptides that made up the adoptive cell transfer (ACT) of ex vivo expanded TMG or peptide pool, and/or by reverting each TILs [49, 52, 54, 55].

individual mutation in the TMG back to the wild‐

The advent of reliable, fast, and relatively inex­ type sequence to see which reversion abrogates or pensive high‐throughput, next‐generation nucleic diminishes T cell reactivity. Testing against the





CHAPTER 3 Somatic Mutations and Immunotherapy 27

Harvest T cells from

tumor and/or blood

Isolate genomic

DNA and RNA

Next-generation sequencing

and bioinformatics to identify

T cells

mutations

A. Synthesize tandem minigenes B. Synthesize long peptides C. In silico HLA-peptide

(TMGs) encoding mutations

containing mutant amino acid

prediction algorithms

Mutation

Mutation

…GCTGGTGGC…

Synthesize short

MTEYKLVVVGADGVGKSALTIQLI

mutant peptides

GDPSYPWLADSWTATSLPVNNSNSG

Minigene

VRATGTIRENRTKKCPLMNVEHMKK

Mutation

MHC-peptide

Tandem minigene

GADGVGKSAL

multimers

GADGVGKSA

Incubate

I

I

I

Introduce TMGs

Introduce long

Pulse short

I

into APCs

peptides to APCs

peptides on APCs

Measure binding

I

II

Co-culture assay

Measure T-cell activation

-Cytokine ELISA or ELISPOT

-Flow cytometry for activation markers

Antigen Presenting Cell

(e.g., 4-1BB, OX40)

(APC)

Figure 3.1 Next‐generation‐sequencing‐based strategies to identify neoantigen‐reactive T cells in patients with cancer.

nonmutated wild‐type sequence should also be

Another method to evaluate neoantigen‐reactive

carried out to determine how specific the T cell T cell responses relies on HLA‐peptide binding response is for the mutant compared to the wild prediction algorithms such as NetMHC [58, 59]

type epitope. In our experience, we general y have and epitope analysis programs from the Immune observed stronger CD4+ T cell responses in vitro to Epitope Database (Figure 3.1C). Since the peptide long peptides containing the neoantigens com­ binding groove of many HLA are known, these pared to TMGs encoding the same neoantigens, algorithms analyze mutated neoepitope sequences while mutated TMGs general y elicited stronger and predict how well these minimal peptides CD8+ T cell responses than long peptides contain­ (usual y 8–11 amino acids in length) would bind to ing the same antigen, although there were the patient’s own HLA molecules. The general exceptions (unpublished data).

concept behind the use of these algorithms is that

28 Immunotherapy in Translational Cancer Research neoepitopes that are predicted to bind strongly to in a higher number of potential neoantigens avail­

HLA may be more stable in the HLA groove and able for presentation to the patient’s immune therefore more likely to elicit a T cell response. The system. However, exceptions to this correlation do predicted neoepitopes can then be synthesized and exist, since some patients with cancers harboring a pulsed onto APCs (Figure 3.1C, left) and tested for low number of mutations such as kidney cancer T cell reactivity as described above. The predicted [17, 18] and virus‐associated Merkel‐Cell carciminimal epitopes can also be incorporated into noma [19] also respond to PD‐1 blockade therapy.

labeled MHC multimers, thereby generating a Second, within a given cancer type that has a high reagent that can be used to stain and isolate neoan­ mean number of mutations such as melanoma and tigen‐reactive T cel s (Figure 3.1C, right). High NSCLC, patients whose tumors have higher numthroughput methods to screen a large number of bers of mutations were more likely to benefit from putative neoepitopes using MHC multimers have PD‐1 or CTLA‐4 blockade than those whose been developed [60]. It should be noted that not tumors possessed fewer mutations [12, 15, 21, 23, every neoepitope predicted to bind strongly to 25]. Final y, using HLA‐peptide binding prediction HLA actual y generates a neoepitope‐reactive T algorithms as described above, a higher number of cell in vivo, and in fact the current data suggest that predicted high binding neoepitopes was positively only a small fraction of predicted neoantigens correlated with clinical benefit to anti‐CTLA‐4

elicits an endogenous T cell response in patients therapy in melanoma [23, 25] and PD‐1 blockade with cancer. Moreover, a limitation of HLA‐pep­ in patients with NSCLC [21]. In one patient with tide binding algorithms is that predictions are less NSCLC, tumor regression after anti‐PD‐1 therapy reliable for less common HLA class I alleles and for was correlated with an increased frequency of T

HLA class II alleles.

cel s in the peripheral blood targeting a patient‐

Recently, other groups have incorporated mass specific neoepitope derived from the HERC1

spectrometry with next‐generation sequencing to protein, as determined using a high‐throughput identify neoepitopes expressed by human mela­ MHC tetramer screening technique. Similarly, in a noma [61, 62]. Briefly, MHC‐peptide molecules different study an increase in the frequency of a were purified from tumors and the bound peptides dominant T cell population reactive against a neowere eluted and underwent mass spectrometry epitope derived from the ATR protein kinase was analysis. Coupled with the mutation data derived detected in the blood of a patient with melanoma from next‐generation sequencing, unique neoepit­ who experienced a clinical response during anti-opes were identified from several patients with CTLA‐4 treatment [26]. Because of the highly melanoma; however, the sensitivity and robustness complex nature of the endogenous immune of this technique is unknown since it was not com­ response to a patient’s given tumors, the antigens pared to other methods to identify neoepitopes.

that are critical for mediating tumor rejection

Inhibitors to the PD‐1 and CTLA‐4 checkpoint cannot be defined in patients treated with immune pathways have had remarkable success in a subset checkpoint inhibitors. This is especial y relevant in of patients with a variety of cancers such as mela­ the setting of metastatic melanoma, where it is well noma, renal cell cancer, and non‐small‐cell lung known that melanoma TILs contain reactivities to cancer (NSCLC). The effector cel s mediating shared melanoma‐associated antigens such as tumor regression in these patients are not known, MART‐1, GP100, and other CG antigens [64].

but several lines of correlative evidence suggest that Moreover, studies have found that both antiT cel s targeting neoantigens may be playing a role. CTLA‐4 and TIL therapy can broaden T cell First, immune checkpoint inhibitors appear to be responses against shared melanoma‐associated more effective in cancers that have a high average antigens [65, 66]. Thus, the foregoing studies pronumber of mutations such as NSCLC [21, 22], vide indirect correlative evidence that bladder cancer [20], melanoma [12, 23–26], and neoantigen‐reactive T cel s may be involved with hyper‐mutated cancers due to defects in DNA mis­ the clinical responses after checkpoint blockade, match repair machinery [13, 14, 16, 63]. The higher but they do not prove that T cel s targeting neoannumber of mutations in these cancers could result tigens are mediating tumor regression.

CHAPTER 3 Somatic Mutations and Immunotherapy 29

Perhaps more direct evidence that T cel s recog­ patients were then screened for neoepitope recognizing neoantigens are likely major contributors to nition using a high‐throughput HLA‐tetramer/

tumor regression after immunotherapy comes peptide exchange technique which revealed that from clinical trials of adoptive cell transfer therapy, five of the eight patients contained HLA‐A-which has been shown to mediate durable complete restricted neoepitope‐reactive T cel s in both TILs regressions in approximately 20%–25% of patients and peripheral blood prior to cell therapy. In with metastatic melanoma [6, 9]. One unique fea­ addition to neoantigen‐reactive CD8+ T cel s, ture of ACT is that the treatment product can be CD4+ T cel s that recognize neoantigens have been characterized, and thus clinical responses can more found in patients with melanoma that responded strongly be associated to the contents of the deliv­ to TIL therapy [11]. Although the neoantigen ered product. As mentioned briefly above, landscape of melanoma has been the most reported techniques that relied on screening of tumor cDNA of all cancer types, it is perhaps surprising then that libraries to identify neoantigen‐reactive T cel s the strongest evidence to date that neoantigen-found early evidence of neoantigen‐reactive TILs reactive T cel s can cause regression of human in patients who had dramatic tumor regressions cancer comes from two patients with metastatic after ACT. These findings were further strength­ epithelial gastrointestinal cancers treated with cell ened with studies that used high‐throughput transfer immunotherapy. In the first case study, a next‐generation sequencing techniques combined patient with metastatic bile duct cancer that with common immunological screening methods contained 26 nonsynonymous mutations experias described in Figure 3.1. The first study of human enced some tumor regression and stabilization of ACT immunotherapy to use whole‐exome disease for approximately one year after treatment sequencing (WES) to identify neoantigen‐reactive with 42 billion autologous TILs, which were retro­

T cel s was reported by Robbins et al. in 2013 [67]. spectively determined to contain approximately The infusion TILs from three patients with mela­ 25% CD4+ T helper 1 cel s that specifical y targeted noma who underwent dramatic tumor regressions a mutated ERBB2IP neoepitope expressed by the after therapy were tested against candidate neoepi­ tumors [57]. When the tumors progressed, the topes, which were determined by WES combined patient was treated with 126 billion TILs, approxiwith an HLA‐peptide binding algorithm mately 95% of which recognized the ERBB2IP

(Figure 3.1C). All three TIL products were found to neoepitope, and experienced dramatic tumor contain CD8+ T cel s that targeted neoepitopes regression that lasted 35 months. The neoantigen-that were expressed by their autologous cancer, reactive T cel s comprised approximately a third of although one of these TILs also had evidence of T all her T cel s circulating in the peripheral blood cel s that targeted a shared melanoma‐associated three months after cell transfer and were the top-antigen. In another patient with melanoma who ranked T cell clonotype persisting in the patient’s experienced a complete response after ACT, the use blood over two and a half years after treatment of WES combined with the TMG approach and (unpublished). This case report was the first to HLA‐peptide binding algorithms (Figure 3.1A, C) demonstrate that treatment with a highly enriched led to the identification of HLA‐I‐restricted T cel s population of neoantigen‐reactive T cel s could in the infusion product that reacted to 10 different mediate regression of human tumors.

neoantigens expressed by the patient’s tumor [68].

In the second case study, a patient with meta­

Approximately 25% of the total infusion product static colorectal cancer who harbored 61

was estimated to be neoantigen reactive, and after nonsynonymous mutations was found to have treatment, the majority of the neoantigen‐reactive CD8+ TILs that recognized the KRASG12D neoanti­

T cel s were detectable in the patient’s peripheral gen in the context of the HLA‐C*08:02 allele [70].

blood one year after cell transfer. In another study, KRASG12D is the most common hotspot driver WES combined with an HLA‐peptide binding mutation found in patients with various gastroinalgorithm was used to identify candidate neoepit­ testinal cancers, but to date it has been undruggable.

opes predicted to bind to the HLA‐A alleles from The patient was treated with 148 billion TILs, eight patients with melanoma [69]. TILs from these approximately 75% of which were reactive against

30 Immunotherapy in Translational Cancer Research KRASG12D, and experienced regression of all of the to target based on their likelihood of being driver seven metastatic lung nodules. However, at approx­ or trunk mutations, which are more likely to be imately nine months post cell transfer, one lung expressed by all cancer cel s. This is in contrast to lesion began to progress. This sole progressing the targeting of passenger or branch mutations, lesion was resected and underwent genomic anal­ which are not likely to be expressed by every canysis, which revealed evidence for the genetic loss cer cel . Given that in murine models, the adoptive of the copy of chromosome 6 encoding the transfer of highly differentiated effector T cel s is HLA‐C*08:02 restriction element. Loss of less effective at mediating tumor regression than HLA‐C*08:02 abrogated tumor recognition by the the transfer of younger less differentiated T cel s transferred HLA‐C*08:02‐restricted KRASG12D‐ [72], and that the majority of tumor‐reactive reactive T cel s and thus provided a mechanism of T cel s found in human TILs are differentiated immune evasion by the tumor. Nevertheless, these effector cel s, strategies to generate less differentitwo case reports provided direct evidence that the ated neoantigen‐reactive T cel s might improve administration of highly enriched populations of therapeutic efficacy. This could be achieved either CD4+ or CD8+ T cel s targeting a patient‐ through TCR‐gene engineering (Figure 3.2C), specific neoepitope can mediate clinical responses whereby the genes encoding the neoantigen-in patients with metastatic cancer.

reactive TCRs are identified and then cloned into

It is important to note, however, that although either a viral vector [31] or nonviral gene transfer the adoptive transfer of neoantigen‐reactive TILs transposon/transposase system [73]. Autologous, can mediate tumor regression as described above, less‐differentiated T cel s (e.g., naïve, stem cel most patients with gastrointestinal cancers thus far memory, or central memory) from the patient are have not experienced durable tumor regression then isolated and genetical y modified to express when treated with TILs containing T cel s that tar­ the neoantigen‐reactive TCR. Furthermore, neogeted a neoantigen expressed by the patient’s tumor antigen‐reactive T cel s could be grown in the (unpublished). The reasons for the relative lack of presence of compounds such as inhibitors to AKT

efficacy are unknown, but factors such as the fre­ [74, 75] or cytokines such as IL‐21 [76], that appear quency and number of neoantigen‐reactive T cel s to partial y restrain the differentiation program of infused, the number and type of neoantigens tar­ proliferating T cel s. Strategies from the stem cel geted (passenger versus driver mutation), the field also have been used to dedifferentiate mature differentiation state of the infused T cel s, and the T cel s to a state of induced pluripotency through expression of the targeted neoantigen in vivo could the introducing of the specific genes OCT‐3/4, impact therapeutic efficacy.

SOX2, c‐MYC, and KLF4 [77–79]; however, However, the finding that the majority of biological and technical hurdles still exist, such as patients with epithelial gastrointestinal cancers the redifferentiation of induced pluripotent cel s natural y harbor neoantigen‐reactive T cel s [71] back into conventional T cel s, and have to be opens up opportunity to investigate strategies to resolved before this strategy can be translated to potential y enhance cell transfer immunotherapy the clinic. Neoantigen‐reactive T cel s could also against neoantigens (Figure 3.2). To reliably infuse be genetical y modified to become more active and a high frequency of T cel s that target multiple less susceptible to in vivo tumor immunosupneoantigens, methods to purify neoantigen‐ pression through gene‐editing techniques such as reactive cel s in vitro could be used (e.g., with a Zinc Finger Nucleases, meganucleases, TALENS, clinical grade cell sorter) (Figure 3.2A), or T cel s and CRISPR. Specifical y, these technologies could be repeatedly stimulated in vitro with neoan­ could be used to delete (or insert) genes, such as tigen constructs to promote selective outgrowth of PD‐1 [80], that could impact in vivo antitumor the neoantigen‐reactive T cel s (Figure 3.2B). This T cell responses. Once infused, the in vivo would be especial y relevant in cases where the activity of neoantigen‐reactive T cel s could poteninitial precursor frequency of neoantigen‐reactive tial y be promoted by the administration of T cel s in tumor or blood is very low. Bioinformatic systemic immunomodulators such as immune approaches could be used to prioritize neoantigens checkpoint inhibitors, agonists to immune

CHAPTER 3 Somatic Mutations and Immunotherapy 31

A. Purification of neoantigen-reactive T cells using T-cell activation markers or MHC-multimers T cells from tumor

or blood

I

II

Co-culture

4-1BB

CD8

APCs expressing

Expand

neoantigens

Purify

Cell infusion

T cells from tumor

or blood

Incubate

Multimer

MHC-multimers loaded

with neoepitope

CD8

B. In vitro stimulation to enrich neoantigen-reactive T cells T cells from tumor

or blood

I

I

Expand

II

II

Cell infusion

Co-culture

Co-culture

1st stim.

2nd stim.

(repeat if

required)

APCs expressing

APCs expressing

neoantigens

neoantigens

C. TCR-gene therapy targeting neoantigens

Identify neoantigen-reactive T cells

(e.g., as in Fig. 3.1, Fig. 3.2A, B)

Gene engineer less

Clone TCR into

differentiated T cells to

Expand

expression vector

express neoantigen-

Cell infusion

reactive TCR

Isolate neoantigen-

reactive TCR genes

During cell culture, T cells can potentially be enhanced by:

Activity of the transferred T cells may be

1) Culturing in the presence of compounds that partially restrain enhanced by combining with:

T-cell differentiation (e.g., AKT inhibitor, IL-21).

1) Checkpoint inhibitors.

2) Gene modification (e.g., using gene editing technology to knock 2) Agonists to costimulatory molecules.

out PD-1 or other negative regulators of T-cell function).

3) Neoantigen vaccines.

3) Dedifferentiating into younger T cells using stem cell factors.

4) Oncolytic viruses.

Figure 3.2 Strategies to potentially enhance T cell transfer immunotherapy targeting neoantigens.

costimulatory molecules, neoantigen vaccines, antigens, for which central tolerance may have and/or oncolytic viruses.

deleted high‐avidity T cel s targeting these antigens.

Therapeutic cancer vaccines thus far have been There now exists a newfound enthusiasm for the largely ineffective in mediating regression of meta­ development of therapeutic cancer vaccines targetstatic human cancer [81]. However, the vast ing patient‐specific neoantigens because these majority of these vaccines targeted self tumor antigens are tumor‐specific, non‐self antigens, and





32 Immunotherapy in Translational Cancer Research thus high‐avidity T cel s may exist against these neoantigen‐reactive T cel s are likely mediating antigens. Also, technologies are now advanced some of the clinical responses in patients receiving enough to perform comprehensive and rapid immunotherapy, and the tumor regression sequencing of tumors to identify mutations, and observed after the transfer of highly enriched popproduction of personalized experimental reagents ulations of neoantigen‐reactive T cel s provided and clinical treatments can be generated relatively direct evidence for the therapeutic utility of targetquickly. Moreover, other immunomodulators with ing this class of antigens. However, although clinical activity such as immune checkpoint inhibi­ neoantigens may be the optimal antigens to target, tors now exist that may enhance neoantigen‐based tumors have a number of mechanisms to evade the vaccines. A dendritic cell (DC)–based neoantigen antitumor/neoantigen T cell response. In addition vaccine was recently reported [82] where tumors to an immunosuppressive tumor microenvironfrom three patients with melanoma underwent ment, loss of components of MHC has been next‐generation sequencing followed by an in silico documented in patient tumors after immunotheranalysis to select patient‐specific neoepitopes pre­ apy as described above and in other studies [70, dicted to bind with high affinity to the HLA‐A*02:01 89–91]. Correlative evidence also exists in humans allele that was expressed by all patients. Mature that some tumors progressing after immunother­

DCs were generated for each patient and pulsed apy do not express the neoantigens potential y with their autologous neoepitope peptides. targeted by T cel s [92, 93], and this form of immu­

Although the clinical impact of this DC vaccine noediting has been directly observed in mouse could not clearly be measured, the infusion of the tumor models [94]. Some tumors progressing after DC vaccine was accompanied by an increase in anti‐PD‐1 therapy have also been found to contain TCR‐clonotype diversity targeting the neoanti­ mutations in genes that make them resistant to gens. Therapeutic cancer vaccines based on RNA antiproliferative signals mediated by T cell–proencoding patient‐specific neoantigens or mutated duced IFN‐γ [89, 95]. Thus, future therapies aimed peptides are also being developed based on some at targeting mutated antigens may need to overpromising preclinical studies in mice [83–86]. come these and other barriers in order to bring These personalized neoepitope vaccines will likely about meaningful clinical responses to a larger be used in combination with other immunother­ number of patients with cancer.

apies such as immune checkpoint inhibitors and/or

adoptive cell therapies.

Mutated antigens appear to be the ideal immu­ References

notherapeutic target since they are truly

tumor‐specific, and so their targeting should be 1. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveil ance and immunoediting: the roles of immunity in safe. Moreover, all cancers contain mutations and

suppressing tumor development and shaping tumor

therefore neoantigens that could potential y be tarimmunogenicity. Advances in Immunology. 2006; getable. Indeed, the Surgery Branch, National

90:1–50.

Cancer Institute, has observed that the vast 2. Rosenberg SA. IL‐2: the first effective immunotherapy for majority of patients with metastatic melanoma or

human cancer. Journal of Immunology. 2014;192(12):

gastrointestinal cancers harbor natural y occurring

5451–8.

neoantigen‐reactive T cel s, and the characteriza­ 3. Besser MJ, Shapira‐Frommer R, Treves AJ, Zippel D, tion of over 150 neoantigens from these patients

Itzhaki O, Hershkovitz L, et al. Clinical responses in a

[49, 54–57, 67, 69–71, 87, 88] (and unpublished

phase II study using adoptive transfer of short‐term culdata) has revealed that every immunogenic neoantured tumor infiltration lymphocytes in metastatic melatigen is unique to the autologous patient, except for noma patients. Clinical Cancer Research. 2010;16(9):

2646–55.

a shared KRASG12D neoantigen that was targeted by 4. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry HLA‐C*08:02‐restricted CD8+ T cel s from two

RM, Yang JC, et al. CD8+ enriched “young” tumor infilpatients with metastatic colorectal cancer [70, 71].

trating lymphocytes can mediate regression of metastatic

As described in this chapter, accumulating

melanoma. Clinical Cancer Research. 2010;16(24):

correlative data from clinical trials suggests that

6122–31.

CHAPTER 3 Somatic Mutations and Immunotherapy 33

5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, 16. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare Topalian SL, Restifo NP, et al. Adoptive cell transfer

S, Lane K, et al. Immune activation and response to

therapy following non‐myeloablative but lymphodepletpembrolizumab in POLE‐mutant endometrial cancer.

ing chemotherapy for the treatment of patients with

Journal of Clinical Investigation. 2016;126(6):2334–40.

refractory metastatic melanoma. Journal of Clinical 17. Motzer RJ, Escudier B, McDermott DF, George S, Oncology. 2005;23(10):2346–57.

Hammers HJ, Srinivas S, et al. Nivolumab versus evero6. Goff SL, Dudley ME, Citrin DE, Somerville RP, limus in advanced renal‐cell carcinoma. New England

Wunderlich JR, Danforth DN, et al. Randomized,

Journal of Medicine. 2015;373(19):1803–13.

prospective evaluation comparing intensity of lym18. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel phodepletion before adoptive transfer of tumor‐infil­

TM, Harrison MR, et al. Nivolumab for Metastatic

trating lymphocytes for patients with metastatic

renal cell carcinoma: results of a randomized phase II

melanoma. Journal of Clinical Oncology.

trial. Journal of Clinical Oncology. 2015;33(13):

2016;34(20):2389–97.

1430–7.

7. Rosenberg SA, Dudley ME. Cancer regression in 19. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller patients with metastatic melanoma after the transfer of

NJ, Annamalai L, et al. PD‐1 blockade with pembroliautologous antitumor lymphocytes. Proceedings of the zumab in advanced Merkel‐cell carcinoma. New

National Academy of Sciences of the United States of

England Journal of Medicine. 2016;374(26):2542–52.

America. 2004;101(Suppl 2):14639–45.

20. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, 8. Rosenberg SA, Restifo NP. Adoptive cell transfer as peret al. MPDL3280A (anti‐PD‐L1) treatment leads to sonalized immunotherapy for human cancer. Science.

clinical activity in metastatic bladder cancer. Nature.

2015;348(6230):62–8.

2014;515(7528):558–62.

9. Rosenberg SA, Yang JC, Sherry RM, Kammula US, 21. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Hughes MS, Phan GQ, et al. Durable complete responses

Makarov V, Havel JJ, et al. Cancer immunology.

in heavily pretreated patients with metastatic melanoma

Mutational landscape determines sensitivity to PD‐1

using T‐cell transfer immunotherapy. Clinical Cancer

blockade in non‐small cell lung cancer. Science.

Research. 2011;17(13):4550–7.

2015;348(6230):124–8.

10. Stevanovic S, Draper LM, Langhan MM, Campbell TE, 22. Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy Kwong ML, Wunderlich JR, et al. Complete regression of

GK, Antonia SJ, et al. Activity and safety of nivolumab,

metastatic cervical cancer after treatment with human

an anti‐PD‐1 immune checkpoint inhibitor, for patients

papillomavirus‐targeted tumor‐infiltrating T cel s.

with advanced, refractory squamous non‐small‐cell lung

Journal of Clinical Oncology. 2015;33(14):1543–50.

cancer (CheckMate 063): a phase 2, single‐arm trial. The

11. Linnemann C, van Buuren MM, Bies L, Verdegaal EM,

Lancet Oncology. 2015;16(3):257–65.

Schotte R, Calis JJ, et al. High‐throughput epitope dis23. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, covery reveals frequent recognition of neo‐antigens by

Desrichard A, et al. Genetic basis for clinical response to

CD4+ T cel s in human melanoma. Nature Medicine.

CTLA‐4 blockade in melanoma. New England Journal

2015;21(1):81–5.

of Medicine. 2014;371(23):2189–99.

12. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu‐

24. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith

Lieskovan S, et al. Genomic and transcriptomic features

DC, McDermott DF, et al. Safety, activity, and immune

of response to anti‐PD‐1 therapy in metastatic melacorrelates of anti‐PD‐1 antibody in cancer. New England noma. Cel . 2016;165(1):35–44.

Journal of Medicine. 2012;366(26):2443–54.

13. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, 25. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Perry A, et al. Immunogenomics of hypermutated glio­

Zimmer L, et al. Genomic correlates of response to

blastoma: a patient with germline pole deficiency treated

CTLA‐4 blockade in metastatic melanoma. Science.

with checkpoint blockade immunotherapy. Cancer

2015;350(6257):207–11.

Discovery. 2016;6(11):1230–6.

26. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes

14. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H,

M, Heemskerk B, et al. Tumor exome analysis reveals

Eyring AD, et al. PD‐1 blockade in tumors with misneoantigen‐specific T‐cell reactivity in an ipilimumab-match‐repair deficiency. New England Journal of

responsive melanoma. Journal of Clinical Oncology.

Medicine. 2015;372(26):2509–20.

2013;31(32):e439–42.

15. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, 27. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell

T. Tumour antigens recognized by T lymphocytes: at the

immunoreactivity and sensitivity to immune checkpoint

core of cancer immunotherapy. Nature Reviews Cancer.

blockade. Science. 2016;351(6280):1463–9.

2014;14(2):135–46.

34 Immunotherapy in Translational Cancer Research 28. van der Bruggen P, Traversari C, Chomez P, Lurquin C, 40. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, De Plaen E, Van den Eynde B, et al. A gene encoding an

Berends‐van der Meer DM, Vloon AP, et al. Vaccination

antigen recognized by cytolytic T lymphocytes on a

against HPV‐16 oncoproteins for vulvar intraepithelial

human melanoma. Science. 1991;254(5038):1643–7.

neoplasia. New England Journal of Medicine.

29. Vigneron N, Stroobant V, Van den Eynde BJ, van der

2009;361(19):1838–47.

Bruggen P. Database of T cell‐defined human tumor 41. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch antigens: the 2013 update. Cancer Immunity. 2013;15:13.

LF, Kerpershoek G, van Persijn van Meerten EL, et al.

30. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan

HPV16 synthetic long peptide (HPV16‐SLP) vaccina­

RA, Feldman SA, et al. A pilot trial using lymphocytes

tion therapy of patients with advanced or recurrent

genetical y engineered with an NY‐ESO‐1‐reactive T‐

HPV16‐induced gynecological carcinoma, a phase II

cell receptor: long‐term follow‐up and correlates with

trial. Journal of Translational Medicine. 2013;11:88.

response. Clinical Cancer Research. 2015;21(5): 42. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora 1019–27.

JP, Wolfel T, et al. Immunogenic (tum‐) variants of

31. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry

mouse tumor P815: cloning of the gene of tum‐ antigen

RM, Dudley ME, et al. Tumor regression in patients with

P91A and identification of the tum– mutation.

metastatic synovial cell sarcoma and melanoma using

Proceedings of the National Academy of Sciences of the

genetical y engineered lymphocytes reactive with NY‐

United States of America. 1988;85(7):2274–8.

ESO‐1. Journal of Clinical Oncology. 2011;29(7): 43. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora 917–24.

JP, Janssens C, et al. Structure of the gene of tum‐ trans32. Kerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, plantation antigen P91A: the mutated exon encodes a

et al. MAGE‐A is more highly expressed than NY‐ESO‐1

peptide recognized with Ld by cytolytic T cel s. Cel .

in a systematic immunohistochemical analysis of 3668

1989;58(2):293–303.

cases. Journal of Immunotherapy. 2016;39(4):181–7.

44. Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen

33. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T,

E, Maryanski JL, et al. Structure of the gene of tum‐

Zielinski M, Kim MS, et al. Efficacy of the MAGE‐A3

transplantation antigen P198: a point mutation genercancer immunotherapeutic as adjuvant therapy in ates a new antigenic peptide. Journal of Experimental

patients with resected MAGE‐A3‐positive non‐small‐

Medicine. 1990;172(1):35–45.

cell lung cancer (MAGRIT): a randomised, double‐

45. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C,

blind, placebo‐controlled, phase 3 trial. The Lancet

Andrawiss M, et al. A mutated intron sequence codes for

Oncology. 2016;17(6):822–35.

an antigenic peptide recognized by cytolytic T lympho34. Morgan RA, Chinnasamy N, Abate‐Daga D, Gros A, cytes on a human melanoma. Proceedings of the

Robbins PF, Zheng Z, et al. Cancer regression and neu­

National Academy of Sciences of the United States of

rological toxicity following anti‐MAGE‐A3 TCR gene

America. 1995;92(17):7976–80.

therapy. Journal of Immunotherapy. 2013;36(2):133–51.

46. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C,

35. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang

Klehmann­Hieb E, et al. A p16INK4a­insensitive CDK4

JC, Hughes MS, et al. Gene therapy with human and

mutant targeted by cytolytic T lymphocytes in a human

mouse T‐cell receptors mediates cancer regression and

melanoma. Science. 1995;269(5228):1281–4.

targets normal tissues expressing cognate antigen. 47. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg Blood. 2009;114(3):535–46.

SA. Cloning genes encoding MHC class II­restricted

36. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan

antigens: mutated CDC27 as a tumor antigen. Science.

DA, Feldman SA, et al. T cel s targeting carcinoembry1999;284(5418):1351–4.

onic antigen can mediate regression of metastatic 48. Echchakir H, Mami‐Chouaib F, Vergnon I, Baurain JF, colorectal cancer but induce severe transient colitis.

Karanikas V, Chouaib S, et al. A point mutation in the

Molecular Therapy. 2010;19(3):620–6.

alpha‐actinin‐4 gene generates an antigenic peptide rec37. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, ognized by autologous cytolytic T lymphocytes on a

Forman D, et al. Global burden of cancers attributable to

human lung carcinoma. Cancer Res. 2001;61(10):

infections in 2008: a review and synthetic analysis. The

4078–83.

Lancet Oncology. 2012;13(6):607–15.

49. Huang J, El‐Gamil M, Dudley ME, Li YF, Rosenberg SA,

38. zur Hausen H. Viruses in human cancers. Science.

Robbins PF. T cel s associated with tumor regression rec1991;254(5035):1167–73.

ognize frameshifted products of the CDKN2A tumor

39. Schiller JT, Lowy DR. Understanding and learning from the suppressor gene locus and a mutated HLA class I gene

success of prophylactic human papillomavirus vaccines.

product. Journal of Immunology. 2004;172(10):

Nature Reviews Microbiology. 2012;10(10):681–92.

6057–64.

CHAPTER 3 Somatic Mutations and Immunotherapy 35

50. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J,

melanoma tissue by mass spectrometry. Nature

Gutierrez‐Roelens I, et al. High frequency of cytolytic T

Communications. 2016;7:13404.

lymphocytes directed against a tumor‐specific mutated 62. Kalaora S, Barnea E, Merhavi‐Shoham E, Qutob N, Teer antigen detectable with HLA tetramers in the blood of a

JK, Shimony N, et al. Use of HLA peptidomics and

lung carcinoma patient with long survival. Cancer

whole exome sequencing to identify human immuno­

Research. 2001;61(9):3718–24.

genic neo‐antigens. Oncotarget. 2016;7(5):5110–7.

51. Mandruzzato S, Brasseur F, Andry G, Boon T, van der 63. Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Bruggen P. A CASP‐8 mutation recognized by cytolytic

Schlessinger J, et al. Regression of chemotherapy‐resistant

T lymphocytes on a human head and neck carcinoma.

polymerase epsilon (POLE) ultra‐mutated and MSH6

Journal of Experimental Medicine. 1997;186(5):785–93.

hyper‐mutated endometrial tumors with nivolumab.

52. Robbins PF, El‐Gamil M, Li YF, Kawakami Y, Loftus D,

Clinical Cancer Research. 2016;22(23):5682–7.

Appel a E, et al. A mutated beta‐catenin gene encodes a 64. Rosenberg SA. A new era for cancer immunotherapy melanoma‐specific antigen recognized by tumor infilbased on the genes that encode cancer antigens.

trating lymphocytes. Journal of Experimental Medicine.

Immunity. 1999;10(3):281–7.

1996;183(3):1185–92.

65. Kvistborg P, Philips D, Kelderman S, Hageman L,

53. Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M,

Ottensmeier C, Joseph‐Pietras D, et al. Anti‐CTLA‐4

Hanagiri T, et al. A point mutation in the NFYC gene genertherapy broadens the melanoma‐reactive CD8+ T cell ates an antigenic peptide recognized by autologous cytolytic

response. Science Translational Medicine. 2014;6(254):

T lymphocytes on a human squamous cell lung carcinoma.

254ra128.

International Journal of Cancer. 2006;118(8):1992–7.

66. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue

54. Zhou J, Dudley ME, Rosenberg SA, Robbins PF.

CA, Toebes M, et al. TIL therapy broadens the tumor‐

Persistence of multiple tumor‐specific T‐cell clones is

reactive CD8(+) T cell compartment in melanoma

associated with complete tumor regression in a melapatients. Oncoimmunology. 2012;1(4):409–18.

noma patient receiving adoptive cell transfer therapy. 67. Robbins PF, Lu YC, El‐Gamil M, Li YF, Gross C, Gartner J Immunotherapy. 2005;28(1):53–62.

J, et al. Mining exomic sequencing data to identify

55. Lu YC, Yao X, Li YF, El‐Gamil M, Dudley ME, Yang JC,

mutated antigens recognized by adoptively transferred

et al. Mutated PPP1R3B is recognized by T cel s used to

tumor‐reactive T cel s. Nature Medicine. 2013;19(6):

treat a melanoma patient who experienced a durable

747–52.

complete tumor regression. Journal of Immunology. 68. Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst 2013;190(12):6034–42.

MR, Gartner JJ, et al. Durable complete response from

56. Lu YC, Yao X, Crystal JS, Li YF, El‐Gamil M, Gross C, et al.

metastatic melanoma after transfer of autologous T cel s

Efficient identification of mutated cancer antigens recogrecognizing 10 mutated tumor antigens. Cancer nized by T cel s associated with durable tumor regressions.

Immunology Research. 2016;4(8):669–78.

Clinical Cancer Research. 2014;20(13):3401–10.

69. Cohen CJ, Gartner JJ, Horovitz‐Fried M, Shamalov K,

57. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley

Trebska‐McGowan K, Bliskovsky VV, et al. Isolation of

ME, et al. Cancer immunotherapy based on mutation‐

neoantigen‐specific T cel s from tumor and peripheral

specific CD4+ T cel s in a patient with epithelial cancer.

lymphocytes. Journal of Clinical Investigation.

Science. 2014;344(6184):641–5.

2015;125(10):3981–91.

58. Andreatta M, Nielsen M. Gapped sequence alignment 70. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, using artificial neural networks: application to the MHC

et al. T‐cell transfer therapy targeting mutant KRAS in

class I system. Bioinformatics. 2016;32(4):511–7.

cancer. New England Journal of Medicine. 2016;375(23):

59. Nielsen M, Lundegaard C, Worning P, Lauemoller SL,

2255–62.

Lamberth K, Buus S, et al. Reliable prediction of T‐cell 71. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, epitopes using neural networks with novel sequence rep­

Robbins PF, et al. Immunogenicity of somatic mutations

resentations. Protein Science. 2003;12(5):1007–17.

in human gastrointestinal cancers. Science. 2015;350

60. Rodenko B, Toebes M, Hadrup SR, van Esch WJ,

(6266):1387–90.

Molenaar AM, Schumacher TN, et al. Generation of 72. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stempeptide‐MHC class I complexes through UV‐mediness: building the ultimate antitumour T cel . Nature ated ligand exchange. Nature Protocols. 2006;1(3):

Reviews Cancer. 2012;12(10):671–84.

1120–32.

73. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R,

61. Bassani‐Sternberg M, Braunlein E, Klar R, Engleitner T,

Olivares S, et al. Phase I trials using Sleeping Beauty to

Sinitcyn P, Audehm S, et al. Direct identification of clingenerate CD19‐specific CAR T cel s. Journal of Clinical ical y relevant neoepitopes presented on native human

Investigation. 2016;126(9):3363–76.

36 Immunotherapy in Translational Cancer Research 74. Crompton JG, Sukumar M, Roychoudhuri R, Clever D,

topes drive therapeutic immune responses to cancer.

Gros A, Eil RL, et al. Akt inhibition enhances expansion

Nature. 2015;520(7549):692–6.

of potent tumor‐specific lymphocytes with memory cell 86. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, characteristics. Cancer Research. 2015;75(2):296–305.

Tanguay J, Bumbaca S, et al. Predicting immunogenic

75. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh

tumour mutations by combining mass spectrometry and

CM, Tamas P, et al. Protein kinase B controls transcriptional exome sequencing. Nature. 2014;515(7528):572–6.

programs that direct cytotoxic T cell fate but is dispensable 87. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, for T cell metabolism. Immunity. 2011;34(2):224–36.

Ilyas S, et al. Prospective identification of neoantigen‐

76. Li Y, Bleakley M, Yee C. IL‐21 influences the frequency, specific lymphocytes in the peripheral blood of melaphenotype, and affinity of the antigen‐specific CD8 T

noma patients. Nature Medicine. 2016.

cell response. Journal of Immunology. 2005;175(4): 88. Parkhurst MR, Gros A, Pasetto A, Prickett TD, Crystal JS, 2261–9.

Robbins PF, et al. Isolation of T cell receptors specifical y 77. Loh YH, Hartung O, Li H, Guo C, Sahalie JM, Manos

reactive with mutated tumor associated antigens from

PD, et al. Reprogramming of T cel s from human

tumor infiltrating lymphocytes based on CD137 expresperipheral blood. Cell Stem Cel . 2010;7(1):15–9.

sion. Clinical Cancer Research. 2016;

78. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D,

doi:10.1158/1078‐0432.CCR‐16‐2680.

et al. Generation of induced pluripotent stem cel s from 89. Zaretsky JM, Garcia‐Diaz A, Shin DS, Escuin‐Ordinas human terminal y differentiated circulating T cel s. Cell

H, Hugo W, Hu‐Lieskovan S, et al. Mutations associated

stem cel . 2010;7(1):11–4.

with acquired resistance to PD‐1 blockade in melanoma.

79. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K,

New England Journal of Medicine. 2016;375(9):819–29.

Fujii S, et al. Regeneration of human tumor antigen‐

90. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J,

specific T cel s from iPSCs derived from mature CD8(+)

Yannelli JR, Rosenberg SA. Loss of functional beta 2‐

T cel s. Cell Stem Cel . 2013;12(1):31–6.

microglobulin in metastatic melanomas from five

80. Beane JD, Lee G, Zheng Z, Mendel M, Abate‐Daga D,

patients receiving immunotherapy. Journal of the

Bharathan M, et al. Clinical scale zinc finger nuclease‐

National Cancer Institute. 1996;88(2):100–8.

mediated gene editing of PD‐1 in tumor infiltrating lym91. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, phocytes for the treatment of metastatic melanoma.

van Hall T. The urgent need to recover MHC class I in

Molecular Therapy. 2015;23(8):1380–90.

cancers for effective immunotherapy. Current Opinion

81. Rosenberg SA, Yang JC, Restifo NP. Cancer immunoin Immunology. 2016;39:44–51.

therapy: moving beyond current vaccines. Nature 92. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, Medicine. 2004;10(9):909–15.

van Buuren MM, Andersen RS, et al. Neoantigen

82.

Carreno BM, Magrini V, Becker‐Hapak M,

landscape dynamics during human melanoma‐T cell

Kaabinejadian S, Hundal J, Petti AA, et al. Cancer

interactions. Nature. 2016;536(7614):91–5.

immunotherapy. A dendritic cell vaccine increases the 93. Anagnostou V, Smith KN, Forde PM, Niknafs N, breadth and diversity of melanoma neoantigen‐specific

Bhattacharya R, White J, et al. Evolution of neoantigen

T cel s. Science. 2015;348(6236):803–8.

landscape during immune checkpoint blockade in non–

83. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer small cell lung cancer. Cancer Discovery. 2016;7(3):264–76.

N, de Graaf J, et al. Exploiting the mutanome for tumor vac94. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, cination. Cancer Research. 2012;72(5):1081–91.

Uppaluri R, Magrini VJ, et al. Cancer exome analysis

84. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP,

reveals a T‐cell‐dependent mechanism of cancer immu­

Noguchi T, et al. Checkpoint blockade cancer immunonoediting. Nature. 2012;482(7385):400–4.

therapy targets tumour‐specific mutant antigens. 95. Shin DS, Zaretsky JM, Escuin‐Ordinas H, Garcia‐Diaz Nature. 2014;515(7528):577–81.

A, Hu‐Lieskovan S, Kalbasi A, et al. Primary resistance

85. Kreiter S, Vormehr M, van de Roemer N, Diken M,

to PD‐1 blockade mediated by JAK1/2 mutations.

Lower M, Diekmann J, et al. Mutant MHC class II epi­

Cancer Discovery. 2016;7(2):188–201.





CHAPTER 4

4 Checkpoint Blockade

Tracy A. Proverbs‐Singh1, Jedd Wolchok2, and

Alexandra Snyder3

1 John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY, USA, Swim Across America–Ludwig Col aborative Research Laboratory, Immunology Program, Ludwig Center for Cancer Immunotherapy 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Preclinical mechanism

immuno‐oncology has evolved with an increased

understanding of immune activation and

Introduction

regula tion.

The immune system is powerful and highly regu-

Interactions of T lymphocytes contribute to the

lated in its protection of the body (self) against a ability to recognize and even thwart tumor growth wide range of foreign pathogens (non‐self). T lym- [5–8]. Both the innate and the adaptive immune phocytes are principle players in mediating this system are involved in protecting the body against process [1]. Tight control is necessary to avoid an tumor development and growth through a process unrestrained attack on the host. Immune tolerance, known as immune surveil ance [9–11]. Tumors the process to avoid self‐recognition, consists of have developed methods to evade immune surveil-central tolerance—thymic selection and elimination lance by exploiting the very mechanisms that of self‐recognizing T cel s early in development— modulate immune response to self‐antigen.

and peripheral tolerance—a complex network of Antibodies targeting two of the coinhibitor signals, stimulatory and inhibitory signals controlling the cytotoxic T lymphocyte‐associated protein 4

action of T lymphocytes [1, 2]. These signals or (CTLA‐4) and programmed cell death receptor‐1

“checkpoints” help control the immune system’s (PD‐1), have demonstrated antitumor activity in response to self.

some cancers and are the most advanced in

For over a century, the immune system has development. This chapter focuses on the preclin-been implicated in the recognition and control of ical development of these agents and the most tumors (altered self). In the 1890s, William promising clinical experience to date.

Coley appreciated that tumors could regress in

the presence of Streptococcus pyogenes infection.

This observation led to the development of T‐cell activation

“Coley’s toxins,” which were made from bacteria T cell receptor (TCR) activation alone is insuffi-or bacterial products and were injected into cient for T cell clonal expansion and differentiation; hundreds of bone sarcomas with clinical benefit a second signal is needed. In the late 1980s, the in some patients [3, 4]. Since then, the field of discovery of a costimulatory receptor, CD28, with Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

37





38 Immunotherapy in Translational Cancer Research its corresponding ligands, CD80 and CD86 (B7.1 of T cell activation [33]. PD‐1, a member of the or B7.2), confirmed the need for a two‐signal pro- immunoglobulin superfamily, is expressed in cess [12, 13]. In the absence of the CD28:B7 inter- tumor‐infiltrating lymphocytes (TILs) including T

action, the T cell response is impaired and results cel s, B cel s, and NK cel s. PD‐L1 is expressed on in an unresponsive state known as clonal anergy the surface of numerous solid tumors [12, 34–37]

[14, 15]. Furthermore, both costimulatory and and hematologic malignancies [38–42] and corre-coinhibitory signaling are needed to coordinate the lates with outcome in multiple tumors [35, 43, 44].

optimal antigen‐specific immune response [16].

PD‐L1 is also expressed on tumor‐infiltrating

immune cel s [45] (Figure 4.1, adapted from

CTLA‐4

Postow et al. [46]).

In 1987, CTLA‐4 was identified as a member of the

The interaction of PD‐1 and PD‐L1/2 directly

CD28:B7 immunoglobulin superfamily, a surface inhibits tumor apoptosis, downregulating glycoprotein bound to the same ligands present on peripheral T cell effector function with promotion activated cytotoxic T cel s [15, 17–19]. Normal y of T regs [34, 47], thus blocking T cell activation expressed at low levels on naïve effector T cel s and and proliferation. The PD‐1:PD‐L1 interaction is regulatory T cel s (Tregs), CTLA‐4 is upregulated to also thought to maintain peripheral tolerance [48].

the cell surface upon activation of the TCR [20, 21]. The use of inhibitory antibodies to PD‐L1 restores Initial y thought to be another costimulatory signal, T cell responses including proliferation, cytokine further study revealed its inhibitory role [22–24]. secretion, and killing of viral y infected cel s [49, Following TCR engagement, CD28 ligation pro- 50]. The PD‐1 pathway appears to protect the host vides the necessary costimulatory signal required from immune‐mediated tissue destruction in for T cell activation [24]. CTLA‐4, with a higher setting of chronic antigen stimulation [28]. PD‐1/

affinity for CD80/CD86 (B7‐1 and B7‐2) than PD‐L1 is upregulated when proinflammatory cyto-CD28, directly competes for binding to CD28 and kines IL‐12 and IFN gamma are present [51, 52].

ultimately inhibits T cell activation [25]. CTLA‐4 PD‐1‐deficient mice demonstrated a delayed‐onset effectively acts to release the physiologic “brakes” organ‐specific autoimmune infiltration [53–55].

on the immune system, thus promoting enhanced Additional y, blockade of the PD‐1 pathway in effector function [26–28]. CTLA‐4–deficient mice murine models demonstrates antitumor activity suffer a rapid catastrophic lymphoproliferative state and therapeutic potential [56]. Antibodies directed with lymphocyte infiltration throughout all organs against PD‐1 and PD‐L1 are in development.

[29]. Mice administered anti‐CTLA‐4 monoclonal Nivolumab (Opdivo, BMS‐936558, or MDX1106) antibody experienced the rejection of engrafted and pembrolizumab (Keytruda, MK‐3475), both syngeneic colon and fibrosarcoma tumors [30]. The PD‐1 inhibitors, and avelumab (MSB0010718C) first clinical antibody developed targeting CTLA‐4 and atezolizumab (MPDL3280A), both PD‐L1

was ipilimumab (Yervoy); this became the first inhibitors, have shown antitumor effects in several immune checkpoint inhibitor approved by the solid and hematologic malignancies (discussed in Food and Drug Administration (FDA) for patients further detail, below).

with metastatic melanoma [31]. Tremelimumab

(CP‐675,206), another anti‐CTLA‐4 antibody, did Clinical activity of CTLA‐4, PD‐1, not demonstrate a survival advantage over chemo- and PD‐L1‐blocking agents therapy in patients with advanced melanoma and

has yet to receive approval; however, access to ipili- A summary of the clinical activity of the agents mumab among patients randomized to not receive furthest in development is il ustrated in Table 4.1.

tremelimumab and/or inadequate dosing schedule An increasing number of clinical trials are in may have contributed to these results [32].

development to understand the antitumor activity of

these agents across different tumor subtypes.

PD‐1 and PD1 ligand 1 and 2

Notably, in addition to the Response Evaluation

PD‐1 (CD279) and corresponding ligands PD‐L1 Criteria in Solid Tumors (RECIST) typical y used in (B7‐H1) and PD‐L2 (B7‐H2) are transmembrane trials to study solid tumors, because of the distinct proteins that serve a nonredundant role in regulation behavior that immunotherapy‐treated tumors can





CHAPTER 4 Checkpoint Blockade 39

Antigen

Antigen

presenting

presenting

cell

cell

Anti-CTLA-4

therapy

CD80/86

CD80/86

TCR

CTLA-4

TCR

CD28

Anergic

Activated

T-cell

T-cell

CD28

CTLA-4

Tumor

Tumor

Anti-PD-(L)1

6

therapy

PD-L1

CD80/8

TCR

PD-1

TCR

CD28

Exhausted

Effector

T-cell

T-cell

CD28

PD-1

Figure 4.1 Graphic demonstrating where in the immune

costimulatory interaction with B7 ligand. Regulation of T

response neoantigens resulting from tumor mutations are

cell activation involves multiple coinhibitory and

thought to play a role (orange hexagon = putative tumor

costimulatory mechanisms, including upregulation of

neoantigen; black hexagon = costimulatory signal). Two

cytotoxic T lymphocyte associated protein–4 (CTLA‐4),

signals are required for T cell activation: (1) antigen (Ag)

which competes for B7 ligand binding and inhibits T cell

presented to T cells via major histocompatibility complex

activation, and programmed cell death–1 (PD‐1)

interaction with T cell receptor (TCR) and (2) CD28

interaction with ligand PD‐L1/2.

exhibit, recent immunotherapy studies now incor- survival in two Phase III trials, leading to its porate radiographic assessment using the immune‐ approval. In the first, 676 previously treated related response criteria (irRC), initial y reported by patients were randomized to one of three arms: Wolchok and colleagues [57]. These criteria added ipilimumab with the glycoprotein 100 (gp100)

“nonconventional” responses, including response vaccine, ipilimumab alone, or gp100 alone. Overal in the presence of new lesions, delayed response survival (OS) was increased to 10 months in the (growth of existing lesions followed by tumor shrink- ipilimumab plus gp100 arm, 10.1 months in age), and prolonged stable disease. Prolonged stable the ipilimumab alone arm, and 6.4 months in the disease was particularly important in il ustrating gp100 alone arm [58]. In the second study, 502

how ipilimumab demonstrated a modest overal patients with metastatic melanoma were radom-response rate as compared to overall survival [58].

ized to ipilimumab with dacarbazine or dacarba-

zine alone; again, there was an OS advantage for

Melanoma

those patients who received ipilimumab (11.2 months,

The first FDA approvals of checkpoint blockade 95% CI 9.4–13.6, compared with 9.1 months, 95%

agents occurred in melanoma, a hitherto rapidly CI, 7.8–10.5) [59].

progressing deadly disease in the metastatic

Two phase III trials have shown the efficacy of

setting. Ipilimumab, a monoclonal antibody the anti‐PD‐1 agent pembrolizumab in metastatic targeting CTLA‐4, exhibited increased overal melanoma with or without prior exposure to

Table 4.1 Summary of checkpoint blockade agents most advanced in clinical development as of early 2016.

Study Drug

Disease

n

Phase

Results

FDA Designation

Reference

Anti‐CTLA‐4

Ipilimumab

Unresectable/ stage IV

676

III

Ipi + gp100: 6% ORR; 14% SD; OS 10.0 vs 6.0 months (gp100 arm).

Approved 3/2011

58

melanoma

502

III

Ipi + dacarbazine vs dacarbazine alone. ORR 15.2% vs 10.3% ( p = .09), 59

median duration of response 19.3 months vs 8.3 ( p = .03). Median OS

11.2 vs 9.1 months.

Stage III melanoma

951

III

Ipi vs placebo. RFS 26.1 vs 17.1 months. 3 yr RFS 46.5% vs 34.8%. OS not Approved 10/2015

135

(adjuvant)

reached.

Tremelimumab

Advanced melanoma

655

III

Treme vs chemo. 10.7% ORR vs 9.8% (ns); OS 12.6 vs 10.7 months (ns).

Not approved

32

Malignant mesothelioma

29

II

No CR, 2 (7%) PR. SD in 9 (31%). Median PFS 6.2 months. Median OS

Orphan drug #

81

10.2 months.

Anti‐PD‐1

Nivolumab

Melanoma, advanced

418

III

Nivolumab + dacarbazine vs dacarbazine alone. ORR 40% vs 13.9%.

Approved 9/2014

132

untreated

Median PFS 5.1 vs 2.2 months. OS at 1 year 72.9% vs 42.1%.

Approved with

945

III

Nivo + ipi vs ipi vs nivo. Median PFS 11.5 months vs 2.9 vs 6.9.

ipilimumab 9/2015 ‡

61

142

I

Nivo + ipi vs ipi. ORR 61% (16 CR) vs 11% (0 CR). Median PFS not 124

reached (nivo + ipi) vs 4.4 months.

Melanoma, advanced

631

III

Nivo vs ICC. ORR 31.7% (4 CR, 34 PR) vs 10.6% (0 CR, 5 PR). 6 month 134

progressed after

PFS 48% vs 34%.

ipilimumab

Advanced NSCLC

582

III

Nivo vs docetaxel. ORR 19% vs 12% p = .02. OS 12.2 months vs Approved 10/2015

136

nonsquamous platinum

9.4 months. PD‐L1 expression predictive of response for ORR, PFS, and Approved with

refractory

OS.

companion PD‐L1

IHC 22C3 pharmDx

test

Advanced NSCLC squamous

272

III

Nivo vs docetaxel. ORR 20% vs 9% ( p = .008). Median PFS 3.5 vs 2.8. OS

Approved 3/2015

73

platinum refractory

9.2 vs 6 months.

Hodgkin lymphoma

23

I

ORR 87% (4 CR 16 PR), PFS at 24 weeks is 86%. Median OS not reached.

Approved 5/2017 *

94

Renal cell carcinoma

821

III

Nivo vs everolimus. ORR 25% vs 5%. Median OS 25 months vs

Approved 11/2015

79

19.6 months ( p < .001).

Table 4.1 Summary of checkpoint blockade agents most advanced in clinical development as of early 2016.

Study Drug

Disease

n

Phase

Results

FDA Designation

Reference

Anti‐CTLA‐4

Ipilimumab

Unresectable/ stage IV

676

III

Ipi + gp100: 6% ORR; 14% SD; OS 10.0 vs 6.0 months (gp100 arm).

Approved 3/2011

58

melanoma

502

III

Ipi + dacarbazine vs dacarbazine alone. ORR 15.2% vs 10.3% ( p = .09), 59

median duration of response 19.3 months vs 8.3 ( p = .03). Median OS

11.2 vs 9.1 months.

Stage III melanoma

951

III

Ipi vs placebo. RFS 26.1 vs 17.1 months. 3 yr RFS 46.5% vs 34.8%. OS not Approved 10/2015

135

Pembrolizumab

Melanoma

834

III

Pembro q 2 weeks vs pembro q 3 weeks vs ipi. ORR 33.7% ( p < .001 vs Approved 9/2014 ‡ ,

[137]

(adjuvant)

reached.

(MK‐3475)

ipi) vs 32.9% ( p < 0.001 vs ipi) vs 11.9%. Median PFS 5.5 vs 4.4 vs 12/2015

Tremelimumab

Advanced melanoma

655

III

Treme vs chemo. 10.7% ORR vs 9.8% (ns); OS 12.6 vs 10.7 months (ns).

Not approved

32

2.8 months. Median OS.

Malignant mesothelioma

29

II

No CR, 2 (7%) PR. SD in 9 (31%). Median PFS 6.2 months. Median OS

Orphan drug #

81

Advanced melanoma ipi

540

II

Pembro 2 mg/kg vs pembro 10 mg/kg vs ICC. ORR 21% vs 25% vs 8%.

[60]

10.2 months.

refractory

Median PFS 2.9 vs 2.9 vs 2.7 months.

Anti‐PD‐1

NSCLC

495

II

Pembro 2 mg/kg q 3 weeks vs 10 mgkg q 3 weeks vs 10 mg/kg q 2

Approved 10/2015 ‡

[74]

Nivolumab

Melanoma, advanced

418

III

Nivolumab + dacarbazine vs dacarbazine alone. ORR 40% vs 13.9%.

Approved 9/2014

132

weeks. No major differences between doses/schedule. All patients ORR

Approved with

untreated

Median PFS 5.1 vs 2.2 months. OS at 1 year 72.9% vs 42.1%.

Approved with

19.4%. Median PFS 3.7 months, median OS 12 months.

companion PD‐L1

945

III

Nivo + ipi vs ipi vs nivo. Median PFS 11.5 months vs 2.9 vs 6.9.

ipilimumab 9/2015

IHC 22C3 pharmDx

‡

61

142

I

Nivo + ipi vs ipi. ORR 61% (16 CR) vs 11% (0 CR). Median PFS not 124

test

reached (nivo + ipi) vs 4.4 months.

Anti‐PD‐L1

Melanoma, advanced

631

III

Nivo vs ICC. ORR 31.7% (4 CR, 34 PR) vs 10.6% (0 CR, 5 PR). 6 month 134

Avelumab

NSCLC

184

I

ORR 13.6% (1 CR, 24 PR), DCR 50.5%. Median PFS 11.6 weeks. OS

Breakthrough status *

[75]

progressed after

PFS 48% vs 34%.

(MSB00010718C)

8.4 months.

ipilimumab

Atezolizumab

Urothelial carcinoma

316

II

ORR 15% in all comers, 18% in PDL1≥1% and ORR 27% in PD‐L1 ≥5%.

Approved 5/2016 *

[85]

Advanced NSCLC

582

III

Nivo vs docetaxel. ORR 19% vs 12% p = .02. OS 12.2 months vs Approved 10/2015

136

(MPDL3280A)

12 CR and 35 PR. Median duration of response not reached by 24

nonsquamous platinum

9.4 months. PD‐L1 expression predictive of response for ORR, PFS, and Approved with

weeks.

refractory

OS.

companion PD‐L1

IHC 22C3 pharmDx

# The Orphan Drug Act grants special status to a drug to treat a rare disease upon request of a sponsor and provides developmental incentives.

test

‡ Accelerated approval: Allows drugs for serious conditions that fulfill an unmet medical need to be approved based on a surrogate endpoint.

Advanced NSCLC squamous

272

III

Nivo vs docetaxel. ORR 20% vs 9% ( p = .008). Median PFS 3.5 vs 2.8. OS

Approved 3/2015

73

* Breakthrough therapy: A process designed to expedite the development and review of drugs that may demonstrate substantial improvement over available therapy.

platinum refractory

9.2 vs 6 months.

Note: ORR = objective response rate; SD = stable disease OS = overall survival; RFS = recurrence‐free survival; CR = complete response; PR = partial response; PFS = progression‐free Hodgkin lymphoma

23

I

ORR 87% (4 CR 16 PR), PFS at 24 weeks is 86%. Median OS not reached.

Approved 5/2017 *

94

survival; ICC = investigator’s choice chemotherapy; DCR = disease control rate; ipi = ipilimumab; nivo = nivolumab; pembro = pembrolizumab.

Renal cell carcinoma

821

III

Nivo vs everolimus. ORR 25% vs 5%. Median OS 25 months vs

Approved 11/2015

79

19.6 months ( p < .001).





42 Immunotherapy in Translational Cancer Research anti‐CTLA‐4. In the KEYNOTE‐006 study, 834 of BRAF‐targeted agents and immunomodulatory patients were randomized to pembrolizumab agents in patients with BRAF‐mutant melanomas 10 mg/kg every 2 or 3 weeks up to 2 years, or ipili- remains to be established.

mumab 3 mg/kg every 3 weeks for 4 doses (the

FDA‐approved regimen). OS was improved in both Non‐small‐cell lung cancer (NSCLC) pembrolizumab arms, at 74.1 and 68.4% (every 2 In the United States, lung cancer is the leading and every 3 week schedules, respectively) versus cause of cancer‐related death [62]. Although lung 58.2% in the ipilimumab arm. The objective cancer incidence rates are higher in patients with response rates (ORRs) were also higher (33.7 and an immunosuppressed state, such as HIV/AIDS

32.9%, every 2 and every 3 week schedules, respec- and postsolid organ transplant [63–65], immune tively) in the pembrolizumab arms compared to manipulation with cytokine therapy [66, 67] or ipilimumab (11.9%), and grade 3–5 adverse events vaccine therapy [68] failed to show benefit.

(AEs) were less frequent (13% and 10% versus 20% Ipilimumab with or without chemotherapy dem-for ipilimumab).

onstrated minimal benefit [69, 70]. However,

In the KEYNOTE‐002 study, 540 patients who renewed interest in immune therapy for lung can-had progressed on or after ipilimumab received cer arose with the success of early phase trials for pembrolizumab (2 or 10 mg/kg every 3 weeks) or the safety and early clinical efficacy of nivolumab chemotherapy. Progression‐free survival (PFS) was in the treatment of squamous and nonsquamous improved with pembrolizumab treatment; the NSCLC [71, 72].

ORR was 21% and 26% in the two pembrolizumab‐

Two phase III studies tested the efficacy of

containing groups (2 and 10 mg/kg, respectively), nivolumab 3 mg/kg every 2 weeks compared to versus 4% for chemotherapy. Pembrolizumab was docetaxel 75 mg/m2 IV every 3 weeks, in NSCLC

well tolerated, with grade 3–4 AE in 11% and 14% patients with squamous cell histology (CheckMate of the pembrolizumab‐treated arms, as compared 017) and nonsquamous type (CheckMate 057).

with 26% in the chemotherapy arm [60].

Biomarker evaluation was tested concurrently as

The combination of ipilimumab with nivolumab PD‐L1 expression was retrospectively investigated (PD‐1 inhibitor) exhibits greater efficacy than using an immunohistochemistry (IHC) antibody either agent alone, as exhibited in a Phase III study, assay (Dako, clone 28‐8, Epitomics) with pre-CheckMate 067 [61]. This combination also defined cutoffs of 1%, 5%, and 10% in both trials.

received accelerated FDA approval in 2015. In this In the CheckMate 017, 272 patients with squamous study, 945 patients who had not received prior NSCLC who previously progressed on a platinum treatment were randomized to nivolumab (1 mg/kg doublet were treated. ORR was 20% in the group every 3 weeks) with ipilimumab (3 mg/kg every 3 treated with nivolumab compared to 9% in the weeks) for 4 doses followed by nivolumab (3 mg/kg docetaxel group ( p = 0.008), and OS was improved every 2 weeks) or ipilimumab (3 mg/kg every 3 with nivolumab (9.2 months vs. 6 months, HR 0.59, weeks for four doses); nivolumab was continued in p < .001). There were fewer grade 3 and 4 AEs after the nivolumab‐containing arms. The PFS for the treatment with nivolumab (7%) compared to combination, nivolumab alone, or ipilimumab docetaxel (55%). In this trial, 63 (47%) of patients alone was 11.5, 6.9, and 2.9 months, respectively. treated with nivolumab had ≥1% PD‐L1 expres-ORRs were 58%, 44%, and 19%, respectively. As sion. Expression at any of the predefined cutoff expected, toxicities were greater in the combination values was not prognostic or predictive of response arm. Grade 3–4 AE for the combination, nivolumab, to nivolumab [73].

or ipilimumab were 55%, 16%, and 27%, respec-

In patients with nonsquamous NSCLC

tively, and led to treatment discontinuation in (CheckMate 057) similar results were seen. 582

36.4%, 7.7%, and 14.8% of patients.

patients were enrolled, with 287 treated with

Due to the results of these studies, checkpoint nivolumab and 268 with docetaxel. The ORR was blockade therapy is now used in the first‐line 19% in the nivolumab group compared to 12% in setting in patients with metastatic melanoma the chemotherapy group ( p = .002). The OS favored without a BRAF mutation. The optimal sequencing nivolumab (12.2 months vs 9.4 months, HR 0.73,





CHAPTER 4 Checkpoint Blockade 43

p = .002). Grade 3 and 4 toxicity was less in the of patients. The ORR was not significantly different nivolumab group (10% vs 54%). Seventy‐eight per- in PD‐L1 positive patients (ORR 15.6% vs 10% (not cent of tumors expressed PD‐L1 (≥1%); there was a significant) and median OS 8.9 months vs strong association with clinical response for 4.6

months (not significant)). In this trial,

patients treated with nivolumab (ORR for PDL‐1 ≥ treatment‐related AEs occurred in 77.2%

1% vs <1% was 31% vs 9%, p = .002). The association of patients, with 2 treatment‐related deaths between PD‐L1 expression and OS was not (acute respiratory failure and radiation pneumo-significant at ≥1% but is significant at ≥5% nitis) [75].

( p < .001) and ≥10% ( p < .001) [58].

The above results have led to the FDA approval

Further trials studying anti‐PD‐1 agent pembro- of the nivolumab for the treatment of squamous lizumab and anti‐PD‐L1 agent avelumab were and nonsquamous NSCLC. Pembrolizumab is recently presented. In CheckPoint‐001, 495 patients approved for use in PD‐L1 positive NSCLC with a with treatment‐naïve ( n = 101) and prior treated companion diagnostic, the PD‐L1 IHC 22C3

( n = 394) NSCLC were treated with pembroli- pharmDx test, the first test designed to detect PD-zumab (2 mg/kg or 10 mg/kg every 3 weeks or L1 expression in non‐small‐cell lung tumors.

10 mg/kg every 2 weeks). In this single‐agent study, Avelumab has received breakthrough status.

responses by dose level were similar, and ORR

reported for all patients was 19.4%. Treatment Renal cell carcinoma responses were slightly higher in previously Cytokine therapy including interleukin‐2 (IL‐2) untreated patients (ORR 24.8%) and in smokers and interferon alpha (IFN‐α) were the mainstay of (ORR 22.5%) when compared to nonsmokers therapy in the 1990s for a selected group of other-

(10.8%). Median PFS was 3.7 months (95% CI of wise healthy metastatic renal cell carcinoma 2.9 to 4.1) in all groups, with median OS of 12 (mRCC) patients, prior to the use of targeted months (95% CI 9.3 to 14.7) for all patients. In pre- therapies with mammalian target of rapamycin viously untreated patients the median OS was 16.2 (mTOR) inhibitors and vascular endothelial (16.2 to not reached), whereas patients who failed growth factor tyrosine kinase inhibitors (VEGF-prior therapies had a median OS of 9.3 months TKI) for metastatic disease. Clinical benefit for (95% CI 8.4 to 12.4). Grade ≥3 toxicities occurred IL‐2 treatment was modest (~15% response rate) in 9.3% (47) patients with 1 treatment‐related but was offset by substantial toxicities [76].

death from pneumonitis. The Merck 22C3 IHC Furthermore, while targeted agents such as assay was concurrently studied as a companion sorafenib, sunitinib, everolimus, temsirolimus, assay to assess the predictive value of PD‐L1 and bevacizumab improved PFS and OS, rarely did expression in this cohort. PD‐L1 staining was clas- complete responses occur, and tumors ultimately sified as positive at ≥50% staining. In the 313 developed resistance [77].

patients tested, 73 had positive PD‐L1 expression

Anti‐PD‐1 inhibition with nivolumab demon-

with a higher ORR when compared to patients with strated clinical efficacy in mRCC with an PD‐L1 staining of 1%–49% (ORR 45.2% vs 16.5% acceptable safety profile in a phase II trial [78] and ( p < .001) [74].

was quickly followed by the phase III trial

Avelumab (MSB00010718C), an anti‐PD‐L1 (CheckMate 025), which compared nivolumab to inhibitor, was tested in 184 patients after progres- standard of care treatment with an mTOR

sion on first‐line platinum‐based therapy. Patients inhibitor, everolimus, in patients with advanced in this phase I trial received avelumab 10 mg/kg q 3 clear cell mRCC, who had progressed on at least 1

weeks. The ORR was 13.6%, with 1 complete prior VEGF‐TKI [79]. Patients ( n = 821) were response (CR) and 24 partial response (PR); 68 randomized (1:1) to receive either nivolumab (37%) experienced stable disease (SD) and the dis- 3 mg/kg every 2 weeks or everolimus 10 mg daily; ease control rate was 50.5%. OS was 8.4 months 803 patients received therapy [79, 80]. The (95% CI of 7.3 to 10.7 months), with a survival at primary endpoint of OS favored nivolumab one year of 37%. PD‐L1 positivity was defined as (25 months versus 19.6 months, HR 0.73 p = .002) PD‐L1 staining (≥41%) and was present in 66.3% and demonstrated a five‐fold improvement in





44 Immunotherapy in Translational Cancer Research ORR (25% vs 5%, Odds Ratio 5.98, p < .001) [79]. treatment of cisplatin‐refractory mUC [86].

Grade 3–4 toxicities occurred in 76 (19% of Additional y, pembrolizumab has demonstrated patients). Discontinuation of therapy due to antitumor activity in mUC with the report of the therapy‐related AEs occurred in 31 (8%) patients KEYNOTE‐012 study. In the phase Ib trial, patients taking nivolumab versus 52 (13%) taking everoli- were treated with pembrolizumab 10 mg/kg every 2

mus. Overal , these results led to approval for weeks. Responses were correlated with higher PD-nivolumab for mRCC by the FDA. Subgroup anal- L1 expression in this study [87].

ysis determined that a survival benefit occurred

irrespective of Memorial Sloan‐Kettering Cancer Hodgkin lymphoma Center prognostic score [79, 80]. Although PD‐L1 PD‐1 pathway inhibition has demonstrated expression (positive defined as ≥1% staining using durable clinical responses in solid tumors, and the Dako IHC assay) was observed in 181 of 756 evidence suggests potential benefit in selected (24%) patients, this factor did not predict response hematologic malignancies [88–90]. One mecha-to anti‐PD1 therapy [79].

nism by which Reed‐Sternberg cel s, a hallmark

for Hodgkin lymphoma (HL), evade the immune

Bladder

system is through the PD‐1 pathway [91, 92]. In

classic HL (cHL), the malignant Reed‐Sternberg

Metastatic urothelial carcinoma is often a rapidly cel s are few in number (usual y <1%) but are sur-progressing lethal disease [81], and no treatment rounded by a reactive immune infiltrate com-exists that confers a survival advantage for patients posed of lymphocytes, leukocytes, plasma cel s, who progress on platinum‐based therapy. Many and fibroblasts [91–93]. Additional y, the genes bladder tumors express PD‐L1 [37, 82], and lym- that encode the ligands for PD‐1, CD274 and phocytes infiltrating in the tumor are correlated PDCD1LG2, are targets of chromosome 9p24.1, with improved survival [82]. Additional y, the use which can be amplified in HL, leading to overex-of other immune‐modulating therapies, including pression of PD‐L1 and PD‐L2 [91].

bacillus Calmette‐Guérin, has demonstrated

Nivolumab and pembrolizumab have been tested

positive results in bladder cancer [82–84].

in heavily pretreated patients with cHL [94]. In a

Atezolizumab and pembrolizumab have demon- phase II trial, 23 patients with relapsed, refractory strated antitumor activity in early phase trials. cHL were treated with nivolumab 3 mg/kg every 2

Atezolizumab was tested after progression on weeks. At the time of the report, 20 of the 23 patients platinum‐based therapy for patients with meta- had a clinical response (ORR of 87%, 95% CI of static urothelial carcinoma (mUC), reported from 66%–77%), with 4 CR and 16 PR and the remaining the phase II IMvigor 210 trial [85]. The study 3 patients with SD. The 24‐week PFS is 86% (62%–

enrolled 316 patients and treated them with atezoli- 95%), and median OS was not reached at 40 weeks zumab 1200 mg IV every 3 weeks. One third of the (0–75 weeks). Six patients went on to allogenic stem 311 patients had liver metastasis; 40% of patients cell transplant [94, 95]. Treatment‐related AEs had ≥2 prior lines of therapy, with 74% having occurred in most of the patients (78%), with the received cisplatin therapy in the past. The results most common being rash (22%) and thrombocyto-were reported by PD‐L1 expression using SP142 penia (17%). Grade 3 drug‐related AEs occurred in IHC assay. The primary endpoint of ORR was 15% 5 patients (22%) evaluated, including myelodysplas-for all patients treated, ORR 18% for PD‐L1 expres- tic syndrome, pancreatitis, pneumonitis, stomatitis sion ≥ 1% and ORR 27% for PD‐L1 expression ≥ colitis, and thrombocytopenia; no drug‐related 5%. Twelve patients achieved a CR and 35 achieved grade 4 or 5 events occurred [94]. Nivolumab a PR. Treatment‐related grade 3 and 4 AEs occurred achieved approval by the FDA in May 2016, for the in 15% of patients, of which the most common was treatment of relapse refractory HL after autologous fatigue (2%). Three percent of patients discontin- stem cell transplantation and brentuximab vedotin.

ued treatment due to toxicity [85]. The results of Similarly, single agent pembrolizumab 10 mg/kg this trial led the FDA to designate atezolizumab every 2 weeks was studied in a phase II trial with breakthrough status in June 2014, for the (KEYNOTE‐013). The 15 patients assessed had





CHAPTER 4 Checkpoint Blockade 45

received a median of 4 prior therapies. The ORR was ≥24 weeks at time of reporting. AEs attributed to 53% (3 CR and 5 PR). Therapy was tolerable, with drug occurred in 69.2% of patients with grade ≥3

primarily grade 1–2 AEs, including respiratory occurring in 1 patient [100].

events and thyroid disorders, each in 20% of patients,

Avelumab (MSB00010718C), an anti‐PDL1 anti-

and no treatment‐related deaths were observed [95]. body, was administered to women with pretreated refractory and relapsed ovarian cancer. The phase

Preliminary positive clinical data

Ib dose expansion of single‐agent avelumab admin-

istered 10 mg every 2 weeks was reported in

Ovarian cancer

patients unselected for PD‐L1 status. Seventy‐five

Ovarian cancer is diagnosed in advanced stage in patients were treated, the majority of whom had over 70% of patients [96], and even with effective serous subtype (78%), with a median of four prior multimodality treatment including cytoreductive therapies. Twenty‐three were evaluable for efficacy surgery and systemic chemotherapy with platinum at the time of presentation. The best overall and taxanes, over 70% of patients experience dis- response was 17.4% (95% CI 11.5%–57.2%); 47.8%

ease recurrence [97]. The immune system’s role in (11) had SD and 2 patients showed >30% tumor ovarian tumorigenesis is supported by the presence shrinkage after reported progression. Median PFS

of TILs and PD‐L1 expression of tumor cel s [9, 98, was 11.9 weeks and PFS rate at 24 weeks was 33.3%

99]. Early clinical activity combined with an (95% CI 11.5%–57.2%). The most common acceptable safety profile has been demonstrated in treatment‐associated AEs were fatigue, nausea, and the phase I and II trials of nivolumab, pembroli- diarrhea (>10% of patients). Only 2 patients had to zumab (anti‐PD‐1), and avelumab (anti‐PD‐L1).

discontinue therapy due to grade ≥3 toxicity (1

Nivolumab 1 mg/kg or 3 mg/kg was tested in 20 autoimmune myositis and 1 elevated lipase). No heavily pretreated patients, 75% with serous his- serious adverse events were reported [102].

tology. Half (55%) of the patients had 4 or more prior

lines of therapy. The ORR across both cohorts was Colon cancer with mismatch repair–

15% (2 CR, one of which was clear cell and 1 PR). deficient tumors Disease control (SD) was established in 45% (95% CI Colon cancers with mismatch repair (MMR) defi-23.1%–68.5%) of patients. The PFS overall in both ciency exhibit microsatellite instability. Although cohorts was 3.5 (1.7–3.9) months with OS of 20 representing a small proportion of colorectal can-months (7 to NR). Grade 3 and 4 AEs were reported cer (CRC) [103], MMR deficient tumors harbor in 40% of patients, with two AEs requiring treatment from 10 to 100 times the number of somatic muta-discontinuation, and were most frequently related to tions than do MMR‐proficient tumors [104, 105].

thyroid function. PD‐L1 expression was tested using

In a small phase II trial, 32 patients with CRC

formalin‐fixed, paraffin‐embedded tissue with were administered pembrolizumab 10 m/kg every murine PD‐L1 antibody (clone 27A2, MBL, Japan by 2 weeks until progression. Among patients with LSI Medicine) [100, 101]. An independent review MMR deficient tumors the ORR was 40% (95% CI demonstrated no differences in treatment effect 12%–74%) and PFS at 20 weeks was 78% (95%

based on PD‐L1 expression [101].

CI 40%–97%). This contrasts with patients with

In contrast, pembrolizumab (10 mg/kg every 2 MMR‐proficient CRC where ORR was 0% (0%–

weeks for up to 2 years) was tested in a PD‐L1‐ 20%) and PFS at 20 weeks was 11% (95% CI selected population (PD‐L1 positive defined by 2%–13%). While progression‐free and overall

≥1% of cel s in tumor nest or PD‐L1 positive bands survival parameters were not reached in the MMR

in stroma as determined by IHC) in the phase Ib deficient group, in the proficient group median KEYNOTE‐028 trial of pembrolizumab. Of the 26 PFS was 2.2 months (1.4–2.8 months) and OS was 5

patients treated, 84.6% had received prior therapy months. High somatic mutation loads were associ-and 38.4% had received ≥5 prior treatments in the ated with response [106]. In 2017, pembrolizumab metastatic setting. Three patients demonstrated an was approved for mismatch repair-deficient objective response (1 CR, 2 PR) and 6 SD. Of the 3 (MMR-D) unresectable cancers, and nivolumab patients who responded, responses were durable: for MMR-D colorectal cancers.





46 Immunotherapy in Translational Cancer Research Breast cancer

nausea, vomiting, and leukopenia, and one grade 5

The role for checkpoint inhibitors in breast cancer event of pulmonary hypertension in a patient with is currently being investigated in the triple‐negative atrial septal defect [115].

breast cancer (TNBC) subgroup. This heteroge-

neous group of tumors is identified clinical y by the Other malignancies absence of estrogen, progesterone, and human Additional preliminary evidence of activity data is epidermal growth factor (HER2) receptors. When emerging across tumor types. The KEYNOTE‐012

compared to other receptor‐positive types, TNBC trial is a phase Ib trial of pembrolizumab in solid demonstrate increased PD‐L1 expression [107, tumors, and the KEYNOTE‐028 trial is a phase Ib 108] and a higher proportion of TILs, which have trial studying pembrolizumab in PD‐L1‐selected demonstrated prognostic significance [109–112]. solid tumors. Emerging results are encouraging for The first two trials studying checkpoint blockade squamous cell head and neck cancer [116, 117], in this subgroup, pembrolizumab and atezoli- mesothelioma [118], and gastric [119, 120], esoph-zumab (MPDL3280A), showed promise due to ageal [121], ovarian [100], and breast [114] can-durability of responses and low toxicity profile.

cers, for which results have been presented.

In TNBC, 32 heavily pretreated patients with

The tumors in which checkpoint blockades have

PD‐L1 positive tumors were treated with pembroli- been less successful, demonstrating minimal zumab. Of the 27 evaluable for response, ORR was clinical or survival benefit, include nivolumab-18% (1 CR and 4 PR), and PFS 1.9 months (95% CI, treated multiple myeloma [122], MMR‐proficient 1.7–5.4) However, 3 of the 5 responders were still colon cancer [106], and prostate cancer [123].

on study for at least 48 weeks with median duration

of response not reached (5–40+ weeks). Slightly Combination strategies over half of the patients experienced treatment-related toxicities of any grade. The most common The inhibitory but nonredundant mechanisms of were arthralgia and fatigue (18.8%), myalgia CTLA‐4 and PD‐1/PD‐L1 provide mechanistic (15.6%), and nausea (15.6%). Grade 3 and 4 AEs in rationale for cotreatment with checkpoint blockade 15.6% patients included anemia, headache, aseptic agents. Ipilimumab and nivolumab have recently meningitis, and pyrexia. The isolated grade 4 event been approved in metastatic melanoma due to of decreased blood fibrinogen level ultimately led survival benefit [61, 124]. As expected, grade 3 and to death with disseminated intravascular coagula- 4 toxicities increased with the combination com-tion [113]. Recently, early clinical activity of pared to single agent, but no fatal toxicities were pembrolizumab in estrogen receptor–positive, reported [61].

HER2‐negative disease was described, with an

Other clinical trials combining checkpoint

ORR of 12% (3 PR) and clinical benefit rate at 24 blockade inhibitors are ongoing in other tumor weeks of 20%. Treatment‐related AEs were similar subtypes, including NSCLC, ovarian cancer, colo-to prior reported, with 16% of patients experi- rectal cancer, Hodgkin lymphoma, renal cell encing grade 3/4 toxicities [114].

carcinoma, breast cancer, and soft‐tissue sarcoma.

In unselected patients with TNBC, the PD‐L1 Current trials are studying various novel check-inhibitor atezolizumab (MPDL3280A) every 3 point blockade antagonists and agonists, as well as weeks (15 or 20 mg/mg or flat dose 1200 mg) was combination therapies with chemotherapy, radi-studied in a phase I trial. Twenty‐seven patients ation, targeted therapy, vaccines, chimeric antigen were enrolled, with 59% having visceral disease, receptor T cel s, and oncolytic viruses.

85% having received –4 prior systemic treatments.

Of the 21 evaluable patients, the unconfirmed ORR Biomarkers was 24% (8% to 47%) with 3 PRs and 2 CRs. The

duration of response was up to 42 months, and the Useful biomarkers can assist clinicians in treatment study is still ongoing. Therapy‐related AEs decision making and patient selection. For example, occurred in 67% of patients, with grade 3 events lung cancer patients who express epidermal growth including adrenal insufficiency, neutropenia, factor or anaplastic lymphoma kinase rearrangement





CHAPTER 4 Checkpoint Blockade 47

can be treated with erlotinib or crizotinib, respec- References tively. The clinical studies reviewed in this chapter

demonstrate the incredible promise of checkpoint

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M.

Regulatory T cel s and immune tolerance. Cel . 2008;

agents with durable responses in some patients.

133(5):775–87.

However, not all patients respond, revealing a need

2. Bluestone JA, Bour‐Jordan H, Cheng M, Anderson M.

to identify and select patients who would benefit

T cel s in the control of organ‐specific autoimmunity.

from the therapy, without exposing patients who

Journal of Clinical Investigation. 2015;125(6):

would not benefit. Continued efforts to establish

2250–60.

clinical y relevant biomarkers to predict response 3. Coley WB. The treatment of inoperable sarcoma by to therapy is critical. No validated marker is in

bacterial toxins (the mixed toxins of the Streptococcus

widespread clinical use, although many have been

erysipelas and the Bacillus prodigiosus). Proceedings

studied [106, 125–130].

of the Royal Society of Medicine. 1910;3(Surg

PD‐L1 is the most developed candidate bio-

Sect):1–48.

marker; it is expressed on the surface of many 4. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunology and Cell Biology.

solid tumors as well as tumor‐infiltrating

2003;81(2):106–13.

immune cells, and in some settings correlates 5. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson with prognosis and with benefit from PD‐1 and

PE, Old LJ, et al. IFNgamma and lymphocytes prevent

PD‐L1 inhibitors, as discussed above. However,

primary tumour development and shape tumour immu-

PD‐L1 expression is dynamic and may fluctuate

nogenicity. Nature. 2001;410(6832):1107–11.

depending on the tumor microenvironment and

6. Matsushita H, Vesely MD, Koboldt DC, Rickert CG,

cytokine feedback signaling [51]. Moreover, the

Uppaluri R, Magrini VJ, et al. Cancer exome analysis

optimal antibody for testing and the cutoff

reveals a T‐cell‐dependent mechanism of cancer immu-

values for positivity and negativity remain con-

noediting. Nature. 2012;482(7385):400–4.

troversial [131]. Although in most cases patients

7. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old

with tumors expressing PD‐L1 may have higher

LJ, et al. Adaptive immunity maintains occult cancer in

an equilibrium state. Nature. 2007;450(7171):903–7.

likelihood of response to checkpoint blockade, 8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer patients without PD‐L1 expression do not nec-immunoediting. Annual Review of Immunology. 2004;

essarily fail to respond [61, 132–134], and there

22:329–60.

are some prospective studies that fail to demon-

9. Zwaal RF, Schroit AJ. Pathophysiologic implications of

strate a difference in response based on PD‐L1

membrane phospholipid asymmetry in blood cel s.

expression levels [73, 79, 101, 132]. Additionally,

Blood. 1997;89(4):1121–32.

PD‐L1 staining does not appear to predict 10. de Visser KE, Eichten A, Coussens LM. Paradoxical roles response to dual checkpoint blockade with

of the immune system during cancer development.

nivolumab and ipilimumab in metastatic mela-

Nature Reviews Cancer. 2006;6(1):24–37.

noma [61]. Continued biomarker discovery 11. Caligiuri MA. Human natural killer cel s. Blood.

efforts are ongoing.

2008;112(3):461–9.

12. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL,

Young HA, Emerson SG, et al. CD28 activation pathway

Conclusions

regulates the production of multiple T‐cell‐derived lym-

phokines/cytokines. Proceedings of the National

Checkpoint blockade therapies provide durable

Academy of Sciences of the United States of America.

responses and clinical benefit in a subset of

1989;86(4):1333–7.

patients, with side effect profiles that are often 13. Schwartz RH. A cell culture model for T lymphocyte tolerable or reversible. However, not all patients

clonal anergy. Science. 1990;248(4961):1349–56.

respond, and no clinically available biomarker 14. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, to predict response to therapy is available.

Sharpe AH. CTLA‐4 regulates induction of anergy in

Continued studies combining immune‐targeted

vivo. Immunity. 2001;14(2):145–55.

agents and different treatment modalities show 15. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, et al. Differential T cell costimulatory

preliminary evidence of promise to improve

requirements in CD28‐deficient mice. Science. 1993;

response rates.

261(5121):609–12.

48 Immunotherapy in Translational Cancer Research 16. Kyi C, Postow MA. Checkpoint blocking antibodies in 30. Leach DR, Krummel MF, Allison JP. Enhancement of cancer immunotherapy. FEBS letters. 2014;588(2):

antitumor immunity by CTLA‐4 blockade. Science.

368–76.

1996;271(5256):1734–6.

17. Brunet JF, Denizot F, Luciani MF, Roux‐Dosseto M, 31. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin Suzan M, Mattei MG, et al. A new member of the immu-K, Hamid O, et al. Pooled analysis of long‐term survival

noglobulin superfamily: CTLA‐4. Nature. 1987;

data from phase II and phase III trials of ipilimumab in

328(6127):267–70.

unresectable or metastatic melanoma. Journal of Clinical

18. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani

Oncology. 2015;33(17):1889–94.

MF, Golstein P. CTLA‐4 and CD28 activated lympho-

32. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB,

cyte molecules are closely related in both mouse and

Marmol M, et al. Phase III randomized clinical trial

human as to sequence, message expression, gene struc-

comparing tremelimumab with standard‐of‐care che-

ture, and chromosomal location. Journal of Immunology.

motherapy in patients with advanced melanoma. Journal

1991;147(3):1037–44.

of Clinical Oncology. 2013;31(5):616–22.

19. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle 33. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expres-NK, Ledbetter JA. CTLA‐4 is a second receptor for the B

sion of PD‐1, a novel member of the immunoglobulin

cell activation antigen B7. Journal of Experimental

gene superfamily, upon programmed cell death. The

Medicine. 1991;174(3):561–9.

EMBO Journal. 1992;11(11):3887–95.

20. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo 34. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich VA, Jr., Lombard LA, et al. Cloning of B7‐2: a CTLA‐4

JR, Dudley ME, White DE, et al. Tumor antigen‐specific

counter‐receptor that costimulates human T cell prolif-

CD8 T cel s infiltrating the tumor express high levels of

eration. Science. 1993;262(5135):909–11.

PD‐1 and are functional y impaired. Blood. 2009;114(8):

21. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, 1537–44.

Reynolds PJ, et al. Characterization of CTLA‐4 structure 35. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, and expression on human T cel s. Journal of

Flies DB, et al. Tumor‐associated B7‐H1 promotes T‐cell

Immunology. 1993;151(7):3489–99.

apoptosis: a potential mechanism of immune evasion.

22. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS,

Nature Medicine. 2002;8(8):793–800.

Bluestone JA, et al. Absence of B7‐dependent responses 36. Zou W, Chen L. Inhibitory B7‐family molecules in the in CD28‐deficient mice. Immunity. 1994;1(6):501–8.

tumour microenvironment. Nature Reviews Immunology.

23. Krummel MF, Allison JP. CTLA‐4 engagement inhibits

2008;8(6):467–77.

IL‐2 accumulation and cell cycle progression upon 37. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, activation of resting T cel s. Journal of Experimental

et al. Association of PD‐1, PD‐1 ligands, and other fea-

Medicine. 1996;183(6):2533–40.

tures of the tumor immune microenvironment with

24. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS,

response to anti‐PD‐1 therapy. Clinical Cancer Research.

Freeman GJ, Green JM, et al. CTLA‐4 can function as a

2014;20(19):5064–74.

negative regulator of T cell activation. Immunity. 38. Xerri L, Chetaille B, Serriari N, Attias C, Guil aume Y, 1994;1(5):405–13.

Arnoulet C, et al. Programmed death 1 is a marker of

25. Walker LS, Sansom DM. The emerging role of CTLA4 as

angioimmunoblastic T‐cell lymphoma and B‐cell small

a cell‐extrinsic regulator of T cell responses. Nature

lymphocytic lymphoma/chronic lymphocytic leukemia.

Reviews Immunology. 2011;11(12):852–63.

Human Pathology. 2008;39(7):1050–8.

26. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto 39. Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, A, Allison JP. CTLA‐4‐mediated inhibition of early

Hyodo H, et al. Expression of functional B7‐H2 and B7.2

events of T cell proliferation. Journal of Immunology.

costimulatory molecules and their prognostic implica-

1999;162(10):5813–20.

tions in de novo acute myeloid leukemia. Clinical

27. Cal ahan MK, Wolchok JD. At the bedside: CTLA‐4‐

Cancer Research. 2005;11(16):5708–17.

and PD‐1‐blocking antibodies in cancer immunother-

40. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P,

apy. Journal of Leukocyte Biology. 2013;94(1):41–53.

Gascoyne RD, et al. Molecular diagnosis of primary

28. Intlekofer AM, Thompson CB. At the bench: preclinical

mediastinal B cell lymphoma identifies a clinical y favor-

rationale for CTLA‐4 and PD‐1 blockade as cancer

able subgroup of diffuse large B cell lymphoma related to

immunotherapy. Journal of Leukocyte Biology.

Hodgkin lymphoma. Journal of Experimental Medicine.

2013;94(1):25–39.

2003;198(6):851–62.

29. Waterhouse P, Penninger JM, Timms E, Wakeham A, 41. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski Shahinian A, Lee KP, et al. Lymphoproliferative disorK, Hetuin D, et al. Plasma cel s from multiple myeloma

ders with early lethality in mice deficient in CTLA‐4.

patients express B7‐H1 (PD‐L1) and increase expression

Science. 1995;270(5238):985–8.

after stimulation with IFN‐{gamma} and TLR ligands

CHAPTER 4 Checkpoint Blockade 49

via a MyD88‐, TRAF6‐, and MEK‐dependent pathway. 54. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Blood. 2007;110(1):296–304.

Wang J, et al. Autoantibodies against cardiac troponin

42. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ.

I are responsible for dilated cardiomyopathy in PD‐1‐

Programmed death‐1 (PD‐1) is a marker of germinal

deficient mice. Nature Medicine. 2003;9(12):1477–83.

center‐associated T cel s and angioimmunoblastic T‐cell 55. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T.

lymphoma. American Journal of Surgical Pathology.

Establishment of NOD‐Pdcd1‐/‐ mice as an efficient

2006;30(7):802–10.

animal model of type I diabetes. Proceedings of the

43. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato

National Academy of Sciences of the United States of

N. Involvement of PD‐L1 on tumor cel s in the escape

America. 2005;102(33):11823–8.

from host immune system and tumor immunotherapy 56. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo by PD‐L1 blockade. Proceedings of the National

T, et al. PD‐L1/B7H‐1 inhibits the effector phase of

Academy of Sciences of the United States of America.

tumor rejection by T cell receptor (TCR) transgenic

2002;99(19):12293–7.

CD8+ T cel s. Cancer Research. 2004;64(3):1140–5.

44. Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong 57. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe H, Leibovich BC, et al. B7‐H1 glycoprotein blockade: a

C, et al. Guidelines for the evaluation of immune therapy

novel strategy to enhance immunotherapy in patients with

activity in solid tumors: immune‐related response criteria.

renal cell carcinoma. Urology. 2005;66(5 Suppl):10–4.

Clinical Cancer Research. 2009;15(23): 7412–20.

45. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, 58. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman Gordon MS, et al. Predictive correlates of response to the

JA, Haanen JB, et al. Improved survival with ipilimumab

anti‐PD‐L1 antibody MPDL3280A in cancer patients.

in patients with metastatic melanoma. New England

Nature. 2014;515(7528):563–7.

Journal of Medicine. 2010;363(8):711–23.

46. Postow MA, Cal ahan MK, Wolchok JD. Immune 59. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Checkpoint Blockade in Cancer Therapy. Journal of

Garbe C, et al. Ipilimumab plus dacarbazine for previ-

Clinical Oncology. 2015;33(17):1974–82.

ously untreated metastatic melanoma. New England

47. Francisco LM, Salinas VH, Brown KE, Vanguri VK,

Journal of Medicine. 2011;364(26):2517–26.

Freeman GJ, Kuchroo VK, et al. PD‐L1 regulates the 60. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid development, maintenance, and function of induced

O, Robert C, et al. Pembrolizumab versus investigator‐

regulatory T cel s. Journal of Experimental Medicine.

choice chemotherapy for ipilimumab‐refractory mela-

2009;206(13):3015–29.

noma (KEYNOTE‐002): a randomised, controlled,

48. Okazaki T, Honjo T. The PD‐1‐PD‐L pathway in immu-

phase 2 trial. The Lancet Oncology. 2015;16(8):908–18.

nological tolerance. Trends in Immunology. 2006;27(4): 61. Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Cowey 195–201.

CL, Lao CD, et al. Combined nivolumab and ipilim-

49. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP,

umab or monotherapy in untreated melanoma. New

Sharpe AH, et al. Restoring function in exhausted CD8

England Journal of Medicine. 2015;373(1):23–34.

T cel s during chronic viral infection. Nature. 62. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015.

2006;439(7077):682–7.

CA Cancer J Clin. 2015;65(1):5–29.

50. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley 63. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, ES, Reddy S, et al. PD‐1 expression on HIV‐specific T

D’Souza G, et al. Cumulative incidence of cancer among

cel s is associated with T‐cell exhaustion and disease

persons with HIV in North America: a cohort study.

progression. Nature. 2006;443(7109):350–4.

Ann Intern Med. 2015;163(7):507–18.

51. Kinter AL, Godbout EJ, McNal y JP, Sereti I, Roby GA, 64. Carenco C, Faure S, Herrero A, Assenat E, Duny Y, O’Shea MA, et al. The common gamma‐chain cytokines

Danan G, et al. Incidence of solid organ cancers after

IL‐2, IL‐7, IL‐15, and IL‐21 induce the expression of

liver transplantation: comparison with regional

programmed death‐1 and its ligands. Journal of

cancer incidence rates and risk factors. Liver Int.

Immunology. 2008;181(10):6738–46.

2015;35(6):1748–55.

52. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha 65. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, TT, et al. Up‐regulation of PD‐L1, IDO, and T(regs) in

Brown ST, et al. HIV as an independent risk factor for

the melanoma tumor microenvironment is driven by

incident lung cancer. AIDS. 2012;26(8):1017–25.

CD8(+) T cel s. Science Translational Medicine. 66. Ardizzoni A, Salvati F, Rosso R, Bruzzi P, Rubagotti A, 2013;5(200):200ra116.

Pennucci MC, et al. Combination of chemotherapy and

53. Nishimura H, Nose M, Hiai H, Minato N, Honjo T.

recombinant alpha‐interferon in advanced non‐small

Development of lupus‐like autoimmune diseases by dis-

cell lung cancer. Multicentric Randomized FONICAP

ruption of the PD‐1 gene encoding an ITIM motif‐

Trial Report. The Italian Lung Cancer Task Force.

carrying immunoreceptor. Immunity. 1999;11(2):141–51.

Cancer. 1993;72(10):2929–35.

50 Immunotherapy in Translational Cancer Research 67. Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M,

mus in patients with metastatic renal cell carcinoma.

Recchia F, et al. Chemotherapy with or without low‐dose

Journal of Clinical Oncology. 2014;32(25):2765–72.

interleukin‐2 in advanced non‐small cell lung cancer: 79. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel results from a phase III randomized multicentric trial.

TM, Harrison MR, et al. Nivolumab for metastatic renal

Int J Oncol. 2011;39(4):1011–7.

cell carcinoma: results of a randomized phase II trial.

68. Thomas A, Giaccone G. Why has active immunotherapy

Journal of clinical Oncology. 2015;33(13):1430–7.

not worked in lung cancer? Annals of Oncology. 80. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, 2015;26(11):2213–20.

Marion S, et al. Prognostic factors for survival in previ-

69. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi

ously treated patients with metastatic renal cell carci-

F, Chacko R, et al. Ipilimumab in combination with pac-

noma. Journal of Clinical Oncology. 2004;22(3):454–63.

litaxel and carboplatin as first‐line treatment in stage 81. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, IIIB/IV non‐small‐cell lung cancer: results from a

Giannarelli D, et al. Tremelimumab for patients with

randomized, double‐blind, multicenter phase II study.

chemotherapy‐resistant advanced malignant mesothe-

Journal of Clinical Oncology. 2012;30(17):2046–54.

lioma: an open‐label, single‐arm, phase 2 trial. The

70. O’Day SJ, Maio M, Chiarion‐Sileni V, Gajewski TF,

Lancet Oncology. 2013;14(11):1104–11.

Pehamberger H, Bondarenko IN, et al. Efficacy and 82. Brancato SJ, Lewi K, Agarwal PK. Evolving immuno-safety of ipilimumab monotherapy in patients with pre-

therapy strategies in urothelial cancer. American Society

treated advanced melanoma: a multicenter single‐arm

of Clinical Oncology educational book/ASCO meeting.

phase II study. Annals of Oncology. 2010;21(8):1712–7.

2015;35:e284–90.

71. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian 83. Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang SL, Hwu P, et al. Safety and activity of anti‐PD‐L1 anti-HH, Mapes J, et al. Molecular analyte profiling of the

body in patients with advanced cancer. New England

early events and tissue conditioning following intravesi-

Journal of Medicine. 2012;366(26):2455–65.

cal bacil us Calmette‐Guerin therapy in patients with

72. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith

superficial bladder cancer. Journal of Urology.

DC, McDermott DF, et al. Safety, activity, and immune

2009;181(4):1571–80.

correlates of anti‐PD‐1 antibody in cancer. New England 84. Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Journal of Medicine. 2012;366(26):2443–54.

Shinka T. Intravesical instil ation therapy with bacil us

73. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE,

Calmette‐Guerin for superficial bladder cancer: study of

Poddubskaya E, et al. Nivolumab versus docetaxel in

the mechanism of bacil us Calmette‐Guerin immuno-

advanced squamous‐cell non‐small‐cell lung cancer.

therapy. International Journal of Urology.

New England Journal of Medicine. 2015;373(2):123–35.

2007;14(2):140–6.

74. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian 85. Rosenberg J, Petrylak D, Abidoye O, Van der Heijden AS, Eder JP, et al. Pembrolizumab for the treatment of

MS, Hofman‐Censits J, Necchi A, et al. Atezolizumab in

non‐small‐cell lung cancer. New England Journal of

patients (pts) with local y‐advanced or metastatic uro-

Medicine. 2015;372(21):2018–28.

thelial carcinoma (mUC): Results from a pivotal multi-

75. Gulley J, Spigel D, Kel y K, Chandler J, Rajan A, Hassan R, center phase II study (IMvigor 210). Eur J Cancer.

et al., editors. Avelumab (MSB0010718C), an anti‐PD‐L1

2015;51:S720.

antibody, in advanced NSCLC patients: a phase 1b, open‐

86. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, label expansion trial in patients progressing after

et al. MPDL3280A (anti‐PD‐L1) treatment leads to

platinum‐based chemotherapy. J Clin Oncol. 2015;33.

clinical activity in metastatic bladder cancer. Nature.

76. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP,

2014;515(7528):558–62.

Leitman S, et al. A progress report on the treatment of 87. Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery 157 patients with advanced cancer using lymphokine-RB, Heath K, et al. Pembrolizumab (MK‐3475) for

activated killer cel s and interleukin‐2 or high‐dose

advanced urothelial cancer: updated results and bio-

interleukin‐2 alone. New England Journal of Medicine.

marker analysis from KEYNOTE‐012. Journal of

1987;316(15):889–97.

Clinical Oncology. 2015;33(15).

77. Escudier B, Goupil MG, Massard C, Fizazi K. Sequential 88. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, therapy in renal cell carcinoma. Cancer. 2009;115(10

Timmerman JM. Programmed death ligand 1 is

Suppl):2321–6.

expressed by non‐Hodgkin lymphomas and inhibits the

78. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T,

activity of tumor‐associated T cel s. Clinical Cancer

Harker WG, et al. Phase II randomized trial comparing

Research. 2011;17(13):4232–44.

sequential first‐line everolimus and second‐line suni-

89. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE,

tinib versus first‐line sunitinib and second‐line everoli-

Chen YB, et al. Disabling immune tolerance by

CHAPTER 4 Checkpoint Blockade 51

programmed death‐1 blockade with pidilizumab after 100. Varga A, Piha‐Paul S, Ott P, Mehnert J, Berton‐Rigaud autologous hematopoietic stem‐cell transplantation for

D, Johnson E, et al., editors. Antitumor activity and

diffuse large B‐cell lymphoma: results of an interna-

safety of pembrolizumab in patients (pts) with PD‐L1

tional phase II trial. Journal of Clinical Oncology.

positive advanced ovarian cancer: interim results from

2013;31(33):4199–206.

a phase Ib study. ASCO; 2015; Chicago, IL.

90. Berger R, Rotem‐Yehudar R, Slama G, Landes S, Kneller 101. Hamanishi J, Mandai M, Ikeda T, Minami M, A, Leiba M, et al. Phase I safety and pharmacokinetic

Kawaguchi A, Murayama T, et al. Safety and antitumor

study of CT‐011, a humanized antibody interacting with

activity of anti‐PD‐1 antibody, nivolumab, in patients

PD‐1, in patients with advanced hematologic malig-

with platinum‐resistant ovarian cancer. Journal of

nancies. Clinical Cancer Research. 2008;14(10):3044–51.

Clinical Oncology. 2015;33(34):4015–22.

91. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, 102. Disis M, Patel M, Pant S, Infante J, Lockhart A, Kel y K, O’Donnell E, et al. Integrative analysis reveals selective

et al., editors. Avelumab (MSB0010718C), an anti‐PD‐

9p24.1 amplification, increased PD‐1 ligand expression,

L1 antibody, in patients with previously treated, recur-

and further induction via JAK2 in nodular sclerosing

rent or refractory ovarian cancer: a phase Ib, open‐label

Hodgkin lymphoma and primary mediastinal large B‐

expansion trial. ASCO; 2015; Chicago, IL.

cell lymphoma. Blood. 2010;116(17):3268–77.

103. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg

92. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K,

MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mis-

Abramson J, et al. The AP1‐dependent secretion of

match repair system in patients with sporadic advanced

galectin‐1 by Reed Sternberg cel s fosters immune privi-

colorectal cancer. Br J Cancer. 2009;100(2):266–73.

lege in classical Hodgkin lymphoma. Proceedings of the 104. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong National Academy of Sciences of the United States of

SF, et al. Multicenter retrospective analysis of meta-

America. 2007;104(32):13134–9.

static colorectal cancer (CRC) with high‐level micro-

93. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R,

satellite instability (MSI‐H). Annals of Oncology.

Fischer R, et al. Hodgkin disease: Hodgkin and Reed‐

2014;25(5):1032–8.

Sternberg cel s picked from histological sections show 105. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler clonal immunoglobulin gene rearrangements and appear

KW, Vogelstein B, et al. Epitope landscape in breast and

to be derived from B cel s at various stages of development.

colorectal cancer. Cancer Research. 2008;68(3):889–92.

Proceedings of the National Academy of Sciences of the 106. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, United States of America. 1994;91(23):10962–6.

Eyring AD, et al. PD‐1 Blockade in tumors with mis-

94. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott

match‐repair deficiency. New England Journal of

EC, Gutierrez M, et al. PD‐1 blockade with nivolumab in

Medicine. 2015;372(26):2509–20.

relapsed or refractory Hodgkin’s lymphoma. New 107. Muenst S, Schaerli AR, Gao F, Daster S, Trel a E, England Journal of Medicine. 2015;372(4):311–9.

Droeser RA, et al. Expression of programmed death

95. Moskowitz C, Ribrag V, Michot N, Martinelli G, Zinzani

ligand 1 (PD‐L1) is associated with poor prognosis in

P, Gutierrez M, et al., editors. PD‐1 blockade with the

human breast cancer. Breast Cancer Research and

monoclonal antibody pembrolizumab (MK‐3475) in

Treatment. 2014;146(1):15–24.

patients with classical Hodgkin lymphoma after brentux-

108. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet imab vedotin failure: preliminary results from a phase 1b

M, Ali HR, et al. Prognostic and predictive value of

study (KEYNOTE‐013). ASH; 2014; San Francisco, CA.

PDL1 expression in breast cancer. Oncotarget.

96. Barakat R, Berchuck A, Markman M, Randall M.

2015;6(7):5449–64.

Principles and Practice of Gynecologic Oncology, sixth 109. Denkert C, Loibl S, Noske A, Roller M, Muller BM, ed. Lippincott Williams & Wilkins; 2013.

Komor M, et al. Tumor‐associated lymphocytes as an

97. Herzog TJ. Recurrent ovarian cancer: how important is

independent predictor of response to neoadjuvant che-

it to treat to disease progression? Clinical Cancer

motherapy in breast cancer. Journal of Clinical

Research. 2004;10(22):7439–49.

Oncology. 2010;28(1):105–13.

98. Zhang L, Conejo‐Garcia JR, Katsaros D, Gimotty PA, 110. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Massobrio M, Regnani G, et al. Intratumoral T cel s,

Guarneri V, et al. Prognostic value of tumor‐infiltrating

recurrence, and survival in epithelial ovarian cancer.

lymphocytes on residual disease after primary chemo-

New England Journal of Medicine. 2003;348(3):203–13.

therapy for triple‐negative breast cancer: a retrospective

99. Hwang WT, Adams SF, Tahirovic E, Hagemann IS,

multicenter study. Annals of Oncology. 2015;26(7):1518.

Coukos G. Prognostic significance of tumor‐infiltrating 111. Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge T cel s in ovarian cancer: a meta‐analysis. Gynecologic

S, Andre F, et al. Prognostic and predictive value of

Oncology. 2012;124(2):192–8.

tumor‐infiltrating lymphocytes in two phase III

52 Immunotherapy in Translational Cancer Research randomized adjuvant breast cancer trials. Annals of

noma: Preliminary results from KEYNOTE‐028.

Oncology. 2015;26(8):1698–704.

ASCO; 2015; Chicago, IL.

112. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen

122. Lesokhin A, Ansell S, Armand P, Scott E, Halwani A,

F, Pruneri G, et al. The evaluation of tumor‐infiltrating

Gutierrez M, et al., editors. Preliminary results of a

lymphocytes (TILs) in breast cancer: recommendations

phase I study of nivolumab (BMS‐936558) in patients

by an international TILs working group 2014. Annals

with relapsed or refractory lymphoid malignancies.

of Oncology. 2015;26(2):259–71.

ASH; 2014; San Francisco, CA.

113. Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R, 123. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van et al., editors. A phase Ib study of pembrolizumab

den Eertwegh AJ, et al. Ipilimumab versus placebo after

(MK‐3475) in patients with advanced triple‐negative

radiotherapy in patients with metastatic castration‐

breast cancer. San Antonio Breast Cancer Symposium;

resistant prostate cancer that had progressed after

2014; San Antonio, TX.

docetaxel chemotherapy (CA184‐043): a multicentre,

114. Rugo H, Delord J‐P, Im S, Ott P, Piha‐Paul S, Bedard P, randomised, double‐blind, phase 3 trial. The Lancet

et al., editors. Preliminary efficacy and safety of pembro-

Oncology. 2014;15(7):700–12.

lizumab (MK‐3475) in patients with PD‐L1–positive, 124. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann estrogen receptor‐positive (ER+)/HER2‐negative

K, McDermott D, et al. Nivolumab and ipilimumab

advanced breast cancer enrolled in KEYNOTE‐028. San

versus ipilimumab in untreated melanoma. New England

Antonio Breast Cancer Symposium; 2015; San

Journal of Medicine. 2015;372(21):2006–17.

Antonio, TX.

125. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang

115. Emens L, Braiteh F, Cassier P, Delord J, Eder J, Fasso M, DS, Sun J, et al. Preoperative CTLA‐4 blockade: tolera-et al., editors. Inhibition of PD‐L1 by MPDL3280A

bility and immune monitoring in the setting of a pre-

leads to clinical activity in patients with metastatic tri-

surgical clinical trial. Clinical Cancer Research.

ple‐negative breast cancer (TNBC). AACR; 2015;

2010;16(10):2861–71.

Philadephia, PA.

126. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L,

116. Chow L, Weiss J, Eder. J., Gonzalez E, Pulini J, Johnson Chaput N, et al. Experience in daily practice with ipili-J, et al., editors. A phase Ib study of pembrolizumab

mumab for the treatment of patients with metastatic

(Pembro; MK‐3475) in patients (Pts) with human

melanoma: an early increase in lymphocyte and eosin-

papiilloma virus (HPV)‐positive and negative head and

ophil counts is associated with improved survival.

neck cancer (HNC). ESMO; 2014; Madrid, Spain.

Annals of Oncology. 2013;24(6):1697–703.

117. Seiwert T, Haddad R, Gupta S, Mehra R, Tahara M, 127. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Berger R, et al. Antitumor activity and safety of pem-Carvajal RD, et al. Single‐institution experience with

brolizumab in patients (pts) with advanced squamous

ipilimumab in advanced melanoma patients in the

cell carcinoma of the head and neck (SCCHN): prelim-

compassionate use setting: lymphocyte count after 2

inary results from KEYNOTE‐012 expansion cohort. J

doses correlates with survival. Cancer. 2010;

Clin Oncol. 2015;33(suppl; abstr LBA6008).

116(7):1767–75.

118. Alley E, Molife L, Santoro A, Beckey K, Yuan S, Cheng 128. Luke JJ, Cal ahan MK, Postow MA, Romano E, Ramaiya J, et al., editors. Clinical safety and efficacy of pembro-N, Bluth M, et al. Clinical activity of ipilimumab for

lizumab (MK‐3475) in patients with malignant pleural

metastatic uveal melanoma: a retrospective review of

mesothelioma: preliminary results from

the Dana‐Farber Cancer Institute, Massachusetts

KEYNOTE‐028. AACR; 2015; Philadelphia, PA.

General Hospital, Memorial Sloan‐Kettering Cancer

119. Bang Y, Chung H, Shankaran V, Geva R, Catenacci D,

Center, and University Hospital of Lausanne experi-

Gupta S, et al., editors. Relationship between PD‐L1

ence. Cancer. 2013;119(20):3687–95.

expression and clinical outcomes in patients with 129. Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, advanced gastric cancer treated with the anti‐PD‐1

Stern PL, et al. Modulation of lymphocyte regulation

monoclonal antibody pembrolizumab (MK‐3475) in

for cancer therapy: a phase II trial of tremelimumab in

KEYNOTE‐012. ASCO; 2015; Chicago, IL.

advanced gastric and esophageal adenocarcinoma.

120. Muro. K, Bang Y, Shankaran V, Geva R, Catenacci D,

Clinical Cancer Research. 2010;16(5):1662–72.

Gupta S, et al., editors. A phase 1b study of pembroli-

130. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E,

zumab (Pembro; MK‐3475) in patients (Pts) with

Gal ardo HF, et al. Integrated NY‐ESO‐1 antibody and

advanced gastric cancer. ESMO; 2015; Madrid, Spain.

CD8+ T‐cell responses correlate with clinical benefit in

121. Doi T, Piha‐Paul S, Ibrahim Jalal S, Dang H, Yuan S,

advanced melanoma patients treated with ipilimumab.

Koshiji M, et al., editors. Pembrolizumab (MK‐3475)

Proceedings of the National Academy of Sciences of the

for patients (pts) with advanced esophageal carci-

United States of America. 2011;108(40):16723–8.

CHAPTER 4 Checkpoint Blockade 53

131. McLaughlin J, Han G, Schalper KA, Carvajal‐Hausdorf

domised, controlled, open‐label, phase 3 trial. The

D, Pelakanou V, Rehman J, et al. Quantitative

Lancet Oncology. 2015;16(4):375–84.

assessment of the heterogeneity of PD‐L1 expression in 135. Eggermont AM, Chiarion‐Sileni V, Grob JJ, Dummer non‐small‐cell lung cancer. JAMA Oncol. 2015:1–9.

R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab

132. Robert C, Long GV, Brady B, Dutriaux C, Maio M,

versus placebo after complete resection of high‐risk

Mortier L, et al. Nivolumab in previously untreated

stage III melanoma (EORTC 18071): a randomised,

melanoma without BRAF mutation. New England

double‐blind, phase 3 trial. The Lancet Oncology.

Journal of Medicine. 2015;372(4):320–30.

2015;16(5):522–30.

133. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak 136. Borghaei H, Paz‐Ares L, Horn L, Spigel DR, Steins M, CE, Inzunza HD, et al. Safety, efficacy, and biomarkers

Ready NE, et al. Nivolumab versus docetaxel in

of nivolumab with vaccine in ipilimumab‐refractory or

advanced nonsquamous non‐small‐cell lung cancer.

‐naive melanoma. Journal of Clinical Oncology.

New England Journal of Medicine. 2015;373(17):

2013;31(34):4311–8.

1627–39.

134. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, 137. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Neyns B, et al. Nivolumab versus chemotherapy in

Mortier L, et al. Pembrolizumab versus ipilimumab in

patients with advanced melanoma who progressed

advanced melanoma. New England Journal of

after anti‐CTLA‐4 treatment (CheckMate 037): a ran-

Medicine. 2015;372(26):2521–32.





CHAPTER 5

5 Myeloid Leukemia Vaccines

Paul M. Armistead and Jonathan S. Serody

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hil , NC, USA Evidence for T‐cell‐mediated killing or oral busulfan [13–19]. While IFN‐α demon-of myeloid leukemia

strated clear survival advantages, its side effects

often became intolerable with ~20% of patients dis-

Acute myeloid leukemia (AML) and chronic continuing therapy in early IFN‐α studies and 89%

myelogenous leukemia (CML) are the two most of patients crossing over from the IFN‐α + cytara-common forms of myeloid leukemia with an bine cohort to the imatinib cohort in the landmark annual incidence of roughly 20,000 and 8,000 cases IRIS trial [6, 13, 16]. While IFN‐α is no longer in the United States, respectively [1]. Several lines commonly used in current practice for the of evidence point to the fact that these diseases can treatment of patients with CML, correlative studies be cured by T‐cell‐mediated therapies. However, performed in association with the clinical trials current immunotherapy strategies aimed at both investigating IFN‐α showed that the treatment led CML and AML are associated with significant to the expansion of CD8+ T cel s specific for leu-morbidity and mortality.

kemia‐associated self‐antigens. More importantly,

CML is a hematopoietic stem cell disorder char- the expansion of these T cel s was associated with acterized by the t(9;22) translocation, which results clinical response [20]. Beyond IFN‐α, CML has in the generation of the BCR‐ABL fusion protein also been treated with allogeneic stem cell trans-

[2–4]. While current treatment strategies involve plantation (allo SCT) with good success. SCT

the use of small molecule inhibitors that block the outcomes starting from the late 1980s have shown function of the mutant tyrosine kinase, BCR‐ABL continued improvements in long‐term survival,

[5–12], treatment for CML before the development with initial 2‐year survival of ~50% increasing to of these pharmaceuticals often involved immuno- ~60% by 2000 [21]. As supportive care and donor therapeutic approaches. Early clinical investigations human leucocyte antigen (HLA) matching have in the 1980s showed that long‐term treatment with improved, survival has continued to improve, with interferon alpha (IFN‐α) could induce complete a recent report describing 3‐year overall survival of hematological remissions in 30%–70% of patients 91% of CML patients who undergo allo SCT in with median overall survival of ~5 years—significantly chronic phase, and 59% overall survival in patients better than prior therapies involving hydroxyurea transplanted in advanced phase [22]. While allo Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

54





CHAPTER 5 Myeloid Leukemia Vaccines 55

SCT is curative in many CML patients, roughly T‐cell‐mediated targeting of the malignant cel s; 30% of patients develop chronic graft‐versus‐host however, the current treatments are far from disease [22]. One of the striking features about optimal due to limited efficacy and significant CML susceptibility to T‐cell‐mediated therapy is morbidity and mortality. Given these shortcom-the very high response rate of CML to donor lym- ings, less‐toxic vaccination strategies have been phocyte infusion (DLI) for patients whose disease attempted.

relapses following SCT. DLI can induce molecular

remissions in 75%–95% of CML patients whose Barriers to successful cancer disease relapses post‐SCT, depending upon the vaccine strategies degree (molecular, cytogenetic, or hematologic) of

relapse at the time of DLI [23]. These results Conventional antimicrobial vaccines typical y strongly suggest that CML is more susceptible to T involve the administration of the killed or dena-cell therapy than many other hematologic malig- tured organism or selected recombinant microbial nancies, including AML.

proteins designed to induce a robust and coordi-

In contrast to CML, the only broadly used form nated immune response [35]. The microbial proof immunotherapy for AML is allo SCT. While teins that are used in vaccines are foreign to the some patients with AML (e.g., patients with host immune system. These foreign microbial prot(15;17), inv(16), t(8;21), or diploid cytogenetics teins typical y elicit robust humoral responses with with isolated NPM1 mutations) can be cured with the generation of high‐affinity antibodies against chemotherapy alone [24–29], the majority of AML protein epitopes, which can be highly effective in patients will suffer disease relapse, which is associ- producing strong immunity against primarily ated with an extremely poor outcome [30]. As a extracel ular organisms. In addition, when micro-result, allo SCT is recommended, if possible, for bial proteins are taken up by antigen‐presenting AML patients with relapsed disease (if brought cel s, microbial antigens can be presented both by back into remission) [31] and for patients with class II HLA to activate CD4+ helper T cell (T ) H

cytogenetic or mutational abnormalities associated responses and by class I HLA, via cross‐presenta-with a high rate of relapse [24, 26]. For these high‐ tion, to activate CD8+ cytotoxic T cel s (T ) as wel C

risk patients, allo‐SCT performed for patients in (Figure 5.1). The activated T and T cel s often H

C

complete remission is associated with a long‐term possess T cell receptors with high affinity for their overall survival rate of 30%–40% [24, 31]. The microbial peptide/HLA antigen because the host T

importance of T‐cell‐mediated immunity for cell repertoire has not been tolerized through effecting cures in AML patients undergoing allo either central or peripheral mechanisms to these SCT was demonstrated in studies showing antigens, resulting in high‐avidity interactions increased relapse rates and worse overall survival with cel s presenting these peptide/HLA antigens in patients who underwent allo SCT with donor T [36, 37]. Subsets of these high‐avidity T cel s can cell depletion or with identical sibling donors, become memory T cel s, which can rapidly respond which would eliminate the contribution of minor to rechallenge with antigen. This coordinated T

histocompatibility antigens in donor‐derived T cell cell response is particularly relevant in the genera-targeting of AML [32, 33]. While survival out- tion of immune responses against viruses and comes are better for high‐risk AML patients who intracel ular organisms such as Mycobacterium undergo allo SCT compared with similar patients tuberculosis.

who do not, the impact of donor T cell immunity in

In contrast to the combined humoral and cel-

effecting cures is likely less for AML compared to lular adaptive immune responses that can be CML, as outcomes from DLI for AML are signifi- elicited from antimicrobial vaccines, antitumor, cantly worse, with 2‐year survival of only 15% for including antimyeloid leukemia, vaccines are often AML patients who undergo DLI for treatment of greatly hindered in their ability to induce robust, active disease [34].

long‐term immune responses [38–40]. The

Taken together, these data show that CML and antigenic targets of most myeloid leukemia (ML) AML can be cured by strategies aimed at enhancing vaccines are typical y peptides derived from





56 Immunotherapy in Translational Cancer Research

(A)

(B)

CD8+ T cell membrane

CD4+ T cell membrane

TCRα chain

TCRβ chain

TCRα chain

TCRβ chain

Peptide

Peptide

Class l HLA

Class ll HLA

Cell membrane

Cell membrane

Figure 5.1 Class I and class II antigen presentation. A. All these amino acids with different affinities, which influences cells, apart from red blood cells, express class I human

which peptides can be presented by which HLA molecules.

leucocyte antigen (HLA) molecules, which express endoge-

B. Only professional antigen‐presenting cells such as nous peptide fragments. For class I HLA the first and last

monocytes, macrophages, and B cells express class II HLA. For couple of residues of the presented peptide chain are

class II HLA, the presented peptides are typically longer than primarily responsible for anchoring the peptide to the HLA,

for class I restricted peptides, and they can extend beyond

and a cognate T cell receptor expressed by a CD8+ T cell

the actual binding cleft on the class II HLA molecule. T cell primarily interacts with the middle amino acids and, to some

receptors expressed on CD4+ T cells recognize the peptide/

extent the HLA molecule itself. Different HLA molecules bind

HLA complex. Source: Courtesy of Molly Roth Creative LLC.

aberrantly or overexpressed intracel ular proteins, potential and the ability of T cel s to coordinate H

which can be presented by class I HLA, or follow- further adaptive responses [40]. Final y, because ing uptake of the leukemia proteins by the ML vaccines often use peptides, B‐cell antigen‐presenting cel s (monocytes, macrophages, responses are very difficult to induce.

and B lymphocytes) class II HLA.

Because most ML vaccines target peptides Myeloid vaccine targets derived from normal but aberrantly expressed proteins, the number of T cel s with high‐affinity In contrast for foreign pathogens, human tumors, TCRs that can recognize these antigens is greatly including CML and AML, have genomes very reduced as a result of central tolerance of high‐ similar to the patient’s germline. Because of this ge-avidity T cel s specific for these antigens in the netic similarity, the number and diversity of thymus [41, 42]. Furthermore, as ML vaccines antigenic targets for successful immunotherapy is are given after diagnosis (as opposed to most quite limited. These antigens can be crudely anti‐infectious vaccines, which are given prophy- divided into groups of leukemia‐associated lactical y), it is likely that additional peripheral antigens (LAAs), which are preferential y expressed tolerance mechanisms lead to further reductions in by leukemia but present to some degree in normal high‐avidity T cell populations. This paucity of tissue, and leukemia‐specific antigens, which are high‐avidity T cel s greatly hinders T cytotoxic only expressed by leukemia cel s because of a C



CHAPTER 5 Myeloid Leukemia Vaccines 57

leukemia‐specific genetic defect that yields a novel are expressed in the thymus, where central toler-antigen, or neoantigen. The mechanism for presen- ance leads to the removal of high‐avidity T cel s tation of antigens as peptides to class I MHC (major toward these antigens (Figure 5.3). These types of histocompatibility complex) is demonstrated in proteins are usual y expressed in very restricted Figure 5.2.

tissues such as testis, ovary, and genitourinary

LAAs typical y are identified as proteins that are tract [43, 44]. Alternatively, these proteins can be expressed on some normal tissues but are prefer- expressed in subcel ular compartments that do not ential y presented by class I HLA on leukemia. undergo processing through the typical class I These proteins are self‐antigens, and as such, they HLA pathway such as PRTN3, which is normal y Epitope

HLA

Endoplasmic Reticulum

Nucleus

C

DNA

E

TAP

D

A

B

mRNA

Peptides

Protein

Cellular Compartment

Cell

Figure 5.2 Types of presented cancer antigens. Many

that generates a gene fusion product with a resulting

mechanisms can lead to the presentation of cancer peptide

peptide that can be presented by class I HLA (purple

epitopes. A. The most commonly reported are cancer self-arrows). D. The development of genome sequencing has

antigens derived from proteins overexpressed in the tumor

allowed for the prediction, and in a small number of cases,

and minimally expressed in normal tissue (blue arrows).

discovery of neoantigens the result from single‐nucleotide

These peptides are derived from proteins with a wild‐type

variations between the patient’s germline DNA sequence

primary sequence and are best considered cancer (or

and the tumor genome (pink arrows). E. Neoantigens could leukemia)‐associated self‐antigens. B. A related form of also derive from aberrantly spliced mRNA molecules,

cancer‐associated self‐antigen can arise from a wild‐type

leading to aberrant protein primary sequences (black

protein that is aberrantly localized in the cancer cell

arrows). This mechanism of neoantigen production could

facilitating presentation by class I HLA (green arrows). The

be important in acute myeloid leukemia and myelodysplastic

best examples of these are the neutrophil granule proteins,

syndrome, where mutations in spliceosome genes are

which are present in high abundance in the cytosol of

common. All of these mechanisms yield proteins that

leukemia blasts. Neoantigens are distinct from self‐antigens

ultimately undergo degradation through the proteasome

because they are derived from mutated proteins that are

and transportation via the TAP proteins into the

specific to the tumor cell. C. The best characterized endoplasmic reticulum, where they are bound to class I HLA

leukemia neoantigen is derived from the t(9;22) translocation molecules. Source: Courtesy of Molly Roth Creative LLC.



58 Immunotherapy in Translational Cancer Research

Central Tolerance

Peripheral Tolerance

Thymus

Self-reactive T cell

Lymphoid

precursor

Non-self reactive

T cells

Self-peptide/

HLA

Thymic

epithelial

cell

Anergy

Myleoid Derived Suppressor Cell

Bone

Senescence

M2 Macrophage

Exhaustion

Regulatory T Cell

Figure 5.3 Tolerance mechanisms. Multiple mechanisms

mechanisms of peripheral tolerance can dampen immune

for the development of tolerance to cancer antigens exist.

responses. T cells can lose function through lack of

Lymphoid precursors exit the bone marrow and migrate to

costimulation (anergy), upregulation of checkpoint

the thymus where they undergo both positive and

inhibitory proteins (exhaustion), and long‐term antigen

negative selection mechanisms to eliminate T cells

stimulation (senescence). In addition to these direct

possessing T cell receptors that can bind to self‐antigen/

interactions between effector T cells and target cells,

HLA complexes. This process of central tolerance is

other extrinsic cell types such as myeloid‐derived

extremely effective and greatly reduces the frequency of

suppressor cells, M2 macrophages, and regulatory T cells

T cells that can bind with high affinity to cancer self‐

can also impact the antitumor effect of cancer. Source: antigens. Central tolerance should not influence T cell

Courtesy of Molly Roth Creative LLC.

reactivity towards neoantigens; however, multiple other

expressed in neutrophil granules (and not suscep- high‐avidity T cel s from a patient’s T cell repertible to class I HLA presentation) but is aberrantly toire [41, 42]. Peripheral tolerance mechanisms localized in the cytosol of leukemia blasts [45]. may still exist, however (Figure 5.3). Neo‐antigens Despite central tolerance, T cel s that can recog- can arise from different genetic perturbations.

nize and react against LAAs presented by the Nonsynonymous single‐nucleotide variants that appropriate class I HLA have been observed in leu- induce an amino acid change in a protein antigen kemia patients, which has led to the targeting of are likely the most common source of neoantigens these antigens in vaccine trials, described in the [47, 48]; however, for myeloid leukemias, the most following section [46].

well‐characterized neoantigen is the BCR‐ABL

Neo‐antigens (or leukemia‐specific antigens) fusion protein that is the driving mutation for CML

occur as the result of specific mutational events [49]. This protein has a novel amino acid sequence that occur in the leukemia cel . Because these at the fusion site, and various resulting peptides events are leukemia specific, the source proteins for can be presented by class I HLA and elicit T cell the antigens are not expressed in the thymus, which responses. Vaccine studies against these antigens would prevent central tolerance from eliminating have been performed (see below). Final y, another





CHAPTER 5 Myeloid Leukemia Vaccines 59

potential source of neoantigens is proteins that However, other investigators have generated DCs have undergone aberrant splicing. During tran- from leukemia cel s [55] or fused leukemia cel s scription, nascent RNA molecules undergo a highly with DCs to generate a vaccine [56]. In addition, regulated process of intron removal and exon DCs have been treated with apoptotic tumor cel s splicing that is mediated by the spliceosome, a so that multiple antigens can be presented both ribonucleoprotein macromolecular complex. by class II HLA and class I HLA via cross‐presenta-Roughly 15% of AML and 50% of myelodysplastic tion [52–54].

syndrome (which can evolve into AML) cases have

mutations in at least one spliceosome gene, which Leukemia‐associated antigen vaccines could lead to the synthesis of aberrantly spliced The majority of ML vaccines have sought to elicit mRNA and protein molecules [50, 51]. These pro- T cell responses to LAAs. These antigens are pep-teins could serve as a large source of neoantigens. tide/HLA complexes with the peptide being Methodologies to confirm this type of neoantigen derived from proteins that are either aberrantly are under development.

expressed or overexpressed by the leukemia cel .

Because these peptides are derived from normal

Vaccine types

proteins, they are considered self‐antigens.

The simplest and most commonly used myeloid WT1

vaccines have been peptide vaccines. These vac-

cines are composed of an antigenic peptide or pep- The WT1 gene is located on chromosome 11p13

tide mixture often administered with an adjuvant and is an intracel ular transcription factor. The and granulocyte‐macrophage colony stimulating protein has very limited expression in normal factor (GM‐CSF) [46]. Most peptides are derived tissue, being only detectable in the developing uro-from LAAs and are expected to stimulate CD8+ genital system, testis, placenta, ovaries, kidney, T cell responses.

mesenchymal cel s, and CD34+ hematopoietic cel s

Dendritic cell (DC) vaccines are the second [43, 44, 57]; however, it is overexpressed in many common type of vaccine. Whereas peptide vac- tumors, including lung, breast, colorectal cancer, cines rely on the addition of an adjuvant and and AML [58–62]. In cancer, the WT1 protein can endogenous antigen presenting cel s, which can be function as either an oncogene or tumor suppressor deficient in cancer patients, to elicit T cell based on the isoform expressed [63]. WT1 plays an responses, DC vaccines involve the infusion of important role in leukemogenesis, and its inhibi-autologous, functional DCs that present a leukemia tion leads to growth inhibition and eventual y apo-antigen, express costimulatory molecules, and ptosis [64]. Because WT1‐specific CD8+ T cel s can secrete cytokines to enhance the antileukemia T be expanded in vitro relatively easily, adoptive cel-cell response [52–56]. In most cases, patient‐ lular therapy trials have been conducted to test this derived CD14+ monocytes are induced to form of cel ular therapy [65].

differentiate to DCs that present the leukemia

In addition to the adoptive cel ular therapy

vaccine with the DCs either infused, or more com- trials, multiple WT1 vaccine trials have been con-monly, injected intradermal y into the patient. ducted in AML. Oka et al. reported the first WT1

Following infusion, the DCs home to regional peptide vaccine trial in AML in 2004 [66]. In that lymph nodes and induce CD8+ and CD4+ T cell study, 12 patients with AML who expressed HLA-responses, which is an advantage over standard A24, which is the MHC protein that presents peptide‐only vaccines. DCs and their antigen pay- the WT1 peptide, who had molecular evidence of load vaccines have been prepared in multiple disease but were in hematological complete different ways to present their tumor antigens. The remission, received the WT1p235‐243 peptide most common method is peptide loading of (CMTWNQMNL) and a peptide, WT1p235 pep-the DCs. DCs have also been transduced with tide (CYTWNQMNL), with enhanced binding either DNA or RNA encoding the tumor antigen so affinity, termed heteroclitic, with incomplete that the antigen can be endogenously expressed. Freund’s adjuvant (IFA) (for amino acid single

60 Immunotherapy in Translational Cancer Research letter terminology, see Figure 5.4). Of these 14 tetramer before vaccine (0.09% to 0.98%) with patients, 5 showed a reduction in their disease patients who showed an immunologic response burden as measured by RT‐PCR of WT1 tran- to tetramer‐based enumeration, having post-scripts and 2 showed a reduction of their leukemic vaccine WT‐1‐specific CD8+ T cel s ranging from blast percentage. Immune responses were mea- 0.26% to 6.61% of total CD8+ T cel s. HLA‐A24 is sured using WT1/HLA‐A24 tetramers, and 9 the most prevalent HLA type in the Japanese patients showed an increase in tetramer+ CD8+ population, but it is rare in other ethnic groups, T cel s following vaccination. The tetramer reagent including Caucasians, where HLA‐A2 is the most is generated by using avidin to link four of the prevalent type.

same peptide/MHC complexes together. A fluo-

Mailänder et al. reported the first HLA‐A2

rochrome is linked to the complex that allows for restricted WT‐1 epitope (WT1p126‐134, the detection of the tetramer complex using multi- RMFPNAPYL) vaccine in one patient in 2004 [67].

parameter flow cytometry. One remarkable finding The patient had detectable disease at the start of in this study was the relatively high frequency of therapy, but after four vaccinations had <5% bone WT‐1‐specific CD8+ T cel s enumerated by marrow blasts, a >1‐log reduction in WT1

Aliphatic side chains

S

NH2

NH2

NH2

NH

NH

2

2

NH2

O

O

O

O

O

O

OH

OH

OH

OH

OH

OH

G = Glycine

A = Alanine

V = Valine

I = Isoleucine

L = Leucine

M = Methionine

Aromatic side chains

OH

Uncharged polar side chains

NH

NH2

NH2

O

OH

O

HO

NH2

NH2

NH2

NH

NH

NH

NH

2

2

2

2

O

O

O

O

O

O

O

OH

OH

OH

OH

OH

OH

OH

P = Phenylalanine Y = Tyrosine

W = Tryptophan

Q = Glutamine

N = Asparagin

T = Threonine

S = Serine

NH2

Charged side chains

Other side chains

+

+H

NH

2N

3

O–

NH

–O

O

+HN

NH

SH

O

NH

NH

NH

NH

NH

NH

NH

2

2

2

2

2

2

O

O

O

O

O

O

O

OH

OH

OH

OH

OH

OH

OH

D = Glutamate

E = Aspartate

H = Histidine

R = Arginine

K = Lysine

P = Proline

C = Cysteine

Figure 5.4 Amino acids. The 20 naturally occurring

amino acids at the HLA binding or “anchor” positions,

amino acids are shown. They can be classified generally

located at the ends of the peptide epitope, are generally

by their side chain properties, with the majority

hydrophobic and small; however, multiple exceptions to

possessing aliphatic side chains but others containing

this principle are known. Source: Courtesy of Molly Roth aromatic, polar, or charged side chains. In general, the

Creative LLC.





CHAPTER 5 Myeloid Leukemia Vaccines 61

transcript levels, and achieved a hematologic convert from a partial remission after their salvage remission after 16 weeks of therapy. A phase II chemotherapy to a complete remission (CR), and 3

study using the same epitope with GM‐CSF and other patients who were in CR at the time of vacci-keyhole limpet hemocyanin adjuvant was subse- nation had reductions in the WT1 transcript level quently performed in 19 HLA‐A2 patients with as measured by RT‐PCR [72].

measurable disease [68]. Following treatment, 10

patients had stable disease, with 2 more showing an RHAMM

improvement in neutrophil count. Immune

responses were also observed with an increase in RHAMM (CD168) is a hyaluronan receptor whose WT1‐specific T cell count of 44%; 38% of subjects gene is located on chromosome 5q33.2 [73, 74].

had a reduction in WT1 transcripts.

RHAMM overexpression in normal fibroblasts

WT1 vaccination has also been performed for leads to increased cel ular motility and anchorage-patients with CML. Two patients, reported independent growth [75]. Its overexpression is separately, received the HLA‐A24 restricted necessary for H‐ras‐induced transformation [75].

WT1p235‐243 with IFA while also receiving ima- RHAMM can also be secreted from cel s and sub-tinib [69, 70]. Both patients showed reductions in sequently associates with the hyaluronan receptor BCR‐ABL transcript levels by RT‐PCR, with 1 (CD44) that is anchored to the cel ’s plasma mem-patient entering a complete molecular response. brane. There it can induce mitotic arrest [76].

Both patients also had evidence of WT1‐specific T Inside the cel , RHAMM interacts with microtu-cell expansion following vaccination.

bules and is involved in the regulation of mitosis

Polyvalent WT1 vaccine approaches have also and mitotic spindle integrity [77, 78]. Outside the been investigated. Maslak et al. used a four‐peptide cel , binding of hyaluronan to the RHAMM/hyal-pool with the aim of eliciting WT1 antigen specific uronan receptor complex leads to activation of the to both CD8+ and CD4+ T cel s [71]. The first MAP‐kinase pathway through ERK1 and ERK2



peptide was a heteroclitic WT1p126 analog [77]. Because of its function, RHAMM is maxi-

(YMFPNAPYL, with Y substituted in position 1 mal y expressed during mitosis [79]. It has very low instead of R). Two long peptides WT1p427 expression in normal tissues; however, it is overex-

(RSDELVRHHNMHQRNMTKL) and WT1P331 pressed in many tumor types, including leukemia (PGCNKRYFKLSHLQMHSRKHTG) were

blasts [80–84]. To date, peptide vaccine trials

selected to bind to class I and class II HLA (HLA‐ against RHAMM have targeted the RHAMM‐R3

DRB1). The final peptide, a heteroclitic WT1‐p122 epitope (p165‐173, ILSLELMKL), which is endoge-

(SGQAYMFPNAPYLPSCLES, with Y substituted nously processed and presented on HLA‐A2 [79].

in position 5 instead of R), was intended to be able Because RHAMM is endogenously processed for to stimulate both CD8+ and CD4+ T cel s. Of the 9 presentation by class I HLA and is also present on HLA‐A2+ AML patients in complete hematologic the cell surface, it can elicit both cel ular and remission who received vaccination, 4 relapsed and humoral immune responses [85].

5 remained in complete remission, with WT1 tran-

The first RHAMM vaccine trial using RHAMM‐

script levels decreasing over time to either R3 peptide with the adjuvant ISA‐51 and GM‐CSF

undetectable or at very low levels.

was performed in 10 patients, 6 of whom had AML

DC vaccines have also been used to target WT1 or MDS [86]. Of these 6 patients, 4 showed evi-in AML patients. WT1 mRNA was electroporated dence of an immune response as measured by into patient‐derived DCs, which were subsequently expansion of CD8+ T cel s recognizing RHAMM-infused into patients. Because the entire WT1 R3/HLA‐A2 tetramer. Three of the 4 patients mRNA was electroporated into the patient‐derived demonstrating a RHAMM‐R3 T cell expansion DCs, multiple class I WT1 epitopes could be pro- response showed clinical improvement, with 2

duced, allowing enrollment of patients with patients demonstrating a reduction in bone multiple different HLA‐types. In one study of 10 marrow blast percentage and another patient AML patients treated with WT1 mRNA electro- becoming transfusion independent. A subsequent porated DCs, 2 patients had their disease status study on 6 AML and MDS patients demonstrated





62 Immunotherapy in Translational Cancer Research immune responses in 2 patients. One patient had a demonstrated PR‐1 and WT1p126‐134‐specific T

reduction in bone marrow blasts and another had cell responses after the first vaccination; however, normalization of blood counts [87].

repeat vaccination was associated with a decrease

in PR‐1 and WT1p126‐134‐specific T cel s. By

PR1 (PRTN3 and ELANE)

the end of the study, no patients had demonstrable

PR‐1 or WT1p126‐130specific T cell populations

Proteinase‐3 (PRTN3) and neutrophil elastase [91]. A subsequent one‐dose booster vaccination (ELANE) are primary neutrophilic granule pro- given three months after the original series was teins that are aberrantly expressed in the cytoplasm able to induce the expansion of PR‐1 and of AML blasts [88]. When the proteins are present WT1p126‐134 ‐specific T cel s; however, these T

in the cytosol they undergo proteosomal digestion, cel s only had low avidity T cell receptors for their and peptide epitopes can be presented by class I cognate antigens [91].

HLA on the cell surface. The best characterized

epitope derived from is PR1 (VLQELNVTV), Leukemia‐specific neoantigens which is present in both proteinase‐3 and neutrophil elastase [45]. PR1 vaccine was tested, with Neoantigens are derived most commonly from the IFA‐51 and GM‐CSF, in 66 HLA‐A2 AML, MDS, driver or passenger somatic mutations that are and CML patients, 53 of whom had measurable present in tumor cel s. There is strong correlation disease at the time of vaccination [89]. Immune between the number of somatic mutations present responses, defined as a ≥2‐fold increase in the in specific tumor cel s and the generation of neo-percentage of PR1‐specific CD8+ T cel s measured antigen peptides from those mutations that can by tetramer enumeration, were measured in 35 of bind to class I HLA proteins [48]. For patients with the 66 patients (53%), with responses being associ- leukemia, this process is complicated, as the ated with lower disease burden at vaccination and number of mutations/cel s in patients with acute younger patient age. Of the 53 patients with mea- myeloid leukemia is much lower than for carcin-surable disease at the time of vaccination, 12 (24%) ogen‐induced tumors such as melanoma, had a measurable clinical response, with 8 complete squamous or adenocarcinoma of the lung, or uro-responses, and there was an association between thelial cancer [50, 92]. However, this approach is the development of an immune response with a attractive as a vaccine candidate because the epi-clinical response. The 10‐year event free and topes derived from these mutated proteins cannot overall survival rates were 20% and 38%, respec- be expressed in the thymus. Thus, central toler-tively [89].

ance does not eliminate high‐avidity T cel s as it

In addition to vaccination with the single PR1 does in the case of leukemia‐associated self-epitope, PR1 has been combined with HLA‐A2‐ antigens. However, it is possible that neoantigens specific WT‐1 epitopes in clinical trials for patients can be generated from processes that mediate with acute and chronic myeloid leukemia. A study translocations or splicing abnormalities, which of 8 patients with myeloid leukemia, of whom 5 are much more common in leukemia than are were in CR at the start of the study, involved one single‐nucleotide variants.

vaccination with WT1p126‐134 and PR‐1 with

To date, no AML neoantigen‐specific vaccine

IFA‐51 and GM‐CSF. Following vaccination, 7 studies have been performed; however, a vaccine patients demonstrated CD8+ T cel s reactive to study targeting gliomas with IDH1 mutations PR‐1, and 5 had T cel s reactive to WT‐1p126‐134, (which are common in AML) has been recently with all patients having a response to at least one reported [93]. While AML neoantigen vaccine epitope. Of the 5 patients in CR, 3 remained in CR, studies have not been undertaken, many different and 2 relapsed several months after discontinua- vaccine strategies have been employed to target one tion of the vaccine [90]. A subsequent study on 6 of the most well‐characterized cancer‐specific AML and 2 MDS patients was performed using a mutant proteins: the BCR‐ABL fusion protein, different vaccination schedule. Six patients which is the pathognomonic mutation associated completed the full vaccination protocol. All 6 with CML.





CHAPTER 5 Myeloid Leukemia Vaccines 63

BCR‐ABL

vaccination. T cel s from 5 patients receiving

concurrent IFN‐α showed increased numbers of

The BCR‐ABL protein results from the t(9;22) vaccine‐epitope‐specific IFN‐γ‐secreting T cel s (q34;q11) translocation [2–4]. The translocation following vaccination [101].

breakpoint occurs either between exon 2 and 3 or 3

A three‐peptide b3a2 vaccine was investigated in

and 4 of bcr with subsequent joining to exon 2 of combination with GM‐CSF and the pan class II abl. The protein fusions are 210 kDa and are called binding epitope, PADRE, as adjuvants for 19

b2a2 and b3a2 [94]. The b3a2 fusion results in the patients with CML in chronic phase or complete insertion of a novel lysine residue that is not present hematological response who had previously in either bcr or abl. Several peptides from received imatinib therapy [102]. Stimulated this region of b3a2 (e.g., KQSSKALQR and PBMCs (peripheral blood mononuclear cel s) from GFKQSSKAL) can be endogenously processed and 11 of the 19 patients demonstrated peptide‐specific presented on relatively common class I HLA types: T cell responses to a short peptide based upon HLA‐A3, HLA‐A11, and HLA‐B8 [95–97]. BCR‐ ELISPOT analysis, and 14 of the 19 patients dem-ABL fusion peptides can also be presented on class onstrated longer peptide‐specific responses. Of the II HLA [98].

19 patients enrolled, 13 patients demonstrated a

The first BCR‐ABL vaccine used five b3a2 pep- “molecular response” defined as a 1‐log reduction tides, four of which were predicted to be presented in BCR‐ABL transcripts. All 13 of the molecular by HLA‐A3, HLA‐A11, or HLA‐B8 and one pep- responders entered the trial after having achieved a tide predicted to be presented by HLA‐DR1, major cytogenetic response to their prior therapy.

HLA‐DR4, or HLA‐DR11 coadministered with Five enrolled patients had not demonstrated a QS‐21 adjuvant. The study evaluated 12 CML cytogenetic response to therapy prior to vaccina-patients in either complete or partial remission at tion, and none of these patients demonstrated a the start of vaccination [99]. Importantly, the molecular response. One patient’s disease became vaccine was administered concurrently with stan- undetectable by BCR‐ABL nested PCR analysis.

dard CML therapy at the time (IFN‐α or

To broaden the application of BCR‐ABL vaccine

hydroxyurea). T cell responses were observed in strategies to more CML patients, Maslak et al. con-50% of the patients ( n = 6) who received the two ducted a vaccine trial using peptides from both highest doses, but conclusions about clinical effi- b3a2 and b2a2 junction sequences that were pre-cacy could not be made because of the concurrent dicted to elicit CD4+ responses, as well as three therapies. A similar follow‐up study evaluating 14 heteroclitic peptides encompassing the b3b2 and CML patients in chronic phase treated with a sim- b2a2 junctions that were predicted to be presented ilar six‐peptide vaccine and IFN‐α resulted in 5 by HLA‐A2 [103]. Immune responses to the pre-patients achieving a complete cytogenetic remis- dicted HLA‐A2 restricted peptide were detected, sion; however, it is again unclear how much of the by IFN‐γ ELISPOT, in 4 of the 7 HLA‐A2 express-effect was a result of the vaccine or the concurrent ing patients, and 9 of the 13 patients demonstrated IFN‐α [100].

T cell responses to the long, predicted class II epi-

A similar vaccine using the same five b3a2 pep- topes. Clinical effectiveness in this study was tides was used in combination with QS‐21 and complicated because the patients had very low-GM‐CSF on a six biweekly injection vaccine burden disease: 3 had disease detectable by FISH, schedule in 16 patients who were either receiving and the remainder only had disease that was concurrent IFN‐α or imatinib therapy [101]. Three detectable by nested PCR. Two of the 3 patients months after the completion of the vaccine series, 6 with FISH‐detectable disease had disease that was of the 12 patients whose disease was in partial cyto- undetectable by FISH following vaccination. All of genetic remission at the start of the vaccine series the patients, however, had detectable BCR‐ABL

were in complete cytogenetic remission. Thirteen transcripts after the vaccine series [103].

of the 14 patients who expressed an appropriate

A similar study using combinations of the het-

HLA class II molecule demonstrated antigen‐ eroclitic HLA‐A2 b2a2 and b3a2 peptides and the specific CD4+ T cell expansion following class II binding b2a2 and b3a2 peptides with





64 Immunotherapy in Translational Cancer Research IFA‐51 and GM‐CSF as adjuvants was tested on 10 early study of 3 CML patients, autologous PBMCs patients who were in complete cytogenetic response were differentiated into DCs and readministered to but had BCR‐ABL transcripts detectable by PCR. patients with keyhole limpet hemocyanin adjuvant.

Three patients had transient 1‐log reductions Autologous CD4+ T cel s showed enhanced IFN‐γ

in BCR‐ABL transcripts after the vaccine series secretion when coincubated with the CML‐derived

[104]. Please see Table 5.1 for a summary of DCs in vitro; however, no hematologic responses the above trials.

were observed [106]. A similar phase I/II trial of 22

AML patients has also been performed. In this

Complex (undefined) antigen

study, 5 patients entered a CR after initial chemo-

dendritic cell vaccine strategies

therapy and had blasts that were successful y

differentiated into “dendritic‐like leukemia cel s.”

DC vaccines can be developed to stimulated Of the 5 patients who underwent vaccination, 4

immune responses to specific antigens. As showed evidence of an immune response based on described above, such an approach has been used ELISPOT analysis; however, only 2 remained in to target WT1 in AML [72]; however, this is the remission one year after vaccination [107]. A only example of a DC vaccine presenting a specific pragmatic limitation to the broad application of epitope being evaluated for the treatment of a mye- this approach is that leukemia cel s possessing a loid leukemia. Alternatively, DC vaccines intended FLT3 mutation or lacking CD14 cannot mature to target multiple tumor‐associated antigens at into a DC phenotype [54, 108, 109].

once have also been developed. While early antitu-

More recently, an alternative approach to

mor DC vaccine approaches involved priming DCs inducing leukemia‐derived DCs is the actual syn-with autologous tumor lysate (as a source of poten- thesis of AML/DC fusion cel s that result from the tial LAAs and neoantigens), this approach has not fusion of a patient’s AML blasts with the patient’s been actively pursued in myeloid malignancies autologous DCs. The results of the first trial of 17

[52]. Rather, several other approaches have been or AML patients who received their personalized are in the process of active investigation [52–54].

AML/DC fusion vaccines was recently reported

One approach has involved priming autologous [56]. All of the patients were in CR following DCs with apoptotic bodies derived from patient induction chemotherapy and received vaccine AML blasts based on evidence that apoptotic ~6 months after entering CR. After median follow-bodies possess antigen that can be taken up more up of 57 months, 12 of the 17 patients who received efficiently by DCs compared to priming using vaccine were alive and still in CR.

tumor lysates. In one study, 4 AML patients were

treated with apoptotic‐body‐primed autologous Conclusions

DC vaccine with coinjected Streptococcus pyogenes

OK‐432 as an adjuvant biweekly for five doses. Two Myeloid leukemias can be effectively treated via Tpatients were observed to have increases in the cell‐mediated immunotherapy. However, current numbers of WT1 and hTERT epitope‐specific treatments such as IFN‐α and allo SCT are associ-T cel s [105].

ated with significant morbidity and, in the case of

Several research groups have demonstrated that allo SCT, mortality. AML and CML have a limited myeloid leukemia blasts can be driven to differen- number of antigenic targets, most of them being tiate to have an antigen‐presenting phenotype like LAAs. Several LAAs, such as WT1, RHAMM, and DCs [55]. These DCs could be valuable vaccine PR1, have been targeted in vaccine trials; however, reagents, as they should be able to present both the clinical efficacy of these studies has been class I and class II epitopes efficiently, with appro- limited. Peptide vaccines have also been developed priate costimulatory molecules. Leukemia‐derived against leukemia‐specific neoantigens derived DCs have been generated both from AML blasts from the BCR‐ABL fusion protein. Several differ-and CML cel s. Small clinical studies have been ent DC vaccine strategies for AML have been performed to investigate these cel s’ ability to tested, but no large‐scale studies, to date, show induce responses to both CML and AML. In an broad efficacy.

Table 5.1 Myeloid leukemia vaccine trials.

Peptide Sequence ref

HLA Type

Dosing Schedule

Adjuvant

Myeloid Patients

Clinical Status

Clinical Outcome

WT1



CMTWNQMNL or C Y TWNQMNL 66

A24

200 μ g SC q2 weeks × 4 doses

IFA

12 AML, 2 MDS

2 active disease, 12 CR

5 decrease in WT1 transcripts, 2

then q28d × 23 (or progression).

decrease in blast percentage

Note: bold underline signifies

heteroclitic amino acids.

RMFPNAPYL 68

A2

200 μ g SC q2 weeks × 4 doses

KLH

17 AML, 2 MDS

18 active disease, 1 CR

2 erythroid response, 4 improved

then q28d × 23 (or progression)

GM‐CSF

blast percentage

RMFPNAPYL 71 ,

A2, DR.B1

200 μ g SC q2 weeks × 6 doses

IFA

9 AML

9 CR

5 continuous CR (4 relapse)

RSDELVRHHNMHQRNMTKL,

GM‐CSF

PGCNKRYFKLSHLQMHSRKHTG,

SGQAYMFPNAPYLPSCLES

RHAMM



ILSLELMKL (R3) 86

A2

300 μ g SC q2 weeks × 4 doses

IFA

3 AML, 3 MDS

Limited disease

1 CR (AML), 1 PR (MDS)

GM‐CSF

ILSLELMKL (R3) 87

A2

1000 μ g SC q2 weeks × 4 doses

IFA

1 AML, 5 MDS

Limited disease

1 blast reduction (MDS), 1

GM‐CSF

hematologic improvement (MDS)

PR1



VLQELNVTV 89

A2

250, 500, or 1000 μ g SC q3 weeks × 3

IFA

42 AML, 13 CML, 9

53 measurable disease, 8 CR, 1 PR, 3 hematologic

doses (×6 doses for 12 patients)

GM‐CSF

MDS

13 CR

improvement

WT1 + PR1



RMFPNAPYL 90

A2

200 μ g WT1, 500 μ g PR1 SC × 1

IFA

5 AML, 1 CML, 2 MDS

5 CR, 1 CP

3 continuous CR (2 relapse), 1

VLQELNVTV

dose

GM‐CSF

molecular response

RMFPNAPYL 91

A2

200 μ g WT1, 500 μ g PR1 SC q2

IFA

6 AML, 2 MDS

6 CR

2 continuous CR (3 relapse), 2 SD

VLQELNVTV

weeks × 6 doses followed by 1

GM‐CSF

after 12 weeks

BCR‐ABL



IVHSATGFKQSSKALQRPVASDFEP 99

All

10, 30, 100, 300 μ g of the mixed

QS‐21

12 CML

12 CR/PR

10 CP, 1 AP, 1 BC

ATGFKQSSK

b3a2 peptides SC on days 0, 14,

KQSSKALQR

28, 42, 70

HSATGFKQSSK

GFKQSSKAL

( Continued )

Table 5.1 ( Continued )

Peptide Sequence ref

HLA Type

Dosing Schedule

Adjuvant

Myeloid Patients

Clinical Status

Clinical Outcome

IVHSATGFKQSSKALQRPVASDFEP 100

All

10, 30, 100, 300 μ g of the mixed

QS‐21

14 CML

6 CCR, 2 PCR, 5 MCR,

5 CCR, 2 complete molecular

ATGFKQSSK

b3a2 peptides SC on days 0, 14,

1 cytogenetic

remission, 5 SD, 2 PD

KQSSKALQR

28, 42, 70

relapse s/p allo‐SCT

HSATGFKQSSK

GFKQSSKAL

SSKALQRPV

IVHSATGFKQSSKALQRPVASDFEP 101

A11, A3,

100 μ g of the mixed b3a2 peptides Molgramostim 16 CML

1 CCR, 12 PCR, 3

7 CCR, 6 PCR, 2 minimal

ATGFKQSSK

B8,

SC q2 weeks × 6 doses

QS‐21

minimal cytogeneic

cytogenetic remission

KQSSKALQR

DR1,

GM‐CSF

remission

HSATGFKQSSK

DR4,

GFKQSSKAL

DR11

KQSSKALQR 102

All

100, 300, 1000 μ g of the mixed

PADRE

19 CML

14 major cytogenetic

13 of 14 major cytogenetic

GFKQSSKAL

b3a2 peptides ID on days 1, 8,

GM‐CSF

response, 5

response had 1 log reduction in

GFKQSSKALQRPV

15, 22, 36

cytogenetic

bcr‐abl. No response in

non‐response

cytogenetic non‐response

patients

IVHSATGFKQSSKALQRPVASDFE 103

All

Either combined b3a2 or b2a2

IFA

13 CML

10 CCR, 2 PCR, 1

13 with detectable bcr‐abl in

KQSSKALQR

peptides SC q2 weeks × 5 doses,

GM‐CSF

0.4% Ph + by FISH

peripheral blood or marrow

GFKQSSKAL

then q28 days × 4 doses, then at

YL KALQRPV

9 and 12 months. Note: bold

K L LQRPVAV

underline signifies heteroclitic

VHSIPLTINKEEALQRPVASDFE

amino acids.

YL INKEEAL

IVHSATGFKQSSKALQRPVASDFE 104

All

100 μ g of either combined b3a2

IFA

10 CML

10 CCR

3 with transient 1 log reduction in

KQSSKALQR

or b2a2 peptides SC q2

GM‐CSF

bcr‐abl transcripts

GFKQSSKAL

weeks × 4 doses, then on week

YL KALQRPV

9, then, q28 days × 10 doses.

K L LQRPVAV

Note: bold underline signifies

VHSIPLTINKEEALQRPVASDFE

heteroclitic amino acids

YL INKEEAL (100)



Note: AML = acute myeloid leukemia; MDS =; CR = complete remission; PR = partial remission; IFA = incomplete Freund’s adjuvant; KLH = keyhole limpet hemocyanin; GM‐CSF = granulocyte‐macrophage colony stimulating factor; CML = chronic myelogenous leukemia.





CHAPTER 5 Myeloid Leukemia Vaccines 67

As the fields of cancer genomics and computa-

diagnosed chronic myeloid leukemia. N Engl J Med.

tional immunology develop, it is likely that

2010;362(24):2251–9.

tumor‐specific neoantigens will be identified more 11. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-readily, which could lead to more personalized

Passerini C, Baccarani M, Kim DW, et al. Bosutinib is

vaccine strategies with the goal of inducing high‐

active in chronic phase chronic myeloid leukemia after

avidity T cell responses to multiple tumor‐specific

imatinib and dasatinib and/or nilotinib therapy failure.

Blood. 2012;119(15):3403–12.

epitopes.

12. Cortes JE, Kim DW, Pinil a‐Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in

Acknowledgement

Philadelphia chromosome‐positive leukemias. N Engl J

Med. 2013;369(19):1783–96.

Illustrations for this chapter were provided by 13. Interferon alfa‐2a as compared with conventional cheMol y Roth Creative LLC.

motherapy for the treatment of chronic myeloid leu-

kemia. The Italian Cooperative Study Group on Chronic

Table 5.1 ( Continued )

Peptide Sequence ref

HLA Type

Dosing Schedule

Adjuvant

Myeloid Patients

Clinical Status

Clinical Outcome

References

Myeloid Leukemia. N Engl J Med. 1994;330(12):820–5.

14. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H,

IVHSATGFKQSSKALQRPVASDFEP 100

All

10, 30, 100, 300 μ g of the mixed

QS‐21

14 CML

6 CCR, 2 PCR, 5 MCR,

5 CCR, 2 complete molecular

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016.

Hossfeld DK, et al. Randomized comparison of inter-

ATGFKQSSK

b3a2 peptides SC on days 0, 14,

1 cytogenetic

remission, 5 SD, 2 PD

KQSSKALQR

28, 42, 70

relapse s/p allo‐SCT

CA Cancer J Clin. 2016;66(1):7–30.

feron‐alpha with busulfan and hydroxyurea in chronic

HSATGFKQSSK

2. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T,

myelogenous leukemia. The German CML Study Group.

GFKQSSKAL

SSKALQRPV

Geurts van Kessel A, Bootsma D, et al. Translocation of

Blood. 1994;84(12):4064–77.

IVHSATGFKQSSKALQRPVASDFEP 101

A11, A3,

100 μ g of the mixed b3a2 peptides Molgramostim 16 CML

1 CCR, 12 PCR, 3

7 CCR, 6 PCR, 2 minimal

c‐ab1 oncogene correlates with the presence of a 15. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU.

ATGFKQSSK

B8,

SC q2 weeks × 6 doses

QS‐21

minimal cytogeneic

cytogenetic remission

KQSSKALQR

DR1,

GM‐CSF

remission

Philadelphia chromosome in chronic myelocytic leu-

Leukocyte interferon‐induced myeloid cytoreduction in

HSATGFKQSSK

DR4,

kaemia. Nature. 1983;306(5940):277–80.

chronic myelogenous leukemia. Blood. 1983;62(3):

GFKQSSKAL

DR11

3. Nowell PC, Hungerford DA. A minute chromosome in

689–92.

KQSSKALQR 102

All

100, 300, 1000 μ g of the mixed

PADRE

19 CML

14 major cytogenetic

13 of 14 major cytogenetic

GFKQSSKAL

b3a2 peptides ID on days 1, 8,

GM‐CSF

response, 5

response had 1 log reduction in

human chronic granulocytic leukemia. Science. 16. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa GFKQSSKALQRPV

15, 22, 36

cytogenetic

bcr‐abl. No response in

1960;142: 1497–501.

K, Kuramoto A, et al. A randomized trial comparing

non‐response

cytogenetic non‐response

patients

4. Rowley JD. Letter: A new consistent chromosomal

interferon‐alpha with busulfan for newly diagnosed

IVHSATGFKQSSKALQRPVASDFE 103

All

Either combined b3a2 or b2a2

IFA

13 CML

10 CCR, 2 PCR, 1

13 with detectable bcr‐abl in

abnormality in chronic myelogenous leukaemia identi-

chronic myelogenous leukemia in chronic phase. Blood.

KQSSKALQR

peptides SC q2 weeks × 5 doses,

GM‐CSF

0.4% Ph + by FISH

peripheral blood or marrow

then q28 days × 4 doses, then at

fied by quinacrine fluorescence and Giemsa staining.

1995;86(3):906–16.

GFKQSSKAL

YL KALQRPV

9 and 12 months. Note: bold

Nature. 1973;243(5405):290–3.

17. Al an NC, Richards SM, Shepherd PC. UK Medical

K L LQRPVAV

underline signifies heteroclitic

5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E,

Research Council randomised, multicentre trial of inter-

VHSIPLTINKEEALQRPVASDFE

amino acids.

YL INKEEAL

Ford JM, et al. Efficacy and safety of a specific inhibitor

feron‐alpha n1 for chronic myeloid leukaemia: improved

IVHSATGFKQSSKALQRPVASDFE 104

All

100 μ g of either combined b3a2

IFA

10 CML

10 CCR

3 with transient 1 log reduction in

of the BCR‐ABL tyrosine kinase in chronic myeloid

survival irrespective of cytogenetic response. The UK

KQSSKALQR

or b2a2 peptides SC q2

GM‐CSF

bcr‐abl transcripts

GFKQSSKAL

weeks × 4 doses, then on week

leukemia. N Engl J Med. 2001;344(14):1031–7.

Medical Research Council’s Working Parties for

YL KALQRPV

9, then, q28 days × 10 doses.

6. O’Brien SG, Guilhot F, Larson RA, Gathmann I,

Therapeutic Trials in Adult Leukaemia. Lancet.

K L LQRPVAV

Note: bold underline signifies

Baccarani M, Cervantes F, et al. Imatinib compared with

1995;345(8962):1392–7.

VHSIPLTINKEEALQRPVASDFE

heteroclitic amino acids

YL INKEEAL (100)

interferon and low‐dose cytarabine for newly diagnosed 18. Interferon alfa versus chemotherapy for chronic myeloid chronic‐phase chronic myeloid leukemia. N Engl J Med.

leukemia: a meta‐analysis of seven randomized trials:



Note: AML = acute myeloid leukemia; MDS =; CR = complete remission; PR = partial remission; IFA = incomplete Freund’s adjuvant; KLH = keyhole limpet hemocyanin; GM‐CSF = granulocyte‐macrophage colony stimulating factor; CML = chronic myelogenous leukemia.

2003;348(11):994–1004.

Chronic Myeloid Leukemia Trialists’ Col aborative

7. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J,

Group. J Natl Cancer Inst. 1997;89(21):1616–20.

Paquette R, et al. Dasatinib in imatinib‐resistant 19. Hasford J, Pfirrmann M, Hehlmann R, Al an NC, Philadelphia chromosome‐positive leukemias. N Engl J

Baccarani M, Kluin‐Nelemans JC, et al. A new prog-

Med. 2006;354(24):2531–41.

nostic score for survival of patients with chronic myeloid

8. Cortes JE, Jones D, O’Brien S, Jabbour E, Konopleva M,

leukemia treated with interferon alfa. Writing

Ferrajoli A, et al. Nilotinib as front‐line treatment for

Committee for the Col aborative CML Prognostic

patients with chronic myeloid leukemia in early chronic

Factors Project Group. J Natl Cancer Inst. 1998;90(11):

phase. J Clin Oncol. 2010;28(3):392–7.

850–8.

9. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, 20. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Ayala M, et al. Dasatinib versus imatinib in newly diag-Champlin RE, et al. Evidence that specific T lympho-

nosed chronic‐phase chronic myeloid leukemia. N Engl

cytes may participate in the elimination of chronic

J Med. 2010;362(24):2260–70.

myelogenous leukemia. Nat Med. 2000;6(9):1018–23.

10. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, 21. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Lobo C, et al. Nilotinib versus imatinib for newly

Corradini P, et al. Allogeneic hematopoietic stem cell

68 Immunotherapy in Translational Cancer Research transplantation for chronic myeloid leukemia in Europe

relapsed acute myelogenous leukemia. Biology of Blood

2006: transplant activity, long‐term data and current

and Marrow Transplantation. 2009;15(11):1431–8.

results. An analysis by the Chronic Leukemia Working 32. Gale RP, Horowitz MM, Ash RC, Champlin RE, Party of the European Group for Blood and Marrow

Goldman JM, Rimm AA, et al. Identical‐twin bone

Transplantation (EBMT). Haematologica. 2006;91(4):

marrow transplants for leukemia. Ann Intern Med.

513–21.

1994;120(8):646–52.

22. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes 33. Horowitz MM, Gale RP, Sondel PM, Goldman JM, D, Schwerdtfeger R, et al. Allogeneic hematopoietic stem

Kersey J, Kolb HJ, et al. Graft‐versus‐leukemia reactions

cell transplantation (allo SCT) for chronic myeloid leu-

after bone marrow transplantation. Blood. 1990;75(3):

kemia in the imatinib era: evaluation of its impact within

555–62.

a subgroup of the randomized German CML Study IV. 34. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Blood. 2010;115(10):1880–5.

Fassas A, et al. Donor lymphocyte infusion in the

23. Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM,

treatment of first hematological relapse after allogeneic

Nadal E, et al. Response to donor lymphocyte infusions

stem‐cell transplantation in adults with acute myeloid

for chronic myeloid leukemia is dose‐dependent: the

leukemia: a retrospective risk factors analysis and

importance of escalating the cell dose to maximize

comparison with other strategies by the EBMT Acute

therapeutic efficacy. Leukemia. 2007;21(5):943–8.

Leukemia Working Party. Journal of Clinical Oncology.

24. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald

2007;25(31):4938–45.

M, Jacky E, Daenen SM, et al. Results of a HOVON/

35. De Gregorio E, Rappuoli R. From empiricism to rational

SAKK donor versus no‐donor analysis of myeloablative

design: a personal perspective of the evolution of vaccine

HLA‐identical sibling stem cell transplantation in first

development. Nat Rev Immunol. 2014;14(7):505–14.

remission acute myeloid leukemia in young and middle‐

36. Walker LS, Abbas AK. The enemy within: keeping self‐

aged adults: benefits for whom? Blood. 2007;109(9):

reactive T cel s at bay in the periphery. Nat Rev Immunol.

3658–66.

2002;2(1):11–9.

25. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison 37. Klein L, Hinterberger M, Wirnsberger G, Kyewski B.

C, Harrison G, et al. The importance of diagnostic cyto-

Antigen presentation in the thymus for positive selec-

genetics on outcome in AML: analysis of 1,612 patients

tion and central tolerance induction. Nat Rev Immunol.

entered into the MRC AML 10 trial. The Medical

2009;9(12):833–44.

Research Council Adult and Children’s Leukaemia 38. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Working Parties. Blood. 1998;92(7):2322–33.

Burg SH. Therapeutic cancer vaccines. J Clin Invest.

26. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J,

2015;125(9):3401–12.

Djulbegovic BJ, et al. Allogeneic stem cell transplanta-

39. Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis

tion for acute myeloid leukemia in first complete remis-

ML, Dranoff G, et al. The Human Vaccines Project: A

sion: systematic review and meta‐analysis of prospective

roadmap for cancer vaccine development. Sci Transl

clinical trials. Jama. 2009;301(22):2349–61.

Med. 2016;8(334):334ps9.

27. Lo‐Coco F, Avvisati G, Vignetti M, Thiede C, Orlando 40. van der Burg SH, Arens R, Ossendorp F, van Hall T, SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide

Melief CJ. Vaccines for established cancer: overcoming

for acute promyelocytic leukemia. N Engl J Med.

the challenges posed by immune evasion. Nat Rev

2013;369(2):111–21.

Cancer. 2016;16(4):219–33.

28. Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, 41. Bos R, van Duikeren S, van Hall T, Kaaijk P, Taubert R, Fiorentino J, et al. Effective treatment of acute promyelo-Kyewski B, et al. Expression of a natural tumor antigen

cytic leukemia with all‐trans‐retinoic acid, arsenic tri-

by thymic epithelial cel s impairs the tumor‐protective

oxide, and gemtuzumab ozogamicin. J Clin Oncol.

CD4+ T‐cell repertoire. Cancer Res. 2005;65(14):

2009;27(4):504–10.

6443–9.

29. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu 42. Pedersen SR, Sorensen MR, Buus S, Christensen JP,

A, Bullinger L, et al. Mutations and treatment outcome

Thomsen AR. Comparison of vaccine‐induced effector

in cytogenetical y normal acute myeloid leukemia.

CD8 T cell responses directed against self‐ and

N Engl J Med. 2008;358(18):1909–18.

non‐self‐tumor antigens: implications for cancer immu-

30. Estey EH. Treatment of relapsed and refractory acute

notherapy. J Immunol. 2013;191(7):3955–67.

myelogenous leukemia. Leukemia. 2000;14(3):476–9.

43. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber 31. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X,

DA, et al. Isolation and characterization of a zinc finger

Thall PF, et al. Quantifying the survival benefit for allo-

polypeptide gene at the human chromosome 11 Wilms’

geneic hematopoietic stem cell transplantation in

tumor locus. Cel . 1990;60(3):509–20.

CHAPTER 5 Myeloid Leukemia Vaccines 69

44. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, 57. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Sohn RL, et al. An internal deletion within an 11p13 zinc

Schwartz S, et al. Presence of Wilms’ tumor gene (wt1)

finger gene contributes to the development of Wilms’

transcripts and the WT1 nuclear protein in the majority

tumor. Cel . 1990;61(7):1257–69.

of human acute leukemias. Leukemia. 1995;9(6):

45. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis

1060–7.

D, Hensel N, et al. Targeted T‐cell therapy for human 58. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, leukemia: cytotoxic T lymphocytes specific for a peptide

Buluwela L, et al. Wilms’ tumor suppressor gene (WT1)

derived from proteinase 3 preferential y lyse human

is expressed in primary breast tumors despite tumor‐

myeloid leukemia cel s. Blood. 1996;88(7):2450–7.

specific promoter methylation. Cancer Res. 2001;

46. Casalegno‐Garduno R, Schmitt A, Schmitt M. Clinical

61(3):921–5.

peptide vaccination trials for leukemia patients. Expert 59. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Rev Vaccines. 2011;10(6):785–99.

Tamaki H, et al. High expression of Wilms’ tumor

47. McGranahan N, Furness AJ, Rosenthal R, Ramskov S,

suppressor gene predicts poor prognosis in breast cancer

Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell

patients. Clinical Cancer Research. 2002;8(5):1167–71.

immunoreactivity and sensitivity to immune checkpoint 60. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, blockade. Science. 2016;351(6280):1463–9.

Nakatsuka S, et al. Overexpression of the Wilms’ tumor

48. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P,

gene WT1 in de novo lung cancers. Int J Cancer.

Makarov V, Havel JJ, et al. Cancer immunology.

2002;100(3):297–303.

Mutational landscape determines sensitivity to PD‐1 61. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, blockade in non‐small cell lung cancer. Science.

Nakatsuka S, et al. Overexpression of the Wilms’ tumor

2015;348(6230):124–8.

gene WT1 in colorectal adenocarcinoma. Cancer Sci.

49. Vonka V, Petrackova M. Immunology of chronic mye-

2003;94(8):712–7.

loid leukemia: current concepts and future goals. Expert 62. Sugiyama H. Cancer immunotherapy targeting Wilms’

Rev Clin Immunol. 2015;11(4):511–22.

tumor gene WT1 product. Expert Rev Vaccines.

50. Genomic and epigenomic landscapes of adult de novo

2005;4(4):503–12.

acute myeloid leukemia. The New England Journal of 63. Burwell EA, McCarty GP, Simpson LA, Thompson KA, Medicine. 2013;368(22):2059–74.

Loeb DM. Isoforms of Wilms’ tumor suppressor gene

51. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y,

(WT1) have distinct effects on mammary epithelial cel s.

Yamamoto R, et al. Frequent pathway mutations of splic-

Oncogene. 2007;26(23):3423–30.

ing machinery in myelodysplasia. Nature. 64. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa 2011;478(7367):64–9.

T, et al. Wilms’ tumor gene (WT1) competes with

52. Constantino J, Gomes C, Falcao A, Cruz MT, Neves BM.

differentiation‐inducing signal in hematopoietic pro-

Antitumor dendritic cell‐based vaccines: lessons from

genitor cel s. Blood. 1998;91(8):2969–76.

20 years of clinical trials and future perspectives. Transl 65. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Res. 2016;168:74–95.

Pufnock JS, Schmitt TM, et al. Transferred WT1‐

53. Ni M, Hoffmann JM, Schmitt M, Schmitt A. Progress of

reactive CD8+ T cel s can mediate antileukemic activity

dendritic cell‐based cancer vaccines for patients with

and persist in post‐transplant patients. Sci Transl Med.

hematological malignancies. Expert Opin Biol Ther.

2013;5(174):174ra27.

2016.

66. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H,

54. Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of

et al. Induction of WT1 (Wilms’ tumor gene)‐specific

dendritic cell‐based cancer vaccines in hematologic

cytotoxic T lymphocytes by WT1 peptide vaccine and

malignancies. Hum Vaccin Immunother. 2014;10(11):

the resultant cancer regression. Proc Natl Acad Sci U S

3125–31.

A. 2004;101(38):13885–90.

55. Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, 67. Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau Scholl N, et al. Dendritic cel s (DCs) can be successful y

IW, Keilholz U. Complete remission in a patient with

generated from leukemic blasts in individual patients

recurrent acute myeloid leukemia induced by vaccina-

with AML or MDS: an evaluation of different methods.

tion with WT1 peptide in the absence of hematological

Journal of Immunotherapy. 2010;33(2):185–99.

or renal toxicity. Leukemia. 2004;18(1):165–6.

56. Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, 68. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Levine JD, et al. Individualized vaccination of AML

Blau IW, et al. A clinical and immunologic phase 2 trial

patients in remission is associated with induction of

of Wilms tumor gene product 1 (WT1) peptide vaccina-

antileukemia immunity and prolonged remissions. Sci

tion in patients with AML and MDS. Blood.

Transl Med. 2016;8(368):368ra171.

2009;113(26):6541–8.

70 Immunotherapy in Translational Cancer Research 69. Narita M, Masuko M, Kurasaki T, Kitajima T, Takenouchi

80. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A,

S, Saitoh A, et al. WT1 peptide vaccination in

Kirchner D, Krahn G, et al. Receptor for hyaluronan

combination with imatinib therapy for a patient with

acid‐mediated motility (RHAMM) is a new immuno-

CML in the chronic phase. Int J Med Sci.

genic leukemia‐associated antigen in acute and chronic

2010;7(2):72–81.

myeloid leukemia. Exp Hematol. 2002;30(9):1029–35.

70. Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, 81. Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR.

Shirakata T, et al. WT1 peptide vaccine induces

The human hyaluronan receptor RHAMM is expressed

reduction in minimal residual disease in an Imatinib‐

as an intracel ular protein in breast cancer cel s. J Cell

treated CML patient. Eur J Haematol.

Sci. 1998;111 (Pt 12):1685–94.

2010;85(4):358–60.

82. Abetamann V, Kern HF, Elsasser HP. Differential expres-

71. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T,

sion of the hyaluronan receptors CD44 and RHAMM in

Zakhaleva V, et al. Vaccination with synthetic analog

human pancreatic cancer cel s. Clinical Cancer Research.

peptides derived from WT1 oncoprotein induces T‐cell

1996;2(9):1607–18.

responses in patients with complete remission from 83. Teder P, Bergh J, Heldin P. Functional hyaluronan recep-acute myeloid leukemia. Blood. 2010;116(2):171–9.

tors are expressed on a squamous cell lung carcinoma

72. Van Tendeloo VF, Van de Velde A, Van Driessche A,

cell line but not on other lung carcinoma cell lines.

Cools N, Anguille S, Ladell K, et al. Induction of

Cancer Res. 1995;55(17):3908–14.

complete and molecular remissions in acute myeloid 84. Crainie M, Belch AR, Mant MJ, Pilarski LM.

leukemia by Wilms’ tumor 1 antigen‐targeted dendritic

Overexpression of the receptor for hyaluronan‐medi-

cell vaccination. Proc Natl Acad Sci U S A.

ated motility (RHAMM) characterizes the malignant

2010;107(31):13824–9.

clone in multiple myeloma: identification of three

73. Spicer AP, Roller ML, Camper SA, McPherson JD,

distinct RHAMM variants. Blood. 1999;93(5):

Wasmuth JJ, Hakim S, et al. The human and mouse

1684–96.

receptors for hyaluronan‐mediated motility, RHAMM, 85. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt genes (HMMR) map to human chromosome 5q33.2-A, Dohner H, et al. Characterization of several leu-

qter and mouse chromosome 11. Genomics.

kemia‐associated antigens inducing humoral immune

1995;30(1):115–7.

responses in acute and chronic myeloid leukemia. Int J

74. Misra S, Hascall VC, Markwald RR, Ghatak S.

Cancer. 2003;106(2):224–31.

Interactions between hyaluronan and its receptors 86. Schmitt M, Schmitt A, Rojewski MT, Chen J, (CD44, RHAMM) regulate the activities of inflamma-Giannopoulos K, Fei F, et al. RHAMM‐R3 peptide

tion and cancer. Front Immunol. 2015;6:201.

vaccination in patients with acute myeloid leukemia,

75. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S,

myelodysplastic syndrome, and multiple myeloma

et al. Overexpression of the hyaluronan receptor

elicits immunologic and clinical responses. Blood.

RHAMM is transforming and is also required for H‐ras

2008;111(3):1357–65.

transformation. Cel . 1995;82(1):19–26.

87. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT,

76. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg

Gotz M, Funk I, et al. High‐dose RHAMM‐R3 peptide

AH. Soluble hyaluronan receptor RHAMM induces

vaccination for patients with acute myeloid leukemia,

mitotic arrest by suppressing Cdc2 and cyclin B1 expres-

myelodysplastic syndrome and multiple myeloma.

sion. J Exp Med. 1996;183(4):1663–8.

Haematologica. 2010;95(7):1191–7.

77. Hall CL, Lange LA, Prober DA, Zhang S, Turley EA. 88. Dengler R, Munstermann U, al‐Batran S, Hausner I, pp60(c‐src) is required for cell locomotion regulated by

Faderl S, Nerl C, et al. Immunocytochemical and flow

the hyaluronanreceptor RHAMM. Oncogene.

cytometric detection of proteinase 3 (myeloblastin) in

1996;13(10):2213–24.

normal and leukaemic myeloid cel s. British Journal of

78. Joukov V, Groen AC, Prokhorova T, Gerson R, White E,

Haematology. 1995;89(2):250–7.

Rodriguez A, et al. The BRCA1/BARD1 heterodimer 89. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu modulates ran‐dependent mitotic spindle assembly.

S, et al. PR1 peptide vaccine induces specific immunity

Cel . 2006;127(3):539–52.

with clinical responses in myeloid malignancies.

79. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos

Leukemia. 2017;31(3):697–704.

K, Guil aume P, et al. Identification and characterization 90. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, of epitopes of the receptor for hyaluronic acid‐mediated

Superata J, et al. Leukemia‐associated antigen‐specific

motility (RHAMM/CD168) recognized by CD8+ T cel s

T‐cell responses following combined PR1 and WT1 pep-

of HLA‐A2‐positive patients with acute myeloid

tide vaccination in patients with myeloid malignancies.

leukemia. Blood. 2005;106(3):938–45.

Blood. 2008;111(1):236–42.

CHAPTER 5 Myeloid Leukemia Vaccines 71

91. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, 101. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Le RQ, et al. Repeated PR1 and WT1 peptide vaccina-Tabilio A, et al. Effect of a p210 multipeptide vaccine

tion in Montanide‐adjuvant fails to induce sustained

associated with imatinib or interferon in patients with

high‐avidity, epitope‐specific CD8+ T cel s in myeloid

chronic myeloid leukaemia and persistent residual

malignancies. Haematologica. 2011;96(3):432–40.



disease: a multicentre observational trial. Lancet.

92. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S,

2005;365(9460):657–62.

Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. 102. Rojas JM, Knight K, Wang L, Clark RE. Clinical evalu-Science. 2013;339(6127):1546–58.

ation of BCR‐ABL peptide immunisation in chronic

93. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B,

myeloid leukaemia: results of the EPIC study.

Quandt J, et al. A vaccine targeting mutant IDH1

Leukemia. 2007;21(11):2287–95.

induces antitumour immunity. Nature. 2014;512(7514):

103. Maslak PG, Dao T, Gomez M, Chanel S, Packin J,

324–7.

Korontsvit T, et al. A pilot vaccination trial of synthetic

94. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused

analog peptides derived from the BCR‐ABL break-

transcript of abl and bcr genes in chronic myelogenous

points in CML patients with minimal disease.

leukaemia. Nature. 1985;315(6020):550–4.

Leukemia. 2008;22(8):1613–6.

95. Bocchia M, Wentworth PA, Southwood S, Sidney J, 104. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, McGraw K, Scheinberg DA, et al. Specific binding of

et al. Synthetic tumor‐specific breakpoint peptide

leukemia oncogene fusion protein peptides to HLA

vaccine in patients with chronic myeloid leukemia and

class I molecules. Blood. 1995;85(10):2680–4.

minimal residual disease: a phase 2 trial. Cancer.

96. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre 2009;115(17):3924–34.

AR, et al. Direct evidence that leukemic cel s present 105. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, HLA‐associated immunogenic peptides derived from

Maekawa T, Ohmori K, et al. Cross‐priming of CD8(+)

the BCR‐ABL b3a2 fusion protein. Blood. 2001;98(10):

T cel s in vivo by dendritic cel s pulsed with autologous

2887–93.

apoptotic leukemic cel s in immunotherapy for elderly

97. Norbury LC, Clark RE, Christmas SE. b3a2 BCR‐ABL

patients with acute myeloid leukemia. Exp Hematol.

fusion peptides as targets for cytotoxic T cel s in

2011;39(4):424–33 e2.

chronic myeloid leukaemia. British Journal of 106. Ossenkoppele GJ, Stam AG, Westers TM, de Gruijl TD, Haematology. 2000;109(3):616–21.

Janssen JJ, van de Loosdrecht AA, et al. Vaccination of

98. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da

chronic myeloid leukemia patients with autologous in

Silva P, et al. BCR/ABL leukemia oncogene fusion pep-

vitro cultured leukemic dendritic cel s. Leukemia.

tides selectively bind to certain HLA‐DR alleles and can

2003;17(7):1424–6.

be recognized by T cel s found at low frequency in the 107. Roddie H, Klammer M, Thomas C, Thomson R, repertoire of normal donors. Blood. 1996;88(6):

Atkinson A, Sproul A, et al. Phase I/II study of vaccina-

2118–24.

tion with dendritic‐like leukaemia cel s for the immu-

99. Pinil a‐Ibarz J, Cathcart K, Korontsvit T, Soignet S,

notherapy of acute myeloid leukaemia. British Journal

Bocchia M, Caggiano J, et al. Vaccination of patients

of Haematology. 2006;133(2):152–7.

with chronic myelogenous leukemia with BCR‐ABL 108. Anguille S, Willemen Y, Lion E, Smits EL, Berneman oncogene breakpoint fusion peptides generates specific

ZN. Dendritic cell vaccination in acute myeloid leu-

immune responses. Blood. 2000;95(5):1781–7.

kemia. Cytotherapy. 2012;14(6):647–56.

100. Cathcart K, Pinil a‐Ibarz J, Korontsvit T, Schwartz J, 109. Houtenbos I, Westers TM, Hess CJ, Waisfisz Q, Zakhaleva V, Papadopoulos EB, et al. A multivalent

Ossenkoppele GJ, van de Loosdrecht AA. Flt‐3 internal

BCR‐ABL fusion peptide vaccination trial in patients

tandem duplication hampers differentiation of AML

with chronic myeloid leukemia. Blood. 2004;103(3):

blasts towards leukemic dendritic cel s. Leukemia.

1037–42.

2006;20(10):1892–5.





CHAPTER 6

6 Cancer Vaccines for Solid Tumors

Timothy J. Vreeland1, Garth S. Herbert2, and George E. Peoples3

1 Department of Surgery, Womack Army Medical Center, Fort Bragg, NC, USA 2 Department of Surgery, San Antonio Military Medical Center, San Antonio, TX, USA 3 Cancer Vaccine Development Program, San Antonio, TX, USA

Introduction

progress towards this goal has been made recently,

but the full realization remains elusive.

In the late 19th century, Dr. William Coley

famously noted tumor regression in sarcoma

patients after local infections. He hypothesized that Cancer vaccine strategies the immune system, while fighting the infection, The basic formula to induce an active immune becomes primed to recognize tumor cel s as patho- response involves presenting one or more tumor-gens and then lyses them. Dr. Coley deliberately associated antigens (TAAs) in the correct context.

inoculated cancer patients with streptococcus This typical y requires that antigens are taken up, bacteria as well as various viruses; he again saw processed, and presented by antigen‐presenting local regression of their tumors [1]. The field of cel s (APCs). In this chapter, we attempt to compre-cancer immunotherapy was born, but Dr. Coley’s hensively review the strategies that have been findings were met with great skepticism, relegating developed to accomplish this goal and the exam-immunotherapy to a very minimal role in the ples of each strategy that have made it to phase III treatment of cancer. Recent clinical successes in the trials. We divide these vaccines by strategy, covering form of monoclonal antibodies and checkpoint each of the following: dendritic cell (DC) vaccines, inhibitors (CPIs) have brought immunotherapy tumor cell vaccines, protein‐based vaccines, viral into the mainstream, renewing interest in the vaccines, and an anti‐idiotypic antibody vaccine.

development of cancer vaccines. The appeal of can- Tables 6.1–6.5 include a comprehensive list of these cer vaccines over classic chemotherapy, and even vaccines with pertinent details; the chapter follows over other immunotherapies, is the ability to these tables closely.

induce active immunity. A ful , active immune

response primed against tumor cel s will not only Dendritic cell vaccines lyse current tumor cel s, but will also induce long-lasting immune memory, enabling the immune Dendritic cel s are the body’s most potent system to attack dormant tumor cel s and decrease professional APCs, which uptake, process, and present the chance of a future recurrence. Substantial antigens to naïve T cel s in lymphoid organs [2].

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

72

Table 6.1 Dendritic cell vaccines.

Vaccine

Disease

Strategy Type Vaccine

Immuno‐

Phase

Patient Population

# Patients Study

Result

Reference NCT Number

adjuvant

Name

Sipuleucel‐T Prostate cancer DC

Autologous DC

3

Metastatic

512

IMPACT

Median OS 25.8 vs 21.7,

3





(Provenge)

primed with PAP

p = 03; PFS: 14.6 vs 14.4wk

p = .63

DCVax

Prostate cancer DC

Autologous DC

1, 2

33

74% developed significant

4





primed with PSMA

prolifererative responses

to PSMA.

3

Unknown

612

Cleared by FDA for 612 pt

5





trial, not started yet

GBM

DC

Autologous DC

2

New diagnosis/

39

Median OS 30mo vs

6





pulsed with

recurrence

14.6mo historical control;

autologous whole

33% of patients reached

tumor lysate

4 years survival

3

New diagnosis

331

Estimated completion 2017

7

NCT 00045968

ICT‐107

GBM

DC

Autologous DC

2

HLA‐A1/A2 resected,

124

Increased OS by 2mo

8





pulsed with 6

with <1 cm 3 residual

( p = .58)

peptides

tumor

Per protocol (PP) OS by 3mo

( p = .40)

Increased PFS by 2mos

( p = .02)

Increased PP PFS by 3mo

( p = .01)

3

Resected, min residual 414

Starting Nov 2015,

7

NCT 02546102

disease

estimated completion Dec

2019

AGS‐003

RCC

DC

Autologous DC w/

2

Metastatic

25

OS twice expected rate;

9





autologous tumor

24% survived >5 years

RNA & CD‐40 L

3

Metastatic or

450

ADAPT

Estimated completion April

10, 7

NCT 01582672

RNA

advanced disease

2017



Note: DC = dendritic cell; PAP = prostatic acid phosphatase; OS = overall survival; PFS = progression‐free survival; PSMA = prostate‐specific membrane antigen; GBM = glioblastoma multiforme; RCC = renal cell carcinoma.

Table 6.2 Protein-based vaccines.

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient

# Patients Study

Result

Reference NCT Number

adjuvant

Population

Name

Nelipepimut‐S Breast

Peptide

HER‐2/neu peptide

GM‐CSF

2

Disease free

187

5 yr DFS: 89.7 vs 80.2 ( p = .08);

11



(Neuvax)

cancer

Optimal dosing 5 yr DFS: 94.6%

vs 80.2% ( p = .05)

3

Disease free, node

700

PRESENT

Halted after interim review. Data

12,

NCT 01479244

positive, HER2 1+,2+

being analyzed.

7

gp100

Melanoma Peptide

gp100:209‐217

Montanide 3

Stage III/IV unresectable 177

OS: 17.8 vs 11.1mo, p = .06

14



peptide

ISA‐51

melanoma

PFS: 2.2 vs 1.6mo, p = .008

Response rate 16% vs 6%, p = .03

3

Stage III/IV, progressed 676

OS: gp100:6.4 vs ipi + gp100:10.0mo, 15



on SOC therapy

p < 0.001

OS: gp100: 6.4 vs ipi alone: 10.1mo,

p = .003

Emepepimut

NSCLC

Peptide

MUC1 lipopeptide

BSC

2

Stage IIIB/IV NSCLC

171

All pts 3 yr OS 31% vs 17%,

16



(tecemotide)

p = .035; stg IIIB OS 49% vs

27%, p = .07

MPL

3

Unresectable Stage III

1513

START

Median OS 25.6 vs 22.3mo

17



Trial

p = .123; TTP: HR = 0.87, p = .016

Concurrent chemotherapy

(chemo) grp:

Median OS 30.8 vs 20.6mo,

p = .016

3

Unresectable stage III, 35

START 2

Terminated August 2014

18

NCT 02049151

concurrent CRT

Trial

3

Unresectable stage III, 285

INSPIRE

Terminated August 2014

18

NCT 01015443

stable after CRT

Elpamotide

Pancreatic Peptide

VEGFR2 peptide

Montanide Phase Locally advanced or

153

PEGASUS‐ OS HR = 0.87, p = .897; Severe inj site

19



cancer

ISA‐51

2/3

metastatic

PC

reaction pts with better OS

(15.67mo) compared to placebo

(8.54), p = NS

Table 6.2 Protein-based vaccines.

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient

# Patients Study

Result

Reference NCT Number

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient

# Patients Study

Result

Reference NCT Number

adjuvant

Population

Name

adjuvant

Population

Name

Nelipepimut‐S Breast

Peptide

HER‐2/neu peptide

GM‐CSF

2

Disease free

187

5 yr DFS: 89.7 vs 80.2 ( p = .08);

11



GV1001

Pancreatic Peptide

Telomerase peptide

GM‐CSF

3

Locally advanced or

1062

Median OS Chemo vs sequential

21



(Neuvax)

cancer

Optimal dosing 5 yr DFS: 94.6%

cancer

metastatic

chemo + vaccine (vax): 7.89 vs

vs 80.2% ( p = .05)

6.94mo, p = .05

3

Disease free, node

700

PRESENT

Halted after interim review. Data

12,

NCT 01479244

Median OS chemo vs concurrent

positive, HER2 1+,2+

being analyzed.

7

chemo + vax: 7.89 vs 8.36,

gp100

Melanoma Peptide

gp100:209‐217

Montanide 3

Stage III/IV unresectable 177

OS: 17.8 vs 11.1mo, p = .06

14



p = .11

peptide

ISA‐51

melanoma

PFS: 2.2 vs 1.6mo, p = .008

Rindopepimut GBM

Peptide

14‐mer peptide of

GM‐CSF

2

EGFRvIII + w/o progression 82

ACT III

vs matched control from ACTIVATE: 23



Response rate 16% vs 6%, p = .03

(CDX‐110)

EGFRvIII with KLH

after SOC

median OS 24.6 vs 15.2mo; PFS

3

Stage III/IV, progressed 676

OS: gp100:6.4 vs ipi + gp100:10.0mo, 15



12.3mo vs PFS 6.4mo

on SOC therapy

p < 0.001

3

EGFRvIII + pts w/o

374

ACT IV

Discontinued. Vax vs control arms: 24

NCT 01480479

OS: gp100: 6.4 vs ipi alone: 10.1mo,

progression after SOC

HR = 0.99

p = .003

Vitespen

Melanoma Multiple

Autologous tumor

N/A

3

Adjuvant; at least

ITT 322 PT C‐100‐21 ITT OS no diff HR1.16, p = .32; 26



Emepepimut

NSCLC

Peptide

MUC1 lipopeptide

BSC

2

Stage IIIB/IV NSCLC

171

All pts 3 yr OS 31% vs 17%,

16



(HSPPC‐96)

peptides

derived peptides

partially resectable

219

study

PerTreat M1a + M1b: HR = 0.45,

(tecemotide)

p = .035; stg IIIB OS 49% vs

complexed with

stage IV disease (dz)

Group

p = .03

27%, p = .07

RCC

gp96 (HSP)

3

Post‐nephrectomy in

818

ITT RFS HR = 0.923, p = .506;

27



MPL

3

Unresectable Stage III

1513

START

Median OS 25.6 vs 22.3mo

17



non‐metastatic,

Subset with stage I or II: RFS HR

Trial

p = .123; TTP: HR = 0.87, p = .016

resectable RCC

0.576, p = .056

Concurrent chemotherapy

IMA901

RCC

Multiple

10 peptide vaccine

GM‐CSF

2

Metastatic RCC,

68

OS of immune responder + Cy vs

28



(chemo) grp:

peptides

HLA‐A2+

‐Cy HR = 0.38, p = .04

Median OS 30.8 vs 20.6mo,

3

Locally advanced or

339

IMPRINT

Sunitinib only vs sunitinib + vax:

29

NCT 01265901

p = .016

metastatic, HLA‐A2+

HR: 1.34, p = .087

3

Unresectable stage III, 35

START 2

Terminated August 2014

18

NCT 02049151

Seviprotimut

Melanoma Multiple

Shed peptides from 3 Alum

2

Resected, high‐risk

38

Median OS: 3.8 vs 2.7 year

31



concurrent CRT

Trial

(POL‐103A)

peptides

allogenic melanoma

stage III

( p = NS); TTP 1.6 vs 0.6 yr

3

Unresectable stage III, 285

INSPIRE

Terminated August 2014

18

NCT 01015443

cell lines

( p = .03)

stable after CRT

2

Resected, stage II/III

116

Vaccine vs placebo RFS:

30



Quadravalent HR = 0.63,

Elpamotide

Pancreatic Peptide

VEGFR2 peptide

Montanide Phase Locally advanced or

153

PEGASUS‐ OS HR = 0.87, p = .897; Severe inj site

19



p = .095; Trivalent HR = 0.407,

cancer

ISA‐51

2/3

metastatic

PC

reaction pts with better OS

p = .0018

(15.67mo) compared to placebo

3

Stage IIb‐III

1059

MAVIS

Est comp Oct 2018

7

NCT 01546571

(8.54), p = NS

postresection

( Continued )

Table 6.2 ( Continued )

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient

# Patients Study

Result

Reference NCT Number

adjuvant

Population

Name

Theratope

Breast

Protein

STn (MUC1

Enhanzyn

3

Metastatic; no dz

1028

OS: 23.1 vs 22 months, p = .916

33



(STn‐KLH)

cancer

epitope) + KLH

progression after

Concomitant endocrine therapy

32



SOC

OS 36.5 vs 30.7mo, p = .03;

>median Ab response 41.3

vs25.4mo, p = .009

CIMAvax‐EGF NSCLC

Protein

recEGF + recNeisseria Montanide 2

Stage IIIB/IV after SOC 80

Median OS 12.7 vs 8.5mo, p = NS

56



protein

ISA‐51

≤60 Median OS 11.57 vs 5.33,

p = .0124

3

Stage IIIB/IV after SOC 579

UK trail

57



MAGE‐A3

NSCLC

Protein

recMAGE‐A3

AS02B

2

Adjuvant ‐ resected

182

OS HR 0.81, p = .454

35



stage IB/II

DFS HR 0.76, p = .248

AS15

3

Completely MAGE‐A3 2272

MAGRIT

DFS 60.5 vs 57.9mo, p = .74

36



positive, resected

stage IB, II, IIIA

NSCLC

Melanoma Protein

recMAGE‐A3

AS15 vs

2

Unresectable

75

OS: 33mo AS15 vs 19.9mo AS02B 34



ASO2B

metastatic

6mo PFS AS15 25% vs ASO2B

melanoma

14%

AS15

3

dz free stage IIIB/C

1351

DERMA

Trial terminated after initial

38,

NCT 00796445

melanoma

analysis showed no difference in 7

DFS



Note: DFS = disease‐free survival; SOC = standard of care; RFS = recurrence‐free survival; TTP = time to progression; CRT = chemoradiotherapy; ITT = intention to treat; MPL = monophosphoryl lipid A; KLH = keyhole limpet hemocyanin.

Table 6.3 Tumor cell vaccines.

Table 6.2 ( Continued )

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient Population

# Patients Study

Result

Reference NCT Number

Vaccine

Disease

Strategy

Type Vaccine

Immuno‐

Phase Patient

# Patients Study

Result

Reference NCT Number

adjuvant

Name

adjuvant

Population

Name

GVAX

Prostate

Tumor cell

Allogenic tumor cell

2

Neoadjuvant,

6

4 had downstaging, 3 had

58



Theratope

Breast

Protein

STn (MUC1

Enhanzyn

3

Metastatic; no dz

1028

OS: 23.1 vs 22 months, p = .916

33



cancer

lines PC‐3 and

combined with

undetectable PSA at 2mo

(STn‐KLH)

cancer

epitope) + KLH

progression after

Concomitant endocrine therapy

32



LNCaP expressing

docetaxel

post‐op

SOC

OS 36.5 vs 30.7mo, p = .03;

GM‐CSF

3

Asymptomatic

626

VITAL‐1

Stopped early after HR 1.01

39

NCT 00089856

>median Ab response 41.3

metastatic

less than 30% of

vs25.4mo, p = .009

achieving endpoint

CIMAvax‐EGF NSCLC

Protein

recEGF + recNeisseria Montanide 2

Stage IIIB/IV after SOC 80

Median OS 12.7 vs 8.5mo, p = NS

56



3

Symptomatic

408

VITAL‐2

Terminated for safety

39

NCT 00133224

protein

ISA‐51

≤60 Median OS 11.57 vs 5.33,

metastatic

concerns

p = .0124

Pancreatic

Tumor cell

2 irradiated allogenic

2

Metastatic pancreatic

93

Median OS 6.0 vs 3.4mo,

40



3

Stage IIIB/IV after SOC 579

UK trail

57



cancer

PDA cell lines

ductal carcinoma

p = .006, favored

MAGE‐A3

NSCLC

Protein

recMAGE‐A3

AS02B

2

Adjuvant ‐ resected

182

OS HR 0.81, p = .454

35



expressing GM‐CSF

Gvax + CRS‐207

stage IB/II

DFS HR 0.76, p = .248

Algenpantucel‐L

Pancreatic

Tumor cell

Allogeneic tumor cell

2

Adjuvant stage I/II,

70

Median DFS 14.1 vs expected

41



AS15

3

Completely MAGE‐A3 2272

MAGRIT

DFS 60.5 vs 57.9mo, p = .74

36



(Hyperacute)

cancer

lines expressing

after R0/R1

11.4mo; higher dose 12mo

positive, resected

α Gal

resection

DFS 81% vs predicted <50%

stage IB, II, IIIA

3

Adjuvant, after R0/

722

IMPRESS

No difference in OS: SOC

42

NCT 01072981

NSCLC

R1 resection

30.5mo vs SOC + vax 27.3mo

Melanoma Protein

recMAGE‐A3

AS15 vs

2

Unresectable

75

OS: 33mo AS15 vs 19.9mo AS02B 34



Belagenpumatecel‐L

NSCLC

Tumor cell

Allogenic tumor cell

3

Stage III/IV, stable dz

532

STOP

No improvement overall, some

43,

NCT 01072981

ASO2B

metastatic

6mo PFS AS15 25% vs ASO2B

(Lucanix)

w/ antisense

after chemo

Trial

in pts enrolled w/in 12wks

44

melanoma

14%

plasmid

AS15

3

dz free stage IIIB/C

1351

DERMA

Trial terminated after initial

38,

NCT 00796445

OncoVAX

Colorectal

Tumor cell

Autologous tumor

3

Adjuvant, stage II/III

412

ECOG

Pts with immune response vs

45



melanoma

analysis showed no difference in 7

cancer

cells + BCG

5283

control OS: HR = 1.65,

DFS

p = .012; stage II with

immune response OS



Note: DFS = disease‐free survival; SOC = standard of care; RFS = recurrence‐free survival; TTP = time to progression; CRT = chemoradiotherapy; ITT = intention to treat; HR = 2.0, p = .018

MPL = monophosphoryl lipid A; KLH = keyhole limpet hemocyanin.

3

Adjuvant, stage II/III

254

ECOG

Overall reduced rate of

45



8701

recurrence by 44%, p = .023;

stage II by 61%, p = .011

3

Adjuvant, stage II

550

Est completion July 2020

7

NCT 02448173



Note: PSA = prostate‐specific antigen.

Table 6.4 Viral vaccines.

Vaccine

Disease

Strategy Type Vaccine

Immuno‐

Phase Patient Population

# Patients Study

Result

Reference NCT Number

adjuvant

Name

ProstVac‐VF

Prostate

Viral

PROSTVAC Vaccinia virus

recGM‐CSF 2

Biochemical progression

64

ECOG

Median time to PSA Prog:

47



cancer

(rV‐PSA) and Fowlpox virus

after local therapy

7897

rF‐PASx4 9.2 months,

(rF‐PSA)

rF‐PSA then rV‐PSA

9.2 months,

rV‐PSA then

rF‐PSA18.2 months, p = .15

rV‐PSA‐TRICOM prime,

recGM‐CSF 2

Metastatic, adjuvant

125

Median OS 25.1 vs 16.6,

48



rF‐PSA‐TRICOM boost

deprivation therapy

HR = 0.56, p = .006

resistant

rV‐PSA‐TRICOM prime,

±

3

Metastatic, castration

1297

Est. completion date

49,

NCT 01322490

rF‐PSA‐TRICOM boost

recGM‐

resistant

August 2017

7

CSF

TG4010

NSCLC

Viral

Modified vaccinia Ankara

2

Metastatic; first‐line

170

TIME

Overall PFS HR = 0.76,

50



encoding MUC1 and IL‐2

therapy

p = NS

Increased 6 months PFS in

non‐squamous,

HR = 0.67, p = .016

3

1000

Phase III trial terminated

50

NCT 01383148

2

Metastatic; dz progression 33

Vax + nivolumab Est.

7





after first‐line therapy

completion date

December 2018

TroVax

RCC

Viral

Modified vaccinia Ankara

3

Locally advanced/

732

Trovax + IL‐2 vs

52

(MVA‐5 T4)

encoding 5 T4

metastatic, after

placebo + IL‐2: OS 20.1

nephrectomy

vs 19.2 months, p = .55

Good prognosis subgroup,

HR = 0.54, p = .046

Table 6.4 Viral vaccines.

Vaccine

Disease

Strategy Type Vaccine

Immuno‐

Phase Patient Population

# Patients Study

Result

Reference NCT Number

adjuvant

Name

ProstVac‐VF

Prostate

Viral

PROSTVAC Vaccinia virus

recGM‐CSF 2

Biochemical progression

64

ECOG

Median time to PSA Prog:

47



cancer

(rV‐PSA) and Fowlpox virus

after local therapy

7897

rF‐PASx4 9.2 months,

(rF‐PSA)

rF‐PSA then rV‐PSA

9.2 months,

rV‐PSA then

rF‐PSA18.2 months, p = .15

rV‐PSA‐TRICOM prime,

recGM‐CSF 2

Metastatic, adjuvant

125

Median OS 25.1 vs 16.6,

48



rF‐PSA‐TRICOM boost

deprivation therapy

HR = 0.56, p = .006

resistant

rV‐PSA‐TRICOM prime,

±

3

Metastatic, castration

1297

Est. completion date

49,

NCT 01322490

Table 6.5 Anti‐idiotypic antibody vaccine.

rF‐PSA‐TRICOM boost

recGM‐

resistant

August 2017

7

Vaccine

Disease Strategy

Type Vaccine

Immuno‐

Phase Patient Population

# Patients Study

Result

Reference NCT Number

CSF

adjuvant

Name

TG4010

NSCLC

Viral

Modified vaccinia Ankara

2

Metastatic; first‐line

170

TIME

Overall PFS HR = 0.76,

50



encoding MUC1 and IL‐2

therapy

p = NS

Racotumomab

NSCLC

Antibody

Anti‐P3 anti‐idiotypic

Alum

2

Stage IIIb/IV dz, objective

176

Median OS 8.23 vs 6.8mo

55



Increased 6 months PFS in

monoclonal AB IEI0

response or stable dz after

p = .004

non‐squamous,

SOC

Median PFS 5.33 vs 2.9 p = .039

HR = 0.67, p = .016

3

1082

Est. completion early 2017

7

NCT 01460472

3

1000

Phase III trial terminated

50

NCT 01383148

2

Metastatic; dz progression 33

Vax + nivolumab Est.

7





after first‐line therapy

completion date

December 2018

TroVax

RCC

Viral

Modified vaccinia Ankara

3

Locally advanced/

732

Trovax + IL‐2 vs

52

(MVA‐5 T4)

encoding 5 T4

metastatic, after

placebo + IL‐2: OS 20.1

nephrectomy

vs 19.2 months, p = .55

Good prognosis subgroup,

HR = 0.54, p = .046





80 Immunotherapy in Translational Cancer Research A DC vaccine exploits the function by enhancing safe, immunogenic, and capable of inducing a presentation of TAAs, typical y by loading the high rate of disease stabilization in patients with antigens directly into the DC. One way to accom- metastatic androgen‐independent prostate cancer plish this is to select a single antigen, synthetical y [4]. The FDA has given approval for a phase III produce it, and load it into autologous DCs trial based on these early results, though at the (Provenge and DCVax‐Prostate). Other DC vac- time of publication of this chapter, the trial had yet cines are similar, but instead DCs are loaded with to begin [5]. DCVax‐L has completed phase I/II multiple synthetical y produced peptides trials in 39 patients with newly diagnosed or (ICT‐107). Another strategy is to expose DCs to recurrent glioblastoma multiforme (GBM). The autologous tumor components and allow the DCs median survival rate was 30 months—a vast to select which epitopes are presented (DCVax‐L). improvement over historical controls with a typ-Final y, one vaccine loads the DCs with autologous ical median survival of 14.6 months [5]. A phase tumor RNA (ASG‐003). The primary advantage of III trial is ongoing to measure progression‐free this strategy is that investigators directly load DCs, survival (PFS) and overall survival (OS) in 331

instead of assuming that the patient’s DCs will take patients with newly diagnosed GBMs. This trial up and process the selected cell or antigen in vivo. has completed enrollment and it should reach The disadvantage, however, is that the process of completion in 2017 [6, 7].

extracting, loading, and reinfusing these cel s is

rather expensive, potential y limiting the wide ICT‐107 (ImmunoCellular) applicability of this technology. These vaccines are ICT‐107 consists of autologous DCs pulsed with summarized in Table 6.1.

six synthetic class I peptides from a variety of TAAs

known to be expressed on GBM tumor cel s. The

Sipuleucel‐T (Provenge®, Dendreon)

results of a phase II trial of ICT‐107, in which

In many ways the most successful cancer vaccine to patients with minimal residual disease ( n = 124) date, Provenge remains the only Food and Drug were randomized after resection of a GBM to Administration (FDA)‐approved cancer vaccine. receive ICT‐107 or unpulsed DCs, showed Provenge uses autologous peripheral‐blood mono- improved PFS in both intention to treat (HR = 0.56, nuclear cel s and activates them against prostate p = .02) and per‐protocol analysis (HR = 0.53, cancer cel s by loading a fusion protein of prostate‐ p = .01) [8]. Based on these impressive results, a specific antigen and granulocyte macrophage phase III randomized, controlled, double‐blinded colony‐stimulating factor (GM‐CSF). In the phase study of ICT‐107 in GBM has begun and is actively III trial that led to FDA approval, 512 patients with recruiting patients; this trial is estimated to reach metastatic, castration‐resistant prostate cancer completion in 2019 [7].

were randomized to Provenge or placebo. After a

median follow‐up of 34.1 months, there was a 22% AGS‐003 (Rocapuldencel-T) relative risk reduction of mortality in the Provenge AGS‐003 is a vaccine against renal cell carcinoma group (HR = 0.78, p = .03), and median survival was (RCC) prepared ex vivo from autologous DCs co-increased (25.8 vs 21.7 months) [3].

electroporated with two types of RNA, the patient’s

amplified tumor RNA and synthetic CD40L RNA.

DCVax® (Northwest Biotherapeutics)

After promising early studies in patients with met-

DCVax is a family of vaccines consisting of autol- astatic RCC, a phase II trial was conducted in ogous DCs pulsed with various TAAs. The two which 25 patients were given ASG‐003 in addition most advanced forms are DCVax‐Prostate, in to planned sunitinib therapy. Results of the trial which DCs are pulsed with recombinant prostate‐ indicated minimal toxicity, and roughly a doubling specific membrane antigen whole protein, and of expected survival, with 24% of patients surviving DCVax‐L, in which DCs are pulsed with epitopes more than 5 years [9]. After these promising acid‐eluted from autologous tumor cel s [4]. Two results, a phase III trial (the ADAPT trial) started, small phase I/II studies have been completed with randomizing patients with advanced or metastatic DCVax‐Prostate, which showed the vaccine to be RCC to sunitinib with or without AGS‐003 [10].





CHAPTER 6 Cancer Vaccines for Solid Tumors 81

The ADAPT trial completed enrollment with 462 Single peptide vaccines patients randomized to standard therapy with

Rocapuldencel‐T versus standard therapy in 2:1 Nelipepimut‐S (NeuVax™, Galena Biopharma) fashion. Although there was no significant Nelipepimut‐S is a vaccine composed of GM‐CSF

difference between the groups with regard to and E75, a peptide from the transmembrane por-overall survival (Hazard Ratio 1.10 (0.83, 1.46) for tion of HER2, a well‐known breast cancer TAA.

combination therapy vs. standard therapy), more E75 was identified as the most immunodominant than half of the subjects in both treatment groups peptide from a number of HER2‐derived peptides, were censored for survival. The study authors note and then studied in a large phase I/II trial, where the potential for delayed treatment effect, as the patients receiving the vaccine had improved dis-objective response rate and overall response rate ease‐free survival (DFS) over patients receiving trended toward improvement in the combination GM‐CSF alone (89.7% vs 80.2%, p = .08). Subset group. Longer‐term follow‐up will be necessary to analysis showed that patients with HER2 low-determine whether Rocapuldencel‐T in addition to expressing (IHC 1+ or 2+) tumors, a population standard therapy improves outcomes.

with few current therapeutic options, also had

improved DFS over placebo (88.1% vs 77.5%,

p = .16) [11]. Based on these findings, the phase III Protein‐based vaccines

PRESENT study, which began in 2014, compared

Protein‐based vaccines rely on normal pathways of nelipepimut‐S vs GM‐CSF in patients with node-antigen uptake and presentation to facilitate immune positive, HER2 low‐expressing breast cancer. In response to one or more TAAs of the investigator’s June 2016, the PRESENT trial was halted after choosing, typical y delivered through subcutaneous interim review. Data from the study are currently injection. Although the proteins or peptides selected being analyzed [12]. This vaccine is also being are general y immunogenic, they often require an studied in combination with trastuzumab in two immunoadjuvant to increase the likelihood of gen- phase II trials [7].

erating ful , active immunity. The major advantage

of this strategy is that the same synthetical y derived Glycoprotein 100 (gp100) compound can be produced cheaply in large quan- Gp100 is a melanosomal protein that has been tities and given to a large number of patients. The shown to induce a strong immune response. A disadvantage, however, is that the patient’s immune vaccine was created based on a specific immuno-system must perform the crucial step of loading DCs genic peptide of gp100 (amino acids 209–217) and with the administered antigen.

has been tested in clinical trials in combination

A protein‐based vaccine can consist of a single with the immunoadjuvant Montanide ISA‐51. In immunogenic peptide, which allows the immune early clinical studies, gp100 was shown to induce a system to focus on one highly expressed TAA and meaningful immune response against melanoma makes assessing immune response to the vaccine cel s in HLA‐A0201‐positive patients. A phase II more straightforward. Alternatively, multiple trial was performed administering gp100 with specific peptides can be given at the same time, IL‐2, which showed improved objective response allowing for more widespread application of the rates compared to previous reports of IL‐2 alone vaccine to patients with tumors expressing mul- [13]. This prompted a phase III trial, which tiple TAAs and potential y attacking tumors on randomized 177 patients with stage III/IV mela-multiple fronts. Final y, an entire protein can be noma to IL‐2 alone or the gp100 vaccine plus IL‐2.

used as the inoculant, allowing the patient’s APCs The vaccine group showed a higher clinical to select the most immunogenic epitopes within response rate (16% vs 6%, p = .03) and longer PFS

the larger complex to be presented. Here we discuss (2.2 months vs 1.6 months, p = .008) [14]. This examples of each of the three separate strategies: gp100 vaccine was then used as control in a land-single peptide vaccines, multiple peptide vaccines, mark study that led to the FDA approval of ipilim-and full protein vaccines. These vaccines are sum- umab, a CPI that blocks CTLA‐4. The trial had marized in Table 6.2.

three arms: gp100 alone, gp100 with ipilimumab,





82 Immunotherapy in Translational Cancer Research and ipilimumab alone. Patients treated with gp100 Elpamotide had the lowest median OS of the three groups, Elpamotide is a peptide derived from vascular worse than those treated with ipilimumab and endothelial growth factor receptor‐2 (VEGFR2), gp100 (6.4 months vs 10.0 months, p < .001) or ipili- given with Montanide ISA‐51. The idea of pur-mumab alone (6.4 vs 10.1 months, p = .003) [15]. suing a vaccine directed at VEGFR2 was based on While the results of this trial favored ipilimumab the success of anti‐VEGF therapies in a number over the vaccine, research continues with gp100, of advanced malignancies [19]. A phase I study of particularly in vaccines using gp100 as one of mul- elpamotide in combination with gemcitabine in tiple peptides [7].

patients with advanced pancreatic cancer showed

prolonged survival (8.7 months) when compared

Emepepimut‐S (Tecemotide, Cascadian

to historical patients receiving gemcitabine. This

Therapeutics)

positive result led to a phase II/III study

Emepepimut‐S, formerly known as Stimuvax or (PEGASUS‐PC), in which 159 patients with BLP25 liposomal vaccine, is a single‐peptide locally advanced or metastatic pancreatic adeno-vaccine but with a more complicated delivery carcinoma who had received no prior chemora-system. The vaccine is composed of a MUC1‐based diotherapy were randomized to the vaccine or peptide, tecemotide, which has been combined Montanide ISA‐51 alone; both arms were given with an immunoadjuvant, monophosphoryl lipid standard of care (SOC) gemcitabine. The overall A, and anchored into the membrane of a liposome. results of this study were largely disappointing, This liposomal formulation is designed to facilitate with no difference in OS ( p = .918). In subgroup efficient uptake of the peptide into APCs. While analysis, vaccinated patients having a strong MUC1 is overexpressed in multiple malignancies, injection site reaction had better OS

the largest trials with emepepimut‐S have been (15.67

months) than those without severe

completed in non‐small‐cell lung cancer (NSCLC). reactions (8.28 months) and patients receiving A phase IIb trial was completed in patients with Montanide only (8.54 months, p value not either stage IIIB or IV NSCLC and showed the reported) [19]. The authors of this paper suggest vaccine to have the most promise in the subgroup a potential role for this vaccine in patients who of patients with loco‐regional disease (stage IIIB) are preselected based on reaction to a skin test,

[16]. The first phase III trial, the START trial, was but there are no current ongoing trials using completed in 1513 patients with unresectable stage elpamotide.

III NSCLC who did not progress on primary

chemoradiotherapy. Median OS was not signifi-

cantly different between groups (25.6 months vs GV1001

22.3 months, HR = 0.88, p = .123), but a secondary GV1001 is a subunit of human telomerase reverse endpoint of time to symptom progression was transcriptase. The vaccine, GV1001 plus GM-improved in vaccinated patients (HR

=

0.85, CSF, targets telomerase, which is required to

p = .023). Also, in predefined subgroup analysis, lengthen telomeres shortened by the repeated patients undergoing concurrent chemoradiother- DNA replication required for tumor growth. After apy showed a significant increase in median OS promising phase II results showing immunoge-when receiving the vaccine (30.8

months vs nicity and a signal of efficacy [20], the vaccine was 20.6 months, p = .016) [17]. Given the positive studied in a phase III trial (TeloVac) [21]. This results in the subgroup analysis, two additional phase III trial randomized 1062 patients with phase III trials, the START 2 and INSPIRE studies, local y advanced or metastatic pancreatic adeno-were started. Following the disappointing results of carcinoma to one of three arms: chemotherapy, an interim analysis of a phase I/II trial in Japanese sequential chemo‐immunotherapy, or concurrent patients (the EMR 63325‐009 study), however, the chemo‐immunotherapy. Median OS was higher two ongoing phase III trials were terminated, and in the chemotherapy alone group than the sequen-there are currently no further trials of emepep- tial chemo‐immunotherapy group (7.89 months imut‐S [18].

vs 6.94 months, p = .05) and was similar between





CHAPTER 6 Cancer Vaccines for Solid Tumors 83

chemotherapy and concurrent chemo‐immuno- analysis showed no improvement in OS in vacci-therapy groups (7.89 months vs 8.36 months, nated patients, whether intention‐to‐treat p = .64) [21].

population (HR = 1.16, p = .32) or treated

population (HR = 1.29, p = .25). Exploratory

Rindopepimut (Rintega®, Celldex

landmark analyses showed that patients with less

Therapeutics)

disease burden (M1a and M1b) receiving full

Rindopepimut (CDX‐110) is composed of an treatment with Vitespen (defined as 10 or more EGFRvIII peptide conjugated to the immune stim- inoculations) had a significant increase in OS

ulant, keyhole limpet hemocyanin (KLH). over similar patients in the physician’s choice Interestingly, this peptide was original y studied in arm (HR = 0.45, p = .03) [26]. A second phase III phase I trials as a part of DC therapy composed of trial of Vitespen was completed in which 728

autologous DCs pulsed with rindopepimut [22]. patients with nonmetastatic RCC were The use of DCs was abandoned in later trials due randomized to either vaccine therapy or obser-to the expense and difficulty of culturing these vation after undergoing nephrectomy. In this cel s. Instead, in phase II trials, it was given with trial, only 8% of patients had vaccine production GM‐CSF as a peptide vaccine. Three small phase failure. At the time of initial analysis, there was II trials were completed in patients with newly no significant difference in recurrence‐free diagnosed GBM: the ACTIVATE, ACT II, and survival (RFS) ( p = .506) or OS ( p = .896). A pre-ACT III trials. The last of these trials (ACT III) defined exploratory analysis of patients with showed an increase in PFS and OS in vaccinated lower disease burden (stage I and II disease), patients over historical controls from the however, showed a trend towards improved ACTIVATE trial [23]. This prompted a phase III recurrence rates with vaccination over observa-trial (ACT IV), which was discontinued in March tion (HR = 0.576, p = .056) [27]. There are no of 2016 after an interim analysis showed the ongoing trials of this vaccine in patients with treatment and control arms performed essential y RCC, but the platform is now being studied in the same (HR = 0.99; median OS: treatment arm phase I and II trials in patients with GBM [7].

20.4 months vs control 21.1 months) [23, 24].

IMA901

IMA901 is made up of 10 peptides (9 HLA‐A2‐

Multiple peptide vaccines

restricted and 1 HLA‐DR‐restricted) that were

Vitespen® (HSPPC‐96)

selected based on immunogenicity and overexpres-

Vitespen (HSPPC‐96), formerly known as sion in primary tumor tissues using an antigen dis-Oncophage®, is a vaccine composed of heat shock covery platform, XPRESIDENT, given with GM‐CSF

protein (HSP)‐derived peptide complexes puri- [28]. The vaccine was tested in a phase II trial in fied from autologous tumor cells. This vaccine which 68 HLA‐A2‐positive patients with meta-takes advantage of the natural immunogenicity static RCC were randomized to the vaccine with or of HSPs, which are known to have high uptake without cyclophosphamide pretreatment. This trial by DCs without need for an immunoadjuvant. showed that patients who were immune responders Proof of principle was completed in phase I and to the vaccine and were pretreated with cyclophos-II trials of patients with both melanoma and phamide had prolonged survival over those RCC [25]. The first phase III trial was completed without pretreatment (HR = 0.38, p = .04) [28]. A in patients with untreated stage IV melanoma. In randomized, phase III trial (the IMPRINT trial) this trial, 322 patients were randomly assigned to was completed in 2015. In this trial, 339 HLA‐A2

Vitespen or physician’s choice of standard mela- positive patients with advanced or metastatic RCC

noma therapy. Of note, 61 of 215 patients were randomized to sunitinib (standard first‐line randomized to the Vitespen arm did not receive treatment) with or without IMA901. Patients the vaccine because it could not be prepared for receiving combination therapy actual y had a trend them, highlighting the downside of using autolo- toward decreased OS (HR = 1.34, p = .087). T cell gous, instead of recombinant, proteins. Survival responses in the phase III trial were significantly





84 Immunotherapy in Translational Cancer Research diminished compared with those in the phase II receiving Enhanzyn. The overall results of this trial trial, which may have explained the lack of clinical showed similar median time to progression (3.4 vs response [29].

3.0 months, p = .305) and median OS (23.1 vs 22.

months, p = .916) between arms [33]. A post hoc

Seviprotimut‐L (POL‐103A)

analysis, however, showed a survival advantage for

The Seviprotimut‐L vaccine is composed of Theratope in the subgroup of patients receiving multiple surface peptides from three allogenic mel- concomitant endocrine therapy (median OS 36.5

anoma cell lines given with alum as the immuno- vs 30.7 months, p = .0287). Moreover, women in adjuvant. This vaccine is generated using a variation this subgroup with a median or higher antibody of a proprietary technology that involves isolating response had significantly longer median OS than and purifying shed proteins from three proprietary those with lower antibody response (41.3 vs melanoma cell lines [30]. A similar polyvalent 25.4 months, p = .009) [32]. While the overall vaccine created using this technology was studied results for this trial were somewhat disappointing, in a phase II trial in which 38 patients with resected this analysis offers hope for future use of Theratope stage III melanoma were randomized to vaccine or in a subset of women.

placebo. Vaccinated patients had significantly

increased median time to progression (1.6 years vs MAGE‐A3

0.6 years, p = .03) and a nonsignificantly increased The MAGE‐A3 protein is expressed in very few median OS (3.8 years vs 2.7 years) [31]. A more normal adult tissues but is commonly expressed in recent phase II trial compared a trivalent and a tumor cel s (up to 76% of melanomas) [34], mak-quadravalent vaccine, each produced in the same ing it an ideal target for a cancer vaccine. The manner as Seviprotimut‐L, to a null‐vaccine used MAGE‐A3 vaccine is a recombinant protein as a control. In this trial, 116 patients with stage II combined with one of two immunoadjuvants.

and III melanoma were randomized to either one Small pilot studies showed MAGE‐A3 to be immu-of the vaccines or placebo. RFS was better among nogenic and induce antitumor activity in multiple patients receiving the quadravalent vaccine malignancies [35], especial y melanoma and (HR = 0.632, p = .095) and the trivalent vaccine NSCLC. A small phase II trial conducted in mela-

(HR = 0.407, p = .0018) compared to null vaccine noma patients explored the best immunoadjuvant

[30]. Based on these findings, the phase III MAVIS to accompany MAGE‐A3, randomizing 75 patients trial of Seviprotimut‐L was started. This trial, to MAGE‐A3 plus either AS15 or AS02. Patients which is currently active but not recruiting patients, receiving AS15 as the immunoadjuvant showed enrolled patients with stage IIb‐III melanoma after improved immunologic response, longer median complete resection. Patients are randomized to the OS, and higher PFS at six months [34]. Based on vaccine or placebo; the trial is estimated to reach these results, MAGE‐A3 was paired with AS15 in completion in October 2018 [7].

future trials. The first phase III trial with the

MAGE‐A3 vaccine (the MAGRIT trial)

randomized 2272 patients with MAGE‐A3 positive

Full‐protein vaccines

stage IB, II, or IIIA NSCLC tumors (after resec-

Theratope (STn‐KLH)

tion) to standard adjuvant therapy plus either the

Theratope is a vaccine composed of a fusion pro- MAGE‐A3 vaccine or placebo. The median DFS

tein made up of sialy‐Tn (STn), a TAA found on was similar between the two groups (60.5 months cancer‐associated mucins, and KLH [32] combined and 57.9 months, p = .74), and an overall treatment with Enhanzyn as the immunoadjuvant. Early effect was not observed [36]. A second phase III trials in breast cancer showed the vaccine to be trial in melanoma (the DERMA trial) enrolled immunogenic and efficacious. A phase III trial 1351 patients with stage IIIB‐C melanoma and randomized 1,028 women with metastatic breast randomized 2:1 to treatment with the vaccine or cancer who had no evidence of disease or no pro- placebo [37]. Initial analysis of this trial in gressive disease following first‐line chemotherapy September of 2013 revealed a failure to meet the to either Theratope or KLH alone, with both arms coprimary endpoint of improved DFS in the





CHAPTER 6 Cancer Vaccines for Solid Tumors 85

overall MAGE‐A3 positive population. The termination of this trial [39]. Despite these DERMA trial was continued as investigators results in prostate cancer, research is ongoing attempted to identify a subpopulation that might with GVAX in pancreatic cancer, where early benefit from the vaccine, but it was terminated in studies showed the vaccine to effectively induce September 2016 [7, 38].

T cells against multiple pancreatic ductal adeno-

carcinoma antigens; multiple phase II trials are

Tumor cell vaccines

ongoing [7, 40].

Tumor cell vaccines are conceptual y the simplest Algenpantucel‐L (Hyperacute) vaccines, relying on the basic premise, which Algenpantucel‐L is a cancer vaccine that utilizes Dr. Coley exploited, that the immune system is the mechanism of action of hyperacute rejection primed against tumors following cell lysis, presen- of xenotransplants, which is based on the tation of the encountered epitopes by APCs, and presence of α(1,3)‐galactosyl epitopes (αGal) on priming of T cel s that interact with those APCs. In nonhuman mammalian cells. The vaccine is com-general, these vaccines consist of allogenic or autol- posed of two pancreatic ductal adenocarcinoma ogous tumor cel s that are irradiated and modified cell lines (HAPa‐1 and HAPa‐2) that have been to increase immunogenicity. The patient’s immune genetically engineered to express αGal [41]. A system will select the immunogenic epitopes from phase II study was performed in the adjuvant lysed cel s in vivo, thus priming the immune system setting after R0 or R1 resection of stage I or II against tumor cel s bearing the same epitopes. pancreatic cancer in which 73 patients were These vaccines are summarized in Table 6.3.

enrolled and given one of two doses of the vaccine

(100 million or 300 million cells/dose) in addition

GVAX

to SOC therapy. The overall median DFS

The GVAX vaccine is more of a concept than a

compared favorably with historical controls

specific vaccine. It consists of irradiated allo- (14.1

months vs 11.4

months). Furthermore,

genic tumor cell lines of one of many malig- patients in the higher dose cohort had increased nancies that have been genetically modified to 12‐month DFS over the lower dose cohort (81%

secrete GM‐CSF. Treatment with GVAX has vs 51%, p = .02), which led to the use of the higher reached phase III trials for use in one solid tumor dose for future trials [41]. Based on these results, cancer, prostate cancer, but has also shown suc- the vaccine was studied in a phase III trial (the cess in pancreatic cancer and leukemia. GVAX IMPRESS trial), which was recently completed.

for prostate cancer is composed of irradiated This trial enrolled 722 patients with pancreatic PC‐3 and LNCaP allogenic tumor cells. Two cancer following R0 or R1 resection and phase III trials have been conducted in meta- randomized them to SOC adjuvant therapy with static prostate cancer, the VITAL‐1 and VITAL‐2 or without algenpantucel‐L. Final analysis of this studies. VITAL‐1 enrolled men with asymptom- trial showed no improvement in OS (SOC: atic prostate cancer and randomized them to 30.4 months vs SOC and vaccine: 27.3 months) receive either vaccine or SOC. VITAL‐2 enrolled or long‐term survival (3 year survival: 41.4% vs men with symptomatic prostate cancer and 42.1%) [42].

randomized them to treatment with the vaccine

and docetaxel or to prednisone and docetaxel. In Belagenpumatucel‐L (Lucanix®, 2008, a routine safety review of VITAL‐2 showed NovaRx)

an increase in deaths in the treatment arm (67 vs Belagenpumatucel‐L is a vaccine produced from 47 in control arm); the trial was terminated. A irradiated allogeneic NSCLC cel s transfected with a safety review of VITAL‐1 showed no safety con- TGF‐B2 antisense gene plasmid. TGF‐B2 has been cerns, but efficacy concerns prompted a futility shown to have immunosuppressive effects in cancer analysis. Based on this analysis, the trial was patients and is inversely correlated with prognosis.

reported to have less than a 30% chance of meet- Vaccinating with tumor cel s and simultaneously ing an improved survival end point, leading to decreasing local levels of TGF‐B2 is thought to





86 Immunotherapy in Translational Cancer Research enhance the immune response to antigens from after curative resection. The vaccine will again be these tumor cel s [43]. A phase II trial randomized produced in a centralized lab [7].

75 patients with stage II–IV NSCLC after conven-

tional therapy to one of three doses of the vaccine Viral vaccines (1.25, 2.5, or 5 × 107 cel s/injection). Patients who

received 2.5 or 5 × 107 cel s/injection had increased Viral vaccines are similar to tumor cell vaccines, survival compared to the lowest dose cohort but they are natural y immunogenic and are modi-

( p = .0069) [43]. The phase III STOP trial was con- fied to contain TAAs. In general, a recombinant ducted in 532 patients with stage IIIA–IV NSCLC plasmid that codes for a TAA is inserted into the with stable disease after chemotherapy, randomizing genome of a virus, sometimes along with a plasmid them to vaccine or placebo. Median OS was coding for an immunoadjuvant or cytokine. The 20.3 months for the vaccine group and 17.4 months virus is then injected into a patient, where the for the placebo group ( p = .594). A subgroup of inherent viral proteins will induce a strong immune patients with stage IIIB/IV disease randomized response, inducing the recruitment of APCs. The within 12 weeks of completion of chemotherapy had APCs that have been recruited and activated will improved median OS over placebo (20.7 months vs then process and present the viral proteins, 13.4 months; HR = 0.75, p = .083). Stage IIIB/IV non- including the TAAs that have been selected by adenocarcinoma patients randomized within 12 investigators and inserted into the virus. Thus, the weeks had a statistical y significant improvement immune system will be primed against these TAAs over placebo (19.9 months vs 12.3 months; HR = 0.55, and the tumors that express them. These vaccines p = .036) [44]. Although the overall results were non- are summarized in Table 6.4.

significant, the subgroups analyses support

continued trials with this vaccine.

ProstVac‐VF (Bavarian Nordic)

ProstVac is composed of one of two viruses, each

OncoVAX® (Vaccinogen, Inc.)

modified to express prostate‐specific antigen (PSA)

OncoVAX is composed of autologous tumor cells and used to treat prostate cancer. Two forms of the mixed with bacillus Calmette‐Guérin. Multiple vaccine, fowlpox‐PSA (rF‐PSA) and vaccinia‐PSA small phase III trials have been completed with (rV‐PSA), have been studied in phase II trials. The this vaccine in patients with stage II or III colon first trial tested the theory of prime/boost vaccina-cancer after curative resection. Two of these tion with combinations of these two vaccines and studies showed the vaccine to be beneficial, par- found the best results when patients were primed ticularly in patients with stage II disease [45]. with rV‐PSA and boosted with rF‐PSA [47]. Based The trials were similar, though the most recent on this result, the vaccine became known as trial (ECOG 8701) was conducted with an addi- PROSTVAC‐VF, priming patients with rV‐PSA and tional booster inoculation at six months and used boosting with rF‐PSA. A triad of costimulatory mol-vaccine manufactured at a centralized lab (after ecules (referred to as TRICOM) was then added to quality control concerns during the previous the vaccine (along with GM‐CSF). A phase II trial trial, ECOG 5283, which did not utilize a central- was conducted in which 125 patients were enrolled ized lab). A meta‐analysis of these phase III trials and randomized to the finalized form of the vaccine has also been completed and showed increased or placebo. Vaccinated patients showed improved OS

RFS with the vaccine over placebo in patients compared with those randomized to placebo who met quality control specifications ( p = .024). (HR = 0.56, p = .006) [48]. These results inspired a Additionally, stage II patients receiving at least three‐arm phase III trial comparing PROSTVAC‐VF

four doses of the vaccine showed improved RFS plus GM‐CSF, PROSTVAC‐VF without GM‐CSF, ( p = .009) and OS ( p = .018) compared with and placebo. The trial has completed enrollment of patients receiving placebo [46]. Based on these 1297 patients, and two interim analyses have con-findings, a phase III trial has started, expecting to firmed that the study will continue as planned. Final enroll 550 patients with stage II colon cancer results are expected in the second half of 2017 [7, 49].





CHAPTER 6 Cancer Vaccines for Solid Tumors 87

TG4010 (Transgene)

Anti‐idiotypic antibody vaccine

TG4010 is created from modified vaccinia strain

Ankara (MVA), to which plasmids for MUC‐1 (a There is only one example of anti‐idiotypic well‐known TAA) and IL‐2 have been added. antibody vaccine that has reached a phase III trial.

This vaccine is being studied in a phase IIb/III The strategy with this vaccine is to give an immu-trial (the TIME trial) in patients with NSCLC. In nogenic antibody that mimics a TAA and induces the phase IIb portion of this trial, 170 patients an antigen‐specific immune response against this were randomized to standard first‐line therapy TAA. This novel technique is similar to a peptide plus either the vaccine or placebo. While the vaccine but instead uses a murine antibody, which overall analysis of PFS showed a nonsignificant should be more immunogenic. This vaccine is difference (HR = 0.76, p = NS), the subgroup summarized in Table 6.5.

with nonsquamous cell tumors did show an

improved 6 months PFS (HR = 0.67, p = .016). Racotumomab Initially, a phase III continuation of this trial was Racotumomab, previously known as 1E10, is a planned, but this trial has since been terminated murine anti‐idiotype monoclonal antibody that

[7, 50]. Development of this vaccine will con- mimics NeuGcGM3 given with alum. NeuGc gly-tinue instead in the form of a phase II trial colipids are not found on membranes of normal combining TG4010 and nivolumab in patients human cel s but are found on multiple human with metastatic NSCLC who have progressed tumors, including NSCLC. NeuGcGM3, one of after one line of systemic therapy [7].

these glycolipids, is known to be a potent immuno-

suppressive molecule, making it an attractive target

for a cancer vaccine. After early studies showed the

TroVax® (MVA‐5T4, Oxford

vaccine to be immunogenic and efficacious [54], a

Biomedica)

phase II/III trial was conducted in 176 patients

Trovax is also an MVA‐based vaccine, modified with stage III or IV NSCLC who had stable disease instead to express 5 T4, which is an oncofetal or regression after SOC therapy. One hundred sev-antigen expressed in >80% of carcinomas of the enty‐six patients were randomized to vaccine or kidney, breast, colon/rectum, prostate, and ovary placebo, and both median OS (HR = 0.63, p = .004)

[51]. This vaccine underwent multiple phase I/II and median PFS (HR = 0.73, p = .039) were signifi-trials and was found not only to be well tolerated cantly improved in vaccinated patients [55]. Based but also able to induce 5 T4‐specific immune on these results, a larger phase III trial was started responses, which correlated with clinical benefit in which 1082 patients with nonresectable stage III

[51]. The vaccine has been most successful or IV NSCLC with stable disease or objective in treatment of RCC, where a phase III trial response after standard therapy were enrolled. This randomized 732 patients who had undergone trial has reached target enrollment and is nearing nephrectomy for locally advanced or metastatic completion [7].

disease to vaccine or placebo in addition to SOC

therapy. Although the overall results of this trial

showed no difference in OS, exploratory analyses Summary

of subgroups revealed that patients with high While there is much promise in the field of cancer 5 T4‐specific antibodies had favorable survival vaccines, only one vaccine, Provenge, has achieved outcomes (HR = 0.55, 95% CI 0.39–0.97) [52]. the ultimate goal of FDA approval and clinical use.

Trovax continues to be examined in multiple Each vaccine strategy has its merits and has found ongoing phase II trials studying patients who are some level of success, so meaningful research predicted to have strong 5 T4‐specific immune should continue with each of these strategies.

responses based on an immune response Overal , these vaccines are very well tolerated with surrogate, which has been developed by the man- minimal toxicity, which is part of what makes them ufacturers of Trovax [53].

attractive as definitive therapies for cancer. As





88 Immunotherapy in Translational Cancer Research demonstrated by the multiple trials with disap-8. Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi

pointing overall results but promising results in

JC, Curry WT, et al. A randomized, double‐blind,

certain subsets of patients, identifying the correct

placebo‐controlled phase 2 trial of dendritic cell (DC)

patient population for these vaccines is paramount

vaccination with ICT‐107 in newly diagnosed glioblas-

to future success. Multiple studies have shown

toma (GBM) patients. Journal of Clinical Oncology.

increased efficacy in patients with minimal disease,

2014;32(15 Suppl):2005.

9. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein

which is not surprising based on the mechanism of

JM, Knox JJ, et al. Survival with AGS‐003, an autologous

these vaccines. Patients who are healthy enough to

dendritic cell‐based immunotherapy, in combination

receive all doses of the vaccine will derive more

with sunitinib in unfavorable risk patients with advanced

benefit, and minimal disease burden is a more rea-

renal cell carcinoma (RCC): phase 2 study results. J

sonable target for immune mechanisms, which

Immunother Cancer. 2015;3:14.

may not be capable of overcoming a large tumor 10. Daley A. Independent Data monitoring committee rec-burden. Final y, multiple trials found vaccines to be

ommends continuation of pivotal adapt phase 3 clinical

more efficacious in patients with improved

trial of AGS‐003 for metastatic renal cell carcinoma

immune responses; thus, maximizing the immune

Argos Therapeutics. Available from: ir.argostherapeu-

response to vaccines is paramount to the success of

tics.com [Cited 10 October 2015].

future trials. One very promising way to improve 11. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al. Final report of the phase I/II

the response to vaccine therapy is combination

clinical trial of the E75 (nelipepimut‐S) vaccine with booster therapy with vaccines and CPIs. CPIs serve to

inoculations to prevent disease recurrence in high‐risk

unleash the full power of the immune system,

breast cancer patients. Ann Oncol. 2014;25(9): 1735–42.

while the vaccine directs the response toward the 12. Galena Biopharma Discontinues NeuVax™ (nelipepimut‐S) tumor. The hope is that this will not only increase

Phase 3, PRESENT interem analysis based on

the efficacy of vaccines but potential y decrease the

independent data monitoring committee recommen-

toxicity of CPIs simultaneously. This new strategy

dation. Available from: http://investors.galenabiopharma.

is being investigated in multiple trials and holds

com/. Accessed 10 January 2017.

great promise for the future.

13. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P,

Marincola FM, Topalian SL, et al. Immunologic and

therapeutic evaluation of a synthetic peptide vaccine for

References

the treatment of patients with metastatic melanoma. Nat

Med. 1998;4(3):321–7.

1. Coley WB. The treatment of inoperable sarcoma by 14. Schwartzentruber DJ, Lawson DH, Richards JM, Conry bacterial toxins (the mixed toxins of the Streptococcus

RM, Miller DM, Treisman J, et al. gp100 peptide vaccine

erysipelas and the Bacil us prodigiosus). Proc R Soc Med.

and interleukin‐2 in patients with advanced melanoma.

1910;3(Surg Sect):1–48.

N Engl J Med. 2011;364(22):2119–27.

2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu 15. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman YJ, et al. Immunobiology of dendritic cel s. Annu Rev

JA, Haanen JB, et al. Improved survival with ipilimumab

Immunol. 2000;18:767–811.

in patients with metastatic melanoma. N Engl J Med.

3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ,

2010;363(8):711–23.

Penson DF, et al. Sipuleucel‐T immunotherapy for castra-

16. Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E,

tion‐resistant prostate cancer. N Engl J Med. 2010;363(5):

Cormier Y, et al. Updated survival analysis in patients

411–22.

with stage IIIB or IV non‐small‐cell lung cancer

4. Knutson KL. Technology evaluation: DCVax, Northwest

receiving BLP25 liposome vaccine (L‐BLP25): phase IIB

Biotherapeutics. Curr Opin Mol Ther. 2002;4(4):403–7.

randomized, multicenter, open‐label trial. J Cancer Res

5. Northwest Biotherapeutics Pipeline. Available from: http://

Clin Oncol. 2011;137(9):1337–42.

www.nwio.com/clinical‐trials. Accessed 5 January 2017.

17. Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L,

6. Hdeib A, Sloan AE. Dendritic cell immunotherapy for

Krzakowski MJ, et al. START: A phase III study of L‐

solid tumors: evaluation of the DCVax(R) platform in the

BLP25 (tecemotide) cancer immunotherapy for unre-

treatment of glioblastoma multiforme. CNS Oncol.

sectable stage III non‐small cell lung cancer. J Clin

2015;4(2):63–9.

Oncol. 2013;31(Suppl):Abstract 7500.

7. National Institute of Health ClinicalTrials.gov. Available 18. Merck KGaA discontinues clinical development from: http://clinicaltrials.gov. Accessed 10 January 2016.

program of tecemotide as a monotherapy in stage III

CHAPTER 6 Cancer Vaccines for Solid Tumors 89

non‐small cell lung cancer. PR Newswire. Available 29. Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, from: http://www.prnewswire.com. Accessed 8 October

Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus

2015.

sunitinib versus sunitinib alone, as first‐line therapy for

19. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K,

advanced or metastatic renal cell carcinoma (IMPRINT): a

Mizuno N, et al. Randomized phase II/III clinical trial of

multicentre, open‐label, randomised, controlled, phase 3

elpamotide for patients with advanced pancreatic can-

trial. Lancet Oncol. 2016;17(11): 1599–611.

cer: PEGASUS‐PC Study. Cancer Sci. 2015;106(7): 30. Prior clinical trials: seviprotimut‐L phase II clinical 883–90.

trials. Available from: www.polynoma.com. Accessed 5

20. Bernhardt SL, Gjertsen MK, Trachsel S, Moller M,

October 2015.

Eriksen JA, Meo M, et al. Telomerase peptide vaccina-

31. Bystryn JC, Zeleniuch‐Jacquotte A, Oratz R, Shapiro RL,

tion of patients with non‐resectable pancreatic cancer: A

Harris MN, Roses DF. Double‐blind trial of a polyvalent,

dose escalating phase I/II study. Br J Cancer. 2006;95(11):

shed‐antigen, melanoma vaccine. Clin Cancer Res.

1474–82.

2001;7(7):1882–7.

21. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, 32. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample Propper D, et al. Gemcitabine and capecitabine with or

D, Tautchin M, et al. Survival advantage in patients with

without telomerase peptide vaccine GV1001 in patients

metastatic breast cancer receiving endocrine therapy

with local y advanced or metastatic pancreatic cancer

plus sialyl Tn‐KLH vaccine: post hoc analysis of a large

(TeloVac): an open‐label, randomised, phase 3 trial.

randomized trial. J Cancer. 2013;4(7):577–84.

Lancet Oncol. 2014;15(8):829–40.

33. Miles D, Roche H, Martin M, Perren TJ, Cameron DA,

22. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey

Glaspy J, et al. Phase III multicenter clinical trial of the

PA, Kurpad SN, et al. Monoclonal antibodies against

sialyl‐TN (STn)‐keyhole limpet hemocyanin (KLH)

EGFRvIII are tumor specific and react with breast and

vaccine for metastatic breast cancer. Oncologist.

lung carcinomas and malignant gliomas. Cancer Res.

2011;16(8):1092–100.

1995;55(14):3140–8.

34. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C,

23. Swartz AM, Li QJ, Sampson JH. Rindopepimut: A prom-

Chiarion‐Sileni V, et al. Selection of immunostimulant

ising immunotherapeutic for the treatment of glioblas-

AS15 for active immunization with MAGE‐A3 protein:

toma multiforme. Immunotherapy. 2014;6(6):679–90.

results of a randomized phase II study of the European

24. Celldex Therapeutics. RINTEGA (rindopepimut): a

Organisation for Research and Treatment of Cancer

phase 3 immunotherapy targeting EGFRvIII‐expressing

Melanoma Group in Metastatic Melanoma. J Clin Oncol.

glioblastoma (GBM). Available from: www.celldex.com/

2013;31(19):2413–20.

pipeline/ Accessed 9 January 2017.

35. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J,

25. Srivastava P. Interaction of heat shock proteins with pep-Gonzalez EE, Malinowski W, et al. Adjuvant MAGE‐A3

tides and antigen presenting cel s: chaperoning of the

immunotherapy in resected non‐small‐cell lung cancer:

innate and adaptive immune responses. Annu Rev

phase II randomized study results. J Clin Oncol.

Immunol. 2002;20:395–425.

2013;31(19):2396–403.

26. Testori A, Richards J, Whitman E, Mann GB, Lutzky 36. Vansteenkiste JF, Cho B, Vanakesa T, De Pas T, Zielinski J, Camacho L, et al. Phase III comparison of vitespen,

M, Kim MS, et al. 1173O MAGRIT, a double‐blind,

an autologous tumor‐derived heat shock protein

randomized, plaebo‐controlled phase III study to assess

gp96 peptide complex vaccine, with physician’s

the efficacy of the RECMAGE‐A3 + AS15 cancer immu-

choice of treatment for stage IV melanoma: the

notherapeutic as adjuvant therapy in patients with

C‐100‐21 Study Group. J Clin Oncol. 2008;26(6):

resected MAGE‐A3‐positive non‐small cell lung cancer

955–62.

(NSCLC). Ann Oncol. 2014;25(suppl_4):iv409–iv.

27. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov 37. Kirkwood JM, Dreno B, Hauschild A, Schadendorf D, AI, Gorelov S, et al. An adjuvant autologous therapeutic

Testori A, Hersey P, et al. DERMA phase III trial of

vaccine (HSPPC‐96; vitespen) versus observation alone

MAGE‐A3 antigen‐specific cancer immunotherapeutic

for patients at high risk of recurrence after nephrectomy

(ASCI) as adjuvant therapy in patients with MAGE‐A3‐

for renal cell carcinoma: a multicentre, open‐label, ran-

positive resected stage III melanoma. J Clin Oncol.

domised phase III trial. Lancet. 2008;372(9633):145–54.

2011;29(15 Suppl):TPS232‐TPS.

28. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, 38. GlaxoSmithKline. Update on phase III clinical trial of Pluzanska A, Szczylik C, et al. Multipeptide immune

investigational MAGE‐A3 antigen‐specific cancer

response to cancer vaccine IMA901 after single‐dose

immunotherapeutic in non‐small cell lung cancer.

cyclophosphamide associates with longer patient

Available from: http://us.gsk.com/en‐us/media/press‐

survival. Nat Med. 2012;18(8):1254–61.

releases/. Accessed 8 January 2017.

90 Immunotherapy in Translational Cancer Research 39. Drake CG. Immunotherapy for prostate cancer: walk,

poxviruses expressing PSA in hormone dependent

don’t run. J Clin Oncol. 2009;27(25):4035–37.

prostate cancer: follow‐up clinical results from ECOG

40. Le DT, Wang‐Gil am A, Picozzi V, Greten TF, Crocenzi

7897. J Clin Oncol. 2005;23(16S):Abstract 4501.

T, Springett G, et al. Safety and survival with GVAX pan-

48. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM,

creas prime and Listeria monocytogenes–expressing

Bilhartz DL, Wyand M, et al. Overall survival analysis of

mesothelin (CRS‐207) boost vaccines for metastatic

a phase II randomized controlled trial of a Poxviral‐

pancreatic cancer. J Clin Oncol. 2015;33(12):1325–33.

based PSA‐targeted immunotherapy in metastatic

41. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel



castration‐resistant prostate cancer. J Clin Oncol.

J, Krishnamurthi S, et al. Addition of algenpantucel‐L

2010;28(7):1099–105.

immunotherapy to standard adjuvant therapy for 49. Bavarian Nordic provides update on anticipated tim-pancreatic cancer: a phase 2 study. J Gastrointest Surg.

ing of prospect study. Available from: http://www.

2013;17(1):94–100; discussion p. 1.

bavarian‐nordic.com/investor/news/. Accessed 8

42. NewLink Genetics announces results from phase 3

January 2017.

IMPRESS trial of algenpantucel‐l for patients with 50. Quoix E. Therapeutic vaccination with TG4010 and resected pancreatic cancer. Available from: http://

first‐line chemotherapy in advanced NSCLC: a con-

investors.linkp.com/. Accessed 28 December 2016.

trolled phase 2B trial. Lancet Oncol. 2011;12.

43. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer 51. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley N, Cunningham C, Cutler J, et al. Phase II study of bela-M, Stern PL. Immunohistological distribution of 5 T4

genpumatucel‐l, a transforming growth factor beta‐2

antigen in normal and malignant tissues. Br J Cancer.

antisense gene‐modified allogenic tumor cell vaccine in

1990;61:89–95.

non‐small cell lung cancer. J Clin Oncol. 2006;24(29): 52. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, 4721–30.

Tomczak P, Szczylik C, et al. Vaccination of metastatic

44. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhasz

renal cancer patients with MVA‐5T4: a randomized,

E, Ramlau R, et al. A phase III study of belagenpumatu-

double‐blind, placebo‐controlled phase III study. Clin

cel‐L, an allogeneic tumour cell vaccine, as maintenance

Cancer Res. 2010;16(22):5539–47.

therapy for non‐small cell lung cancer. Eur J Cancer. 53. Oxford BioMedica announces publication of Trovax 2015;51(16):2321–9.

phase III analyses in cancer immunology, immunother-

45. Hoover HC, Jr., Brandhorst JS, Peters LC, Surdyke MG,

apy [press release]. Available from: oxfordbiomedica.

Takeshita Y, Madariaga J, et al. Adjuvant active specific

co.uk. Accessed 1 October 2015.

immunotherapy for human colorectal cancer: 6.5‐year 54. Alfonso S, Díaz RM, de la Torre A, Santiesteban E, median follow‐up of a phase III prospectively

Aguirre F, Pérez K, et al. 1E10 anti‐idiotype vaccine in

randomized trial. J Clin Oncol. 1993;11(3):390–9.

non‐small cell lung cancer: Experience in stage IIIb/IV

46. Hanna MG, Jr., Hoover HC, Jr., Vermorken JB, Harris JE,

patients. Cancer Biol Ther. 2007;6(12):1847–52.

Pinedo HM. Adjuvant active specific immunotherapy of 55. Alfonso S, Valdés‐Zayas A, Santiesteban ER, Flores YI, stage II and stage III colon cancer with an autologous

Areces F, Hernández M, et al. A randomized, multi-

tumor cell vaccine: first randomized phase III trials

center, placebo‐controlled clinical trial of racotu-

show promise. Vaccine. 2001;19(17–19):2576–82.

momab‐alum vaccine as switch maintenance therapy in

47. Kaufman H, Wang W, Manola J, Dipaola RS, Ko Y,

advanced non–small cell lung cancer patients. Clin

Sweeney J, et al. Phase II prime/boost vaccination using

Cancer Res. 2014;20(14):3660–71.





CHAPTER 7

7 Immunotherapy with

Non–Genetical y Modified T Cel s

Cassian Yee

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Introduction

Tumor‐infiltrating lymphocyte

therapy

Immunotherapy represents a promising modality

for the treatment of patients with cancer and has The premise that tumor sites harbor a population of emerged as the standard of care for some cancer effector cel s enriched for tumor reactivity was first types. The basis for immune‐based approaches demonstrated in murine studies where TILs were stems from studies demonstrating a significant role found to be 50–100 times more effective than for T cel s as evidenced by studies where the

lymphokine‐activated killer cel s derived from

transfer of T cel s from tumor‐immunized animals peripheral lymphocytes [2, 3]. In an approach pioto tumor‐bearing animals resulted in the transfer neered by the Surgery Branch at the NCI, lymphoof antitumor immunity [1]. Significant advances in cytes culled from tumor sites collected from patients understanding and manipulating the immune with metastatic melanoma were expanded in vitro response over the last decade have shown that with high dose IL‐2 and adoptively transferred into tumor‐associated antigens can be identified that patients who then also received systemic high‐dose elicit a robust T cell response in patients; thus, IL‐2 [3]. While the original study results were comstrategies to isolate and expand such T cel s ex vivo pelling, a significant difference over the use of would allow the adoptive transfer of an immune high‐dose IL‐2 alone could not be conclusively response capable of rejecting host tumor cel s. For demonstrated in the metastatic setting, although the purposes of this chapter, two sources of T cel s evidence of benefit was seen in a randomized trial will be considered: those derived from the tumor when used as adjuvant therapy [4]. The subsequent site, known as tumor‐infiltrating lymphocytes advance in the use of TIL therapy as a therapeutic (TILs), and those derived from the peripheral modality for patients with metastatic melanoma can blood, known as endogenous T cel s (ETCs) be attributed to two important modifications to the (Table 7.1).

original protocol: first, the use of a rapid‐expansion

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

91

92 Immunotherapy in Translational Cancer Research Table 7.1 A comparison of tumor‐infiltrating lymphocyte (TIL) vs. endogenous T cell (ETC) therapy outlines distinguishing features in source, method, and use. Depending on the accessibility of tumor, knowledge of antigen, and tumor type, the approaches can be complementary and both can provide novel means of immune targeting.

TIL Therapy

ETC Therapy

Source

Tumor

Peripheral blood

T cell repertoire

Tumor‐site limited

Endogenous

In vitro

High‐dose IL‐2 → REP

Antigen‐specific APC stimulation → Selection → REP

generation

Cell product

CD8, CD4, NK cells

Antigen‐specific CD8 or CD4 T cells

Conditioning

High‐dose lymphodepletion

None or low‐dose lymphodepletion

Clinical results

100 s of patients, 40% + in metastatic

10s of patients, 20%–60% in metastatic melanoma. Breast,

melanoma. Ovarian, breast,

ovarian, sarcoma, Merkel cell, leukemia, colorectal,

colorectal cancers pending.

pancreatic cancer pending. Potential to target most solid

tumors.

Advantages

Prior knowledge of tumor antigen not

Antigen‐specific.

required.

Flexible and agile in targeting.

TIL can be a source of antigen

Broad panel of potential tumors.

discovery.

ETC can validate discovered antigens.

Robust clinical data in melanoma.

Outpatient therapy.

Note: REP = rapid‐expansion protocol.

protocol initial y developed at the Fred Hutchinson activity via endotoxin provided a favorable milieu Cancer Research Center for cultivating antigen‐ for T cell growth and inflammation [14]. A nonmyspecific T cel s to very large numbers [5] and sec­ eloablative hematopoietic stem cell transplant conond, administration of a lymphodepletion regimen ditioning regime [15] was repurposed for use in the to patients prior to T cell infusion [6–8]. The first of TIL treatment protocol, comprising 5 days of fludathese, the rapid expansion protocol method, rabine at 25–30 mg/m2 and 2 days of high‐dose enabled routine expansion of the IL‐2 expanded cyclophosphamide [16]. Single‐institution, nonranpopulation of lymphocytes at least 3 log ‐fold over domized studies yielded a response rate of 40% with 10

a period of 2 weeks using a T cell receptor (TCR) 10%–12% durable complete responses, which was trigger (anti‐CD3 antibody), irradiated feeder cel s not significantly improved when low‐dose total‐

(peripheral blood mononuclear cel s with or body irradiation (2 Gy) was added. At the Surgery without Epstein‐Barr virus–transformed lympho­ Branch, radiation was increased to a myeloablative blastoid cell lines), and relatively low‐dose IL‐2 12 Gy, accompanied by G‐CSF mobilized autologous (50 U/ml). Expansion to numbers (up to 150 × 109) stem cel s to facilitate bone marrow recovery; not previously achievable in vitro with high‐dose although enhanced response rates (up to 70%) were IL‐2 alone now permitted investigators to consider initial y observed, they were later found in a larger scale studies with TIL therapy and lower randomized study to be no different than that achievdropout rates due to technical hurdles associated able using nonmyeloablative regimens, and myeloabwith cell expansion [9]. The second advance, the lative dosing was subsequently abandoned [16, 17].

use of a lymphodepleting regimen, was intended to

Independent trials performed at other instituestablish “space” for the incoming TIL cel s, perhaps tions including Sheba Medical Center, MD

augmented by the homeostatic upregulation of lym­ Anderson Cancer Center, and Moffitt Cancer phokines in the circulation such as IL‐7 and IL‐15 Center confirmed an overall response rate of 40%

and elimination of regulatory cel s sensitive to high‐ in patients with metastatic melanoma, even among dose cyclophosphamide and fludarabine [10–13]. those who had failed prior immune‐based ther­

Additional y, breach of intestinal barriers secondary apies [18–20]. The serious toxicities, often to high‐dose chemotherapy leading to bacterial requiring ICU‐type monitoring and management-translocation and an increase in toll‐like receptor restricted TIL therapy to centers familiar with





CHAPTER 7 Immunotherapy with Non–Genetical y Modified T Cel s 93

high‐dose IL‐2 regimens, contributed to patient express these minigene constructs were used to selection bias [16].

stimulate TILs and reactive T cel s and were subsequently sorted on the basis of CD137 upregulation.

Advances in TIL therapy

When TCRs from these tumor‐reactive T cel s

In an effort to enrich for a more “effective” were sequenced, cloned, and expressed in lymphopopulation of infiltrating lymphocytes, and possibly cytes, they were found to recognize 14 mutated decrease toxicities, the screening step for selecting neoantigens expressed by autologous tumor cel s, reactive cultures prior to expansion was added. demonstrating not only the feasibility of using Those cultures demonstrating growth were assayed CD137 to identify tumor‐reactive T cel s, but that for recognition of autologous tumor cel s and such targets represented by mutated neoepitopes further expanded. However, such an approach can be immunogenic and targeted for adoptive celrequired that sufficient numbers of autologous lular therapy (ACT) [26]. Recent findings using tumor cel s be available for downstream testing, TIL populations have further identified mutated often leading to an increased time to cell product, epitopes for targeting the relatively elusive K‐RAS

and such “selection” did not appreciably increase mutation in colorectal cancer [27] and neoantigens response rates or time to progression. The finding in HPV+ cervical cancer (an unexpected immunothat T cel s upregulate the expression of CD137 on dominant response [28]); these findings have the surface following antigen engagement [21] was extended the possibility of ACT for more common exploited by the MD Anderson group to enrich for solid tumor malignancies.

tumor‐reactive CD8+ T cel s in TIL culture. By sup­

The prospect of extending TIL therapy beyond

plementing anti‐CD137 antibody to TIL cultures, melanoma is now tenable in light of these recent an effector population could be produced with studies. Addressing obstacles to mount a program enhanced antitumor properties and could lead to of TIL therapy for nonmelanoma solid tumor the application of TIL strategies to other nonmela­ malignancies, such as ovarian and colorectal cannoma tumors such as ovarian and colorectal cancer cer, will require access to clinical‐grade reagents

[22]. A similar CD137‐based strategy implemented (i.e., anti‐CD137 and anti‐PD‐1) that will facilitate at the University of Pennsylvania, involving in vitro selection of tumor‐reactive T cel s in TIL cultures, selection of CD137+ T cel s in TIL cultures, was a strategy to streamline the tumor cultivation and also able to identify in preclinical studies, extant TIL expansion process, preferably in a closed tumor‐reactive T cel s for adoptive therapy in system, and final y, a conditioning and postinfupatients with ovarian cancer and melanoma [23].

sion IL‐2 regimen that does not require intensive

When it was discovered that the programmed medical care but is based on careful y designed death–1 receptor (PD‐1) was also upregulated on studies to determine the degree of lymphodeplethe surface of T cel s following activation, the tion (if necessary) and form of postinfusion subset of CD8+ PD‐1+ populations among TIL immunomodulation. Final y, genetic modification samples was found to accurately identify a of TILs to enhance efficacy (e.g., engineered population of more clonal y expanded T cel s [24], expression of IL‐12), undermine immune evasive a factor that may also be used to select for tumor‐ mechanisms of resistance (i.e., dominant negative reactive cytotoxic T lymphocytes (CTLs) in TIL receptor II for transforming growth factor beta) cultures [25]. The strategy of using surrogate [29–31], and enhance tumor trafficking (CXCR3) markers of activation to select for antigen‐specific are already incorporated in ongoing studies and T cel s among TIL cultures was recently used to will likely contribute to the design of second‐ and reveal immunogenicity of candidate‐mutated neo­ third‐generation TIL therapy trials.

antigens expressed by autologous tumor. In this

study, tumor cel s underwent whole exome and Endogenous T cell therapy RNA sequencing to identify candidate‐mutated

targets that were expressed in tandem minigene Endogenous T cell therapy or ETC therapy involves constructs comprising up to 24 mutated gene prod­ the isolation and expansion of antigen‐specific ucts. Autologous dendritic cel s engineered to T cel s from the peripheral blood for adoptive





94 Immunotherapy in Translational Cancer Research transfer [32]. Since a tumor source is not tumor‐associated antigen‐specific CTLs are generrequired, accessible tumor is not a prerequisite for al y present in the peripheral blood at very low ETC. Furthermore, unlike TIL therapy, the frequencies (1:100,000 or less), isolation of such peripheral T cell repertoire is not limited to a natural y occurring T cel s will require enabling skewed population of cel s localized to the tumor technologies to extract and expand them to numsite and is less likely to be clonal y exhausted than bers sufficient for adoptive transfer. There have TIL‐derived T cel s [33, 34]. As T cel s from ETC been two major obstacles in limiting the use of are grown in an antigen‐driven, cyclical manner, ETC therapy beyond melanoma and extending its unlike TIL cel s that are exposed to supraphysio­ use to becoming a treatment modality: (1) streamlogic doses of IL‐2, minimal conditioning and low‐ lining the generation of T cel s, and (2) identification dose IL‐2 can be administered, rendering ETC of immunogenic targets for nonmelanoma appropriate to the outpatient setting [35–37]. Since cancers.

no genetic engineering is required to redirect specificity, ETC therapy is not encumbered by Generating T cells for ETC

regulatory obstacles, and to date, no serious toxic­ (Figure 7.1) ities from cytokine release syndrome or neurotox­ The generation of antigen‐specific T cel s from icities have been observed [38, 39], nor potential y peripheral blood first requires the use of an fatal autoimmune reaction to normal tissues due to artificial or natural antigen‐presenting cell (APC).

epitope cross‐reactivity or overexuberant on‐target The use of autologous dendritic cel s (an example toxicities to normal tissues sharing a tumor‐associated of a natural APC) derived from peripheral blood target antigen. Cases of fatal cytokine release syn­ monocytes offers the advantage of having the reqdrome or neurotoxicity have been observed with uisite restricting allele available for epitope peptide the use of CD19‐specific CAR T cell therapy and presentation. While it may be possible to introduce may be mitigated by titrating the cell dose accord­ more common alleles, such as HLA‐A*0201 in an ingly and designing studies with judicious dosing artificial APC (see below), it would be desirable to and dose escalation parameters [38, 39]. Examples have an APC that already expresses the allele of of on‐target toxicities resulting in fatal outcome interest as more and more epitopes are being disinclude unintended recognition of MAGE‐A12, covered that are presented by non‐A2 alleles. In expressed by neuronal tissues [40], and reactivity addition to being a “professional” APC that to titin antigen expressed by cardiac muscle [41], in expresses the desired costimulatory counterrecboth cases by cel s engineered to express MAGE‐ petors (e.g. CD80, CD86), an RNA or minigene A3 TCR and underline the dangers of using TCR plasmid expressing single or multiple antigen that have either been mutated or escaped thymic sequences can be introduced by direct transfection selection.

(RNA transfection) [43] or nonviral or viral vector

Even when a nonmutated TCR is used, in this approaches [44, 45], enabling the dendritic cel s to case recognizing MART‐1, TCR overexpression or process and present all epitopes of the target

“unnatural y” regulated TCR expression in antigen. In this approach, the actual peptide epiengineered lymphocytes leads to serious toxicity tope need not be known nor individual y syntheamong tissues that express very low levels of the sized for antigen presentation. In addition, shared antigen, and unanticipated autoimmunity presentation of class II–restricted epitopes may (i.e., uveitis, inner ear toxicity) [42]. Such toxicities also be achieved so as to generate CD4 T cel s as were not observed when natural y occurring well [46]. An artificial APC, such as an insect cel , MART‐1‐specific CTLs were used, as in the case K562 cell line, or even bead‐based scaffolding, does of ETC therapy, suggesting that manipulating not allow for robust antigen processing in this TCR affinity and regulation of TCR expression can manner but does provide the advantage of ready lead to unwanted consequences. The use of endog­ availability (eliminating the 3–7 day culture period enous T cel s from the extant peripheral repertoire to enrich for autologous dendritic cell generation) may obviate these concerns, while retaining and off‐the‐shelf capability [47–51]. The desired antitumor efficacy. However, because such restricting allele(s) are engineered to be expressed





CHAPTER 7 Immunotherapy with Non–Genetical y Modified T Cel s 95

SOURCE

SELECTION

PATIENT CONDITIONING

EXPANSION

INFUSION

TIL

HD IL-2

Tumor-infiltrating

Lymphocytes

CONDITIONING

Cloning

ETC

Endogenous

Cell sorting

T cell Therapy

Antigen-specific

T Cell Enrichment

Figure 7.1 Generation of tumor‐infiltrating lymphocyte undergo selection for antigen‐specific T cells after in vitro (TIL) and endogenous T cell (ETC) products for adoptive

stimulation with antigen‐presenting cells expressing target

cellular therapy. TIL are isolated from tumor samples,

of interest. Antigen‐specific T cells are selected and

exposed in vitro to high‐dose IL‐2 and then expanded. ETC

expanded. Patients undergo conditioning (e.g., lymphode-

are isolated from peripheral blood lymphocytes and

pletion) prior to receiving T cells.

by such artificial APCs (aAPCs) and then pulsed expand antigen‐specific CTLs from patient with the known epitope peptide. Using this peripheral blood [35, 46, 52, 53]; however, a handapproach, greater control over the costimula­ ful of studies have exploited the use of insect cel s tory profile and density of peptide major [49] as well as bead‐based and K562‐based APCs histocompatibility complexes (MHCs) is achieved, [48]. Clinical efficacy achieved by ETC in these and scalability is vastly increased, as no human‐ trials, for the treatment of patients with metastatic derived source of peripheral blood mononuclear melanoma, have been relatively modest and, until cel s is required.

recently, have not extended to nonmelanoma solid

Whichever APC is used, artificial or natural, the tumor malignancies, in part because of the time-option of using peptide to charge the APC provides and labor‐intensive nature of identifying and a means to rapidly translate antigen discovery to expanding rare antigen‐specific T cel s from the clinical trials in a matter of a few weeks. After iden­ peripheral blood.

tifying/selecting the desired target antigen and its

corresponding peptide epitope, all that is required Extending targets, expanding is synthesis of good‐manufacturing‐practice‐ or indications

GMP‐grade peptide; there is no protracted engineering of plasmid, viral vector, or other delivery The fraction of antigen‐specific T cel s that are method encumbered by regulatory hurdles and tumor reactive can range in frequency from often months of validation before use. Additional y, <1:100,000 to more than 1%, depending on the epia bank of such aAPCs could be established pro­ tope being evaluated and the assay used. Functional spectively and then made available for targeting assays that measure antigen‐driven release or proknown shared antigens and alleles.

duction of cytokines such as IFN‐α and TNF‐α

In clinical trials, the majority of ETC protocols often underestimate the numeric frequency of have used autologous dendritic cel s to stimulate/ antigen‐specific T cel s. This frequency may be best

96 Immunotherapy in Translational Cancer Research assessed using a structure‐based assay, such as pep­

Recently it was discovered that the source of

tide‐MHC multimer (tetramers) or quantitative antigen‐specific T cel s generated by this approach assessment of CDR3‐specific region of a TCR was a very low frequency population in the known to recognize the epitope/MHC of interest peripheral blood, with an extant frequency below

[54]. Tetramer‐based assays reveal the presence of detection by PCR (<1:1,000,000) [54]. TCR clonocirculating MART‐1‐specific CTLs recognizing the type analysis revealed that the majority of HLA‐A2‐restricted dominant epitope (M27–35) antigen‐specific (in this case MART‐1‐specific) with frequencies upwards of 1% in the circulating CTL in the T cell product comprised in large part T cell population. The reason for this unusual y T cel s that were not found in the peripheral blood high frequency, even among healthy donors, is pos­ of patients preinfusion but that persisted long-sibly attributable to thymic misadventure [55]. term postinfusion. It was further demonstrated However, for most tumor‐associated antigens, that the clinical response observed in patients frequencies are below the level of detection who experienced a complete, partial, or stable (<1:10,000 or 0.01%) and for known CDR3 response after ETC therapy correlated with the sequences, <10−5 to 10−6 based on the sensitivity of duration of in vivo persistence and more directly the polymerase chain reaction (PCR) assay.

with the in vivo half‐life of individual transferred

When human T cel s were primed in vitro in the T cell clones. The significance of this study sugpresence of various gamma‐chain receptor cyto­ gests that strategies to extend the persistence, or kines (IL‐2, IL‐7, IL‐15, IL‐21), it was observed that to select T cel s with an intrinsic capacity for only IL‐21 led to a greater than 10‐fold enhance­ extended persistence, could lead to improved ment in the frequency of tumor‐associated antigen clinical results. Additional y, the demonstration (TAA)‐specific CD8 T cel s that could be isolated that highly robust antigen‐specific CTLs could be

[56], and when CD25 depletion was added, at least isolated from very low frequency populations 100‐fold increase, with a commensurate increase in (likely naïve T cell pool), suggests that the ability absolute numbers of TAA‐specific CTL to 300‐fold to generate T cel s against an increasingly relevant or greater [57]. This was observed for the prototypic and expanding panel of tumor‐associated, non­

MART‐1 epitope as well as other self‐ and cancer mutated self‐antigens is greater than one might testis antigens. Using this strategy, it was possible to expect and supports the strategy of ETC in targetboost levels of TAA‐specific CTL from undetectable ing new epitopes that are being mined using levels in the peripheral blood to >0.2%, sufficient for current strategies [60].

tetramer‐based cell sorting and expansion. Whereas

One outcome of these studies is the possibility of

it had previously been difficult or impossible to iso­ targeting multiple antigens to avoid the emergence late NY‐ESO‐1‐specific CTL from seronegative of antigen‐loss tumor variants. Another finding is donors, it was now possible to routinely isolate such that even though only a single antigen was targeted CTL from both healthy donors and cancer patients (that may be heterogeneously expressed and defiregardless of serologic status [58]. Furthermore, nitely not tumorigenic), complete and durable T cell responses to tumor‐associated self‐antigens responses have been observed. It was discovered such as WT1 and several cancer testis antigens could that under certain conditions, a broadening of now be routinely generated, facilitated by tetramer‐ T cell responses to nontargeted tumor‐associated guided cell sorting [59]. One major limitation had antigens (antigen‐spreading) emerged that in some been translating the use of tetramer‐guided cell sort­ cases was greater in frequency even than that of the ing into an investigational new drug–approved transferred T cell response to the targeted antigen protocol, and this was final y achieved with the use [37, 46, 53]. Whether antigen‐spreading to these of a clinical grade cell sorter, thus enabling inves­ measurable targets was a direct cause‐effect or epitigators to design trials to treat patients with phenomenon representing antigen‐spreading to nonmelanoma solid tumor malignancies such as tumor‐rejection target antigens is unclear and sarcoma, breast, and ovarian cancers for which deserving of further study; nevertheless, it would TAAs such as the cancer‐testis antigens have been appear that strategies that enhance antigen identified in a subpopulation of tumors.

spreading (for example, by lowering the threshold





CHAPTER 7 Immunotherapy with Non–Genetical y Modified T Cel s 97

of activation with CTLA4 blockade) may improve relevant when targeting nononcogenic antigens clinical outcome.

such as MART‐1 [64]. Patients experienced

no additional toxicity beyond what was expected

Combination therapy

with ipilimumab alone, and the entire

treatment regimen was outpatient based, with

It is becoming increasingly apparent that very low‐dose cyclophosphamide conditioning combina tion strategies will be required to mount (300 mg/m2) followed by low‐dose subcutaan effective campaign against solid tumor malig­ neous IL‐2.

nancies. For ACT, that can mean the use of

immune checkpoint inhibitors, costimulatory Conclusions

agonists, or any number of immune‐ and nonimmune‐

based modalities, including vaccination, onco­ The recent emergence of gene‐engineered CAR‐T

lytic virus, radiation therapy, and chemotherapy. cell therapy targeting CD19 for the treatment of While there has been anecdotal evidence for the refractory B cell malignancies has led the charge benefit of adding an immune checkpoint inhib­ in developing ACT as a treatment modality.

itor such as anti‐CTLA4 therapy [48], one of the However, general application of ACT for the first prospective studies combining ACT with treatment of solid tumor malignancies remains a CTLA4 blockade was recently published [37]. major challenge. Consideration should be given Ten patients with refractory metastatic mela­ to two other ACT modalities, TIL therapy and noma, 3 of whom had failed prior ipilimumab ETC therapy, which offer logistical and biological monotherapy, were treated with MART‐1‐ advantages. For TIL, knowledge of the tumor specific CTLs followed immediately by a stan­ antigen target is not required, and mining the TIL

dard regimen of anti‐CTLA4 antibody therapy population for relevant T cel s and their TCRs (3 mg/kg ipilimumab, every three weeks for four may be useful for developing gene‐engineered doses). Two patients achieved a continuous T cel s in future studies. Serious toxicities and the complete response, 2 more experienced a durable prospect of treating only patients with TIL+

and ongoing partial response (‐70%+; by RECIST tumors, however, limit this strategy. ETC reprecriteria), and 3 demonstrated evidence of stable sents a potential y low‐toxicity, high‐accessibility disease, all by immune‐related response criteria. approach, requiring only peripheral blood and T cell persistence was detected in all patients for knowledge of immunogenic epitopes to target, as long as samples could be collected (>500 days), obviating the requirement for tumor access or accompanied by upregulation of central memory genetic modification to redirect specificity. The markers (CD28, CD127, CD62L and CCR7) promise of ETC lies in the ability to streamline among all 7 responders. In this study, the emer­ this therapy, now tenable by leveraging a gence of antigen spreading, defined as the poly­ combination of activation marker– or TCR‐based valent antigen‐specific response to two or more selection and microfluidic/microprocessor technontargeted (non‐MART‐1) antigens postinfu­ nologies as a means of providing a well‐defined sion, was associated with a clinical response [61]. population of effector cel s. In this fashion, ETC

Released tumor antigens presented by local APCs represents an agile platform to evaluate various may have promoted activation of new responses combinations of immunomodulatory reagents to nontargeted melanoma‐associated proteins that can favorably influence the tumor microenvi[37, 53, 61, 62]. Whether T‐cell responses ronment (including, but not limited to, immune directed toward nonmutated antigens or (none­ checkpoint inhibitors, costimulatory agonists, valuable) tumor‐specific mutated antigens [63] metabolic reagents, and other immune‐based contributed to tumor regression cannot be ascer­ modalities such as oncolytic virotherapy and vactained. Yet the combination may represent a cination strategies). Investigators are now faced strategy to specifically increase the number and with the daunting prospect of deciding among strength of T‐cells targeting multiple antigens of dozens of possible combinations an optimal best the patient’s own tumor, which may be particularly regimen. In part, these decisions may be addressed





98 Immunotherapy in Translational Cancer Research by considering the relatively uniform bolus of

cytokine sinks by lymphodepletion enhances the efficacy

well‐characterized adoptively transferred antigen‐

of adoptively transferred tumor‐specific CD8+ T cel s.

specific CTLs as a transferrable cel ular bio­

Journal of Experimental Medicine. 2005; 202(7):907–12.

marker, upon which one can serial y collect from 11. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD.

the peripheral blood and tumor site postinfusion

Interleukin (IL)‐15 and IL‐7 jointly regulate homeostatic

and examine, among the transferred population

proliferation of memory phenotype CD8+ cel s but are

not required for memory phenotype CD4+ cel s. Journal

of cel s, the influence of various immunomodulaof Experimental Medicine. 2002;195(12):1523–32.

tory strategies, providing iterative insights into 12. Dummer W, Niethammer AG, Baccala R, Lawson BR, the design of future studies.

Wagner N, Reisfeld RA, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. Journal References

of Clinical Investigation. 2002;110(2):185–92.

13. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg

1. Greenberg PD. Adoptive T cell therapy of tumors: mech­

KI, et al. IL‐7 is critical for homeostatic proliferation and anisms operative in the recognition and elimination of

survival of naive T cel s. Proceedings of the National

tumor cel s. Adv Immunol. 1991;49:281–355.

Academy of Sciences of the United States of America.

2. Rosenberg SA, Spiess P, Lafreniere R. A new approach to

2001;98(15):8732–7.

the adoptive immunotherapy of cancer with tumor‐

14. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS,

infiltrating lymphocytes. Science. 1986;233(4770):1318–21.

Chieppa M, Cassard L, et al. Microbial translocation

3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D,

augments the function of adoptively transferred self/

Topalian SL, Toy ST, et al. Use of tumor‐infiltrating lymtumor‐specific CD8+ T cel s via TLR4 signaling. Journal phocytes and interleukin‐2 in the immunotherapy of

of Clinical Investigation. 2007;117(8):2197–204.

patients with metastatic melanoma. A preliminary report. 15. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, New England Journal of Medicine. 1988;319(25): 1676–80.

Maris M, Flowers C, et al. Nonmyeloablative hematopoi4. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, etic cell transplantation. Replacing high‐dose cytotoxic

Tessier MH, Bercegeay S, et al. Randomized trial of

therapy by the graft‐versus‐tumor effect. Annals of the

adoptive transfer of melanoma tumor‐infiltrating

New York Academy of Sciences. 2001;938:328–37;

lymphocytes as adjuvant therapy for stage III melanoma.

discussion 37‐9.

Cancer Immunology, Immunotherapy. 2002;51(10): 16. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, 539–46.

Topalian SL, Restifo NP, et al. Adoptive cell transfer

5. Riddell SR, Greenberg PD. The use of anti‐CD3 and

therapy following non‐myeloablative but lymphodepletanti‐CD28 monoclonal antibodies to clone and expand ing chemotherapy for the treatment of patients with

human antigen‐specific T cel s. Journal of Immunological

refractory metastatic melanoma. Journal of Clinical

Methods. 1990;128(2):189–201.

Oncolology. 2005;23(10):2346–57.

6. North RJ. Cyclophosphamide‐facilitated adoptive immu17. Goff SL, Dudley ME, Citrin DE, Somerville RP, notherapy of an established tumor depends on elimina­

Wunderlich JR, Danforth DN, et al. Randomized, protion of tumor‐induced suppressor T cel s. Journal of spective evaluation comparing intensity of lymphode­

Experimental Medicine. 1982;155(4):1063–74.

pletion before adoptive transfer of tumor‐infiltrating

7. Awwad M, North RJ. Cyclophosphamide‐induced

lymphocytes for patients with metastatic melanoma.

immunological y mediated regression of a cyclophos­

Journal of Clinical Oncology. 2016;34(20):2389–97.

phamide‐resistant murine tumor: a consequence of 18. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C.

eliminating precursor L3T4+ suppressor T‐cel s. Cancer

White paper on adoptive cell therapy for cancer with

Research. 1989;49(7):1649–54.

tumor‐infiltrating lymphocytes: a report of the CTEP

8. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P,

subcommittee on adoptive cell therapy. Clinical Cancer

Schwartzentruber DJ, et al. Cancer regression and auto­

Research. 2011;17(7):1664–73.

immunity in patients after clonal repopulation with anti19. Besser MJ, Shapira‐Frommer R, Itzhaki O, Treves AJ, tumor lymphocytes. Science. 2002;298(5594):850–4.

Zippel DB, Levy D, et al. Adoptive transfer of tumor‐

9. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R,

infiltrating lymphocytes in patients with metastatic mel­

Kammula U, et al. Adoptive cell therapy for patients with

anoma: intent‐to‐treat analysis and efficacy after failure

metastatic melanoma: evaluation of intensive myeloabto prior immunotherapies. Clinical Cancer Research.

lative chemoradiation preparative regimens. Journal of

2013;19(17):4792–800.

Clinical Oncolology. 2008;26(32):5233–9.

20. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker

10. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA,

C, Chen JQ, et al. Adoptive T‐cell therapy using autolo­

Palmer DC, Spiess PJ, et al. Removal of homeostatic

gous tumor‐infiltrating lymphocytes for metastatic

CHAPTER 7 Immunotherapy with Non–Genetical y Modified T Cel s 99

melanoma: current status and future outlook. Cancer 32. Yee C. The use of endogenous T cel s for adoptive Journal. 2012;18(2):160–75.

transfer. Immunological Reviews. 2014;257(1):250–63.

21. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, 33. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.

Bleakley M, et al. Activation‐induced expression of

Distinctive features of the differentiated phenotype and

CD137 permits detection, isolation, and expansion of

infiltration of tumor‐reactive lymphocytes in clear cell

the full repertoire of CD8+ T cel s responding to antigen

renal cell carcinoma. Cancer Research.

without requiring knowledge of epitope specificities.

2012;72(23):6119–29.

Blood. 2007;110(1):201–10.

34. Shao H, Ou Y, Wang T, Shen H, Wu F, Zhang W, et al.

22. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ,

Differences in TCR‐Vbeta repertoire and effector phe­

Sarnaik A, Pilon‐Thomas S, et al. Co‐stimulation

notype between tumor infiltrating lymphocytes and

through 4‐1BB/CD137 improves the expansion and

peripheral blood lymphocytes increase with age. PloS

function of CD8(+) melanoma tumor‐infiltrating lym­

One. 2014;9(7):e102327.

phocytes for adoptive T‐cell therapy. PloS One. 35. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis 2013;8(4):e60031.

E, et al. Adoptive T cell therapy using antigen‐specific

23. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C,

CD8+ T cell clones for the treatment of patients with

et al. CD137 accurately identifies and enriches for natumetastatic melanoma: in vivo persistence, migration, ral y occurring tumor‐reactive T cel s in tumor. Clinical

and antitumor effect of transferred T cel s. Proceedings

Cancer Research. 2014;20(1):44–55.

of the National Academy of Sciences of the United States

24. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E,

of America. 2002;99(25):16168–73.

et al. PD‐1 identifies the patient‐specific CD8(+) tumor‐

36. Yee C. Adoptive T‐cell therapy of cancer. Hematology/

reactive repertoire infiltrating human tumors. Journal of

Oncology Clinics of North America. 2006;

Clinical Investigation. 2014;124(5):2246–59.

20(3):711–33.

25. Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, 37. Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Wunderlich JR, Rosenberg SA, et al. Selection of

Bhatia S, Lee SM, et al. T‐cell therapy using inter­

CD8 + PD‐1+ lymphocytes in fresh human melanomas

leukin‐21‐primed cytotoxic T‐cell lymphocytes

enriches for tumor‐reactive T cel s. Journal of

combined with cytotoxic T‐cell lymphocyte antigen‐4

Immunotherapy. 2010;33(9):956–64.

blockade results in long‐term cell persistence and

26. Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS,

durable tumor regression. Journal of Clinical Oncology.

Robbins P, et al. Isolation of T‐cell receptors specifical y

2016.

reactive with mutated tumor‐associated antigens from 38. Davila ML, Brentjens RJ. CD19‐Targeted CAR T cel s as tumor‐infiltrating lymphocytes based on CD137 expresnovel cancer immunotherapy for relapsed or refractory sion. Clinical Cancer Research. 2017;23(10):2491–505.

B‐cell acute lymphoblastic leukemia. Clinical Advances

27. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, in Hematology & Oncology. 2016;14(10):802–8.

et al. T‐Cell Transfer Therapy Targeting Mutant KRAS 39. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, in Cancer. New England Journal of Medicine.

Hudecek M, et al. CD19 CAR‐T cel s of defined

2016;375(23):2255–62.

CD4+:CD8+ composition in adult B cell ALL patients.

28. Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett Journal of Clinical Investigation. 2016;126(6):2123–38.

TD, Howie B, et al. Landscape of immunogenic tumor 40. Morgan RA, Chinnasamy N, Abate‐Daga D, Gros A, antigens in successful immunotherapy of viral y induced

Robbins PF, Zheng Z, et al. Cancer regression and neuepithelial cancer. Science. 2017;356(6334):200–5.

rological toxicity following anti‐MAGE‐A3 TCR gene

29. Bol ard CM, Rossig C, Calonge MJ, Huls MH, Wagner

therapy. Journal of Immunotherapy. 2013;36(2):133–51.

HJ, Massague J, et al. Adapting a transforming growth 41. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, factor beta‐related tumor protection strategy to enhance

Bianchi FC, et al. Identification of a Titin‐derived HLA‐

antitumor immunity. Blood. 2002;99(9):3179–87.

A1‐presented peptide as a cross‐reactive target for

30. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop

engineered MAGE A3‐directed T cel s. Science

HE, et al. Antitumor activity of EBV‐specific T lympho­

Translational Medicine. 2013;5(197):197ra03.

cytes transduced with a dominant negative TGF‐beta 42. Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, receptor. Journal of Immunotherapy. 2008;31(5):500–5.

King KA, Rudy S, et al. Audiovestibular dysfunction

31. Lacuesta K, Buza E, Hauser H, Granville L, Pule M,

associated with adoptive cell immunotherapy for mela­

Corboy G, et al. Assessing the safety of cytotoxic T lymnoma. Otolaryngology—Head and Neck Surgery.

phocytes transduced with a dominant negative trans2012;147(4):744–9.

forming growth factor‐beta receptor. Journal of 43. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Immunotherapy. 2006;29(3):250–60.

et al. Transfection of RNA encoding tumor antigens

100 Immunotherapy in Translational Cancer Research following maturation of dendritic cel s leads to propolyclonal CTL plus CTLA4 blockade controls longed presentation of antigen and the generation of

refractory metastatic melanoma in a patient. Journal of

high‐affinity tumor‐reactive cytotoxic T lymphocytes.

Experimental Medicine. 2016;213(7):1133–9.

Molecular Therapy. 2004;9(5):757–64.

54. Chapuis AG, Desmarais C, Emerson R, Schmitt TM,

44. Kwok A, Eggimann GA, Reymond JL, Darbre T,

Shibuya K, Lai I, et al. Tracking the fate and origin of

Hollfelder F. Peptide dendrimer/lipid hybrid systems are

clinical y relevant adoptively transferred CD8+ T cel s in

efficient DNA transfection reagents: structure‐activity

vivo. Science Immunology. 2017;2(8).

relationships highlight the role of charge distribution 55. Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel across dendrimer generations. ACS Nano. 2013;7(5):

D, Uckert W, et al. Misinitiation of intrathymic MART‐1

4668–82.

transcription and biased TCR usage explain the high fre45. Chen YZ, Yao XL, Tabata Y, Nakagawa S, Gao JQ. Gene quency of MART‐1‐specific T cel s. European Journal of

carriers and transfection systems used in the recombina­

Immunology. 2014;44(9):2811–21.

tion of dendritic cel s for effective cancer immunother56. Li Y, Bleakley M, Yee C. IL‐21 influences the frequency, apy. Clinical & Developmental Immunology. 2010;2010:

phenotype, and affinity of the antigen‐specific CD8 T

565–643.

cell response. Journal of Immunology. 2005;175(4):

46. Hunder NN, Wallen H, Cao J, Hendricks DW, Reil y JZ,

2261–9.

Rodmyre R, et al. Treatment of metastatic melanoma 57. Li Y, Yee C. IL‐21 mediated Foxp3 suppression leads to with autologous CD4+ T cel s against NY‐ESO‐1. New

enhanced generation of antigen‐specific CD8+ cytotoxic

England Journal of Medicine. 2008;358(25):2698–703.

T lymphocytes. Blood. 2008;111(1):229–35.

47. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial 58. Pol ack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, antigen‐presenting cel s transduced with telomerase

et al. Tetramer guided, cell sorter assisted production of

efficiently expand epitope‐specific, human leukocyte

clinical grade autologous NY‐ESO‐1 specific CD8(+)

antigen‐restricted cytotoxic T cel s. Cancer Research.

T cel s. Journal for Immunotherapy of Cancer.

2005;65(12):5417–27.

2014;2(1):36.

48. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, 59. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Murray AP, et al. Long‐lived antitumor CD8+ lympho­

Pufnock JS, Schmitt TM, et al. Transferred WT1‐ reactive

cytes for adoptive therapy generated using an artificial

CD8+ T cel s can mediate antileukemic activity and perantigen‐presenting cel . Clinical Cancer Research.

sist in post‐transplant patients. Science Translational

2007;13(6):1857–67.

Medicine. 2013;5(174):174ra27.

49. Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. 60. Yee C. From the guest editor. The Cancer Journal.

Insect cel s as HLA‐restricted antigen‐presenting cel s

2017;23(2):95–6.

for the IFN‐gamma elispot assay. Journal of 61. Kvistborg P, Philips D, Kelderman S, Hageman L, Immunological Methods. 2000;234(1–2):1–12.

Ottensmeier C, Joseph‐Pietras D, et al. Anti‐CTLA‐4

50. Mitchell MS, Darrah D, Yeung D, Halpern S, Wal ace A,

therapy broadens the melanoma‐reactive CD8+ T cell

Voland J, et al. Phase I trial of adoptive immunotherapy

response. Science Translational Medicine.

with cytolytic T lymphocytes immunized against a

2014;6(254):254ra128.

tyrosinase epitope. Journal of Clinical Oncology. 62. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, 2002;20(4):1075–86.

Parvathaneni U, Hwang JH, et al. Regression of

51. Maus MV, Thomas AK, Leonard DG, Allman D, Addya

metastatic Merkel cell carcinoma following transfer

K, Schlienger K, et al. Ex vivo expansion of polyclonal and

of polyomavirus‐specific T cel s and therapies capable

antigen‐specific cytotoxic T lymphocytes by artificial

of re‐inducing HLA class‐I. Cancer Immunology

APCs expressing ligands for the T‐cell receptor, CD28

Research. 2014;2(1):27–36.

and 4‐1BB. Nature Biotechnology. 2002;20(2): 143–8.

63. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoedit52. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, ing: integrating immunity’s roles in cancer suppression

Lai IP, Dowdy K, et al. Transferred melanoma‐specific

and promotion. Science. 2011;331(6024):1565–70.

CD8+ T cel s persist, mediate tumor regression, and 64. Chandran SS, Paria BC, Srivastava AK, Rothermel LD, acquire central memory phenotype. Proceedings of the

Stephens DJ, Dudley ME, et al. Persistence of CTL

National Academy of Sciences of the United States of

clones targeting melanocyte differentiation antigens

America. 2012;109(12):4592–7.

was insufficient to mediate significant melanoma

53. Chapuis AG, Lee SM, Thompson JA, Roberts IM,

regression in humans. Clinical Cancer Research.

Margolin KA, Bhatia S, et al. Combined IL‐21‐primed

2015;21(3):534–43.





CHAPTER 8

8 Immunotherapy with Geneticaly

Modified T Cel s

Liora Schultz and Crystal Mackal

Division of Hematology/Oncology, Department of Pediatrics, Stanford University, Stanford, CA, USA Introduction

signal, most commonly delivered via CD28 or

41BB, is required for full T cell activation. Upon

T cel s compose a critical component of our adaptive simultaneous activation of both TCR and costimimmune system. Cytotoxic T cel s mediate directed ulatory signals, T cel s undergo phenotypic and immune responses and lasting immune memory functional developmental programming that targeting foreign entities. T cel s are educated in the permits cel ular proliferation and cytotoxicity.

thymus to distinguish self from nonself and eradi­ Following an initial T cell response, a subset of cate cel s expressing antigens of nonself origin. activated cel s enters the long‐term memory T cel Unlike foreign microbes, tumor cel s originate from pool, characterized by the potential for self-self and are armed with a host of mechanisms to renewal and rapid expansion upon future target evade the immune system. Immunotherapy with engagement [1]. In naive cel s, TCR binding to genetical y modified T cel s addresses innate mech­ cognate antigen/MHC complex in the absence of anisms of tumor immune evasion by manipulating costimulation induces T cell anergy, whereupon T cel s to redirect specificity and harness their cyto­ the cell is unable to respond to further exposure to toxic capacity to potentiate tumor eradication.

that antigen. Tumors often downregulate MHC

Methods of tumor immune

and may lack costimulatory signals, thereby cirevasion: Escaping the natural cumventing T cell recognition, activation and

T cells

cytotoxicity and potentially inducing anergy.

Adoptive immunotherapy using genetically

T cell activation

engineered T cel s seeks to leverage activation and

Antigen presentation via the major histocom­ expansion of T cel s, combined with delivery of patibility complex (MHC) permits T cell receptor novel genes or gene editing prior to adoptive (TCR) binding and induction of a necessary but transfer to facilitate tumor recognition and insufficient primary activation signal mediated enhance T cell activation, tumor specific cytotoxvia TCR signaling. A secondary costimulatory icity, and immune memory.

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

101





102 Immunotherapy in Translational Cancer Research Methods of T cell modification

Genetically modified TCRs

for adoptive cellular therapy

The two most common genetic modifications used

in the context of adoptive immunotherapy are The T cell has potent cytotoxic properties, and the expression of transgenes encoding a tumor‐specific TCR directs the specificity of this potent response.

TCR or a chimeric antigen receptor (CAR). Most Binding of a specific TCR to its cognate antigen commonly, to achieve stable, reliable, prolonged initiates T cell selection, activation, and function transgene expression, lentiviral or retroviral trans­ [10]. Every individual has a unique, diverse T cell duction methods are utilized [2, 3]. Electroporation‐ repertoire composed of individual TCRs generated mediated delivery of transposon/transposases can at random through somatic rearrangement of also achieve stable prolonged transgene expression the V(D)J section of the TCR gene. The TCR is a at a potential y lower cost [4, 5]. Alternatively, multisubunit transmembrane complex constructed delivery of mRNA can be utilized if short‐term of alpha and beta chains linked by a disulfide bond, transgene expression is desirable [6]. New plat­ each composed of a constant region and a variable forms such as megaTAL [7] and CRISPR/CAS9 [8] region dictating specificity. TCRs recognize short are available to permit gene deletion, gene editing, contiguous amino acid sequences presented within or more precise gene integration. In contrast to the target cell MHC complex. Native, nonengineered past experiences with genetic manipulation of T cel s express multiple copies of only one TCR.

hematopoietic stem cells, retroviral‐mediated

Among the numerous factors limiting a T cel ’s

insertional oncogenesis of T cel s has not occurred capacity to unleash its cytotoxic potential against

[9], although it remains a theoretical risk.

cancer cel s is ineffective recognition of tumor due

to insufficient binding of native TCRs to peptides

Specific therapeutic strategies

presented by the tumor MHC. In some cases,

this relates to the efficiency of tolerizing mecha­

TCR therapy involves engineering a T cell to nisms during T cell development, wherein T cel s express a T cell receptor specific to a tumor antigen bearing TCRs with high affinity for self‐antigens, to redirect T cell binding to tumor. CARs are including cancer‐testis antigens or tissue differenartificial receptors that fuse an MHC‐independent tiation antigens overexpressed by many cancers, antigen binding domain (usual y comprising a are deleted during thymic differentiation, leaving scFv derived from a mAb) to activation domains only TCRs with insufficient affinity for full within a T cel , thereby linking tumor antigen activation. TCRs reactive with neoantigens that binding to T cell activation. Distinctions between arise through nonsynonymous somatic mutations these approaches are depicted in Table 8.1. Both are not tolerized during development; however, approaches are being developed in parallel and such TCRs may be not be present in sufficient frehave undergone expansive preclinical testing and quency to mediate potent antitumor effects.

early clinical evaluation as described in this

Adoptive cel ular immunotherapy with transchapter.

genic TCRs seeks to provide the host with a larger

Table 8.1 Distinctions between TCR and CAR therapeutics.

TCR Therapy

CAR Therapy

MHC restricted

Yes

No

Targets intracellular antigens

Yes

No

Inclusion of endogenous

No

Yes

costimulatory signals

Methods of tumor escape

MHC downregulation, diminished

Surface antigen

antigen processing and presentation

loss





CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 103

pool of T cel s capable of efficiently recognizing TCR, isolated from tumor‐infiltrating lymphocytes tumor specific antigens, thus potential y enhancing (TILs) of a patient with malignant melanoma [16].

antitumor effects. Genetic engineering can effi­ Cel s were administered following lymphodepletion.

ciently express a transgenic TCR in T cel s with Engraftment was observed in 14 of 15 patients at one high frequency. Such engineered T cel s express a month after adoptive transfer, and 2 patients had native TCR as well as the engineered TCR. Pairing prolonged persistence of modified cel s for >1 year, of the transgenic TCR chains with endogenous accompanied by objective regressions of metastatic TCR chains can diminish expression of the melanoma [16]. Interestingly, the response rate in 2

engineered TCR and poses a potential risk for of 15 patients (13%) was inferior to response rates off‐target reactivity [11, 12]. Substantial work using TILs (see chapter 7). Nonetheless, this experideveloped effective approaches to enhance pairing ence introduced the potential of TCR therapy in of the transgenic alpha and beta chains, thus patients where TILs are not available [16].

diminishing the rate of pairing with endogenous

chains, although a potential risk remains for off‐ NY‐ESO‐1 in hematologic and solid target reactivity due to this phenomena. Genetic tumors

engineering also allows for expression of high‐ NY‐ESO‐1 is a cancer‐testis antigen widely expressed affinity variants of native tumor‐reactive TCRs on both hematologic and common solid tumors

[13–15], predicted to increase the likelihood of including malignant melanoma, synovial sarcoma, tumor recognition. Final y, additional non‐TCR and multiple myeloma, and absent from healthy elements can be coexpressed within the T cell to vital tissue. A human‐derived affinity‐enhanced enhance functionality beyond that which could be TCR targeting the NY‐ESO‐derived antigen preaccomplished by a nonengineered T cel .

sented within HLA‐A*02 was evaluated in patients

One practical challenge of TCR therapy with with NY‐ESO expressing melanoma and synovial clinical import is that TCRs are MHC restricted, sarcoma [17, 18]. Objective clinical responses were since TCRs bind to protein‐derived antigens pre­ seen in 61% of patients (11/18) with synovial sarsented within MHC. This permits targeting of coma and 55% of patients (11/20) with melanoma.

intracel ular antigens but also restricts binding of This promising work in February 2016 led to the any particular TCR to a specific HLA allele. Most FDA’s granting breakthrough therapy designation clinical trials to date have focused on antigens pre­ for affinity‐enhanced TCR targeting NY‐ESO1 in sented within HLA‐A*02, an allele expressed in synovial sarcoma, supporting the potential of TCR

approximately 40% of Caucasians, to demonstrate therapy in solid tumors.

proof of principle for the approach. From a prac­

A phase I/II study evaluating the same TCR

tical standpoint, this means that many patients are in advanced multiple myeloma following autoloineligible for studies involving engineered TCRs gous stem cell transplantation yielded an 80%

due to the absence of the HLA‐A*02 allele. (16/20 patients) clinical response rate. Fourteen of Furthermore, each TCR represents a novel receptor, 20 patients had near complete or complete remisand targeting the same antigen in patients with dif­ sions, 2 of 20 patients had very good partial ferent MHC alleles requires substantial additional remissions, and the median progression‐free preclinical and clinical development.

survival was 19.1 months [19]. This compares to

historic responses of 40% or <40% in high‐risk

Clinical experience

patients when treated with single or tandem

autologous stem cell transplantation. T cel s, lenti­

MART‐1

viral y transduced to express TCR, expanded and

The first clinical trial that demonstrated efficacy of persisted in vivo, trafficked to the bone marrow TCR therapy utilized a TCR targeting the mela­ and exhibited tumor‐specific cytotoxicity. Disease noma‐associated antigen MART‐1 in patients with progression was shown to be associated with a loss malignant melanoma. In 2006, 15 HLA‐A*02 of T cell persistence or antigen escape [19]. These patients with melanoma were treated with T cel s results were among the first to demonstrate potential genetical y modified to express a MART‐1‐specific clinical benefit of the TCR platform.





104 Immunotherapy in Translational Cancer Research Lessons on toxicity learned from MAGE

papillomavirus (HPV)‐16 E6 and E7 oncoproteins

Important lessons regarding the potential for TCR‐ are being explored for the treatment of HPV‐associated mediated toxicity came from early experience epithelial malignancies, including cervical, head using affinity‐enhanced TCRs targeting the and neck, and anogenital tumors [23]. Another melanoma‐associated antigen family (MAGE). promising antigen target is the preferential y MAGE‐A is a cancer‐testis antigen widely induced antigen in melanoma (PRAME). Also a expressed in common epithelial malignancies. A member of the cancer‐testis antigen family, phase I/II study conducted in patients with mela­ PRAME is overexpressed in acute myeloid leunoma, synovial sarcoma, and esophageal cancer kemia (AML), a disease with poor survival outusing a MAGE‐A3/A9‐specific TCR derived from comes and a clear unmet clinical need. High‐affinity murine immunization with a MAGE A3/A9 shared allogeneic T cel s targeting PRAME can be isolated peptide demonstrated cancer regression in 5 out of post–allogeneic stem cell transplant and are highly 9 patients. Unexpectedly, however, significant neu­ reactive against multiple PRAME+ tumor cell lines rotoxicity occurred in 3 of 8 patients, 2 of whom and primary melanoma and AML patient samples, rapidly became comatose and ultimately died. implicating PRAME as a candidate for targeted Radiographic imaging showed periventricular leu­ TCR therapy [24, 25]. Caution must be taken as komalacia in 5 of 8 patients, and autopsy examina­ preclinical data demonstrated that PRAME-tion revealed necrotizing leukoencephalopathy specific allo‐restricted T cel s exerted limited and white matter defects accompanied by T cell mature dendritic cell and renal epithelial toxicity infiltration [20]. The transgenic TCR was later [15]. Clinical trials studying PRAME‐specific found to broadly bind to peptides derived from T cel s equipped with a suicide vector are ongoing.

MAGE A2, A6, and A12, and MAGE‐A12 was

found to be expressed on brain parenchyma [20].

CARs

Another study of MAGE‐A1 targeting TCRs in

patients with myeloma and melanoma revealed Rationale and structure unanticipated cardiac toxicity [21, 22]. The first 2 Several features of engineered TCRs limit their patients treated developed fatal cardiac shock. applicability to mediate tumor eradication.

Autopsy revealed gross myocardial damage and Individual TCRs are restricted to a specific MHC

evidence of histopathologic T cell infiltration. allele, present on only a minority of the population.

Although MAGE‐A1 expression was not found on Tumors not infrequently downregulate MHC as a cardiac myocytes, unanticipated cross‐reactivity mechanism for immune evasion. The TCR does of the engineered TCR was found to peptides not directly mediate costimulation and is therederived from titin, an unrelated protein found on fore reliant on an additional costimulatory signal striated muscle. These adverse events led to the that tumors often lack. Attempts to engineer implementation of sophisticated prediction costimulatory signals into a transgenic TCR have models to assess peptide homology across proteins not yet been successful. A CAR is an artificial, and to evaluate the potential for cross‐reactivity of engineered T cell receptor, designed to overcome engineered TCRs with alternative peptide motifs, these barriers. Importantly, however, standard which thus far has proven sufficient to prevent methods of CAR transduction do not supplant a similar adverse outcomes. Nonetheless, these T cel ’s TCR, they rather induce CAR expression experiences highlight the risks of first‐in human in addition to the T cel ’s endogenous TCR. Gene targeted therapies and remind us of the experi­ editing techniques to eliminate TCR expression mental nature of the field.

are being developed with the goal to reduce the

possibility of graft‐versus‐host disease, eliminate

TCRs under clinical development

the potential for TCR activation to negatively

Currently, several TCR product candidates directed impact CAR function, and permit an off‐the-at other tumor‐associated antigens are under early shelf CAR T cell product that can cross stages of clinical development. TCRs targeting histocompatibility barriers [26]. To date, a single HLA‐A*02:01 restricted epitopes of human pediatric patient who had insufficient T cel s to





CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 105

manufacture an autologous product was treated signal was integrated into the signaling domains, with and achieved remission from an allogeneic and this was termed a second‐generation CAR.

T cell product expressing a CD19 specific CART Clinical data with CD19‐CARs in lymphoma product that was gene edited to eliminate the provided definitive evidence that second‐generation endogenous TCR [27].

CARs show superior expansion and persistence in

The CAR fuses an antigen binding domain to vivo, and the vast majority of clinical trials have T cell activation domains. Antigen binding utilized second‐generation CARs [30–34]. It is domains are most commonly derived from now evident that different costimulatory signals monoclonal antibodies (mAbs), which do not are not equivalent and influence the persistence require antigen presentation from resident and efficacy of the CAR T cell product. Inclusion MHC, thus endowing the T cell with MHC of CD28 potential y confers greater initial cytotoxindependence. Antibody binding domains typi­ icity; however, CARs incorporating CD28 sigcally comprise variable heavy (Vh) and light (Vl) naling endodomains do not demonstrate long‐term, chains, which can be genetically expressed as a high‐level CAR persistence [35]. In contrast, CARs single chain by incorporating flexible linkers to with 41BB costimulatory signals often demonpreserve the antigenic specificity of the parental strate persistence, and such CARs are not infreantibody. Theoretically, single‐chain variable quently found in patients >2 years following CAR

fragments (scFvs) can be generated from anti­ infusion [30].

bodies specific to any target of interest, thereby

Third‐generation CARs, which incorporate

introducing the flexibility to design engineered multiple costimulatory signals, have yet to confer CARs targeting any tumor antigen for which a superiority over second‐generation CARs. The specific antibody is available. In practice, the inclusion of more costimulation may in fact efficacy of CARs derived from mAbs varies sig­ increase the likelihood of developing T cell nificantly, and therefore substantial preclinical exhaustion, thereby restricting maximal long-optimization is typically required to generate an term immune effect. Numerous additional effective CAR for a particular target. The genetic modifications are undergoing testing in addition of costimulatory domains to the CAR CAR T cells, including expression of modifiers receptor eliminates the requirement for costim­ designed to protect the T cell from the tumor ulatory signals to be provided within the tumor inhibitory microenvironment, such as modifying microenvironment, thus further enhancing CARs to express endogenous checkpoint potency.

blockade, chemokine receptors, or cytokine

transgenes [36–38]. In particular, CAR T cells

CARs through the generations

that enforce cytokine or cytokine receptors that

The inception of the CAR dates to 1989 when induce signaling through the common gamma experimental data demonstrated the potential for chain receptor (IL‐2, IL‐7, IL‐15, IL‐21) provide T cell activation following expression of an MHC‐ autocrinous proliferative and proinflammatory independent binding moiety and a T‐cell‐derived signals, enhance CAR function in vitro [39–43], activation domain [28]. Eshhar and colleagues and are being explored clinically. Innovative engineered T cel s to express artificial receptors methods to transform cytokine‐mediated inhibiconstructed of antibody‐derived variable domains tory signals into activating signals by fusing the fused to TCR constant domains. Subsequent work regulatory cytokine IL‐4 receptor to a proinflamdemonstrated that receptors incorporating scFv matory IL7R signaling domain have shown binding domains provide superior antigen recog­ preclinical promise [44]. As the field of CARs nition, leading to the evolution of first‐generation expands and a deeper comprehension of mecha­

CAR constructs that fuse an scFv to a singular nistic factors that influence T cell activation, T cell activation domain. First‐generation CARs inhibition, exhaustion, cytotoxicity, and persisremain dependent on tumor to provide costimu­ tence are elucidated, we anticipate the CAR

latory signals for therapeutic benefit [29]. construct can be tailored to further optimize Subsequently, a CD28 or 4‐1BB costimulatory CAR‐mediated antitumor outcomes.





106 Immunotherapy in Translational Cancer Research Clinical translation

Acute lymphoblastic leukemia (ALL)

Despite the fact that patients with refractory acute

Chronic lymphocytic leukemia (CLL),

leukemia are often pancytopenic or have high

non‐Hodgkin lymphoma (NHL)

circulating blast counts, the phase I B‐ALL experi­

Initial Phase I CD19‐targeting CAR trials in ence has demonstrated not only the feasibility of patients with non‐Hodgkin B cell lymphomas and CAR T cell therapy in this setting but also that CLL were critical in dose finding, identifying toxic­ B‐ALL is uniquely sensitive to CD19‐CAR T cell ities, and demonstrating the importance of a lym­ therapy. Several groups from different institutions phodepleting preparative regimen. The first clinical have now demonstrated that CD19‐targeting CARs report demonstrating CAR efficacy described the can induce striking remissions in adults and use of a second‐generation CD19‐specific CAR children with relapsed/refractory B‐ALL despite with a CD28 costimulatory domain in a patient significant inter‐institutional heterogeneity in with follicular lymphoma. Kochenderfer et al. CAR constructs, preparative regimen, and vector described dramatic tumor regression in a patient platform [30, 31, 33, 34, 50] (Table 8.2). All groups with heavily pretreated advanced follicular lym­ report remarkable complete remission rates rangphoma who experienced CAR‐mediated B cell ing from 70% to 90% in B‐ALL (NCI report aplasia for a duration of 39 weeks and partial remis­ included an NHL, so results were 70% in B‐ALL), sion for 32 weeks [45]. Impressive results followed which are markedly superior to historic complete in 3 patients with CLL [46, 47] treated with CD19‐ remission rates of 20%–30% using standard salvage BB.z‐CARs. CAR T cel s expanded over 1000‐fold chemotherapy in patients with relapsed/refractory and patients expressed CARs for at least 6 months, ALL [50]. These unprecedented outcomes propasome of which conferred a memory phenotype by gated early enthusiasm in the field.

flow cytometry [47, 48]. An additional 8 patients

Insights were gained from the parallel yet

with CLL treated at Memorial Sloan Kettering varying strategies pursued by the different instituprovided data suggesting the importance of lym­ tions. The feasibility of cell production was phodepletion prior to the adoptive transfer of CAR supported by the NCI intent to treat analysis that T cel s. This study also concluded that disease showed that 100% of patients enrolled on their trial response and persistence were inversely correlated received CAR therapy [34]. The evaluated doses in with tumor burden [32]. The first pivotal multi­ all studies ranged from 0.03 to 21 × 106. We addicenter study of CD19‐specific CAR T cel s in tional y learned that CAR T cell expansion refractory aggressive NHL met primary endpoints correlated with response [34]. The UPenn experiof 76% overall response rate (ORR) and 47% ence introduced the first patient to relapse complete remission (CR) ( p < .0001), which is post‐CAR therapy with CD19 negative disease, 6‐fold higher than prior historical CR outcomes [49]. introducing the phenomenon of tumor antigen These results yield promise for CAR therapy for the remodeling under the pressure of targeted CAR

treatment of refractory, aggressive lymphomas.

therapy [30, 31, 34, 51]. We have since seen that in

Table 8.2 Interinstitutional variability in CD19‐CAR trials.

Method of

Complete

Cytokine Release Prolonged

Center

CAR Design

scFv

Gene Transfer

Sample ( n )

Response (CR)

Syndrome (CRS)

B Cell Aplasia

UPENN[30]

4‐1BB, CD3ζ

FMC63

Lentiviral

30

90% (27/30)

Yes

Yes

NCI[34]

CD28, CD3ζ

FMC63

Retroviral

21

70% (14/20)

Yes

No

(20 w ALL)

Intent to treat

MSKCC[73]

CD28, CD3ζ

SJ2SC1

Retroviral

45

80% (37/45)

Yes

No

FHCRC[74]

4‐1BB, CD3ζ

FMC63

Lentiviral

29

93%

Yes

Pending

CD4:CD8, 1:1

(24/26)

Note: UPENN = University of Pennsylvania; NCI = National Cancer Institute; MSKCC = Memorial Sloan‐Kettering Cancer Center; FHCRC = Fred Hutchinson Cancer Research Center.





CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 107

addition to surface antigen remodeling, tumors can trafficking within the tumor microenvironment undergo lineage reprogramming and relapse with [53], and challenges related to CAR engineering myeloid disease [52].

that impact the relative potency of some CARs

CAR persistence was identified as a vital deter­ versus others [35]. One innovative approach that minant of long‐term immune memory, and early permits CARs to target intracel ular antigens is to clinical trials correlated CAR T cell loss with dis­ design a CAR to mimic a TCR and bind to intracel ular-ease relapse [1]. The CAR costimulatory domain derived peptides complexed with surface MHC.

was shown to critical y impact the T cell capacity TCR‐mimetic CARs have been generated targeting for long‐term persistence. CAR T cel s with endog­ WT1 (Wilms Tumor 1 Antigen) and NY‐ESO 1

enous 4‐1BB demonstrated long‐term persistence, and are being explored for other intracel ular tarwhereas CAR T cel s with CD28 costimulation did gets with the hope to expand CAR applicability to not persist beyond 2–3 months [30, 50]. CD28‐ solid tumors that harbor specific intracel ular mediated cel ular tonic signaling has since been tumor antigens.

shown to induce an exhaustive phenotype that is

Encouraging results were initial y reported using

associated with reduced CAR T cell persistence in a first‐generation GD2‐CAR in neuroblastoma (2

vivo [35]. The fundamental mechanisms that drive of 8 patients in initial cohort with objective T cell exhaustion and persistence remain underex­ responses, long‐term complete responses in 2 of 11

plored at this time and serve as drivers for future patients treated) [54, 55]. Based on evidence that CAR T cell biology studies to empower strategies costimulation enhances expansion and persistence for optimized CAR design.

of CD19‐CAR T cel s [56], a subsequent trial used

The United States Food and Drug Administration the same GD2‐CAR scFv but incorporated CD28

granted breakthrough therapy designation to and OX40 costimulatory domains. However, no CTL019, CD19‐targeted CAR on July 1, 2014 and objective responses were seen and the GD2-FDA approval on August 30, 2017, for the CD19­ CAR.28.OX40.z T cel s showed very limited targeted CAR, Kymriah, for children and young expansion and persistence. Subsequent work demadults <age 25 with relapsed/refractory B cell ALL. onstrated that the scFv incorporated into this This landmark designation and approval arrived GD2‐CAR manifests antigen‐independent clus­

>25 years after the initial publication describing the tering on the cell surface, which leads to tonic CAR T cell therapy foundational work in 1989. signaling and early CAR T‐cell exhaustion in the Genetical y modified T cell therapy is the first per­ presence of costimulatory domains [35]. CD28

sonalized cel ular cancer therapy to be translated to costimulation potently enhanced exhaustion, the clinic, and its integration into practice is chang­ whereas a 4‐1BB costimulation provided antiing our approach to B cell tumors. The field is exhaustion signals. In the third‐generation CAR

rapidly expanding, and we anticipate new biologic incorporating CD28 and OX40, the exhaustion and clinical insights will support further optimiza­ phenotype predominates [57]. This experience tion and guide successful translation to less highlighted a critical role for T cell exhaustion in immunogenic solid tumors.

limiting CAR efficacy and provided evidence that

costimulatory domains can both augment or

Solid tumors

adversely impact CAR function.

Recent work in xenograft models using the

Despite several clinical trials targeting numerous GD2‐CAR also il ustrate the impact of local myeloantigens in a variety of cancers, outcomes using suppression on CAR T cel s. In this study, CAR therapy in solid tumors have been less encour­ myeloid‐derived suppressor cel s (MDSCs) in aging than in hematologic tumors (Table 8.3). xenograft models were preferential y expanded in Some of the barriers implicated in restraining CAR sarcoma models compared to neuroblastoma outcomes in solid tumors include a dearth of models, and this correlated with diminished antigens with high‐level universal surface expres­ antitumor efficacy against GD2+ sarcomas [57].

sion on tumor cel s and absent expression on vital Incorporating agents to modulate MDSCs augtissues, immunosuppression and impaired T cel ments CAR efficacy. It is anticipated that future

Table 8.3 Published reports of clinical trials of CAR therapeutics for solid tumors *

Method of Gene

Antigen Target

Disease

CAR Design

Transfer

Sample ( n )

Response

CAIX [72]

Metastatic renal cell carcinoma

FcR γ

Retroviral

12

0/12 tumor responses; on‐target off‐tumor toxicity

observed

HER‐2 [64]

Refractory colon cancer,

4‐1BB, CD28, CD3 ζ

Retroviral

1

Death at 5 days postinfusion (elevated cytokines and

metastatic to lungs and liver

respiratory failure in context of dose of 10 10 CARs)

HER‐2 [58]

Recurrent/

CD28, CD3 ζ

Retroviral

17

4/17 SD

refractory HER2 + sarcoma

GD‐2 [55]

High‐risk neuroblastoma

1st‐generation CAR expressed

Retroviral

19

3/11 CR in patients with active disease

on EBV‐specific CTLs or

(8 = remission,

activated T cells

11 = active

disease)

Mesothelin [75]

Malignant pleural mesothelioma,

4‐1BB, CD3 ζ

mRNA

2

2 tumor responses

pancreatic

transduction

IL13R α 2

Glioblastoma

4‐1BB, CD3 ζ

Lentiviral

1

1 CR ** sustained for 7.5 mo

[60]

(intracavitary and

intraventricular delivery)

CEA [76]

Adenocarcinoma with metastatic

CD28, CD3 ζ

Retroviral

6

1 SD, 5 PD

liver disease

(percutaneous hepatic artery

Increased necrosis or fibrosis of liver metastases in 4/6

delivery)

biospies

MUC‐1 [77]

Seminal vesicle cancer

CD28, 4‐1BB, CD3 ζ

Lentiviral

1

Local tumor necrosis

(intratumoral injection)

* Many additional clinical trials targeting listed and unlisted tumor antigens are recruiting and ongoing. Only results of published reports of clinical trials for solid tumors are summarized here.

** CR in IL13Ra2 CAR trial according to Response Assessment in Neuro‐Oncology criteria.

Note: CAIX = carbonic anhydrase IX; HER‐2 = human epidermal growth factor receptor 2; GD‐2 = disialoganglioside; EBV = Epstein‐Barr virus; CTLs = cytotoxic T lymphocytes; IL13Ra2 = interleukin‐13 receptor subunit alpha‐2; CEA = carcinoembryonic antigen; MUC‐1 = mucin 1; FcRg = Fc receptor g; SD = stable disease; CR = complete remission; PD = progressive disease.





CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 109

studies of CAR T cel s in solid tumors will utilize CAR toxicities combinatorial regimens designed to modulate

tumor‐associated immunosuppression as a step Cytokine release syndrome toward augmenting the efficacy of CAR therapies The most common toxicity from CAR therapy is against solid tumors.

cytokine release syndrome (CRS). Patients can

The initial experience with CARs targeting the develop a clinical syndrome that mimics macro­

Her2 antigen resulted in a severe fatal adverse event phage activation syndrome characterized by fever after infusion of 1 x 1010 third‐generation Her2‐ and hypotension in context of high levels of prointargeted CAR T cel s (CD28.4‐1BB.CD3ζ) [64]. flammatory cytokines. Cytokines are released from Based on knowledge that has emerged since this T cel s, resident immune cel s such as macrophages, patient’s treatment, it is now clear that the CAR T and tumor [61]. Symptoms typical y develop within cell dose administered in this case far exceeds the 1–2 weeks posttreatment and can range from a maximal y tolerated dose reported for other CARs, mild syndrome with constitutional symptoms to a and the clinical deterioration was consistent with severe life‐threatening syndrome necessitating Table 8.3 Published reports of clinical trials of CAR therapeutics for solid tumors *

severe cytokine release syndrome. Furthermore, ICU‐level circulatory and ventilator support.

Method of Gene

although some initial y hypothesized that CAR T Dramatic cytokine elevations including IL‐6, IL‐10, Antigen Target

Disease

CAR Design

Transfer

Sample ( n )

Response

cel s may have attacked the heart and lungs due to IFN‐γ, and TNF‐α correlate with CRS severity CAIX [72]

Metastatic renal cell carcinoma

FcR γ

Retroviral

12

0/12 tumor responses; on‐target off‐tumor toxicity

low‐level expression of Her2 on these tissues, data [62]. IL‐6 has been implicated in propagating the observed

HER‐2 [64]

Refractory colon cancer,

4‐1BB, CD28, CD3 ζ

Retroviral

1

Death at 5 days postinfusion (elevated cytokines and

now increasingly demonstrate that CARs do not clinical syndrome and treatment with tocilizumab, metastatic to lungs and liver

respiratory failure in context of dose of 10 10 CARs)

recognize low‐level antigen expression when com­ an anti‐IL6R monoclonal antibody that has been HER‐2 [58]

Recurrent/

CD28, CD3 ζ

Retroviral

17

4/17 SD

refractory HER2 + sarcoma

pared to TCRs [65–68]. Her2‐CAR T cel s at shown to effectively, promptly reverse the syn­

GD‐2 [55]

High‐risk neuroblastoma

1st‐generation CAR expressed

Retroviral

19

3/11 CR in patients with active disease

on EBV‐specific CTLs or

(8 = remission,

appropriate doses have been well tolerated in drome [61]. Studies are underway to determine activated T cells

11 = active

subsequent studies introducing the possibility for a whether preemptive therapy with IL‐6R blockade disease)

Mesothelin [75]

Malignant pleural mesothelioma,

4‐1BB, CD3 ζ

mRNA

2

2 tumor responses

therapeutic window [58]. Of 17 patients with can improve safety and tolerance without adversely pancreatic

transduction

HER2+ sarcoma who received more than 3x106/m2 impacting efficacy. Corticosteroids provide an IL13R α 2

Glioblastoma

4‐1BB, CD3 ζ

Lentiviral

1

1 CR ** sustained for 7.5 mo

[60]

(intracavitary and

Her2.28.z­CAR T cel s, 4 showed stable disease for alternative treatment for CRS, although unconintraventricular delivery) 12 weeks to 14 months, and CAR T cel s persisted trolled trials suggest that they may mediate more CEA [76]

Adenocarcinoma with metastatic

CD28, CD3 ζ

Retroviral

6

1 SD, 5 PD

liver disease

(percutaneous hepatic artery

Increased necrosis or fibrosis of liver metastases in 4/6

for at least 6 weeks at low levels in the peripheral adverse effects on the antitumor immune response delivery)

biospies

MUC‐1 [77]

Seminal vesicle cancer

CD28, 4‐1BB, CD3

Lentiviral

1

Local tumor necrosis

blood [58]. The basis for limited efficacy in this than IL6 neutralizing strategies [63]. Established ζ

(intratumoral injection)

study was not clarified; however, in preclinical algorithms delineating the threshold for CRS

* Many additional clinical trials targeting listed and unlisted tumor antigens are recruiting and ongoing. Only results of published reports of clinical trials for solid tumors are models using Her2‐CARs to treat glioblastoma, treatment should be used to guide management of summarized here.

rapid selection of antigen loss variants due to high cytokine storm [61].

** CR in IL13Ra2 CAR trial according to Response Assessment in Neuro‐Oncology criteria.

Note: CAIX = carbonic anhydrase IX; HER‐2 = human epidermal growth factor receptor 2; GD‐2 = disialoganglioside; EBV = Epstein‐Barr virus; CTLs = cytotoxic T lymphocytes; levels of heterogeneity in antigen expression was

IL13Ra2 = interleukin‐13 receptor subunit alpha‐2; CEA = carcinoembryonic antigen; MUC‐1 = mucin 1; FcRg = Fc receptor g; SD = stable disease; CR = complete remission; observed [59]. This could be overcome by simulta­

PD = progressive disease.

Neurotoxicity

neously targeting Her2 and an additional target, Neurologic toxicities following CAR therapy most IL13Rα2, via a bispecific CAR. In this work, a often follow CRS, however, the mechanisms may bispecific Her2/IL13Rα2 CAR receptor was differ and cytokine dysregulation alone may not superior to coexpression of both CARs individual y ful y explain CAR‐mediated neurotoxicity [61].

on the same T cel . A recent case report of a patient Symptoms do not localize to a defined anatomic with metastatic glioblastoma multiforme who had a area of the brain and can include headaches, condramatic response to regional delivery of a CAR fusion, delirium, hal ucinations, facial nerve targeting IL13Rα2 [60] provides additional data palsies, apraxia, ataxia, dysmetria, dysphagia, seisuggesting that IL13Rα2 may be a promising target zures, and altered consciousness that can require for CAR‐based targeting of brain tumors [60]. airway protection with ventilator support [69].

These early successes support the potential of CARs These symptoms are nearly always reversible.

to change outcomes in otherwise devastating solid Neurotoxicity has not been shown to directly corretumors.

late with CNS disease, but CAR T cel s and elevated





110 Immunotherapy in Translational Cancer Research cytokine levels have been identified in the CSF of enhance T cell function, modifying clinical aspects patients experiencing neurotoxicity [69]. Recently, of treatment (e.g., timing of infusion, cell dose, this syndrome was replicated in a primate model and lymphodepletion regimen), and combining using a CD20‐CAR, suggesting that the syndrome engineered T cel s with other immunomodulators does not reflect an antigen‐specific effect of CD19‐ all hold promise for enhancing the activity of the CAR T cel s [70].

emerging class of therapeutics. The emergence of

Recently, several cases of fatal cerebral edema antigen‐negative relapse now well documented folfollowing CD19‐CAR T cel s were reported. The lowing CD19‐CAR therapy il ustrates the imporpathophysiology responsible for fatal neurotoxicity tance of crafting multispecific T cel s to diminish is not well understood, and it remains unclear the risk of antigen loss escape.

whether this reflects a more severe version of the

Additional focus has been on studying the

same pathophysiology that leads to reversible neu­ reversal of T cell exhaustion and inhibition. T cel s rotoxicity, or reflects an alternative biology. are inhibited by intrinsic regulatory mechanisms Endothelial dysfunction has been implicated as an and their inhibitory tumor microenvironment.

underlying trigger for CAR­mediated neurotox­ Efforts to reverse T cell inhibition and exhaustion icity and further efforts to mechanistical y using combinatorial approaches of engineered understand neurologic toxicities of CARs are in T cell and checkpoint blockade are being studied.

order so we can learn to avert this possibly devas­ Another approach under evaluation is to engineer tating cause of morbidity and mortality.

the T cel s to have intrinsic mechanisms to inhibit

immune‐regulatory checkpoints.

A major challenge has been the feasibility of

On‐target, off‐tumor toxicities

large‐scale production of adoptive T cell products.

B cell depletion is typical y observed following With improved technology methods, the produc­

CD19‐CAR therapy and persists for the duration tion time has decreased, with many clinical trials of T cell persistence. Notably, this has not been reporting production times of less than 21 days.

associated with significant morbidity and appears The process of apheresis, genetic modification in a to be adequately managed with immunoglobulin sterile facility under good manufacturing, is a techreplacement [71]. Hepatobiliary toxicity, presum­ nical y complex and expensive process. Many ably a manifestation of on‐target, off‐tumor tox­ patients have underlying T cell dysfunction from icity, was observed following treatment with a prior therapies, and their T cel s may not expand CAR targeting carbonic anhydrase IX (CAIX) in sufficiently to meet threshold doses. Not all patients patients with renal cell carcinoma [72]. who undergo apheresis successful y go on to Interestingly, the toxicity could be prevented by receive the intended product. Efforts to reliably pretreatment with a mAb targeting the same improve transduction efficiencies and enhance the antigen. On‐target, off‐tumor toxicity profiles wil precision and reliability of gene engineering are vary depending on the specific antigenic target. being explored with techniques such as CRISPR/

Clinical trials studying CARs targeting novel cas9 gene editing.

antigens will require close monitoring for on‐

Efforts to generate off‐the‐shelf T cell products

target, off‐tumor toxicities.

are also underway. An initial patient was treated

with a CAR T cell product from an HLA‐

mismatched donor that was modified to lack

Future directions

surface TCR expression so as to avoid alloreactiv­

Therapy with engineered T cel s has shown clear ity. We anticipate that precise gene editing signs of activity, and the full potential of this techniques, off the shelf adoptive T cell platforms, therapeutic approach remains untapped. Receptor‐ and combinatorial therapy will all contribute to specific manipulations (e.g., enhancing TCR developments that will enhance the precision, affinity, diminishing tonic signaling in CAR potency, persistence, and availability of this novel T cel s), coexpression of additional modulators to class of therapeutics.





CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 111

References

14. Varela‐Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski

MM, Carroll RG, et al. Control of HIV‐1 immune escape

1. Ghoneim HE, Zamora AE, Thomas PG, Youngblood

by CD8 T cel s expressing enhanced T‐cell receptor. Nat

BA. Cell‐intrinsic barriers of T cell‐based immunother­

Med. 2008;14(12):1390–5.

apy. Trends Mol Med. 2016.

15. Amir AL, van der Steen DM, van Loenen MM,

2. Sadelain M, Riviere I, Brentjens R. Targeting tumours

Hagedoorn RS, de Boer R, Kester MD, et al. PRAME‐

with genetical y enhanced T lymphocytes. Nat Rev

specific Allo‐HLA‐restricted T cel s with potent antitu­

Cancer. 2003;3(1):35–45.

mor reactivity useful for therapeutic T‐cell receptor gene

3. Thomas S, Hart DP, Xue SA, Cesco‐Gaspere M, Stauss

transfer. Clin Cancer Res. 2011;17(17):5615–25.

HJ. T‐cell receptor gene therapy for cancer: the progress 16. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, to date and future objectives. Expert Opin Biol Ther.

Yang JC, Sherry RM, et al. Cancer regression in patients

2007;7(8):1207–18.

after transfer of genetical y engineered lymphocytes.

4. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R,

Science. 2006;314(5796):126–9.

Olivares S, et al. Phase I trials using Sleeping Beauty to 17. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry generate CD19‐specific CAR T cel s. J Clin Invest.

RM, Dudley ME, et al. Tumor regression in patients with

2016;126(9):3363–76.

metastatic synovial cell sarcoma and melanoma using

5. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach

genetical y engineered lymphocytes reactive with NY‐

to gene therapy using Sleeping Beauty to genetical y

ESO‐1. J Clin Oncol. 2011;29(7):917–24.

modify clinical‐grade T cel s to target CD19. Immunol 18. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan Rev. 2014;257(1):181–90.

RA, Feldman SA, et al. A pilot trial using lymphocytes

6. Schutsky K, Song DG, Lynn R, Smith JB, Poussin M,

genetical y engineered with an NY‐ESO‐1‐reactive T‐

Figini M, et al. Rigorous optimization and validation of

cell receptor: long‐term follow‐up and correlates with

potent RNA CAR T cell therapy for the treatment of

response. Clin Cancer Res. 2015;21(5):1019–27.

common epithelial cancers expressing folate receptor. 19. Rapoport AP, Stadtmauer EA, Binder‐Scholl GK, Oncotarget. 2015;6(30):28911–28.

Goloubeva O, Vogl DT, Lacey SF, et al. NY‐ESO‐1‐

7. Sather BD, Romano Ibarra GS, Sommer K, Curinga G,

specific TCR‐engineered T cel s mediate sustained

Hale M, Khan IF, et al. Efficient modification of CCR5 in

antigen‐specific antitumor effects in myeloma. Nat Med.

primary human hematopoietic cel s using a megaTAL

2015;21(8):914–21.

nuclease and AAV donor template. Sci Transl Med. 20. Morgan RA, Chinnasamy N, Abate‐Daga D, Gros A, 2015;7(307):307ra156.

Robbins PF, Zheng Z, et al. Cancer regression and neu8. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex rological toxicity following anti‐MAGE‐A3 TCR gene

genome editing to generate universal CAR T cel s resistherapy. J Immunother. 2013;36(2):133–51.

tant to PD1 inhibition. Clin Cancer Res. 2016.

21. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V,

9. Scholler J, Brady TL, Binder‐Scholl G, Hwang WT, Plesa

Bianchi FC, et al. Identification of a titin‐derived HLA‐

G, Hege KM, et al. Decade‐long safety and function of

A1‐presented peptide as a cross‐reactive target for

retroviral‐modified chimeric antigen receptor T cel s.

engineered MAGE A3‐directed T cel s. Sci Transl Med.

Sci Transl Med. 2012;4(132):132ra53.

2013;5(197):197ra03.

10. Han A, Glanville J, Hansmann L, Davis MM. Linking 22. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, T‐cell receptor sequence to functional phenotype at the

Levine BL, Emery L, et al. Cardiovascular toxicity and

single‐cell level. Nat Biotechnol. 2014;32(7): 684–92.

titin cross‐reactivity of affinity‐enhanced T cel s in mye11. Bialer G, Horovitz‐Fried M, Ya’acobi S, Morgan RA, loma and melanoma. Blood. 2013;122(6):863–71.

Cohen CJ. Selected murine residues endow human TCR 23. Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, with enhanced tumor recognition. J Immunol.

Kerkar S, et al. Targeting of HPV‐16+ epithelial cancer

2010;184(11):6232–41.

cel s by TCR gene engineered T cel s directed against E6.

12. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA.

Clin Cancer Res. 2015;21(19):4431–9.

Enhanced antitumor activity of murine‐human hybrid 24. Ding K, Wang XM, Fu R, Ruan EB, Liu H, Shao ZH.

T‐cell receptor (TCR) in human lymphocytes is associ­

PRAME Gene expression in acute leukemia and its

ated with improved pairing and TCR/CD3 stability.

clinical significance. Cancer Biol Med. 2012;9(1):

Cancer Res. 2006;66(17):8878–86.

73–6.

13. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu 25. Goswami M, Hensel N, Smith BD, Prince GT, Qin L, LY, et al. High‐affinity TCRs generated by phage display

Levitsky HI, et al. Expression of putative targets of

provide CD4+ T cel s with the ability to recognize and

immunotherapy in acute myeloid leukemia and healthy

kill tumor cell lines. J Immunol. 2007;179(9):5845–54.

tissues. Leukemia. 2014;28(5):1167–70.

112 Immunotherapy in Translational Cancer Research 26. Torikai H, Cooper LJ. Translational implications for off-39. Jena B, Dotti G, Cooper LJ. Redirecting T‐cell specificity the‐shelf immune cel s expressing chimeric antigen

by introducing a tumor‐specific chimeric antigen

receptors. Mol Ther. 2016;24(7):1178–86.

receptor. Blood. 2010;116(7):1035–44.

27. Ratner M. Off‐the‐shelf CAR‐T therapy induces remis40. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano sion in child with ALL. Nat Biotechnol. 2016;34(1):12.

Attianese GM, Leen AM, et al. Genetic manipulation of

28. Gross G, Waks T, Eshhar Z. Expression of immunoglobtumor‐specific cytotoxic T lymphocytes to restore ulin‐T‐cell receptor chimeric molecules as functional

responsiveness to IL‐7. Mol Ther. 2009;17(5):880–8.

receptors with antibody‐type specificity. Proc Natl Acad 41. Sogo T, Kawahara M, Tsumoto K, Kumagai I, Ueda H, Sci U S A. 1989;86(24):10024–8.

Nagamune T. Selective expansion of genetical y modi29. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, fied T cel s using an antibody/interleukin‐2 receptor chi­

Lyddane C, et al. Eradication of systemic B‐cell tumors by

mera. J Immunol Methods. 2008;337(1):16–23.

genetical y targeted human T lymphocytes co‐stimulated 42. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, by CD80 and interleukin‐15. Nat Med. 2003;9(3):279–86.

Zhang M, Vera J, et al. Engineering CD19‐specific T

30. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM,

lymphocytes with interleukin‐15 and a suicide gene to

Bunin NJ, et al. Chimeric antigen receptor T cel s for

enhance their anti‐lymphoma/leukemia effects and

sustained remissions in leukemia. N Engl J Med.

safety. Leukemia. 2010;24(6):1160–70.

2014;371(16):1507–17.

43. Markley JC, Sadelain M. IL‐7 and IL‐21 are superior to

31. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL,

IL‐2 and IL‐15 in promoting human T cell‐mediated

Rheingold SR, et al. Chimeric antigen receptor‐modified

rejection of systemic lymphoma in immunodeficient

T cel s for acute lymphoid leukemia. N Engl J Med.

mice. Blood. 2010;115(17):3508–19.

2013;368(16):1509–18.

44. Mohammed S, Sukumaran S, Bajgain P, Watanabe N,

32. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X,

Heslop HE, Rooney CM, et al. Improving chimeric

Stefanski J, et al. Safety and persistence of adoptively

antigen receptor‐modified T cell function by reversing

transferred autologous CD19‐targeted T cel s in patients

the immunosuppressive tumor microenvironment of

with relapsed or chemotherapy refractory B‐cell leukepancreatic cancer. Mol Ther. 2017;25(1):249–58.

mias. Blood. 2011;118(18):4817–28.

45. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME,

33. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita

Stetler‐Stevenson M, Feldman SA, et al. Eradication of

M, La Perle K, et al. Genetical y targeted T cel s eradicate

B‐lineage cel s and regression of lymphoma in a patient

systemic acute lymphoblastic leukemia xenografts. Clin

treated with autologous T cel s genetical y engineered to

Cancer Res. 2007;13(18 Pt 1):5426–35.

recognize CD19. Blood. 2010;116(20):4099–102.

34. Lee DW, Kochenderfer JN, Stetler‐Stevenson M, Cui 46. Porter DL, Levine BL, Kalos M, Bagg A, June CH.

YK, Delbrook C, Feldman SA, et al. T cel s expressing

Chimeric antigen receptor‐modified T cel s in chronic

CD19 chimeric antigen receptors for acute lympholymphoid leukemia. N Engl J Med. 2011;365(8):725–33.

blastic leukaemia in children and young adults: a 47. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, phase 1 dose‐escalation trial. Lancet. 2015;385(9967):

et al. T cel s with chimeric antigen receptors have potent

517–28.

antitumor effects and can establish memory in patients with

35. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai

advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.

M, Ingaramo M, et al. 4‐1BB costimulation ameliorates 48. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric T cell exhaustion induced by tonic signaling of chiantigen receptor therapy for B‐cell malignancies.

meric antigen receptors. Nat Med. 2015;21(6):

J Cancer. 2011;2:331–2.

581–90.

49. Sattva S. Neelapu et al. LBA‐6 Kte‐C19 (anti‐CD19 CAR

36. Pegram HJ, Park JH, Brentjens RJ. CD28z CARs and

T cel s) induces complete remissions in patients with

armored CARs. Cancer J. 2014;20(2):127–33.

refractory diffuse large B‐cell lymphoma (DLBCL):

37. Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ,

results from the pivotal phase 2 Zuma‐1. ASH.; 12.6.2016;

Giralt SA, Barker JN, et al. IL‐12‐secreting CD19‐

Sand Diego: Blood. Late Breaking Abstract LBA‐6.

targeted cord blood‐derived T cel s for the immunother50. Davila ML, Sauter C, Brentjens R. CD19‐targeted T cel s apy of B‐cell acute lymphoblastic leukemia. Leukemia.

for hematologic malignancies: clinical experience to

2015;29(2):415–22.

date. Cancer J. 2015;21(6):470–4.

38. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder 51. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, TF, Sadelain M, et al. Tumor‐targeted T cel s modified to

Wu G, et al. Convergence of acquired mutations and

secrete IL‐12 eradicate systemic tumors without need for

alternative splicing of CD19 enables resistance to CART‐19

prior conditioning. Blood. 2012;119(18):4133–41.

immunotherapy. Cancer Discov. 2015;5(12):1282–95.

CHAPTER 8 Immunotherapy with Genetical y Modified T Cel s 113

52. Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, 64. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot Qin H, et al. CD19 CAR immune pressure induces B-CM, Rosenberg SA. Case report of a serious adverse

precursor acute lymphoblastic leukaemia lineage switch

event following the administration of T cel s transduced

exposing inherent leukaemic plasticity. Nat Commun.

with a chimeric antigen receptor recognizing ERBB2.

2016;7:12320.

Mol Ther. 2010;18(4):843–51.

53. Newick K, Moon E, Albelda SM. Chimeric antigen 65. Weijtens ME, Hart EH, Bolhuis RL. Functional balance receptor T‐cell therapy for solid tumors. Mol Ther

between T cell chimeric receptor density and tumor

Oncolytics. 2016;3:16006.

associated antigen density: CTL mediated cytolysis

54. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV,

and lymphokine production. Gene Ther. 2000;7(1):

Dotti G, et al. Virus‐specific T cel s engineered to coex35–42.

press tumor‐specific receptors: persistence and antitu66. Turatti F, Figini M, Bal adore E, Alberti P, Casalini P, mor activity in individuals with neuroblastoma. Nat

Marks JD, et al. Redirected activity of human antitumor

Med. 2008;14(11):1264–70.

chimeric immune receptors is governed by antigen and

55. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers

receptor expression levels and affinity of interaction.

GD, et al. Antitumor activity and long‐term fate of chi­

J Immunother. 2007;30(7):684–93.

meric antigen receptor‐positive T cel s in patients with 67. Anurathapan U, Chan RC, Hindi HF, Mucharla R, neuroblastoma. Blood. 2011;118(23):6050–6.

Bajgain P, Hayes BC, et al. Kinetics of tumor destruction

56. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ,

by chimeric antigen receptor‐modified T cel s. Mol

Carrum G, et al. CD28 costimulation improves expan­

Ther. 2014;22(3):623–33.

sion and persistence of chimeric antigen receptor‐ 68. Walker AJ, Majzner RG, zhang L, Wanhainen KM, modified T cel s in lymphoma patients. J Clin Invest.

Long AH, Nguyen SM, et al. Tumor antigen and

2011;121(5):1822–6.

receptor densities regulate efficacy of a novel chimeric

57. Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ,

antigen receptor targeting anaplastic lymphoma

Ramakrishna S, et al. Reduction of MDSCs with all‐

kinase. 2017.

trans retinoic acid improves CAR therapy efficacy 69. Brudno JN, Kochenderfer JN. Toxicities of chimeric for sarcomas. Cancer Immunol Res. 2016;4(10):

antigen receptor T cel s: recognition and management.

869–80.

Blood. 2016;127(26):3321–30.

58. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi 70. Taraseviciute A, Kean L, Jensen M, editors. Creation of A, Gerken C, et al. Human epidermal growth factor

the first non‐human primate model that faithful y recareceptor 2 (HER2)‐specific chimeric antigen pitulates chimeric antigen receptor (CAR) T cell-receptor‐modified T cells for the immunotherapy of

mediated cytokine release syndrome (CRS) and

HER2‐positive sarcoma. J Clin Oncol. 2015;33(15):

neurologic toxicity following B cell‐directed CAR‐T cell

1688–96.

therapy. Blood; 2016 2016.

59. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, 71. Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Navai SA, et al. Tandem CAR T cel s targeting HER2 and

Callahan CA, Ellebrecht CT, et al. Persistence of long‐

IL13Ralpha2 mitigate tumor antigen escape. J Clin

lived plasma cells and humoral immunity in individ­

Invest. 2016;126(8):3036–52.

uals responding to CD19‐directed CAR T‐cell therapy.

60. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR,

Blood. 2016;128(3):360–70.

Naranjo A, et al. Regression of glioblastoma after chi72. Lamers CH, Sleijfer S, van Steenbergen S, van meric antigen receptor T‐cell therapy. N Engl J Med.

Elzakker P, van Krimpen B, Groot C, et al. Treatment of

2016;375(26):2561–9.

metastatic renal cell carcinoma with CAIX

CAR‐

61. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N,

engineered T cel s: clinical evaluation and manage­

Jensen M, et al. Current concepts in the diagnosis and

ment of on‐target toxicity. Mol Ther. 2013;21(4):

management of cytokine release syndrome. Blood.

904–12.

2014;124(2):188–95.

73. Park J. et al., CD19‐targeted CAR T‐cell therapeutics for 62. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ.

hematologic malignancies: interpreting clinical out­

Toxicity and management in CAR T‐cell therapy. Mol

comes to date. ASH; 12.2016. San Diego. Blood, 2016.

Ther Oncolytics. 2016;3:16011.

127:3312–3320.

63. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran 74. Turtle CJ, Riddell SR, Maloney DG. CD19‐targeted chi­

K, et al. Efficacy and toxicity management of 19‐28z

meric antigen receptor‐modified T‐cell immunotherapy

CAR T cell therapy in B cell acute lymphoblastic leufor B‐cell malignancies. Clin Pharmacol Ther. 2016; kemia. Sci Transl Med. 2014;6(224):224ra25.

100(3):252–8.

114 Immunotherapy in Translational Cancer Research 75. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen

receptor‐modified T‐cell therapy for CEA+ liver metas­

MC, Plesa G, et al. Mesothelin‐specific chimeric antigen

tases. Clin Cancer Res. 2015;21(14):3149–59.

receptor mRNA‐engineered T cel s induce anti‐tumor 77. You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, et al.

activity in solid malignancies. Cancer Immunol Res.

Phase 1 clinical trial demonstrated that MUC1 positive

2014;2(2):112–20.

metastatic seminal vesicle cancer can be effectively

76. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring

eradicated by modified Anti‐MUC1 chimeric antigen

W, Point GR, et al. Phase I hepatic immunotherapy for

receptor transduced T cel s. Sci China Life Sci.

metastases study of intra‐arterial chimeric antigen

2016;59(4):386–97.





CHAPTER 9

9 Immunomodulation

with Adjuvants and Cytokines

Dae won Kim1 and Adi Diab2

1 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA 2 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Introduction

cel s. Traditional y, peptide and protein vaccines

have been administered with delivery carriers such

Cancer immunotherapy recently gained attention as mineral adjuvants and oil adjuvants. With recent with the remarkable success of checkpoint blockade advancements in identifying and understanding therapy. However, only patients with specific can- the regulators and stimulators in cancer immu-cers experience significant and durable clinical nology, various adjuvants have been used local y benefits. Several molecules and cytokines have and/or systemical y in preclinical and clinical been tested to improve the antitumor immunity studies, including cytokines, checkpoint inhibitors, and limited clinical benefits of checkpoint blockade costimulatory molecules, radiation, and even therapy. Adjuvants are vaccine components that are chemotherapy. In this chapter, we summarize and able to enhance antigen‐specific immune responses discuss diverse adjuvants and cytokines to enhance induced by the tumor and the tumor environment. antitumor immunity in cancer immunotherapy.

They augment the potency and longevity of the

antitumor immunity induced by the cancer Carriers

vaccine, since the vaccine itself is not immuno-

genic enough to overcome the immune suppres- Aluminum salts have been used as adjuvants in sion characteristics of cancer. In general, adjuvants several prophylactic viral and bacterial vaccines are divided into two categories: (1) vaccine delivery due to their capacity to enhance innate immunity carriers, which facilitate vaccine antigen delivery [1]. However, they are not ideal adjuvants for can-into antigen presenting cel s (APCs), and (2) cer vaccines since they fail to induce strong cel ular immunostimulants, which mainly activate innate immune responses [2].

immune systems.

Oil adjuvants are mixtures of oil and injectable

Ideal cancer vaccine adjuvants differ from tradi- surfactants. Oil adjuvants form a depot at the tional prophylactic vaccines. Cancer vaccines injection sites to release antigens slowly to APCs typical y elicit type I T helper cell (Th1) immune and protect the antigens from degradation [3].

responses in a tumor microenvironment composed Incomplete Freund’s adjuvant (IFA) and Montanide of immune suppressive cytokines, molecules, and ISA are the commonly used oil adjuvants. These Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

115





116 Immunotherapy in Translational Cancer Research adjuvants have been shown to induce cytotoxic phase III studies with BCG adjuvant cancer T cell activation in peripheral blood [4]. However, vaccines failed to show clinical efficacy [10, 11]. In recent preclinical and clinical studies demonstrated addition, since BCG is a live mycobacterial prod-that IFA induced retention and dysfunction of uct, systemic infection is a risk. This is a significant antigen‐specific CD8 T cel s at the injection sites limitation for its widespread use as an adjuvant for with minimal interferon (IFN)‐γ production in cancer vaccines.

response to peptide stimulation [5, 6].

Polyinosinic‐polycytidylic acid

Toll‐like receptors (TLRs)

(poly‐IC)

The innate immune system is a first line of defense Poly‐IC, a synthetic viral dsRNA analog, is a potent against microbial or viral infection, especial y dur- TLR3 agonist (Figure 9.1) that induces the producing the first several hours and days of the initial tion of type I interferon and IL‐12 and the upregu-exposure, before activation and expansion of lation of MHC and costimulatory molecules on adaptive immune cel s, such as B cel s and T cel s. APCs, which enhances cross‐presentation. Since In contrast to adaptive immune cel s, innate poly‐IC is rapidly inactivated by natural y occur-immune cel s have pattern‐recognition receptors ring enzymes in the blood, it is commonly stabion their membranes or in their cytoplasms to rec- lized with poly‐lysine. The stabilized form is known ognize pathogen‐associated molecular patterns as poly‐ICLC. When used as vaccine adjuvants in (PAMPs) expressed by microorganisms. TLRs are preclinical studies, poly‐IC and poly‐ICLC were essential pattern‐recognition receptors. Upon rec- shown to enhance DC maturation, IL‐12 secretion, ognition of microbial PAMPs, TLR signaling results and tumor‐specific T cell response [12, 13]. After in maturation of innate immune cel s, upregulation intratumoral injection of poly‐ICLC, tumor of major histocompatibility complex (MHC) and inflammation followed by significant tumor regres-costimulatory molecules (CD40, CD80, and sion and extended survival was reported in a CD86), and enhancement of cross‐presentation of patient with advanced facial rhabdomyosarcoma antigen, which drives the development of Th1, [14]. Currently, poly‐ICLC is being tested in several Th2, or Th17 immune response [7].

clinical trials for patients with melanoma, prostate

cancer, and breast cancer.

BCG

Lipopolysaccharide (LPS)

Bacille Calmette‐Guérin (BCG) is a bacterial prod-

uct that activates TLR2 and TLR4 (Figure 9.1) [8]. LPS, the major outer surface membrane compo-Although both TLR2 and TLR4 stimulate dendritic nent of Gram‐negative bacteria, is a potent stimu-cel s (DCs), they have different effects on the lator of TLR4 (Figure 9.1), which leads to activation immune system. TLR2 signaling is associated with of DCs, secretion of type I interferons, and IL‐12, Th2 immune responses and induces tolerogenic and induction of Th1 immune response [15].

DCs and regulatory T cel s by forming a heterodi- Although LPS has shown significant antitumor mer with TLR6 [9]. Activating TLR2 through the effects in multiple preclinical and clinical studies MyD88 pathway increases myeloid‐derived [16–18], it is considered too toxic for clinical use suppressor cel s, enhancing the immune suppres- because it is associated with severe toxicities, sive activity and promoting growth, invasion, and including cytokine storm [19].

metastasis of tumors [9]. In contrast, TLR4 sig-

Monophosphoryl lipid A is a detoxified form of

naling leads to interleukin (IL)‐12 production, LPS from Salmonel a minnesota [20]. It is a TLR4

secretion of type I interferons, and a Th1 cel ular agonist and induces a potent Th1 cell response with immune response [9]. BCG has been evaluated secretion of proinflammatory cytokines [21]. Due extensively as a cancer vaccine adjuvant and has to the strong immunostimulatory activity and the been approved for local treatment of superficial lack of significant toxicity, monophosphoryl lipid A bladder cancer. However, several randomized is being used as an adjuvant in several ongoing





CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 117

BCG

BCG

BCG

LPS

TLR1 TLR2

TLR2 TLR6

TLR4

Imiquimod

Resiquimod

CPG

PolyIC

TLR7 TLR8

TLR3

TLR9

Endosome

Figure 9.1 Toll‐like receptors and their ligands that have been tested preclinically and clinically.

phase III cancer vaccine trials such as MAGE‐A3 peptide vaccination and more frequent circulating vaccine and MUC‐1 antigen vaccine (Stimuvax®).

peptide‐specific CD8 T cel s than controls. Several

case reports and case series reports have demon-

Imiquimod

strated successful treatment of mucosal melanoma

and metastatic skin disease of breast cancer with

Imiquimod, a TLR7 agonist (Figure 9.1), is a top- topical imiquimod [25, 26]. In a small prospective ical treatment for condylomata acuminate, actinic study, topical application of imiquimod showed keratosis, and basal cell carcinoma. TLR7 is two partial responses (20%) without grade 3/4 tox-expressed in plasmocytoid DCs (pDCs) and to a icities in patients with skin metastasis of breast lesser extend in myeloid DCs (mDCs), but not in cancer [27]. Another pilot study of the NY‐ESO‐1

natural killer (NK) cel s or T cel s [22]. Once TLR7 peptide vaccine combined with imiquimod as a is activated by imiquimod, pDCs secrete IL12 and vaccine adjuvant has shown an excellent safety pro-IFN‐α, which activates effector cel s such as NK file of topical imiquimod and successful humoral-cel s and T cel s, and enhances the expression of and cel ular‐NY‐ESO‐1 specific immune responses costimulatory molecules and the antigen‐presenting in patients with resected melanoma [28].

ability by upregulating MHC class I and II on pDCs

[23]. In addition, imiquimod treatment directly Resiquimod

activates pDCs tumoricidal activity by upregulat-

ing TRAIL, granzyme, and perforin [23]. The Resiquimod stimulates TLR8 as well as TLR7

immunoadjuvant activity of imiquimod was evalu- (Figure 9.1). TLR8 is phylogenetical y similar to ated in metastatic melanoma patients treated with TLR7 and is expressed in monocytes, neutrophils, an FMS‐like tyrosine kinase 3 (Flt3) ligand and and myeloid DCs, but not in pDCs. In pDCs TLR8

peptide vaccines [24]. In the study, topical imiqui- partial y complements expression of TLR7 [23, 29].

mod induced more frequent cutaneous reactions to While the TLR7 pathway is associated with





118 Immunotherapy in Translational Cancer Research activation of pDCs and secretion of IFN‐α, TLR8 to these in patients receiving the same vaccine lack-stimulation activates mDCs and secretion of IL‐12 ing CpG. In another clinical study, metastatic mel-

[30]. Similar to imiquimod, resiquimod induces anoma patients were treated with a multiepitope secretion of IFN‐α, tumor necrosis factor α peptide vaccine including MART‐1, gp100, and (TNF‐α), IL‐6, and IL‐12; upregulation of costimu- tyrosinase in montanide with CpG, IFA, and GM-latory molecule expression on DCs; enhancement CSF [36]. The treatment was well tolerated without of cross‐presentation of DCs; and activation of significant toxicities; 10% (2 patients) had objective cytotoxic T cel s [9]. Resiquimod has been evalu- response rates, and 48% (10) of disease control ated as an immunologic adjuvant for the NY‐ rates were observed with median progression‐free ESO‐1 protein vaccine in combination with survival (PFS) of 1.9 months. The median overall montanide in patients with resected, high‐risk mel- survival (OS) was 13.4 at a median follow‐up of anoma [31]. Although topical resiquimod with 7.4 months.

montanide induced both antibody‐and CD4 T cell‐

CpG was incorporated in the immunogenic

responses to NY‐ESO‐1 in the majority of patients, virus-like nanoparticle and Melan‐A/MART‐1 pep-NY‐ESO‐1‐specific CD8 T cell responses were tide (MelQbG10 vaccine) to enhance the antitumor detected in only 3 of 12 patients [31].

immunity in several clinical studies. In a phase II

study, 7 patients with resected undetectable mela-

CpG

noma and 15 with detectable metastatic melanoma

were treated with MelQbG10 [37]. The vaccine was

CpG oligodeoxynucleotides are among the most safe and generated detectable Melan‐A/MART‐1-potent cel ular immune adjuvants to stimulate specific T cell responses such as degranulation and TLR9 (Figure 9.1). TLR9 is expressed primarily in production of IL‐2, IFN‐γ, and TNF‐α in pDCs and B cel s [32]. TLR9 can induce both 14 patients (66%). Among the 14 evaluable patients strong cel ular and humoral immune responses by with targetable disease, 1 had a partial response activating pDCs and memory B cel s [32]. A and 1 had stable disease. MelQbG10 in combination number of preclinical studies have demonstrated with IFA and/or topical imiquimod was also tested that CpG can enhance tumor‐antigen‐specific in patients with metastatic melanoma [38]. While immune responses against coadministered cancer MelQbG10 plus IFA induced a high frequency of T

vaccines with a significant decrease in tumor cel s with predominant effector memory cel s, the burden [32]. Given the immunostimulatory combination of MelQbG10 with imiquimod gener-activity of CpG in murine studies, CpG has been ated higher proportion of central memory cel s studied extensively in multiple clinical studies. with increased CD127+ T cel s. In the study, Continuous intratumoral CpG infusion as a single objective response was not observed. CpG was also agent was evaluated in patients with recurrent glio- evaluated as an immunostimulant in a phase I blastoma in phase I and II studies [33, 34]. In these study of Wilms’ tumor 1 peptide vaccine emulsified studies, CpG was well tolerated with mild fever and with IFA [39]. A total of 28 patients with refractory transient neurological worsening. Although they solid malignancy were treated with vaccine alone, were small and uncontrolled studies, one‐year vaccine plus GM‐CSF, or vaccine plus CpG. The survival rates of CpG‐treated patients (24%) were treatment was well tolerated without significant higher than historic controls (15%). A phase I toxicities, and results in disease control rates of study of melanoma peptide vaccines in combination vaccine alone ( n = 10), vaccine plus GM‐CSF

with CpG and IFA showed that the frequency of ( n = 8), and vaccine plus CpG ( n = 10) in the initial circulating‐tumor‐specific T cel s in patients who two months were 20%, 25%, and 60%, respectively.

received the peptide vaccine with CpG was 10

times higher than in patients who were vaccinated Checkpoint inhibitors with IFA [35]. In addition, type I cytokine production (IFN‐γ, TNF‐α, and IL‐2) and the expression Immune checkpoint inhibitors such as anti-of CD107a (degranulation marker) were increased CTLA‐4/PD‐1 have demonstrated remarkable up to 10‐fold in CpG‐vaccinated patients compared clinical efficacy as a single agent for melanoma,





CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 119

non‐small‐cell lung cancer, and renal cell carci- patients with resected stage IIIC or IV melanoma noma. In several preclinical and clinical studies, [44]. The treatment was well tolerated. At a median these checkpoint inhibitors were used with cancer follow‐up of 32.1 months, the estimated median vaccines to enhance antitumor immunity. Since PFS was 47.1 months, and the median OS was not most of the studies with checkpoint inhibitors are reached.

extensively described in the accompanying chap-

ters of this book, here we only discuss representa- Costimulatory molecules tive clinical studies briefly.

Costimulatory molecules can potentiate antitumor

Ipilimumab (anti‐CTLA‐4)

immunity by directly targeting T cel s. Thus,

In a phase III study, previously treated patients interest in the use of costimulatory molecules as with advanced melanoma were randomized to immunoadjuvants is emerging.

receive gp100 vaccine, ipilimumab, or ipilimumab

plus gp100 vaccine [40]. The objective response CD28

rate and median OS were 10.9% and 10.1 months CD28 is constitutively expressed on resting naïve T

for ipilimumab and 5.7% and 10.0 months for ipili- cel s, and the ligation of CD28 by CD80 or CD86

mumab with gp100. Long‐term survival data of results in the induction of Th1 and Th2 type cyto-the study showed survival rates at 2 and 3 years kines, the expansion of T cel s, and the increased were 25% and 25% with ipilimumab alone and resistance to apoptosis of T cel s by upregulating 19% and 15% with ipilimumab plus gp100 [41]. antiapoptotic protein, Bcl‐xL [45]. In a phase I However, ipilimumab plus gp100 demonstrated study of TGN1412 (superagonist anti‐CD28 anti-shorter PFS (hazard ratio with ipilimumab plus body), which activates T cel s without TCR engage-gp100, 1.25; p = .04) and lower survival rates at 2 ment, all 6 healthy volunteers who received the and 3 years than ipilimumab alone. Ipilimumab antibody developed nearly fatal systemic was also combined with PROSTVAC, recombinant inflammatory syndromes with multiorgan failure poxviruses expressing PSA and TRICOM (LFA‐3, [46]. Due to the serious adverse events, use of the ICAM‐1, and B7.1), in a phase I study [42]. CD28 agonist is discouraged.

Patients with castration‐resistant metastatic

prostate cancer were treated with PROSTVAC plus 4‐1BB

escalating doses of ipilimumab. The median OS 4‐1BB (CD137) is expressed on activated T cel s, was 31.3

months for all dose cohorts and activated NK cel s, DCs, B cel s, and myeloid cel s, 37.2 months for highest dose (10 mg/kg), and 20% and the ligation of 4‐1BB by the 4‐1BB ligand on of patients at 10 mg/kg of ipilimumab were alive at APCs leads to T cell proliferation, IL‐2 production, 80 months.

granzyme B and perforin expression, and T cell

longevity [47]. 4‐1BB costimulation is essential for

Nivolumab (anti‐PD‐1)

expansion of memory CD8 T cel s, and is better

In a phase I study, patients with ipilimumab‐naïve than CD28 costimulation for the generation of or refractory advanced melanoma were treated cytotoxic T cel s and enhancement of cytolytic with nivolumab plus multipeptide (gp100, activity [48]. Agonist anti‐4‐1BB antibodies have MART‐1, NY‐ESO‐1) vaccine emulsified in IFA paradoxical immunosuppressive activity by

[43]. The treatment was well tolerated and safe. depleting immune cel s, including B, NK, and CD4

Objective response rates were 24% (8 patients) for T cel s, and upregulating indolemamine dioxygen-ipilimumab‐naïve patients treated with nivolumab ase [49, 50]. In addition, several preclinical studies plus vaccine. Among ipilimumab refractory demonstrated that stimulation of 4‐1BB suppressed patients, 4 patients (27%) treated with nivolumab the progression of autoimmune diseases [49, 51].

plus vaccine had objective response and 10 patients Interestingly, the combination of anti‐CTLA‐4 and (26%) with nivolumab alone had objective agonist anti‐4‐1BB antibodies enhanced antitumor response. Nivolumab with multipeptide vaccine immunity while reducing anti‐CTLA‐4‐treatment-was also studied as an adjuvant treatment in related autoimmune disease by increasing the





120 Immunotherapy in Translational Cancer Research function of Tregs in mice [52]. Despite the immu- OX40 antibody showed acceptable toxicity pro-nosuppressive activity, 4‐1BB costimulation is file without any objective responses [63]. Clinical emerging as an attractive target for cancer immu- trials with agonistic anti‐OX40 antibodies are notherapy due to the critical role of 4‐1BB in the ongoing.

expansion and cytolytic function of memory CD8

T cel s and the potent antitumor activity of agonist Glucocorticoid‐induced TNFR-anti‐4‐1BB antibodies in murine studies [50, 52]. related protein (GITR) In preclinical studies, an agonist anti‐4‐1BB antibody with peptide tumor vaccine or DC vaccine is GITR is expressed at low levels on resting T cells, able to regress established, poorly immunogenic and the expression of GITR is upregulated 24–72

tumors by polarizing the T cell response toward a hours after stimulation [64]. In contrast, Tregs type 1, increasing survival and proliferation of constitutively express GITR. GITR ligation by activated T cel s, and activating NK cel s [53, 54]. the GITR ligand (GITRL), which is expressed on In addition, another preclinical study demon- activated APCs, leads to the enhancement of T

strated an agonist anti‐4‐1BB antibody with a pep- cell proliferation and effector function by upreg-tide vaccine and CpG‐induced eradiation of ulating CD25, IL‐2, and IFN‐γ, and protecting T

established melanoma by generating antigen‐ cells from activation‐induced cell death [65].

specific cytotoxic T cel s and their subsequent infil- GITR ligation also disrupts tolerance to self and tration into the tumor sites [55]. There are several tumor antigens by abrogating Treg‐mediated ongoing clinical trials with agonist anti‐4‐1BB anti- suppression [66, 67]. In multiple mouse tumor bodies, including urelumab and PF‐05082566, models including sarcoma, CT26, and small B16

though one of clinical studies with urelumab was tumors, stimulation of GITR using an agonist terminated due to unusual y high incidence of antimouse GITR antibody (DTA‐1) has been grade 4 hepatic toxicities [56].

shown to regress established tumors and protect

mice from tumor rechallenge with long‐lasting

OX40

memory T cells [68–70]. DTA‐1 treatment with

OX40 is a member of tumor necrosis factor DNA vaccination enhanced tumor‐antigen-receptor (TNFR) family expressed on activated T specific CD8 T cell response and survival and cells. Engagement of OX40 by its ligand, OX40L, increased recall CD8 T cell response to a booster expressed on activated APCs promotes survival vaccination [71]. T cell vaccination combined and expansion of T cells by enhancing expres- with DTA‐1 resulted in complete and permanent sion of prosurvival molecules and production of eradication of HPV oncogene‐expressing tumors cytokines [57]. OX40 is also expressed constitu- (TC1) compared to other combinations such as tively in mice Tregs, whereas OX40 expression is imiquimod, anti‐CD4, and IFN‐α [72]. The mel-upregulated upon activation in human Tregs anoma DC vaccine in combination with DCs

[57]. An agonistic anti‐OX40 antibody alone transfected with mRNA encoding anti‐CTLA‐4

showed eradication of immunogenic tumors in and agonistic anti‐GITR antibodies improved mice, though OX40 monotherapy failed to show antitumor immunity and survival of melanoma-antitumor activity in poorly immunogenic bearing mice [73]. Currently, several clinical tumors such as B16 melanoma [58]. Studies of studies with a humanized agonist anti‐GITR

OX40 agonists in combination with cancer antibody and GITRL‐expressing DCs plus a DC

vaccines demonstrated an improvement of esta- tumor vaccine are ongoing.

blished tumor control by enhancing prolifera-

tion and survival of effector T cells [59], reducing CD27

Tregs frequency, and inhibiting immune sup-

pressive Treg function [60, 61]. In addition, In contrast to other costimulatory molecules, OX40 stimulation induces unique CD4 T cells, CD27 is constitutively expressed on naïve T cel s which have tumoricidal function [62]. The first and Tregs, and its expression is upregulated upon clinical study with a mouse IgG1 anti‐human activation [74]. CD70, the ligand for CD27, is





CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 121

transiently expressed on activated APCs and T cytokines secreted by activated DCs activate NK

cel s. CD27 ligation by CD70 enhances prolifera- cel s indirectly [83]. CD40 expression has been tion, survival, and effector function of T cell and reported for several tumor cel s such as B cell lym-generation of memory T cel s [75]. Constitutive phoma, melanoma, and renal cell carcinoma, and expression of CD70 on several tumors including CD40 ligation on tumor cel s results in the recruit-renal cell carcinoma, lymphoma, and head and ment of immune effector cel s with tumoricidal neck cancer has been reported [76], and interac- effects into the tumor microenvironment by upreg-tion of CD27 on effector cel s with CD70 on ulated expression of ICAM‐1 and Fas and secretion tumors enhances NK‐cell‐ and T‐cell‐mediated of IL‐6, IL‐8, GM‐CSF, and TNF‐α [84]. CD40

tumor rejection by perforin‐ and IFN‐γ‐dependent ligation of tumor cel s also induces growth arrest mechanisms in a CD70‐expressing murine lym- by inhibiting entry into the S‐phase [84].

phoma model [77]. CD27 stimulation by an ago-

An agonist CD40 antibody enhances the effi-

nistic CD27 antibody is able to protect against cacy of peptide cancer vaccines, converts lymphoma even without a DC maturation signal peripheral cytotoxic T cell tolerance induced by in a preclinical study [78]. However, CD27 stimu- minimal epitope vaccine, and augments antitu-lation has been reported to induce T cel mor vaccine efficacy in tumor‐bearing mice [85].

dysfunction in chronic viral infection with pro- Several CD40 agonists, including agonistic CD40

longed expression of CD70 [79] and promote antibodies and recombinant CD40L, have been tumor progression with an increase in the fre- tested in clinical trials. A phase I study of quency of Tregs in the tumor environment and recombinant human CD40L in patients with solid tumor‐draining lymph nodes [80]. Since CD27 tumor or high‐grade non‐Hodgkin lymphoma signals can induce both antitumor immunity and (NHL) showed a 6% (2 patients) objective immunosuppression, likely depending on the response rate with one long‐term complete remis-environment where the CD27 stimulation signals sion [86]. The CP‐870,893 agonistic CD40

are delivered and the duration of CD27 stimula- antibody was evaluated in patients with advanced tion, a precise stimulation of CD27 may be solid tumors [87]. In the study, 29 patients required to enhance antitumor immunity. received single‐dose treatment, and 4 patients Currently, varlilumab (ful y humanized agonistic (14%) with melanoma had objective responses.

CD27 antibody) is being evaluated in several phase However, a subsequent study of CP‐870,893

I studies, including a combination study with administered weekly failed to show any objective ONT‐10 (MUC1 peptide vaccine) in patients with responses [88].

advanced breast or ovarian cancer.

Dacetuzumab is another humanized agonistic

CD40 antibody and is a weaker agonist than

CD40

CP‐870,893. Dacetuzumab monotherapy showed

12% (6 patients) objective response rates with

CD40 is expressed on APCs including DCs and manageable toxicity profiles in patients with macrophages. CD40 interactions with its ligand refractory or recurrent NHL [89]. Several clinical (CD40L), which is mainly expressed on activated trials of agonistic CD40 antibodies in combination CD4 T cel s, results in the activation and matura- with other therapies are underway.

tion of APCs with subsequent upregulation of

costimulatory molecules (CD70, CD80, and CD86) Cytokines

as well as tumor necrosis factor superfamily mem-

bers such as 4‐1BBL, OX40L, and GITRL [81]. The initial clinical success with IFN‐α and IL‐2 in CD40 ligation also induces secretion of proinflam- renal cell carcinoma and melanoma attracted matory cytokines including IL‐1β, IL‐6, and IL‐12 interest in the application of cytokines for cancer by DCs [82]. This process enhances the T cell therapy. Although cytokines play an important role activation and differentiation of naïve CD4 and in developing innate and adaptive immune CD8 T cel s into helper T cel s and cytotoxic T cel s, response, in certain environments they can respectively [81]. In addition, the proinflammatory enhance tumor growth instead of suppressing





122 Immunotherapy in Translational Cancer Research tumors. The biological relevance and clinical of 7.6 years, the 7‐year RFS rate was 39.1% vs 34.6%

outcomes of extensively studied cytokines is ( p = .055) without any OS difference. Both IFN‐α

reviewed below.

and PEG IFN‐α have been approved as adjuvant

therapy for patients with resected high‐risk mela-

Interferon‐α

noma. IFN‐α has been studied as a cancer vaccine

IFN‐α enhances maturation and cross‐presenta- adjuvant in several clinical studies since it can act tion of DCs and cytotoxicity and survival of NK as a bridge between the innate and acquired cel s. It also generates cytotoxic T cel s and memory immune systems. In a pilot phase I‐II study of T cel s. In addition, IFN‐α has direct antitumor MART‐1 and gp100 peptide vaccination in activity by upregulating MHC class I molecules on combination with IFN‐α, 5 patients (71.4%) with tumor cel s, promoting tumor cell apoptosis and metastatic melanoma induced high level of CD8 T

antiangiogenic effects on tumor neovasculature cel s recognizing MART‐1 and gp100 peptides

[90]. In initial clinical studies, single agent of IFN‐α with upregulation of CD40 and CD86 costimula-demonstrated approximately 16% of overall tory molecules in monocytes [97]. IFN‐α combined response rates in advanced melanoma patients [90, with a modified vaccinia virus Ankara encoding 91]. However, subsequent studies of IFN‐α failed to oncofetal antigen 5 T4 (MVA‐5 T4/TroVax) vaccine show clinical efficacy in advanced melanoma [92]. mounted effective 5 T4 specific antibody and cel-In contrast to metastatic disease, IFN‐α has proved lular responses in metastatic renal cell carcinoma clinical efficacy in patients with resected high‐risk patients [98]. However, it failed to demonstrate melanoma. In a randomized controlled study, 287 clinical efficacy in a randomized phase III trial patients with resected stage IIb or stage III were (Table 9.1) [99].

randomly assigned to 1 year of high‐dose IFN‐α or

Several phase I and II studies of a survivin (anti-

close observation. At a median follow‐up of apoptotic protein) or TP53 peptide vaccine also 6.9 years, IFN‐α prolonged the relapse‐free survival showed IFN‐α enhanced the peptide specific cyto-

(RFS) (median RFS: 1.7 vs 1 year, p = .0023) and toxic T cell response in metastatic colorectal cancer, overall survival (median OS: 3.8 vs 2.8 years, pancreatic cancer, and urothelial cancer [100].

p = .0237) compared with controls [93]. Subsequent However, objective clinical responses were not long‐term follow‐up data confirmed RFS benefit observed. Several clinical trials combining IFN‐α

from IFN‐α but did not demonstrate OS benefit with checkpoint inhibitors as well as peptide vac-

[94]. Pegylated (PEG) IFN‐α, which maintains cines are underway.

maximum exposure to IFN‐α with less frequent

administration, was evaluated in a phase III trial IL‐2

[95, 96]. In the study, 1256 patients with resected IL‐2 is a growth factor normal y secreted by CD4

stage III melanoma were randomly assigned to helper cel s that can induce the expansion of T

PEG IFN‐α or observation. At a median follow‐up cel s, promote the growth and differentiation of Table 9.1 Clinical efficacy data of phase II and III studies of vaccine and cytokine therapy.

Treatment

Hazard Ratio

Regimen

n

Cancer Type

Setting

Primary Endpoint

(95% CI)

p value Ref

MVA‐5 T4 plus inteferon α,

365

Metastatic renal

First line

Overall survival

1.07

.55

99

IL‐2, or sunitinib

cell carcinoma

20.1 months

(0.86–1.32)

vs placebo plus inteferon α,

367

19.2 months

IL‐2, or sunitinib

MVA‐5 T4 plus high dose IL‐2

25

Metastatic renal

First line

Objective response

106

cell carcinoma

0%

High dose IL‐2 plus GP100 vs

91

Metastatic

First line

Objective response

.03

107

high dose IL‐2 alone

94

melanoma (HLA

16%, 6%

A0201)





CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 123

activated B cel s, and enhance the cytotoxicity and not reach statistical significance (17.8 versus proliferation of NK cel s [101]. It also works as an 11.1 months, p = .06).

immune suppressant by activating the proliferation

A recent study has demonstrated that an

of Tregs [102] and elimination of overstimulated T engineered IL‐2 “superkine” has a higher binding cel s using Fas‐mediated apoptosis in CD4 T cel s affinity for IL‐2Rβ and can activate naïve T cells,

[103]. Once IL‐2 binds to an IL‐2 receptor, which which are usually insensitive to IL‐2 due to the comprises three subunits—IL‐2Rα (CD25), IL‐2Rβ lack of IL‐2Rα expression. IL‐2 superkine (CD122), and IL‐2Rγ (CD132)—it releases proin- induces improved antitumor responses by flammatory cytokines such as TNF‐α, IL‐1β, IL‐6, enhancing the expansion of cytotoxic T cells, and IFN‐γ [90]. Several clinical studies demon- decreasing the expansion of Tregs, and reducing strated that high‐dose IL‐2 therapy achieved pulmonary edema in comparison to IL‐2. A clinical responses in 15% of patients with meta- phase I/II study of CD122 (IL‐2Rβ) biased ago-static melanoma or renal cell carcinoma, including nist (NKTR‐214) is recruiting patients with 5% of complete responders [104]. The majority of metastatic solid tumor.

complete responders remained disease‐free for

more than 10 years in long‐term follow‐up. IL‐10

However, severe toxicities, including capil ary leak IL‐10 is a well‐known anti‐inflammatory cytokine syndrome, which can cause hypotension, that inhibits CD4 T cell proliferation and Th1

pulmonary edema, and renal failure, limit its wide- immune response. General y, IL‐10 is thought to spread use.

support tumor progression. In multiple preclinical

IL‐2 is also an essential component in adoptive T studies, IL‐10 signaling blockade plus other immu-cell transfer therapy using autologous ex vivo– notherapeutic agents, such as CpG, and peptide expanded tumor‐infiltrating lymphocytes (TILs) vaccines induced strong effector T cell responses in patients with metastatic melanoma. Isolated with tumor rejection and cytotoxic memory T cell TILs from surgical y resected tumor are expanded responses with rejection of tumor rechallenge [108, with IL‐2 ex vivo and then the expanded TILs are 109]. This suggests IL‐10 signaling blockade can infused after lymphodepletion. TIL infusion is fol- enhance potent cytotoxic T cell responses at the lowed by high‐dose IL‐2 for proliferation and priming stage. However, there is a growing body of survival of TILs. Overal , the clinical response rates evidence supporting that IL‐10 induces potent of adoptive T cell transfer therapy are 40%–50% antitumor immunity. Genetic ablation of IL‐10 in with durable response [105].

mice promotes tumor development from chemical

IL‐2 has been evaluated to enhance efficacy carcinogen, growth of transplanted tumor, and of cancer vaccines in patients with metastatic formation of metastasis with increased frequencies melanoma and renal cell carcinoma. In a phase of MDSCs and Tregs in the tumor microenviron-II clinical study of the Trovax (MVA‐5 T4) ment and tumor draining lymph nodes [110].

vaccine plus IL‐2, the combination treatment While IL‐10 injection before or soon after cancer was able to induce the 5 T4‐specific antibody vaccine treatment induces immune suppression and T cell responses in metastatic renal cell car- and enhances tumor progression, IL‐10 just after a cinoma (Table 9.1) [106]. However, no objective booster vaccination significantly enhances antitu-clinical responses were observed. A randomized mor immunity and vaccine efficacy by maintaining multicenter phase III trial of high‐dose IL‐2 the number and function of effector T cel s [111].

with or without gp100 cancer vaccine in 185 PEG IL‐10 treatment results in the rejection of metastatic melanoma patients demonstrated established tumors by activating and expanding that the addition of gp100 significantly intratumoral CD8 T cel s with an increase in the improved overall response rate (16% vs 6%) expression of granzyme B and IFN‐γ in CD8 T cel s and progression‐free survival (2.2 vs 1.6 months, [112, 113]. Taken together, IL‐10 may inhibit antip = .008) (Table 9.1) [107]. Patients treated with tumor immunity at the priming stage, but IL‐10

the combination therapy also showed a trend signaling is essential for the activation of intratu-of improved overall survival, but this did moral CD8 T cel s. Therefore, IL‐10 needs to be





124 Immunotherapy in Translational Cancer Research administered at a precise time point and site to of cyclophosphamide resulted in complete tumor enhance antitumor immunity and avoid immune eradication, but not late after cyclophosphamide suppression. Currently, a phase I study of PEG‐ treatment, which suggests the importance of tim-IL‐10 in patients with advanced solid tumors is ing for immunotherapy when combined with ongoing.

chemotherapy [120].

The antitumor activity of IL‐12 has been evalu-

IL‐12

ated in several clinical studies. Unfortunately,

IL‐12 is a potent Th1 cytokine that is mainly systemic administration of IL‐12 demonstrated secreted from activated APCs in response to poor clinical response and severe adverse events, antigen stimulation. IL‐12 induces activation and including toxicity‐related deaths even after proliferation of T cel s and NK cel s and enhances established maximum tolerated dose in patients their effector functions by producing IFN‐γ, gran- with solid tumor [121]. In contrast to solid tumors, zyme B, and perforin [114]. It also inhibits angio- IL‐12 demonstrated promising results in hemato-genesis, IL‐4‐mediated suppression of IFN‐γ logic malignancies. Subcutaneous or intratumoral synthesis, and the development of TGF‐β‐ injection of IL‐12 resulted in objective response dependent Treg and Th17 development [114]. rates of up to 56% in patients with cutaneous T cel IL‐12 has been shown to reduce tumor growth, lymphoma [122, 123]. Systemic IL‐12 treatment increase survival, and prevent metastasis by cyto- demonstrated objective response rates of 21% (6

toxic T cel s and NK/NKT cel s in a variety of patients) with relapsed and refractory NHL [124].

mouse tumors in a dose‐ and tumor model– When IL‐12 was combined with rituximab, the dependent manner [115]. IL‐12 has been reported response rates increased by up to 69% (29 patients) to enhance antitumor efficacy when combined in NHL [125]. Intratumoral delivery of IL‐12 has with other therapeutic modalities such as cyto- been tested to avoid severe systemic toxicities. A kines, cancer vaccines, monoclonal antibodies, and local injection of plasmid DNA coding for IL‐12

chemotherapies in mouse tumor models. The with electroporation demonstrated marked tumor combination of IL‐12 with other cytokines, necrosis and lymphocyte infiltration with disease including IL‐2, IL‐7, IL‐15, IL‐18, IL‐21, GM‐CSF, control rates of 52% (10 patients) including two and IFN‐α, is able to induce durable and effective complete responders in metastatic melanoma antitumor immunity in preclinical studies [116]. [126]. A local delivery of viral vectors expressing However, it was associated with a considerable IL‐12 was also evaluated in advanced digestive degree of toxicity due to the high level of systemic tumors and melanoma [127, 128]. However, it IFN‐γ production.

failed to show clinical y significant clinical

IL‐12 combined with allogenic tumor cell vacci- responses. Currently, several clinical trials of nation reduced tumor incidence by 90%, and intratumoral delivery using IL‐12 expressing increased survival in HER2/neu transgenic mice plasmid, biopolymer, and adenovirus vector are

[117]. In the HER2/neu‐expressing murine colon underway in several solid and hematologic malig-adenocarcinoma model, IL‐12 enhanced antitu- nancy [121].

mor efficacy of trastuzumab via NK cell IFN‐γ

production [118]. Previously, it was believed that IL‐15

chemotherapy was associated with significant IL‐15, a member of the family of IL‐2 cytokines, immune suppression since it induces lymphopenia shares receptors (IL‐2/IL‐15Rβ (CD122) and and apoptosis, which is less immunogenic cell γc(CD132)), signaling pathways, and biologic death than necrosis. However, recent data have activity with IL‐2. IL‐15 is produced by monocytes, demonstrated that chemotherapy can enhance macrophages, and DCs upon stimulation with type antitumor immunity by suppressing Treg, inducing I interferon and TLR agonists [101]. IL‐15 plays an immunologic cell death, and enhancing cross‐ important role in the generation of CD8 memory presentation and tumor cytoreduction [119]. T cel s and proliferation and differentiation of CD8

Interestingly, IL‐12 treatment before or at the time T cel s and NK cel s [101]. It increases survival of





CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 125

naïve and memory CD8 T cel s and NK cel s by higher absolute number of circulating CD8

upregulation of antiapoptotic protein Bcl‐2 [129]. memory T cel s than IL‐2 or IL‐21 alone in the B16

In contrast to IL‐2, IL‐15 inhibits IL‐2‐mediated melanoma model [136]. Administration of IL‐21

activation‐induced cell death and has no effect on combined with IL‐15 promoted the proliferation of the survival of Tregs [130]. Several preclinical naïve and memory CD8 T cel s and led to significant studies have demonstrated antitumor effects of tumor regression of established B16 melanomas IL‐15 that were mediated by enhancing the cyto- [137]. Phase I and II studies of IL‐21 in patients lytic activity and ADCC function of NK cel s as with metastatic melanoma and/or renal cell carci-well as the cytotoxicity of tumor‐antigen‐specific noma demonstrated that IL‐21 treatment was safe CD8 T cel s [130]. Interestingly, IL‐15 has been and well tolerated with modest clinical response reported to increase expression of PD‐1 on CD8 T rates (8%–22%) [138–140]. IL‐21 has been cel s and IL‐10 secretion. Combining IL‐15 with combined with other therapeutic agents for syner-anti‐PD‐L1 and anti‐CTLA‐4 antibodies resulted gistic antitumor effects. In a phase I trial of IL‐21

in a significant decrease in PD‐1 expression on with cituximab in metastatic colorectal cancer, the CD8 T cel s and IL‐10 secretion and prolongation treatment was well tolerated, with disease control of the survival of colon‐cancer‐bearing mice [131]. rate of 60% (9 patients) [141]. The combination of In a phase I study of IL‐15 in metastatic melanoma IL‐21 with rituximab demonstrated promising or renal cell carcinoma, IL‐15 treatment showed results, with 42% of objective response rates in several grade 3 toxicities, including hypotension, refractory low‐grade B cell proliferative disorders thrombocytopenia, and transaminitis with no [142]. Several trials of IL‐21 with checkpoint inhib-objective responses [132]. A number of clinical itors are ongoing.

studies of IL‐15 are underway.

Conclusion

IL‐21

IL‐21 is another member of the IL‐2 family that Cancer immunotherapy has been extensively shares the γc receptor with IL‐2 and IL‐15. It is pre- studied since William Coley used streptococcal dominately produced by CD4 T cel s and has the organisms for the treatment of inoperable cancer capacity to regulate both innate and adoptive in 1891. A number of molecules and cytokines immune responses. IL‐21 stimulates B cel s, have been tested as immunoadjuvants, and some memory T cel s, and bone marrow progenitor cel s of them have demonstrated significant antitu-and enhances the cytotoxicity of CD8 T cel s and mor activity in preclinical studies. However, only NK cel s [133]. It also promotes Th17 differentiation a few of them have shown limited success in and IL‐17 production and induces apoptosis of B clinical studies. Most of them have diverse cel s and DCs [133]. Due to the IL‐21 ability to immune effects, including immunostimulation enhance the cytotoxicity of CD8 T cel s and NK and immunosuppression, depending on their cel s, the antitumor activity of IL‐21 has been eval- environments. Better understanding of innate uated in a number of preclinical studies. Systemic and adoptive immune responses in the tumor administration of plasma DNA encoding IL‐21 microenvironment may help find the precise and inhibited growth of B16 melanoma and MCA205 optimal time point, dose, and combination of fibrosarcoma by enhancing cytolytic activity of NK these immunoadjuvants and cytokines to maxi-cel s [134]. When the antitumor activity of IL‐2, mize antitumor activity and avoid immune IL‐15, and IL‐21 was compared, IL‐21 was the only suppression.

cytokine to achieve durable cures in the thymoma

murine model due to increased survival of CD8 Acknowledgement memory T cel s, as well as activation and expansion

of effector T cel s [135]. Combination of IL‐21 with This work was supported by The University of IL‐2 induced better tumor‐free survival and pro- Texas MD Anderson Cancer Center Melanoma tection from tumor rechallenge with a 2–3‐fold Moon Shots Program.





126 Immunotherapy in Translational Cancer Research References

14. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman

RB. Therapeutic in situ autovaccination against solid

1. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants

cancers with intratumoral poly‐ICLC: case report, hypo-

activate caspase‐1 and induce IL‐1beta and IL‐18 release.

thesis, and clinical trial. Cancer Immunol Res.

J Immunol. 2007;178(8):5271–6.

2014;2(8):720–4.

2. Pashine A, Valiante NM, Ulmer JB. Targeting the innate 15. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduc-immune response with improved vaccine adjuvants. Nat

tion pathway. Cytokine. 2008;42(2):145–51.

Med. 2005;11(4 Suppl):S63–8.

16. Berendt MJ, North RJ, Kirstein DP. The immunological

3. Freund J. The mode of action of immunologic adjuvants.

basis of endotoxin‐induced tumor regression.

Bibl Tuberc. 1956(10):130–48.

Requirement for T‐cell‐mediated immunity. J Exp Med.

4. Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi

1978;148(6):1550–9.

M, Itoh K, et al. Evaluation of a new oil adjuvant for use 17. Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S.

in peptide‐based cancer vaccination. Cancer Sci.

Intradermal administration of lipopolysaccharide in

2010;101(10):2110–4.

treatment of human cancer. Cancer Immunol

5. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA,

Immunother. 1996;42(4):255–61.

Huang XF, et al. Persistent antigen at vaccination sites 18. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun induces tumor‐specific CD8(+) T cell sequestration,

M, et al. Phase II trial of intravenous endotoxin in

dysfunction and deletion. Nat Med. 2013;19(4):465–72.

patients with colorectal and non‐small cell lung cancer.

6. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrel y

Eur J Cancer. 1996;32A(10):1712–8.

M, Collins S, et al. Phase I/II study of immunotherapy 19. Engelhardt R, Mackensen A, Galanos C, Andreesen R.

with T‐cell peptide epitopes in patients with stage IV

Biological response to intravenously administered endo-

melanoma. Cancer Immunol Immunother. 2005;54(3):

toxin in patients with advanced cancer. J Biol Response

208–18.

Mod. 1990;9(5):480–91.

7. Kaisho T, Akira S. Toll‐like receptors as adjuvant recep-

20. Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell

tors. Biochim Biophys Acta. 2002;1589(1):1–13.

TC. The low‐toxicity versions of LPS, MPL adjuvant and

8. Kumar H, Kawai T, Akira S. Pathogen recognition in the

RC529, are efficient adjuvants for CD4+ T cel s. J Leukoc

innate immune response. Biochem J. 2009;420(1):1–16.

Biol. 2005;78(6):1273–80.

9. Toussi DN, Massari P. Immune adjuvant effect of molec-

21. Kathaperumal K, Park SU, McDonough S, Stehman S,

ularly‐defined toll‐like receptor ligands. Vaccines

Akey B, Huntley J, et al. Vaccination with recombinant

(Basel). 2014;2(2):323–53.

Mycobacterium avium subsp. paratuberculosis proteins

10. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK,

induces differential immune responses and protects

Agarwala SS, Ernstoff MS, et al. High‐dose interferon

calves against infection by oral challenge. Vaccine.

alfa‐2b significantly prolongs relapse‐free and overall

2008;26(13):1652–63.

survival compared with the GM2‐KLH/QS‐21 vaccine 22. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, in patients with resected stage IIB‐III melanoma: results

Qiu X, et al. Synthetic TLR agonists reveal functional

of intergroup trial E1694/S9512/C509801. J Clin Oncol.

differences between human TLR7 and TLR8. J Immunol.

2001;19(9):2370–80.

2005;174(3):1259–68.

11. Morton DL, Mozzillo N, Thompson JF, Kelley MC, 23. Kobold S, Wiedemann G, Rothenfusser S, Endres S.

Faries M, Wagner J, et al., editors. An international,

Modes of action of TLR7 agonists in cancer therapy.

randomized, phase III trial of bacil us Calmette‐Guerin

Immunotherapy. 2014;6(10):1085–95.

(BCG) plus allogeneic melanoma vaccine (MCV) or 24. Shackleton M, Davis ID, Hopkins W, Jackson H, placebo after complete resection of melanoma metastatic

Dimopoulos N, Tai T, et al. The impact of imiquimod, a

to regional or distant sites. Journal of Clinical Oncology,

Toll‐like receptor‐7 ligand (TLR7L), on the immunoge-

2007 ASCO Annual Meeting Proceedings; 2007.

nicity of melanoma peptide vaccination with adjuvant

12. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE,

Flt3 ligand. Cancer Immun. 2004;4:9.

Eguchi J, et al. Toll like receptor‐3 ligand poly‐ICLC pro-

25. Henriques L, Palumbo M, Guay MP, Bahoric B, Basik

motes the efficacy of peripheral vaccinations with tumor

M, Kavan P, et al. Imiquimod in the treatment of breast

antigen‐derived peptide epitopes in murine CNS tumor

cancer skin metastasis. J Clin Oncol. 2014;32(8):

models. J Transl Med. 2007;5:10.

e22–5.

13. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, et al. 26. Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, TLR3‐stimulated dendritic cel s up‐regulate B7‐H1 expres-Costantino PD, Chi DS, et al. Treatment of local y recur-

sion and influence the magnitude of CD8 T cell responses to

rent mucosal melanoma with topical imiquimod. J Clin

tumor vaccination. J Immunol. 2009;183(6):3634–41.

Oncol. 2011;29(33):e809–11.

CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 127

27. Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga 39. Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto L, Liebes L, et al. Topical TLR7 agonist imiquimod can

M. Phase I trial of Wilms’ Tumor 1 (WT1) peptide

induce immune‐mediated rejection of skin metastases

vaccine with GM‐CSF or CpG in patients with solid

in patients with breast cancer. Clin Cancer Res.

malignancy. Anticancer Res. 2012;32(6):2263–9.

2012;18(24):6748–57.

40. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman

28. Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga

JA, Haanen JB, et al. Improved survival with ipilimumab

L, Siu K, et al. Immunization of malignant melanoma

in patients with metastatic melanoma. N Engl J Med.

patients with full‐length NY‐ESO‐1 protein using TLR7

2010;363(8):711–23.

agonist imiquimod as vaccine adjuvant. J Immunol. 41. McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, 2008;181(1):776–84.

Investigators MDX. Efficacy and safety of ipilimumab in

29. Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8:

metastatic melanoma patients surviving more than

the forgotten relative revindicated. Cell Mol Immunol.

2 years following treatment in a phase III trial

2012;9(6):434–8.

(MDX010‐20). Ann Oncol. 2013;24(10):2694–8.

30. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, 42. Singh H, Madan R, Dahut W, Coyne G, Rauckhorst M, Uehira K, et al. Interferon‐alpha and interleukin‐12 are

McMahon S, et al., editors. Combining active immuno-

induced differential y by Toll‐like receptor 7 ligands in

therapy and immune checkpoint inhibitors in prostate

human blood dendritic cell subsets. J Exp Med.

cancer. 2015 Genitourinary Cancer Symposium; 2015;

2002;195(11):1507–12.

Orlando, Florida, USA.

31. Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, 43. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak Hasan F, et al. Resiquimod as an immunologic adjuvant

CE, Inzunza HD, et al. Safety, efficacy, and biomarkers

for NY‐ESO‐1 protein vaccination in patients with high‐

of nivolumab with vaccine in ipilimumab‐refractory

risk melanoma. Cancer Immunol Res. 2015;3(3):278–87.

or ‐naive melanoma. J Clin Oncol. 2013;31(34):

32. Shirota H, Tross D, Klinman DM. CpG oligonucleotides

4311–8.

as cancer vaccine adjuvants. Vaccines (Basel). 44. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, 2015;3(2):390–407.

Czupryn MP, Tetteh L, et al. Safety, correlative markers,

33. Carpentier A, Laigle‐Donadey F, Zohar S, Capelle L,

and clinical results of adjuvant nivolumab in

Behin A, Tibi A, et al. Phase 1 trial of a CpG oligodeoxy-

combination with vaccine in resected high‐risk meta-

nucleotide for patients with recurrent glioblastoma.

static melanoma. Clin Cancer Res. 2015;21(4):712–20.

Neuro Oncol. 2006;8(1):60–6.

45. Watts TH. Staying alive: T cell costimulation, CD28, and 34. Carpentier A, Metel us P, Ursu R, Zohar S, Lafitte F,

Bcl‐xL. J Immunol. 2010;185(7):3785–7.

Barrie M, et al. Intracerebral administration of CpG 46. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-oligonucleotide for patients with recurrent glioblastoma:

Cortes A, Brunner MD, et al. Cytokine storm in a phase

a phase II study. Neuro Oncol. 2010;12(4):401–8.

1 trial of the anti‐CD28 monoclonal antibody TGN1412.

35. Baumgaertner P, Jandus C, Rivals JP, Derre L, Lovgren T, N Engl J Med. 2006;355(10):1018–28.

Baitsch L, et al. Vaccination‐induced functional compe-

47. Karin M, Gal agher E. TNFR signaling: ubiquitin‐

tence of circulating human tumor‐specific CD8 T‐cel s.

conjugated TRAFfic signals control stop‐and‐go for

Int J Cancer. 2012;130(11):2607–17.

MAPK signaling complexes. Immunol Rev.

36. Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y,

2009;228(1):225–40.

et al. Safety and immunogenicity of vaccination with 48. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor MART‐1 (26‐35, 27 L), gp100 (209–217, 210 M), and

V, June CH, et al. 4‐1BB is superior to CD28 costimula-

tyrosinase (368–376, 370D) in adjuvant with PF‐3512676

tion for generating CD8+ cytotoxic lymphocytes for

and GM‐CSF in metastatic melanoma. J Immunother.

adoptive immunotherapy. J Immunol. 2007;179(7):

2012;35(4):359–66.

4910–8.

37. Speiser DE, Schwarz K, Baumgaertner P, Manolova V, 49. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Devevre E, Sterry W, et al. Memory and effector CD8

et al. 4‐1BB‐mediated immunotherapy of rheumatoid

T‐cell responses after nanoparticle vaccination of mela-

arthritis. Nat Med. 2004;10(10):1088–94.

noma patients. J Immunother. 2010;33(8):848–58.

50. Vinay DS, Kwon BS. 4‐1BB (CD137), an inducible

38. Goldinger SM, Dummer R, Baumgaertner P, Mihic‐

costimulatory receptor, as a specific target for cancer

Probst D, Schwarz K, Hammann‐Haenni A, et al. Nano‐

therapy. BMB Rep. 2014;47(3):122–9.

particle vaccination combined with TLR‐7 and ‐9 51. Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, ligands triggers memory and effector CD8(+) T‐cell

et al. Costimulatory molecule‐targeted antibody therapy

responses in melanoma patients. Eur J Immunol.

of a spontaneous autoimmune disease. Nat Med.

2012;42(11):3049–61.

2002;8(12):1405–13.

128 Immunotherapy in Translational Cancer Research 52. Kocak E, Lute K, Chang X, May KF, Jr., Exten KR, Zhang 65. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini H, et al. Combination therapy with anti‐CTL antigen‐4

R, Nocentini G, et al. GITR, a member of the TNF

and anti‐4‐1BB antibodies enhances cancer immunity

receptor superfamily, is costimulatory to mouse T lym-

and reduces autoimmunity. Cancer Res. 2006;66(14):

phocyte subpopulations. Eur J Immunol. 2004;34(3):

7276–84.

613–22.

53. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, 66. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi Chapoval AI, et al. Provision of antigen and CD137 sig-S. Stimulation of CD25(+)CD4(+) regulatory T cel s

naling breaks immunological ignorance, promoting

through GITR breaks immunological self‐tolerance. Nat

regression of poorly immunogenic tumors. J Clin Invest.

Immunol. 2002;3(2):135–42.

2002;109(5):651–9.

67. Turk MJ, Guevara‐Patino JA, Rizzuto GA, Engelhorn

54. Ito F, Li Q, Shreiner AB, Okuyama R, Jure‐Kunkel MN,

ME, Sakaguchi S, Houghton AN. Concomitant tumor

Teitz‐Tennenbaum S, et al. Anti‐CD137 monoclonal

immunity to a poorly immunogenic melanoma is

antibody administration augments the antitumor effi-

prevented by regulatory T cel s. J Exp Med. 2004;200(6):

cacy of dendritic cell‐based vaccines. Cancer Res.

771–82.

2004;64(22):8411–9.

68. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K,

55. Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, et al.

Yamaguchi T, et al. Treatment of advanced tumors with

Combined stimulation of TLR9 and 4.1BB augments

agonistic anti‐GITR mAb and its effects on tumor‐

Trp2 peptide vaccine‐mediated melanoma rejection by

infiltrating Foxp3 + CD25 + CD4+ regulatory T cel s.

increasing Ag‐specific CTL activity and infiltration into

J Exp Med. 2005;202(7):885–91.

tumor sites. Cancer Lett. 2013;330(2):190–9.

69. Zhou P, L’Italien L, Hodges D, Schebye XM. Pivotal roles 56. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I.

of CD4+ effector T cel s in mediating agonistic anti‐

Clinical experiences with anti‐CD137 and anti‐PD1

GITR mAb‐induced‐immune activation and tumor

therapeutic antibodies. Semin Oncol. 2010;37(5):

immunity in CT26 tumors. J Immunol. 2007;179(11):

508–16.

7365–75.

57. Croft M. Control of immunity by the TNFR‐related 70. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-molecule OX40 (CD134). Annu Rev Immunol.

Cymmerman D, Kim SC, et al. Agonist anti‐GITR

2010;28:57–78.

monoclonal antibody induces melanoma tumor immu-

58. Weinberg AD, Morris NP, Kovacsovics‐Bankowski M,

nity in mice by altering regulatory T cell stability and

Urba WJ, Curti BD. Science gone translational: the

intra‐tumor accumulation. PLoS One. 2010;5(5):e10436.

OX40 agonist story. Immunol Rev. 2011;244(1):218–31.

71. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G,

59. Linch SN, McNamara MJ, Redmond WL. OX40 agonists

Merghoub T, et al. Agonist anti‐GITR antibody enhances

and combination immunotherapy: putting the pedal to

vaccine‐induced CD8(+) T‐cell responses and tumor

the metal. Front Oncol. 2015;5:34.

immunity. Cancer Res. 2006;66(9):4904–12.

60. Kitamura N, Murata S, Ueki T, Mekata E, Reil y RT, 72. Hoffmann C, Stanke J, Kaufmann AM, Loddenkemper Jaffee EM, et al. OX40 costimulation can abrogate

C, Schneider A, Cichon G. Combining T‐cell vaccina-

Foxp3+ regulatory T cell‐mediated suppression of anti-

tion and application of agonistic anti‐GITR mAb

tumor immunity. Int J Cancer. 2009;125(3):630–8.

(DTA‐1) induces complete eradication of HPV onco-

61. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, et al.

gene expressing tumors in mice. J Immunother.

Active vaccination with Dickkopf‐1 induces protective

2010;33(2):136–45.

and therapeutic antitumor immunity in murine multiple 73. Pruitt SK, Boczkowski D, de Rosa N, Haley NR, Morse myeloma. Blood. 2012;119(1):161–9.

MA, Tyler DS, et al. Enhancement of anti‐tumor immu-

62. Hirschhorn‐Cymerman D, Budhu S, Kitano S, Liu C,

nity through local modulation of CTLA‐4 and GITR by

Zhao F, Zhong H, et al. Induction of tumoricidal

dendritic cel s. Eur J Immunol. 2011;41(12):3553–63.

function in CD4+ T cel s is associated with concomitant 74. Schaer DA, Hirschhorn‐Cymerman D, Wolchok JD.

memory and terminal y differentiated phenotype. J Exp

Targeting tumor‐necrosis factor receptor pathways for

Med. 2012;209(11):2113–26.

tumor immunotherapy. J Immunother Cancer. 2014;2:7.

63. Curti BD, Kovacsovics‐Bankowski M, Morris N, Walker 75. van de Ven K, Borst J. Targeting the T‐cell co‐stimula-E, Chisholm L, Floyd K, et al. OX40 is a potent immune‐

tory CD27/CD70 pathway in cancer immunotherapy:

stimulating target in late‐stage cancer patients. Cancer

rationale and potential. Immunotherapy. 2015;7(6):

Res. 2013;73(24):7189–98.

655–67.

64. Schaer DA, Murphy JT, Wolchok JD. Modulation of 76. Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, GITR for cancer immunotherapy. Curr Opin Immunol.

Silence K, Rottey S, et al. CD70: An emerging target in

2012;24(2):217–24.

cancer immunotherapy. Pharmacol Ther. 2015; 155:1–10.

CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 129

77. Kel y JM, Darcy PK, Markby JL, Godfrey DI, Takeda K,

refractory or recurrent non‐Hodgkin’s lymphoma. J

Yagita H, et al. Induction of tumor‐specific T cell

Clin Oncol. 2009;27(26):4371–7.

memory by NK cell‐mediated tumor rejection. Nat 90. Floros T, Tarhini AA. Anticancer cytokines: biology Immunol. 2002;3(1):83–90.

and clinical effects of interferon‐alpha2, interleukin

78. French RR, Taraban VY, Crowther GR, Rowley TF, Gray

(IL)‐2, IL‐15, IL‐21, and IL‐12. Semin Oncol.

JC, Johnson PW, et al. Eradication of lymphoma by CD8

2015;42(4): 539–48.

T cel s following anti‐CD40 monoclonal antibody 91. Kim‐Schulze S, Taback B, Kaufman HL. Cytokine therapy is critical y dependent on CD27 costimulation.

therapy for cancer. Surg Oncol Clin N Am.

Blood. 2007;109(11):4810–5.

2007;16(4):793–818, viii.

79. Matter M, Odermatt B, Yagita H, Nuoffer JM, 92. Agarwala SS, Kirkwood JM. Interferons in melanoma.

Ochsenbein AF. Elimination of chronic viral infection

Curr Opin Oncol. 1996;8(2):167–74.

by blocking CD27 signaling. J Exp Med. 2006;203(9):

93. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith

2145–55.

TJ, Borden EC, Blum RH. Interferon alfa‐2b adjuvant

80. Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk

therapy of high‐risk resected cutaneous melanoma: the

T, Ochsenbein AF. CD27 signaling increases the fre-

Eastern Cooperative Oncology Group Trial EST 1684.

quency of regulatory T cel s and promotes tumor

J Clin Oncol. 1996;14(1):7–17.

growth. Cancer Res. 2012;72(14):3664–76.

94. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff

81. Fonsatti E, Maio M, Altomonte M, Hersey P. Biology and

MS, Rao U, et al. A pooled analysis of Eastern

clinical applications of CD40 in cancer treatment. Semin

Cooperative Oncology Group and Intergroup trials of

Oncol. 2010;37(5):517–23.

adjuvant high‐dose interferon for melanoma. Clin

82. Summers deLuca L, Gommerman JL. Fine‐tuning of

Cancer Res. 2004;10(5):1670–7.

dendritic cell biology by the TNF superfamily. Nat Rev

95. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit

Immunol. 2012;12(5):339–51.

WH, Marsden J, et al. Adjuvant therapy with pegylated

83. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z,

interferon alfa‐2b versus observation alone in resected

Imboden M, Sondel PM, et al. Anti‐CD40 antibody

stage III melanoma: final results of EORTC 18991, a ran-

induces antitumor and antimetastatic effects: the role of

domised phase III trial. Lancet. 2008;372(9633):117–26.

NK cel s. J Immunol. 2001;166(1):89–94.

96. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit

84. Hassan SB, Sorensen JF, Olsen BN, Pedersen AE. Anti‐

WH, Marsden J, et al. Long‐term results of the

CD40‐mediated cancer immunotherapy: an update of

randomized phase III trial EORTC 18991 of adjuvant

recent and ongoing clinical trials. Immunopharmacol

therapy with pegylated interferon alfa‐2b versus obser-

Immunotoxicol. 2014;36(2):96–104.

vation in resected stage III melanoma. J Clin Oncol.

85. Diehl L, den Boer AT, Schoenberger SP, van der Voort

2012;30(31):3810–8.

EI, Schumacher TN, Melief CJ, et al. CD40 activation in

97. Di Pucchio T, Pil a L, Capone I, Ferrantini M,

vivo overcomes peptide‐induced peripheral cytotoxic

Montefiore E, Urbani F, et al. Immunization of stage IV

T‐lymphocyte tolerance and augments anti‐tumor

melanoma patients with Melan‐A/MART‐1 and gp100

vaccine efficacy. Nat Med. 1999;5(7):774–9.

peptides plus IFN‐alpha results in the activation of

86. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt

specific CD8(+) T cel s and monocyte/dendritic cell

SG, Stephans KF, Razvil as B, et al. Phase I study of

precursors. Cancer Res. 2006;66(9):4943–51.

recombinant human CD40 ligand in cancer patients. J

98. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL.

Clin Oncol. 2001;19(13):3280–7.

TroVax, a recombinant modified vaccinia Ankara virus

87. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS,

encoding 5 T4: lessons learned and future development.

Bajor DL, Hutnick NA, et al. Clinical activity and

Hum Vaccin. 2010;6(10):784–91.

immune modulation in cancer patients treated with

99. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA,

CP‐870,893, a novel CD40 agonist monoclonal anti-

Tomczak P, Szczylik C, et al. Vaccination of metastatic

body. J Clin Oncol. 2007;25(7):876–83.

renal cancer patients with MVA‐5 T4: a randomized,

88. Ruter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide

double‐blind, placebo‐controlled phase III study. Clin

RH. Immune modulation with weekly dosing of an ago-

Cancer Res. 2010;16(22):5539–47.

nist CD40 antibody in a phase I study of patients with 100. Rizza P, Moretti F, Capone I, Belardelli F. Role of type I advanced solid tumors. Cancer Biol Ther. 2010;

interferon in inducing a protective immune response:

10(10):983–93.

perspectives for clinical applications. Cytokine Growth

89. Advani R, Forero‐Torres A, Furman RR, Rosenblatt JD,

Factor Rev. 2015;26(2):195–201.

Younes A, Ren H, et al. Phase I study of the humanized 101. Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A.

anti‐CD40 monoclonal antibody dacetuzumab in

Common gamma chain cytokines in combinatorial

130 Immunotherapy in Translational Cancer Research immune strategies against cancer. Immunol Lett. 115. Smyth MJ, Taniguchi M, Street SE. The anti‐tumor 2015;169:61–72.

activity of IL‐12: mechanisms of innate immunity that

102. Ahmadzadeh M, Rosenberg SA. IL‐2 administration

are model and dose dependent. J Immunol. 2000;165(5):

increases CD4+ CD25(hi) Foxp3+ regulatory T cel s in

2665–70.

cancer patients. Blood. 2006;107(6):2409–14.

116. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.

103. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas

Immunotherapy of cancer by IL‐12‐based cytokine

AK. Biochemical mechanisms of IL‐2‐regulated Fas‐

combinations. Expert Opin Biol Ther. 2007; 7(11):

mediated T cell apoptosis. Immunity. 1998;8(5):

1705–21.

615–23.

117. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di

104. Rosenberg SA. IL‐2: the first effective immunotherapy

Carlo E, Cavallo F, et al. Combined allogeneic tumor

for human cancer. J Immunol. 2014;192(12):5451–8.

cell vaccination and systemic interleukin 12 prevents

105. Rosenberg SA, Yang JC, Sherry RM, Kammula US,

mammary carcinogenesis in HER‐2/neu transgenic

Hughes MS, Phan GQ, et al. Durable complete

mice. J Exp Med. 2001;194(9):1195–205.

responses in heavily pretreated patients with metastatic

118. Jaime‐Ramirez AC, Mundy‐Bosse BL, Kondadasula S,

melanoma using T‐cell transfer immunotherapy. Clin

Jones NB, Roda JM, Mani A, et al. IL‐12 enhances the

Cancer Res. 2011;17(13):4550–7.

antitumor actions of trastuzumab via NK cell IFN‐

106. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler

gamma production. J Immunol. 2011;186(6):3401–9.

WH, Moroziewicz D, et al. Phase II trial of Modified 119. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-Vaccinia Ankara (MVA) virus expressing 5 T4 and high

based mechanisms of cytotoxic chemotherapy: impli-

dose Interleukin‐2 (IL‐2) in patients with metastatic

cations for the design of novel and rationale‐based

renal cell carcinoma. J Transl Med. 2009;7:2.

combined treatments against cancer. Cell Death Differ.

107. Schwartzentruber DJ, Lawson DH, Richards JM,

2014;21(1):15–25.

Conry RM, Miller DM, Treisman J, et al. gp100 peptide 120. Zhang L, Feng D, Yu LX, Tsung K, Norton JA.

vaccine and interleukin‐2 in patients with advanced

Preexisting antitumor immunity augments the antitu-

melanoma. N Engl J Med. 2011;364(22):2119–27.

mor effects of chemotherapy. Cancer Immunol

108. Vicari AP, Chiodoni C, Vaure C, Ait‐Yahia S, Dercamp

Immunother. 2013;62(6):1061–71.

C, Matsos F, et al. Reversal of tumor‐induced dendritic 121. Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum cell paralysis by CpG immunostimulatory oligonucleo-K, Vom Berg J, et al. New insights into IL‐12‐mediated

tide and anti‐interleukin 10 receptor antibody. J Exp

tumor suppression. Cell Death Differ. 2015;22(2):

Med. 2002;196(4):541–9.

237–46.

109. Chen S, Wang X, Wu X, Wei MQ, Zhang B, Liu X, et al. 122. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, IL‐10 signalling blockade at the time of immunization

Sherman ML, et al. Interleukin‐12 therapy of cuta-

inhibits Human papillomavirus 16 E7 transformed

neous T‐cell lymphoma induces lesion regression

TC‐1 tumour cel s growth in mice. Cell Immunol.

and cytotoxic T‐cell responses. Blood. 1999;94(3):

2014;290(1):145–51.

902–8.

110. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, 123. Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Nunez G, et al. Interleukin‐10 ablation promotes

Foss F, et al. A phase II open‐label study of recombinant

tumor development, growth, and metastasis. Cancer

human interleukin‐12 in patients with stage IA, IB, or

Res. 2012;72(2):420–9.

IIA mycosis fungoides. J Am Acad Dermatol.

111. Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin‐10

2006;55(5):807–13.

promotes the maintenance of antitumor CD8(+) T‐cell 124. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera effector function in situ. Blood. 2001;98(7):2143–51.

JE, Hagemeister F, et al. Phase II clinical trial of

112. Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H,

interleukin‐12 in patients with relapsed and refractory

McClanahan T, et al. IL‐10 directly activates and

non‐Hodgkin’s lymphoma and Hodgkin’s disease. Clin

expands tumor‐resident CD8(+) T cel s without de

Cancer Res. 2004;10(16):5432–8.

novo infiltration from secondary lymphoid organs. 125. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Cancer Res. 2012;72(14):3570–81.

Howell KG, et al. Phase 1 study of interleukin‐12 in

113. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze

combination with rituximab in patients with B‐cell

S, et al. IL‐10 elicits IFNgamma‐dependent tumor

non‐Hodgkin lymphoma. Blood. 2002;99(1):67–74.

immune surveil ance. Cancer Cel . 2011;20(6):781–96.

126. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI,

114. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12:

Sondak VK, et al. Phase I trial of interleukin‐12

still a promising candidate for tumor immunotherapy?

plasmid electroporation in patients with metastatic

Cancer Immunol Immunother. 2014;63(5):419–35.

melanoma. J Clin Oncol. 2008;26(36):5896–903.

CHAPTER 9 Immunomodulation with Adjuvants and Cytokines 131

127. Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio 135. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant AF, Conry RM. Phase I study of the intratumoral

PA. IL‐21 enhances and sustains CD8+ T cell responses

administration of recombinant canarypox viruses

to achieve durable tumor immunity: comparative

expressing B7.1 and interleukin 12 in patients with

evaluation of IL‐2, IL‐15, and IL‐21. J Immunol.

metastatic melanoma. Clin Cancer Res. 2005; 11(11):

2004;173(2):900–9.

4168–75.

136. He H, Wisner P, Yang G, Hu HM, Haley D, Miller W,

128. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J,

et al. Combined IL‐21 and low‐dose IL‐2 therapy

Herrero I, et al. Phase I trial of intratumoral injection

induces anti‐tumor immunity and long‐term curative

of an adenovirus encoding interleukin‐12 for advanced

effects in a murine melanoma tumor model. J Transl

digestive tumors. J Clin Oncol. 2004;22(8):1389–97.

Med. 2006;4:24.

129. Waldmann TA. The shared and contrasting roles of IL2 137. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, and IL15 in the life and death of normal and neoplastic

Hinrichs CS, et al. Synergy of IL‐21 and IL‐15 in regu-

lymphocytes: implications for cancer therapy. Cancer

lating CD8+ T cell expansion and function. J Exp Med.

Immunol Res. 2015;3(3):219–27.

2005;201(1):139–48.

130. Pagliari D, Cianci R, Frosali S, Landolfi R, Cammarota 138. Petrel a TM, Tozer R, Belanger K, Savage KJ, Wong R, G, Newton EE, et al. The role of IL‐15 in gastrointes-Smylie M, et al. Interleukin‐21 has activity in patients

tinal diseases: a bridge between innate and adaptive

with metastatic melanoma: a phase II study. J Clin

immune response. Cytokine Growth Factor Rev.

Oncol. 2012;30(27):3396–401.

2013;24(5):455–66.

139. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber

131. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA.

JS, Agarwala SS, et al. Phase I study of recombinant

Simultaneous blockade of multiple immune system

interleukin‐21 in patients with metastatic melanoma

inhibitory checkpoints enhances antitumor activity

and renal cell carcinoma. J Clin Oncol. 2008;

mediated by interleukin‐15 in a murine metastatic

26(12):2034–9.

colon carcinoma model. Clin Cancer Res. 2010;16(24): 140. Davis ID, Brady B, Kefford RF, Mil ward M, Cebon J, 6019–28.

Skrumsager BK, et al. Clinical and biological efficacy of

132. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo

recombinant human interleukin‐21 in patients with

AT, Morris JC, et al. Redistribution, hyperprolifera-

stage IV malignant melanoma without prior treatment:

tion, activation of natural killer cells and CD8 T cells,

a phase IIa trial. Clin Cancer Res. 2009;15(6):2123–9.

and cytokine production during first‐in‐human 141. Steele N, Anthony A, Saunders M, Esmarck B, clinical trial of recombinant human interleukin‐15

Ehrnrooth E, Kristjansen PE, et al. A phase 1 trial of

in patients with cancer. J Clin Oncol. 2015;33(1):

recombinant human IL‐21 in combination with cetux-

74–82.

imab in patients with metastatic colorectal cancer. Br J

133. Spolski R, Leonard WJ. Interleukin‐21: a double‐edged

Cancer. 2012;106(5):793–8.

sword with therapeutic potential. Nat Rev Drug Discov.

142. Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE,

2014;13(5):379–95.

Kramer J, Muthusamy N, et al. A phase I dose‐finding

134. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C,

trial of recombinant interleukin‐21 and rituximab in

et al. In vivo antitumor activity of interleukin 21 medi-

relapsed and refractory low grade B‐cell lymphopro-

ated by natural killer cells. Cancer Res. 2003; 63(24):

liferative disorders. Clin Cancer Res. 2012;18(20):

9016–22.

5752–60.





CHAPTER 10

10 Immune Cell Migration in Cancer

and Immunotherapy

Timothy Murray and Daniel E. Speiser

Ludwig Cancer Research, Department of Oncology, University of Lausanne, Épalinges, Switzerland Introduction

outcome. The situation is rather more complex

since several other types of immune cel s can exert

The immune contexture in cancer

protumor, immunosuppressive effects within the

The microenvironment of solid tumors comprises microenvironment. T regulatory (T ) cel s and M2

a complex network of tumor cel s, stromal cel s,

reg

macrophages, for example, are typical immunosup-

lymphatic and vascular endothelial cel s, extracel- pressive immune populations found within solid lular matrix proteins, soluble factors, and immune tumors.

cel s. Many subpopulations of innate and adaptive

Ultimately, disease outcome is determined by the

immune cel s are found within human tumors, complex interplay between tumor cel s, tissue cel s, including T and B lymphocytes, natural killer (NK) soluble factors within the microenvironment, and cel s, macrophages, and dendritic cel s (DCs). The the presence of pro‐ and anti‐tumor components of nature, location, and functionality of tumor‐ the immune system. One branch of immunotherapy infiltrating leukocytes has been termed the aims to target cancer by shifting this balance in favor

“immune contexture,” and there is a growing of the host immune system by modulating the migra-appreciation that this has a significant impact on tory behavior of pro‐ and anti‐tumor immune cel s.

the clinical outcome for cancer patients [1].

Certain populations of immune cel s, such as

CD8+ T lymphocytes and NK cel s, have the Immune cell migration capacity to recognize and eliminate tumor cel s. As Over the last 20 years, our understanding of the one would expect, the presence of these cel s within migration of many types of immune cel s has solid tumors general y correlates with a more expanded exponential y. While some aspects of the favorable prognosis [1–3]. In addition, mice with process of tissue and tumor infiltration remain immunodeficiencies that affect T and NK cel s are unclear, many of the genes and mechanisms by more susceptible to carcinogen‐induced and which the immune contexture is formed have been spontaneous tumors.

unveiled.

However, the presence of immune cel s in the

Most immune cel s originate from hematopoi-

tumor does not always correlate with better clinical etic stem cel s in the bone marrow. The first phase Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

132





CHAPTER 10 Immune Cell Migration in Cancer and Immunotherapy 133

of migration in the lifetime of an immune cell recognition with appropriate costimulation is occurs following their development, upon which mediated by professional antigen‐presenting cel s, cel s leave the bone marrow and enter the blood or such as DCs, upon arrival in tissue‐draining lymph lymphatic circulation. T lymphocytes are the nodes following activation in peripheral tissues.

exception to this rule, since they migrate initial y to Final y, activated T and B lymphocytes migrate out the thymus for completion of the development pro- of the lymphatic system and into sites of inflamma-cess before entry into the circulation.

tion in peripheral tissues, where they are poised

Following development, the migratory behavior to exert effector functions on the front line.

of different immune cell populations varies Figure 10.1 gives an overview of the migratory according to their function. Dendritic cel s and behavior of different immune cell subtypes.

macrophages, for example, provide front‐line

defense against infection and therefore migrate Organ‐specific “area codes”

directly into peripheral tissues where they patrol in The complex movements and interactions of search of invading pathogens. Granulocytes, such leukocytes throughout the organs of the body as neutrophils and eosinophils, circulate in the require exquisite regulation. Defects in these blood until recruited to peripheral tissues upon processes can lead to autoimmunity or, conversely, infection. Naïve B and T lymphocytes, in contrast, susceptibility to infection. Tissue compartments circulate between secondary lymphatic organs and are divided by epithelial and endothelial barriers blood. This is because proper activation of the that restrict immune cell migration. Entry into adaptive immune system requires interaction with each tissue occurs by extravasation across the other immune cell populations, a process that vascular endothelial barrier, a process that is occurs most efficiently when the relevant cell types dependent on the repertoire, abundance, and func-and cytokines are concentrated within specialized tionality of homing receptors expressed on the regions of a lymph node. In the case of B cel s, leukocyte cell surface, as well as the presence of antigen recognition is followed by interaction with cognate receptor ligands on the endothelial cell CD4+ T cel s and subsequent differentiation within wal . These interactions can be considered as a the lymph node. In the case of T cel s, antigen “lock and key” system: leukocyte homing receptors DC Monocyte

T cell

Precursors

Thymus

Bone

Activated

Marrow

APC

Naive

T Cells

Peripheral tissues

Naive

B Cells

Activated

Lymph node

lymphocytes

Figure 10.1 Overview of the migratory pathways of various immune cell types.





134 Immunotherapy in Translational Cancer Research are the “keys” that allow entry to particular tissue peripheral endothelium. The short‐lived interac-compartments by unlocking the endothelial barrier tions between selectins and their ligands lead to when the corresponding “locks” are present. As an “rolling” of leukocytes along endothelial cell beds, example, entry of naïve lymphocytes into lymph the first step in the extravasation cascade.

nodes requires both the expression of the lympho-

Chemokine receptors are a diverse family of

cyte homing receptors CD62L and CCR7 and the G‐protein coupled receptors expressed by leukocytes presence of their respective ligands, PNAd and as well as many other cel s. Their chemoattractant CCL21, on the specialized endothelial vessels that ligands (chemokines) are secreted and displayed feed the lymph node. Receptor‐ligand engagement on the surface of tissue cel s in order to guide leads, ultimately, to transendothelial extravasation. migration during homeostasis or in response to Distinct patterns of homing receptor expression inflammatory stimuli. Leukocyte rolling on the are required for entry into each tissue. These endothelial cell surface allows for the binding of expression profiles are collectively described by the chemokine receptors to chemokines, should they hypothesis of organ‐specific “area codes.” In be present. This interaction has diverse downstream support of this concept, a wealth of literature has effects on leukocytes, including the activation of demonstrated that leukocyte migration to lymph integrin‐mediated adhesion.

node, gut, or skin, for example, requires strikingly

Integrins are a family of 24 heterodimers that

different patterns of homing receptor expression. mediate firm adhesion of leukocytes to both endo-Skin tropism is typical y conferred by E‐ and thelial cel s and components of the extracel ular P‐selectin ligands, CCR4, and/or CCR10, whereas matrix. Each family member comprises an alpha gut homing, in contrast, requires a4b7 integrin and and a beta subunit. The adhesive capacity of integ-CCR9. Lymph tropism, as described above, is con- rins is regulated by alterations in conformation, ferred by L‐selectin and CCR7. These organ‐specific transcriptional control, and cell‐surface organiza-area codes, combined with inflammation‐induced tion. Firm adhesion by integrins is induced upon expression of corresponding endothelial ligands, engagement of chemokine receptors. For T cel s, allows fine‐tuning of leukocyte distribution such ligation of the T cell receptor also plays a central that appropriate immune effectors migrate to role in modulating cel ular adhesion by integrins.

tissues where they are most needed for efficient

Thus, leukocyte extravasation occurs by a

immunity.

multistep cascade of events, beginning with selectin‐

mediated rolling, followed by the triggering of

Molecular mechanisms of leukocyte

chemokine receptors which, subsequently, induces

migration

integrin‐mediated firm adhesion and extravasa-

The vast majority of leukocyte homing receptors tion. The schematic in Figure 10.2 summarizes belong to one of four classes: the selectin, selectin these steps. Final y, chemotaxis within the tissue ligand, integrin, and G‐protein coupled receptor (interstitial migration) is much less well under-

(often chemokine receptor) families. Members of stood but certainly involves both chemokine each family play distinct roles in the cascade of receptors and integrins.

events that occur when leukocytes migrate from

one tissue compartment to another.

Targeting leukocyte migration by

The selectin family comprises three highly con- immunotherapy served C‐type lectins, L‐, P‐, and E‐selectin. The

selectins bind weakly to a variety of glycoprotein Immune cell migration in cancer: ligands on the surface of other cel s. L‐selectin is Current knowledge and open questions expressed on the surface of lymphocytes and binds The primary objective of most immunotherapeutic to PNAd on lymph node endothelial vessels. E‐ and strategies, such as adoptive cell transfer and cancer P‐selectin, in contrast, are expressed by peripheral vaccines, is to efficiently induce and activate anti-tissue endothelium, general y in response to tumor immune cel s such as DCs, NK cel s, and T

inflammation. Leukocytes may express ligands for lymphocytes. In many cases these approaches E‐ and P‐selectin that facilitate weak adhesion to successful y amplify tumor immune responses in





CHAPTER 10 Immune Cell Migration in Cancer and Immunotherapy 135

Blood flow

Tethering

Rolling

Firm Adhesion

Diapedesis

Endothelial cell

Leukocyte Receptors

Endothelial Ligands

Selectin ligand

Selectin

Chemokine

Chemokine receptor

Inactive integrin

Integrin ligand

Active integrin

Figure 10.2 Molecular mechanisms of leukocyte extravasa-endothelial‐displayed chemokines. Finally, firm adhesion

tion. The initial tethering of leukocytes to the vascular

of leukocytes to the endothelial bed is mediated by

endothelium is mediated by low‐affinity selectin binding.

integrins. Firm adhesion allows for leukocyte diapedesis

This facilitates the engagement of chemokine receptors by

into the interstitial space.

patients, and yet long‐lasting clinical benefit or into the clinic, and there is great potential for complete responses are reported in only a minority clinical development in the future.

of cases. One potential explanation for this discrep-

Immunotherapies that target the migration of

ancy is that, despite stimuli that boost the immune immune cel s can be broadly divided into the response, immune cel s (i) do not efficiently following three categories: interact with one another (for example, DCs and 1 Ex vivo modification of immune cel s CD8+ T cel s) or (ii) do not migrate to and accumu- 2 Delivery of homing stimuli directly to the tumor late within the tumor mass (for example, CD8+ T

microenvironment

cel s or NK cel s). Indeed, several studies have 3 Systemic application of drugs and biologicals demonstrated that only a small fraction of ex vivo

expanded, adoptively transferred T cel s actual y Immunotherapy by ex vivo home to the site of the tumor [4, 5]. Hence, even modification of immune migration when large numbers of highly activated antitumor Recent advances in both tissue culture and genetics immune cel s are available in vivo, clinical benefit is technologies have facilitated the isolation, expan-likely to be very limited if interaction and tumor sion, and modification of antitumor immune cel s homing of the relevant effector cel s is inefficient.

for subsequent reinfusion to the host. Immune

Novel approaches to immunotherapy that over- migratory properties can be modified by various come such immune migratory limitations are means, such as cytokine treatment and viral trans-urgently needed, and this has become an area of duction. The latter involves the use of engineered intensive research over the past decade. Much of viruses that infect and integrate in the immune cell our current understanding has come from preclin- genome, forcing the expression of selected genes, ical animal models, in which there is no shortage of such as chemokine receptors. These techniques success stories. Some strategies are now translating are particularly aimed at modifying the homing

136 Immunotherapy in Translational Cancer Research properties of T lymphocytes and NK cel s, two main branches of adoptive cell transfer: expansion populations whose presence in human solid tumors of tumor‐derived lymphocytes, and genetic modi-has been shown to correlate with enhanced fication of blood‐derived lymphocytes.

patient survival.

Studies of colorectal cancer patients have dem-

The efficacy of such approaches is dependent on onstrated that the chemokines CXCL9 and CXCL10

the identification of discrepancies between are frequently present within tumors. These che-immune cell homing receptor expression and the mokines are recognized by the receptor, CXCR3, presence of chemotactic ligands at the tumor site. the expression of which can be induced on subsets Several recent studies have addressed this question of both NK and T cel s. Genetic manipulation of for various tumor types, demonstrating that can- NK cel s has proven more challenging than when cers of distinct origin display unique chemokine working with T lymphocytes [12]; therefore, secretion signatures for which antitumor immune research has focused on alternative means of NK

cel s often lack the corresponding homing recep- cell modification. Wennerberg et al [13] have tors. First, human metastatic melanomas are developed a novel in vitro protocol for the expan-characterized by secretion of CXCL1 and CXCL8 sion of NK cel s that induces expression levels of

[6, 7], yet the receptors for these chemokines, CXCR3 greater than 10‐fold relative to normal CXCR1 and CXCR2, are rarely expressed on T activated NK cel s. This specialized expansion pro-cel s. Second, human lung tumors frequently tocol involves coculture of purified NK cel s with express CCL2 [8, 9], for which T cel s general y lack Epstein‐Barr‐transformed lymphoblastoid cel s, the receptor, CCR2. Final y, numerous studies have together with the growth cytokine interleukin‐2.

demonstrated the expression of CXCR3 ligands Expanded NK cel s were adoptively transferred within colorectal tumors [10], as well as the impor- into mice bearing subcutaneous melanoma tumors tance of these ligands for NK cell recruitment to that were either CXCL10 positive or negative. NK

tumors [11]. However, CXCR3 expression is cel s with the modified homing profile (CXCR3

restricted to a minority of mature NK cel s, unlike positive) migrated significantly more efficiently to activated T cel s in which this receptor is broadly CXCL10‐positive tumors, resulting in a reduction expressed.

of the tumor burden and prolonged survival.

Several groups have recently developed strat-

An alternative means of modifying the migra-

egies to overcome these deficits. Moon et al [9] tory properties of NK cel s is trogocytosis, a employed a xenograft mouse model of lung cancer contact‐dependent process in which patches of in order to observe the impact of forced CCR2 membrane (and the receptors contained therein) expression in tumor‐specific T cel s on lung tumor are transferred between cel s such as antigen-growth. Human malignant pleural mesothelioma presenting cel s and lymphocytes [14]. Many cel s expressing the tumor‐associated antigen cancer cel s metastasize initial y to local lymph mesothelin were engrafted subcutaneously into nodes by gaining expression of the chemokine immunodeficient mice. Next, bulk CD4 and CD8 T receptor CCR7 [15–18]. This receptor binds the cel s were isolated from human blood, stimulated, ligands CCL19 and CCL21 that are highly expressed and transduced with a lentivirus encoding a meso- in lymph nodes, but cytotoxic NK cel s do not thelin‐specific chimeric antigen receptor express CCR7 and thus do not home to lymph (MesoCAR) with or without a second lentivirus node metastases [19]. Thus, Somanchi et al [20]

encoding the human chemokine receptor, CCR2. engineered the transient expression of CCR7 on in Final y, transduced cel s (MesoCAR or Meso vitro expanded human NK cel s via trogocytosis-CAR‐CCR2) were adoptively transferred into inducing coculture with a CCR7‐expressing tumor‐bearing mice and tumor growth was moni- leukemia cell line. Acquired CCR7 expression on tored over several weeks. T cel s transduced with NK cel s conferred enhanced migration to CCL19

both MesoCAR and CCR2 were superior to those and CCL21 in vitro as well as to lymph nodes in transduced with MesoCAR alone, both in terms of immunodeficient mice. This methodology pres-tumor infiltration and control of tumor growth. ents a novel means for the modification of immune The schematic in Figure 10.3 il ustrates the two cell migration.





CHAPTER 10 Immune Cell Migration in Cancer and Immunotherapy 137

Viral vector

Enhanced anti-tumor

Gene-modified

response

tumor-specific

Blood-derived

lymphocytes

lymphocytes

Tumor

Tumor-derived

lymphocytes

Lymphocytes

selection and

expansion

Figure 10.3 The two principal branches of adoptive cell of tumor‐derived lymphocytes. In both cases, reinfusion of

transfer immunotherapy: ex vivo genetic modification of ex vivo modified cells may lead to enhanced antitumor blood‐derived lymphocytes, and selection and expansion

immunity.

These studies, among others, demonstrate that A simple approach to this problem from a different enhanced migration and tumor homing of human point of view is the injection of CXCL10 directly at immune cel s can be engineered in vitro. Similar the tumor site. Wendel et al. [11] engrafted mice strategies are likely applicable for the modification subcutaneously with the lymphoma cell line RMA of tumor‐derived lymphocytes, in addition to mixed with recombinant CXCL10 protein. Five blood‐derived cells. Such approaches hold days after engraftment tumors were analyzed for significant promise for the future of cancer NK cell infiltration and it was observed that immunotherapy.

CXCL10 delivery to the tumor site led to a

significant increase in the number of NK cel s.

Immunotherapy at the tumor site

Since engraftment of tumor cel s mixed with

to enhance immune cell migration

recombinant chemokine is not a realistic

Besides the direct modification of immune cel s, therapeutic model, the authors then tested whether recent research has also focused on the delivery of they could achieve similar results by injecting immune migratory stimuli to the tumor site—an recombinant CXCL10 into established lymphoma alternative means to a similar end. There are mul- tumors. Indeed, intratumoral injection of this che-tiple means to deliver chemoattractants to the mokine at regular intervals led to significantly tumor site, including intratumoral injection, in longer survival of tumor‐bearing mice.

vivo transfection and transduction of tumor cel s,

Numerous other groups have reported similar

and local y applied oncolytic viruses. Several exam- findings in other models. However, it is likely that ples of such approaches will be described in this exogenously applied chemoattractant proteins, like section.

CXCL10, are rapidly degraded and diffuse widely

As discussed in the previous chapter, the within the interstitial space, leading to unstable CXCR3‐CXCL10 axis is important for the infiltra- chemotactic gradients. One study recently tion of NK cel s into subcutaneous tumors, such addressed this question by comparing the recruit-that adoptive transfer of CXCR3‐enriched NK cel s ment of T cel s to subcutaneous tumors when into tumor‐bearing mice leads to longer survival. chemokines were applied by intratumoral injection,

138 Immunotherapy in Translational Cancer Research or by transient transfection of tumor cel s with a mice injected with CCL19, CCL20, CCL22, or DNA expression vector. Briefly, the chemokine XCL1‐encoding viruses, those mice that received CCL21 is known to attract both T cel s and antigen‐ CCL17, CCL21, CCL27, or CX3CL1‐encoding presenting cel s to subcutaneous B16 melanoma viruses showed significantly slower tumor growth, tumors in mice [21]. Igoucheva et al. [22] con- and even some complete tumor regressions.

structed viral vectors encoding the CCL21 gene CCL17, the ligand for the T cell chemokine receptor and developed a method to introduce this plasmid CCR4, was the most effective chemokine for boost-DNA directly into tumor cel s in vivo by intratu- ing the antitumor immune response. Importantly, moral injection followed by electroporation. The mice that completely regressed from the initial phospholipid bilayer is disrupted when subjected tumor burden were subjected to a second tumor to an electrical pulse, leading to pore formation. challenge three months later, and all mice that had Charged molecules like DNA are then driven received CCL17‐encoding adenovirus (AdRGD-within the cell due to the membrane potential and CCL17) were protected against rechallenge without are transiently expressed by the endogenous tran- the need for further treatment. Histological anal-scription and translation machinery. Using this ysis of CT26 tumors revealed that AdRGD‐CCL17

approach, the authors demonstrate that in vivo induced significantly greater infiltration of CD8 T

electroporation leads to CCL21 expression by cel s (but not CD4 T cel s) to subcutaneous tumors.

tumor cel s for at least 72 hours, and to signifi- Together these data demonstrate the efficacy of cantly superior recruitment of both CD4 and chemoattractant gene delivery by intratumoral CD8 T cel s when compared with intratumoral injection of chemokine‐encoding, replication-injection of protein. Hence, techniques that involve incompetent viruses. In contrast with the continued production of chemoattractants by electroporation technique described above, viral tumor cel s are likely more efficient for the recruit- transduction in this model led to gene expression ment of antitumor immune cel s than direct by tumor cel s for at least nine days and is thus injection (and rapid dispersion) of chemoattrac- likely superior in terms of continued immune cel s tant proteins.

recruitment.

An alternative means of gene therapy that targets

A potential limitation of the two approaches

the tumor is the use of engineered viral vectors. As already described in this chapter is that immune briefly discussed in the previous section, certain effector cel s are only recruited to lesions that are viruses are highly specialized in the delivery of directly targeted by injection, leaving metastases in genetic material to mammalian cel s. Modern tech- other organs or less‐accessible locations untreated.

niques in molecular biology allow the insertion of a

Final y, gene delivery specifical y to tumor cel s

gene of interest into the viral genome while main- can be achieved with the use of oncolytic viruses taining the ability of the virus to infect. Importantly, (OVs). Various OVs have been developed, viral components required for replication can be including herpes, adenoviruses, and vaccinia.

removed, thus rendering viral particles that are These were original y conceived as a method of infective but nonreplicative, a safe system for use in specifical y inducing the lysis of tumor cel s, since mammalian model systems and humans. Kanagawa viruses preferential y infect dividing cel s, such as et al. [23] have developed an adenovirus vector cancer cel s. Typical y, this is done by systemic system for the delivery of chemokine genes to infection, after which tumor cel s are “specifical y”

tumor cel s. They generated viral particles encod- infected. There are obvious safety concerns associ-ing the chemokines CCL17, CCL19, CCL20, ated with any therapy involving an infective virus, CCL21, CCL22, CCL27, XCL1, and CX3CL1, but recent efforts have overcome many of these which are capable of infecting the murine colon issues to yield highly tumor‐specific viruses with carcinoma cell line, CT26. Mice bearing subcuta- minimal off‐target infection. For example, the neous tumors were treated with an adenovirus deletion of essential DNA replication components encoding one chemokine by intratumoral injection (the thymidine kinase gene, TK) from vaccinia and tumor growth was monitored. While the leads to greater dependence on host cell replica-growth of tumors was comparable with controls in tion, thus reducing successful propagation within





CHAPTER 10 Immune Cell Migration in Cancer and Immunotherapy 139

resting cel s. Alternatively, deletion of growth targeting the tumor microenvironment. In addition factors (such as vaccinia growth factor, VGF) to those strategies already discussed, there are prevents the division and subsequent infection of numerous means by which immune cell migration nearby resting cel s, thus restricting infection to can be altered using drugs and biologicals that are actively dividing cells. Indeed, these two modi- applied systemical y. Numerous studies have fications act synergistical y, such that the reported effects on T cell migratory behavior TK−VGF− strain of vaccinia (ddVV) displays induced by therapeutics that were not original y enhanced tumor selectivity. Nonetheless, some designed for this objective. This includes degree of off‐target infection and replication is to both immunotherapeutic agents and standard be expected with such approaches.

chemotherapies.

Li et al. [24] have recently extended the concept of

CTLA‐4 is a T cell inhibitory receptor. Its

OVs, to incorporate gene delivery to tumor cel s. The structure is similar to that of the costimulatory authors engineered ddVV to incorporate the gene molecule CD28, and both receptors share the same encoding the inflammatory chemokine, CCL5 ligands, CD80 and CD86, on antigen‐presenting (ddCCL5). This chemokine is recognized by several cel s. However, while CD28 engagement activates receptors on effector T cel s, including CCR1, CCR3, stimulatory T cell signaling pathways, CTLA‐4

and CCR5. Mice bearing subcutaneous colon adeno- engagement potently suppresses T cell immu-carcinomas (MC38) were systemical y infected with nity. Thus, monoclonal antibodies against ddCCL5 and the tumor growth monitored. Infection CTLA‐4, such as ipilimumab, prevent inhibitory with ddCCL5 led to significantly better tumor con- receptor engagement and promote T cell activation trol than ddVV, and this correlated with much higher (known as “checkpoint blockade”).

recruitment of both CD4 T cel s and DCs (but not

The exact mechanism by which anti‐CTLA‐4

CD8 T cel s). Moreover, the effects of vvCCL5 were antibodies boost T cell function remains a subject synergistic when combined with another immuno- of some controversy. Pentcheva‐Hoang et al. [25]

therapeutic modality, DC vaccination. DCs were recently investigated whether CTLA‐4 blockade loaded with MC38 cell lysate prior to subcutaneous may have any impact on T cell motility. The authors injection. This was followed by systemic infection observed that in a mouse model of melanoma, with ddVV or vvCCL5. The combination of DC vac- chronic systemic treatment with anti‐CTLA‐4 anti-cination and vvCCL5 induced the best tumor control, bodies led to increased mobility of intratumoral T

with superior infiltration of both CD4 and CD8 T cel s, specific for a defined tumor antigen. This was cel s as well as NK cel s.

not the case for T cel s within tumor‐draining

In summary, there are numerous options to lymph nodes. However, the mobility of T cel s deliver immunotherapies that boost the tumor infil- within these lymph nodes was increased upon tration of immune cel s by directly targeting the acute treatment with anti‐CTLA‐4 antibodies.

tumor. Each of these has associated potential bene- Hence, despite different effects, depending on the fits and safety concerns. Intratumoral injection of tissue context (lymph node or tumor), anti-either chemoattractant proteins or chemokine‐ CTLA‐4 treatment increased the mobility of encoding vectors represent low risk strategies, but tumor‐specific T cel s in this model. Given the they likely induce weaker, short‐term effects. established success of anti‐CTLA‐4 treatment of Targeting of tumor‐specific viruses by intratumoral melanoma patients, this effect likely promotes injection or by systemic infection are more robust more efficient movement of antitumor T cel s bet-strategies that impact the immune response over a ween antigen‐presenting target cel s. Thus, T cel s longer period but have significant safety concerns.

within tumors of anti‐CTLA‐4‐treated subjects are

likely to successful y engage and lyse greater num-

Systemic application of drugs

bers of tumor cel s.

and biologicals

Several chemotherapy drugs have also been

The two preceding sections discussed techniques reported to affect the infiltration of T lymphocytes for boosting the migration of anticancer immune into various solid tumors, including melanoma and cel s either by ex vivo modification or by directly breast cancer [26, 27]. Two recent studies have





140 Immunotherapy in Translational Cancer Research investigated the basis for this phenomenon. First, specifically antagonizes CCR5, was given Nardin et al. [26] characterized molecular changes systemical y to tumor‐bearing mice during the within the microenvironment of human melanoma early phase of tumor growth. This treatment lesions that were either refractory or responsive to resulted in a significant decrease in the rate of therapy with the chemotherapeutic agent dacarba- tumor growth, accompanied by a striking reduction zine. Important changes associated with clinical in the proportion of T cel s infiltrating the tumor.

reg

response were increased infiltration of CD8 T cel s Second, Priceman et al. [30] performed similar and associated genes (such as TNF), as well as analyses in the context of MDSC infiltration of increased expression of genes associated with lung and prostate tumors. In this case, a small mol-extracel ular matrix remodeling, such as secreted ecule inhibitor (GW2580) of colony‐stimulating protein acidic and rich in cysteine (SPARC). A factor 1 receptor (CSF1R), a myeloid cell cytokine subsequent study by Hong et al. [28] established receptor with an established role in the recruitment that dacarbazine, as well as other chemotherapy of MDSCs to solid tumors, was given to tumor-agents including temozolomide and cisplatin, bearing mice by oral gavage. CSF1R inhibition directly induce the expression of chemokines by blocked the recruitment of MDSCs to tumors, human melanoma cel s. Induced chemokines resulting in a reduction in the intratumoral blood included CCL5, CXCL9, and CXCL10. Second, vessel density and expression of immunosuppres-chemotherapy‐induced expression of these chemo- sive molecules. When mice bearing lung carcinoma kines was associated with better T cell infiltration tumors were treated with GW2580 in combination and longer survival in melanoma patients. Thus, with an antiangiogenic therapy (anti‐VEGFR‐2

chemotherapy drugs appear to contribute to tumor mAb), a synergistic inhibition of tumor growth was control not only by blocking cell division but also observed. Hence, blockade of immunosuppressive by inducing local chemokine secretion and extra- and proangiogenic cell recruitment to the tumor in cel ular matrix remodeling that promotes immune combination with existing therapies may hold cell infiltration.

significant potential for cancer treatment.

Migration of immune effector cel s, like T and

NK cel s, is an essential component of the antitu- Conclusions and perspectives mor immune response. However, not all immune

cel s exert antitumor effects. Indeed, many tumors This chapter il ustrates the broad range of immu-evolve to specifical y recruit immune cell subsets, notherapy strategies that impact the migratory such as T cel s and myeloid‐derived suppressor properties of immune cel s. These approaches can reg

cel s (MDSCs), both of which create an immuno- be broadly divided into three categories: suppressive microenvironment, dampening the 1 Ex vivo modification and reinfusion of immune effector functions of antitumor immune cel s, as

cel s,

well as enhancing tumor angiogenesis. The 2 Delivery of chemoattractants directly to the therapeutic models discussed so far in this chapter

tumor microenvironment,

each aim to enhance the migration of antitumor 3

Treatment with systemic agents that either

immune cel s. In contrast, blocking the migration

enhance the recruitment of antitumor immune

of immunosuppressive cel s presents an alternative

cells or inhibit the recruitment of protumor

approach to boosting the anticancer response.

immune cel s to the tumor microenvironment.

Two recent studies have demonstrated this con-

The examples cited throughout this chapter

cept in different murine tumor models. First, Tan il ustrate the variety of possible approaches within et al. [29] observed that in mice with pancreatic each of these three categories.

adenocarcinoma, the proportion of intratumoral

In the majority of cases, these studies were

T cel s expressing the chemokine receptor CCR5 carried out in preclinical mouse models and have reg

was significantly higher than for effector CD4 T yet to be tested in the context of human clinical cel s. This suggests that CCR5 may be involved in trials. However, intensive efforts to bring immuno-preferential recruitment of T cel s to this tumor therapies to the clinic in recent years will certainly reg

type. A small molecule inhibitor, TAK‐779, which facilitate the essential next steps. For example, as the





CHAPTER 10 Immune Cell Migration in Cancer and Immunotherapy 141

availability of adoptive cell transfer immunotherapy

chimeric antibody receptor. Clin Cancer Res.

becomes increasingly widespread, so too wil

2011;17(14):4719–30.

opportunities to test variations of basic protocols 10. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, that incorporate genetic modification of lympho-Bindea G, Berger A, et al. Biomolecular network recon-

cytes or that induce particular cel ular phenotypes.

struction identifies T‐cell homing factors associated

The importance of immune cell migration, both

with survival in colorectal cancer. Gastroenterology.

2010;138(4):1429–40.

anti‐ and pro‐tumorigenic, is now well established. 11. Wendel M, Galani IE, Suri‐Payer E, Cerwenka A.

Immunotherapies that influence these processes

Natural killer cell accumulation in tumors is dependent

hold great promise for continued progress toward

on IFN‐gamma and CXCR3 ligands. Cancer Res.

cures for metastatic disease.

2008;68(20):8437–45.

12. Carlsten M, Childs RW. Genetic manipulation of NK

References

cel s for cancer immunotherapy: techniques and clinical

implications. Front Immunol. 2015;6:266.

1. Fridman WH, Pagès F, Sautès‐Fridman C, Galon J. The 13. Wennerberg E, Kremer V, Childs R, Lundqvist A.

immune contexture in human tumours: impact on

CXCL10‐induced migration of adoptively transferred

clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.

human natural killer cel s toward solid tumors causes

2. Takanami I, Takeuchi K, Giga M. The prognostic value of

regression of tumor growth in vivo. Cancer Immunol

natural killer cell infiltration in resected pulmonary ade-

Immunother. 2015;64(2):225–35.

nocarcinoma. J Thorac Cardiovasc Surg. 2001;121(6): 14. Rosenits K, Keppler SJ, Vucikuja S, Aichele P. T cel s 1058–63.

acquire cell surface determinants of APC via in vivo

3. Coca S, Perez‐Piqueras J, Martinez D, Colmenarejo A,

trogocytosis during viral infections. Eur J Immunol.

Saez MA, Vallejo C, et al. The prognostic significance of

2010;40(12):3450–7.

intratumoral natural killer cel s in patients with colorectal 15. Pan M‐R, Hou M‐F, Chang H‐C, Hung W‐C.

carcinoma. Cancer. 1997;79(12):2320–8.

Cyclooxygenase‐2 up‐regulates CCR7 via EP2/EP4 receptor

4. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, signaling pathways to enhance lymphatic invasion of breast

Topalian SL, et al. Tumor localization of adoptively trans-

cancer cel s. J Biol Chem. 2008;283(17): 11155–63.

ferred indium‐111 labeled tumor infiltrating lymphocytes 16. Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, in patients with metastatic melanoma. J Clin Oncol.

Hirakawa K. Chemokine receptor CCR7 expression cor-

1989;7(2):250–61.

relates with lymph node metastasis in pancreatic cancer.

5. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS,

Oncology. 2008;74(1‐2):69–75.

Leitman SF, et al. Localization of 111indium‐labeled tumor 17. Günther K, Leier J, Henning G, Dimmler A, Weissbach R, infiltrating lymphocytes to tumor in patients receiving

Hohenberger W, et al. Prediction of lymph node metastasis

adoptive immunotherapy. Cancer. 1994;73(6):1731–7.

in colorectal carcinoma by expression of chemokine

6. Sapoznik S, Ortenberg R, Galore‐Haskel G, Kozlovski S,

receptor CCR7. Int J Cancer. 2005;116(5): 726–33.

Levy D, Avivi C, et al. CXCR1 as a novel target for direct-

18. Fang L, Lee VC, Cha E, Zhang H, Hwang ST. CCR7 reg-

ing reactive T cel s toward melanoma: implications for

ulates B16 murine melanoma cell tumorigenesis in skin.

adoptive cell transfer immunotherapy. Cancer Immunol

J Leukoc Biol. 2008;84(4):965–72.

Immunother. 2012;61(10):1833–47.

19. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ.

7. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M,

Evidence for NK cell subsets based on chemokine

et al. Transduction of tumor‐specific T cel s with CXCR2

receptor expression. J Immunol. 2006;177(11):7833–40.

chemokine receptor improves migration to tumor and 20. Somanchi SS, Somanchi A, Cooper LJN, Lee DA.

antitumor immune responses. Clin Cancer Res.

Engineering lymph node homing of ex vivo‐expanded

2010;16(22):5458–68.

human natural killer cel s via trogocytosis of the chemo-

8. Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K,

kine receptor CCR7. Blood. 2012;119(22):5164–72.

et al. Co‐introduced functional CCR2 potentiates in vivo 21. Novak L, Igoucheva O, Cho S, Alexeev V. Characterization anti‐lung cancer functionality mediated by T cel s double

of the CCL21‐mediated melanoma‐specific immune

gene‐modified to express WT1‐specific T‐cell receptor.

responses and in situ melanoma eradication. Mol Cancer

PLoS ONE. 2013;8(2):e56820.

Ther. 2007;6(6):1755–64.

9. Moon EK, Carpenito C, Sun J, Wang L‐CS, Kapoor V, 22. Igoucheva O, Grazzini M, Pidich A, Kemp DM, Larijani Predina J, et al. Expression of a functional CCR2 receptor

M, Farber M, et al. Immunotargeting and eradication of

enhances tumor localization and tumor eradication by

orthotopic melanoma using a chemokine‐enhanced

retargeted human T cel s expressing a mesothelin‐specific

DNA vaccine. Gene Ther. 2013;20(9):939–48.

142 Immunotherapy in Translational Cancer Research 23. Kanagawa N, Niwa M, Hatanaka Y, Tani Y, Nakagawa S, 27. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Fujita T, et al. CC‐chemokine ligand 17 gene therapy

Formenti SC, et al. Development of tumor‐infiltrating

induces tumor regression through augmentation of

lymphocytes in breast cancer after neoadjuvant

tumor‐infiltrating immune cel s in a murine model of

paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):

preexisting CT26 colon carcinoma. Int J Cancer.

3025–30.

2007;121(9):2013–22.

28. Hong M, Puaux A‐L, Huang C, Loumagne L, Tow C,

24. Li J, O’Malley M, Urban J, Sampath P, Guo ZS, Kalinski

Mackay C, et al. Chemotherapy induces intratumoral

P, et al. Chemokine expression from oncolytic vaccinia

expression of chemokines in cutaneous melanoma,

virus enhances vaccine therapies of cancer. Mol Ther.

favoring T‐cell infiltration and tumor control. Cancer

2011;19(4):650–7.

Res. 2011;71(22):6997–7009.

25. Pentcheva‐Hoang T, Simpson TR, Montalvo‐Ortiz W, 29. Tan MCB, Goedegebuure PS, Belt BA, Flaherty B, Allison JP. Cytotoxic T lymphocyte antigen‐4 blockade

Sankpal N, Gil anders WE, et al. Disruption of CCR5‐

enhances antitumor immunity by stimulating melanoma‐

dependent homing of regulatory T cel s inhibits tumor

specific T‐cell motility. Cancer Immunol Res. 2014;

growth in a murine model of pancreatic cancer.

2(10):970–80.

J Immunol. 2009;182(3):1746–55.

26. Nardin A, Wong W‐C, Tow C, Molina TJ, Tissier F, 30. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Audebourg A, et al. Dacarbazine promotes stromal

Col ado AX, Moughon DL, et al. Targeting distinct

remodeling and lymphocyte infiltration in cutaneous

tumor‐infiltrating myeloid cel s by inhibiting CSF‐1

melanoma lesions. J Invest Dermatol. 2011;131(9):

receptor: combating tumor evasion of antiangiogenic

1896–905.

therapy. Blood. 2010;115(7):1461–71.





CHAPTER 11

11 Repurposing of Drugs

for Immunotherapy

Jyothishmathi Swaminathan and Vidya Gopalakrishnan

Departments of Pediatrics and Molecular and Cel ular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Background

Adoptive cell therapy (ACT), in which the

patient’s own lymphocytes are collected from var­

The introduction of immunotherapy revolutionized ious tissues, expanded ex vivo and delivered back to the cancer treatment field with its potential for the same patient, has seen dramatic induction of intelligent fighting against a multitude of different responses [4, 5]. T cel s engineered to include antitypes of cancer. It takes advantage of immune cel s body function and T cell‐like recognition (CAR T

to target the tumor both by suppressing tumor cel s), have been investigated in clinical trials and growth potential as well as by enhancing the host appear to have promise in melanoma, sarcoma, immune response to combat tumor initiation and B‐cell malignancies, and neuroblastoma [6–11].

growth. The normal function of the immune system

Another aspect of immunotherapy with clinical

is to identify abnormal cel s that may cause cancer promise is checkpoint blockade. This refers to the and destroy them. However, tumor cel s evolve to brake normal y employed to prevent runaway hide their identity and remain unnoticed by immune responses but is hijacked by cancer cel s immune cel s, and this sustains their growth. in order to block their immune‐mediated cytolysis Misregulation of the immune system can also con­ [12]. Natural killer (NK) cel s have also been tribute to tumor growth by production of ineffec­ investigated, with modest clinical success, followtive T cel s or by generation of suppressive regulatory ing exciting results in preclinical studies [13].

T cel s (Tregs) generated by the tumors to neutralize

Thus, despite their potential, each of these

the host T cell defense mechanisms (M2 vs M1 etc.). approaches has limitations, but combination Traditional immunotherapy has yielded various therapy may circumvent these issues [14].

drugs that contribute to boosting the cel ’s immu­ Repurposing or repositioning of orphan drugs, or nity against tumors or to suppress the tumor’s clinical y applicable agents, with immunotherapy ability to mask the antigens and go incognito. could be a powerful tool to address this problem.

Several clinical trials currently underway have This would reduce the cost of and the need for employed drugs that target the immune system expensive testing that goes along with a new drug with positive outcomes, but improvement is needed identification.

to make this approach more successful [1–3].

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

143





144 Immunotherapy in Translational Cancer Research

This review will focus on known epigenetic DNA hypomethylation, leading to genomic instadrugs, such as DNA methylation inhibitors, bility, reactivation of transposons, and improper histone deacetylase inhibitors, nonsteroidal anti‐ imprinting [18, 19]. On the other hand, hyperinflammatory drugs, and chemotherapy/DNA methylation of DNA is seen in a more targeted intercalating drugs that have found new immune fashion at promoter regions of tumor suppressor modulating functions and their repurposing genes, leading to their aberrant silencing and towards more efficient cancer therapy.

to the promotion of cancer growth [18].

Methylation on DNA is brought about by three

DNMT inhibitors (Figure 11.1)

different DNA methyl transferases (DNMTs):

Historical y, accumulation of mutations in tumor DNMT1, DNMT3A, and DNMT3B, which bind suppressors and oncogenes was thought of as a to and methylate cytosine at CpG islands. The major cause of cancer initiation and progression DNMT inhibitors (DNMTIs), azacytidine (AZA)

[15]. Work from numerous groups has clearly and decitabine (DAC), are prodrugs, a ribonucleshown that changes in chromatin architecture oside and a deoxyribonucleoside, respectively, contribute to pathogenic states including cancer that incorporate as azacytosine‐guanine pairs

[16]. DNA methylation is one of the most studied into DNA and trap DNMTs to form covalently modifications in mammalian cel s. In normal linked adducts that cause cytotoxicity. They also cel s DNA methylation, in coordination with elicit a DNA damage response to promote degraother events such as histone modifications, is dation of DNMTs and reactivate gene expression necessary for proper regulation of gene expres­ [20]. AZA and DAC have been successful y used sion [17]. Carcinogenesis is associated with global in clinical trials for myelodysplastic syndrome, Dendritic cell

CD8 T cell

Antigen presentation

Immune response

CD4 help

NK cell

NKGD2 receptor for

IFNγ and TNFα

Stress ligands

CD4 T cell

and IL-17

IFNγ and TNFα

IFNγ and TNFα

and IL-17

DNMTI

HDACI

Activation of NKs

MHC specificCTL response

DC maturation

MHC, MIC A,B and

TReg cell

cytokines

CTAs in the tumor

FOXP3 and

Tumor cells

Dendritic cell

regulatory potential

Increased recognition

of the tumor cell by NKs

MHC, CTAs

MIC A/B (stress ligands)

Figure 11.1 Pictorial representation of DNMTIs’ and

enhance cytotoxic effects of T cells and NK cells towards

HDACIs’ influence on immune cells and the tumor cell.

the tumor. HDACIs also efficiently downregulate cytokine

DNMTIs and HDACIs increase MHC and antigen presenta-

release and decrease FOXP3 levels in Tregs.

tion in the tumor, making it more visible to T cells, and

CHAPTER 11 Repurposing of Drugs for Immunotherapy 145

acute myeloid leukemia, and chronic myelo­ cel s and activated CD8 cel s [19, 30]. DAC alone monocytic leukemia [21].

increased the expression of MICB in embryonic

AZA and DAC have been largely evaluated in kidney cel s (HEK293T cel s), whereas in combthe context of reactivating tumor suppressor genes ination with the histone deacetylase inhibitor in cancer cel s. However, recent reports have sug­ valproic acid, it upregulated MICA levels in gested that these drugs may have potential for myeloma cel s [19, 30, 31].

combination with immunotherapy because of their

Other studies have identified AZA‐ and DAC‐

ability to modulate antigen expression on tumors dependent effects on immune cell activity, ranging and their presentation by major histocompatibility from increased cytokine production by effector complex class I (MHC‐I), which can impact their immune cel s to enhanced immune infiltration of recognition by immune cel s [22–24]. Of particular tumors and regulatory immune cel s such as Tregs interest to this review is a class of molecules called and myeloid‐derived suppressive cel s (MDSCs) cancer testis antigens, which are uniquely expressed [22–24]. Cytokines such as interferon gamma in neoplastic cel s and increase the visibility of (IFNγ), tumor necrosis factor alpha (TNFα), and tumor cel s to cytotoxic T lymphocytes (CTLs) interleukin‐2 (IL‐2) regulate cytotoxic CD8 T cell

[25]. Examples of cancer testis antigens include activity. The levels of these cytokines were elevated NY‐ESO1, nuclear RNA export factor (NXF2), following AZA or DAC treatment and were associsynovial sarcoma X chromosome (SSX‐2), prefer­ ated with superior cytolysis of ovarian and ential y expressed antigen in melanoma (PRAME), melanoma cel s [23, 24, 32, 33]. Interestingly, this and melanoma‐associated antigens (MAGE 1, 2, 3, effect was specific to naïve CD8 T cel s [34].

and 4) that are downregulated in cancer cel s. AZA Production of IFNγ by T cel s is tightly controlled has shown ability to upregulate expression of by DNA methylation of CpG islands at its pro­

PRAME and SSX‐2 and improve the lytic activity moter, and DNA demethylation of the gene and its of CTLs against melanoma and myeloma cel s in re‐expression were shown to precede the activation vitro. This was also observed in melanoma and of CD8 T cel s. In mouse models of ovarian cancer, myeloma patients treated with AZA [26]. In mela­ DAC treatment was associated with increased noma cel s AZA not only increased MHC‐I IFNγ and TNFα production by NK cel s and either expression but also facilitated antigen presentation IFNγ or TNFα by CD8 T cel s resulting in extended by MHCs to T cel s by activating intercel ular adhe­ survival in mice bearing ovarian cancer [24].

sion molecule 1 (ICAM‐1) expression. ICAM‐1 is Expression of the proinflammatory cytokine interimportant for cell‐cell interaction and transmigra­ leukin‐17 (IL‐17) is also regulated by DNA tion of monocytes for tumor infiltration. The methylation, and consistent with this, an increase increased expression of ICAM‐1 was also seen in in its expression was seen in T‐helper (Th) cel s renal cell carcinoma lines. [27, 28]. Subsequently, following treatment of peripheral blood mononuother studies in chronic lymphocytic leukemia and clear cel s with AZA [35]. In patients with acute myeloid leukemia showed similar effects of myelodysplastic syndrome (MDS), upregulated AZA on MHC‐I expression and cancer testis expression of IL‐17 was noted upon treatment of antigen expression. Specifical y, AZA treatment of CD4 T cel s with AZA in vitro [36]. DAC also chronic lymphocytic leukemia cell lines and caused an increase in polarization towards a more patient‐derived cel s caused de novo expression of Th1 phenotype and increased lytic activity, which NY‐ESO1, NXF2, and SSX‐2, while elevated con­ correlated with increased demethylation of IL‐17

stitutive expression of MAGE‐1, ‐2, and ‐4 were and enhanced IL‐17 production [37]. In a separate observed. In acute myeloid leukemia cell lines, study, AZA treatment of CD4 T cel s isolated from expression of SSX‐2 and PRAME were elevated. patients with MDS revealed similar increase in

[26, 29]. DNMTIs are also able to influence tumor polarization towards the Th1 phenotype, which recognition by immune cel s. MICA and MICB are correlated with improved therapeutic response.

stress response ligands expressed on tumor cel s, [38]. DAC and AZA‐mediated increase in IFNγ

which are recognized and bound by NK group production resulted in increased NK cytolytic cel s member D (NKGD2) receptor present on NK activity in vitro [39]. In an ovarian cancer mouse





146 Immunotherapy in Translational Cancer Research model, Wang et al. demonstrated that DAC induced Dacogen alone with or without chemotherapy [43].

higher numbers of infiltrating NK cel s and CD8 These findings suggest that low‐dose DAC might T cells [24]. The expression of killer immuno­ have an effect on cytokine‐induced killer cel s. In a globulin‐like receptors (KIRs) is regulated by DNA phase I trial of pediatric patients with relapsed neumethylation, and its expression on NK cel s roblastoma and sarcoma, the combination of is necessary for tumor recognition. KIR expression Dacogen with DC peptide vaccine against the canis downregulated in cancers and DAC has cer testis antigens MAGE‐A1, MAGE‐A3, and shown ability to increase KIR expression, thereby NY‐ESO1 was evaluated [44]. Peripheral blood was improving recognition of tumor cel s by NK collected pre‐ and posttreatment and the number cel s. [40].

of activated T cel s to peptide ratio was measured

Dampening of immune responses requires the by flow cytometry. Two of the 10 patients showed activity of Tregs and MDSCs, which suppress an increase in CD4 and CD8 recruitment/response.

antigen presentation and inhibit cytokine produc­ Interestingly, 1 of these patients remained disease tion. Blocking the unregulated activity of these free for two years post therapy, although the other cel s is being explored as an alternate approach to relapsed within 10 months [44]. A growing body of improve immunotherapy. In a preclinical study of data emerging from laboratory studies suggests a ovarian cancer and myeloma, AZA and DAC tremendous potential for the combined use of epidecreased proliferation of MDSCs, induced their genetic modulators with immunotherapy, and differentiation, and final y inhibited their ability to several clinical trials are underway in the United infiltrate tumors [24, 41, 42]. These studies provide States, Canada, and Europe to examine if epigepreclinical evidence in support of DNMTIs for netic drugs can enhance the efficacy of checkpoint combination with immunotherapy.

inhibitors in solid tumors [45]. However, the

DAC and AZA, marketed under the trade names downside to combining two drugs is that they each Vidaza (Celgene, 2004‐FDA approved) and come with their own side effects and in combination Dacogen (Eisai), respectively, are currently may result in serious side effects in patients. [46].

approved for the treatment of patients with all sub­ Epigenetic drugs like DNMTIs general y show an types of MDS. In one of the first clinical studies to increase in white blood cel s, but immunotherapy explore the use of these agents in an immuno­ drugs blocking checkpoint inhibitors, like ipilimmodulatory capacity, patients with MDS were umab, overstimulate the immune system and administered Vidaza subcutaneously at a dose of trigger an auto immune response that targets 75 mg/m2/day for 7 days every 28 days. Peripheral cancer and normal cel s [45].

blood from patients was collected and percentages

and absolute numbers of Tregs were calculated. HDAC inhibitors (Figure 11.1

Vidaza administration correlated with a decline in and Table 11.1) proliferation of Tregs associated with downregula­ The most intensely studied epigenetic modification tion of FOXP3 expression and an increase in IL‐17 is DNA methylation. However, the diversity of expression. The latter also indicated a shift away modifications that occur on histones is signififrom the classic Treg phenotype and therefore a cantly larger and can increase or decrease the possible relief from immunosuppression [38]. In accessibility of DNA to various transcription a separate phase I/II trial, the use of low‐dose complexes by changing chromatin architecture.

Dacogen, either alone or mixed with a dose of Histone acetylation is an important modification approved chemotherapy drugs (R‐COP, CHOP, catalyzed by a class of enzymes called histone acetyl COP or R‐GEMOX) or low dose Dacogen followed transferases, leading to chromatin decompaction by infusion of cytokine‐induced killer cel s was and upregulation of transcription [47]. The activity tested in patients with 14 different malignancies. of histone acetyl transferases is countered by his[43]. A significant improvement in progression‐ tone deacetylases (HDACs), which remove acetyl free survival was noted in patients receiving cel ular groups from histones and cause chromatin comtherapy in combination with low‐dose Dacogen paction and repression of gene expression [48].

compared to the cohort receiving low‐dose HDACs are a family of zinc‐containing enzymes

Table 11.1 Recent clinical trials with histone deacetylase (HDAC) inhibitors.

HDAC Inhibitor

Target

Clinical Trial

Cancer Type

Clinical Trial Number

Panobinostat (LBH‐589)

Pan HDACs

Phase II

Cutaneous T cell lymphoma

Duvic et al . (2013)

NCT00425555

Belinostat (PXD101)

HDAC1, HDAC2, HDAC6

Phase II

Thymoma

Giaccone G et al .

(2011)

NCT00589290

Entinostat (MS275)

HDAC1, HDAC2, HDAC3

Phase II

Melanoma

NCT02437136

Mocetinostat (MGCD01030)

HDAC1, HDAC2, HDAC3

Phase II

B‐cell malignancies

NCT02282358

Givinostat (ITF2357)

HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC9

Phase II

Myeloproliferative neoplasms

NCT00928707

Pracinostat (SB939)

HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC9, HDAc6

Phase II

Prostate cancer

NCT01075308

Quisinostat (JNJ‐26481585)

HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC9

Phase II

Cutaneous T cell lymphoma

NCT01486277

Abexinostat (PCI‐24781)

HDAC1, HDAC2, HDAC3, HDAC6, HDAC10

Phase II

B cell lymphoma

NCT00724984

148 Immunotherapy in Translational Cancer Research that can be classified into class I (HDACs 1, 2, 3, below, have provided interesting insights into and 8), class IIA (HDACs 4, 5, 7, and 9), class IIB HDACI‐mediated effects on antigen presentation (HDACs 6 and 10), class III (Sirtuins), and class IV by tumor cel s and their recognition by immune (HDAC11) [49, 50]. HDACs are part of various cel­ cel s, differentiation of immune cel s, and regulalular repressor complexes and a large portfolio tion of their activity (Table 11.1). These reports of their activity influences histone acetylation. have set the stage for testing HDACIs in However, their ability to regulate acetylation of var­ combination with immunotherapy in controlled ious nonhistone proteins in the nuclear and cel ular clinical trial settings.

compartment cannot be ignored.

Gp100, a glycoprotein, is a tumor‐associated

Drugs that block the activity of HDACs first antigen whose expression is elevated in melanomas gained prominence in cancer therapeutics because [60]. It promotes improved tumor cell recognition of their ability to induce differentiation of cancer by CTLs in the context of MHC‐I [61] and has been cel s. Subsequent preclinical studies revealed their tested as a peptide vaccine formulation in patients enormous potential for modulation of cel ular pro­ [62]. Unfortunately, clinical response was not cess such as transcription, DNA replication, cel ular robust for several reasons, including human leukodifferentiation, apoptosis, and DNA repair, which cyte antigen restriction and gp100 peptide stability are frequently deregulated in various pathological [63]. However, gp100 levels could be upregulated conditions including cancers, inflammation, in human and murine melanoma cel s by subcytoimmunity, and neurological disorders [51]. As toxic doses of depsipeptide [64] in vivo, using shown in Table 11.1, HDAC inhibitors (HDACIs) depsipeptide‐enhanced cytolysis by melanoma-vary in their specificity and range from pan‐ antigen‐specific CTLs, suggesting that this HDACI inhibitors (panobinostat (LBH‐589), vorinostat/ may have potential for synergy with T cell therapy suberanilohydroxamic acid (SAHA), sodium buty­ of melanoma [64]. Tumor cel s are able to escape rate, valproic acid (VPA), and trichostatin‐A) to immune responses mediated by CTLs by downothers that are more specific to class I (depsipep­ regulating MHC class‐I molecules [65]. Treatment tide, entinostat), class II (tubacin), or class IV of MHC‐class‐I deficient murine lung epithelial (mocetinostat and quisinostat) HDACs [52]. cancers with tumor‐specific antigen (TSA), reacti­

Sirtuins are an exception because they have a vated its expression and cytolysis by CTLs [66].

catalytic mechanism that is distinct from other Mechanistic studies linked MHC class‐I re‐expression HDAC classes and hence are not targeted by drugs and upregulated expression of a component of the that block the activity of the remaining family antigen‐processing machinery called transporter members. To date, three HDAC inhibitors, vorino­ associated with antigen processing (TAP) to stat (Zolinza: Merck), romidepsin (Istodax: improved antigen presentation [66]. The effect was Celgene) and belinostat (Beleodaq: Spectrum seen in both TAP‐positive and ‐negative tumors, Pharmaceuticals), have been approved for clinical suggesting that epigenetic inactivation of TAP conapplication, all for the treatment of refractory cuta­ tributed to inefficient antigen presentation by neous and peripheral T cell lymphomas [53–56]. In MHC I [66, 67]. These effects were recapitulated in addition, VPA (FDA approved for neurological vivo in immunocompetent mice but not in animals applications), butyrate, panobinostat, givinostat lacking B and T cel s, implicating one or both of (ITF2357), mocetinostat (MGCD01030), belino­ these cel s in preventing tumor growth [67]. A stat (PXD101), pracinostat (SB939), and entinostat study assessing the use of panobinostat in mouse (MS275) have been evaluated in patients, with var­ models of melanoma similarly concluded that iable success [57–59].

HDACI‐dependent upregulated expression of

Despite a series of studies that have underscored melanoma‐specific antigens, MHC class‐I molethe importance of HDACs in the development of cules, as well as costimulatory molecules (CD40

the immune system, the possibility of targeting and CD86) and proinflammatory cytokines (IL‐2

HDACs for immune modulation or enhancing and IFNγ) contributed to improved tumor recogimmunotherapy has only recently been explored nition and antitumor activity of CTLs in mice

[49, 51]. Several preclinical studies, described [68]. A separate body of work demonstrated that

CHAPTER 11 Repurposing of Drugs for Immunotherapy 149

hyperacetylation of histones occurred at the IFNγ expression. In addition, TSA also increased the and IL‐2 loci in memory CD8 T cel s and required levels of immunosuppressive cytotoxic T lympho­

CD4 T cell help for the enhanced responsiveness cyte antigen 4 (CTLA4) and glucocorticoid induced

[69, 70]. Use of panobinostat following bone tumor necrosis factor family receptor (GITR), molmarrow transfer in a mouse model of graft‐versus‐ ecules with known immunosuppressive functions host disease also uncovered HDACI‐mediated [82]. Consistent with this, both TSA‐ and VPA-improvement in cross talk between CD4 and CD8 enhanced Treg‐dependent immunosuppression in T cel s [71]. Superior T cell infiltration into tumors a mouse model of dextran‐sodium sulfate induced is known to strongly correlate with improved colitis [81]. These results were recapitulated with patient survival [72–74]. Indeed, the HDACI entinostat in a rat model of autoimmune prostatitis romidepsin enhanced the efficacy of checkpoint [83, 84]. Engagement of the programmed cell death blockade inhibitors in mouse models of lung can­ protein 1 (PD‐1) ligand and PD‐1 axis promotes cers by upregulating the expression of chemokines tolerance, and therapies targeting this interaction (CXCL5, CXCL9, CXCL10) in tumor cel s and have been successful y used for the treatment of tumor macrophages. This was associated with metastatic melanoma and non‐small‐cell lung cansignificantly elevated T cell recruitment and infil­ cer [85, 86]. Combining panobinostat with PD‐1

tration into tumors [75].

blockade was more successful than either agent

While the above studies strongly support the use alone in slowing down melanoma progression and of HDACIs to augment immunotherapy, a growing increasing survival in mice. Mechanistical y, body of evidence also suggests that these agents HDACI treatment promoted acetylation of hisdampen immune response and therefore may be tones at the PD‐L1 gene and upregulated its better suited for treating inflammatory diseases expression [68]. In summary, there is conflicting such as rheumatoid arthritis and colitis [76, 77]. An information in the literature regarding the utility of investigation comparing the pro‐ and anti‐ HDACIs in enhancing immunotherapy. HDAC6 is inflammatory properties of vorinostat and BML281 a class IIB histone deacetylase and in complex with in a rat model of col agen‐induced arthritis STAT3 and HDAC11 acts as a regulator of anti-revealed that these drugs variably modulated lipo­ inflammatory cytokine IL‐10 [13]. Interestingly, polysaccharide‐induced cytokine release (IL12p40, HDAC11 acts as an inhibitor of this pathway and IL6, TNF, IL1β) from macrophages, with lower keeps HDAC6 activity in check [87]. In the absence doses causing an anti‐inflammatory response and of HDAC11, HDAC6 induces the tolerogenic higher doses generating a proinflammatory reac­ STAT‐3/IL‐10 pathway activity in antigen‐presenttion and exacerbating disease pathology [78]. ing cel s. Genetic or pharmacological ablation of These observations indicate that long‐term safety HDAC6 in a macrophage cell line activated of vorinostat and BML281 use for cancer treatment antigen‐presenting cel s and naïve CD4 T cel s conin patients may require a careful dose‐response currently [13]. In a follow‐up study using a examination. Expression of the proinflammatory melanoma model, HDAC6 inhibitors, tubastatin-cyclooxygenase‐2 (COX‐2) could be suppressed by A, and nexturastat‐A directly decreased cell TSA treatment in an interleukin beta (ILβ1)‐ proliferation and also enhanced MHC class I predependent manner in endometrial stromal cel s sentation of melanoma‐specific antigens like,

[79]. Peroxisome proliferator‐activated receptor‐γ gp100, MART‐1, tyrosinase related proteins, (PPAR‐γ) also promotes the release of proinflam­ TYRP‐1, and TYRP‐2. In other studies, HDAC6

matory cytokines (RANTES‐regulated upon inhibition downregulated the expression of PD‐L1, activation normal T cell expressed and secreted); as well as other checkpoint molecules such as PD-however, its upregulation by TSA treatment would L2, B7‐H4 and TRAIL‐R1 [88].

argue for its application in modulating cancer

Clarification of the roles of HDACs in tumors

immunotherapy [80]. TSA has also been shown to will allow a more accurate determination of increase the thymic production of Foxp3+ CD4 HDACIs as anticancer drugs. HDACs may have Treg cel s in mice [81]. TSA promoted Foxp3 pro­ opposing roles at different stages of tumor progrestein acetylation leading to repression of IL‐2 sion and also in the subpopulations of cancer stem





150 Immunotherapy in Translational Cancer Research

cel s. While HDACIs alone have shown anticancer strated a reduction in tumor incidence in response activity, when HDACIs are given in combination to use of NSAIDs, although the underlying mechawith other drugs there may be enhanced tumori­ nisms are not well understood. [89–91]. NSAIDs cidal effects. However, the benefits of HDACIs will are pharmacological y similar to antipyretics and need to be weighed against their potential lack of analgesics, and their application in suppressing specificity, which may sometimes contribute to inflammation stems mainly from their ability to their cytotoxicity. In summary, while HDACIs may decrease production of PGs by inhibiting the augment or dampen the immune response, there is activity of cyclooxygenases COX‐1 and COX‐2 [92, a need to develop more potent, narrow‐spectrum 93]. COX‐1 is constitutively expressed in most tis­

HDACIs that result in superior cancer cell death in sues, whereas COX‐2 expression is rapidly upregutandem with fewer negative cytotoxic side effects.

lated during inflammation and cancer [91, 94].

Cyclooxygenase‐mediated increase in PGs, specifi­

Nonsteroidal anti‐inflammatory drugs

cal y PGE2, is believed to act directly on tumor and

(NSAIDs) (Figure 11.2, Table 11.2)

stromal cel s to promote tumor progression. A

Chronic inflammation is a hallmark of gastric, recent seminal study provided the first evidence esophageal, pancreatic, liver, and colorectal cancers that COX enzymes and PGE2 promote tumor and is characterized by elevation of proinflamma­ growth by facilitating immune evasion [95]. This tory cytokines, chemokines, and prostaglandins process is frequently characterized by a shift from (PGs), accompanied by deregulated immune cell Th1 to Th2 immune response, aberrant antigen-infiltration. Support for a role for inflammation in presenting cell migration and activity, impaired cancers has mostly come from studies that demon­ cytotoxic CD8 T cel s and NK cell activity, and NSAIDs

NSAIDs

Indomethacin and

diclofenac

Reverse tumor mediated immune suppression

Celecoxib and refecoxib

-Indomethacin and Celecoxib

CD4 T cell

CD8 T cell

PGE2/IDO induce

FOXP3+ Tregs

Tumor cells

TReg cell

T effector cells control

tumor growth

FOXP3+ Tregs

Induce tumor cell growth

NK cells control tumor

TAM TAM

growth through cytotoxicity

TAM TAM

TAM

Inhibit pro-tumor effects -

NK cell

NSAIDs

Indomethacin and Celecoxib

Enhance anti-tumor effects -

Refecoxib and Indomethacin

Enhance NK cell mediated cytotoxicity

Indomethacin and Celecoxib

Figure 11.2 Schematic of NSAIDs’ effects on variety of They inhibit protumor effects mediated by tumor‐asso-immune modulatory processes to aid in cancer

ciated macrophages. NSAIDs increase T cell prolifera-

therapy. NSAIDS act by reversing tumor‐mediated

tion and enhance NK cells’ mediated cytotoxicity to

immune suppression and by repressing FOXP3+ Tregs.

the tumor.

Table 11.2 Clinical trials evaluating epigenetic drugs, NSAIDs, and chemotherapy with immunotherapy [141] .

Epigenetic Modulator/NSAID/

Clinical Trial ID

Phase

Cancer

Chemotherapy

Immune Agent

NCT02453620

I

Breast cancer

Entinostat

Nivolumab

Ipilimumab

NCT02032810

I

Melanoma

Panobinostat

Ipilimumab

NCT01928576

II

NSCLC

Entinostat and azacytidine

Nivolumab

NCT02437136

I/II

NSCLC and melanoma

Entinostat

Pembrolizumab

NCT02538510

I/II

HNSCC and SGC

Vorinostat

Pembrolizumab

NCT02638090

I/II

Stage IV NSCLC

Vorinostat

Pembrolizumab

NCT02619253

I/II

Advanced renal or urothelial carcinoma

Vorinostat

Pembrolizumab

NCT02395627

II

Hormone therapy resistant breast cancer

Vorinostat

Pembrolizumab

NCT02530463

II

MDS

Azacytidine

Nivolumab and/or

ipilimumab

NCT02399917

II

AML

Azacytidine

Lirilumab

NCT02599649

II

MDS

Azacytidine

Lirilumab or nivolumab

NCT02397720

II

AML

Azacytidine

Nivolumab

NCT02260440

II

Metastatic CRC

Azacytidine

Pembrolizumab

NCT02546986

II

Advanced/metastatic NSCLC

Oral azacytidine

Pembrolizumab

NCT02512172

I

MSS advanced CRC

Romidepsin and/or azacytidine

Pembrolizumab

NCT02508870

I

MDS

Azacytidine

Atezolizumab

NCT02151448

I/II

Pancreatic cancer, peritoneal mesothelioma,

Celecoxib

DC vaccine, interferon alpha‐2b,rintatolimod

peritoneal carcinomatosis



Note: NSCLC = non‐small cell lung cancer; HNSCC = head and neck squamous cell carcinoma; SGC = salivary gland cancer; AML = acute myeloid leukemia; CRC = colorectal cancer; MSS = microsatellite stable; MDS = myelodysplastic syndrome; DC = dendritic cell.

152 Immunotherapy in Translational Cancer Research augmented activity of immunosuppressive cel s allogeneic/autologous tumors but had an inhibisuch as MDSCs and Tregs. In a study by Zelenay tory effect on the lytic activity of macrophages et al., it was observed that PGE2 secretion from obtained from patients with head and neck cancers mouse melanoma tumor cel s promoted secretion [103, 104]. A number of more recent studies with of chemokines CXCL1 and IL6, and granulocyte‐ celecoxib and/or indomethacin identified enhancecolony‐stimulating factor by myeloid cel s [96]. ment of NK cell activity against breast cancer, Polarization of macrophages from antitumor M1 hepatoma, and gastric cancers. [105–109].

(IL‐12, TNFα, and MHCII positive) to the protu­

Information regarding underlying mechanisms

mor M2 phenotype (IL‐10, IL‐4, and IL‐13 was obtained from two separate clinical studies of positive) was also noted [95]. Genetic data from patients with head and neck cancer, where it was mouse models of breast cancer, colorectal cancer, determined that rofecoxib increased the expression and melanoma have also implicated PGE2 in pro­ of ICAM1 on monocytes, which resulted in their moting tumor growth by interfering with the improved migration and infiltration [110, 111].

differentiation and maturation of myeloid progeni­ Similarly, celecoxib also promoted an elevation in tors/monocytes into dendritic cel s, and instead ICAM1 expression on lung cancer cel s, which led promoting their differentiation into MDSCs, which to their augmented lysis by lymphokine‐activated are immunosuppressive [24, 97, 98]. Final y, killer cel s [112]. TNFα secretion by monocytes MDCSs can suppress effector T cell activation, pro­ and lytic activity against tumors was significantly liferation, migration, and persistence; block NK improved following irradiation or lipopolysacchacell activity; and support Treg activation and ride stimulation of pelvic cancer patients, indicating expansion. Despite the promise held by checkpoint that the inclusion of COX inhibitors during radiainhibitors, the fact remains that very few patients tion therapy may enhance antitumor response with colorectal, breast, pancreatic, and gastric can­ [113, 114].

cer, and less than 30% of patients with melanoma,

In other reports, effects on immune cell growth

renal cell carcinoma, or non‐small‐cell lung cancer were observed following treatment with NSAIDs.

have shown response to these agents [99, 100]. It For example, sulindac treatment offered a has been suggested that tumor‐infiltrating MDSCs significant survival advantage in mouse models of and their effect on effector T cel s, NK cel s, and breast cancer [115]. The effect was mediated by Tregs may contribute to this poor responsiveness, CD8 T cel s and also correlated with a reduction in which has been supported by the enhanced efficacy the number of M2 macrophages and proinflammaof anti‐PD1 therapies against mouse models of tory cytokines like TNFα, IL1β, and IL6, as well as rhabdomyosarcoma when combined with blockade a reduction in tumor vasculature [115].

of MDSC activity [89].

In clinical studies, indomethacin was shown to

Since PGs ultimately influence inflammation‐ promote a substantial increase in T cell proliferamediated immune processes, it is not unreasonable tion in lung cancer patients [116]. Celecoxib, to expect that NSAID‐mediated inhibition of rofecoxib, diclofenac, nimesulide, and indometh­

PG production will have immunomodulatory acin either alone or in combination with other properties. NSAIDs, including nonselective vaccines improved survival in patients with (indomethacin) and selective COX‐2 inhibitors cervical, colorectal, breast, and gastrointestinal (celecoxib, aspirin, rofecoxib and diclofenac), cancers, which was associated with a significant inhibit PGE2 secretion [101]. In probably one of increase in tumor infiltrating T cel s [117–120].

the earliest studies to test this hypothesis, the

Other nonselective COX inhibitors such as

combination of indomethacin with the immuno­ aspirin and the selective COX‐2 inhibitor celecoxib suppressive drug OK‐432 reduced PGE2 synthesis have also shown ability to synergize with anti‐PD1

and increased antitumor activity of monocytes and therapy in mouse models of melanoma and colomacrophages against uterine and cervical cancer rectal cancer [95].

cel s [102]. Subsequently, indomethacin was shown

In conclusion, NSAIDs are the most frequently

to improve the lytic activity of macrophages iso­ used medicines in the world and have been shown lated from patients with breast cancer against to have anticancer activities specifical y regarding





CHAPTER 11 Repurposing of Drugs for Immunotherapy 153

melanoma, renal cell carcinoma, non‐small‐cell studied for its effects at metronomic doses in anti-lung cancer, colorectal, colon, breast, and pancreatic angiogenesis and immune modulatory functions.

cancers; however, historical y their efficacy is [121]. Although the effect of chemotherapy on decreased when compared to current chemo­ tumor vasculature has been described, cytotoxicity therapy agents. The anticancer activity of NSAIDS to normal tissue has impeded its use as an antianmay be improved by derivatization, but the giogenic agent. However, several studies described subsequent different formulations will need to be below have attributed immune modulatory studied in both preclinical and clinical trials before capacity at low doses, which is more practical for they can become part of standard immunotherapy. clinical application.

In a study by Lutsiak et al., low‐dose CTX

Repurposing chemotherapy agents

administration reduced Tregs and MDSCs found

towards immunomodulatory

in abundance in the tumor microenvironment and

functions

to a smaller extent in peripheral blood. [119, 122].

Chemotherapeutic drugs, while cytotoxic to tumor In multiple myeloma, low‐dose CTX administration cel s, also suffer from the disadvantage that they at 45‐day intervals prolonged survival and reduced cause damage to normal cel s and tissues. Recent recurrence, which was associated with diminished interest in repurposing drugs for combination Treg cell renewal [123].

therapy has generated renewed interest in testing

Using CTX in combination with doxorubicin

these agents at lower doses. Here, we review the decreased tumor growth in colon cancer cel s and application of some chemotherapeutic agents as correlated with an elevation of IFN‐γ‐producing immune modulators when used at metronomic cel s and suppression of FOXP3 and TGF β expresdoses.

sion in tumor cel s [124]. A separate study showed

that single administration of low‐dose CTX in

Cyclophosphamide (CTX) (Figure 11.3)

tumor‐bearing mice significantly increased DC‐

CTX is an alkylating agent that is converted into its mediated T cell proliferation, which al udes to active metabolite, phosphoramide mustard, in the increased antigen‐presenting function of the DCs liver. This derivative inhibits DNA replication by [125]. Low‐dose CTX has also been tested in forming interstrand and intrastrand DNA cross­ combination with DC‐based immune therapy, links. Currently it is the best‐known drug to be which led to a synergistic increase in survival of Dendritic cell

CD4 T cell

CD8 T cell

Low dose CTX and PTX

Tumor cells

TReg cell

Myeloid derived

Suppressive cell

Figure 11.3 Effects of low‐dose chemotherapy in cancer microenvironment. Metronomic doses of CTX and PTX also

treatment.Low doses of CTX and PTX repress the

enhance cytotoxicity to the tumor by upregulating

inhibitory molecules such as Tregs and MDSC of the tumor

DC‐ and T‐cell‐mediated killing of the tumor cells.





154 Immunotherapy in Translational Cancer Research tumor‐bearing mice compared to either treatment and some solid tumors. However, emerging data alone [126]. In addition, restoration of myelopoie­ suggest that combinatorial treatment might have sis and mobilization of early DC progenitors to the to be employed for it to be more effective on a tumor site, their differentiation into functional number of other cancers.

DCs, increased presence of antigen‐presenting

The use of HDACIs as a potential adjuvant to

cel s, and recruitment of T cel s were also observed. T cell therapies has been described in a few pre[127, 128].

clinical studies. Romidepsin treatment and

subsequent adoptive transfer of gp100 tumor‐

Paclitaxel (PTX)

associated‐antigen‐specific T cells enhanced

PTX is a mitotic inhibitor that causes cell cycle T‐cell‐mediated killing of B16/F10 murine melaarrest by stabilizing tubulin in microtubules. noma cells and decreased tumor growth Similar to CTX, combining low‐dose PTX with compared to either T cell transfer or Romidepsin DC vaccine was effective in inhibiting tumor alone. [64]. Similarly, panobinostat, when used growth and increasing tumor‐infiltrating CD4+ with gp100‐specific T cell immunotherapy, and CD8+ T cell responses [129]. At these low decreased tumor burden and created a proindoses, toxicity to bone marrow cel s was avoided; flammatory environment in vivo in a B16 murine in addition, a decrease in DC apoptosis as well as melanoma model [136].

a direct effect on DC maturation and function

HDACIs have also been used to improve CAR

were noted [127]. In murine and breast lung can­ response of genetical y modified T cel s.

cer models, the combination promoted improved Pretreatment with VPA enhanced the adoptive survival, which correlated with increased IFN‐γ transfer of T cel s in ovarian cancer cel s and selecsecretion. [130, 131].

tively sensitized cancer cel s to T cel s by inducing

Other drugs such as 5‐FU, gemcitabine, and expression of the recognition ligand, NKG2D, on oxaliplatin are also being evaluated and have been their surface [137]. Although combination therapy found to selectively reduce MDSCs and enhance with HDACI seems promising, concerns regarding antitumor resistance by stimulating CD8+ and NK autoimmune toxicity and long‐term effects exist cel s, [132, 133]. Thus, the choice of drugs, the and need to be better understood prior to clinical sequence of drugs being administered, and the type introduction.

of cancer being treated should all be taken into

Preconditioning host cel s with chemotherapy‐

account while deciding on combinations with or radiation‐induced lymphodepletion may immunotherapy [134].

improve survival and functionality of transferred T cel s in adoptive T cell transfer [138].

Adoptive T cell therapy

Mechanisms include depletion of suppressive

Adoptive T cell therapy typically involves ex vivo T cel s (Tregs) or increased production proliferaexpansion of autologous T cells that have been tive cytokine production [139]. The alkylating genetically modified to identify and attack agent cyclophosphamide has been used to pretumors more effectively. The two most widely condition patients for adoptive T cell therapy.

used techniques used in clinical testing involve However, Ding et al. showed that in mice with activating the blood‐derived T cells with tumor lymphoma, while preconditioning with CTX

antigen, either transducing with high‐affinity caused a robust increase in antitumor response, it T cell receptor or transducing with chimeric also increased immune suppressive myeloid antigen receptor (CAR) that has been artificially monocytic cel s [140]. These results indicate that constructed to express the tumor antigen binding a careful longitudinal evaluation of changes in domain of an antibody fused to the T cell sig­ immune cell population following chemotherapy naling domain. These engineered T cells possess administration and prior to immunotherapy superior recognition of cancer antigen with high needs to be performed. The outcomes may also avidity [135]. Initial testing with adoptive T cells vary depending on the cancer type and the chehas yielded very promising results in leukemia motherapy agent under investigation.





CHAPTER 11 Repurposing of Drugs for Immunotherapy 155

References

16. Baylin SB, Jones PA. A decade of exploring the cancer

epigenome: biological and translational implications.

1. Mellman I, Coukos G, Dranoff G. Cancer immunother­

Nature Reviews Cancer. 2011;11(10):726–34.

apy comes of age. Nature. 2011;480(7378):480–9.

17. Kulis M, Esteller M. DNA methylation and cancer.

2. Sharma P, Allison JP. Immune checkpoint targeting in

Advances in Genetics. 2010;70:27–56.

cancer therapy: toward combination strategies with 18. Esteller M. Epigenetics in cancer. New England Journal curative potential. Cel . 2015;161(2):205–14.

of Medicine. 2008;358(11):1148–59.

3. Topalian SL, Weiner GJ, Pardoll DM. Cancer immu19. Rodriguez‐Paredes M, Esteller M. Cancer epigenetics notherapy comes of age. J Clin Oncol. 2011;29(36):

reaches mainstream oncology. Nature Medicine.

4828–36.

2011;17(3):330–9.

4. Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, 20. Stresemann C, Lyko F. Modes of action of the DNA Exley MA, Stauss H, et al. Adoptive T cell therapy for

methyltransferase inhibitors azacytidine and decitabine.

cancer in the United kingdom: a review of activity for the

International Journal of Cancer. 2008;123(1):8–13.

British Society of Gene and Cell Therapy annual meeting 21. Derissen EJ, Beijnen JH, Schellens JH. Concise drug 2015. Human Gene Therapy. 2015;26(5):276–85.

review: azacitidine and decitabine. The Oncologist.

5. Hinrichs CS, Rosenberg SA. Exploiting the curative

2013;18(5):619–24.

potential of adoptive T cell therapy for cancer. Immunol 22. Bubenik J. MHC class I down‐regulation: tumour escape Rev. 2014;257(1):56–71.

from immune surveil ance? (review). International

6. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang

Journal of Oncology. 2004;25(2):487–91.

JC, Hughes MS, et al. Gene therapy with human and 23. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, mouse T cell receptors mediates cancer regression and

et al. The biology of cancer testis antigens: putative

targets normal tissues expressing cognate antigen. Blood.

function, regulation and therapeutic potential.

2009;114(3):535–46.

Molecular Oncology. 2011;5(2):164–82.

7. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers 24. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, GD, et al. Antitumor activity and long‐term fate of chi­

Orsulic S, et al. Decitabine enhances lymphocyte migrameric antigen receptor‐positive T cel s in patients with tion and function and synergizes with CTLA‐4 blockade

neuroblastoma. Blood. 2011;118(23):6050–6.

in a murine ovarian cancer model. Cancer Immunology

8. Maher J. Immunotherapy of malignant disease using

Research. 2015;3(9):1030–41.

chimeric antigen receptor engrafted T cel s. ISRN 25. Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Oncology. 2012;2012:278093.

Z, Hosseini Bereshneh A, Rezaei N. Cancer/testis

9. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM,

antigens: expression, regulation, tumor invasion, and

Bunin NJ, et al. Chimeric antigen receptor T cel s for

use in immunotherapy of cancers. Immunological

sustained remissions in leukemia. New England Journal

Investigations. 2016;45(7):619–40.

of Medicine. 2014;371(16):1507–17.

26. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y,

10. Maus MV, Grupp SA, Porter DL, June CH. Antibody‐

Hildebrandt Y, et al. Cancer‐testis antigen expression

modified T cel s: CARs take the front seat for hematoand its epigenetic modulation in acute myeloid leulogic malignancies. Blood. 2014;123(17):2625–35.

kemia. American Journal of Hematology. 2011;

11. Robbins PF, Morgan RA, Feldman SA, Yang JC,

86(11):918–22.

Sherry RM, Dudley ME, et al. Tumor regression in 27. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L.

patients with metastatic synovial cell sarcoma and

Epigenetic targets for immune intervention in human

melanoma using genetically engineered lymphocytes

malignancies. Oncogene. 2003;22(42):6484–8.

reactive with NY‐ESO‐1. J Clin Oncol. 2011;29(7): 28. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation 917–24.

of immune escape genes in cancer. Cancer Immunology,

12. Pardoll DM, Topalian SL. The role of CD4+ T cell

Immunotherapy: CII. 2006;55(10): 1159–84.

responses in antitumor immunity. Current Opinion in 29. Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Immunology. 1998;10(5):588–94.

Sotomayor EM, Pinil a‐Ibarz JA. Treatment of chronic

13. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell‐based

lymphocytic leukemia with a hypomethylating agent

immunotherapy for malignant diseases. Cel ular &

induces expression of NXF2, an immunogenic cancer

Molecular Immunology. 2013;10(3):230–52.

testis antigen. Clinical Cancer Research. 2009;15(10):

14. Webster RM. Combination therapies in oncology.

3406–15.

Nature Reviews Drug Discovery. 2016;15(2):81–2.

30. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid

15. Hanahan D, Weinberg RA. Hallmarks of cancer: the

upregulates NKG2D ligand expression through an

next generation. Cel . 2011;144(5):646–74.

ERK‐dependent mechanism and potentially enhances

156 Immunotherapy in Translational Cancer Research NK cell‐mediated lysis of myeloma. Neoplasia. 42. Triozzi PL, Aldrich W, Achberger S, Ponnazhagan S, 2012;14(12):1178–89.

Alcazar O, Saunthararajah Y. Differential effects of low‐

31. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS, et al.

dose decitabine on immune effector and suppressor

Induction of MHC class I‐related chain B (MICB) by

responses in melanoma‐bearing mice. Cancer

5‐aza‐2’‐deoxycytidine. Biochemical and Biophysical

Immunology, Immunotherapy. 2012;61(9):1441–50.

Research Communications. 2008;370(4):578–83.

43. Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, et al. Low‐

32. Fonsat i E, Nicolay HJ, Sigalot i L, Calabro L, Pezzani L, dose decitabine‐based chemoimmunotherapy for

Colizzi F, et al. Functional up‐regulation of human leukocyte patients with refractory advanced solid tumors: a phase

antigen class I antigens expression by 5‐aza‐2’‐deoxycytidine I/II report. Journal of Immunology Research. 2014;

in cutaneous melanoma: immunotherapeutic implications.

2014:371087.

Clinical Cancer Research. 2007;13(11): 3333–8.

44. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan

33. Adair SJ, Hogan KT. Treatment of ovarian cancer cell

JE, Cheerva AC, et al. A phase I trial combining

lines with 5‐aza‐2’‐deoxycytidine upregulates the

decitabine/dendritic cell vaccine targeting MAGE‐A1,

expression of cancer‐testis antigens and class I major

MAGE‐A3 and NY‐ESO‐1 for children with relapsed or

histocompatibility complex‐encoded molecules. Cancer

therapy‐refractory neuroblastoma and sarcoma. Cancer

Immunology, Immunotherapy. 2009;58(4):589–601.

Immunology, Immunotherapy. 2015;64(10):1251–60.

34. Kersh EN, Fitzpatrick DR, Murali‐Krishna K, Shires J, 45. Weintraub K. Take two: combining immunotherapy Speck SH, Boss JM, et al. Rapid demethylation of the

with epigenetic drugs to tackle cancer. Nature Medicine.

IFN‐gamma gene occurs in memory but not naive CD8

2016;22(1):8–10.

T cel s. Journal of Immunology. 2006;176(7):4083–93.

46. Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Cowey

35. Frikeche J, Clavert A, Delaunay J, Brissot E, Gregoire M, CL, Lao CD, et al. Combined nivolumab and ipilim­

Gaugler B, et al. Impact of the hypomethylating agent

umab or monotherapy in untreated melanoma. New

5‐azacytidine on dendritic cel s function. Experimental

England Journal of Medicine. 2015;373(1):23–34.

Hematology. 2011;39(11):1056–63.

47. Bannister AJ, Kouzarides T. Regulation of chromatin by

36. Janson PC, Linton LB, Bergman EA, Marits P,

histone modifications. Cell Res. 2011;21(3):381–95.

Eberhardson M, Piehl F, et al. Profiling of CD4+ T cel s 48. Marks PA, Richon VM, Rifkind RA. Histone deacetylase with epigenetic immune lineage analysis. Journal of

inhibitors: inducers of differentiation or apoptosis of

Immunology. 2011;186(1):92–102.

transformed cel s. J Natl Cancer Inst. 2000;92(15):

37. Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor

1210–6.

EM, Pinil a‐Ibarz JA. Epigenetic repolarization of T lym49. Kroesen M, Gielen P, Brok IC, Armandari I, phocytes from chronic lymphocytic leukemia patients

Hoogerbrugge PM, Adema GJ. HDAC inhibitors and

using 5‐aza‐2’‐deoxycytidine. Leukemia Research.

immunotherapy: a double edged sword? Oncotarget.

2011;35(9):1193–9.

2014;5(16):6558–72.

38. Costantini B, Kordasti SY, Kulasekararaj AG, Jiang J, 50. Mottamal M, Zheng S, Huang TL, Wang G. Histone Seidl T, Abel an PP, et al. The effects of 5‐azacytidine on

deacetylase inhibitors in clinical studies as templates

the function and number of regulatory T cel s and

for new anticancer agents. Molecules. 2015;20(3):

T‐effectors in myelodysplastic syndrome. Haematologica.

3898–941.

2013;98(8):1196–205.

51. Falkenberg KJ, Johnstone RW. Histone deacetylases and

39. Schmiedel BJ, Arelin V, Gruenebach F, Krusch M,

their inhibitors in cancer, neurological diseases and

Schmidt SM, Salih HR. Azacytidine impairs NK cell

immune disorders. Nature Reviews Drug Discovery.

reactivity while decitabine augments NK cell responsive2014;13(9):673–91.

ness toward stimulation. International Journal of 52. West AC, Johnstone RW. New and emerging HDAC

Cancer. 2011;128(12):2911–22.

inhibitors for cancer treatment. J Clin Invest. 2014;

40. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin

124(1):30–9.

MP, Mace BE, et al. DNA methylation maintains allele‐

53. Akhtar MW, Raingo J, Nelson ED, Montgomery RL,

specific KIR gene expression in human natural killer

Olson EN, Kavalali ET, et al. Histone deacetylases 1 and

cel s. The Journal of Experimental Medicine.

2 form a developmental switch that controls excitatory

2003;197(2):245–55.

synapse maturation and function. J Neurosci. 2009;29(25):

41. Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S.

8288–97.

Generation of antigen‐presenting cel s from tumor‐

54. Graff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM,

infiltrated CD11b myeloid cel s with DNA demethylatet al. An epigenetic blockade of cognitive functions in ing agent 5‐aza‐2’‐deoxycytidine. Cancer Immunology,

the neurodegenerating brain. Nature. 2012;483(7388):

Immunotherapy. 2010;59(5):697–706.

222–6.

CHAPTER 11 Repurposing of Drugs for Immunotherapy 157

55. Majdzadeh N, Morrison BE, D’Mello SR. Class IIA 67. Setiadi AF, David MD, Seipp RP, Hartikainen JA, Gopaul HDACs in the regulation of neurodegeneration. Front

R, Jefferies WA. Epigenetic control of the immune

Biosci. 2008;13:1072–82.

escape mechanisms in malignant carcinomas. Mol Cell

56. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA,

Biol. 2007;27(22):7886–94.

Olson EN. Histone deacetylases 1 and 2 control the pro68. Woods DM, Woan K, Cheng F, Wang H, Perez‐Vil arroel gression of neural precursors to neurons during brain

P, Lee C, et al. The antimelanoma activity of the histone

development. Proc Natl Acad Sci U S A. 2009;106(19):

deacetylase inhibitor panobinostat (LBH589) is medi7876–81.

ated by direct tumor cytotoxicity and increased tumor

57. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with immunogenicity. Melanoma Res. 2013;23(5):341–8.

’epigenetic’ drugs: an update. Molecular Oncology. 69. Northrop JK, Thomas RM, Wel s AD, Shen H. Epigenetic 2012;6(6):657–82.

remodeling of the IL‐2 and IFN‐gamma loci in memory

58. New M, Olzscha H, La Thangue NB. HDAC inhibitor‐

CD8 T cel s is influenced by CD4 T cel s. Journal of

based therapies: can we interpret the code? Molecular

Immunology. 2006;177(2):1062–9.

Oncology. 2012;6(6):637–56.

70. Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y, Shen

59. Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y, et al.

H. Epigenetic manipulation restores functions of defec­

Effects of treatment with histone deacetylase inhibitors

tive CD8(+) T cel s from chronic viral infection. Mol

in solid tumors: a review based on 30 clinical trials.

Ther. 2014;22(9):1698–706.

Future Oncol. 2013;9(2):255–69.

71. Wang D, Iclozan C, Liu C, Xia C, Anasetti C, Yu XZ.

60. Yang S, Kittlesen D, Slingluff CL, Jr., Vervaert CE, Seigler LBH589 enhances T cell activation in vivo and acceler­

HF, Darrow TL. Dendritic cel s infected with a vaccinia

ates graft‐versus‐host disease in mice. Biol Blood

vector carrying the human gp100 gene simultaneously

Marrow Transplant. 2012;18(8):1182–90 e1.

present multiple specificities and elicit high‐affinity T 72. Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, cel s reactive to multiple epitopes and restricted by

Massengill M, et al. Lung tumor NF‐kappaB signaling

HLA‐A2 and ‐A3. Journal of Immunology. 2000;164(8):

promotes T cell‐mediated immune surveil ance. J Clin

4204–11.

Invest. 2013;123(6):2509–22.

61. Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins 73. Pages F, Berger A, Camus M, Sanchez‐Cabo F, Costes A, PF, Hwu P. Retroviral y transduced human dendritic

Molidor R, et al. Effector memory T cel s, early metascel s can generate T cel s recognizing multiple MHC

tasis, and survival in colorectal cancer. New England

class I and class II epitopes from the melanoma antigen

Journal of Medicine. 2005;353(25):2654–66.

glycoprotein 100. Journal of Immunology (Baltimore, 74. Zhang L, Conejo‐Garcia JR, Katsaros D, Gimotty PA, Md: 1950). 2001;167(8):4758–64.

Massobrio M, Regnani G, et al. Intratumoral T cel s,

62. Schwartzentruber DJ, Lawson DH, Richards JM, Conry

recurrence, and survival in epithelial ovarian cancer.

RM, Miller DM, Treisman J, et al. gp100 peptide vaccine

New England Journal of Medicine. 2003;348(3):

and interleukin‐2 in patients with advanced melanoma.

203–13.

New England Journal of Medicine. 2011;364(22):2119–27.

75. Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie

63. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK.

M, et al. HDAC inhibitors enhance T‐cell chemokine

Peptide vaccine: progress and challenges. Vaccines

expression and augment response to PD‐1 immunother­

(Basel). 2014;2(3):515–36.

apy in lung adenocarcinoma. Clinical Cancer Research.

64. Murakami T, Sato A, Chun NA, Hara M, Naito Y,

2016;22(16):4119–32.

Kobayashi Y, et al. Transcriptional modulation using 76. Gupta P, Reid RC, Iyer A, Sweet MJ, Fairlie DP. Towards HDACi depsipeptide promotes immune cell‐mediated

isozyme‐selective HDAC inhibitors for interrogating

tumor destruction of murine B16 melanoma. J Invest

disease. Curr Top Med Chem. 2012;12(14):1479–99.

Dermatol. 2008;128(6):1506–16.

77. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone

65. Garrido F, Ruiz‐Cabello F, Cabrera T, Perez‐Vil ar JJ,

deacetylase inhibitors in inflammatory disease. Curr

Lopez‐Botet M, Duggan‐Keen M, et al. Implications for

Top Med Chem. 2009;9(3):309–19.

immunosurveil ance of altered HLA class I phenotypes 78. Lohman RJ, Iyer A, Fairlie TJ, Cotterell A, Gupta P, Reid in human tumours. Immunol Today. 1997;18(2):89–95.

RC, et al. Differential anti‐inflammatory activity of

66. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova

HDAC inhibitors in human macrophages and rat

J, Hejnar J, et al. Induction of MHC class I molecule cell

arthritis. J Pharmacol Exp Ther. 2016;356(2):387–96.

surface expression and epigenetic activation of antigen‐

79. Wu Y, Guo SW. Suppression of IL‐1beta‐induced COX‐2

processing machinery components in a murine model

expression by trichostatin A (TSA) in human endomefor human papilloma virus 16‐associated tumours.

trial stromal cel s. Eur J Obstet Gynecol Reprod Biol.

Immunology. 2008;123(2):218–27.

2007;135(1):88–93.

158 Immunotherapy in Translational Cancer Research 80. Wu Y, Guo SW. Peroxisome proliferator‐activated receptor-94. Wang D, Dubois RN. Eicosanoids and cancer. Nature

gamma and retinoid X receptor agonists synergistical y

Reviews Cancer. 2010;10(3):181–93.

suppress proliferation of immortalized endometrial stromal

95. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ,

cel s. Fertil Steril. 2009;91(5 Suppl): 2142–7.

Rogers N, Acton SE, et al. Cyclooxygenase‐dependent

81. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L,

tumor growth through evasion of immunity. Cell.

Porrett PM, et al. Deacetylase inhibition promotes the

2015;162(6):1257–70.

generation and function of regulatory T cel s. Nature

96. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T.

Medicine. 2007;13(11):1299–307.

COX‐2 expression in malignant melanoma: a novel

82. Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD.

prognostic marker? Melanoma Res. 2009;19(1):8–16.

Modulation of CTLA‐4 and GITR for cancer immunother97. Broz ML, Binnewies M, Boldajipour B, Nelson AE, apy. Curr Top Microbiol Immunol. 2011;344: 211–44.

Pol ack JL, Erle DJ, et al. Dissecting the tumor myeloid

83. Lucas JL, Mirshahpanah P, Haas‐Stapleton E, Asadul ah

compartment reveals rare activating antigen‐presenting

K, Zollner TM, Numerof RP. Induction of Foxp3+

cel s critical for T cell immunity. Cancer Cel .

regulatory T cel s with histone deacetylase inhibitors.

2014;26(5): 638–52.

Cell Immunol. 2009;257(1–2):97–104.

98. Chen JH, Perry CJ, Tsui YC, Staron MM, Parish IA,

84. Zhang ZY, Schluesener HJ. Oral administration of his­

Dominguez CX, et al. Prostaglandin E2 and

tone deacetylase inhibitor MS‐275 ameliorates neuroinprogrammed cell death 1 signaling coordinately impair flammation and cerebral amyloidosis and improves

CTL function and survival during chronic viral infecbehavior in a mouse model. J Neuropathol Exp Neurol.

tion. Nature Medicine. 2015;21(4):327–34.

2013;72(3):178–85.

99. Wang D, DuBois RN. Immunosuppression associated

85. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman

with chronic inflammation in the tumor microenvi­

JA, Haanen JB, et al. Improved survival with ipilimumab

ronment. Carcinogenesis. 2015;36(10):1085–93.

in patients with metastatic melanoma. New England 100. Kyi C, Postow MA. Checkpoint blocking antibodies in Journal of Medicine. 2010;363(8):711–23.

cancer immunotherapy. FEBS Letters. 2014;588(2): 368–76.

86. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato 101. Balch CM, Dougherty PA, Cloud GA, Tilden AB.

N. Involvement of PD‐L1 on tumor cel s in the escape

Prostaglandin E2‐mediated suppression of cel ular immufrom host immune system and tumor immunotherapy nity in colon cancer patients. Surgery. 1984;95(1):71–7.

by PD‐L1 blockade. Proc Natl Acad Sci U S A. 102. Ohshika Y, Umesaki N, Sugawa T. Immunomodulating 2002;99(19):12293–7.

capacity of the monocyte‐macrophage system in

87. Cheng F, Lienlaf M, Perez‐Vil arroel P, Wang HW, Lee C,

patients with uterine cervical cancer. Nihon Sanka

Woan K, et al. Divergent roles of histone deacetylase 6

Fujinka Gakkai Zasshi. 1988;40(5):601–8.

(HDAC6) and histone deacetylase 11 (HDAC11) on the 103. Cameron DJ, O’Brien P. Relationship of the supprestranscriptional regulation of IL10 in antigen presenting sion of macrophage mediated tumor cytotoxicity in

cel s. Molecular Immunology. 2014;60(1):44–53.

conjunction with secretion of prostaglandin from the

88. Lienlaf M, Perez‐Vil arroel P, Knox T, Pabon M,

macrophages of breast cancer patients. Int J Immuno­

Sahakian E, Powers J, et al. Essential role of HDAC6 in

pharmacol. 1982;4(5):445–50.

the regulation of PD‐L1 in melanoma. Molecular 104. Cameron DJ, Stromberg BV. The ability of macro­

Oncology. 2016;10(5):735–50.

phages from head and neck cancer patients to kill

89. Wang D, DuBois RN. The role of prostaglandin E in

tumor cel s. Effect of prostaglandin inhibitors on cyto2

tumor‐associated immunosuppression. Trends in

toxicity. Cancer. 1984;54(11):2403–8.

Molecular Medicine. 2016;22(1):1–3.

105. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV,

90. Harris RE. Cyclooxygenase‐2 (COX‐2) blockade in the

Missitzis I, Papamichail M. Elevated prostaglandin E2

chemoprevention of cancers of the colon, breast, prostate,

production by monocytes is responsible for the

and lung. Inflammopharmacology. 2009;17: 55–67.

depressed levels of natural killer and lymphokine‐

91. Crusz SM, Balkwill FR. Inflammation and cancer:

activated killer cell function in patients with breast

advances and new agents. Nat Rev Clin Oncol. 2015;

cancer. Cancer. 1993;72(2):491–501.

12(10):584–96.

106. Kundu N, Walser TC, Ma X, Fulton AM.

92. Vane JR. Inhibition of prostaglandin synthesis as a

Cyclooxygenase inhibitors modulate NK activities that

mechanism of action for aspirin‐like drugs. Nat New

control metastatic disease. Cancer Immunology,

Biol. 1971;231(25):232–5.

Immunotherapy. 2005;54(10):981–7.

93. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De 107. Shparyk Ia V. [The dynamic indices of the natural killer Marzo AM. Cyclooxygenases in cancer: progress and

cel s in the chemotherapy of patients with digestive

perspective. Cancer Lett. 2004;215(1):1–20.

organ cancer]. Vrach Delo. 1990(7):14–6.

CHAPTER 11 Repurposing of Drugs for Immunotherapy 159

108. Tanaka N, Okamoto Y, Gotoh K, Hizuta A, Yunoki S, 121. Kerbel RS, Kamen BA. The anti‐angiogenic basis of Orita K. Combined therapy with interleukin 2 and

metronomic chemotherapy. Nature Reviews Cancer.

indomethacin in mice inoculated with MH134 hepa2004;4(6):423–36.

toma. Acta Med Okayama. 1995;49(5):241–5.

122. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV,

109. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S,

Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T

Galeotti L, et al. NK cel s and cancer. Journal of

regulatory cell function implicated in enhanced

Immunology. 2007;178(7):4011–6.

immune response by low‐dose cyclophosphamide.

110. Lang S, Lauffer L, Clausen C, Lohr I, Schmitt B, Holzel Blood. 2005;105(7):2862–8.

D, et al. Impaired monocyte function in cancer 123. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, patients: restoration with a cyclooxygenase‐2 inhibitor.

Cathelin D, Garrido C, et al. CD4 + CD25+ regulatory

FASEB J. 2003;17(2):286–8.

T cel s suppress tumor immunity but are sensitive to

111. Lang S, Tiwari S, Andratschke M, Loehr I, Lauffer L,

cyclophosphamide which allows immunotherapy of

Bergmann C, et al. Immune restoration in head and neck

established tumors to be curative. Eur J Immunol.

cancer patients after in vivo COX‐2 inhibition. Cancer

2004;34(2):336–44.

Immunology, Immunotherapy. 2007;56(10):1645–52.

124. Tongu M, Harashima N, Yamada T, Harada T, Harada

112. Schel horn M, Haustein M, Frank M, Linnebacher M,

M. Immunogenic chemotherapy with cyclophospha­

Hinz B. Celecoxib increases lung cancer cell lysis by

mide and doxorubicin against established murine

lymphokine‐activated killer cel s via upregulation of

carcinoma. Cancer Immunology, Immunotherapy.

ICAM‐1. Oncotarget. 2015;6(36):39342–56.

2010;59(5):769–77.

113. Ikemoto S, Kishimoto T, Iimori H, Morikawa Y, 125. Kaneno R, Shurin GV, Tourkova IL, Shurin MR.

Hayahara N, Maekawa M. Defective interleukin‐1 pro­

Chemomodulation of human dendritic cell function by

duction of monocytes in patients with bladder cancer.

antineoplastic agents in low noncytotoxic concentra­

Br J Urol. 1990;65(2):181–5.

tions. J Transl Med. 2009;7:58.

114. Petrini B, Wolk G, Wasserman J, Vedin I, Strannegard 126. Veltman JD, Lambers ME, van Nimwegen M, de Jong O, Blomgren H, et al. Indomethacin modulation of

S, Hendriks RW, Hoogsteden HC, et al. Low‐dose

monocyte cytokine release following pelvic irradiation

cyclophosphamide synergizes with dendritic cell‐

for cancer. Eur J Cancer. 1991;27(5):591–4.

based immunotherapy in antitumor activity. J Biomed

115. Yin T, Wang G, Ye T, Wang Y. Sulindac, a non‐steroidal

Biotechnol. 2010;2010:798467.

anti‐inflammatory drug, mediates breast cancer inhibi127. Moschel a F, Proietti E, Capone I, Belardelli F.

tion as an immune modulator. Sci Rep. 2016;6:19534.

Combination strategies for enhancing the efficacy of

116. Han T, Takita H. Indomethacin‐mediated enhanceimmunotherapy in cancer patients. Ann N Y Acad Sci.

ment of lymphocyte response to mitogens in healthy

2010;1194:169–78.

subjects and lung cancer patients. Cancer. 1980;46(11): 128. Radojcic V, Bezak KB, Skarica M, Pletneva MA, 2416–20.

Yoshimura K, Schulick RD, et al. Cyclophosphamide

117. Blomgren H, Rotstein S, Wasserman J, Petrini B,

resets dendritic cell homeostasis and enhances antitu­

Hammarstrom S. In vitro capacity of various cyclooxymor immunity through effects that extend beyond genase inhibitors to revert immune suppression caused

regulatory T cell elimination. Cancer Immunology,

by radiation therapy for breast cancer. Radiother

Immunotherapy. 2010;59(1):137–48.

Oncol. 1990;19(4):329–35.

129. Nars MS, Kaneno R. Immunomodulatory effects of low

118. Ferrandina G, Ranelletti FO, Legge F, Salutari V,

dose chemotherapy and perspectives of its combination

Martinelli E, Fattorossi A, et al. Celecoxib up‐regulates

with immunotherapy. International Journal of Cancer.

the expression of the zeta chain of T cell receptor com2013;132(11):2471–8.

plex in tumor‐infiltrating lymphocytes in human 130. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, cervical cancer. Clinical Cancer Research. 2006;12(7 Pt

Cho HI, Antonia S, et al. Chemotherapy enhances

1):2055–60.

tumor cell susceptibility to CTL‐mediated killing dur119. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, et al.

ing cancer immunotherapy in mice. J Clin Invest.

Single administration of low dose cyclophospha mide aug2010;120(4):1111–24.

ments the antitumor effect of dendritic cell vaccine. Cancer 131. Zhong H, Han B, Tourkova IL, Lokshin A, Immunology, Immunotherapy. 2007;56(10): 1597–604.

Rosenbloom A, Shurin MR, et al. Low‐dose pacli120. Walmesley AJ, Zweiri J, Christmas SE, Watson AJ.

taxel prior to intratumoral dendritic cell vaccine

Rofecoxib has different effects on chemokine production

modulates intratumoral cytokine network and lung

in colorectal cancer cel s and tumor immune splenocytes.

cancer growth. Clinical Cancer Research. 2007;13(18

J Immunother. 2007;30(6):614–23.

Pt 1):5455–62.

160 Immunotherapy in Translational Cancer Research 132. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY,

attack of human ovarian cancer is enhanced by histone

et al. A combination of chemoimmunotherapies can

deacetylase inhibition. Human Gene Therapy.

efficiently break self‐tolerance and induce antitumor

2013;24(3):295–305.

immunity in a tolerogenic murine tumor model. 138. Salem ML, Kadima AN, El‐Naggar SA, Rubinstein MP, Cancer Res. 2007;67(15):7477–86.

Chen Y, Gil anders WE, et al. Defining the ability of

133. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM.

cyclophosphamide preconditioning to enhance the

Gemcitabine selectively eliminates splenic Gr‐1+/

antigen‐specific CD8+ T‐cell response to peptide

CD11b + myeloid suppressor cel s in tumor‐bearing

vaccination: creation of a beneficial host microenvianimals and enhances antitumor immune activity.

ronment involving type I IFNs and myeloid cel s.

Clinical Cancer Research. 2005;11(18):6713–21.

J Immunother. 2007;30(1):40–53.

134. He Q, Li J, Yin W, Song Z, Zhang Z, Yi T, et al. Low‐

139. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA,

dose paclitaxel enhances the anti‐tumor efficacy of

Palmer DC, Spiess PJ, et al. Removal of homeostatic

GM‐CSF surface‐modified whole‐tumor‐cell vaccine

cytokine sinks by lymphodepletion enhances the effiin mouse model of prostate cancer. Cancer cacy of adoptively transferred tumor‐specific CD8+ T

Immunology, Immunotherapy. 2011;60(5):715–30.

cel s. Journal of Experimental Medicine. 2005;202(7):

135. Fesnak AD, June CH, Levine BL. Engineered T cel s:

907–12.

the promise and challenges of cancer immunotherapy. 140. Ding ZC, Lu X, Yu M, Lemos H, Huang L, Chandler P, Nature Reviews Cancer. 2016;16(9):566–81.

et al. Immunosuppressive myeloid cel s induced by

136. Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM.

chemotherapy attenuate antitumor CD4+ T‐cell

The histone deacetylase inhibitor, LBH589, promotes

responses through the PD‐1‐PD‐L1 axis. Cancer Res.

the systemic cytokine and effector responses of adop2014;74(13):3441–53.

tively transferred CD8+ T cel s. J Immunother Cancer. 141. Terranova‐Barberio M, Thomas S, Munster PN.

2014;2:8.

Epigenetic modifiers in immunotherapy: a focus on

137. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ, Jr.

checkpoint inhibitors. Immunotherapy. 2016;8(6):

Chimeric NKG2D CAR‐expressing T cell‐mediated

705–19.





CHAPTER 12

12 Immunomodulation

with Radiation

Jonathan E. Schoenhals1, Taylor R. Cushman1, Alexandra P.

Cadena1, Sandra Demaria2, and James W. Welsh1

1 Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

Radiation therapy has long been a pil ar of cancer Radiation and the antitumor treatment. Traditional y, the model describing the immunity cycle interaction of radiation with the tumor and its

microenvironment has been based on four mecha- Conceptual y, the development of antitumor nisms, the “four Rs of radiation”—repair, redistri- immunity can be divided into two phases, each of bution, repopulation, and reoxygenation. This which comprises defined steps. During the priming concept has driven the use of fractionated radia- phase, dying cancer cel s release antigens that are tion in cancer therapy. However, numerous pre- taken up, processed, and presented by dendritic clinical studies have shown that radiation also cel s (DCs) to T cel s. This usual y takes place in interacts with the immune system and in fact relies tumor‐draining lymph nodes, where the T cel s are strongly on immune responses to drive tumor primed, proliferate, and develop into T effector destruction [1, 2]. This evidence, together with the cel s. During the effector phase, the primed T cel s tremendous advances in the use of immunotherapy travel to the tumor, infiltrate it, and recognize and to treat cancer, has opened a new era in which kill the constituent tumor cel s. This cyclic process radiation is being tested as an adjuvant to becomes self‐sustaining once immune activation immunotherapy.

overcomes the typical y immune‐suppressive state

This chapter focuses on the effects of radiation of the tumor microenvironment [3]. Thus, gener-on the antitumor immunity cycle, which describes ating an effective antitumor immune response the multistep process that drives T‐cell‐mediated requires counteracting the immune‐suppressive immune responses [3]. Evidence is emerging that mechanisms present at each step in the process.

radiation can modulate all of the steps in this pro-

The interactions of radiation with the immune

cess and can help to shift the balance in immune system are complex but general y result in immune system function toward tumor rejection. We dis- activation. Radiation contributes to the antitumor cuss current preclinical findings that demonstrate immunity cycle by killing cancer cel s and prompt-immune activation after irradiation as well as ing the release of antigens from those cel s (step 1; ongoing clinical trials to explore the clinical trans- Figure 12.1), eliciting “danger signals” that prolation of these concepts.

mote the uptake and presentation of tumor antigen

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

161





162 Immunotherapy in Translational Cancer Research

2 Presentation by DCs

1 Release of Antigen

STING

B-cell

MHC1

MHC1

IFN-β

MDSC CD8+

3 T-cell Priming

Treg

M2

Treg

MDSC

M2

M1

CD8+

M2

M1

MHC1

MHC1

MHC1

MHC1

Trafficking &

4

5 Upregulation of MHC1

T-cell infiltration

Figure 12.1 The effects of radiation on the tumor

increased IFN‐β production and the STING pathway, (4)

microenvironment. Radiation therapy results in (1) the

increasing T cell infiltration, and (5) upregulation of MHC1

release of tumor‐specific antigens, (2) presentation of

in the tumor microenvironment.

antigens to dendritic cells, (3) priming of T cells through

by DCs (step 2) [4, 5], amplifying the activation of attests to the growing interest in the use of radia-DCs, mediated by autocrine production of type I tion as an immune adjuvant [14]. Below, we review interferon (IFN) that promotes priming of T cel s combinations of radiation with immunotherapies (step 3) [6], inducing chemokines and vascular that target different steps in the antitumor immune adhesion molecules that facilitate trafficking to response.

tumors (step 4) and infiltration of T cel s into

tumors (step 5) [7–9], and upregulating major Preclinical studies of radiation histocompatibility complex (MHC) proteins and and immunotherapy death receptors on the cancer cel s, which enhances

recognition and killing of cancer cel s by T cel s Combining radiation with (steps 6 and 7) [10–13]. Thus, radiation can work immunotherapy agents that target in concert with a variety of immunotherapy agents tumor antigen presentation that target different processes and steps in the can- The availability of sufficient numbers of DCs to cer immunity cycle [3] (Table 12.1).

cross‐present antigens that are released by dying

The number of investigations underway to cancer cel s is critical for the development of both determine if radiation enhances the effectiveness of natural and radiation‐induced T‐cell responses various immunotherapies is increasing, which [15–17]. Growth factors that increase the generation

Table 12.1 Combinations of radiotherapy and immune response modifi ers tested in preclinical tumor models.

Main Step of Antitumor Immune

Response Targeted a

Agent

Main Effect

RT Regimen Tested

Reference

Tumor antigen presentation

Flt3‐ligand

Growth factor for DCs, increased systemic

60 Gy × 1

[18]

availability of DCs

2 Gy × 1, 6 Gy × 1

[1]

Exogenous DC

Increase local and systemic availability of DCs

10 Gy × 3‐5

[19]

s.c., i.v.

Exogenous DC

Increase availability of DCs in irradiated tumor

8.5 Gy × 5

[20]

s.c., i.t.

15 Gy × 1

[21]

CpG s.c. peritumorally and i.t.

TLR9 agonist, DCs activation

10‐55 Gy × 1

[23]

Imiquimod, topical

TLR7 agonist, local DCs activation

8 Gy × 3

[25]

R848, i.v.

TLR7 agonist, systemic DCs activation

10 Gy × 1

[26]

ECI301 (CCL3 variant) i.v.

Recruitment of DCs, T cells, NK cells

6 Gy × 1

[22]

2 ′ 3 ′ ‐cGAMP, i.t.

STING agonist, IFN‐I production

20 Gy × 1

[6]

Vaccinia and avipox recombinants expressing CEA

Generation of tumor antigen–specific T cells

8 Gy × 1

[27]

and T‐cell costimulatory molecules

Autologous tumor cell vaccine expressing GM‐CSF

4 Gy × 2

[28]

T cell priming and activation

Anti‐CTLA‐4 antibody, i.p.

Immune checkpoint inhibitor

12 Gy × 1‐2

[32]

6 Gy × 5, 8 Gy × 3,

[33]

20 Gy × 1

Anti‐CD137 antibody, i.v or i.p.

Costimulatory receptor agonist

5 Gy × 1, 10 Gy × 1,

[40]

15 Gy × 1

4 Gy × 2

[41]

Anti‐OX40 antibody, i.p.

Costimulatory receptor agonist

20 Gy × 3

[42]

IL‐2, i.t.

T cell growth factor

2 Gy × 10

[44]

NHS‐IL‐2 (fusion of antibody to necrotic DNA with

Modified T cell growth factor, targeted to

3.6 Gy × 5

[45]

modified IL‐2), i.v.

tumor

TGF β neutralizing antibody, i.p

Blocks immunosuppressive effects of TGF β on

6 Gy × 5

[46]

DC and T cells

Killing of cancer cells

Anti‐PD‐1 antibody, i.p.

Immune checkpoint inhibitor

12 Gy × 1

[48]

10 Gy × 1

[49]

Anti‐PDL‐1 antibody, i.p.

Blocks PD‐1 ligand on tumor cells/infiltrating

12 Gy × 1, 20 Gy × 1

[50]

myeloid cells

2 Gy × 5

[51]

( Continued)

Table 12.1 ( Continued)

Main Step of Antitumor Immune

Response Targeted a

Agent

Main Effect

RT Regimen Tested

Reference

Adoptively transferred T cells

Activated tumor antigen–specific CD8 T cells

8 Gy × 1

[11]

10 Gy × 1

[10]

2 Gy × 1

[56]

CSF1R inhibitor

Reduced post‐RT recruitment of MDSC and

3 Gy × 5



[55]

TAM



Note: CEA = carcinoembryonic antigen; CpG = C‐G enriched, synthetic oligodeoxynucleotide; CTLA‐4 = cytotoxic T lymphocyte–associated antigen 4; DC = dendritic cells; GM-CSF = granulocyte‐macrophage colony‐stimulating factor; i.p. = intraperitoneally; i.t. = intratumorally; i.v. = intravenously; MDSC = myeloid‐derived suppressor cells; MHC = major histocompatibility complex; NK = natural killer cells; PD‐1 = programmed death‐1; s.c. = subcutaneously; TAM = tumor‐associated macrophages; TLR = Toll‐like receptor.

a See reference [3] .





CHAPTER 12 Immunomodulation with Radiation 165

of DCs such as the Flt‐3 ligand have been used in extended the long‐term survival of the mice relative combination with local radiotherapy in mouse to either treatment alone [26]. In addition to TLR

models of lung and breast cancer [1, 18]. In the agonists, STING agonists such as 2′3′‐cGAMP

relatively immunogenic 67NR breast cancer model, (which also activates the NF‐k β and IFN type I a small radiation dose of 2 Gy directed to a subcu- pathways) have successful y enhanced the antitu-taneous tumor was sufficient to induce antitumor mor immune responses elicited by radiation [6].

T cel s capable of mediating an abscopal effect (i.e.,

Final y, radiation used with various tumor vac-

regression of a tumor outside of the field of radia- cines can markedly improve tumor rejection. In tion) against a synchronous, nonirradiated tumor one study, the effects of radiation were mediated when used in combination with Flt3‐Ligand [1]. In largely by upregulation of Fas/CD95 death receptor the more aggressive and less immunogenic Lewis on the tumor cel s, leading to improved killing by lung carcinoma, considerably larger radiation the vaccine‐generated T cel s. Interestingly, T‐cell doses were used (60 Gy given in a single dose). responses were also seen to tumor antigens that Although a single dose of this size is not clinical y were not present in the vaccine, indicating that this relevant, this study provided the first proof of prin- combination primed a broader T‐cell response ciple that adding a DC growth factor to local irra- [27]. In another study, complete cure of established diation can induce T cel s capable of inhibiting GL261 glioma cel s growing in the brain of mice systemic metastases [18]. Other investigators have was achieved only by the combination of whole-tested the inoculation of autologous DCs near or brain irradiation and peripheral vaccination with Table 12.1 ( Continued)

within irradiated tumors in mouse models of fibro- autologous tumor cel s modified to produce granu-sarcoma, melanoma, lymphoma, and colorectal locyte‐macrophage colony‐stimulating factor Main Step of Antitumor Immune

Response Targeted a

Agent

Main Effect

RT Regimen Tested

Reference

cancer. In these studies, radiation was given either (GM‐CSF). Radiation improved T cell infiltration Adoptively transferred T cells

Activated tumor antigen–specific CD8 T cells

8 Gy × 1

[11]

as a single dose or in 3–5 fractions, and in every into the tumor and upregulated MHC class I 10 Gy × 1

[10]

case more powerful antitumor immune responses antigens on the invading glioma cel s, rendering 2 Gy × 1

[56]

CSF1R inhibitor

Reduced post‐RT recruitment of MDSC and

3 Gy × 5



[55]

were generated from the combination of DC inoc- them better targets for CD8 T cel s [28].

TAM

ulation and irradiation [19–21]. Another strategy



Note: CEA = carcinoembryonic antigen; CpG = C‐G enriched, synthetic oligodeoxynucleotide; CTLA‐4 = cytotoxic T lymphocyte–associated antigen 4; DC = dendritic cells; GM-used to enhance the homing of DCs to the tumor is Combining radiation CSF = granulocyte‐macrophage colony‐stimulating factor; i.p. = intraperitoneally; i.t. = intratumorally; i.v. = intravenously; MDSC = myeloid‐derived suppressor cells; MHC = major histocompatibility complex; NK = natural killer cells; PD‐1 = programmed death‐1; s.c. = subcutaneously; TAM = tumor‐associated macrophages; TLR = Toll‐like receptor.

to administer a variant of the chemokine macro- with immunotherapy agents that a See reference [3] .

phage inflammatory protein‐1 alpha, also known target T‐cell priming and activation as CCL3 [22].

The immune checkpoint receptors CTLA4 and

Other studies have tested the combination of PD1 regulate T cell responses via several mecha-radiation with immune response modifiers that nisms. However, CTLA4 is thought to have a increase the activation of DCs by stimulating toll‐ central role during priming, whereas PD1 acts pre-like receptors (TLRs), which are upstream of the dominantly during the effector phase [29, 30].

NF‐k β and IFN type I pathways. Local injection of Typical y a response to anti‐CTLA4 antibodies the TLR9 agonist C‐G enriched synthetic oligode- requires some degree of preexisting antitumor oxynucleotide (CpG) improved the radiocurability immunity, which means that many patients with of the tumor in mouse fibrosarcoma models treated cancer will not respond to this strategy without with single‐dose or fractionated radiation [23, 24]. additional interventions that synergize with anti-The TLR7 agonist imiquimod, given topical y in a CTLA4 in inducing antitumor T cel s [31].

mouse model of cutaneous breast cancer metas- Radiation has been shown to be one such interven-tases, had modest effects on tumor growth when tion, able to synergize with anti‐CTLA4 to induce given alone, but when combined with fractionated antitumor T cel s that improve control of both irra-radiation (in three 8‐Gy fractions [8 Gy × 3]), it diated tumors and distant metastases [32]. The achieved complete rejection of the irradiated tumor synergy initial y observed in a mouse model of and partial responses at nonirradiated abscopal poorly immunogenic triple‐negative breast cancer tumor sites [25]. In mouse models of lymphoma, a refractory to immunotherapy alone has been single 10‐Gy dose of radiation combined with the confirmed in additional models of breast and colo-TLR7 agonist R848 administered intravenously rectal cancer, and, more recently, melanoma [32–





166 Immunotherapy in Translational Cancer Research 34]. Notably, a side‐by‐side comparison of different activity in a phase Ib trial of patients with meta-radiation regimens demonstrated that not all regi- static lung cancer [45].

mens were equal y effective: abscopal responses

Final y, inhibition of the immunosuppressive

were achieved when radiation was given in 6‐Gy cytokine transforming growth factor‐beta (TGF β) fractions over five consecutive days or in 8‐Gy frac- was shown to have synergistic effects with fractions over three consecutive days, but a single tionated radiotherapy in two mouse models of 20‐Gy dose was not effective [33]. The potential breast cancer, inducing abscopal effects and clinical relevance of this observation is supported improving survival mediated by the activation of T

by the achievement of abscopal effects in patients cel s that recognized several endogenous tumor with melanoma or lung cancer who received radio- antigens [46].

therapy and anti‐CTLA4 antibody ipilimumab

with similar hypofractionated radiation regimens Combining radiation

[35–37].

with immunotherapy agents that

In addition to inhibitory receptors, multiple improve T‐cell‐mediated killing costimulatory receptors regulate T cell activation, of cancer cells and therapeutic antibodies have been developed Upregulation of PDL1 in the tumor microenviron-for some of those targets [38]. One such target is ment is a major mechanism by which tumors CD137 (4‐1BB), a member of the tumor necrosis escape from immune‐mediated control [47].

factor receptor family expressed on T cel s after Several preclinical studies have investigated combi-their activation that mediates signals that increase nations of antibodies targeting PDL1 or its receptor T cell proliferation, survival, and effector functions PD1 with radiotherapy. In one such study, PD1

when bound to agonistic antibodies [39]. Anti‐ blockade improved the response to radiotherapy CD137 antibodies have enhanced the response of and anti‐CD137 in mouse models of breast cancer tumors to single‐dose irradiation in mouse models [48]. In another study, PD1 blockade improved the of breast and lung carcinoma [40]. They were also survival of mice with intracranial glioma treated effective in an orthotopic mouse model of glioma with stereotactic radiation [49]. Anti‐PDL1 anti-treated with whole‐brain irradiation given as two bodies were shown to improve local control and 4‐Gy fractions, leading to complete tumor eradica- induce abscopal effects in mouse models of breast tion and long‐term survival in most mice so treated and colorectal cancer by reducing PDL1+ myeloid‐

[41]. Agonistic antibodies to OX40 (CD134), derived suppressor cel s (MDSCs) in the tumor another costimulatory receptor, were shown to microenvironment [50]. Moreover, the optimal improve survival when used with radiation in a scheduling of giving anti‐PDL1 monoclonal antimouse model of lung cancer [42].

bodies with radiation was addressed in a study

Use of the T cell growth factor interleukin‐2 which showed that concomitant administration (IL‐2) to achieve T‐cell‐mediated tumor rejection with fractionated radiotherapy was required to was the first immunotherapy to be used clinical y achieve therapeutic benefit [51]. Anti‐PD1 anti-

[43]. In a mouse model of colorectal cancer, intra- bodies have also been shown to improve survival tumoral IL‐2 improved the regression of both a achieved with radiation and TGF β blockade in a subcutaneous irradiated tumor and nonirradiated mouse model of metastatic breast cancer by over-liver metastases [44]. In a recent study, a novel coming induced resistance [46].

form of IL‐2 (NHS‐IL2+) was engineered in which

The combination of two immune checkpoint

a tumor‐homing signal provided by an antibody inhibitors targeting CTLA4 and PD1 has been specific for necrotic DNA was fused to genetical y shown to improve the responses achieved with modified human IL‐2 so as to selectively activate either antibody alone in preclinical models of mel-the high‐affinity IL‐2 receptor. Used in combination anoma as well as in patients [52, 53]. In one with radiation, this modified IL‐2 was shown to preclinical study, local radiation of B16 mouse mel-induce antitumor immune responses and complete anoma induced T cell responses and tumor tumor regressions in 80%–100% of mice so treated, rejection when given in combination with anti-and this treatment showed promising clinical CTLA4, effects that were significantly improved by





CHAPTER 12 Immunomodulation with Radiation 167

the further addition of anti‐PD1 [54]. Thus, in situ with radiation, such as increases in TGFβ, MDSCs, vaccination by in vivo tumor irradiation produced or regulatory T cel s (T ).

regs

effects similar to vaccination with autologous

tumor cel s modified to express GM‐CSF [53]. Enhancing tumor antigen presentation Importantly, abscopal effects were also improved As highlighted above, presentation of tumor-with the combination approach, which was effec- derived antigens by DCs is critical for generation of tive against B16 melanoma cel s that stably T‐cell responses against tumors. Thus, strategies expressed high levels of PDL1, because the anti‐ aimed at enhancing tumor antigen presentation PD1 “reinvigorated” exhausted T cel s [34].

have been tested for the ability to improve responses

Another strategy to improve tumor rejection is to radiation therapy. Fortunately, several therapeu-through reducing MDSC recruitment to the tumor tics that have shown positive effects with radiation after irradiation. One such study using agents that in mouse models are being developed for clinical block CSFR1 signaling improved tumor responses use, including FLT3 ligand and TLR7 and TLR9

[55]. Final y, radiation improved tumor rejection agonists. Some of the clinical trials now in progress mediated by adoptively transferred tumor‐specific to evaluate this approach in combination with radiT cel s by enhancing the expression of Fas and/or ation are described below.

MHC‐I on cancer cel s, resulting in enhanced

killing of cancer cel s by T cel s [10, 11]. Another Exogenous DC therapy mechanism by which radiation improves tumor A completed phase I trial (NCT00365872) tested rejection is through normalization of the vascula- intratumoral injection of DCs with radiation before ture, which allows adoptively transferred T cel s to surgery for sarcoma. The 17 patients in this trial had infiltrate the tumor [56].

large (>5 cm), high‐grade soft tissue sarcoma treated

with 50.4 Gy in 28 fractions in addition to intratu-

The next step: Clinical applications

moral DC injections. The treatment was well toler-

ated, and 9 patients developed a tumor‐specific

The preclinical studies described above have immune response that lasted from 11 to 42 weeks.

helped pave the way for numerous trials testing The authors reported a “dramatic accumulation of T

immunotherapy in combination with radiation for cel s in the tumor” and a progression‐free survival nearly all types of cancer. Historical y, most such rate of 70.6% at 1 year [58].

trials have focused on melanoma; much pioneering

Another phase I/II trial (NCT00547144) tested

work has been done with immunomodulatory the use of intratumoral DC with gemcitabine and agents such as IL‐2, which expands active T cel s radiation for unresectable pancreatic cancer.

and has led to tumor responses in patients with Initiated in October 2007, this trial was particularly metastatic melanoma [57]. The recent approval by interesting because pancreatic cancer has tra-the U.S. Food and Drug Administration (FDA) of ditionally shown little or no response to checkpoint inhibitors such as anti‐CTLA4 and immunotherapy. Although the desmoplastic anti‐PD1 has led to the rapid expansion of new trial stroma associated with pancreatic tumors has been concepts in which these agents are used with radia- thought to exclude lymphocytes from pancreatic tion. Such studies will be crucial not only for eval- tumors, the hypothesis was that injecting DCs uating the safety of this strategy but also for directly into the tumors could help to overcome identifying the optimal dose, timing, and this barrier. Unfortunately, the financial cost of DC

sequencing of the radiation within it. The next expansion and delivery proved to be too high, and steps will involve expanding the number of this trial was terminated.

combination trials in which “cocktails” of immuno-

Another trial of DC therapy for resectable

therapy agents are used to overcome several poten- esophageal cancer (NCT01691664) is underway in tial mechanisms of immune evasion. Although China. Initiated in September 2012, this trial several new agents are now available to choose involves collecting DCs from patients after surgical from, perhaps the most beneficial combinations resection but before radiation therapy; the DCs are will target the inhibitory immune effects associated then infused back into the patient at three different





168 Immunotherapy in Translational Cancer Research time points during the course of the radiation. The NCT02474186, which began in 2003 and showed primary endpoint is disease‐free survival. This trial evidence of abscopal responses in 11 of 41 enrolled is designed to accrue 40 patients.

patients [64]. Radiation therapy was given as 35 Gy

in 10 fractions, concurrent with systemic therapy

TLR9/TLR7 agonists

and subcutaneous GM‐CSF. The most common

Agonists to TLR9 and TLR7 are powerful immune grade 3–4 toxicities were fatigue and hematolog-activators that are too toxic to be administered sys- ical, and one patient experienced grade 4

temical y but have shown some efficacy when given pulmonary embolism. Importantly, patients with local y to the tumor [59–62]. This approach is par- abscopal responses had significantly better overall ticularly attractive for combining such agents with survival with a median of 20.98 months versus local radiation.

8.33 months in nonresponders [64].

In a study by Brody and colleagues, patients with

A phase II trial, NCT00652860, at the Mayo

lymphoma received local injections of CpG TLR9 Clinic evaluated a recombinant form of GM‐CSF, agonists in combination with low‐dose radiation sargramostim, with radiation before surgery for

[63]. This approach led to abscopal responses in soft tissue sarcoma. Patients were given either sub-nonirradiated lesions in almost one third of cutaneous GM‐CSF or aerosolized GM‐CSF before patients. TLR9 agonists activate plasmacytoid DCs, surgery, and aerosolized GM‐CSF was begun again which then produce high local concentrations of at four weeks after surgery. A total of 39 patients type I IFN and activate antitumor CD8+ T cel s to were enrolled between November 2001 and April express PD1.

2006. When this study was completed in 2011,

Another phase I/II trial evaluating a triple most patients (76%) had experienced grade 3–4

combination of a TLR9 agonist with the anti‐ hematologic toxicity; however, 24 of the first 35

CTLA4 antibody ipilimumab and X‐ray therapy, evaluable patients were free of pulmonary metas-NCT02254772, was opened in September 2014 for tasis at two years, and 58% of patients were free of patients with recurrent low‐grade B cell lymphoma. disease progression at three years. However, this Both the TLR9 agonist and the ipilimumab are to trial failed to meet its primary endpoint of reducing be injected local y, with a short two‐day course of the rate of pulmonary metastases at two years [65].

radiation. This study is expected to accrue a total of

Another phase II trial of GM‐CSF for stage IV

27 patients.

non‐small‐cell lung cancer (NSCLC), NCT02623595,

The first study of a TLR7 agonist with radiation is one of the first to combine hypofractionated is NCT01421017, a phase I/II trial for patients with high‐dose radiation with GM‐CSF for patients for metastatic or recurrent breast cancer involving the whom second‐line chemotherapy had failed. The skin. Based on prior preclinical data supporting the plan is to treat 40 patients with stage IV NSCLC

efficacy of the combination [25] and on a clinical with radiation to a total dose of 50 Gy in 5 frac-study supporting activity of topical TLR7 agonist tions, given with concurrent GM‐CSF. Abscopal imiquimod in breast cancer cutaneous metastases responses will be evaluated at 1, 2, 3, 6, and 12

[59], this trial was designed to evaluate responses months. The study was opened in November 2015

in irradiated and nonirradiated skin lesions treated and is currently accruing patients.

with imiquimod as well as in untreated skin or

visceral metastases. The study was modified to T‐cell priming and activation include the addition of low‐dose cyclophospha- T cel s are key players in antitumor immune mide as a strategy to reduce T , and accrual is response, and several therapeutics targeting T cel s regs

close to completion.

have been developed or are under development for

use in the clinic. Activation of tumor‐specific

Granulocyte‐macrophage colony‐

T cel s requires that antigens be presented together

stimulating factor

with appropriate costimulatory signals and survival

Three trials have been undertaken to date to test factors. Signaling pathways involved include major GM‐CSF in combination with radiation for patients histocompatibility complex–T cell receptor inter-with cancer. Results have been reported for actions and CD28 costimulation on the T cel s,





CHAPTER 12 Immunomodulation with Radiation 169

with B7.1 and B7.2 expressed on the antigen‐ (10%) had stable disease (SD) [69]. Immune check-presenting cel s. These signals activate T cel s, which point blockade has also been combined with can then produce IL‐2 and proliferate. Other sig- radiation for metastatic prostate cancer; Slovin naling pathways involved in T cell proliferation and et al. reported responses and declines in prostate-activation include costimulatory receptors OX40 specific antigen in a phase I/II trial when treating (CD134) and 4‐1BB (CD137). Inhibitory signals 50 men with 3.5 or 10‐mg/kg doses of ipilimumab regulate T cell activation to prevent autoimmunity with or without 8‐Gy radiation fractions per meta-but are often overly active in the setting of cancer. static lesion [70]. However, when comparing One such signal is mediated by the inhibitory ipilimumab versus placebo with radiation, the receptor CTLA4 (CD152), which binds with high‐ resulting phase III trial failed to reach its endpoint affinity to B7.1 and B7.2 and precludes the CD28 of increased median overall survival with a p value signal and T cell activation. Another immunosup- of 0.053 between the two groups [71].

pressive factor is TGFβ, which acts in multiple

Recent results of a phase I study testing radiation

ways to blunt T cell responses [66]. Clinical trials of and ipilimumab for 22 patients with metastatic drugs that modulate these pathways in combination melanoma showed that 18% of patients had a with radiation are discussed briefly below.

partial response as the best response, and another

18% had SD in nonirradiated lesions [54]. In that

CTLA4

study, radiation was given in a dose‐escalation

Numerous trials are now underway to test anti‐ protocol starting with two doses of 6 or 8 Gy and CLTA4 antibodies in combination with radiation. increasing to three doses. Encouragingly, Ipilimumab was the first immune checkpoint drug combining radiation with ipilimumab did not to be approved by the FDA, and it was the first increase toxicity. However, the response rate in this such drug to be readily available for testing in small group of patients was quite similar to combination with radiation. Early trials of this response rates for ipilimumab alone [72]. On the combination involved patients with melanoma and basis of preclinical data indicating that anti‐CTLA4

were then expanded to include patients with other inhibits T but promotes expansion of effector T

regs

types of tumors. Despite its potential for durable cel s (thereby increasing the CD8/T ratio) and reg

long‐term control in some patients, most do not that radiation enhances the diversity of the TCR

respond to ipilimumab, and even some who do repertoire, these investigators proposed that an respond later develop refractory disease. Thus, optimal response in melanoma and other types of much interest has been expressed in evaluating cancer would require a triple combination of radia-whether radiation can increase response rates tion, anti‐CTLA4, and anti‐PDL1/PD1.

achieved with anti‐CTLA4 alone.

A large, 100‐patient phase I/II trial now

Several clinical case reports support the underway at The University of Texas MD Anderson effectiveness of radiation combined with immuno- Cancer Center (NCT02239900) is open to patients therapy. A patient with melanoma who was not with any type of solid tumor as long as metastatic responding to ipilimumab was given palliative lesions are present in the lung or liver to which ste-radiotherapy to a paraspinal mass (three 9.5‐Gy reotactic ablative radiotherapy (SABR) can be fractions, total dose 28.5 Gy), followed by addi- safely delivered. This trial is testing various tional ipilimumab [67]; this patient had a dramatic sequences of anti‐CLTA4 with radiation, different response with regression of nonirradiated metas- radiation doses (50 Gy in four fractions vs. 60 Gy in tases. A similar case was reported by Hiniker et al., 10 fractions), and differences in T cell priming who treated a patient with melanoma with ipilim- according to the location of the irradiated tumor umab and concurrent radiation to 54 Gy (in 18‐Gy (liver vs. lung). Initial findings have shown that this fractions) and observed complete regression in all combination is safe and may show signs of immune metastatic lesions [68]. In a retrospective analysis activation [73].

of melanoma patients receiving radiotherapy dur-

As of February 2017, 45 trials were listed as test-

ing ipilimumab, Grimaldi et al. found abscopal ing anti‐CTLA4 with radiation. Although most of responses in 9 of 21 patients (43%), and 2 patients those trials focus on melanoma, others are testing





170 Immunotherapy in Translational Cancer Research this combination for cancer of the head and neck, The same study reported a retrospective evaluation lung, prostate, colon, rectum, liver, and cervix, as of patients who received SABR prior to high‐dose well as non‐Hodgkin lymphoma. The next several IL‐2 treated at their institution. Ten patients were years should bring a much better understanding of identified for this analysis, 8 with melanoma and 2

not only the safety of combining anti‐CTLA4 with with renal cell carcinoma. Five of 8 patients with radiation but also the most effective radiation dose melanoma had clinical responses outside of the and sequencing for clinical use.

irradiated field (3 CR) and both patients with renal

cell carcinoma had partial responses (PR).

OX40

Preliminary findings from a separate trial [75] of

The combination of the OX40 agonist MEDI6469 IL‐2 with three 6–12 Gy doses of radiation to a with radiation is currently being tested in two trials tumor site for melanoma and renal cell carcinoma at the Providence Portland Medical Center in (NCT01884961) demonstrated tumor control in 3

Oregon. The first (NCT01303705) is a phase I/II of 9 evaluable patients (1 CR, 1 PR, and 1 SD) [76].

trial that is currently recruiting men with meta- Moreover, 4 of 7 evaluable patients had immune static prostate cancer. The goal of that study is to cel s that recognized surviving and other tumor find the maximum tolerated dose of cyclophospha- antigens, suggesting that radiation can activate mide in conjunction with one 8‐Gy fraction of tumor‐specific T cel s and that IL‐2 can stimulate radiation and three 0.4‐mg/kg doses of MEDI6469. their survival and proliferation. This trial is Cyclophosphamide will be given first, followed by ongoing and will aim to enroll 19 total patients; both radiation and OX40 on day 4, and OX40 will however, more patients will be needed to evaluate be given on days 4, 6, and 8. The sequencing in the whether this combination is beneficial.

study design was based on preclinical findings, and

the radiation will be given as palliation to bone Transforming growth factor‐beta (TGF β) metastases. The rationale for this approach is the Four clinical trials are currently testing TGF β inhi-expectation that the combination of radiation and bition with radiation: two phase II trials for breast cyclophosphamide will act as an “in situ” vaccine, cancer (NCT01401062 and NCT02538471), one prompting the release of antigens that will be rec- phase I/II trial for glioma (NCT01220271), and ognized by T cel s; the OX40 serves as the catalyst one phase I/II trial for NSCLC (NCT02581787).

to tip the scale in favor of tumor rejection.

Currently, two TGF β inhibitors are being tested, The second study (NCT01862900), also a phase either as a small molecule (LY2157299) or an antiI/II trial, involves giving OX40 with SABR to lung body (fresolimumab). In the trial testing fresolim-or liver metastases from breast cancer. That study umab with radiation for metastatic breast cancer does not involve chemotherapy and will test single‐ (NCT01401062), patients are randomly assigned to fraction doses of 15 Gy, 20 Gy, or 25 Gy. The OX40 receive either 1 or 10 mg/kg fresolimumab and is to be given at 0.4 mg/kg on days 3 and 5 after the radiation to two separate lesions, given in three SABR. The objective of this trial of single‐dose fractions of 7.5 Gy each. The study has completed radiation (as opposed to standard fractionated accrual and results are expected soon. The other radiation) is to establish the maximum tolerated breast cancer trial is testing a small molecule inhib-dose of radiation with OX40; the secondary itor of TGF β, LY2157299, given at 300 mg/kg daily outcome is abscopal responses.

for two weeks on and two weeks off, with radiation

to one disease site. The primary endpoint in both

Interleukin‐2

trials is the presence of an abscopal effect.

The combination of high dose IL‐2 with SABR was

In the glioma trial, chemoradiation is being

tested in patients with metastatic melanoma and tested with LY2157299 given at 80 mg/kg or renal cell carcinoma in a phase I trial. Patients 150 mg/kg twice daily for two weeks on and two received 20Gy X‐ray therapy in one, two, or three weeks off, a schedule similar to that in the breast fractions. Eight of 12 patients had a clinical cancer trials. Both radiation and chemotherapy response according to RECIST in total tumor will be given concurrently during the first portion burden, and 1 had a complete response (CR) [74]. of the study, with a radiation dose of 1.8–2 Gy per





CHAPTER 12 Immunomodulation with Radiation 171

day for five days a week to a total dose of 60 Gy and at least one type of systemic therapy or, for the alkylator temozolomide given during and after melanoma and NSCLC, after anti‐PD1 therapy.

the radiation. The primary objectives in this trial Some ongoing phase I trials of the anti‐PD1 anti-are to identify appropriate doses and evaluate body pembrolizumab include NCT02608385, changes in response biomarkers with evidence of which is examining pembrolizumab and SABR for clinical benefit. An interim analysis showed that advanced solid tumors at the University of Chicago; the toxicity of this combination therapy was man- or NCT02303990 (“RADVAX”), a stratified trial of ageable [77].

pembrolizumab with hypofractionated radiation

The NSCLC trial, to be led by investigators at for advanced and metastatic cancers at the Stanford University, will test fresolimumab in University of Pennsylvania; or NCT02318771, combination with SABR to identify safe doses and which is examining pembrolizumab and hypofrac-document the incidence and severity of radiation tionated radiation for recurrent or metastatic pneumonitis (NCT02581787). The drug and radia- cancer of head and neck, renal cell carcinoma, lung tion doses have yet to be specified, but the radiation cancer, or melanoma.

will be given in four fractions.

Lung cancer is one of the most thoroughly

It will be interesting to see which radiation dose studied diseases at this time, and several new and fractionation scheme will produce the best combination trial concepts have been proposed for response in combination with anti‐TGFβ therapy, virtual y every stage of the disease. For stage I and whether the antibody or small molecule tumors, the Immunotherapy‐STARS trial is being approach will be more effective. Results from these developed as a successor to the previous successful trials will certainly shed light on the role of TGFβ STARS trial, in which patients with surgical y release during radiation therapy and its effects on resectable lung cancer were randomly assigned to immune responses.

undergo SABR versus lobectomy [78]. Other trials

are underway to evaluate induction immunother-

apy before surgery for stage II lung cancer;

Killing cancer cells

although none of these trials currently include

Anti‐PD1/Anti‐PDL1

concurrent radiation, that would be a logical next

Combining radiation with agents that target the step in their evolution. For patients with unresect-PD1/PDL1 pathway is currently of great interest, in able stage III lung cancer, several trials are part because anti‐PD1/PDL1 agents have shown underway in which immunotherapy is combined activity in multiple malignancies and are less toxic with radiation. One such trial, a phase I/II study than anti‐CLTA4. Numerous trials are now at MD Anderson Cancer Center, evaluates underway with these agents in combination with concurrent immunotherapy with the anti‐PDL1

radiation for many types of cancer. Early trials were drug atezolizumab (Genentech, Inc.) plus for patients with stage IV disease and evaluated the concurrent chemoradiation. Both the Southwest safety of this approach and its potential for pro- Oncology Group and the Radiation Therapy ducing abscopal responses; more recent trials are Oncology Group are also planning to test immu-evaluating this approach for disease at earlier notherapy given after radiation has been delivered.

stages, with the hope that combining anti‐PD1/ Other trials for stage IV NSCLC include another PDL1 with radiation can address micrometastases. study at MD Anderson in which patients with The rationale for giving radiation and immuno- stage IV NSCLC will be randomly assigned to therapy before surgery is that this therapy may turn receive anti‐PD1 with or without radiation the tumor itself into an “in‐situ vaccine” before (NCT02444741). Patients in the anti‐PD1‐only resection, potential y improving both local and dis- group who experience disease progression will be tant control. The following is a brief review of given radiation to see if the radiation can induce ongoing trials based on disease site.

immune responses to refractory disease. The

Initial trials investigating immunotherapy plus rationale for this design comes from recent work radiation are largely performed in patients with showing that response to anti‐PD1 may depend on solid tumors that have recurred or progressed after MHC I expression [79] and that radiation‐induced





172 Immunotherapy in Translational Cancer Research MHC I may resensitize tumors to anti‐PD1‐medi- phase II trial evaluating pembrolizumab with ated T cell killing. The PEAR trial in the United radiation is currently ongoing, either in conven-Kingdom (NCT02587455) is also evaluating tional fractions or as SABR, for patients with immunotherapy given with palliative radiation for metastatic colorectal cancer (NCT02437071).

NSCLC.

Another trial, NCT02298946, is a phase I trial

Immunotherapy is also being tested for the evaluating anti‐PD1 with SABR to liver lesions long‐term local control of high‐grade glial for patients with metastatic CRC, regardless of tumors. Ongoing trials for this purpose include a microsatellite instability status. The starting multicenter, open‐label, nonrandomized phase II dose is a single fraction of 8 Gy, which is then study of the anti‐PDL1 checkpoint inhibitor dur- escalated to three fractions of 8 Gy each. The valumab (MEDI4736) for patients with newly trial design also includes low‐dose cyclophos-diagnosed, unmethylated MGMT glioblastoma; phamide, which has been shown to reduce T

regs

durvalumab is given every 2 weeks in combination [81, 82], with the thought that this would further with standard radiation (NCT02336165). A phase improve T‐cell responses. Another phase II trial I trial of PD1 blockade with pembrolizumab plus (NCT02586610) evaluates pathologic complete bevacizumab with hypofractionated SABR in five response rates among patients with rectal days for recurrent high‐grade glial tumors has

cancer after neoadjuvant pembrolizumab in

been initiated by H. Lee Moffitt Cancer Center combination with chemoradiation. The advantage and Research Institute (NCT02313272).

of this trial design is the ability to analyze tumor

The PD1 inhibitor pembrolizumab is being tissue before and after treatment, which will pro-tested in phase II trials for patients with surgi- vide insights into the modes of action of the cally resectable head and neck squamous cell combination treatment.

carcinoma; it is given intravenously approxi-

Because the induction of PDL1 expression in the

mately two or three weeks before surgery, to be tumor microenvironment is often associated with followed by intensity‐modulated radiation the presence of infiltrating T cel s [83], in the future therapy to 60 Gy (in daily 2‐Gy fractions) to anti‐PD1 therapy may become a component of patients at high risk of recurrence many combinations that include radiation and (NCT02296684) or those with recurrent disease other immune modulators.

(NCT02318771) or as reirradiation for patients

with inoperable locoregionally recurrent or sec- Summary

ond primary squamous cell carcinomas

(NCT02289209). Pembrolizumab is also being Combinations of radiation with various types of tested in a phase I single‐arm, open‐label trial in immunotherapy are being vigorously tested in combination with standard cisplatin‐based clinical trials. Preclinical data suggest that such definitive chemoradiation (70 Gy delivered in combinations should be successful; however, once‐daily 2‐Gy fractions) for patients with several critical questions need to be addressed stage III‐IVB squamous cell carcinoma of the before the use of radiation to increase responses head and neck; the accrual goal for this study is to immunotherapy can be incorporated into 39 patients (NCT02586207).

clinical care [84]. Future preclinical studies will

Colorectal cancer (CRC) is known to respond test novel immunotherapies with radiation and well to radiation, especially cancer of the rectum will define the mechanisms to achieve optimal and anal canal. The question now is whether in situ vaccination by radiation, as well as define immunotherapy could enhance the antitumor the timing of each given drug versus radiation effects of radiation and help to prevent recur- delivery. Results of these preclinical studies and rence and/or metastatic disease. Immune the many ongoing and future clinical trials are checkpoint drugs are largely ineffective in colo- eagerly awaited and are expected to change the rectal cancer (except for patients with high use of radiation in advanced disease from a microsatellite instability) [80]. To determine if largely local treatment to one that can improve radiation may sensitize CRC to anti‐PD1, a systemic tumor control.





CHAPTER 12 Immunomodulation with Radiation 173

Acknowledgments

the peptide repertoire, enhances MHC class I expres-

sion, and induces successful antitumor immunotherapy.

We thank Christine F. Wogan of MD Anderson’s

Journal of Experimental Medicine. 2006;203(5):

Division of Radiation Oncology for editorial

1259–71.

assistance. We also thank Mr. Tamotsu Mabuchi 11. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott and the family of Mr. Mohammed A. Hamed for

T, Coleman CN, et al. Irradiation of tumor cel s up‐reg-

generous funding support, and we are indebted to

ulates Fas and enhances CTL lytic activity and CTL

the resources of the Immunotherapy Platform at

adoptive immunotherapy. Journal of Immunology.

MD Anderson.

2003;170:6338–47.

12. Garnett CT, Palena C, Chakarborty M, Tsang KY,

Schlom J, Hodge JW. Sublethal irradiation of human

References

tumor cel s modulates phenotype resulting in enhanced

killing by cytotoxic T lymphocytes. Cancer Res.

1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N,

2004;64:7985–94.

Liebes L, et al. Ionizing radiation inhibition of distant 13. Ruocco MG, Pilones KA, Kawashima N, Cammer M, untreated tumors (abscopal effect) is immune mediated.

Huang J, Babb JS, et al. Suppressing T cell motility

International Journal of Radiation Oncology, Biology,

induced by anti‐CTLA‐4 monotherapy improves anti‐

Physics. 2004;58(3):862–70.

tumor effects. J Clin Invest. 2012;122(10):3718–30.

2. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, 14. Demaria S, Golden EB, Formenti SC. Role of local radi-et al. Therapeutic effects of ablative radiation on local

ation therapy in cancer immunotherapy. JAMA Oncol.

tumor require CD8+ T cel s: changing strategies for can-

2015;1(9):1325–32.

cer treatment. Blood. 2009;114(3):589–95.

15. Diamond MS, Kinder M, Matsushita H, Mashayekhi M,

3. Chen DS, Mellman I. Oncology meets immunology: the

Dunn GP, Archambault JM, et al. Type I interferon is

cancer‐immunity cycle. Immunity. 2013;39(1):1–10.

selectively required by dendritic cel s for immune

4. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van

rejection of tumors. Journal of Experimental Medicine.

Endert P, et al. Calreticulin exposure is required for the

2011;208(10):1989–2003.

immunogenicity of gamma‐irradiation and UVC light‐

16. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM,

induced apoptosis. Cell Death and Differentiation.

Murphy KM, et al. Host type I IFN signals are required

2007;14(10):1848–50.

for antitumor CD8+ T cell responses through

5. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C,

CD8{alpha} + dendritic cel s. Journal of Experimental

Criollo A, et al. Toll‐like receptor 4‐dependent contribu-

Medicine. 2011;208(10):2005–16.

tion of the immune system to anticancer chemotherapy 17. Pilones KA, Aryankalayil J, Babb JS, Demaria S.

and radiotherapy. Nature Medicine. 2007;13:1050–9.

Invariant natural killer T cel s regulate anti‐tumor

6. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A,

immunity by controlling the population of dendritic

et al. STING‐dependent cytosolic DNA sensing pro-

cel s in tumor and draining lymph nodes. J Immunother

motes radiation‐induced type I interferon‐dependent

Cancer. 2014;2:37.

antitumor immunity in immunogenic tumors. Immunity. 18. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka 2014;41(5): 843–52.

KE, Vikram B, et al. Flt3‐Ligand administration after

7. Matsumura S, Wang B, Kawashima N, Braunstein S,

radiation therapy prolongs survival in a murine model

Badura M, Cameron TO, et al. Radiation‐induced

of metastatic lung cancer. Cancer Res. 1999;59:6028–32.

CXCL16 release by breast cancer cel s attracts effector T 19. Nikitina EY, Gabrilovich DI. Combination of gamma-cel s. Journal of Immunology. 2008;181:3099–107.

irradiation and dendritic cell administration induces a

8. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger

potent antitumor response in tumor‐bearing mice:

JG, Lord EM. Local radiation therapy of B16 melanoma

approach to treatment of advanced stage cancer.

tumors increases the generation of tumor antigen‐specific

International Journal of Cancer. 2001;94(6):825–33.

effector cel s that traffic to the tumor. Journal of 20. Teitz‐Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis Immunology. 2005; 174:7516–23.

MA, McGinn CJ, et al. Radiotherapy potentiates the

9. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger

therapeutic efficacy of intratumoral dendritic cell

JG, Lord EM. Radiation‐induced IFN‐gamma production

administration. Cancer Res. 2003;63:8466–75.

within the tumor microenvironment influences antitumor 21. Kim KW, Kim SH, Shin JG, Kim GS, Son YO, Park SW, immunity. Journal of Immunology. 2008;180(5): 3132–9.

et al. Direct injection of immature dendritic cel s into

10. Reits EA, Hodge JW, Herberts CA, Groothuis TA,

irradiated tumor induces efficient antitumor immunity.

Chakraborty M, Wansley EK, et al. Radiation modulates

International Journal of Cancer. 2004;109:685–90.

174 Immunotherapy in Translational Cancer Research 22. Shiraishi K, Ishiwata Y, Nakagawa K, Yokochi S, Taruki

abscopal effect when combined with anti‐CTLA‐4 anti-

C, Akuta T, et al. Enhancement of antitumor radiation

body. Clin Cancer Res. 2009;15(17):5379–88.

efficacy and consistent induction of the abscopal effect 34. Twyman‐Saint Victor C, Rech AJ, Maity A, Rengan R, in mice by ECI301, an active variant of macrophage

Pauken KE, Stelekati E, et al. Radiation and dual check-

inflammatory protein‐1alpha. Clinical Cancer Research.

point blockade activate non‐redundant immune mecha-

2008;14(4):1159–66.

nisms in cancer. Nature. 2015;520(7547):373–7.

23. Milas L, Mason KA, Ariga H, Hunter N, Neal R, 35. Postow MA, Cal ahan MK, Barker CA, Yamada Y, Yuan Valdecanas D, et al. CpG oligodeoxynucleotide enhances

J, Kitano S, et al. Immunologic correlates of the abscopal

tumor response to radiation. Cancer Res.

effect in a patient with melanoma. New England Journal

2004;64:5074–7.

of Medicine. 2012;366(10):925–31.

24. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, 36. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti Krieg AM, et al. Targeting Toll‐like receptor 9 with CpG

SC. An abscopal response to radiation and ipilimumab

oligodeoxynucleotides enhances tumor response to frac-

in a patient with metastatic non‐small cell lung cancer.

tionated radiotherapy. Clinical cancer research. 2005;11:

Cancer Immunology Research. 2013;1(6):365–72.

361–9.

37. Golden EB, Chachoua A, Fenton‐Kerimian MB,

25. Dewan MZ, Vanpouille‐Box C, Kawashima N, DiNapoli

Demaria S, Formenti SC. Abscopla responses in meta-

S, Babb JS, Formenti SC, et al. Synergy of topical Toll‐

static non‐small cell lung cancer (NSCLC) patients treat-

like receptor 7 agonist with radiation and low‐dose

ded on a phase 2 study of combined radiation therapy

cyclophosphamide in a mouse model of cutaneous

and ipilimumab: evidence for the in situ vaccination hy-

breast cancer. Clinical Cancer Research. 2012;18(24):

pothesis of radiation. International Journal of Radiation

6668–78.

Oncology, Biology, Physics. 2015;93(3S):S66–7.

26. Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, 38. Sanmamed MF, Pastor F, Rodriguez A, Perez‐Gracia JL, Stratford IJ, Honeychurch J, et al. Systemic delivery of a

Rodriguez‐Ruiz ME, Jure‐Kunkel M, et al. Agonists of

TLR7 agonist in combination with radiation primes

co‐stimulation in cancer immunotherapy directed

durable antitumor immune responses in mouse models

against CD137, OX40, GITR, CD27, CD28, and ICOS.

of lymphoma. Blood. 2013;121(2):251–9.

Semin Oncol. 2015;42(4):640–55.

27. Chakraborty M, Abrams SI, Coleman CN, Camphausen 39. Sanchez‐Paulete AR, Labiano S, Rodriguez‐Ruiz ME, K, Schlom J, Hodge JW. External beam radiation of

Azpilikueta A, Etxeberria I, Bolaños E, et al. Deciphering

tumors alters phenotype of tumor cel s to render them

CD137 (4‐1BB) signaling in T‐cell costimulation for

susceptible to vaccine‐mediated T‐cell killing. Cancer

translation into successful cancer immunotherapy. Eur J

Res. 2004;64:4328–37.

Immunol. 2016;46(3):513–22.

28. Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee 40. Shi W, Siemann DW. Augmented antitumor effects of T, Kawashima N, et al. The combination of ionizing radi-radiation therapy by 4‐1BB antibody (BMS‐469492)

ation and peripheral vaccination produces long‐term

treatment. Anticancer Res. 2006;26(5A):3445–53.

survival of mice bearing established invasive GL261 gli-

41. Newcomb EW, Lukyanov Y, Kawashima N, Alonso‐

omas. Clinical Cancer Research. 2006;12:4730–7.

Basanta M, Wang S‐C, Liu M, et al. Radiotherapy

29. Pardoll DM. The blockade of immune checkpoints in

enhances antitumor effect of anti‐CD137 therapy in a

cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):

mouse Glioma model. Radiat Res. 2010;173(4):426–32.

252–64.

42. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK,

30. Sharma P, Allison JP. The future of immune checkpoint

Vetto JT, et al. Adjuvant therapy with agonistic anti-

therapy. Science. 2015;348(6230):56–61.

bodies to CD134 (OX40) increases local control after

31. Ji R‐R, Chasalow SD, Wang L, Hamid O, Schmidt H,

surgical or radiation therapy of cancer in mice. J

Cogswell J, et al. An immune‐active tumor microenvi-

Immunother. 2010;33(8):798–809.

ronment favors clinical response to ipilimumab. Cancer 43. Rosenberg SA. IL‐2: the first effective immunotherapy Immunology, Immunotherapy. 2012;61(7):1019–31.

for human cancer. Journal of Immunology. 2014;192(12):

32. Demaria S, Kawashima N, Yang AM, Devitt M‐L, Babb

5451–8.

JS, Allison JP, et al. Immune‐mediated inhibition of 44. Yasuda K, Nirei T, Tsuno NH, Nagawa H, Kitayama J.

metastases following treatment with local radiation and

Intratumoral injection of interleukin‐2 augments the

CTLA‐4 blockade in a mouse model of breast cancer.

local and abscopal effects of radiotherapy in murine

Clinical Cancer Research. 2005;11:728–34.

rectal cancer. Cancer Sci. 2011;102(7):1257–63.

33. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert 45. van den Heuvel MM, Verheij M, Boshuizen R, Belderbos JK, Babb JS, Formenti SC, et al. Fractionated but not

J, Dingemans AM, De Ruysscher D, et al. NHS‐IL2

single dose radiotherapy induces an immune‐mediated

combined with radiotherapy: preclinical rationale and

CHAPTER 12 Immunomodulation with Radiation 175

phase Ib trial results in metastatic non‐small cell lung 58. Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, cancer following first‐line chemotherapy. J Transl Med.

Ramakrishnan R, Ahmed J, et al. Combination of

2015;13:32.

external beam radiotherapy (EBRT) with intratumoral

46. Vanpouille‐Box C, Diamond JM, Pilones KA, Zavadil J,

injection of dendritic cel s as neo‐adjuvant treatment of

Babb JS, Formenti SC, et al. TGFβ is a master regulator

high‐risk soft tissue sarcoma patients. International

of radiation therapy‐induced anti‐tumor immunity.

Journal of Radiation Oncology, Biology, Physics.

Cancer Res. 2015;75(11):2232–42.

2012;82(2):924–32.

47. Topalian SL, Drake CG, Pardoll DM. Immune check-

59. Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga

point blockade: a common denominator approach to

L, Liebes L, et al. Topical TLR7 agonist imiquimod can

cancer therapy. Cancer Cel . 2015;27(4):450–61.

induce immune‐mediated rejection of skin metastases

48. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A,

in patients with breast cancer. Clinical Cancer Research.

McLaughlin NM, et al. Radiotherapy increases the per-

2012;18(24):6748–57.

missiveness of established mammary tumors to rejection 60. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, by immunomodulatory antibodies. Cancer Res.

Trefzer U. Phase 1 evaluation of intralesional y injected

2012;72(13):3163–74.

TLR9‐agonist PF‐3512676 in patients with basal cell car-

49. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z,

cinoma or metastatic melanoma. J Immunother.

Ruzevick J, et al. Anti‐PD‐1 blockade and stereotactic

2008;31(5):520–7.

radiation produce long‐term survival in mice with intra-

61. Krieg AM. Toll‐like receptor 9 (TLR9) agonists in the

cranial gliomas. International Journal of Radiation

treatment of cancer. Oncogene. 2008;27(2):161–7.

Oncology, Biology, Physics. 2013;86(2):343–9.

62. Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A,

50. Deng L, Liang H, Burnette B, Beckett M, Darga T,

Fridman WH, et al. Trial watch: immunostimulation

Weichselbaum RR, et al. Irradiation and anti‐PD‐L1

with Toll‐like receptor agonists in cancer therapy.

treatment synergistical y promote antitumor immunity

Oncoimmunology. 2016;5(3):e1088631.

in mice. J Clin Invest. 2014;124(2):687–95.

63. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M,

51. Dovedi SJ, Adlard AL, Lipowska‐Bhal a G, McKenna C,

Advani RH, et al. In situ vaccination with a TLR9 agonist

Jones S, Cheadle EJ, et al. Acquired resistance to frac-

induces systemic lymphoma regression: a phase I/II

tionated radiotherapy can be overcome by concurrent

study. J Clin Oncol. 2010;28(28):4324–32.

PD‐L1 blockade. Cancer Res. 2014;74(19):5458–68.

64. Golden EB, Chhabra A, Chachoua A, Adams S, Donach

52. Curran MA, Montalvo W, Yagita H, Allison JP. PD‐1 and

M, Fenton‐Kerimian M, et al. Local radiotherapy and

CTLA‐4 combination blockade expands infiltrating T

granulocyte‐macrophage colony‐stimulating factor to

cel s and reduces regulatory T and myeloid cel s within

generate abscopal responses in patients with metastatic

B16 melanoma tumors. Proc Natl Acad Sci U S A.

solid tumours: a proof‐of‐principle trial. Lancet Oncol.

2010;107(9):4275–80.

2015;16(7):795–803.

53. Wolchok JD, Kluger H, Cal ahan MK, Postow MA, Rizvi 65. Okuno S, Petersen I, Shives T, Mahoney M, Haddock M, NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in

Sim F, et al. Chemotherapy, irradiation, and surgery for

advanced melanoma. New England Journal of Medicine.

function‐preserving curative therapy of primary

2013;369:122–33.

extremity soft tissue sarcomas: initial treatment with I‐

54. Twyman‐Saint Victor C, Rech AJ, Maity A, Rengan R,

MAP and inhalation GM‐CSF during preoperative irra-

Pauken KE, Stelekati E, et al. Radiation and dual check-

diation and postoperatively. Am J Clin Oncol.

point blockade activate non‐redundant immune mecha-

2016;39(2):204–9.

nisms in cancer. Nature. 2015;520(7547):373–7.

66. Li MO, Flavell RA. TGF‐beta: a master of all T cell

55. Xu J, Escamil a J, Mok S, David J, Priceman S, West B, et al.

trades. Cel . 2008;134(3):392–404.

CSF1R signaling blockade stanches tumor‐infiltrating 67. Postow MA, Cal ahan MK, Barker CA, Yamada Y, Yuan myeloid cel s and improves the efficacy of radiotherapy in

J, Kitano S, et al. Immunologic correlates of the abscopal

prostate cancer. Cancer Res. 2013;73(9):2782–94.

effect in a patient with melanoma. N Engl J Med.

56. Klug F, Prakash H, Huber PE, Seibel T, Bender C,

2012;366(10):925–31.

Halama N, et al. Low‐dose irradiation programs macro-

68. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC,

phage differentiation to an iNOS+/M1 phenotype that

Mollick JA, et al. A systemic complete response of meta-

orchestrates effective T cell immunotherapy. Cancer

static melanoma to local radiation and immunotherapy.

Cel . 2013;24(5):589–602.

Translational Oncology. 2012;5(6):404–7.

57. Rosenberg SA. IL‐2: the first effective immunotherapy 69. Grimaldi AM, Simeone E, Giannarelli D, Muto P, for human cancer. Journal of Immunology.

Falivene S, Borzillo V, et al. Abscopal effects of radio-

2014;192(12):5451–8.

therapy on advanced melanoma patients who progressed

176 Immunotherapy in Translational Cancer Research after ipilimumab immunotherapy. Oncoimmunology. 77. Wick W, Suarez C, Rodon J, Desjardins A, Forsyth P, 2014;3:e28780.

Gueorguieva I, et al. Phase 1b/2a study evaluating safety,

70. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A,

pharmacokinetics and pharmacodynamics responses of

Alumkal JJ, et al. Ipilimumab alone or in combination

the oral transforming growth factor‐beta (TGF‐β)

with radiotherapy in metastatic castration‐resistant

receptor I kinase inhibitor LY2157299 monohydrate

prostate cancer: results from an open‐label, multicenter

combined with chemoradiotherapy in newly diagnosed

phase I/II study. Ann Oncol. 2013;24(7):1813–21.

malignant gliomas. Poster presented at: 18th Annual

71. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van

SNO Scientific Meeting and Education Day; November

den Eertwegh AJ, et al. Ipilimumab versus placebo after

22, 2013; San Francisco, CA: Society of Neurooncology;

radiotherapy in patients with metastatic castration‐

2013.

resistant prostate cancer that had progressed after 78. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, docetaxel chemotherapy (CA184‐043): a multicentre,

Balter P, et al. Stereotactic ablative radiotherapy versus

randomised, double‐blind, phase 3 trial. Lancet Oncol.

lobectomy for operable stage I non‐small‐cell lung can-

2014;15(7):700–12.

cer: a pooled analysis of two randomised trials. Lancet

72. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J,

Oncol. 2015;16(6):630–7.

Garbe C, et al. Ipilimumab plus dacarbazine for previ-

79. Zaretsky JM, Garcia‐Diaz A, Shin DS, Escuin‐Ordinas

ously untreated metastatic melanoma. New England

H, Hugo W, Hu‐Lieskovan S, et al. Mutations associated

Journal of Medicine. 2011;364(26):2517–26.

with acquired resistance to PD‐1 blockade in melanoma.

73. Tang C, Welsh JW, de Groot P, Masserelli E, Chang JY,

New England Journal of Medicine. 2016;375(9):819–29.

Hess KR, et al. Phase I trial combining ipilimumab + 80. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, high dose stereotactic radiation: Results and serum

Eyring AD, et al. PD‐1 blockade in tumors with mis-

immune correlates. Journal of Clinical Oncology.

match‐repair deficiency. New England Journal of

2016;34(suppl; abstr 3022).

Medicine. 2015;372(26):2509–20.

74. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, 81. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective Siebert JC, et al. Phase 1 study of stereotactic body radio-depletion of CD4+CD25+Foxp3+ regulatory T cel s by

therapy and interleukin‐2: tumor and immunological

low‐dose cyclophosphamide is explained by reduced intra-

responses. Sci Transl Med. 2012;4(137):137ra74.

cel ular ATP levels. Cancer Res. 2010;70(12): 4850–8.

75. Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, 82. Son CH, Bae JH, Shin DY, Lee HR, Jo WS, Yang K, et al.

Scarpi E, et al. Radiotherapy as an immunological

Combination effect of regulatory T‐cell depletion and

booster in patients with metastatic melanoma or renal

ionizing radiation in mouse models of lung and colon

cell carcinoma treated with high‐dose Interleukin‐2:

cancer. International Journal of Radiation Oncology,

evaluation of biomarkers of immunologic and

Biology, Physics. 2015;92(2):390–8.

therapeutic response. J Transl Med. 2014;12:262.

83. Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller 76. Ridolfi L, De Rosa F, Granato AM, Pancisi E, Bulgarelli J, DS, et al. Immune infiltration and PD‐L1 expression in

Romeo A, et al. Radiotherapy as an immunological

the tumor microenvironment are prognostic in osteo-

booster in patients with metastatic melanoma or renal

sarcoma. Sci Rep. 2016;6:30093.

cell carcinoma treated with high‐dose interleukin‐2: 84. Demaria S, Coleman CN, Formenti S. Radiotherapy: Interim analysis data. Journal of Clinical Oncology.

changing the game in immunotherapy. Trends in Cancer.

2015;33(Suppl; abstr e14007).

2016;2(6):286–94.





CHAPTER 13

13 Good Manufacturing Practices

Facilities for Cel ular Therapy

Andrew D. Fesnak1 and Bruce L. Levine2

1 Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

2 Department of Pathology and Laboratory Medicine and Center for Cel ular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Introduction to current Good

clinical grade immunotherapies that fall under

Manufacturing Practices

these regulations.

Cel ular therapies may hold advantages over

Current Good Manufacturing Practices (cGMP) small molecule therapies for indications such as are the minimum processes necessary to manufac- cancer and inflammation due to the selectivity, ture drug products administered to humans. GMPs potency, migratory activity, and persistence of cel s were first developed in 1963 to help regulate the [3]. For cel ular therapy products that are “more pharmaceutical industry shortly after thalidomide than minimal y manipulated” in FDA terms, the was found to cause phocomelia in approximately regulatory burden is greater than for minimal y 10,000 children who were exposed to the drug in manipulated cell products such as hematopoietic utero [1]. During the next several decades, updated stem cell transplant. The “more than minimal cGMPs were established to help regulate increasing manipulation” categorization applies to cell prod-aspects of drug development and processing. ucts including those that are used for a function Adherence to cGMPs is the first step in ensuring that is not homologous to their tissue or cell type of the production of safe products that contain the origin, undergo a period of cell culture ex vivo, or stated ingredients at the stated strength. Under are gene modified. Most hematopoietic stem cell cGMP, producers must adhere to the regulatory laboratories operate under Good Laboratory requirements described in Title 21 of the Code of Practices (GLP) but do not meet cGMP standards Federal Regulations [2]. Operation within this for more than minimal manipulation. While some regulatory framework carries the power of federal laboratories process both hematopoietic stem cell law, and compliance is assessed by the United States products and more advanced, highly manipulated Food and Drug Administration (FDA). When immunotherapies, it is crucial to ensure that required, nonadherence to cGMP standards could appropriate standard operating procedures (SOPs) result in responses ranging from FDA warning and workflows are in place to meet regulatory letters to criminal prosecution. Therefore, under- requirements.

standing of and adherence to cGMP are of the

SOPs apply to many aspects of operating a

utmost importance for facilities manufacturing cGMP facility, including the validation, calibration, Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

177





178 Immunotherapy in Translational Cancer Research operation, maintenance, and cleaning of the equip- both starting material and desired end product.

ment, as well as the receipt, quarantine, labeling, Therefore, a cGMP laboratory must validate and and storage of materials. SOPs also cover the document each specific intervention (e.g., cell training and qualification of personnel, environ- washing, selection, culture, harvest, and formula-mental monitoring, and cleaning of the facility. tion/storage) for a given protocol. Such validation Complex processes, such as production of immu- should match the final process; however, this may notherapies, leave opportunities for deviations and not always be possible. For instance, patient cel-errors due to the requirement for human interven- lular material may be unavailable and healthy tion and decision making. A robust quality system donor tissue may have to substitute, although this specifical y identifies gaps and provides guidance carries risks in imperfect modeling of the behavior to avoid error through SOPs. Nonetheless, cata- of cel s derived from patient material.

strophic failures due to preventable errors may

Cell washing presents particular challenges in

occur when quality standards are violated. the cGMP setting. Many cell washing methods Therefore, a quality management system and the have been adapted from other clinical applications team to implement it are essential components of such as intraoperative blood recovery systems, cGMP immunotherapy laboratory operations. including the CellSaver5 (Haemonetics, Braintree, Extensive training of all personnel is required to MA, USA). These types of instruments were not reduce failure and bring quality products to original y designed for immunotherapy products, patients. As compared with GLP, cGMP requires and so they often have limited capabilities.

more rigorous documentation and verification, Recognizing the demand, new cell‐therapy‐specific as well as a more robust quality system. cell washing instrumentation has been developed.

Importantly, staff must know exactly what the Newer instruments offer immunotherapy‐specific standards are and be appropriately trained to meet improvements such as closed systems, real-those requirements.

time monitoring of data, and greater degrees of

automation.

Manufacture of cellular

Two centrifugal‐based cell washers, the

immunotherapies in the cGMP

CytoMate (Baxter International, Deerfield, IL,

setting

USA) and the Lovo (Fenwal, Lake Zurich, IL, USA)

have in the past or can now be used to demonstrate

While many promising discoveries may be made in the importance of evolution and flexibility of the research laboratory, successful translation of cel ular therapy‐specific instruments for immuno-these immunotherapeutics into the cGMP setting therapy product manufacturing. The CytoMate, is not guaranteed. cGMP production presents sev- which has been discontinued, was a ful y automated eral challenges not encountered in the research lab- device designed for washing and concentrating oratory and may require modification of the leukocytes. While the CytoMate efficiently depleted protocol established at the research bench. These platelets and some red blood cel s through a challenges touch on all aspects of immunothera- spinning membrane filter, it had a limited flow rate.

peutic development, from receipt of starting bio- At volumes above 5 liters, long runs times meant material, reagents, and supplies to the final that cell yield and viability may have been compro-disposition of the product.

mised during the several hours required for

cGMP manufacturing of cel ular immunother- harvest. The CytoMate had been discontinued for apies begins with obtaining biomaterial from the several years when the technology was resurrected patient or donor. This can be achieved via leuka- in the form of the Lovo, which was designed with pheresis, bone marrow aspiration, whole blood modular cartridges for harvesting different vol-collection, cord blood collection, or excision of umes [4].

tissue. While procedures to obtain starting bioma-

Cell separation and culture also provide cGMP‐

terial must adhere to clinical standards, subsequent specific challenges. Ficoll gradient separation after processing steps prior to seeding cultures are not apheresis can effectively enrich lymphocytes and standardized. Protocols will vary depending on monocytes and deplete red cel s, platelets, and





CHAPTER 13 Good Manufacturing Practices Facilities for Cel ular Therapy 179

granulocytes. However, in our experience the high- up cell manufacture and are currently used in many est yields are obtained with experienced technicians cGMP facilities to move beyond the problems in open systems of centrifuge tubes, rather than inherent in generating very large numbers of cel s closed automated systems, which require equip- in static cell culture [9].

ment and capital investment.

Elutriation separates cell populations based on Modification of cells for centrifugal force and increasing buffer counter immunotherapy flow, and in our facility it is performed in a closed Cell modifications, such as selective expansion or system using the Elutra (Terumo BCT, Lakewood, transduction, require particular cGMP consider-CO, USA) [5]. The advantage of this technology is ations. Antibody‐based reagents can be used to that it can separate lymphocytes from monocytes selectively expand or differentiate target cell popu-and also can deplete red blood cel s and platelets. lations. In the cGMP setting, each of these reagents Further cell separation of cel s of similar size and must be individual y controlled and certified as density requires the use of antibody/ligand‐based cGMP grade prior to addition to the culture.

separation methods. Some, such as flow cytometry cGMP‐grade antibody reagents may not be com-sorting, are open systems. Others, such as the mercial y available for every protocol, however.

Miltenyi CliniMACS and associated tubing kits, are

Several gene delivery techniques for cel ular

closed systems. The availability of cGMP‐grade therapies have been developed, including viral reagents is the limiting factor in the use of any of vectors [10–14], transposons [14–17], and RNA these systems.

transfection [17–19]. Viral vectors, including

Culture of cel s in the cGMP laboratory differs gamma‐retroviruses and ‐lentiviruses, are cur-significantly from cell culture in the research envi- rently the most commonly used methods of ronment. While ubiquitous in the research world, modifying cel s for clinical trials of cel ular ther-fetal bovine serum or fetal calf serum should be apies. Gamma‐retroviruses and ‐lentiviruses avoided in cGMP cell culture, because exposure to deliver RNA, which is reverse transcribed into xeno‐antigens can cause serious adverse reactions DNA and permanently integrated into the genomic in patients [6, 7]. The amount of bovine serum cur- DNA of the host cel , resulting in a stable transduc-rently available is predicted to support the tion and long‐term expression of the gene of development of 400,000 therapeutic doses of cel- interest [20]. However, viral vectors must meet lular therapy per year, according to one estimate cGMP quality control standards, and one must

[8]. Therefore, if cel ular therapies become widely assay for potential residual replication‐competent used across many indications in the near future, retroviruses (RCR) in the vector lot and after cell alternatives to bovine serum as well as human transduction. Production and use of viral vectors serum will be imperative. When adapting research for gene transfer is typical y performed under bio-protocols to the cGMP laboratory, human serum safety level 2 conditions due to regulations or serum mimics may replace xenogeneic serum; regarding the use of viral vectors and recombinant however, this may require alteration of the current products.

protocols for cell culture. Certain preclinical

Transfection of RNA into cel s via electropora-

studies should be carried out in a cGMP facility or tion is a newer method of gene transfer that has with cGMP reagents to determine whether it is fea- also been used in the clinic [21]. In contrast to sible to adapt the preclinical protocol to produce transduction with a viral vector, electroporation of clinical‐grade cel ular therapies.

RNA results in a transient expression of the gene

An additional concern when transitioning from product [22]. The model we have employed in preclinical experiments to clinical studies is the clinical trial design using RNA‐modified chimeric scale at which the cel s need to be manufactured. antigen receptor (CAR) T cel s involves multiple Growing cel s at a larger scale requires careful cell infusions spread over two weeks. If toxicity to consideration of cell density, media exchange, and healthy tissues is observed in trials using CAR T

gas exchange requirements. Bioreactors have been cel s transfected with RNA, the next scheduled developed to help streamline the process of scaling infusion of CAR T cel s can be cancelled, and the





180 Immunotherapy in Translational Cancer Research toxicity becomes self‐limiting. This alleviates the

Another aspect of cGMP cel ular therapy to con-

potential concerns of toxicity arising from long‐ sider is the personal nature of the product. In most lived cel ular therapies and the theoretic risk of cases, cell therapies are manufactured using the genotoxicity. However, the shorter timeframe of patient’s own cel s, which have been obtained transgene expression also limits the duration of through an apheresis procedure. The patients who therapeutic efficacy. Another advantage of the are treated with cel ular therapies typical y have RNA transfection strategy is that RCR testing does very poor prognoses with available therapies and not need to be performed on the final product, as are receiving a cel ular therapy product in a clinical with viral vector‐transduced cel ular therapies. trial as a last resort. Thus, in the cases where cell Final y, RNA production and testing can be per- and gene therapy products fail to meet a release cri-formed at a fraction of the cost and time needed for terion apart from a sterility assay or RCR assay, viral vector production [23, 24].

additional consideration may be needed on a per

patient basis before disposing of the product

Criteria for use of cellular therapies

entirely. Current research is underway to develop

generated in a cGMP facility

“off‐the‐shelf” cel ular therapies, which can be

Products made in cGMP facilities must meet spec- manufactured using cel s from healthy donors and ified acceptance/rejection criteria necessary for may result in cel ular therapies becoming more determining whether a batch of product will meet readily available to patients [28]. This approach has regulatory specifications for the safety, purity, had some activity in preclinical experiments, but potency, and identity of the drug product. Specific results from clinical trials have not yet been assays for cel ular therapy product release have reported.

been developed [25–27]. Potency tests for cel ular

therapies general y involve cytotoxicity or cytokine Infrastructure considerations release assays in vitro to determine that the cel s in cGMP manufacture have the capacity to exert the desired effector

functions. Sterility testing is another important Organizational infrastructure release assay for cel ular therapies. A Gram stain of and quality standards the cel s can rapidly identify bacteria in the prod- Technical aspects of production are just one com-uct; however, this test is considered unreliable, of ponent of cGMP immunotherapy laboratory oper-low sensitivity, and often results in false positive ation. The infrastructure of the laboratory, whether outcomes. Cel ular therapy products are also tested it is physical or organizational, is also crucial to for endotoxin and mycoplasma, and the purity and maintaining a high‐quality cGMP facility identity of the cel s can be examined by flow cy- (Figure 13.1). cGMP laboratories for processing tometry or other phenotypic assays.

cel ular immunotherapies typical y have several

If the cel s are cryopreserved prior to infusion different rooms, including separate rooms for into the patient, it is important to freeze the cel s in sample staging, cell expansion, incoming material several aliquots so that a small sample may be quarantine and release, waste removal, and per-tested without thawing the entire product. Cel s sonnel changing areas. If space is limited, then are typical y cryopreserved in a cryoprotectant‐ materials must be clearly labeled on separate cabi-supplemented media and stored in the vapor phase nets or shelves, or in separate refrigerators and of liquid nitrogen. An important part of any cel freezers. These distinct areas are very important for processing facility involves the integrity of the liquid separating quarantined materials from quality nitrogen tanks and freezers. Alarm systems can assurance release materials. The personnel in the automatical y alert facility personnel by phone or facility should ideal y be able to move from room email of changes in temperature, ideal y with to room in one direction, so as to further avoid any enough time for transfer of the samples to a new cross‐contamination between rooms of the facility.

storage location before the samples thaw. Therefore, Airlock systems with differential air pressure can backup freezers and liquid nitrogen tanks must further aid in preventing cross‐contamination.

be available and dutiful y maintained at cGMP

The organizational infrastructure of a cGMP

facilities.

laboratory involves several levels of management



CHAPTER 13 Good Manufacturing Practices Facilities for Cel ular Therapy 181

R

Patient

aw mater

Testing

ial

Acceptance Criteria

Cell Source

- Safety (e.g., absence of adventitious agents,

replication competent viral vector, off target

- Leukapheresis

gene modification

- Bone marrow aspiration

- Purity

- Whole blood

- Potency

- Cord blood

- Identity

- Excised tissue

- Stability

Cell Washing/Separation

Gene delivery

- CellSaver5

- CliniMACS Prodigy (magnetic selection)

- Murine oncoretrovirus

- Elutra (enrich for lymphocytes)

- Lentivirus

- Lovo

- Electroporation

- Ficoll

- Nucleofection

Manufacturing

- Sefia

- Sepax

Physical

Quality Management

Documentation

Infrastructure

System

Practices

Accreditations and

Regulatory Compliance

Quality and Infrastructure

Figure 13.1 Clinical cell processing operational systems.

then be tested according to FDA acceptance criteria for

Raw material for cellular immunotherapy products can be

safety, purity, potency, identity, and stability. All

obtained from the patient from a number of sources

manufacturing for clinical use and testing must occur

depending on the application. Methods of cell washing,

within a system of quality and regulatory compliance that

manufacturing, and gene delivery generate a cell product

covers facilities, equipment, documentation, and quality

endowed with enhanced or novel functions that must

operations.

and personnel. The head of the laboratory is personnel monitoring results, and equipment responsible for determining that all of the key staff malfunctions. The quality team ensures that each of the cGMP facility have been adequately trained product has been tested properly and was produced and are appropriately supervised. The technical under appropriate cGMP facility conditions.

management personnel oversee the calibration of

A key quality standard that must be monitored

instruments, environmental monitoring, materials by the quality team involves the documentation of storage, and staff training programs. The technical all manufacturing and testing that occurs in cGMP

staff must be qualified in the background and pro- facilities. This includes documents detailing the cedures relevant to the work required.

policies, SOPs, batch records, quality control test

A cGMP laboratory must also include a quality methods, and product specifications. Product team. This group’s primary responsibility is to specifications include tests on identity, content, develop, enact, and monitor a comprehensive quality purity, potency, and quality of the product, as well management system to ensure production and test- as any intermediates, water, solvents, or other ing of reliably safe and defined products. This team reagents used in the manufacturing process.

is expected to be independent from the personnel Documents describing the procedures used in the involved in production within the facility. The facility should be clearly written and thoroughly quality team is responsible for any investigations and reviewed to prevent errors in communication. Any corrective actions that are taken in the event that a corrections made to a document should be signed finished product is rejected. Products may be and dated, and corrections must not obscure the rejected for a variety of reasons, including failure original information present on the document.

of sterility tests, unexpected testing results, prod-

In addition, the quality team must oversee the

uct degradation, unacceptable environmental or labeling of all equipment, packaging, directions,





182 Immunotherapy in Translational Cancer Research and manuals within the facility. The FDA considers intervals. Storage and integrity of the data are any devices within a cGMP facility that are unla- crucial in the event of an audit of the facility.

beled or labeled improperly inappropriate for

cGMP manufacturing. The product labels should Environmental monitoring and cleaning include the name, concentration, date of manufac- Monitoring of both viable and nonviable particles ture, expiration date, storage condition, and control at various locations throughout the facility is number of the product. Documents describing the important to ensure that the facility is operating procedures used in the facility should be clearly within specifications [29]. The environment of a written and thoroughly reviewed to prevent errors cGMP facility should be sampled during the in communication. Any corrections made to a doc- normal operation of processes and with facility ument should be signed and dated, and corrections personnel present, in order to guarantee the collec-must not obscure the original information present tion of accurate data. Particle counts reflect both on the document.

the design of the air handling system and personnel

practices. Air cleanliness can be especial y impor-

Physical infrastructure

tant during open processing steps, and the loca-

Some infrastructure standards are encoded in reg- tions where these processes take place should be ulations or guidelines for the production of cGMP‐ heavily monitored.

grade cell products for clinical use. These include

Environmental monitoring, gowning and per-

unidirectional workflow, water, heating, ventila- sonnel practices, cleaning within and just outside tion, air conditioning, and electricity. The air input the cGMP facility, and pest control must all be for the facility should pass through high‐efficiency covered in SOPs. The environmental monitoring particulate air (HEPA) filters to reduce contami- SOPs should describe the required frequency of air nating particles. Additional y, any processes that sampling, the duration of sampling, the surface may generate aerosols or present a risk to the prod- area or volume of air that must be sampled, the uct during processing should be performed in bio- equipment and techniques utilized, and how to safety cabinets.

respond to readings that are outside of acceptable

Importantly, however, there are numerous unique limits [30]. Contaminating air particles are typi-and specific considerations for each individual cal y quantified as the number of colony‐forming program. For instance, the design, construction, and units detectable on a culture plate. The gowns and implementation of a brand new facility present dif- gloves worn by the personnel in the facility should ferent costs and benefits than retrofitting an existing also be monitored for cleanliness. The cleaning laboratory. When adapting a cGMP facility for a new SOPs should describe the methods and frequency product, the unidirectional workflow of the existing of cleaning, including rotation of cleaning agents.

facility must be considered and ideal y will be used

by the new facility. Additional y, in multiproduct Global systems and organizations facilities in academia, designing and building (let for cellular therapy cGMP facilities alone funding) a facility to industry standards can be A coding and labeling system for cel ular therapy problematic. Ultimately, effective use of physical products, known as the International Society of infrastructure in the cGMP environment will evolve Blood Transfusion (ISBT) 128, provides global y from the interaction of regulatory requirements and unique identification numbers for blood products fulfillment of a programmatic need.

[31, 32]. Using international y applied definitions

The equipment involved in processing the data and codes to maintain the data for cel ular ther-generated by cGMP facilities should also be care- apies streamlines international transport of blood ful y monitored and controlled. This includes all and cell products and reduces language barriers in automated equipment in the laboratory as well as the labeling of the products. Additional y, trace-computers and critical software used to document ability is improved with the ISBT 128 system processing or release testing. The data generated by because each product has a unique number and the the equipment or calculated by software must be software used to track the products can be used protected and retrievably backed up at regular worldwide [31].





CHAPTER 13 Good Manufacturing Practices Facilities for Cel ular Therapy 183

Interlaboratory interaction can provide an successful product to commercial failure. One important infrastructure for growth of the field as a example of this is Provenge, a cel ular therapy man-whole. Standards organizations such as the ufactured by Dendreon that was approved by the Foundation for the Accreditation of Cel ular FDA to treat patients with prostate cancer in 2010.

Therapy (FACT) and the Joint Accreditation The product that was approved by the FDA Committee of the International Society for Cel ular required a freshly collected apheresis product that Therapy (ISCT) and the European Society for was not cryopreserved and was formulated as three Blood and Marrow Transplantation (EBMT)— vaccines, each delivered as fresh product. This (JACIE)—develop global standards and an required highly orchestrated logistics to source and international y recognized system of accreditation. collect the apheresis product, schedule the manu-In addition, professional organizations such as the facture and testing, and deliver the final products.

American Association of Blood Banks (AABB), the Furthermore, the manufacturing process was ISCT, the American Society of Gene & Cell Therapy almost entirely manual and dependent on highly (ASGCT), and the European Society of Gene & trained personnel. In 2014, Dendreon filed for Cell Therapy (ESGCT) aim for col aboration bankruptcy, followed a few months later by the between academia, regulatory bodies, industry purchase of the company by Valeant partners, and patient advocates to promote Pharmaceuticals International. However, in 2017

research, clinical practice, and standards relating to both Novartis and Kite filed Biologics License cel ular therapies. Professional advocacy organiza- Applications with the FDA for chimeric antigen tions, including the Alliance for Regenerative receptor T cel s for leukemia and lymphoma.

Medicine (ARM), promote legislative, regulatory,

Human trials with more than minimal y manip-

investment, and technical initiatives to help the ulated cell therapy products will require development and public understanding of novel cGMP‐grade production. At this time, demand for medical technologies worldwide. At a national these products is leading the supply of systems level, regional consortia such as the Cell including facilities, materials, reagents, equipment, Therapy Catapult in the UK, the Centre for and trained personnel necessary for production. As Commercialization of Regenerative Medicine the tools and devices for this industry improve, (CCRM) in Canada, and the National Heart, cGMP immunotherapy laboratories will enjoy even Lung, and Blood Institute (NHLBI) Production greater production capabilities. Much of this will Assistance for Cel ular Therapies (PACT) in the derive from the development of immunotherapy-United States promote col aboration and efficiency specific reagents and automated instruments. An within specific countries in bringing cel ular ther- example of a cell‐therapy‐specific automated prod-apies to the clinic. The successes of many of these uct is the CliniMACS Prodigy (Miltenyi Biotec, organizations argue in favor of greater development Bergisch Gladbach, Germany). This instrument is of regional and national infrastructure to support designed to maintain cel s in a closed system, auto-cGMP laboratories.

mate the majority of processes, and automatical y

obtain and store quality metrics. While the

Evolution of cGMP

CliniMACS Prodigy has limitations, it is an

immunotherapies

example of how cGMP elements can be incorpo-

rated into instrument design. As the field continues

Recent clinical success has invigorated the field of to progress, other well‐designed instruments can immunotherapy. One great need for the field is be expected to make cGMP production a reality for consideration of logistics and automation. Current laboratories that otherwise could not manufacture costs for cGMP immunotherapy development and cGMP‐grade products. Other considerations for production are prohibitive for small‐ and medium‐ cGMP cel ular processing laboratories include how sized academic medical centers and even small bio- much demand is anticipated for new products.

technology companies. Even for well‐funded Because cell and gene therapies are relatively new industry laboratories, failure to commit an ade- types of therapies with rapidly increasing demand, quate upfront investment could doom a clinical y the need for greater cell processing capability may





184 Immunotherapy in Translational Cancer Research increase dramatical y within the next five years as 5. Powell DJ, Jr., Brennan AL, Zheng Z, Huynh H, Cotte J, therapies currently under investigation are used in

Levine BL. Efficient clinical‐scale enrichment of lym-

larger clinical trials and for greater numbers of

phocytes for use in adoptive immunotherapy using a

indications.

modified counterflow centrifugal elutriation program.

Cytotherapy. 2009;11(7):923–35.

6. Mackensen A, Drager R, Schlesier M, Mertelsmann R,

Concluding remarks

Lindemann A. Presence of IgE antibodies to bovine

serum albumin in a patient developing anaphylaxis after

The use of cGMP facilities for cel ular therapies is

vaccination with human peptide‐pulsed dendritic cel s.

essential for bringing the highest quality cell prod-

Cancer Immunol Immunother. 2000;49(3):152–6.

ucts to patients. In this chapter, we have discussed 7. Selvaggi TA, Walker RE, Fleisher TA. Development of some of the infrastructure, documentation, envi-antibodies to fetal calf serum with arthus‐like reactions

ronmental monitoring, personnel, and other con-

in human immunodeficiency virus‐infected patients

cerns that must be addressed when designing or

given syngeneic lymphocyte infusions. Blood.

using a cGMP facility. Because there are many cel-

1997;89(3): 776–9.

lular therapies currently in preclinical development,

8. Brindley DA, Davie NL, Culme‐Seymour EJ, Mason C,

early‐phase clinical trials, and multicenter clinical

Smith DW, Rowley JA. Peak serum: implications of

trials, many new cGMP facilities will be built in the

serum supply for cell therapy manufacturing. Regen Med.

2012;7(1): 7–13.

near future or adapted from existing facilities. It is 9. Somerville RP, Dudley ME. Bioreactors get personal.

important for physicians and academic scientists as

Oncoimmunology. 2012;1(8):1435–7.

well as members of this growing industry to know 10. Frecha C, Levy C, Cosset FL, Verhoeyen E. Advances in the basics of cGMP manufacture when testing or

the field of lentivector‐based transduction of T and B

administering these therapies. This will allow for

lymphocytes for gene therapy. Mol Ther. 2010;

an easier transition from therapies in preclinical

18(10):1748–57.

development to clinical‐grade drugs, and therefore 11. Verhoeyen E, Costa C, Cosset FL. Lentiviral vector gene greater efficiency in getting novel therapeutics to

transfer into human T cel s. Methods Mol Biol.

the patients who need treatment.

2009;506:97–114.

12. Durand S, Cimarelli A. The inside out of lentiviral

vectors. Viruses. 2011;3(2):132–59.

Acknowledgments

13. Levine BL, Humeau LM, Boyer J, MacGregor RR,

Rebello T, Lu X, et al. Gene transfer in humans using a

B.L. Levine has commercial research grants from

conditional y replicating lentiviral vector. Proc Natl

Novartis Pharmaceuticals and has ownership

Acad Sci U S A. 2006;103(46):17372–7.

interest (including patents) in the University of 14. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Pennsylvania, which holds patent applications.

Olivares S, et al. piggyBac transposon/transposase

Financial support for medical editorial assistance

system to generate CD19‐specific T cel s for the

was provided by Novartis Pharmaceuticals. We

treatment of B‐lineage malignancies. Hum Gene Ther.

thank Judith Murphy, PhD, for assistance with this

2010;21(4):427–37.

manuscript.

15. Liu H, Visner GA. Applications of Sleeping Beauty

transposons for nonviral gene therapy. IUBMB Life.

2007;59(6):374–9.

References

16. Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, Dupuy AJ,

et al. Gene transfer into genomes of human cel s by the

1. Vargesson N. Thalidomide‐induced teratogenesis: history

sleeping beauty transposon system. Mol Ther.

and mechanisms. Birth Defects Res C Embryo Today.

2003;8(1):108–17.

2015;105(2):140–56.

17. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC,

2. Code of Federal Regulations: Title 21, (2015).

Restifo NP, et al. High‐efficiency transfection of primary

3. Fischbach MA, Bluestone JA, Lim WA. Cell‐based thera-

human and mouse T lymphocytes using RNA electro-

peutics: the next pil ar of medicine. Sci Transl Med.

poration. Mol Ther. 2006;13(1):151–9.

2013;5(179):179ps7.

18. Riet T, Holzinger A, Dorrie J, Schaft N, Schuler G, Abken 4. Wegener C, Heber C, Min K. Novel cell washing device

H. Nonviral RNA transfection to transiently modify T

using spinning membrane filtration. Cytotherapy.

cel s with chimeric antigen receptors for adoptive

2013;14(4):Abstract 86.

therapy. Methods Mol Biol. 2013;969:187–201.

CHAPTER 13 Good Manufacturing Practices Facilities for Cel ular Therapy 185

19. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, 25. Gee A. Product Manufacturing. Springer Science + Business Kampgen E, et al. Transfer of mRNA encoding

Media, LLC: 2009.

recombinant immunoreceptors reprograms CD4+ and 26. Cross PJ. Assays for the release of cel ular gene therapy CD8+ T cel s for use in the adoptive immunotherapy of

products. In: Concepts in Genetic Medicine [Internet].

cancer. Gene Ther. 2009;16(5):596–604.

John Wiley & Sons, Inc: 2006. Available from: http://

20. Coffin JM, Hughes SH, Varmus HE. The interactions of

onlinelibrary.wiley.com/doi/10.1002/9780470184585.

retroviruses and their hosts. In: Coffin JM, Hughes SH,

fmatter/pdf.

Varmus HE, editors. Retroviruses. Cold Spring Harbor, 27. Bravery CA, Carmen J, Fong T, Oprea W, Hoogendoorn NY: 1997.

KH, Woda J, et al. Potency assay development for cel-

21. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen

lular therapy products: an ISCT review of the require-

MC, Plesa G, et al. Mesothelin‐specific chimeric antigen

ments and experiences in the industry. Cytotherapy.

receptor mRNA‐engineered T cel s induce anti‐tumor

2013;15(1):9–19.

activity in solid malignancies. Cancer Immunol Res. 28. Poirot L, Philip B, Schiffer‐Mannioui C, Le Clerre D, 2014;2(2):112–20.

Chion‐Sotinel I, Derniame S, et al. Multiplex genome‐

22. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X,

edited T‐cell manufacturing platform for “off‐the‐shelf”

Brennan AL, et al. Multiple injections of electroporated

adoptive T‐cell immunotherapies. Cancer Res.

autologous T cel s expressing a chimeric antigen receptor

2015;75(18):3853–64.

mediate regression of human disseminated tumor. 29. U.S. Pharmacopeia. Microbiological evaluation of clean Cancer Res. 2010;70(22):9053–61.

rooms and other controlled environments.

23. Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley

Pharmacopeia forum. 211995. p. 440‐1‐61.

R, Olivares S, et al. Manufacturing of gene‐modified 30. Sutton S. The environmental monitoring program in a cytotoxic T lymphocytes for autologous cel ular therapy

GMP environment. Journal of GMP Compliance.

for lymphoma. Cytotherapy. 2006;8(2):105–17.

2010;14(3):22‐3‐30.

24. Singh H, Moyes JS, Huls MH, Cooper LJ. Manufacture 31. Slaper‐Cortenbach I. ISBT 128 coding and labeling for cel-of T cel s using the Sleeping Beauty system to enforce

lular therapy products. Cell Tissue Bank. 2010;11(4):375–8.

expression of a CD19‐specific chimeric antigen receptor. 32. Distler P. ISBT 128: A global information standard. Cell Cancer Gene Ther. 2015;22(2):95–100.

Tissue Bank. 2010;11(4):365–73.





CHAPTER 14

14 T Cell Receptor Mimic Antibodies

Gheath Alatrash and Jeffrey J. Mol drem

Department of Stem Cell Transplantation and Cel ular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

The T cell receptor (TCR) is a complex structure K of 1‐90 μM, in contrast to antibody affinity, D

that governs the recognition of the target cell or which can have a K in the low nM range, repreD

antigen‐presenting cell (APC) by the T cel . senting a high‐affinity interaction. The low affinity Although the specificity of the TCR for its target is of the TCR is a result of both its slow association primarily determined by the affinity of the TCR for rate (k ) and fast dissociation rate (k ) with the on

off

the peptide/major histocompatibility (MHC) pMHC [1, 2]. This low‐affinity, rapid interaction of antigen complex (pMHC), a number of additional the TCR/pMHC allows a T cell to efficiently screen molecules also play a critical role in the interaction a large number of peptides that are presented by between the target cell and the T cel , which could the MHC on normal and diseased cel s so that it result in subsequent T cell activation. The contact can establish an activation‐inducing immune syn-between the T cell and the target cell or APC, apse with the appropriate cel s.

known as the immune synapse, is composed of a

In addition to the contributions of the TCR/

multitude of receptor/ligand complexes in addition pMHC interaction to the activation of the T cel , to the TCR/pMHC. There are three broad cate- the TCR is a multisubunit extracel ular receptor gories of molecules at the cell surface that are that forms a complex with a number of corecep-involved in the recognition and activation of the T tors, including CD3 (composed of CD3γ, CD3δ, cell by the target. These include the TCR corecep- and CD3ε chains) and the ζ‐chain [3]. These core-tors (i.e., CD3, CD4, and CD8), costimulatory/ ceptors compose what is commonly known as the coinhibitory molecules (e.g., CD28, CTLA4, and TCR complex and are highly critical to the function PD1), and adhesion molecules (e.g., LFA‐1).

of the TCR; indeed, in many publications this com-

plex is termed the T cell “receptor.” CD3 and the

TCR interactions with pMHC,

ζ‐chain are critical for permitting the TCR to

coreceptors, and costimulatory

trigger T cell activation because the TCR lacks

molecules

intrinsic signaling capacity. CD3 and the ζ‐chain

contain phosphorylation sites, known as immune

The interaction of the TCR with the pMHC is char- receptor tyrosine‐based activation motifs (ITAMs), acterized as being a low‐affinity interaction, with a which are phosphorylated by the Src family Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

186





CHAPTER 14 T Cell Receptor Mimic Antibodies 187

tyrosine kinases LCK and FYN during T cell intricacies of coreceptor interactions with inhibi-activation [3]. Following phosphorylation, sig- tory components of the tumor microenvironment.

naling proteins with SH2 domains (e.g., TCR mimic (TCRm) antibodies, also known as ζ‐chain‐associated protein (ZAP‐70)) are recruited TCR‐like antibodies, provide a direct approach to to the TCR complex, and signaling cascades are target pMHC on the tumor cell surface with a propagated to activate the T cell [3, 4].

higher affinity than T‐cell‐based immunotherapy

In addition to CD3 and ζ‐chain, CD4 and CD8 that utilizes conventional TCRs. TCRm antibodies are important TCR coreceptors that are expressed may prove to be a great tool in the armamentarium by helper T cel s and cytotoxic T cel s, respectively. of cancer immunotherapies.

Although structural y different, CD4 and CD8

have very similar functions in the context of T cell TCRm development activation. CD4 and CD8 have two primary

functions: (1) they bind appropriate MHC on the TCRm antibodies are antibodies that bind to the surface of the antigen‐presenting cell or target cel , pMHC complex, similar to the TCR. The epitope thereby stabilizing the TCR‐pMHC and increasing of a TCRm is a conformational epitope comthe avidity of the TCR [5, 6]; and (2) they enhance posed of the peptide and the MHC complex.

phosphorylation of the ITAMs within the TCR TCRm antibodies are structurally identical to complex [7–11].

conventional antibodies, containing two light

In addition to the TCR and its coreceptors, a chains and two heavy chains. The light and heavy number of molecules that are expressed on the T chains are composed of a variable region that cell surface play a major role in regulating T cell determines the binding of the antibody to the activation following TCR‐pMHC binding. These pMHC, while the constant region determines the immune checkpoint molecules regulate the binding of the antibody to the Fc receptor on activation state of the T cell by either amplifying or immune cells as well as the ability of the anti-attenuating TCR signaling. Immune checkpoint body to fix complement. However, unlike con-receptors can be divided into two categories: coin- ventional antibodies, which target cell surface hibitory molecules and costimulatory molecules. molecules, TCRm antibodies target peptides Examples of these molecules include cytotoxic T derived from intracellular proteins and therefore lymphocyte antigen 4 (CTLA4) and programmed provide an approach to target an entire class of cell death protein 1 (PD1), which are the two most tumor‐associated or tumor‐specific intracellular well‐characterized coinhibitory checkpoint mole- antigens.

cules [12–15], and CD28, which is a costimulatory

Because the antigenic peptide (typically nine

molecule that is primarily involved in T cell amino acids) is a very small component of the priming [16–18]. There is a growing list of immune pMHC structure, which is dominated by the checkpoint molecules, and some have been tar- MHC molecule, generating TCRm antibodies geted clinical y with promising efficacy results can be a challenging task. The difficulties are

[19–26].

due to the high likelihood that an antibody that

Although the complexities of the checks and bal- binds the pMHC will have a high affinity for the ances system that are imparted on the T cell are MHC component of the pMHC, irrespective of essential for normal immune homeostasis, these the peptide that is found within the antigen-factors often cause major obstacles in developing binding groove of the pMHC. In the following cancer immunotherapies. The complex interac- sections, we will discuss two main approaches to tions between the TCR, coreceptors, costimulatory/ developing TCRm antibodies: antibody library inhibitory molecules, and the pMHC determine and immunization/hybridoma approaches whether a T cell can ultimately recognize and kill (Figure 14.1a and 14.1b), and we will highlight its target. This highlights the need to develop the most well‐developed antitumor TCRm anti-simple immunotherapies that can specifical y bind bodies, which combine the complexity of tumor the pMHC and initiate cytotoxic processes that specificity with the efficiency of an antibody emulate the T cell activity while circumventing the approach to cancer immunotherapy.





188 Immunotherapy in Translational Cancer Research

(a)

(b)

B-cells

Peptide

Antibody-coding

DNA

Spleen

Phage display

B cells

Myeloma cells

Hybridoma

Screening

process

Screening

process

Figure 14.1 Approaches to generating TCRm

the second approach (b), mice are immunized with peptide/

antibodies. There are two main approaches to generating MHC class I complexes. Mouse spleen cells (i.e., antibody-TCRm antibodies. (a) An antibody library is generated from

producing cells) are immortalized by fusion with myeloma

a synthetic DNA library or from B cells. The antibody‐coding

cell lines. The hybridomas are selected for reactivity with

nucleic acid sequence is packaged into a particle linked to

pMHC complexes, and the reactive hybridomas are then

the antibody for which the DNA codes. The particles are

used as the source of antibody for further validation.

screened for reactivity with pMHC complexes. After

TCRm = T cell receptor‐mimic; MHC = major

identifying the antibodies that have high binding affinity

histocompatibility; pMHC = peptide MHC. Source: Courtesy for the pMHC, the genetic code for that antibody can then

of David M. Aten (Sr. Medical Illustrator, Media Services,

be used to generate the antibody for further validation. In

University of Texas MD Anderson Cancer Center).

Antibody library approach

libraries are composed of a phenotype molecule

to generating TCRm

(i.e., antibody) that is linked to its genotype (i.e.,

An antibody library is a tool that allows for the nucleic acid sequence that encodes that particular selection of antibodies based on their affinity for an antibody) in a display particle. A variety of particles antigen using an antibody that is linked to its have been used to contain the antibody and its nucleic acid coding sequence [27]. Antibody linked nucleic acid, including phage, yeast, mammalian





CHAPTER 14 T Cell Receptor Mimic Antibodies 189

cel s, bacteria, and viruses. In addition, there are have a low affinity for their cognate pMHC.

displays that use microbeads and direct protein However, unlike the T cell—in which interactions linked to mRNA or DNA. The antibody genetic of the TCR with its cognate pMHC on the target code in these systems is either cloned from B cell cell by themselves do not determine T cell light‐chain (V ) and heavy‐chain (V ) variable activation and target killing, processes that are L

H

domains or generated from synthetic DNA, dependent on a number of factors in addition to providing a large pool of potential antibodies for the TCR affinity for the pMHC—the activity of the screening [28, 29]. Once the antibodies are linked antibody against its target cell is driven primarily to their genotype and are packaged within the by its affinity for the antigen, with higher affinity display system, they can be used to screen antigens. correlating with improved activity.

In the case of TCRm antibodies, the antigens are

In the physiologic setting, after an antigen binds

presented in the form of pMHC monomers or cel s to the B cell surface immunoglobulin, it stimulates displaying the particular pMHC. After identifying B cel s to undergo fine‐tuning of the antigen-the antibodies that have high binding affinity for binding fragment (Fab) of the antibody through a the pMHC, the genetic code that is linked to that process known as affinity maturation. Somatic antibody can then be used to generate the antibody hypermutation is the major mechanism of the for further validation.

affinity maturation process, whereby activation‐

induced cytidine deaminase introduces random

Immunization approach to

mutations into the V and V regions of the

L

H

generating TCRm

antibody, thereby leading to the generation of anti-

The immunization approach is a standard method bodies with a range of affinities for the antigen. B

for generating an antibody‐mediated immune cel s containing mutations that enhance the affinity response against a target antigen. Using this of the antibody for its antigen are positively selected approach, mice are vaccinated with either pMHC and proliferate, whereas B cel s with mutations that monomers or APCs that have high expression of decrease the affinity of the antibody for the antigen the antigen of interest [30–32]. After generating a undergo apoptosis. This process yields antibodies hybridoma using conventional methods, clones are with a very high affinity for their antigens.

screened for their ability to produce TCRm anti-

One advantage of using a vaccine methodology

bodies that target the pMHC using cel s that are is that it allows normal immune processes to gen-known to express the pMHC or pMHC monomers. erate the antibody, and therefore many of the Once clones are identified, they can be expanded antibodies that are developed using antigen and utilized to produce large amounts of the TCRm immunization and hybridoma generation natural y antibody. A modified approach that combines possess a higher affinity for the pMHC in immunization with an antibody library also has comparison with antibody display libraries [32, been applied to generating TCRm antibodies with 35]. However, technologies are available to increase some success [33, 34]. Using this methodology, the affinity of antibodies that are developed using mice are immunized with pMHC complexes and antibody libraries that introduce mutations into phage display libraries are generated from the the Fab of the antibody. These methodologies have spleens of the mice and then screened for the anti- proven to be effective in enhancing the binding body of interest by conventional methods.

affinity of the antibody for its antigen, including

TCRm [36–39].

Advantages and disadvantages

In addition to affinity maturation, humanizing

to antibody display libraries

antibodies is a major step that facilitates the

and hybridomas

development of an antibody clinical y. Although

Several methods exist to optimize antibodies for chimeric monoclonal antibodies (e.g., rituximab, clinical use to accelerate development in the clinical cetuximab, and trastuzumab) have been used in the setting. Developing an antibody with a very high clinic successful y and are the standard of care for a affinity for the antigen is critical for the therapeutic number of malignancies, antibodies that are not application of the antibody, since natural TCRs ful y humanized run the risk of causing major





190 Immunotherapy in Translational Cancer Research

immune complications in patients receiving them.

NK cell

Antibody humanization refers to the humanization

not only of the constant region of the antibody that

mediates the activity of the antibody in humans

(i.e., antibody‐dependent cell‐mediated cytotoxic-

ADCC

ity (ADCC) or complement‐dependent cytotoxicity

MHC-l/Peptide

(CDC)) but also of the Fab region. This is a major

effort, especial y in antibodies that were generated

Direct

killing

using murine hybridomas. Nevertheless, available

technologies allow for the humanization of the

Tumor cell

antigen‐binding portion of the antibody by grafting

human complementary determining regions and

framework residues into the Fab of the antibody

[40–42]. These methodologies have proven effec-

tive in humanizing murine antibodies while

retaining the affinity and function of the antibody.

CDC

One of the major advantages to antibody

Toxin

display libraries is that they provide an efficient

and relatively rapid procedure to generate anti- Figure 14.2 Mechanisms of action for TCRm antibodies. TCRm antibodies kill tumor cells by a number of bodies that target pMHC. This is not the case mechanisms. These include direct killing by inducing tumor when vaccine approaches are used for antibody cell apoptosis after binding the pMHC, activating immune development, as they require a longer duration cells (e.g., NK cells) that mediate antibody‐dependent for effective mouse immunization and subsequent cellular cytotoxicity (ADCC), or by fixing complement and hybridoma generation. In addition, the immune activating complement‐dependent cytotoxicity (CDC). The Fc region of the antibody is critical for determining

response elicited following the immunization ADCC‐ and CDC‐mediated processes. In addition, TCRm process requires that the immunogen (i.e., pMHC antibodies can be directly linked to a toxin that mediates complex) be stable for a sufficient duration to cell lysis. TCRm = T cell receptor‐mimic; pMHC = peptide interact with murine immune cells. However, MHC; NK = natural killer; Fc = fragment crystallizable. Source: unlike antibodies that are generated through Courtesy of David M. Aten (Sr. Medical Illustrator, Media Services, University of Texas MD Anderson Cancer Center).

immunization, which contain the full antibody

structure, albeit of mouse background, antibody

display libraries generate monovalent antibodies Leukemia

composed of the single chain variable fragments

(scFv) or the Fab portion of the antibody. These TCRm antibodies have been studied in the setting monovalent forms can be conjugated to toxins or of leukemia, specifical y acute myeloid leukemia fluorophores and used as therapeutics or tools to (AML) and acute lymphoblastic leukemia (ALL).

detect cell surface pMHC, respectively. Further, The targets in the setting of leukemia have focused this sequence can ultimately be cloned into on HLA class I peptides derived from leukemia-immunoglobulin vectors to produce the bivalent associated antigens: Wilms tumor antigen (WT1), secreted conventional antibodies that have var- neutrophil elastase, and proteinase‐3. WT‐1 is a ious mechanisms of action (Figure 14.2). In the tumor‐associated antigen that plays an impor-following sections, the designation TCRm anti- tant role in cell survival and normal cel ular bodies will refer not only to bivalent conventional development. WT‐1 is a zinc finger transcription antibodies that target pMHC but also to scFv and factor required for normal embryonic kidney Fab that target pMHC. Although a number of development. In addition to its expression in TCRm antibodies have been developed and hold kidney, low‐level expression of WT‐1 has been promise as anticancer therapeutics, the following demonstrated in normal tissues, including ovary, sections will focus on the TCRm antibodies that testis, and hematopoietic tissue as well as peritoneal are closest to clinical development (Table 14.1).

and pleural mesothelium [43, 44]. In malignant

Table 14.1 Cancer‐targeting TCRm antibodies.

Antibody

Designation

Peptide

HLA Restriction

Tumor Type

Source Protein

Method

Reference

RL1B

KIFGSLAFL

A*0201

Breast cancer and other HER2‐expressing

HER2

Immunization

[80]

solid tumor malignancies

RL6A

YLLPAIVHI

A*0201

Breast cancer

RNA helicase protein

Immunization

[82, 89]

RL4B

GVLPALPQV

A*0201

Breast cancer

hCG β

Immunization

[35, 85]

8 F4

VLQELNVTV

A*0201

Leukemia, breast cancer, melanoma

Proteinase 3 and neutrophil

Immunization

[32]

elastase

G2D12

KTWGQYWQV

A*0201

Melanoma

gp100

Phage display

[33, 95, 96]

1A7 and G1

ITDQVPFSV

A*0201

2 F1

YLEPGPVTA

A*0201

CAG10

EAAGIGILTV

A*0201

Melanoma

MART1

Phage display

[96]

CLA12

ELAGIGILTV

G8

EADPTGHSY

A1

Melanoma and other solid tumors

MAG1‐A1

Phage display

[36, 106, 107]



Note: hCG‐ β = human chorionic gonadotropin.





192 Immunotherapy in Translational Cancer Research disease, WT‐1 has been detected in solid tumors, including molecular remissions, were seen follow-including cancers of the lung, colon, breast, ovary, ing PR1 vaccine administration in patients with and kidney [45–49]. In addition, WT‐1 is also AML, chronic myeloid leukemia (CML), and expressed in hematologic malignancies, including myelodysplastic syndrome. However, because most acute and chronic myeloid and lymphoid malig- patients with AML present with a large leukemia nancies, as well as myelodysplastic syndrome [50, burden and many are immunocompromised 51]. WT‐1 has been targeted in solid tumors and because of the direct effects of leukemia on the hematologic malignancies with vaccines and adop- bone marrow, which limit the efficacy of vaccines, tive cel ular therapy [52–57]. However, targeting the anti‐PR1/HLA‐A2 TCRm antibody 8F4 was WT‐1 using a TCRm to date has been limited to developed. 8F4 is a mouse monoclonal antibody AML and ALL [58, 59].

that was engineered using immunization tech-

The anti‐WT‐1 TCRm antibody, ESK1, was nology [32]. It showed potent specific cytolysis of developed using phage display technology to target leukemia, including leukemic stem cel s but not the HLA‐A2‐restricted WT1‐derived, 9‐mer normal hematopoietic cel s, in vitro and in vivo [32, peptide RMF (amino acid (aa) sequence, 68]. 8F4 was shown to mediate direct apoptosis as RMFPNAPYL) [58]. Using this approach, single well as complement‐dependent cytotoxicity. Since phage clones that were specific for HLA‐A2/RMF its initial development, a humanized IgG1 anti-monomers and that did not bind HLA‐A2/irrele- PR1/HLA‐A2 antibody has been engineered and vant peptide complexes were first selected and then will soon be tested in a phase I clinical study in validated using binding assays with T2 cel s that patients with AML. In addition to its activity were pulsed with RMF or irrelevant peptide; the T2 against myeloid leukemia, one study showed that cell line is an HLA‐A2+ B/T cell hybridoma that is through neutrophil elastase and proteinase‐3

deficient in the transporter associated with antigen cross‐presentation, PR1 is presented on the surface processing (TAP) [60, 61]. HLA‐A2/RMF‐specific of breast cancer and melanoma, and as a result clones were then engineered into full‐length these tumor types become susceptible to 8F4.

human monoclonal IgG1. ESK1 showed high Although these data are promising, they have yet to avidity (K = 0.1 nM) and mediated ADCC in a be tested in vivo.

D

number of solid tumors, including ovarian cancer,

mesothelioma, and colon cancer, as well as in leu- Breast cancer kemia in vitro. [62]. Further studies showed that

ESK1 eliminated Philadelphia‐positive ALL cel Some of the most compelling data showing the lines and synergized with tyrosine kinase inhibitors activity of therapeutic monoclonal antibodies were in vivo in a NOD/SCID gamma (NSG) mouse revealed in the setting of breast cancer with the model [59, 62]. Moreover, a second‐generation advent of trastuzumab, a humanized monoclonal ESK1 was engineered by altering ESK1 Fc glycosyl- antibody that targets the oncoprotein HER2 [69, ation [63]. This second‐generation ESK1, ESKM, 70]. HER2 is part of the epidermal growth factor was up to 10‐fold more potent in vitro in ADCC (EGF) family of receptors. It is expressed on normal assays. In vivo data showed activity of ESKM against breast cel s but is highly expressed (up to 100‐fold) mesothelioma and AML cell lines, as well as pri- in approximately 30% of breast tumors [71, 72]. To mary ALL.

date, there are no known ligands that bind the

In addition to WT1, PR1 also has been targeted extracel ular domain of HER2. However, HER2 has in leukemia using a TCRm. PR1 (VLQELNVTV) is known signaling functions as a membrane‐bound an HLA‐A2‐specific peptide derived from the receptor tyrosine kinase that promotes cell prolif-myeloid‐restricted serine proteases neutrophil eration, differentiation, and migration [73].

elastase and proteinase‐3 [64–66].

HER2 signaling ensues following HER2 homodi-

After its discovery, a PR1 peptide vaccine was merization or heterodimerization with other developed and was shown to induce PR1‐specific members of the EGF family receptors [74, 75].

cytotoxic T lymphocytes in a phase I/II study [67]. Trastuzumab has proven to be a cornerstone in In that study, immune and clinical responses, the treatment of HER2+ breast cancer because it





CHAPTER 14 T Cell Receptor Mimic Antibodies 193

targets the extracel ular domain of the HER2 pro- [85, 88]. In in vivo studies, RL4B eliminated human tein [69, 70]. Although antibodies in addition to breast cancer cell lines and, similar to RL6A, trastuzumab have been developed to target HER2 stained primary breast tumor tissues [35]. In

[76], it is important to note that the following addition, both RL6A and RL4B were shown to discussion will focus on TCRm antibodies that mediate direct tumor apoptosis, independently target breast cancer antigens presented on breast of immune‐mediated mechanisms (e.g., CDC or cancer cell surface HLA class I molecules.

ADCC) [89].

A number of clinical trials have tested the effi-

cacy of targeting HLA class I, HER2‐derived Melanoma

peptides. E75 (KIFGSLAFL) is the best character-

ized of the HER2 peptides. Several clinical trials A number of TCRm Fabs have been developed in have evaluated E75 vaccine in breast cancer and the setting of melanoma. The target for these anti-have shown the efficacy of the vaccine approach bodies is the melanoma antigen gp100, a mem-

[77–79]. Because the E75 peptide is known to be an brane glycoprotein that is melanocyte lineage effective immune target in breast cancer, RL1B, a specific and is expressed on most melanoma cel s TCRm antibody that targets this peptide, was [90]. Numerous studies have targeted gp100-developed and has shown antitumor activity in derived HLA‐A2 epitopes using peptide vaccines, preclinical models [80]. RL1B was developed using with promising results [91, 92]. Furthermore, CD8

immunization methodology, demonstrated stain- T cel s that target gp100 HLA‐A2 epitopes have ing of HLA‐A2+ primary human breast carcinomas, been identified, correlated with tumor regression, and suppressed breast cancer growth in mouse and used clinical y to treat patients with melanoma models. Furthermore, RL1B induced apoptosis in as part of an adoptive cel ular immunotherapy all HER2+ tumors, in contrast with trastuzumab, approach [90, 93, 94]. Because of the clinical effi-which induced apoptosis only in the high HER2‐ cacy seen with immunotherapies that target gp100, expressing tumor cell lines. E75 has also been a number of TCRm Fabs have been developed that targeted using the TCRm Fab, fE75 [81]. Unlike target three gp100‐derived HLA‐A2‐restricted RL1B, fE75 lacks the Fc portion of the antibody. peptides: one TCRm Fab (G2D12) that targets fE75 demonstrated specific binding to HER2‐ gp100‐154 (aa: KTWGQYWQV), two TCRm Fabs expressing tumor cel s and accumulation in tumor (1A7 and G1) that target gp100‐209 (aa: tissues in vivo. Also, fE75 can be conjugated to ITDQVPFSV), and one TCRm Fab (2 F1) that tar-molecules that enable it to be used as a diagnostic gets gp100‐280 (aa: YLEPGPVTA) [33, 95, 96].

and therapeutic tool for HER2‐expressing tumors.

These antibodies were generated using a phage

In addition to HER2, a number of antigens have display approach. In addition to being used as tools been targeted in breast cancer using TCRm anti- in antigen presentation studies, the G1 scFv and bodies. RL6A is a TCRm monoclonal antibody that 2 F1 Fab were conjugated to Pseudomonas exotoxin targets the p68 RNA helicase protein, which is A and used as immunotherapies. G1 scFv‐immu-highly expressed in breast cancer and plays an notoxin fusion protein demonstrated activity important role in tumor cell growth and against peptide‐loaded APCs in vitro [33], while development [82–84]. RL6A eliminated breast can- the 2 F1 Fab‐immunotoxin fusion protein inhibited cer cell lines in in vivo experiments and was shown melanoma growth in mice [96].

to stain breast tumor tissue that highly expressed

In addition to gp100, TCRm antibodies have

p68 but not normal breast tissue [82].

also been developed against MART1, a signal

RL4B is another TCRm monoclonal antibody. anchor protein that is found in the endoplasmic RL4B targets the peptide GVLPALPQV, derived reticulum and Golgi, is expressed in melanoma, from human chorionic gonadotropin (hCG)‐β, and has been shown to elicit cytotoxic T lympho-which has been correlated with poor outcomes in a cyte immune responses [97]. A number of number of cancers, including breast cancer [35, immunogenic peptides have been identified from 85–87]. RL4B was engineered using a mouse the MART1 protein and targeted with immuno-immunization approach with the hCG‐β peptide therapy [98–100]. In addition to vaccines, two





194 Immunotherapy in Translational Cancer Research TCRm Fabs that target MART1 have been isolated

Although native TCR has low avidity for

using phage display libraries and conjugated to antigens, which allows the T cell to establish rapid Pseudomonas exotoxin A. One of the Fab‐ sequential contact with a number of pMHCs on the immunotoxin conjugates, CAG10, targets the native target cell surface, engineered CAR T cel s with HLA‐A2‐restricted MART1 peptide EAAGIGILTV, high pMHC affinities are favored for use in immu-and the other Fab immunotoxin conjugate CLA12 notherapy because they possess a higher affinity for targets the anchor modified MART1 peptide the target and therefore have less nonspecific ELAGIGILTV. MART1‐TCRm Fab‐immunotoxin binding to normal cel s. Modifications of the fusion proteins demonstrated activity against cell TCRm hence enable the engineering of TCRm-lines in vitro and in melanoma mouse models [96]. based CARs with high affinity for a target pMHC.

Such alterations are more easily performed on

TCRm antibodies in the design

TCRm‐based CARs in contrast to native TCRs. As

of chimeric antigen receptor (CAR) a proof of concept, using light chain shuffling and T cells

heavy chain site‐directed mutagenesis, Chames

et al. modified the G8 Fab and generated a TCRm

CAR T cel s are engineered T cel s that express a Fab, Fab‐Hyb3, that had 18‐fold higher affinity for CAR, which provides the T cell with specificity for the MAGEA1 antigen than does G8 [36]. CAR T

its target. The CAR construct is engineered from cel s expressing the Fab‐Hyb3 CAR demonstrated the antigen‐binding portion of the monoclonal higher killing of the MAGE‐A1‐expressing mela-antibody that is specific for an individual antigen, noma cell line compared with the Fab‐G8 CAR T

with scFv being the most commonly used mole- cel s. In addition to MAGE, TCRm‐based CARs cules in CAR T cel s [101]. The CAR is usual y have been reported for the NY‐ESO‐1 antigen [37, linked to secondary signaling molecules such as 109], and ongoing work is currently investigating CD3ζ and costimulatory molecules that play a crit- the feasibility of generating TCRm‐based CAR T

ical role in the activation of the T cell after the cel s that target WT1 and PR1.

engagement of the CAR with its target antigen. The

most commonly used CAR T cel s have targeted TCRm antibodies as tools the lymphoid leukemia–associated antigen CD19 for antigen presentation

[102–104].

As a natural extension of TCRm technology, a Although TCRm antibodies are promising immu-few studies have explored using TCRm to con- notherapies, they are also valuable tools to study struct a CAR. In one study, a TCRm that targets antigen presentation. Peptide presentation by the melanoma‐associated antigen (MAGE), a can- MHC on the cell surface does not always correlate cer testis antigen that is expressed in a number of with endogenous antigen expression. In fact, pro-solid tumor malignancies, was used in a CAR con- tein half‐life and the subcel ular localization of the struct in the setting of melanoma [36, 105–107]. antigen within the cell play very important roles in A TCRm Fab (G8) that targets the HLA‐A1‐ determining whether or not the intracel ular pro-restricted MAGE antigen (MAGEA1; aa: teins are presented [110–113]. TCRm antibodies EADPTGHSY) was identified using a phage are therefore useful in demonstrating whether display library. The G8 Fab was inserted into a ret- tumor‐associated antigens are presented on the cell roviral expression cassette that also included the surface and consequently if they are immunogenic CD4 transmembrane domain and the intracel ular targets for T cell–based therapies and TCRm anti-domain of the Fc(ε)RIγ chain to increase mem- bodies. Additional y, TCRm antibodies could also brane expression of the CAR [108]. This expression be used to study immune evasion by tumors, as one cassette was then introduced into CD4‐depleted, mechanism of immune evasion involves the down-OKT3 monoclonal antibody–activated human regulation of peptide/MHC from the tumor cell lymphocytes [106]. These Fab‐G8 CAR T cel s surface [114–117]. When all these findings are were then shown to recognize and lyse MAGE‐ considered, TCRm antibodies can provide impor-expressing HLA‐A1+ melanoma cells in vitro.

tant information regarding the basic biology of





CHAPTER 14 T Cell Receptor Mimic Antibodies 195

antigen processing and presentation, which also 3. van der Merwe PA, Dushek O. Mechanisms for T cel could be extrapolated to tailoring personalized

receptor triggering. Nat Rev Immunol. 2011;11(1):47–55.

immunotherapies that target distinct peptide/

4. Yokosuka T, Sakata‐Sogawa K, Kobayashi W, Hiroshima

MHC complexes on the tumor cell surface.

M, Hashimoto‐Tane A, Tokunaga M, et al. Newly gener-

ated T cell receptor microclusters initiate and sustain T

cell activation by recruitment of Zap70 and SLP‐76. Nat

Future directions

Immunol. 2005;6(12):1253–62.

5. Doyle C, Strominger JL. Interaction between CD4 and

Although no TCRm antibodies to date have entered

class II MHC molecules mediates cell adhesion. Nature.

clinical trials, a number of the antibodies discussed in

1987;330(6145):256–9.

the previous sections are currently being developed 6. Norment AM, Salter RD, Parham P, Engelhard VH, for clinical use. Their applications will include the

Littman DR. Cell‐cell adhesion mediated by CD8 and

direct administration of the TCRm antibodies as part

MHC class I molecules. Nature. 1988;336(6194):79–81.

of a conventional antibody therapy, toxin conjugation,

7. Gaspar R, Jr., Bagossi P, Bene L, Matko J, Szollosi J,

and in conjunction with other cancer therapies,

Tozser J, et al. Clustering of class I HLA oligomers with

including chemotherapy. The timing of the

CD8 and TCR: three‐dimensional models based on

administration of these antibodies also will be critical,

fluorescence resonance energy transfer and crystallo-

since antigen presentation may be enhanced by the

graphic data. J Immunol. 2001;166(8):5078–86.

8. Kim PW, Sun ZY, Blacklow SC, Wagner G, Eck MJ. A

administration of chemotherapy or other immuno-

zinc clasp structure tethers Lck to T cell coreceptors

therapy [118, 119]. It is therefore conceivable that

CD4 and CD8. Science. 2003;301(5640):1725–8.

TCRm antibodies could be more effective following

9. Li QJ, Dinner AR, Qi S, Irvine DJ, Huppa JB, Davis MM,

chemotherapy when tumor cell damage leads to the

et al. CD4 enhances T cell sensitivity to antigen by

release of intracel ular antigens into the tumor micro-

coordinating Lck accumulation at the immunological

environment, where they can be cross‐presented by

synapse. Nat Immunol. 2004;5(8):791–9.

APC and other tumor cel s [110, 120]. Final y, because 10. Konig R. Interactions between MHC molecules and co-bispecific T cell engaging antibodies (BiTE) have

receptors of the TCR. Curr Opin Immunol.

demonstrated promising antitumor activity in pre-

2002;14(1):75–83.

clinical studies and clinical trials [121–123], it could 11. Owens T, Fazekas de St Groth B, Miller JF. Coaggregation be feasible to link the Fab of the TCRm to the CD3

of the T cell receptor with CD4 and other T cell surface

molecules enhances T cell activation. Proc Natl Acad Sci

portion of the BiTE and hence allow for the targeting

U S A. 1987;84(24):9209–13.

of intracel ular antigens that are presented by HLA.

12. Krummel MF, Allison JP. CD28 and CTLA‐4 have

In conclusion, TCRm antibodies may in the near

opposing effects on the response of T cel s to stimula-

future provide a novel and effective tool in the

tion. J Exp Med. 1995;182(2):459–65.

armamentarium of cancer immunotherapies.

13. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS,

Freeman GJ, Green JM, et al. CTLA‐4 can function as a

negative regulator of T cell activation. Immunity.

Acknowledgment

1994;1(5):405–13.

14. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T,

We are grateful to David M. Aten (Senior Medical

Nishimura H, et al. Engagement of the PD‐1 immunoin-

Illustrator, Media Services, University of Texas MD

hibitory receptor by a novel B7 family member leads to

Anderson Cancer Center), who created the il us-

negative regulation of lymphocyte activation. J Exp Med.

trations for this chapter.

2000;192(7):1027–34.

15. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde

References

M, Chernova I, et al. PD‐L2 is a second ligand for PD‐1 and

inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.

1. Davis SJ, Ikemizu S, Wild MK, van der Merwe PA. CD2 16. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, and the nature of protein interactions mediating cell‐cell

Peach R. Human B7‐1 (CD80) and B7‐2 (CD86) bind

recognition. Immunol Rev. 1998;163:217–36.

with similar avidities but distinct kinetics to CD28 and

2. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden

CTLA‐4 receptors. Immunity. 1994;1(9):793–801.

B, et al. Ligand recognition by alpha beta T cell receptors. 17. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Annu Rev Immunol. 1998;16:523–44.

Lindsten T, et al. CD28 costimulation can promote T cell

196 Immunotherapy in Translational Cancer Research survival by enhancing the expression of Bcl‐XL.

specific peptide‐MHC class I complexes using a mono-

Immunity. 1995;3(1):87–98.

clonal antibody. Immunity. 1997;6(6):715–26.

18. Parry RV, Rumbley CA, Vandenberghe LH, June CH, 32. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant Riley JL. CD28 and inducible costimulatory protein Src

J, et al. An anti‐PR1/HLA‐A2 T cell receptor‐like anti-

homology 2 binding domains show distinct regulation

body mediates complement‐dependent cytotoxicity

of phosphatidylinositol 3‐kinase, Bcl‐xL, and IL‐2

against acute myeloid leukemia progenitor cel s. Blood.

expression in primary human CD4 T lymphocytes. J

2011;117(16):4262–72.

Immunol. 2003;171(1):166–74.

33. Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y.

19. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman

Selective targeting of melanoma and APCs using a

JA, Haanen JB, et al. Improved survival with ipilimumab

recombinant antibody with TCR‐like specificity directed

in patients with metastatic melanoma. N Engl J Med.

toward a melanoma differentiation antigen. J Immunol.

2010;363(8):711–23.

2003;171(5):2197–207.

20. Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Cowey 34. Krogsgaard M, Wucherpfennig KW, Cannel a B, Hansen CL, Lao CD, et al. Combined nivolumab and ipilimBE, Svejgaard A, Pyrdol J, et al. Visualization of myelin

umab or monotherapy in untreated melanoma. N Engl J

basic protein (MBP) T cell epitopes in multiple sclerosis

Med. 2015;373(1):23–34.

lesions using a monoclonal antibody specific for the

21. Postow MA, Chesney J, Pavlick AC, Robert C,

human histocompatibility leukocyte antigen (HLA)‐

Grossmann K, McDermott D, et al. Nivolumab and ipili-

DR2‐MBP 85‐99 complex. J Exp Med. 2000; 191(8):

mumab versus ipilimumab in untreated melanoma.

1395–412.

N Engl J Med. 2015;372(21):2006–17.

35. Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, 22. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM,

Duty JA, et al. TCR mimic monoclonal antibody targets

Desrichard A, et al. Genetic basis for clinical response to

a specific peptide/HLA class I complex and significantly

CTLA‐4 blockade in melanoma. N Engl J Med.

impedes tumor growth in vivo using breast cancer

2014;371(23):2189–99.

models. J Immunol. 2010;184(4):2156–65.

23. Snyder A, Wolchok JD, Chan TA. Genetic basis for 36. Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem clinical response to CTLA‐4 blockade. N Engl J Med.

L, Schuler G, et al. TCR‐like human antibodies expressed

2015;372(8):783.

on human CTLs mediate antibody affinity‐dependent

24. Wolchok JD, Kluger H, Cal ahan MK, Postow MA, Rizvi

cytolytic activity. J Immunol. 2002;169(2):1110–8.

NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in 37. Stewart‐Jones G, Wadle A, Hombach A, Shenderov E, advanced melanoma. N Engl J Med. 2013;

Held G, Fischer E, et al. Rational development of high‐

369(2):122–33.

affinity T cell receptor‐like antibodies. Proc Natl Acad

25. Yao S, Zhu Y, Chen L. Advances in targeting cell surface Sci U S A. 2009;106(14):5784–8.

signalling molecules for immune modulation. Nat Rev 38. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody Drug Discov. 2013;12(2):130–46.

evolution targeting germline hot spots to increase

26. Pardoll DM. The blockade of immune checkpoints in

activity of an anti‐CD22 immunotoxin. J Biol Chem.

cancer immunotherapy. Nat Rev Cancer. 2012;

2005;280(1):607–17.

12(4):252–64.

39. Pini A, Viti F, Santucci A, Carnemol a B, Zardi L, Neri P, 27. Hoogenboom HR. Selecting and screening recombinant

et al. Design and use of a phage display library. Human

antibody libraries. Nat Biotechnol. 2005;23(9):1105–16.

antibodies with subnanomolar affinity against a marker

28. Hoogenboom HR, Winter G. By‐passing immunisation.

of angiogenesis eluted from a two‐dimensional gel. J Biol

Human antibodies from synthetic repertoires of germline

Chem. 1998;273(34):21769–76.

VH gene segments rearranged in vitro. J Mol Biol. 40. Baca M, Presta LG, O’Connor SJ, Wel s JA. Antibody 1992;227(2):381–8.

humanization using monovalent phage display. J Biol

29. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G.

Chem. 1997;272(16):10678–84.

Phage‐displayed antibody libraries of synthetic heavy 41. Dal ’Acqua WF, Damschroder MM, Zhang J, Woods chain complementarity determining regions. J Mol Biol.

RM, Widjaja L, Yu J, et al. Antibody humanization by

2004;338(2):299–310.

framework shuffling. Methods. 2005;36(1):43–60.

30. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue 42. Wu H, Nie Y, Huse WD, Watkins JD. Humanization of a ER. Characterization and quantitation of peptide‐MHC

murine monoclonal antibody by simultaneous optimi-

complexes produced from hen egg lysozyme using a

zation of framework and CDR residues. J Mol Biol.

monoclonal antibody. Immunity. 1997;6(6):727–38.

1999;294(1):151–62.

31. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain 43. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, RN. Localization, quantitation, and in situ detection of

Tamaki H, et al. Very low frequencies of human normal

CHAPTER 14 T Cell Receptor Mimic Antibodies 197

CD34+ haematopoietic progenitor cel s express the

CD8+ T cel s can mediate antileukemic activity and

Wilms’ tumour gene WT1 at levels similar to those in

persist in post‐transplant patients. Sci Transl Med.

leukaemia cel s. Br J Haematol. 2002;116(2):409–20.

2013;5(174):174ra27.

44. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 pro-

57. Gao L, Bel antuono I, Elsasser A, Marley SB, Gordon MY,

teins: functions in growth and differentiation. Gene.

Goldman JM, et al. Selective elimination of leukemic

2001;273(2):141–61.

CD34(+) progenitor cel s by cytotoxic T lymphocytes

45. Campbell CE, Kuriyan NP, Rackley RR, Caulfield MJ,

specific for WT1. Blood. 2000;95(7):2198–203.

Tubbs R, Finke J, et al. Constitutive expression of the 58. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit Wilms tumor suppressor gene (WT1) in renal cell carciT, et al. Targeting the intracel ular WT1 oncogene prod-

noma. Int J Cancer. 1998;78(2):182–8.

uct with a therapeutic human antibody. Sci Transl Med.

46. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y,

2013;5(176):176ra33.

Tamaki H, et al. High expression of Wilms’ tumor 59. Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, suppressor gene predicts poor prognosis in breast cancer

et al. A TCR‐mimic antibody to WT1 bypasses tyrosine

patients. Clin Cancer Res. 2002;8(5):1167–71.

kinase inhibitor resistance in human BCR‐ABL+ leuke-

47. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H,

mias. Blood. 2014;123(21):3296–304.

Nakatsuka S, et al. Overexpression of the Wilms’ tumor 60. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, gene WT1 in de novo lung cancers. Int J Cancer.

Appel a E, Hunt DF, et al. HLA‐A2.1‐associated peptides

2002;100(3):297–303.

from a mutant cell line: a second pathway of antigen pre-

48. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A,

sentation. Science. 1992;255(5049):1264–6.

Nakatsuka S, et al. Overexpression of the Wilms’ tumor 61. Wei ML, Cresswell P. HLA‐A2 molecules in an antigen-gene WT1 in colorectal adenocarcinoma. Cancer Sci.

processing mutant cell contain signal sequence‐derived

2003;94(8):712–7.

peptides. Nature. 1992;356(6368):443–6.

49. Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M. 62. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Correlation between WT1 expression and cell prolifera-Schweitzer IB, Tennent B, et al. Multiple defects in innate

tion in endometrial cancer. Anticancer Res.

and adaptive immunologic function in NOD/LtSz‐scid

2009;29(11):4887–91.

mice. J Immunol. 1995;154(1):180–91.

50. Miwa H, Beran M, Saunders GF. Expression of the 63. Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky Wilms’ tumor gene (WT1) in human leukemias.

L, et al. Therapeutic efficacy of an Fc‐enhanced TCR‐

Leukemia. 1992;6(5):405–9.

like antibody to the intracel ular WT1 oncoprotein. Clin

51. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y,

Cancer Res. 2014;20(15):4036–46.

et al. Aberrant overexpression of the Wilms tumor gene 64. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, (WT1) in human leukemia. Blood. 1997;89(4): 1405–12.

et al. Chronic myelogenous leukemia shapes host immu-

52. Hashii Y, Sato‐Miyashita E, Matsumura R, Kusuki S,

nity by selective deletion of high‐avidity leukemia‐

Yoshida H, Ohta H, et al. WT1 peptide vaccination fol-

specific T cel s. J Clin Invest. 2003;111(5):639–47.

lowing allogeneic stem cell transplantation in pediatric 65. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A leukemic patients with high risk for relapse: successful

PR1‐human leukocyte antigen‐A2 tetramer can be used to

maintenance of durable remission. Leukemia.

isolate low‐frequency cytotoxic T lymphocytes from

2012;26(3):530–2.

healthy donors that selectively lyse chronic myelogenous

53. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L,

leukemia. Cancer Res. 1999;59(11): 2675–81.

Superata J, et al. Leukemia‐associated antigen‐specific T 66. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, cell responses following combined PR1 and WT1 pep-Champlin RE, et al. Evidence that specific T lympho-

tide vaccination in patients with myeloid malignancies.

cytes may participate in the elimination of chronic

Blood. 2008;111(1):236–42.

myelogenous leukemia. Nat Med. 2000;6(9):1018–23.

54. Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, 67. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu Shirakata T, et al. WT1 peptide vaccine induces reduction

S, et al. PR1 peptide vaccine induces specific immunity

in minimal residual disease in an Imatinib‐treated CML

with clinical responses in myeloid malignancies.

patient. Eur J Haematol. 2010; 85(4):358–60.

Leukemia. 2017;31(3):697–704.

55. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, 68. Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Reik A, et al. Editing T cell specificity towards leukemia

Clise‐Dwyer K, et al. Activity of 8 F4, a T cell receptor‐

by zinc finger nucleases and lentiviral gene transfer. Nat

like anti‐PR1/HLA‐A2 antibody, against primary human

Med. 2012;18(5):807–15.

AML in vivo. Leukemia. 2016;30(7):1475–84.

56. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, 69. Piccart‐Gebhart MJ, Procter M, Leyland‐Jones B, Pufnock JS, Schmitt TM, et al. Transferred WT1‐reactive

Goldhirsch A, Untch M, Smith I, et al. Trastuzumab

198 Immunotherapy in Translational Cancer Research after adjuvant chemotherapy in HER2‐positive breast

in vivo by synthetic antibody fragment. PLoS One.

cancer. N Engl J Med. 2005;353(16):1659–72.

2012;7(8):e43746.

70. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, 82. Verma B, Hawkins OE, Neethling FA, Caseltine SL, Jr., Davidson NE, et al. Trastuzumab plus adjuvant che-Largo SR, Hildebrand WH, et al. Direct discovery and

motherapy for operable HER2‐positive breast cancer.

validation of a peptide/MHC epitope expressed in pri-

New Engl J Med. 2005;353(16):1673–84.

mary human breast cancer cel s using a TCRm mono-

71. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,

clonal antibody with profound antitumor properties.

McGuire WL. Human breast cancer: correlation of

Cancer Immunol Immunother. 2010;59(4):563–73.

relapse and survival with amplification of the HER‐2/

83. Yang L, Lin C, Liu ZR. Phosphorylations of DEAD box

neu oncogene. Science. 1987;235(4785):177–82.

p68 RNA helicase are associated with cancer

72. Burstein HJ. The distinctive nature of HER2‐positive

development and cell proliferation. Mol Cancer Res.

breast cancers. N Engl J Med. 2005;353(16):1652–4.

2005;3(6):355–63.

73. Yarden Y, Sliwkowski MX. Untangling the ErbB signal-

84. Guturi KK, Sarkar M, Bhowmik A, Das N, Ghosh MK.

ling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.

DEAD‐box protein p68 is regulated by beta‐catenin/

74. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy

transcription factor 4 to maintain a positive feedback

DJ, Lemmon MA. EGF activates its receptor by removing

loop in control of breast cancer progression. Breast

interactions that autoinhibit ectodomain dimerization.

Cancer Res. 2014;16(6):496.

Mol Cel . 2003;11(2):507–17.

85. Wittman VP, Woodburn D, Nguyen T, Neethling FA,

75. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An

Wright S, Weidanz JA. Antibody targeting to a class I

allosteric mechanism for activation of the kinase domain

MHC‐peptide epitope promotes tumor cell death. J

of epidermal growth factor receptor. Cel .

Immunol. 2006;177(6):4187–95.

2006;125(6):1137–49.

86. Bieche I, Lazar V, Nogues C, Poynard T, Giovangrandi Y,

76. Gianni L, Llado A, Bianchi G, Cortes J, Kellokumpu‐

Bellet D, et al. Prognostic value of chorionic gonado-

Lehtinen PL, Cameron DA, et al. Open‐label, phase II,

tropin beta gene transcripts in human breast carcinoma.

multicenter, randomized study of the efficacy and safety

Clin Cancer Res. 1998;4(3):671–6.

of two dose levels of Pertuzumab, a human epidermal 87. Stenman UH. Standardization of assays for human growth factor receptor 2 dimerization inhibitor, in

chorionic gonadotropin. Clin Chem. 2004;50(5):

patients with human epidermal growth factor receptor

798–800.

2‐negative metastatic breast cancer. J Clin Oncol. 88. Siva AC, Kirkland RE, Lin B, Maruyama T, McWhirter J, 2010;28(7):1131–7.

Yantiri‐Wernimont F, et al. Selection of anti‐cancer anti-

77. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, bodies from combinatorial libraries by whole‐cell pan-Benavides LC, et al. Clinical trial results of the HER‐2/

ning and stringent subtraction with human blood cel s. J

neu (E75) vaccine to prevent breast cancer recurrence in

Immunol Methods. 2008;330(1–2):109–19.

high‐risk patients: from US Military Cancer Institute 89. Verma B, Jain R, Caseltine S, Rennels A, Bhattacharya R, Clinical Trials Group Study I‐01 and I‐02. Cancer.

Markiewski MM, et al. TCR mimic monoclonal anti-

2012;118(10):2594–602.

bodies induce apoptosis of tumor cel s via immune

78. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA,

effector‐independent mechanisms. J Immunol.

Amin A, Khoo S, et al. Combined clinical trial results of

2011;186(5):3265–76.

a HER2/neu (E75) vaccine for the prevention of recur-

90. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF,

rence in high‐risk breast cancer patients: U.S. Military

Sakaguchi K, Appella E, et al. Identification of a

Cancer Institute Clinical Trials Group Study I‐01 and

human melanoma antigen recognized by tumor‐

I‐02. Clin Cancer Res. 2008;14(3):797–803.

infiltrating lymphocytes associated with in vivo

79. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van

tumor rejection. Proc Natl Acad Sci U S A. 1994;91(14):

Echo D, Ponniah S, et al. Final report of the phase I/II

6458–62.

clinical trial of the E75 (nelipepimut‐S) vaccine with booster 91. Schwartzentruber DJ, Lawson DH, Richards JM, Conry inoculations to prevent disease recurrence in high‐risk

RM, Miller DM, Treisman J, et al. gp100 peptide vaccine

breast cancer patients. Ann Oncol. 2014;25(9):1735–42.

and interleukin‐2 in patients with advanced melanoma.

80. Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA.

New Engl J Med. 2011;364(22):2119–27.

Antitumor activity of a monoclonal antibody targeting 92. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, major histocompatibility complex class I‐Her2 peptide

Marincola FM, Topalian SL, et al. Immunologic and

complexes. J Natl Cancer Inst. 2013;105(3):202–18.

therapeutic evaluation of a synthetic peptide vaccine for

81. Miller KR, Koide A, Leung B, Fitzsimmons J, Yoder B,

the treatment of patients with metastatic melanoma. Nat

Yuan H, et al. T cell receptor‐like recognition of tumor

Med. 1998;4(3):321–7.

CHAPTER 14 T Cell Receptor Mimic Antibodies 199

93. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL,

persist and induce sustained remissions in relapsed

Shabanowitz J, et al. Identification of a peptide recog-

refractory chronic lymphocytic leukemia. Sci Transl

nized by five melanoma‐specific human cytotoxic T

Med. 2015;7(303):303ra139.

cell lines. Science. 1994;264(5159):716–9.

105. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant

94. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang

V, Traversari C, et al. Identification of five MAGE‐A1

X, Southwood S, et al. Recognition of multiple epitopes

epitopes recognized by cytolytic T lymphocytes

in the human melanoma antigen gp100 by tumor‐infil-

obtained by in vitro stimulation with dendritic cel s

trating T lymphocytes associated with in vivo tumor

transduced with MAGE‐A1. J Immunol. 1999;163(5):

regression. J Immunol. 1995;154(8):3961–8.

2928–36.

95. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom 106. Willemsen RA, Debets R, Hart E, Hoogenboom HR, HR, Reiter Y. Direct visualization of distinct T cell epi-Bolhuis RL, Chames P. A phage display selected fab

topes derived from a melanoma tumor‐associated

fragment with MHC class I‐restricted specificity for

antigen by using human recombinant antibodies with

MAGE‐A1 allows for retargeting of primary human T

MHC‐restricted T cell receptor‐like specificity. Proc

lymphocytes. Gene Ther. 2001;8(21):1601–8.

Natl Acad Sci U S A. 2002;99(14):9421–6.

107. Willemsen RA, Ronteltap C, Chames P, Debets R,

96. Klechevsky E, Gallegos M, Denkberg G, Palucka K,

Bolhuis RL. T cell retargeting with MHC class I‐

Banchereau J, Cohen C, et al. Antitumor activity of

restricted antibodies: the CD28 costimulatory domain

immunotoxins with T cell receptor‐like specificity

enhances antigen‐specific cytotoxicity and cytokine

against human melanoma xenografts. Cancer Res.

production. J Immunol. 2005;174(12):7853–8.

2008;68(15):6360–7.

108. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL. A

97. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi

retroviral vector system ’STITCH’ in combination with

D, Levy F, et al. Antigenicity and immunogenicity of

an optimized single chain antibody chimeric receptor

Melan‐A/MART‐1 derived peptides as targets for

gene structure allows efficient gene transduction and

tumor reactive CTL in human melanoma. Immunol

expression in human T lymphocytes. Gene Ther.

Rev. 2002;188:81–96.

1998;5(9):1195–203.

98. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, 109. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Rivoltini L, Yannelli JR, et al. Identification of the

et al. Dissecting cytotoxic T cell responses towards the

immunodominant peptides of the MART‐1 human

NY‐ESO‐1 protein by peptide/MHC‐specific antibody

melanoma antigen recognized by the majority of HLA‐

fragments. Eur J Immunol. 2004;34(10):2919–29.

A2‐restricted tumor infiltrating lymphocytes. J Exp 110. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Med. 1994;180(1):347–52.

Zhang M, St John LS, et al. The role of antigen cross‐

99. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, presentation from leukemia blasts on immunity to the

et al. Phase 1 trial of intranodal injection of a Melan‐A/

leukemia‐associated antigen PR1. J Immunother.

MART‐1 DNA plasmid vaccine in patients with stage

2012;35(4):309–20.

IV melanoma. J Immunother. 2008;31(2):215–23.

111. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR,

100. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G,

Eisenbach L, Reiter Y. Direct detection and quantita-

Marty V, et al. Phase I trial of a MART‐1 peptide

tion of a distinct T cell epitope derived from tumor‐

vaccine with incomplete Freund’s adjuvant for resected

specific epithelial cell‐associated mucin using human

high‐risk melanoma. Clin Cancer Res.

recombinant antibodies endowed with the antigen‐

1999;5(10):2756–65.

specific, major histocompatibility complex‐restricted

101. Sadelain M, Brentjens R, Riviere I. The basic principles specificity of T cel s. Cancer Res. 2002;62(20):

of chimeric antigen receptor design. Cancer Discov.

5835–44.

2013;3(4):388–‐98.

112. Weidanz JA, Nguyen T, Woodburn T, Neethling FA,

102. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL,

Chiriva‐Internati M, Hildebrand WH, et al. Levels of

Rheingold SR, et al. Chimeric antigen receptor‐

specific peptide‐HLA class I complex predicts tumor

modified T cel s for acute lymphoid leukemia. N Engl J

cell susceptibility to CTL killing. J Immunol.

Med. 2013;368(16):1509–18.

2006;177(8):5088–97.

103. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 113. Neethling FA, Ramakrishna V, Keler T, Buchli R, Chimeric antigen receptor‐modified T cel s in chronic

Woodburn T, Weidanz JA. Assessing vaccine potency

lymphoid leukemia. New Engl J Med. 2011;365(8):

using TCRmimic antibodies. Vaccine. 2008;26(25):

725–33.

3092–102.

104. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, 114. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Loren AW, et al. Chimeric antigen receptor T cel s

Harris AL. Loss of transporter in antigen processing 1

200 Immunotherapy in Translational Cancer Research transport protein and major histocompatibility com-cross‐priming rather than cross‐tolerizing host

plex class I molecules in metastatic versus primary

tumor‐specific CD8 T cel s. J Immunol. 2003; 170(10):

breast cancer. Cancer Res. 1995;55(22):5191–4.

4905–13.

115. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. 120.

Alatrash G, Mittendorf EA, Sergeeva A,

Down‐regulation of HLA class I antigen‐processing

Sukhumalchandra P, Qiao N, Zhang M, et al. Broad

molecules in malignant melanoma: association with

cross‐presentation of the hematopoietical y derived

disease progression. American Journal of Pathology.

PR1 antigen on solid tumors leads to susceptibility to

1999;154(3):745–54.

PR1‐targeted immunotherapy. J Immunol. 2012;

116. Campoli M, Chang CC, Ferrone S. HLA class I antigen

189(11):5476–84.

loss, tumor immune escape and immune selection. 121. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Vaccine. 2002;20 Suppl 4:A40–5.

Topp MS, et al. Immunopharmacologic response of

117. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N,

patients with B‐lineage acute lymphoblastic leukemia

Harabuchi Y, et al. HLA class I antigen down‐regula-

to continuous infusion of T cell‐engaging CD19/CD3‐

tion in primary laryngeal squamous cell carcinoma

bispecific BiTE antibody blinatumomab. Blood.

lesions as a poor prognostic marker. Cancer Res.

2012;119(26):6226–33.

2006;66(18):9281–9.

122. Sun LL, Ellerman D, Mathieu M, Hristopoulos M,

118. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K,

Chen X, Li Y, et al. Anti‐CD20/CD3 T cell‐dependent

Nukui H, et al. Trastuzumab (Herceptin) enhances

bispecific antibody for the treatment of B cell malig-

class I‐restricted antigen presentation recognized by

nancies. Sci Transl Med. 2015;7(287):287ra70.

HER‐2/neu‐specific T cytotoxic lymphocytes. Clin 123. Laszlo GS, Gudgeon CJ, Harrington KH, Del ’Aringa J, Cancer Res. 2004;10(7):2538–44.

Newhall KJ, Means GD, et al. Cel ular determinants for

119. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR,

preclinical activity of a novel CD33/CD3 bispecific T

Collins EJ, et al. Induction of tumor cell apoptosis in

cell engager (BiTE) antibody, AMG 330, against human

vivo increases tumor antigen cross‐presentation,

AML. Blood. 2014;123(4):554–61.





CHAPTER 15

15 Stem Cell Transplantation

for Treatment of Malignancy

Lohith S. Bachegowda and Richard E. Champlin

Department of Stem Cell Transplantation and Cel ular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Introduction

Process of allogeneic

hematopoietic stem cell transplant

Hematopoietic stem‐cell transplantation (HSCT)

is a process wherein transfused donor pluripo­ A typical scheme for hematopoietic transplantation tent hematopoietic stem cells engraft and recon­ is shown in Figure 15.1. A pretransplant chemostitute hematopoiesis and immunity. Autologous therapy and/or radiation preparative regimen (also or allogeneic (related or unrelated) cells can be termed “conditioning”) is administered with a goal to used. Autologous HSCT (auto‐HSCT) uses bone eradicate the patient’s malignancy as well as to supmarrow or peripheral blood progenitor cells press the recipient’s T lymphocyte (T cel s) and that have been collected from the patient and natural killer (NK) cell function to prevent rejection.



cryopreserved. The cells are reinfused after This is followed by intravenous infusion of a source administration of a high‐dose, myeloablative of hematopoietic stem cel s; these cel s briefly circuchemotherapy and/or radiation preparative reg­ late and sufficient numbers home to the recipient’s imen, given with the goal of eradicating the bone marrow where they grow and ultimately restore malignancy. The auto‐HSCT is given to restore hematopoiesis and immunity. Donor‐derived normal hematopoiesis.

hematopoietic stem cel s generate the myeloid and

Allogeneic transplantation involves infusion of lymphoid lineages posttransplant, including granuhematopoietic cel s from a normal donor. locytes, erythrocytes, megakaryocytes, and macro­

Allogeneic HSCT (allo‐HSCT) can confer an phages, as well as T cel s, B cel s, and NK cel s. Some additional immunologic graft‐versus‐malignancy T cel s are also derived from mature T cel s present in (GVM) effect, where donor immunocompetent the graft. Osteoclasts are also of donor origin. The cel s can eradicate neoplastic cel s that survive the parenchymal cel s of visceral organs and most meschemo‐radiotherapy preparative regimen.

enchymal cel s remain host in origin.

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

201





202 Immunotherapy in Translational Cancer Research

Allogeneic Hematopoietic Transplantation

D

D

D

Preparative

Regimen

D

D

D

D

HSCT

± DLI

D

D

R

D

R

D

D

R

D

D

RL

D

R

R

L

RL

D

Recipient

Donor Mixed Chimera

Complete Chimera

Figure 15.1 Hematopoietic stem‐cell transplantation

(D) immune cells act to eliminate residual malignant cells

(HSCT) involves administration of a chemotherapy and/or

that may have survived the preparative regimen. Donor

radiotherapy preparative regimen to suppress the

lymphocyte infusion (DLI) may be administered to

recipient’s (R) immunity and cytoreduce recipient

augment the graft‐versus‐malignancy effects. The relative

leukemia (R ) cells. Hematopoietic stem cells are infused

proportion of donor and recipient cells is assessed by

L

to restore hematopoiesis and immunity. Donor

chimerism assays.

Peripheral blood counts are profoundly sup­ some myeloid or lymphoid cells continue to be pressed due to the effects of the conditioning derived from the recipient.

treatment. Myeloid cel s general y recover within 3

to 4 weeks, while T cel s, B cel s, and the function of Histocompatibility requirements the immune system slowly recover over the first

year posttransplant.

Major histocompatibility (MHC) antigens are the

Hematopoietic stem cells can be collected for antigen‐presenting molecules for the immune transplantation from bone marrow, peripheral system. In humans, the human leucocyte antigen blood, or umbilical cord blood. Post‐HSCT, (HLA) complex is the MHC loci. Mismatched HLA engraftment of donor cells can be documented antigens are the strongest stimuli for alloreactive by acquisition of donor type cell surface immune reactions producing graft rejection and antigens, isoenzymes, chromosome markers, graft‐versus‐host disease (GVHD). The HLA antigen and DNA restriction endonuclease polymor­ system is broadly divided into class I and class II molphisms [1]. Following successful transplantation ecules. HLA class I includes HLA‐A, HLA‐B, and and engraftment, cells of the hematologic and HLA‐C antigens and is present on all nucleated cel s.

immunologic systems are derived from the HLA class II, which includes HLA‐DP, HLA‐DQ, transplant donor; if all are donor derived, this is and HLA‐DR, is expressed on a more limited range termed complete chimerism. In some patients of cel s and increased with activation (B cel s, T cel s, mixed hematopoietic chimerism occurs, where monocytes, dendritic cel s, and macrophages).





CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 203

The best results of allo‐HSCT for treatment of unmodified haploidentical HSCT with post ransplant malignancy have occurred with an HLA‐identical treatment with cyclophosphamide, tacrolimus, and sibling donor (also called a matched sibling donor, mycophenolate. The cyclophosphamide is given on MSD). Unfortunately, only about 20% of candidate days 3 and 4 post­transplant to target and eliminate recipients have an MSD available. Due to the tre­ proliferating alloreactive T cel s. This regimen promendous polymorphism of the HLA gene complex, duces a low rate of severe acute and chronic GVHD

finding an HLA matched unrelated donor (MUD) and treatment‐related morbidity/mortality. Recent can be challenging. Searching through a network of results are comparable to matched unrelated donor unrelated donor registries (over 20 million individ­ transplants [11, 12]. At this point, an acceptable uals registered) can identify a MUD for about half related or unrelated donor can be identified for of the patients. Patients are most likely to match an almost all patients in need of an allo‐HSCT. Each individual from the same ethnic background, and donor source has a unique set of advantages and those with rare alleles or linkages or from minority disadvantages (Table 15.1).

or mixed ethnicities are unlikely to have a MUD

identified [2]. The best results with MUD trans­ Historical perspective plants have been achieved with HLA A, B, C, and

DR matched donors using high‐resolution (allele By the mid‐20th century, clinicians treating hemalevel) typing, with recent reported outcomes sim­ tologic neoplasms understood that hematologic ilar to those achieved with MSD [3–6].

malignancies exhibit a dose response relationship

For patients with nonavailable MSD or MUD, to radiation and alkylating agent–based chemoumbilical cord blood (CB) is a potential alternative therapy, with higher doses producing greater source of hematopoietic stem cel s [7]. Immunolo­ responses. However, irreversible marrow suppresgical y naïve CB lymphocytes are less prone to sion was the dose‐limiting toxicity; this could be produce GVHD than are cel s from adult donors. overcome by autologous or allogeneic HSCT.

Based on this concept, CB transplants can be suc­ Allogeneic HSCT can also mediate an immune cessful y performed with a less stringent HLA GVM effect, where donor‐derived immune cel s match (HLA A, B, and DR antigens). However, a react against recipient malignant cel s [13].

cord blood unit has a relatively low stem cell dose, Groundbreaking work by Medawar et al., Thomas which results in slower hematopoietic and immune et al., and others in demonstrating immune tolerrecovery after HSCT [8]. Recent studies involving ance and mechanism of graft rejection by effector transplantation of two or more CB units to increase immune cel s paved the way for clinical trials with the stem cell dose have allowed use of CB trans­ hematopoietic stem cel s in humans.

plants for adult recipients [9]. Centers focusing on

Early clinical trials explored the utility of

CB transplantation have reported results similar to

myeloablative preparative regimens using a

those obtained with adult MUD transplants.

combination of drugs and/or total body radia­

Another option is the use of haploidentical tion designed to eradicate the malignancy, related donors. Parents, children, and half siblings knowing that it would also ablate the recipient’s are haploidentical, so most patients will have a normal hematopoietic cells. The transplant was haploidentical donor available. Historical y, haploi­ given to provide hematopoietic stem cells needed dentical transplants were associated with a to restore hematopoiesis. High doses of alkylating prohibitively high rate of rejection and GVHD. T‐ agents (cyclophosphamide, busulfan, and melcell‐depleted peripheral blood progenitor phalan) and/or total‐body irradiation in different transplants have a low rate of GVHD, but these permutations were generally used as the prepartransplants are associated with a higher rate of ative regimen [14, 15].

rejection, slow immune recovery, and a substantial

Hematologic malignancies are most common in

risk of treatment‐related mortality [10]. This older patients who cannot tolerate the toxicity of approach has been successful in children, but few myeloablative preparative regimens. With the centers actively pursue this strategy in adults. appreciation that much of the benefit of HSCT is A major recent advance involves the use of derived from the immune donor–derived GVM

Table 15.1 Comparison of advantages and disadvantages with different donors.

Likelihood of Availability of Donor

Access to Stem Cells

GVHD

Donor

Based on the Level of HLA Match

and Donors

Cost

Time to Engraftment

Risk

Immune Reconstitution

MRD

Caucasian ‐ 75%

Fast and easy

Low

Quick

Small

Quick

African American ‐ 19%

Hispanic American ‐ 34%

South Asian ‐ 33%

Pacific Islander ‐ 27%

(8/8 match)

MUD

Caucasian ‐ 97%

Slow

High

Quick (slightly slower

Moderate

Quick (slightly slower than MRD)

African American ‐ 76%

than MRD)

Hispanic American ‐ 80%

South Asian ‐ 84%

Pacific Islander ‐ 72%

(7/8 match)

Cord blood

For adult patients (6/6 match):

Fast and easy

Very high

Slow

Small

Slower than MRD and MUD

Caucasian ‐ 17%

African American‐ 2%

Hispanic American ‐ 5%

South Asian ‐ 3%

Pacific Islander ‐ 3%

For adult patients (5/6 match):

Caucasian ‐ 66%

African American ‐ 24%

Hispanic American ‐ 43%

South Asian ‐ 37%

Pacific Islander ‐ 32%

Haplo‐identical

Universal (>90%)

Fast and easy

Low to moderate

Quick

Small

Slower than MRD, MUD, and

(posttransplant

cord blood

cytoxan era)



Note: MRD = matched related donor; MUD = matched unrelated donor; HLA = human leucocyte antigen; GVHD = graft‐versus‐host disease.





CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 205

effect, lower dose nonmyeloablative or reduced‐ the benefits of GVM from the morbidity intensity conditioning regimens have been associated with GVHD.

developed. This has allowed HSCT to be performed

The concept of GVM with allo‐SCT has best

in older patients, up to age 75, and those with been demonstrated for hematologic malignancies comorbidities that would preclude them receiving but has also been reported for renal cell carcimyeloablative conditioning. Although the relapse noma and selected other solid tumors. The risks rate is higher with reduced intensity conditioning, of allogeneic transplantation currently outweigh the risk of transplant‐related mortality is lower, and the benefit for solid tumors, but this approach overall survival is general y comparable with the may be reconsidered as treatment‐related comtwo approaches.

plications become better controlled or prevented.

Improvements in supportive care involving The GVM effect and GVHD are intertwined, but treatments for infections and immunosuppressive the antineoplastic effects of HSCT are potentially therapies have decreased the risk for treatment‐ independent of GVHD. Ongoing research is Table 15.1 Comparison of advantages and disadvantages with different donors.

related mortality and have progressively improved designed to induce GVM while simultaneously Likelihood of Availability of Donor

Access to Stem Cells

GVHD

survival over the last several decades [16]. controlling GVHD.

Donor

Based on the Level of HLA Match

and Donors

Cost

Time to Engraftment

Risk

Immune Reconstitution

Unfortunately, there has not been substantial

Clinical evidence of increased relapse risk in

MRD

Caucasian ‐ 75%

Fast and easy

Low

Quick

Small

Quick

improvement in the risk of relapse of malignancy recipients of HSCT from a twin donor and with African American ‐ 19%

Hispanic American ‐ 34%

posttransplant, and there is major interest to T‐cell‐depleted transplants compared to T‐cell-South Asian ‐ 33%

improve efficacy of the preparative regimen and replete allogeneic grafts, suggests donor T cells Pacific Islander ‐ 27%

(8/8 match)

augment GVM effects.

play a critical role in mediating both the GVHD

MUD

Caucasian ‐ 97%

Slow

High

Quick (slightly slower

Moderate

Quick (slightly slower than MRD)

and GVT effects [17–19]. Donor T cell

African American ‐ 76%

than MRD)

Hispanic American ‐ 80%

activation following HSCT requires recognition

South Asian ‐ 84%

Pacific Islander ‐ 72%

Mechanism of GVM effect

of major or minor histocompatibility antigens

(7/8 match)

as a critical first step. This process is mediated

Cord blood

For adult patients (6/6 match):

Fast and easy

Very high

Slow

Small

Slower than MRD and MUD

Caucasian ‐ 17%

Alloreactive T cells can recognize disparate by the highly polymorphic HLA antigens African American‐ 2%

major and minor histocompatibility antigens on located on chromosome 6. In HLA‐identical Hispanic American ‐ 5%

South Asian ‐ 3%

the malignant cells of recipient origin. NK cells transplants, T cell response is mainly targeted Pacific Islander ‐ 3%

also participate. A large International Bone against the minor histocompatibility antigens For adult patients (5/6 match):

Caucasian ‐ 66%

Marrow Transplant Registry study ( n = 2,254) originating from polymorphism in the MHC

African American ‐ 24%

comprising patients with acute myeloid leu­ region and is thought to be directed against Hispanic American ‐ 43%

South Asian ‐ 37%

kemia (AML) and acute lymphoid leukemia in peptide presented on the surface of HLA Pacific Islander ‐ 32%

Haplo‐identical

Universal (>90%)

Fast and easy

Low to moderate

Quick

Small

Slower than MRD, MUD, and

first complete remission (CR), and chronic antigens (Figure 15.2). In contrast, with HLA (posttransplant

cord blood

myeloid leukemia (CML) in first chronic phase mismatched stem cell transplantation (SCT), cytoxan era)

offered pivotal insights regarding the mecha­ donor T cells can react against major and minor Note: MRD = matched related donor; MUD = matched unrelated donor; HLA = human leucocyte antigen; GVHD = graft‐versus‐host disease.

nism of GVM [17]. Allo‐HSCT in this study was histocompatibility disparities [20, 21]. Once associated with a lower rate of relapse than were activated, T cells (CD 4+ and CD 8+) attack syngeneic transplants, indicating that alloanti­ recipient neoplastic cells by either a direct cytogens are likely the targets of GVM. T cell lytic action or by a cytokine‐derived cellular depleted transplants have a higher relapse rate destruction. Cytolytic actions in CD8‐positive in CML, lymphoma, and many other malig­ T cells target leukemic cell destruction by pernancies, showing that T cells are important forin/granzyme‐assisted degranulation, Fas–fas effector cells in this process. Several studies ligand interactions that ultimately culminate in show no increase in relapse with T cell depleted apoptotic cell death and inflammatory cytokine transplants for AML, and NK cells are believed release [22]. Other important mediators include to be the major mediators of GVM in this NK cells, which have complementary effects to setting. Alloreactive cells may also react T cel s, eliminating malignant cel s that downregwith recipient normal tissues and produce ulate HLA molecules. Dendritic cel s, macrophages, GVHD. Clinically, GVM is primarily associated and antibodies may also play a role as discussed with chronic GVHD. A major goal is to separate in other chapters in this book.





206 Immunotherapy in Translational Cancer Research Malignancy Specific:

(A) Allo specific- Broadly

Idiotype, Fusion peptide of

expressed mha

translocation (bcr-abl)

Implication-GVHD

Lineage restricted mha

Aberrantly expressed

(G-vs-hematopoiesis)

normal cellular constituent

(Proteinase 3, WT1, telomerase)

(B)

Transcription

Donor T

Cell

(CD 154) CD40L

TCR

B

B

7

7

A

G

M

H

C

CTLA4

CD40

CD28

Recipient (APC)

Figure 15.2 A. Targets for graft versus malignancy

regulated either by the stimulatory interaction between

(GVM) could be broadly expressed allo‐minor

the cluster of differentiation (CD)‐28 and B7 molecules

histocompatibility antigens (mha), lineage‐restricted

or an inhibitory response with the interaction of

major histocompatibility complex (MHC) antigens,

cytotoxic T lymphocyte associated (CTLA)‐4 protein with

malignancy‐specific peptides, or aberrantly expressed

the B7 molecule. Interaction between costimulatory

normal cellular constituents by antigen presenting cells.

CD40 molecule with its ligand CD40L (CD154) is also

B. Donor T cell response to antigens (AG) presented by critical in initiating T cell downstream signaling

MHC on recipient’s antigen‐presenting cells (APC) is

pathways.

Indications for HSCT

transplant [25]. High‐dose chemotherapy and

autologous hematopoietic transplantation tem­

Nonmalignant diseases

porarily ablates and resets the immune system,

Allogeneic hematopoietic transplantation can be and can provide remissions in a range of autoused to treat congenital and acquired diseases of immune diseases, including multiple sclerosis the hematopoietic and immune systems. It is the [26] and scleroderma [27].

standard of care for bone marrow failure states,

such as aplastic anemia [23] and severe combined

immune deficiency [24]. It is effective for sickle Malignant diseases cell anemia and hemoglobinopathies, although Hematopoietic transplants are primarily used for the benefits of replacing the defective erythro­ treatment of cancer. Details about differences in cytes must be weighed against the risks of the clinical outcomes with reduced‐intensity conditioning





CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 207

and myeloablative conditioning is beyond the pur­ improved progression‐free survival in patients up view of this chapter, as this has been extensively to age 60. Considering that the median age for reviewed [28]. The main emphasis would remain AML diagnosis is over 67 years, myeloablative conon offering insights about the clinical benefits of ditioning is feasible only for a minority of patients.

allo‐HSCT as an immunotherapeutic modality.

Reduced‐intensity conditioning (RIC) regimens

have made SCT a feasible option for many elderly

Acute myeloid leukemia

and medical y infirm patients. In a large Center for

(AML) [29]

International Blood and Marrow Transplant

Research (CIBMTR) study (age 60–70 years), RIC

AML is the commonest indication for allo‐HSCT. was shown to have a lower risk of relapse (32% vs Chemotherapy alone for AML can cure a minority 81%, p < .01) and a longer leukemia‐free survival of patients, and leukemia relapse occurs in most (32% vs 15%, p = .001) compared with individuals patients. By integrating cytogenetics and molecular receiving chemotherapy in first complete remission data, AML patients are now broadly stratified into [37]. There is a higher rate of leukemia relapse with three risk groups with distinct survival patterns: (1) RIC regimens compared to myeloablative condifavorable, (2) intermediate, and (3) adverse [29, tioning, but the rate of treatment related mortality is 30]. The favorable group has the best reported improved [37].

survival, ranging from 55% to 65%, and the adverse

group has the least survival with reported out­ Myelodysplastic syndrome (MDS) comes in the range of 5%–15% [31, 32]. Allo‐HSCT

has been documented to reduce relapse rates and is MDS is predominantly a disease of the elderly, with considered a standard of care for patients with a median age of diagnosis of approximately 75 years.

intermediate and high‐risk cytogenetic and several An international prognostic system built on molecular abnormalities [22, 32]. Allo‐HSCT is percentage of bone marrow blasts, cytopenias, not recommended in the favorable risk group and karyotype stratifies patients into low, unless the patient fails to achieve complete remis­ intermediate‐1, intermediate‐2, and high risk sion or has residual disease. In contrast, HSCT is groups [38]. Based on this stratification, for low considered the best consolidative strategy for and intermediate‐1 groups, long‐term disease conpatients in the adverse risk group [33]. There is trol can be achieved with upfront nontransplant controversy regarding management of patients options (hypomethylating agents, lenalidomide with intermediate‐risk AML. Some studies indicate (Revlimid), etc.) with HSCT delayed until leuthat individuals with normal karyotype and kemic transformation or worsening disease feanucleophosmin 1 (NPM1) mutation or CEBPA tures, such as transfusion dependence or failure of mutation without the presence of FLT‐3 mutation nontransplant options. In contrast, early HSCT is may fare as well with chemotherapy. However, the usual y recommended for intermediate‐2 and high presence of a mutant FLT3‐ITD mutation confers a risk groups [39, 40]. Since approximately 80% of poor prognosis, and allo‐HSCT has produced patients diagnosed with MDS are >60 years of age, improved progression‐free survival [34].

the impact of age on HSCT outcomes has been

The intensity of the preparative regimen is examined. CIBMTR performed a large registry-important in preventing relapse. For most of the based study and noted two‐year overall survival patients, if they are medical y fit and or young, (OS) of 42%, 35%, 45%, and 38% for age groups high‐dose myeloablative conditioning that utilizes 40–54, 55–59, 60–64, and ≥65 years of age, respecbusulfan in combination with cyclophosphamide tively [41]. In this analysis, age had no significant or fludarabine, or high‐dose total‐body radiation is impact on survival. Based on this report, within its recommended [35, 36].

limitations, recipient age alone is not considered

A recent Blood and Marrow Transplant prohibitive for MDS patients seeking HSCT. For Clinical Trials Network study (BMT CTN #0901) patients who cannot receive myeloablative condi­

(https://clinicaltrials.gov/ct2/show/NCT01339910) tioning, reduced intensity regimens can be offered showed that myeloablative conditioning produced with similar expected outcomes [42].





208 Immunotherapy in Translational Cancer Research Myelofibrosis

There is also improvement in prognostic risk

assessment, including recognition of high‐risk

Myelofibrosis is the advanced stage of myeloprolif­ forms of ALL and determination of the dominant erative neoplasms and can occur as a primary prognostic impact of minimal residual disease clonal disorder or evolve from a pre‐existing detection [52]. An analysis of the Group for polycythemia vera or essential thrombocythemia. Research on Adult Acute Lymphoblastic Leukemia Although targeted agents like Jak2 inhibitors and (GRAALL) multicenter studies found the presence cytokine therapy can control symptoms and reduce of minimal residual disease as the major adverse organomegaly, these treatments do not eradicate risk factor justifying use of allo‐HSCT for patients the disease. Allo‐HSCT is considered a cornerstone in first remission [53]. Allo‐HSCT is also indioption as a potential y curative treatment for mye­ cated for treatment of Philadelphia lofibrosis. Results are related to the stage of the dis­ chromosome–positive ALL, early thymic preease at the time of transplant. Reported five‐year cursor T ALL, and Philadelphia‐like ALL, which survival is 37%, 30%, and 40%, and progression‐ have poor prognosis with chemotherapy alone free survival is 33%, 27%, and 22%, respectively, [54].

with MSD, MUD, and alternative donors in the

Collectively, all these new developments empha­

CIBMTR analysis. Even with the application of size the need for additional randomized studies RIC, similar progression‐free survival (39% at five that can address the optimal timing of allo‐HSCT

years) can be achieved [43].

for ALL patients in the modern era.

Acute lymphoblastic

Chronic myeloid leukemia (CML)

leukemia (ALL)

Allo‐HSCT is a potential y curative treatment for

GVM effects with allo‐HSCT are less potent in CML and was considered the standard of care for ALL compared to other malignancies, but allo‐ this malignancy during the late 20th century [55].

HSCT is an effective strategy in patients with ALL CML is very sensitive to the immunologic GVM

at high risk of relapse or who recur [44, 45]. In one effects [56, 57]. This was demonstrated by the effilarge multicenter prospective study, MSD allo‐ cacy of donor lymphocyte infusions to reinduce HSCT for ALL patients in first remission was asso­ durable molecular complete remissions in patients ciated with a survival benefit (53% vs 45%, p = .01) who relapse after an allo‐SCT [58]. The introducin comparison with patients who had no available tion of imatinib to molecularly target the BCR-MSD and received either consolidation chemo­ ABL tyrosine kinase has revolutionized the therapy or auto‐transplantation. In contrast, allo‐ treatment of this disease and provided a safer and HSCT has shown improved outcomes for high‐risk effective treatment for CML, providing durable groups in most other studies and in a meta‐analysis disease control for most patients. After imatinib,

[46]. For patients who cannot tolerate full multiple other oral tyrosine kinase inhibitors myeloablative conditioning, reduced intensity (TKIs) (dasatinib, ponatinib, nilotinib, and bosutiregimens offer an alternative with similar nib) have also been effective in treatment of CML, outcomes [47, 48].

and second‐line TKI treatment can provide durable

In recent years, several practice‐changing develop­ disease control in some patients resistant to imaments have significantly improved the management tinib. Allogeneic HSCT is now reserved for patients of patients with ALL without hematopoietic trans­ who are intolerant to TKIs, have failed to respond plantation. Improved chemotherapy regimens have optimal y to TKIs, or who have transformed to been developed using pediatric‐inspired protocols accelerated or blastic phase [59, 60]. A large with higher CR rates and improved survival com­ CIBMTR analysis (approximately 50% received pared to traditional chemotherapy [49]. Promising prior imatinib) showed prolonged disease‐free new agents are being evaluated, such as tyrosine survival (DFS) with allo‐HSCT in patients with kinase inhibitors, monoclonal antibodies, and bi‐ advanced CML in second chronic phase (35%–40%), specific agents including blinatumomab [50, 51]. accelerated phase (26%–27%), and blastic phase





CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 209

(8%–11%) [61]. Improved DFS and OS was and auto‐HSCT can increase the fraction achievreported for allo‐HSCT compared to TKI in acce­ ing complete remission, prolong the time to lerated phase CML [62]. There is also emerging

progression, and increase survival [78].

evidence that suggest post‐SCT TKI treatment Maintenance therapy, general y with lenalidomide, may reduce the risk of relapse of CML, particu­ further prolongs remission duration [79].

larly for those with advanced disease [63, 64].

Unfortunately, the majority of multiple myeloma

patients relapse despite this treatment. Allo‐HSCT

Lymphomas

has been evaluated in patients with myeloma.

There is evidence of a GVM effect, as demonstrated

Allo‐HSCT is an effective treatment for selected by responses to donor lymphocyte infusion [80].

patients with advanced lymphomas and Hodgkin Multiple myeloma is general y a disease of older disease. Allo‐HSCT has been highly effective in people. Myeloablative allo‐HSCT can produce advanced follicular lymphomas, with >80% DFS in durable CR in some patients, but is associated with several studies utilizing RIC. Indolent B‐cell lym­ a high rate of treatment‐related morbidity and phomas are also susceptible to the GVM effect. mortality (34%–53%) [81–83]. Reduced intensity Some patients with relapse post allo‐HSCT have conditioning is better tolerated but has a higher responded to withdrawal of immunosuppression rate of relapse than with myeloablative condior use of donor lymphocyte infusions [65, 66]. This tioning. A strategy of tandem transplants, using an observation has been further validated in large retro­ auto‐HSCT for initial cytoreduction, followed by a spective studies that compared outcomes of allo‐ reduced‐intensity allo‐HSCT to induce the GVM

versus auto‐HSCT for non‐Hodgkin lymphomas, effect has been extensively studied [84]. This impact of T‐cell‐depleted grafts on the potency of approach results in complete remission in approxi­

GVM and frequent association of GVHD, and mately 60%, with an 18% rate of treatment‐related protection from relapse [67, 68]. In general, the mortality [85]. There have been several randomized greatest GVM effects are seen in patients with studies comparing tandem auto‐allo transplants chemotherapy‐responsive, low‐tumor‐burden, indo­ with chemotherapy; results are mixed. The largest lent non‐Hodgkin lymphoma [68, 69]. Allo‐HSCT study, conducted by the BMT CTN, did not show is also effective in patients with chemotherapy an advantage with the tandem auto‐allogeneic responsive Hodgkin’s lymphoma that has recurred transplant compared to tandem autologous transafter autologous SCT (3 yr OS and DFS of 43% and plants. At present, this approach is not recom25%, respectively) [70].

mended for initial treatment of multiple myeloma

Unfortunately, the GVM effect in lymphomas is outside of a clinical trial. Despite these limitations, offset by the risks of treatment‐related morbidity allo‐HSCT retains a curative potential in a subset and mortality [71, 72]. Since RIC has been highly of patients with advanced multiple myeloma. Allo-effective and associated with less toxicity than mye­ HSCT is an appropriate option for patients with loablative regimens, RIC regimens are general y chemosensitive relapse of multiple myeloma, and recommended for indolent lymphomas [73, 74].

about 20% of patients achieve a durable complete

Diffuse large B‐cell lymphomas are less suscep­ remission.

tible to GVM than the indolent lymphomas.

Allo‐HSCT does not appear to have an advantage Solid organ tumors to auto‐HSCT for these patients [75].

Allo‐HSCT may also produce a GVM effect

Multiple myeloma

against solid tumors, although this has general y

not been as potent as with hematologic malig­

There have been substantial improvements in the nancies (Table 15.2) [86]. Several small case series treatment of multiple myeloma, but it is still consid­ of patients with concomitant breast cancer showered an incurable disease. Chemotherapy can ing excellent tumor response post‐HSCT were achieve an initial response in most patients [76, 77]. reported [87, 88]. Despite initial enthusiasm, con­

Consolidation therapy using high‐dose melphalan cerns about immediate toxicity and limited





210 Immunotherapy in Translational Cancer Research Table 15.2 Graft‐versus‐Malignancy Effects.

Separation of the beneficial GVM effects from

the toxicity of GVHD is the highest priority in

Level of Activity

Diseases

hematopoietic transplantation. New approaches

High

CML, CLL, low‐grade lymphomas,

for conditioning regimens, GVHD prophylaxis,

mantle cell lymphoma

immunomodulatory treatments, and cel ular

Intermediate

AML, intermediate grade lymphoma,

immunotherapy are undergoing evaluation.

Hodgkin lymphoma, plasma cell

disorders

Low

ALL, high‐grade lymphomas, and

References

solid organ neoplasms

1. Khan F, Agarwal A, Agrawal S. Significance of chimerism

Source: Gragert et al., 2014 [2].

in hematopoietic stem cell transplantation: new varia­

Note: CML = chronic myeloid leukemia; CLL = chronic

tions on an old theme. Bone Marrow Transplant.

lymphocytic leukemia; AML = acute lymphoblastic leukemia.

2004;34(1):1–12.

2. Gragert L, Eapen M, Williams E, Freeman J, Spellman S,

efficacy of tumor regression with myeloablative

Baitty R, et al. HLA match likelihoods for hematopoietic

conditioning allo‐SCT for solid organ tumors

stem‐cell grafts in the U.S. registry. N Engl J Med.

hampered its widespread application [89]. Studies

2014;371(4):339–48.

at the National Institutes of Health in Bethesda 3. Lee SJ, Klein J, Haagenson M, Baxter‐Lowe LA, Confer using RIC regimens examined allo‐HSCT for a

DL, Eapen M, et al. High‐resolution donor‐recipient HLA

subset of tumors that are highly likely to respond

matching contributes to the success of unrelated donor

marrow transplantation. Blood. 2007;110(13):4576–83.

to immunologic modifications. Based on this 4. Flomenberg N, Baxter‐Lowe LA, Confer D, Fernandez-rationale, metastatic renal cell cancer, which had a

Vina M, Filipovich A, Horowitz M, et al. Impact of HLA

track record of being sensitive to immunotherapy,

class I and class II high‐resolution matching on outcomes

was the first tumor studied; a high response rate

of unrelated donor bone marrow transplantation: HLA‐C

(40%) was reported, with several patients attainmismatching is associated with a strong adverse effect on ing CR [90]. These findings were confirmed in

transplantation outcome. Blood. 2004;104(7):1923–30.

data of another large registry, which demon­ 5. Valcarcel D, Sierra J, Wang T, Kan F, Gupta V, Hale GA, strated 28% tumor response and 30% OS at 2

et al. One‐antigen mismatched related versus HLA‐

years [91]. However, given the risks of GVHD and

matched unrelated donor hematopoietic stem cell transa 10%–20% risk of nonrelapse mortality, the plantation in adults with acute leukemia: Center for

overall survival of patients has not been improved,

International Blood and Marrow Transplant Research

results in the era of molecular HLA typing. Biol Blood

and this approach is not currently considered a

Marrow Transplant. 2011;17(5):640–8.

standard of care for renal cell cancer.

6. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee

Allo‐HSCT has also been explored in other solid

S, Anasetti C, et al. Classification of HLA‐matching for

tumors with only modest response rates [92]. Allo‐

retrospective analysis of unrelated donor transplantation:

HSCT is not recommended for treatment of solid

revised definitions to predict survival. Biol Blood Marrow

tumors, outside of the context of a clinical trial.

Transplant. 2008;14(7):748–58.

7. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang

Conclusions

MJ, Champlin RE, et al. Outcomes after transplantation of

cord blood or bone marrow from unrelated donors in

Allo‐HSCT is an advanced form of adoptive

adults with leukemia. N Engl J Med. 2004;351(22):

immuno therapy. The donor‐derived GVM effect

2265–75.

can eradicate drug‐resistant cel s and produce 8. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord durable complete remissions in a range of hematoblood transplantation: the first 25 years and beyond.

logic malignancies. Allo‐HSCT is used for high‐

Blood. 2013;122(4):491–8.

risk hematologic malignancies where it improves 9. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al. Umbilical cord blood transplantation

DFS and OS in selected categories of patients. The

after nonmyeloablative conditioning: impact on trans­

GVM effect occurs against solid tumors as well but

plantation outcomes in 110 adults with hematologic

appears much less potent.

disease. Blood. 2007;110(8):3064–70.

CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 211

10. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A,

structural mimicry. J Biol Chem. 2006;281(45):

Bal anti S, et al. Full haplotype‐mismatched hematopoi34324–32.

etic stem‐cell transplantation: a phase II study in patients 21. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg with acute leukemia at high risk of relapse. J Clin Oncol.

JH, Vossen J, et al. Mismatches of minor

2005;23(15):3447–54.

histocompatibility antigens between HLA‐identical

11. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell

donors and recipients and the development of graft‐

MS, Zahurak M, et al. HLA‐haploidentical bone marrow

versus‐host disease after bone marrow transplantation.

transplantation for hematologic malignancies using

N Engl J Med. 1996;334(5):281–5.

nonmyeloablative conditioning and high‐dose, post22. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M.

transplantation cyclophosphamide. Biol Blood Marrow

The allogeneic graft‐versus‐cancer effect. Br J Haematol.

Transplant. 2008;14(6):641–50.

2009;147(5):614–33.

12. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, 23. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta Appelbaum FR, Aljitawi OS, et al. Haploidentical trans­

BM, Gluckman E, et al. Bone marrow transplantation for

plant with posttransplant cyclophosphamide vs matched

severe aplastic anemia: a randomized controlled study of

unrelated donor transplant for acute myeloid leukemia.

conditioning regimens. Blood. 2007;109(10):4582–5.

Blood. 2015;126(8):1033–40.

24. Rappeport JM, O’Reil y RJ, Kapoor N, Parkman R.

13. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of

Hematopoietic stem cell transplantation for severe

murine leukaemia with X rays and homologous bone

combined immune deficiency or what the children have

marrow; preliminary communication. Br Med J.

taught us. Hematology/Oncology Clinics of North

1956;2(4993):626–7.

America. 2011;25(1):17–30.

14. Graw RG, Jr., Lohrmann HP, Bull MI, Decter J, Herzig 25. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan GP, Bull JM, et al. Bone‐marrow transplantation follow­

N, Songdej D, Chuansumrit A, et al. Hematopoietic stem

ing combination chemotherapy immunosuppression

cell transplantation for homozygous beta‐thalassemia

(B.A.C.T.) in patients with acute leukemia. Transplant

and beta‐thalassemia/hemoglobin E patients from hap­

Proc. 1974;6(4):349–54.

loidentical donors. Bone Marrow Transplant.

15. Santos GW, Tutschka PJ, Brookmeyer R, Saral R,

2016;51(6):813–8.

Beschorner WE, Bias WB, et al. Marrow transplantation 26. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, for acute nonlymphocytic leukemia after treatment with

Griffith LM, et al. High‐dose immunosuppressive

busulfan and cyclophosphamide. N Engl J Med.

therapy and autologous hematopoietic cell transplanta1983;309(22):1347–53.

tion for relapsing‐remitting multiple sclerosis (HALT‐

16. Remberger M, Ackefors M, Berglund S, Blennow O,

MS): a 3‐year interim report. JAMA Neurol. 2015;72(2):

Dahllof G, Dlugosz A, et al. Improved survival after allo159–69.

geneic hematopoietic stem cell transplantation in recent 27. Sullivan KM, Shah A, Sarantopoulos S, Furst DE.

years. A single‐center study. Biol Blood Marrow

Review: Hematopoietic stem cell transplantation for

Transplant. 2011;17(11):1688–97.

scleroderma: effective immunomodulatory therapy for

17. Horowitz MM, Gale RP, Sondel PM, Goldman JM,

patients with pulmonary involvement. Arthritis &

Kersey J, Kolb HJ, et al. Graft‐versus‐leukemia reactions

Rheumatology. 2016;68(10):2361–71.

after bone marrow transplantation. Blood. 1990;75(3): 28. Pingali SR, Champlin RE. Pushing the envelope: nonmy555–62.

eloablative and reduced intensity preparative regimens

18. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM,

for allogeneic hematopoietic transplantation. Bone

Schriber J. Outcomes after matched unrelated donor

Marrow Transplant. 2015;50(9):1157–67.

versus identical sibling hematopoietic cell transplanta29. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum tion in adults with acute myelogenous leukemia. Blood.

FR, Buchner T, et al. Diagnosis and management of

2012;119(17):3908–16.

AML in adults: 2017 ELN recommendations from an

19. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz

international expert panel. Blood. 2017;129(4):424–47.

CJ, Atkinson KA, et al. T‐cell depletion of bone marrow 30. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker transplants for leukemia from donors other than HLA-H, Whitman SP, et al. Prognostic significance of the

identical siblings: advantage of T‐cell antibodies with

European LeukemiaNet standardized system for reportnarrow specificities. Blood. 2000;95(12):3996–4003.

ing cytogenetic and molecular alterations in adults with

20. Archbold JK, Macdonald WA, Miles JJ, Brennan RM,

acute myeloid leukemia. J Clin Oncol. 2012;30(36):

Kjer‐Nielsen L, McCluskey J, et al. Alloreactivity

4515–23.

between disparate cognate and allogeneic pMHC‐I comp31. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, lexes is the result of highly focused, peptide‐dependent

Arthur DC, et al. Pretreatment cytogenetic abnormalities

212 Immunotherapy in Translational Cancer Research are predictive of induction success, cumulative inci42. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, dence of relapse, and overall survival in adult patients

Bornhauser M, et al. Similar outcomes using myeloablawith de novo acute myeloid leukemia: results from tive vs reduced‐intensity allogeneic transplant prepara­

Cancer and Leukemia Group B (CALGB 8461). Blood.

tive regimens for AML or MDS. Bone Marrow

2002;100(13):4325–36.

Transplant. 2012;47(2):203–11.

32. Grimwade D, Hil s RK, Moorman AV, Walker H, 43. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Chatters S, Goldstone AH, et al. Refinement of cytoge­

Bashey A, Bolwell BJ, et al. Outcome of transplantation

netic classification in acute myeloid leukemia: determifor myelofibrosis. Biol Blood Marrow Transplant.

nation of prognostic significance of rare recurring

2010;16(3):358–67.

chromosomal abnormalities among 5876 younger adult 44. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris patients treated in the United Kingdom Medical

MB, Blume KG, et al. Relapse risk in patients with malig­

Research Council trials. Blood. 2010;116(3):354–65.

nant diseases given allogeneic hematopoietic cell trans33. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, plantation after nonmyeloablative conditioning. Blood.

Djulbegovic BJ, et al. Allogeneic stem cell transplanta2007;110(7):2744–8.

tion for acute myeloid leukemia in first complete remis45. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, sion: systematic review and meta‐analysis of prospective

Buck G, Fielding AK, et al. In adults with standard‐risk

clinical trials. JAMA. 2009;301(22):2349–61.

acute lymphoblastic leukemia, the greatest benefit is

34. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu achieved from a matched sibling allogeneic transplanta­

A, Bullinger L, et al. Mutations and treatment outcome

tion in first complete remission, and an autologous

in cytogenetical y normal acute myeloid leukemia. N

transplantation is less effective than conventional consol­

Engl J Med. 2008;358(18):1909–18.

idation/maintenance chemotherapy in all patients: final

35. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell

results of the International ALL Trial (MRC UKALL XII/

BJ, Zhu X, et al. Better leukemia‐free and overall survival

ECOG E2993). Blood. 2008;111(4): 1827–33.

in AML in first remission following cyclophosphamide 46. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic in combination with busulfan compared with TBI.

hematopoietic stem cell transplantation as part of pos­

Blood. 2013;122(24):3863–70.

tremission therapy improves survival for adult patients

36. Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura

with high‐risk acute lymphoblastic leukemia: a meta­

E, Devine SM, et al. Prospective cohort study comparing

analysis. Cancer. 2006;106(12):2657–63.

intravenous busulfan to total body irradiation in hemato47. Martino R, Giralt S, Caballero MD, Mackinnon S, poietic cell transplantation. Blood. 2013;122(24): 3871–8.

Corradini P, Fernandez‐Aviles F, et al. Allogeneic hema37. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, topoietic stem cell transplantation with reduced‐intensity

Mrozek K, et al. Comparison of reduced‐intensity hemaconditioning in acute lymphoblastic leukemia: a feasitopoietic cell transplantation with chemotherapy in bility study. Haematologica. 2003;88(5):555–60.

patients age 60‐70 years with acute myelogenous leu48. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser kemia in first remission. Biol Blood Marrow Transplant.

AA, Rambaldi A, et al. Reduced intensity conditioning

2011;17(12):1796–803.

allogeneic stem cell transplantation for adult patients

38. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia‐

with acute lymphoblastic leukemia: a retrospective study

Manero G, Sole F, et al. Revised international prognostic

from the European Group for Blood and Marrow

scoring system for myelodysplastic syndromes. Blood.

Transplantation. Haematologica. 2008;93(2):303–6.

2012;120(12):2454–65.

49. Stock W. Adolescents and young adults with acute lym39. Bachegowda L, Gligich O, Mantzaris I, Schinke C, phoblastic leukemia. Hematology Am Soc Hematol

Wyville D, Carrillo T, et al. Signal transduction inhibi­

Educ Program. 2010;2010:21–9.

tors in treatment of myelodysplastic syndromes. J 50. Kantarjian HM, DeAngelo DJ, Stel jes M, Martinelli G, Hematol Oncol. 2013;6:50.

Liedtke M, Stock W, et al. Inotuzumab ozogamicin

40. Cutler C. Timing of allogeneic stem cell transplantation versus standard therapy for acute lymphoblastic leufor myelodysplastic syndromes and aplastic anemia.

kemia. N Engl J Med. 2016;375(8):740–53.

Hematology Am Soc Hematol Educ Program. 51. Hunger SP, Mullighan CG. Acute lymphoblastic leu2014;2014(1):77–81.

kemia in children. N Engl J Med. 2015;373(16):

41. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva

1541–52.

G, Tallman MS, Sierra J, et al. Effect of age on outcome of 52. Bruggemann M, Raff T, Kneba M. Has MRD monitoring reduced‐intensity hematopoietic cell transplantation for

superseded other prognostic factors in adult ALL?

older patients with acute myeloid leukemia in first

Blood. 2012;120(23):4470–81.

complete remission or with myelodysplastic syndrome. 53. Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal J Clin Oncol. 2010;28(11):1878–87.

C, Huguet F, et al. Randomized study of reduced‐intensity

CHAPTER 15 Stem Cell Transplantation for Treatment of Malignancy 213

chemotherapy combined with imatinib in adults with 66. van Besien KW, de Lima M, Giralt SA, Moore DF, Jr., Ph‐positive acute lymphoblastic leukemia. Blood.

Khouri IF, Rondon G, et al. Management of lymphoma

2015;125(24):3711–9.

recurrence after allogeneic transplantation: the rele54. Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphovance of graft‐versus‐lymphoma effect. Bone Marrow blastic leukemia. Mayo Clin Proc. 2016;91(11):1645–66.

Transplant. 1997;19(10):977–82.

55. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, 67. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Klein JP, Hurley CK, et al. HLA‐identical sibling com­

Appelbaum F, et al. Autologous versus allogeneic bone

pared with 8/8 matched and mismatched unrelated donor

marrow transplantation for non‐Hodgkin’s lymphoma: a

bone marrow transplant for chronic phase chronic myecase‐controlled analysis of the European Bone Marrow loid leukemia. J Clin Oncol. 2009;27(10):1644–52.

Transplant Group Registry data. J Clin Oncol.

56. Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A,

1992;10(11):1690–5.

Neiman PE, et al. Treatment of chronic granulocytic leu68. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, kaemia in chronic phase by allogeneic marrow trans­

Fenske TS, et al. Allogeneic hematopoietic cell transplantation. Lancet. 1982;2(8299):621–3.

plantation for chemotherapy‐unresponsive mantle cell

57. McGlave PB, Arthur DC, Kim TH, Ramsay NK, Hurd

lymphoma: a cohort analysis from the center for interna­

DD, Kersey J. Successful allogeneic bone‐marrow transtional blood and marrow transplant research. Biol Blood plantation for patients in the accelerated phase of

Marrow Transplant. 2013;19(4):625–31.

chronic granulocytic leukaemia. Lancet. 1982;2(8299): 69. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling 625–7.

M, Lee MS, et al. Eight‐year experience with allogeneic

58. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B,

stem cell transplantation for relapsed follicular lym­

Jacobsen N, Arcese W, et al. Graft‐versus‐leukemia

phoma after nonmyeloablative conditioning with fludaeffect of donor lymphocyte transfusions in marrow rabine, cyclophosphamide, and rituximab. Blood.

grafted patients. Blood. 1995;86(5):2041–50.

2008;111(12):5530–6.

59. Caldemeyer L, Dugan M, Edwards J, Akard L. Long‐

70. Robinson SP, Sureda A, Canals C, Russell N, Caballero

term side effects of tyrosine kinase inhibitors in chronic

D, Bacigalupo A, et al. Reduced intensity conditioning

myeloid leukemia. Current Hematologic Malignancy

allogeneic stem cell transplantation for Hodgkin’s lym­

Reports. 2016;11(2):71–9.

phoma: identification of prognostic factors predicting

60. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger

outcome. Haematologica. 2009;94(2):230–8.

MW, Druker BJ. Human chronic myeloid leukemia stem 71. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, cel s are insensitive to imatinib despite inhibition of

Armitage JO, Bishop MR, et al. Allogeneic bone marrow

BCR‐ABL activity. J Clin Invest. 2011;121(1):396–409.

transplantation for low‐grade lymphoma. Blood.

61. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J,

1998;92(5):1832–6.

Arora M, et al. Prognostic factors for outcomes in alloge72. Peniket AJ, Ruiz de Elvira MC, Taghipour G, neic transplantation for CML in the imatinib era: a

Cordonnier C, Gluckman E, de Witte T, et al. An

CIBMTR analysis. Bone Marrow Transplant.

EBMT registry matched study of allogeneic stem cell

2012;47(6):810–6.

transplants for lymphoma: allogeneic transplantation is

62. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, et al.

associated with a lower relapse rate but a higher

Imatinib mesylate versus allogeneic hematopoietic stem

procedure‐related mortality rate than autologous transcell transplantation for patients with chronic plantation. Bone Marrow Transplantation. 2003;31(8):

myelogenous leukemia in the accelerated phase. Blood.

667–78.

2011;117(11):3032–40.

73. Khouri IF, Keating M, Korbling M, Przepiorka D,

63. Nakasone H, Kanda Y, Takasaki H, Nakaseko C, Sakura

Anderlini P, O’Brien S, et al. Transplant‐lite:

T, Fujisawa S, et al. Prophylactic impact of imatinib

induction of graft‐versus‐malignancy using fludaraadministration after allogeneic stem cell transplantation bine‐based nonablative chemotherapy and allogeneic

on the incidence and severity of chronic graft versus host

blood progenitor‐cell transplantation as treatment

disease in patients with Philadelphia chromosome‐

for lymphoid malignancies. J Clin Oncol. 1998;16(8):

positive leukemia. Leukemia. 2010;24(6):1236–9.

2817–24.

64. Luo Y, Lai XY, Tan YM, Shi JM, Zhao YM, Han XY, et al. 74. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Reduced‐intensity allogeneic transplantation combined

et al. Nonablative allogeneic stem‐cell transplantation

with imatinib mesylate for chronic myeloid leukemia in

for advanced/recurrent mantle‐cell lymphoma. J Clin

first chronic phase. Leukemia. 2009;23(6):1171–4.

Oncol. 2003;21(23):4407–12.

65. Grigg AP, Seymour JF. Graft versus Burkitt’s lymphoma 75. Lazarus HM, Zhang MJ, Carreras J, Hayes‐Lattin BM, effect after allogeneic marrow transplantation. Leukemia

Ataergin AS, Bitran JD, et al. A comparison of HLA‐

& Lymphoma. 2002;43(4):889–92.

identical sibling allogeneic versus autologous transplantation

214 Immunotherapy in Translational Cancer Research for diffuse large B cell lymphoma: a report from the

treatment of multiple myeloma: a prospective evaluation

CIBMTR. Biol Blood Marrow Transplant.

of patients treated in the phase III study HOVON 24

2010;16(1):35–45.

MM. J Clin Oncol. 2003;21(9):1728–33.

76. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, 84. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Vesole DH, Jagannath S, et al. A phase 1/2 study of carfil­

Lonial S, et al. Trends in allogeneic stem cell transplantazomib in combination with lenalidomide and low‐dose tion for multiple myeloma: a CIBMTR analysis. Blood.

dexamethasone as a frontline treatment for multiple

2011;118(7):1979–88.

myeloma. Blood. 2012;120(9):1801–9.

85. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange 77. Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein

T, et al. Long‐term outcome of patients with multiple

J, Kahanic SP, et al. Bortezomib with lenalidomide and

myeloma after autologous hematopoietic cell transplandexamethasone versus lenalidomide and dexamethatation and nonmyeloablative allografting. Blood.

sone alone in patients with newly diagnosed myeloma

2009;113(14):3383–91.

without intent for immediate autologous stem‐cell 86. Bay JO, Choufi B, Pomel C, Dauplat J, Durando X, transplant (SWOG S0777): a randomised, open‐label,

Tournilhac O, et al. Potential allogeneic graft ‐versus‐tumor phase 3 trial. Lancet. 2016.

effect in a patient with ovarian cancer. Bone Marrow

78. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Transplantation. 2000;25(6):681–2.

Rossi JF, et al. A prospective, randomized trial of autolo87. Ben‐Yosef R, Or R, Nagler A, Slavin S. Graft‐versus-gous bone marrow transplantation and chemotherapy in

tumour and graft‐versus‐leukaemia effect in patient

multiple myeloma. Intergroupe Francais du Myelome. N

with concurrent breast cancer and acute myelocytic leu­

Engl J Med. 1996;335(2):91–7.

kaemia. Lancet. 1996;348(9036):1242–3.

79. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, 88. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini Hassoun H, Richardson PG, et al. Lenalidomide after

P, Giralt SA, et al. Allogeneic peripheral‐blood progenstem‐cell transplantation for multiple myeloma. N Engl itor‐cell transplantation for poor‐risk patients with met­

J Med. 2012;366(19):1770–81.

astatic breast cancer. J Clin Oncol. 1998;16(3):986–93.

80. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers 89. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, MH, Fibbe W, Russell I, et al. Donor lymphocyte infu­

Zhang MJ, et al. Allogeneic hematopoietic cell transsions for relapsed multiple myeloma after allogeneic plantation for metastatic breast cancer. Bone Marrow

stem‐cell transplantation: predictive factors for response

Transplant. 2008;41(6):537–45.

and long‐term outcome. J Clin Oncol. 2000;18(16): 90. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump 3031–7.

D, Leitman S, et al. Regression of metastatic renal‐cell

81. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R,

carcinoma after nonmyeloablative allogeneic peripheral‐

Barnett T, et al. Allogeneic marrow transplantation for

blood stem‐cell transplantation. N Engl J Med.

multiple myeloma: an analysis of risk factors on out2000;343(11):750–8.

come. Blood. 1996;88(7):2787–93.

91. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori

82. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L,

J, Massenkeil G, et al. Allogeneic haematopoietic stem

Cavo M, et al. Allogeneic bone marrow transplantation

cell transplantation for metastatic renal carcinoma in

in multiple myeloma. European Group for Bone Marrow

Europe. Annals of Oncology. 2006;17(7):1134–40.

Transplantation. N Engl J Med. 1991;325(18):1267–73.

92. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C,

83. Lokhorst HM, Segeren CM, Verdonck LF, van der Holt

Bail y C, et al. Allogeneic hematopoietic stem cell trans­

B, Raymakers R, van Oers MH, et al. Partial y T‐cell‐

plantation in ovarian carcinoma: results of five patients.

depleted allogeneic stem‐cell transplantation for first‐line

Bone Marrow Transplant. 2002;30(2):95–102.





CHAPTER 16

16 Natural Killer Cell–Based

Immunotherapy

Jennifer A. Foltz1, Jeffrey S. Mil er 2, and Dean A. Lee1

1 Department of Hematology, Oncology, and Bone Marrow Transplantation, Nationwide Children’s Hospital, Columbus, OH, USA

2 Department of Medicine, University of Minnesota, Minneapolis, MN, USA NK cell background and biology

NK cel s are highly important in the surveil ance

and destruction of virus‐ and parasite‐infected

Natural killer (NK) cel s were original y described cel s and tumor cel s [7] because they overexpress in the 1970s as null lymphocytes with natural cyto­ activating ligands and downregulate MHC.

toxicity against mouse tumor cell lines distinct

Phenotypical y, NK cel s in humans are defined

from T cell killing, which is antigen specific and by their lack of CD3 (e.g., lacking a T cell receptor) class I major histocompatibility complex (class I and expression of CD56, CD16, or NKp46. NKp46

MHC) dependent [1–5]. Decades later, we now is part of a distinct family of activating receptors understand that NK cel s differ from T cel s by expressed by NK cel s—the natural cytotoxicity their expression of a repertoire of germline‐ receptors (NCRs)—which are implicated in NK-encoded activating and inhibitory receptors that cell‐mediated killing of tumors and also include bind to conserved cell‐surface protein ligands NKp30 and NKp44. Higher expression levels of the (Table 16.1), in contrast with the recombined NCRs are correlated with increased tumor killing receptors of T cel s that bind to peptide antigens. [8, 9] and are often reduced in cancer patients The activating receptors identify elements of stress compared to healthy individuals [10–13], thus preor danger and are balanced by inhibitory receptors dicting survival from some cancers [14]. NKp46 is that recognize self. Through the balance of these unique among the NK cell receptors because it is activating and inhibitory receptors, NK cells nearly exclusively expressed on NK cel s [15–17].

determine which cel s to kil , such that the engage­ Contrariwise, NKp44 expression is limited to interment of more activating than inhibitory receptors leukin‐2 (IL‐2)‐activated NK cel s and NKp30 is results in signal activation and subsequent effector expressed only on a subset of NK cel s. Despite the responses—cytotoxicity and cytokine release. importance of the NCRs in NK cell killing of Unlike T cel s in which recognition of peptide and tumors, the majority of their ligands on tumors class I MHC leads to activation, NK cel s are gener­ remain unknown [6, 9].

al y inhibited by recognition of class I MHC. Thus,

The primary activating receptors on NK cel s

activation is more likely to occur against cel s that that mediate recognition of cancer cel s include lack MHC expression, termed “missing self” [5, 6]. NKG2D, DNAM‐1, 2B4, NKp80, and CD16 [6].

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

215

216 Immunotherapy in Translational Cancer Research Table 16.1 Major NK cell receptors for which corresponding rituximab therapeutic efficacy [28–30], and loss of

ligands are known.

ADCC through decreased CD16 affinity for IgG is

Receptor

Ligand

a recognized mechanism of loss of clinical benefit

[31]. GD2 is a disialoganglioside that is expressed

Activating Receptors

on many solid tumor types. In vitro and in vivo

FcγRIII (CD16)

IgG1/IgG3 antibody

mouse studies with both primary NK cel s and

NKp30 (CD337)

BAG6, B7‐H6

activated, expanded NK cel s demonstrate that the

NKp44 (CD336)

PCNA

NKp46 (CD335)

Viral hemagglutinin

addition of anti‐GD2 mAb improves NK cell

NKp80

AICL

cytotoxicity against neuroblastoma and survival of

NKG2D (CD314)

MICA, MICB, ULBP1‐6

mice with neuroblastoma xenografts [23, 32].

NKG2C/E (CD159c, e)

HLA‐E

Efficacy of anti‐GD2 mAb in clinical trials is asso­

DNAM‐1 (CD226)

PVR, Nectin‐1

ciated with NK cell function [33, 34].

2B4 (CD244)

SLAMF2 (CD48)

NK cel s possess several inhibitory receptors,

Inhibitory Receptors

which are used to distinguish between healthy cel s

KIR2DL1 (CD158a)

HLA‐C group 2

and malignant or infected cel s. The inhibitory

KIR2DL2/DL3 (CD158b, b2)

HLA‐C group 1

receptors are largely made up of a family of recep­

KIR3DL1/DL2 (CD158e, k)

HLA‐Bw4 and some HLA‐A

tors called killer immunoglobulin receptors (KIR)

NKG2A (CD159a)

HLA‐E

and NKG2A/CD94 receptor. However, some KIRs

and the related NKG2C receptor are activating.

The ligands for inhibitory KIR are classical class I

These activating receptors can act in synergy when MHC (mostly human leukocyte antigen (HLA)‐B, the ligands for more than one activating receptor C) and are grouped into specific receptor‐ligand are present on the target cel s [18].

interaction groups (KIR2DL1 for HLA‐ C1,

NKG2D is a homodimeric lectin receptor that KIR2DL2/3 for HLA‐C2, and KIR3DL1 for Bw4).

recognizes a variety of stress‐induced ligands pre­ While KIR2DS1 binds HLA‐C2, resolving the sent on cancer cel s. The ligands for NKG2D ligands for other activating KIR ligands continues include MHC class I chain‐related protein A and B to evolve. The ligand for NKG2A and NKG2C is and UL16 binding protein 1–6 [19], which are the non‐classical HLA‐E. Inhibitory receptor expressed on virtual y all tumor types, including engagement results in an inhibitory signal indibrain tumors, carcinomas, sarcomas, neuroecto­ cating that the target cell is healthy self. Many dermal cancers, lymphomas, and leukemias cancers downregulate HLA expression, making

[20–26]. 2B4 recognizes stress ligands of the SLAM them more susceptible to NK‐mediated killing family, and DNAM‐1 recognizes the viral receptors [35]. Through HLA typing, adoptive cel ular PVR and Nectin [6].

immunotherapy, and hematopoietic stem cell

CD16 is the low‐affinity immunoglobulin transplantation (HSCT), can exploit the presence receptor (FcγRIII) responsible for mediating anti­ or absence of specific KIR‐ligand groups—

body‐dependent cel ular cytotoxicity (ADCC) in mimicking missing‐self—to evade inhibition and NK cel s. ADCC augments NK cell killing through improve outcome. Termed KIR mismatch, this the binding of IgG antibodies to CD16 and a tumor requires identification of a donor who has an inhibcell ligand [6, 27]. Two examples of exploiting itory KIR ligand (HLA group) that is not expressed ADCC for increasing NK cell killing are rituximab in the recipient. This results in the donor’s NK cel s (anti‐CD20) and dinutuximab (anti‐GD2) anti­ having less potential for inhibition in the recipient, bodies. NK‐cell‐dependent ADCC is a key and therefore increased killing of the recipient’s mechanism of action for both rituximab and dinu­ cancer cel s [36, 37].

tuximab, and preclinical data support their

The 15 KIR genes and 2 KIR pseudogenes can be

combination with NK cell infusions. Rituximab is a inherited in many possible variations of gene chimeric monoclonal antibody (mAb) against content, and these are broadly grouped into KIR

CD20 expressed on B‐cel s. NK‐cell‐mediated genotypes A and B, where type B individuals pos­

ADCC is a major mechanism of action for sess a greater number of activating KIRs. KIR type





CHAPTER 16 Natural Killer Cell–Based Immunotherapy 217

B is significantly associated with better clinical out­ progression. In osteosarcoma, increased lymphocyte comes that will be discussed in more detail later in recovery following chemotherapy is significantly this chapter [6, 18, 27].

associated with improved 5‐year overall survival

NK cel s have several mechanisms by which they (24). In both breast and prostate cancer, the number can kill tumor cel s. These include granzyme B and of activated NK cel s in peripheral blood correlated perforin, Fas, and tumor necrosis factor–related with improved survival [47, 50]. In patients with apoptosis inducing ligand‐ mediated killing melanoma, NK cel s have lower expression of NK

(TRAIL). In addition, NK cel s have indirect anti­ activating receptors and reduced NK functionality tumor effects by stimulating other cel s of the (cytotoxicity, cytokine secretion, and proliferation) immune system through the release of proinflam­ compared to healthy controls. This dysfunction matory cytokines, most notably interferon gamma may be an immune‐escape mechanism induced by (IFN‐γ) and tumor necrosis factor alpha (TNF‐α) cell‐to‐cell contact, as coculture of NK cel s with

[7]. These methods of killing have varying impor­ melanoma results in decreased activating receptor tance dependent on the tumor cel , with some expression and decreased cytotoxicity [12, 13, 51].

tumors being resistant to one or more methods of These dysfunctional changes are also seen in lung killing [7, 38–42]. Immune‐modulating drugs such cancer and can be reversed in vitro with TIM‐3

as bortezomib and lenalidomide can overcome this blockade [52, 53].

resistance and sensitize cancer cel s to NK cell

killing in preclinical models, and they are currently Manipulating the anti‐tumor being tested in clinical trials.

effect of NK cells

Clinical evidence for NK cell impact Hematopoietic stem cell on cancer outcomes

transplantation

The influence of KIR and HLA genotypes on NK

Low NK cell numbers and deficient NK function cell function can significantly impact survival folare correlated with cancer risk [43, 44] and can be lowing HSCT, particularly in HLA‐mismatched highly predictive of treatment outcome [44–47]. In transplants that aggressively deplete T cel s and patients with acute myeloid leukemia (AML), NK therefore remove the confounding impact of T-cel s have reduced NKp30 and NKp46 expression cell‐mediated graft‐versus‐host disease (GVHD).

compared to healthy individuals, and this reduced In a landmark study, patients with leukemia who expression correlates with decreased cytotoxicity received an HLA haploidentical transplant had a against leukemia cel s. Expression of NKp46 and significantly increased 5‐year event‐free survival NKp30 is significantly increased in patients with (60% vs. 5% without mismatch) if there was a AML upon achieving complete remission (CR) as missing ligand in the recipient for at least one compared to expression at the time of diagnosis, donor KIR (referred to as KIR‐ligand mismatch).

and increased expression correlated with overall Importantly, KIR‐ligand mismatched patients had survival [10, 11, 14]. In addition to phenotypic dif­ no evidence of graft rejection or GVHD, while ferences, NK cel s from leukemia patients are defi­ patients who received KIR‐ligand matched transcient in their cytokine production, and cytokine plants had a 15.5% and 13.7% risk of graft rejection production and cytolytic activity against autolo­ and GVHD, respectively [54]. In addition, higher gous leukemic blasts are positively associated with NK cell counts are positively correlated with relapse‐free survival and CR, respectively. NK cell increased event‐free survival and decreased transcytotoxicity against autologous leukemia cel s plant‐related mortality and relapse following alloabove 12% significantly correlated with a 100% geneic hematopoietic stem cell transplant in disease‐free survival of greater than 8 years. Thus, pediatric patients with leukemia or lymphoma and NK cel s play a significant role in the host antileu­ adult patients with AML [55, 56]. In a large retrokemic response [48, 49].

spective study of more than 1500 HLA‐mismatched

Similarly, in solid tumors, NK cell function and unrelated transplants receiving mostly unmanipuphenotype are implicated in disease prognosis and lated grafts (i.e., no T cell depletion), KIR mismatch





218 Immunotherapy in Translational Cancer Research was associated with increased mortality in myeloid

With fewer patients receiving HSCT in the solid

leukemias [57].

tumor setting, there are correspondingly fewer

In matched allogeneic transplants, missing studies investigating the impact of KIR mismatch.

ligand with respect to donor‐recipient differences Nonetheless, the results have been similar to transin HLA is not present. However, missing ligand plants in patients with leukemia. In autologous may still be considered with respect to presence or transplants for neuroblastoma, patients who were absence of each KIR ligand group. In a retro­ missing at least one HLA ligand for one of their spective study of T‐depleted matched‐sibling inhibitory KIRs had improved survival (9.5 years transplants [58], recipients missing at least one KIR vs. 3.8 years) and decreased disease progression ligand (C1, C2, or Bw4) had increased disease‐free than patients who were not mismatched. Patients survival, overall survival, and relapse‐free survival lacking HLA‐C1 had the greatest survival (81% vs.

in AML, acute lymphoblastic leukemia (ALL), and 65%) [64]. For pediatric solid tumors, including myelodysplastic syndrome. Missing two KIR‐ Ewing’s sarcoma, neuroblastoma, and rhabdomyoligands (C1 and Bw4, or C2 and Bw4) conferred the sarcoma, patients receiving allogeneic HSCT from greatest survival. In a separate study of T‐depleted KIR mismatched donors had a trend to an improved matched‐sibling transplants assessing KIR content response, but sample size was very small and reciprather than KIR ligand, presence of the KIR B hap­ ients were highly diverse [65, 66].

lotype genes KIR2DL5, KIR2DS1, and KIR3DS1 in

the donor correlated with decreased relapse [59].

Adoptive transfer of NK cells

In contrast, when only antithymocyte globulin The combination of in vitro findings of cancer senwas used to deplete T cel s for GVHD prophylaxis sitivity to NK cell lysis, in vivo evidence of reduced in patients who received haploidentical HSCT, KIR NK cell number and function in patients with can­

B haplotype donors had decreased overall and dis­ cer, and high sensitivity of NK cel s to chemoease‐free survival compared to patients who therapy and radiation that further decreases NK

received NK cel s from a KIR A haplotype donor cell numbers in these patients results in NK cell

[60]. Thus, the presence of more activating recep­ adoptive transfer having the potential to restore tors when T cel s are not depleted may be correlated NK cell function and improve cancer treatment. To with a worse outcome because of enhancing GVHD. this end, several methods have been developed for Similarly, when T cel s are not depleted in producing an NK cell product for infusion. A lymmatched‐related‐donor HSCT, the best survival phodepleting preconditioning regimen is typical y occurs with donor KIR A haplotype in recipients of included with the goal of making physiological KIR B haplotype, and the reverse phenotypes are “space” in the recipient, which in turn promotes associated with the worst survival. The decreased NK cell expansion in vivo through increased availsurvival with donor KIR B and recipient KIR A ability of the homeostatic cytokine, IL‐15 [67].

haplotypes was also correlated with increased After the preconditioning regimen and NK cell relapse and acute GVHD but was only present infusion, IL‐2 (aldesleukin) (or more recently, when the donor and recipient were both homozy­ IL‐15) administration can be given to further progous for HLA‐C1 [61]. In unrelated HSCT with T mote NK cell persistence and expansion in vivo.

cel s, donor KIR B was associated with increased

The majority of completed studies have used prioverall survival and relapse‐free survival regardless mary NK cel s derived from peripheral blood of KIR mismatch or HLA matching. Further, the apheresis of a normal donor followed by depletion greatest improvement in survival and decrease in of T cel s (CD3 depletion) to prevent GVHD, and relapse rate was seen in donor‐recipient pairs that in some cases B cel s (CD19 depletion) to prevent were HLA‐C mismatched [62, 63]. It is clear that passenger lymphocyte syndrome or reactivation of the extent of T cell depletion largely influences the Epstein Barr virus [67, 68]. Other studies seeking outcome, such that when T cel s are included the to infuse an NK cell product of increased purity increase in activating KIRs has deleterious effects have utilized CD3 depletion followed by CD56-on outcome, presumably due to GVHD instead of positive selection to isolate NK cel s. However, this graft versus leukemia.

method reported reduced NK cell yield, which may





CHAPTER 16 Natural Killer Cell–Based Immunotherapy 219

be an issue especial y in adult patients. After selec­ (median 2.74 × 106/kg) were administered to 13

tion or depletion, the NK cell product can be elderly adult patients with high‐risk AML. Fifty administered immediately, activated with cyto­ percent were still in remission at 18–34 months kines, or expanded ex vivo for generating greater post–NK infusion [71].

NK cell doses.

It is possible that IL‐2 infusions administered to

promote NK cell persistence and expansion may

Leukemias

inadvertently promote the expansion of regulatory

Clinical studies of NK cell adoptive transfer have T cel s (Tregs) resulting in suppressed NK cell most commonly been done for patients with AML, function and proliferation. Denileukin diftitox based in part upon the results in transplant studies (Ontak, Eisai Medical Research Inc.) is an IL‐2-showing sensitivity of AML to NK cel s [54].

diptheria‐toxin (IL2DT) conjugate that targets cel s

Adoptive transfer of T‐cell‐depleted NK cel s expressing the high‐affinity IL‐2 receptor, inducing (approximately 20 × 106 total cel s/kg; mean 8.5 × cell death upon receptor binding. In a study assess106 NK cel s/kg) from haploidentical, related ing the potential benefit of Treg depletion with NK

donors in patients with poor‐prognosis AML, non‐ cell adoptive therapy, patients with AML who Hogkin lymphoma, or metastatic solid tumors received haploidentical NK cel s along with IL‐2DT

(melanoma and renal cell carcinoma) had variable had significantly increased CR, disease‐free remisresults. In AML, 5 of 19 patients achieved CR and sion, and NK cell proliferation compared to in vivo NK cell expansion. No improvement in patients that received only NK cel s. Further, NK

survival, remission, or NK cell proliferation in vivo cell proliferation was positively correlated with was seen in patients with melanoma or renal cell regulatory T cell depletion, providing indirect evicarcinoma; however, these patients received a dence for Treg inhibition of NK cell function [72].

lower dose conditioning regimen. This may

To further augment NK cell function and in vivo

account for the discrepancies between the results in survival, Romee et al. used cytokines (IL‐12, IL‐15, patients with AML or solid tumors. Patients who and IL‐18) to precondition NK cel s to acquire a achieved CR had significantly more circulating NK memory‐like state prior to infusion into 13 elderly cel s than patients who did not achieve CR [67].

patients with relapsed/refractory AML. Of the 9

Rubnitz et al. investigated the safety of infusing evaluable patients, there were 4 CRs and 1 PR [73].

NK cel s (median: 29 × 106/kg) from HLA‐haploi­

The above treatment regimens all included

dentical donors in low‐ to intermediate‐risk cyclophosphamide/fludarabine lymphodepletion pediatric patients with AML in CR. The NK cel s prior to the NK cell infusion, and systemic IL‐2

persisted in the recipient for a median of 10 days after the infusion (except the IL2DT study). Fewer and expanded in vivo. Although designed as a phase studies have evaluated the infusion of NK cel s as I safety study, all 10 patients remained in CR with a part of HSCT. In relapsed multiple myeloma, hapmedian follow‐up of over two years, suggesting loidentical KIR‐mismatched IL‐2 activated NK

potential benefit [69]. In a follow‐up to that study, cel s (range: 2.7–92 × 106/kg total NK infused) were haploidentical NK cell infusions (median: 18.6 × given 14 days prior to autologous peripheral blood 106/kg) were delivered to 29 pediatric patients with HSCT with high‐dose melphalan. Donor NK cel s ALL or AML who had relapsed or refractory with were infused twice and persisted in 90% of recipirelapsed disease. Ninety percent of donors were ents for at least 7 days. Of 10 patients treated, 2

KIR‐ligand or receptor mismatched with the achieved CR and 3 achieved near‐CR [74].

recipient, and the study included 15 patients who

In the matched allotransplant setting, third‐

had relapsed after HSCT. In contrast with the party IL‐2 activated haploidentical NK cel s were previous trial, all of the patients in this trial had infused into 21 patients with high‐risk AML or detectable disease at the time of NK cell infusion. chronic myeloid leukemia at day −8, in a 5‐day Twenty patients obtained either CR or partial window between the myeloablative busulfan/fludaremission (PR) after NK infusions, and 9 patients rabine conditioning and antithymocyte globulin were alive and leukemia free at final follow‐up [70]. (Figure 16.1). There was a significant correlation In a similar study, KIR‐ligand‐mismatched NK cel s between relapse‐free survival and the number of





220 Immunotherapy in Translational Cancer Research Steady-state Leukapheresis

CD3-depletion,

IL-2 activation

Matched Donor Stem Cells

IL2 0.5 x 106 IU

ATG 1.5 mg/kg

Busulfan 130 mg/m2

(last dose level only)

Fludaribine 40 mg/m2

–13 –12 –11 –10 –9

–8

–7

–6

–5

–4

–3

–2

–1

0

1

Treatment Day.

GvHD prophylaxis:

Tacrolimus and mini-Methotrexate

Figure 16.1 Schema for clinical trial delivering third‐party infusion of matched allogeneic stem cells for myeloid

IL‐2‐activated NK cells after chemotherapy and prior to

leukemias (adapted from [75]).

CD56+ cel s administered. There was also a nonsig­ Expanded NK cells nificant trend towards increased survival with KIR Since collection of primary NK cel s by steady‐state ligand mismatched donors or KIR B haplotype apheresis is not able to achieve large NK cell doses, donors [75]. NK cel s have been delivered to ex vivo expansion of NK cel s has been explored to patients in remission after engraftment following enable higher NK cell numbers per infusion and HSCT in an effort to further consolidate remission repeated infusions. Expanded NK cel s are also and prevent relapse, but so far they have been more activated than primary NK cel s against limited to demonstrating safety and feasibility in tumor targets [82, 83]. In addition, NK cel s in this setting [76–79]. Importantly, none of the patients with cancer are often functional y studies described in this section reported any impaired, and infusion of autologous NK cel s in significant toxicities associated with the NK cel s early trials were safe but showed no clear benefit.

adoptive transfer.

Ex vivo activated and expanded NK cel s may

correct that dysfunction.

Solid tumors

Autologous T‐cell‐depleted NK cel s from

In patients with refractory metastatic breast or patients with metastatic melanoma or renal cell ovarian cancer, haploidentical T‐cell‐depleted carcinoma with progressive disease were expanded activated NK cells (median: 2.15 × 107/kg) were with irradiated peripheral blood mononuclear cel s infused and persisted in 69% of recipients for and OKT3. These expanded NK cel s persisted in seven days [80]. Similar to the results reported in the patient for at least one week; however, no patients with AML, Treg expansion was signifi­ clinical response was observed [84]. Autologous cantly increased following NK and IL‐2 infu­ NK cel s were also delivered after expansion with sions, and may be a contributing factor for the retronectin‐activated T cells and lyophilized lack of NK cell expansion or persistence. These group A streptococcus (Picibanil, Chugai Pharmfindings were also observed in patients with aceuticals), achieving a median 4702‐fold NK cell advanced non‐Hodgkin’s lymphoma, where 4 expansion. Patients with advanced/metastatic out of 6 patients who received T‐cell‐depleted digestive cancer received up to 2 × 109 NK cel s/kg/

haploidentical activated NK cells (median: 21 × infusion for three infusions in a dose‐escalation 106/kg) were in objective remission at the two‐ study. NK cell infusions were well tolerated with month follow‐up [81].

50% of patients achieving stable disease [85].





CHAPTER 16 Natural Killer Cell–Based Immunotherapy 221

Using allogeneic NK cel s derived from two rela­ NK cell lines tives for advanced non‐small‐cell lung cancer, NK NK‐92 is a cell line derived from a patient with NK

cel s were expanded in vitro with IL‐15 and hydro­ lymphoma. NK‐92 expresses the prototypic NK cel cortisone for three weeks. Median NK expansion marker CD56 and is highly cytotoxic against NK

was 23‐fold, which allowed for 2–4 NK cell infu­ cell‐sensitive cell lines such as K562 [89]. NK‐92 as a sions (median 4.2 × 106/kg). At a median follow‐up cel ular therapeutic has the advantage of providing a of 22 months, 27% of patients were still alive. A uniform and reproducible population of NK‐like trend towards an increase in survival with increased cel s for allogeneic infusion into patients, and eliminumber of NK cell infusions was observed [86].

nates the complex processes needed for generating

Allogeneic NK cel s expanded for two weeks NK cell products from peripheral blood or apheresis with irradiated peripheral blood mononuclear products, rendering it amenable to an “off‐the‐shelf”

cel s, OKT3, and IL‐2 were infused into patients universal cell product. NK‐92 is not inhibited by with lymphoma or solid tumors at doses up to 3 × class I MHC due to its lack of expression of all KIRs 107/kg/infusion for 3 infusions. In this study, (except KIR2DL4) [90]. Because the NK‐92 cell line postinfusion IL‐2 was not given, and a decrease in originates from a patient with lymphoma, the cel s TGF‐β and Tregs was observed [87].

are irradiated prior to infusion. In a phase 1 dose‐

Expanded NK cel s have been delivered after escalation clinical trial in patients with advanced HSCT for leukemia/lymphoma or sarcoma. In the renal cell carcinoma or melanoma, irradiated NK‐92

leukemia/lymphoma study, 41 patients received cel s were infused three times. Infusions up to 3 ×

two infusions of cytokine‐expanded NK cel s 109 cel s/m2 were well tolerated with minimal severe starting two weeks after HSCT. Compared to a his­ toxicities observed; however, 11/12 patients died torical cohort receiving only HSCT, NK cell before the four‐year follow‐up [91]. Similarly, irradiinfusions after HSCT significantly reduced leu­ ated NK‐92 infusions up to 1 × 109/m2 were wel kemia progression without increasing GvHD [78]. tolerated in patients with chemotherapy‐resistant In the sarcoma study, donor NK cel s were solid tumors [92]. This off‐the‐shelf therapy is expanded for 9–11 days on feeder cel s prior to promising and warrants further study.

infusion. Cell infusions were given on between day

+8 and +36 (Figure 16.2). Surprisingly, 5 of 9 Agents to augment NK cell efficacy patients developed rapid onset of acute GVHD fol­ Bortezomib is a proteasome inhibitor whose mechlowing the NK cell infusion [88]. The etiology of anism of action involves downregulation of HLA, GVHD, distinct in this study from the lack of thereby decreasing KIR‐mediated inhibition.

GVHD seen in all other studies, remains unclear.

Bortezomib also augments TRAIL‐, FasL‐, and

G-CSF-

–

CD3 Depletion

Activation/

mobilized

CD34 Selection

expansion on

CD56 Selection

Apheresis

feeder cells

+

x 4d2

Add-back

x 4d

x 1d

2

2

1–2 x 104 CD3+

Donor Stem Cells

Fludarabine

40 mg/m Cyclophosphamide

1200 mg/m

Melphalan

100 mg/m

–6

–5

–4

–3

–2

–1

0

1

2

3

4

5

6

7

35

Treatment Day.

(No GvHD prophylaxis)

Figure 16.2 Schema for clinical trial delivering

allogeneic stem cell transplant for solid tumors (adapted

IL‐15‐activated donor NK cells after matched

from [88]).





222 Immunotherapy in Translational Cancer Research perforin/granzyme‐mediated NK killing [93–95]. exploit their innate cancer‐killing capacity.

Bortezomib was found safe when administered Preclinical work that will further improve the along with autologous expanded NK cel s at doses potency and specificity of NK cel s includes stable up to 1 × 108 NK cel s/kg. This study also delivered genetic modification of NK cel s (chimeric antigen pentostatin to deplete Tregs. [96].

receptors for tumor targeting [109]), cytokines for

Lenalidomide increases NK cell proliferation, proliferation and persistence [110], studies using IFN‐γ secretion, inhibits NK cell suppression by NK cel s with properties of immune memory [111, IL‐6 and TGF‐β, and increases production of IL‐2 112], chemokine receptors for homing [113], CD4 T cel s, thereby increasing NK cell activation transient genetic or nongenetic modification

[97–102]. Lenalidomide also synergizes with ritux­ (mRNA electroporation [114, 115], trogocytosis imab in vitro to increase NK cell killing of chronic [116], and bi‐ and trispecific antibodies [117] to lymphocytic leukemia and non‐Hodgkin lym­ redirect NK cel s to specific tumor antigens. NK

phoma by increasing expression of CD20, cell therapy promises to have great potential for rituximab’s target antigen [101, 102]. In multiple improving outcomes in a wide variety of cancers.

myeloma, lenalidomide administration increases

NK cell activity, and NK cell activity was positively References correlated with clinical outcome [103].

1. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural

The anti‐inhibitory pan‐KIR mAb, lirilumab

cytotoxic reactivity of mouse lymphoid cel s against synge­

(IPH2101, Bristol‐Myers Squibb), was developed to

neic and allogeneic tumors. II. Characterization of effector

provide global blockade of inhibitory KIR on NK

cel s. Int J Cancer. 1975;16(2):230–9.

cel s, thereby improving activation. Lirilumab has 2. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic been administered both with and without lenalidoreactivity of mouse lymphoid cel s against syngeneic acid mide in myeloma and is well tolerated [104, 105].

allogeneic tumors. I. Distribution of reactivity and speci­

Unfortunately, recent reports from clinical trials

ficity. Int J Cancer. 1975;16(2):216–29.

report unexpected reduction in NK cell responsive­ 3. Kiessling R, Klein E, Pross H, Wigzell H. “Natural” killer ness after treatment with lirilumab [106].

cel s in the mouse. II. Cytotoxic cel s with specificity for

IL‐15 has been identified as a major cytokine for

mouse Moloney leukemia cel s. Characteristics of the

NK cell maturation, activation, and homeostatic

killer cel . Eur J Immunol. 1975;5(2):117–21.

4. Kiessling R, Klein E, Wigzell H. “Natural” killer cells in expansion. Despite IL‐15’s effectiveness in the mouse. I. Cytotoxic cells with specificity for mouse increasing NK and CD8 T cell numbers in patients,

Moloney leukemia cells. Specificity and distribution

as with IL‐2 infusions, higher dosage levels may be

according to genotype. Eur J Immunol. 1975;5(2):

limited by side effects [107]. Modifications of IL‐15

112–7.

that extend its half‐life and permit proper transpre­ 5. Ljunggren HG, Karre K. In search of the ’missing self’: sentation allow for less frequent dosing, which may

MHC molecules and NK cell recognition. Immunol

improve tolerance while preserving the immune

Today. 1990;11(7):237–44.

properties and benefits of IL‐15 [108].

6. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw

MH. Activating and inhibitory receptors of natural killer

Conclusions

cel s. Immunology and cell biology. 2011;89(2):216–24.

7. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects

NK cel s play an important role in anticancer

of natural‐killer‐cell surveil ance and therapy of cancer.

immunity. NK cell function and number are often

Nat Rev Cancer. 2002;2(11):850–61.

reduced in patients with cancer, and many anti­ 8. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, cancer agents synergize with NK cel s to mediate

Biassoni R, et al. NKp46 is the major triggering receptor

their effect. Results from early‐phase clinical trials

involved in the natural cytotoxicity of fresh or cultured

human NK cel s. Correlation between surface density of

of NK cell adoptive immunotherapy are encour­

NKp46 and natural cytotoxicity against autologous, alloaging. NK infusions in these studies have been well geneic or xenogeneic target cel s. Eur J Immunol.

tolerated, and the development of expansion plat1999;29(5):1656–66.

forms that enable repeated infusions of highly 9. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, pure, activated NK cel s make it possible to further

Mingari MC, et al. Activating receptors and coreceptors

CHAPTER 16 Natural Killer Cell–Based Immunotherapy 223

involved in human natural killer cell‐mediated cytolysis. 21. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini Annu Rev Immunol. 2001;19:197–223.

A. Human osteosarcoma cell susceptibility to natural

10. Costello RT, Sivori S, Marcenaro E, Lafage‐Pochitaloff

killer cell lysis depends on CD54 and increases after

M, Mozziconacci MJ, Reviron D, et al. Defective expres­

TNF alpha incubation. FEBS letters.

sion and function of natural killer cell‐triggering recep1997;406(1–2):83–8.

tors in patients with acute myeloid leukemia. Blood. 22. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, 2002;99(10):3661–7.

Campana D. Cytotoxicity of activated natural killer cel s

11. Fauriat C, Just‐Landi S, Mallet F, Arnoulet C, Sainty D, against pediatric solid tumors. Clin Cancer Res.

Olive D, et al. Deficient expression of NCR in NK cel s

2010;16(15):3901–9.

from acute myeloid leukemia: Evolution during leu23. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, kemia treatment and impact of leukemia cel s in

Cooper LJ, et al. Growth and activation of natural killer

NCRdull phenotype induction. Blood. cel s ex vivo from children with neuroblastoma for 2007;109(1):323–30.

adoptive cell therapy. Clin Cancer Res.

12. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X,

2013;19(8):2132–43.

Gervois N, et al. Unique functional status of natural 24. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, killer cel s in metastatic stage IV melanoma patients and

Spies T. Broad tumor‐associated expression and recogniits modulation by chemotherapy. Clin Cancer Res.

tion by tumor‐derived gamma delta T cel s of MICA and

2011;17(9):2628–37.

MICB. Proc Natl Acad Sci U S A. 1999;96(12):6879–84.

13. Fregni G, Messaoudene M, Fourmentraux‐Neves E, 25. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Mazouz‐Dorval S, Chanal J, Maubec E, et al. Phenotypic

Marcenaro S, et al. Role of NKG2D in tumor cell lysis

and functional characteristics of blood natural killer

mediated by human NK cel s: cooperation with natural

cel s from melanoma patients at different clinical stages.

cytotoxicity receptors and capability of recognizing

PLoS One. 2013;8(10):e76928.

tumors of nonepithelial origin. Eur J Immunol.

14. Martner A, Rydstrom A, Riise RE, Aurelius J, Brune M,

2001;31(4):1076–86.

Foa R, et al. NK cell expression of natural cytotoxicity 26. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, receptors may determine relapse risk in older AML

Conte R, et al. Major histocompatibility complex class I‐

patients undergoing immunotherapy for remission

related chain A and UL16‐binding protein expression on

maintenance. Oncotarget. 2015;6(40):42569–74.

tumor cell lines of different histotypes: analysis of tumor

15. Narni‐Mancinelli E, Chaix J, Fenis A, Kerdiles YM,

susceptibility to NKG2D‐dependent natural killer cel

Yessaad N, Reynders A, et al. Fate mapping analysis of

cytotoxicity. Cancer Res. 2002;62(21): 6178–86.

lymphoid cel s expressing the NKp46 cell surface 27. Watzl C, Long EO. Signal transduction during activation receptor. Proc Natl Acad Sci U S A. 2011;108(45):

and inhibition of natural killer cel s. In Current Protocols

18324–9.

in Immunology, edited by John E Coligan et al. Hoboken,

16. Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins NJ: Wiley. 2010;chap 11:unit 11 9B.

SH, et al. Identification, activation, and selective in vivo 28. Golay J, Manganini M, Facchinetti V, Gramigna R, ablation of mouse NK cel s via NKp46. Proc Natl Acad

Broady R, Borleri G, et al. Rituximab‐mediated anti­

Sci U S A. 2007;104(9):3384–9.

body‐dependent cel ular cytotoxicity against neoplastic

17. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L,

B cel s is stimulated strongly by interleukin‐2.

Moretta L, et al. Molecular cloning of NKp46: a novel

Haematologica. 2003;88(9):1002–12.

member of the immunoglobulin superfamily involved in 29. Cartron G, Dacheux L, Salles G, Solal‐Celigny P, Bardos triggering of natural cytotoxicity. J Exp Med.

P, Colombat P, et al. Therapeutic activity of humanized

1998;188(5):953–60.

anti‐CD20 monoclonal antibody and polymorphism in

18. Watzl C, Urlaub D. Molecular mechanisms of natural

IgG Fc receptor FcgammaRIIIa gene. Blood.

killer cell regulation. Frontiers in bioscience.

2002;99(3):754–8.

2012;17:1418–32.

30. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory

19. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Fc receptors modulate in vivo cytotoxicity against tumor

et al. Activation of NK cel s and T cel s by NKG2D, a

targets. Nat Med. 2000;6(4):443–6.

receptor for stress‐inducible MICA. Science. 31. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher 1999;285(5428):727–9.

RI, Leblanc M, et al. Fc gamma receptor 3a genotype

20. Fernandez L, Portugal R, Valentin J, Martin R, Maxwell

predicts overall survival in follicular lymphoma patients

H, Gonzalez‐Vicent M, et al. In vitro natural killer cell

treated on SWOG trials with combined monoclonal

immunotherapy for medulloblastoma. Frontiers in

antibody plus chemotherapy but not chemotherapy

Oncology. 2013;3:94.

alone. Haematologica. 2012;97(6):937–42.

224 Immunotherapy in Translational Cancer Research 32. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon 44. Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, J, et al. Anti‐neuroblastoma effect of ch14.18 antibody

Ilyas M, El‐Sheemy MA, et al. Natural killer (NK) cell

produced in CHO cel s is mediated by NK‐cel s in mice.

profiles in blood and tumour in women with large and

Mol Immunol. 2005;42(11):1311–9.

local y advanced breast cancer (LLABC) and their con33. Tarek N, Le Luduec JB, Gal agher MM, Zheng J, tribution to a pathological complete response (PCR) in

Venstrom JM, Chamberlain E, et al. Unlicensed NK cel s

the tumour following neoadjuvant chemotherapy

target neuroblastoma following anti‐GD2 antibody

(NAC): differential restoration of blood profiles by NAC

treatment. J Clin Invest. 2012;122(9):3260–70.

and surgery. J Transl Med. 2015;13:180.

34. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, 45. Kim JK, Chung JS, Shin HJ, Song MK, Yi JW, Shin DH, Seo S, et al. Genotypes of NK cell KIR receptors, their

et al. Influence of NK cell count on the survival of

ligands, and Fcgamma receptors in the response of neupatients with diffuse large B‐cell lymphoma treated with roblastoma patients to Hu14.18‐IL2 immunotherapy.

R‐CHOP. Blood Research. 2014;49(3):162–9.

Cancer Res. 2010;70(23):9554–61.

46. Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M,

35. Bubenik J. MHC class I down‐regulation: tumour escape

Reynolds PN, et al. Lung cancer is associated with

from immune surveil ance? (review). International

decreased expression of perforin, granzyme B and inter­

Journal of Oncology. 2004;25(2):487–91.

feron (IFN)‐gamma by infiltrating lung tissue T cel s,

36. Moretta A, Pende D, Locatelli F, Moretta L. Activating

natural killer (NK) T‐like and NK cel s. Clin Exp

and inhibitory killer immunoglobulin‐like receptors

Immunol. 2014;178(1):79–85.

(KIR) in haploidentical haemopoietic stem cell trans47. Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-plantation to cure high‐risk leukaemias. Clin Exp

Piana J, Rocchi P, et al. Highly effective NK cel s are asso­

Immunol. 2009;157(3):325–31.

ciated with good prognosis in patients with metastatic

37. Benson DM, Jr., Caligiuri MA. Killer immunoglobulin‐

prostate cancer. Oncotarget. 2015;6(16):14360–73.

like receptors and tumor immunity. Cancer immu48. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural nology research. 2014;2(2):99–104.

killer cell activity and cytokine production as prognostic

38. Browne KA, Blink E, Sutton VR, Froelich CJ, Jans DA,

factors in adult acute leukemia. Leukemia.

Trapani JA. Cytosolic delivery of granzyme B by bacte1996;10(3):478–82.

rial toxins: evidence that endosomal disruption, in 49. Lowdell MW, Craston R, Samuel D, Wood ME, O’Neill E, addition to transmembrane pore formation, is an impor­

Saha V, et al. Evidence that continued remission in patients

tant function of perforin. Molecular and Cel ular

treated for acute leukaemia is dependent upon autologous

Biology. 1999;19(12):8604–15.

natural killer cel s. Br J Haematol. 2002;117(4):821–7.

39. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, 50. Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Perussia B. Natural killer (NK) cell‐mediated cytotoxic­

Scalone S, et al. Improved natural killer cell activity and

ity: differential use of TRAIL and Fas ligand by immaretained anti‐tumor CD8(+) T cell responses contribute ture and mature primary human NK cel s. J Exp Med.

to the induction of a pathological complete response in

1998;188(12):2375–80.

HER2‐positive breast cancer patients undergoing neo40. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, adjuvant chemotherapy. J Transl Med. 2015;13:204.

Akiba H, Tsutsui H, et al. Expression and function of 51. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto TNF‐related apoptosis‐inducing ligand on murine

A, et al. Melanoma cel s inhibit natural killer cell function by activated NK cel s. J Immunol. 1999;163(4):1906–13.

modulating the expression of activating receptors and cyto41. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger lytic activity. Cancer Res. 2012;72(6):1407–15.

LM, Kayagaki N, et al. Tumor necrosis factor‐related 52. da Silva IP, Gallois A, Jimenez‐Baranda S, Khan S, apoptosis‐inducing ligand (TRAIL) contributes to inter­

Anderson AC, Kuchroo VK, et al. Reversal of NK‐cell

feron gamma‐dependent natural killer cell protection

exhaustion in advanced melanoma by Tim‐3 blockade.

from tumor metastasis. J Exp Med. 2001;193(6):661–70.

Cancer Immunology Research. 2014;2(5):410–22.

42. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi 53. Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, et al. Increased N, Yagita H, et al. Involvement of tumor necrosis factor-Tim‐3 expression in peripheral NK cel s predicts a poorer

related apoptosis‐inducing ligand in NK cell‐mediated and

prognosis and Tim‐3 blockade improves NK cell‐medi­

IFN‐gamma‐dependent suppression of subcutaneous

ated cytotoxicity in human lung adenocarcinoma.

tumor growth. Cell Immunol. 2001;214(2):194–200.

International Immunopharmacology. 2015;29(2):635–41.

43. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. 54. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik Natural cytotoxic activity of peripheral‐blood lympho­

WD, Tosti A, et al. Effectiveness of donor natural killer

cytes and cancer incidence: an 11‐year follow‐up study of a

cell alloreactivity in mismatched hematopoietic transgeneral population. Lancet. 2000;356(9244):1795–9.

plants. Science. 2002;295(5562):2097–100.

CHAPTER 16 Natural Killer Cell–Based Immunotherapy 225

55. Huttunen P, Taskinen M, Siitonen S, Saarinen‐Pihkala

enhance the clinical benefit of unrelated transplantation

UM. Impact of very early CD4(+)/CD8(+) T cell counts

for acute myelogenous leukemia. J Immunol.

on the occurrence of acute graft‐versus‐host disease and

2014;192(10):4592–600.

NK cell counts on outcome after pediatric allogeneic 64. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, hematopoietic stem cell transplantation. Pediatr Blood

Cheung IY, et al. KIR and HLA genotypes are associated

Cancer. 2015;62(3):522–8.

with disease progression and survival following autolo56. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, gous hematopoietic stem cell transplantation for high-Yong AS, et al. Rapid natural killer cell recovery deterrisk neuroblastoma. Clin Cancer Res. 2009;15(23): mines outcome after T‐cell‐depleted HLA‐identical

7330–4.

stem cell transplantation in patients with myeloid leuke65. Perez‐Martinez A, de Prada Vicente I, Fernandez L, mias but not with acute lymphoblastic leukemia.

Gonzalez‐Vicent M, Valentin J, Martin R, et al. Natural

Leukemia. 2007;21(10):2145–52.

killer cel s can exert a graft‐vs‐tumor effect in haploi57. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, dentical stem cell transplantation for pediatric solid

Caligiuri MA, et al. The effect of KIR ligand incompatitumors. Exp Hematol. 2012;40(11):882–91 e1.

bility on the outcome of unrelated donor transplanta66. Perez‐Martinez A, Leung W, Munoz E, Iyengar R, tion: a report from the Center for International Blood

Ramirez M, Vicario JL, et al. KIR‐HLA receptor‐ligand

and Marrow Transplant Research, the European Blood

mismatch associated with a graft‐versus‐tumor effect in

and Marrow Transplant Registry, and the Dutch

haploidentical stem cell transplantation for pediatric

Registry. Biol Blood Marrow Transplant.

metastatic solid tumors. Pediatr Blood Cancer.

2006;12(8):876–84.

2009;53(1):120–4.

58. Hsu KC, Keever‐Taylor CA, Wilton A, Pinto C, Heller G, 67. Miller JS, Soignier Y, Panoskaltsis‐Mortari A, Arkun K, et al. Improved outcome in HLA‐identical

McNearney SA, Yun GH, Fautsch SK, et al. Successful

sibling hematopoietic stem‐cell transplantation for acute

adoptive transfer and in vivo expansion of human hapmyelogenous leukemia predicted by KIR and HLA loidentical NK cel s in patients with cancer. Blood.

genotypes. Blood. 2005;105(12):4878–84.

2005;105(8):3051–7.

59. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, 68. Skeate R, Singh C, Cooley S, Geller M, Northouse J, Savani BN, et al. Donor KIR Genes 2DL5A, 2DS1 and

Welbig J, et al. Hemolytic anemia due to passenger lym3DS1 are associated with a reduced rate of leukemia phocyte syndrome in solid malignancy patients treated

relapse after HLA‐identical sibling stem cell transplantawith allogeneic natural killer cell products. Transfusion.

tion for acute myeloid leukemia but not other hemato2013;53(2):419–23.

logic malignancies. Biol Blood Marrow Transplant. 69. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, 2010;16(9):1257–64.

Bell T, et al. NKAML: a pilot study to determine the

60. Kroger N, Binder T, Zabelina T, Wolschke C, Schieder

safety and feasibility of haploidentical natural killer cell

H, Renges H, et al. Low number of donor activating

transplantation in childhood acute myeloid leukemia. J

killer immunoglobulin‐like receptors (KIR) genes but

Clin Oncol. 2010;28(6):955–9.

not KIR‐ligand mismatch prevents relapse and improves 70. Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett disease‐free survival in leukemia patients after in vivo

BM, et al. Natural killer cell therapy in children with relapsed T‐cell depleted unrelated stem cell transplantation.

leukemia. Pediatr Blood Cancer. 2015;62(8):1468–72.

Transplantation. 2006;82(8):1024–30.

71. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E,

61. McQueen KL, Dorighi KM, Guethlein LA, Wong R,

Motta MR, et al. Successful transfer of alloreactive hap­

Sanjanwala B, Parham P. Donor‐recipient combinations

loidentical KIR ligand‐mismatched natural killer cel s

of group A and B KIR haplotypes and HLA class I ligand

after infusion in elderly high risk acute myeloid leuaffect the outcome of HLA‐matched, sibling donor kemia patients. Blood. 2011;118(12):3273–9.

hematopoietic cell transplantation. Hum Immunol. 72. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang 2007;68(5):309–23.

B, McKenna DH, et al. Clearance of acute myeloid leu62. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, kemia by haploidentical natural killer cel s is improved

Klein J, Le CT, et al. Donors with group B KIR haplousing IL‐2 diphtheria toxin fusion protein. Blood.

types improve relapse‐free survival after unrelated

2014;123(25):3855–63.

hematopoietic cell transplantation for acute myelogenous

73. Romee R, Rosario M, Berrien‐Elliott MM, Wagner JA,

leukemia. Blood. 2009;113(3):726–32.

Jewell BA, Schappe T, et al. Cytokine‐induced memory‐

63. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T,

like natural killer cel s exhibit enhanced responses

Marsh SG, et al. Donor killer cell Ig‐like receptor B hapagainst myeloid leukemia. Science Translational lotypes, recipient HLA‐C1, and HLA‐C mismatch

Medicine. 2016;8(357):357ra123.

226 Immunotherapy in Translational Cancer Research 74. Shi J, Tricot G, Szmania S, Rosen N, Garg TK,

to high levels of circulating natural killer cel s but does

Malaviarachchi PA, et al. Infusion of haplo‐identical

not mediate tumor regression. Clin Cancer Res.

killer immunoglobulin‐like receptor ligand mismatched

2011;17(19):6287–97.

NK cel s for relapsed myeloma in the setting of autolo85. Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, gous stem cell transplantation. Br J Haematol.

Ideno M, et al. Phase I clinical trial of autologous NK cell

2008;143(5):641–53.

therapy using novel expansion method in patients with

75. Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J,

advanced digestive cancer. J Transl Med. 2015;13:277.

Fisher T, et al. Haploidentical natural killer cel s infused 86. Iliopoulou EG, Kountourakis P, Karamouzis MV, before allogeneic stem cell transplantation for myeloid

Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I

malignancies: a phase I trial. Biol Blood Marrow

trial of adoptive transfer of allogeneic natural killer cel s Transplant. 2016;22(7):1290–8.

in patients with advanced non‐small cell lung cancer.

76. Klingemann H, Grodman C, Cutler E, Duque M,

Cancer Immunol Immunother. 2010;59(12):1781–9.

Kadidlo D, Klein AK, et al. Autologous stem cell trans87. Yang Y, Lim O, Kim TM, Ahn YO, Choi HN, Chung H, plant recipients tolerate haploidentical related‐donor

et al. Phase I study of random, healthy donor‐derived

natural killer cell‐enriched infusions. Transfusion.

allogeneic natural killer cell therapy in patients with

2013;53(2):412–8; quiz 1.

malignant lymphoma or advanced solid tumors. Cancer

77. Rizzieri DA, Storms R, Chen DF, Long G, Yang Y,

Immunology Research. 2016.

Nikcevich DA, et al. Natural killer cell‐enriched donor 88. Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler lymphocyte infusions from a 3‐6/6 HLA matched family

ME, Rampertaap S, et al. Acute GVHD in patients

member following nonmyeloablative allogeneic stem

receiving IL‐15/4‐1BBL activated NK cel s following T‐

cell transplantation. Biol Blood Marrow Transplant.

cell‐depleted stem cell transplantation. Blood.

2010;16(8):1107–14.

2015;125(5):784–92.

78. Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, et al. 89. Gong JH, Maki G, Klingemann HG. Characterization of Donor‐derived natural killer cel s infused after human

a human cell line (NK‐92) with phenotypical and

leukocyte antigen‐haploidentical hematopoietic cell

functional characteristics of activated natural killer cel s.

transplantation: a dose‐escalation study. Biol Blood

Leukemia. 1994;8(4):652–8.

Marrow Transplant. 2014;20(5):696–704.

90. Tonn T, Becker S, Esser R, Schwabe D, Seifried E.

79. Stern M, Passweg JR, Meyer‐Monard S, Esser R, Tonn T,

Cel ular immunotherapy of malignancies using the

Soerensen J, et al. Pre‐emptive immunotherapy with

clonal natural killer cell line NK‐92. J Hematother Stem

purified natural killer cel s after haploidentical SCT: a

Cell Res. 2001;10(4):535–44.

prospective phase II study in two centers. Bone Marrow 91. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Transplant. 2013;48(3):433–8.

Martinson J, et al. Infusion of the allogeneic cell line

80. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF,

NK‐92 in patients with advanced renal cell cancer or

Argenta PA, et al. A phase II study of allogeneic natural

melanoma: a phase I trial. Cytotherapy. 2008;10(6):

killer cell therapy to treat patients with recurrent ovarian

625–32.

and breast cancer. Cytotherapy. 2011;13(1):98–107.

92. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R,

81. Bachanova V, Burns LJ, McKenna DH, Curtsinger J,

Koehl U, et al. Treatment of patients with advanced can­

Panoskaltsis‐Mortari A, Lindgren BR, et al. Allogeneic

cer with the natural killer cell line NK‐92. Cytotherapy.

natural killer cel s for refractory lymphoma. Cancer

2013;15(12):1563–70.

Immunol Immunother. 2010;59(11):1739–44.

93. Lundqvist A, Abrams SI, Schrump DS, Alvarez G,

82. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi

Suffredini D, Berg M, et al. Bortezomib and depsipep­

K, Mann DL. Ex‐vivo expanded human NK cel s express

tide sensitize tumors to tumor necrosis factor‐related

activating receptors that mediate cytotoxicity of allogeapoptosis‐inducing ligand: a novel method to potentiate neic and autologous cancer cell lines by direct recogninatural killer cell tumor cytotoxicity. Cancer Res.

tion and antibody directed cel ular cytotoxicity. Journal

2006;66(14):7317–25.

of Experimental & Clinical Cancer Research. 94. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R.

2010;29:134.

Bortezomib treatment and regulatory T‐cell depletion

83. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar

enhance the antitumor effects of adoptively infused NK

PV, Kopp LM, Johnson JL, et al. Membrane‐bound IL‐21

cel s. Blood. 2009;113(24):6120–7.

promotes sustained ex vivo proliferation of human 95. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, natural killer cel s. PLoS One. 2012;7(1):e30264.

Tamang DL, et al. Sensitization of tumor cel s to NK cell‐

84. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA.

mediated killing by proteasome inhibition. J Immunol.

Adoptive transfer of autologous natural killer cel s leads

2008;180(1):163–70.

CHAPTER 16 Natural Killer Cell–Based Immunotherapy 227

96. Lundqvist A, Berg M, Smith A, Childs RW. Bortezomib 107. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo treatment to potentiate the anti‐tumor immunity of ex-AT, Morris JC, et al. Redistribution, hyperproliferation,

vivo expanded adoptively infused autologous natural

activation of natural killer cel s and CD8 T cel s, and

killer cel s. Journal of Cancer. 2011;2:383–5.

cytokine production during first‐in‐human clinical

97. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM.

trial of recombinant human interleukin‐15 in patients

Lenalidomide augments actin remodeling and lowers

with cancer. J Clin Oncol. 2015;33(1):74–82.

NK‐cell activation thresholds. Blood. 2015;126(1):50–60.

108. Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC,

98. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ,

et al. IL‐15 superagonist/IL‐15RalphaSushi‐Fc fusion

Trapani JA, et al. The immunostimulatory effect of

complex (IL‐15SA/IL‐15RalphaSu‐Fc; ALT‐803) marklenalidomide on NK‐cell function is profoundly inhibedly enhances specific subpopulations of NK and ited by concurrent dexamethasone therapy. Blood.

memory CD8+ T cel s, and mediates potent anti‐tumor

2011;117(5):1605–13.

activity against murine breast and colon carcinomas.

99. Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, et al.

Oncotarget. 2016;7(13):16130–45.

Lenalidomide overcomes suppression of human natural 109. Imai C, Iwamoto S, Campana D. Genetic modification killer cell anti‐tumor functions by neuroblastoma

of primary natural killer cel s overcomes inhibitory sigmicroenvironment‐associated IL‐6 and TGFbeta1.

nals and induces specific killing of leukemic cel s.

Cancer Immunol Immunother. 2013;62(10):1637–48.

Blood. 2005;106(1):376–83.

100. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, 110. Kellner JN, Cruz CR, Bol ard CM, Yvon ES. Gene mod­

McConkey M, et al. Lenalidomide causes selective degification of human natural killer cel s using a retroviral radation of IKZF1 and IKZF3 in multiple myeloma

vector. Methods Mol Biol. 2016;1441:203–13.

cel s. Science. 2014;343(6168):301–5.

111. Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M,

101. Acebes‐Huerta A, Huergo‐Zapico L, Gonzalez‐Rodriguez

et al. Epigenetic modification and antibody‐dependent

AP, Fernandez‐Guizan A, Payer AR, Lopez‐Soto A, et al.

expansion of memory‐like NK cel s in human cyto­

Lenalidomide induces immunomodulation in chronic

megalovirus‐infected individuals. Immunity.

lymphocytic leukemia and enhances antitumor

2015;42(3):431–42.

immune responses mediated by NK and CD4 T cel s. 112. Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, BioMed Research International. 2014; 2014:265840.

Holmes TD, et al. Cytomegalovirus infection drives

102. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling

adaptive epigenetic diversification of NK cel s with

D, et al. lenalidomide enhances natural killer cell and

altered signaling and effector function. Immunity.

monocyte‐mediated antibody‐dependent cel ular cyto2015;42(3):443–56.

toxicity of rituximab‐treated CD20+ tumor cel s. Clin 113. Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg Cancer Res. 2008;14(14):4650–7.

M, et al. Efficient mRNA‐based genetic engineering of

103. Wolschke C, Stubig T, Hegenbart U, Schonland S,

human NK cel s with high‐affinity CD16 and CCR7

Heinzelmann M, Hildebrandt Y, et al. Postallograft

augments rituximab‐induced ADCC against lymlenalidomide induces strong NK cell‐mediated antimyphoma and targets NK cell migration toward the lymph eloma activity and risk for T cell‐mediated GvHD:

node‐associated chemokine CCL19. Frontiers in

Results from a phase I/II dose‐finding study. Exp

Immunology. 2016;7:105.

Hematol. 2013;41(2):134–42 e3.

114. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T,

104. Benson DM, Jr., Cohen AD, Jagannath S, Munshi NC,

Eldridge P, et al. A clinical y adaptable method to

Spitzer G, Hofmeister CC, et al. A phase I trial of the

enhance the cytotoxicity of natural killer cel s against

anti‐KIR antibody IPH2101 and lenalidomide in

B‐cell malignancies. Cytotherapy. 2012;14(7):830–40.

patients with relapsed/refractory multiple myeloma. 115. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni Clin Cancer Res. 2015;21(18):4055–61.

J, et al. Expression of chimeric antigen receptors in

105. Benson DM, Jr., Hofmeister CC, Padmanabhan S,

natural killer cel s with a regulatory‐compliant non‐

Suvannasankha A, Jagannath S, Abonour R, et al. A

viral method. Cancer Gene Ther. 2010;17(3):147–54.

phase 1 trial of the anti‐KIR antibody IPH2101 in 116. Somanchi SS, Somanchi A, Cooper LJ, Lee DA.

patients with relapsed/refractory multiple myeloma.

Engineering lymph node homing of ex vivo‐expanded

Blood. 2012;120(22):4324–33.

human natural killer cel s via trogocytosis of the

106. Carlsten M, Korde N, Kotecha R, Reger R, Bor S,

chemokine receptor CCR7. Blood. 2012;119(22):5164–72.

Kazandjian D, et al. Checkpoint inhibition of KIR2D 117. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, with the monoclonal antibody IPH2101 induces con­

Reusch U, et al. Rescue of impaired NK cell activity in

traction and hyporesponsiveness of NK cel s in patients

hodgkin lymphoma with bispecific antibodies in vitro

with myeloma. Clin Cancer Res. 2016;22(21):5211–22.

and in patients. Mol Ther. 2013;21(4):895–903.





CHAPTER 17

17 Immunologic Monitoring

in Immuno‐Oncology

Wil iam R. Gwin and Mary L. Disis

Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, USA

Introduction

of PD‐L1 predicts which patients are likely to

respond to anti‐PD‐L1 or anti‐PD‐1 therapy.

Biomarkers in immuno‐oncology

Pharmacodynamic biomarkers are molecular indi-

The evaluation and development of immune‐ cators of the effect of therapy on disease related tar-oncology biomarkers and the application of bio- gets. An example is increased T cell receptor markers for immune monitoring are rapidly clonality after anti‐PD‐1 or PD‐L1 therapy.

evolving fields driven by the clinical success of Pharmacokinetic biomarkers are biomarkers of a recently approved immune checkpoint inhibitor therapy’s distribution, metabolism, and excretion.

therapies. Identifying biomarkers that can predict In chimeric antigen receptor (CAR) T cell therapy, the response to immune therapies will enable the the persistence of CAR T cel s can be measured by selection of patients who are likely to benefit from flow cytometry. A correlative or surrogate end-immunotherapy treatment, while identification of point is a marker that may correlate with a real immune pharmacodynamic and pharmacokinetic clinical endpoint. Defining a surrogate endpoint is biomarkers will provide immune monitoring capa- an area of active investigation, and none have been bilities for clinical trials. Immune biomarkers can validated to date.

be divided into several categories: prognostic, pre-

dictive, pharmacodynamic, pharmacokinetic, and

correlative or surrogate endpoints (Table 17.1). The evolution of immune monitoring Prognostic biomarkers provide information about from an antigen specific to a tumor the likely course of the disease (cancer) in an microenvironment focus untreated individual. An example is the evaluation The role of immune monitoring in immuno-of tumor‐infiltrating T cell subtypes, as determined oncology has evolved over time. Early in the by the immunoscore. Predictive biomarkers can be development of the field, the focus of immune used to identify subpopulations of patients most monitoring was on detecting tumor antigen-likely to respond to a given therapy. An example of specific immune responses through interferon-a predictive biomarker is tumor expression of gamma (IFN‐γ) ELISPOT and flow‐based assays, programmed death‐ligand (PD‐L1). The expression demonstrating the induction of antigen‐specific Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

228





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 229

Table 17.1 Classes of immunologic biomarkers.

Category of Biomarker

Definition

Example

Prognostic

Evaluates overall outcome regardless of

Immunoscore

intervention

Predictive

Evaluates the likelihood of response to

PD‐L1 expression

treatment

Pharmacodynamic

Measures drug effect on the target

TCR sequencing

Pharmacokinetic

Measures drug distribution, metabolism, and

Persistence of CAR T cells

excretion

Correlative or surrogate endpoint

Acts as a substitute for clinically meaningful

Area of active investigation; none have

endpoint

been validated to date

Note: CAR = chimeric antigen receptor.

T cel s [1]. This approach, however, did not account and M etastasis) to determine the stage of cancer for the intricacies of the tumor microenvironment, [3]. The development of the immunoscore for and the role that additional immune cel s and mol- colorectal cancer was based on the observation that ecules play inhibiting and augmenting tumor‐ type, density, and location of immune cel s within a specific immune responses [2].

tumor are a superior predictor of patient survival

In this chapter, we review currently utilized than the histopathological methods currently used prognostic, predictive, and pharmacokinetic/phar- to stage colorectal cancer [3, 4].

macodynamic immune biomarker assays, focusing

The immunoscore is obtained from pathologic

on their backgrounds, biologic tissues required, interpretation of hematoxylin and eosin (H&E)‐

general assay methods, key examples of their use, stained slides derived from paraffin‐embedded and the future of each technology (Tables 17.2 and tissue sections. Two tissue sections are analyzed 17.3). We discuss current candidates for correlative from each region (center of tumor, CT, and inva-and surrogate endpoints and the evidence support- sive margin, IM). These tissue microarray sections ing their use. Figure 17.1 il ustrates a broad view of are incubated (60 minutes at room temperature) the immune cel s, cytokines, immune modulatory with monoclonal antibodies to CD3, CD45RO, molecules, and tumor cell properties that specific CD8, and cytokeratin‐8. DAB‐chromogen is immune monitoring modalities interrogate. It is applied and slides are counterstained with important to recognize that the majority of these methylene blue to complete the immunohisto-immune monitoring modalities only capture data chemistry. Slides are then analyzed using an image on a small number of components of the overall analysis workstation and results are recorded as tumor immune microenvironment and/or systemic the number of positive cel s per tissue surface unit immune environment (Figure 17.1).

[5]. The immunoscore is calculated using densities

and location (CT and IM) of memory T cel s

Immune prognostic biomarkers

(CD3+/CD45RO+) and cytotoxic (CD3+/CD8+)

T cel s. Tissues are assigned points based on the

Immunoscore

high (Hi) (1 pt) or low (0 pt) density of either the

The “immunoscore” is an example of a prognostic CD8+ or CD45RO+ T cel s in each region, and immune biomarker that quantitates the immune points are added to yield the final score: (0)‐Hi cell composition, specifical y CD8+ and CD45RO+ (low immune score), (1‐2)‐Hi, (3)‐Hi, and (4)‐Hi T cel s in the tumor microenvironment, and asso- (high immune score), resulting in four distinct ciates the resulting immune score with clinical prognostic groups [5].

survival endpoints. Immunoscore was demon-

One limitation of the immunoscore is that it

strated to be more reliable in predicting disease‐ cannot be performed on core needle or fine‐needle free survival (DFS) than TNM staging, which aspiration biopsies due to the inability to precisely depends on three key factors ( T umor, lymph N ode, define the tumor center and invasive margin.

Table 17.2 Immune monitoring prognostic and predictive methods: tissue/blood required, limitations, and example of clinical trial use.

Tumor Tissue and Blood

Analysis Method

Required

Methods

Limitations

Key Examples

Future Directions

Prognostic Biomarkers

Immunoscore

Tumor tissue: FFPE



– CD45RO+ and CD8+ T cell

– Cannot perform with core

Galon et al . [8]

– Application to multiple

Blood: N/A

density at tumor center and inv.

biopsy

tumor types

margin

– Cannot

– Multicountry validation



– Points assigned per cell type and

perform

study

location, then added for sum

post–chemo‐radiation

Neutrophil‐to‐lymphocyte

Tumor tissue: N/A



– Absolute neutrophil count and



– Different cutoffs for (+) NLR

Ferrucci et al . [10]



– NLR as a immunotherapy‐

ratio (NLR)

Blood: fresh blood

absolute lymphocyte count used



– Coexisting conditions can

predictive marker

to calculate NLR

affect NLR

Predictive Biomarkers

PD‐1/PD‐L1 expression

Tumor tissue: fresh,



– Percentage of tumor cells



– Expression variable within

Herbst et al . [25]



–

In‐vivo imaging of

(IHC)

frozen, and FFPE

staining for PD‐L1 is scored

tumors

PD‐L1 expression

Blood: N/A



– Positivity generally defined as



– No standard for positivity

>5% staining

Single‐nucleotide

Tumor tissue: fresh and



– Genomic DNA isolated and

– Few patients in trials to date

Breunis et al . [35]



– New SNP analysis

polymorphism (SNP)

frozen tissue

sequenced

– Contradictory results from

methods such as network

analysis

Blood: PBMCs



– Sequencing reactions performed

reported studies

phenotyping strategy



– Bidirectional resequencing of

regions of interest (CTLA4, etc.)



– Software identifies genotype

callings

Neoantigens

Tumor tissue: fresh and



– Genomic DNA obtained and

– Neoantigens do not

McGranahan et al .



– Identify neoantigen‐

(HiSeq)

fresh frozen tissue

Exon regions captured

necessarily overlap between

[48]

specific T cells by

Blood: N/A



– Paired‐end sequencing by Hi‐Seq

patients

immortal B cell



– Sequence data are then mapped

– Not all neoantigens elicit

presentation of

to the reference human genome

T cell responses

neoantigens

sequence and mutations

identified

Table 17.2 Immune monitoring prognostic and predictive methods: tissue/blood required, limitations, and example of clinical trial use.

Tumor Tissue and Blood

Analysis Method

Required

Methods

Limitations

Key Examples

Future Directions

Prognostic Biomarkers

Immunoscore

Tumor tissue: FFPE



– CD45RO+ and CD8+ T cell

– Cannot perform with core

Galon et al . [8]



– Application to multiple

Blood: N/A

density at tumor center and inv.

biopsy

tumor types

margin

– Cannot



– Multicountry validation



– Points assigned per cell type and

perform

study

location, then added for sum

post–chemo‐radiation

Myeloid‐derived supp.

Tumor tissue: fresh and



– Tumor tissue digested

– Heterogeneous immune

Martens et al . [54]

– Consensus on MDSC

Neutrophil‐to‐lymphocyte

Tumor tissue: N/A

– Absolute neutrophil count and

– Different cutoffs for (+) NLR

Ferrucci et al . [10]



– NLR as a immunotherapy‐

cells (flow cytometry)

frozen tissue



– Flow cytometry performed

population

flow cytometry

ratio (NLR)

Blood: fresh blood

absolute lymphocyte count used

– Coexisting conditions can

predictive marker

Blood: fresh, frozen and



– M‐MDSCs: CD11b + CD14 +

– No consensus on how to

identification

to calculate NLR

affect NLR

cryopreserved PBMC

CD15 − IL‐4Ra + MHC −/low

define MDSCs



– Gr‐MDSCs:

– Limitations in gating

Predictive Biomarkers

CD11b + CD14 − CD15 + MHC −/low

standards

PD‐1/PD‐L1 expression

Tumor tissue: fresh,

– Percentage of tumor cells

– Expression variable within

Herbst et al . [25]



–

In‐vivo imaging of

– Contradicting studies

(IHC)

frozen, and FFPE

staining for PD‐L1 is scored

tumors

PD‐L1 expression

correlating MDSC levels and

Blood: N/A



– Positivity generally defined as

– No standard for positivity

survival

>5% staining

Immunosuppressive T cell

Tumor tissue: fresh and



– Tumor tissue digested



– Tregs ‐ small proportion of

Disis et al . [67]

Single‐nucleotide

Tumor tissue: fresh and



– Genomic DNA isolated and

– Few patients in trials to date

Breunis et al . [35]



– New SNP analysis

populations (flow

frozen tissue



– Flow cytometry performed

CD4+ T cells (5%)

Kristensen et al .

polymorphism (SNP)

frozen tissue

sequenced

– Contradictory results from

methods such as network

cytometry):

Blood: fresh, frozen, and



– Tregs: CD4 + CD39 + CD25+



– No consensus on how to

[128]

analysis

Blood: PBMCs



– Sequencing reactions performed

reported studies

phenotyping strategy

– Treg CD4+ cells

cryopreserved PBMC

adenosine producing

define Tregs, FOXP3 not



– Bidirectional resequencing of

– Th2 CD4+ cells



– Th2 CD4+ T cells: flow for

reliable

regions of interest (CTLA4, etc.)

cytokines IL‐4, IL‐6, and IL‐10



– Challenge of differentiating



– Software identifies genotype

naive Tregs, inducible Tregs,

callings

and peripheral Tregs

Neoantigens

Tumor tissue: fresh and



– Genomic DNA obtained and

– Neoantigens do not

McGranahan et al .



– Identify neoantigen‐

(HiSeq)

fresh frozen tissue

Exon regions captured

necessarily overlap between

[48]

specific T cells by



Note: FFPE = formalin‐fixed, paraffin‐embedded; PBMCs = peripheral blood mononuclear cells; IHC = immunohistochemistry; M‐MDSCs = monocytic myeloid‐derived suppressor cells; Blood: N/A



– Paired‐end sequencing by Hi‐Seq

patients

immortal B cell

Gr‐MDSC = granulocytic myeloid‐derived suppressor cells.



– Sequence data are then mapped

– Not all neoantigens elicit

presentation of

to the reference human genome

T cell responses

neoantigens

sequence and mutations

identified

Table 17.3 Immune monitoring pharmacokinetic/pharmacodynamic methods: tissue/blood required, limitations, and example of clinical trial use.

Tumor Tissue and Blood

Analysis Method

Required

Methods

Limitations

Key Examples

Future Directions

Pharmacokinetic and Pharmacodynamic Biomarkers

TCR sequencing

Tumor tissue: fresh, frozen,



– DNA or RNA isolation



– Limited by sequencing depth

Tumeh et al . [85]



– Linking specific TCR clones

and FFPE tissue



– V and J gene primers amplify

and accuracy

and their target epitope

Blood: fresh and

rearranged V(D)J segments



– Depending on the stage of T cell

cryopreserved PBMCs



– Sequence of unique amplified

activation, activated T cells

CDR3 segments determined,

might or might not synthesize

identifying V, D, and J genes

TCRs.

Genomic immune

Tumor tissue: fresh, frozen,



– DNA or RNA isolation, genomic



– Fluctuations in immune cell

Bedognetti et al . [93]

– Standardized gene expression

analysis

and FFPE tissue

analysis performed

subtype frequency (macro-

panels

Blood: PBMCs (RNA tubes)



– DNA or RNA quality assessed

phages, Th2 cells, and Tregs)



– Gene expression values

analyzed

ELISPOT

Tumor tissue: N/A



– ELISPOT plates coated with an



– Does not directly evaluate

Datta et al . [129]



Blood: fresh and frozen

anticytokine capture Ab

cell‐mediated cytotoxicity

PBMCs



– PBMCs incubated w/ target



– No consensus on how to

antigen, detection Ab added

analyze ELISPOT positive vs

serially to reveal spot formation

negative data

ELISA

Tumor tissue: N/A



– Target antigen applied to ELISA



– Evaluation of immune response Montgomery et al . [118] – High‐density programmable Blood: fresh and frozen

plates

to only a single antigen at a

protein microarrays (NAPPA)

PBMCs



– Serum added in serial dilutions

time

allow >5000 tumor antigens



– Anti-human 2 o antibody is

added



– Absorbance is read and control

signal is subtracted from

protein signal

Table 17.3 Immune monitoring pharmacokinetic/pharmacodynamic methods: tissue/blood required, limitations, and example of clinical trial use.

Tumor Tissue and Blood

Analysis Method

Required

Methods

Limitations

Key Examples

Future Directions

Pharmacokinetic and Pharmacodynamic Biomarkers

TCR sequencing

Tumor tissue: fresh, frozen,

– DNA or RNA isolation



– Limited by sequencing depth

Tumeh et al . [85]



– Linking specific TCR clones

and FFPE tissue

– V and J gene primers amplify

and accuracy

and their target epitope

Blood: fresh and

rearranged V(D)J segments



– Depending on the stage of T cell

cryopreserved PBMCs

– Sequence of unique amplified

activation, activated T cells

Cytokine flow

Tumor tissue: fresh tissue

– Mononuclear cells are isolated

– Gating remains highly

Michelin et al . [103]



CDR3 segments determined,

might or might not synthesize

cytometry

Blood: fresh, frozen, and



– T cells are fixed, permeabilized,

subjective, resulting in interassay

identifying V, D, and J genes

TCRs.

cryopreserved PBMCs

and stained for cytokines of

variability in flow cytometry.

Genomic immune

Tumor tissue: fresh, frozen,



– DNA or RNA isolation, genomic – Fluctuations in immune cell Bedognetti et al . [93]



– Standardized gene expression

interest using the appropriate

analysis

and FFPE tissue

analysis performed

subtype frequency (macro-

panels

antibodies

Blood: PBMCs (RNA tubes)



– DNA or RNA quality assessed

phages, Th2 cells, and Tregs)



– Flow cytometry performed



– Gene expression values

MHC tetramers

Tumor tissue: fresh tissue



– Biotinylated HLA monomers

– TCR affinity required for T cell

Cohen et al . [109]



– MHC dextramers allowing for

analyzed

Blood: fresh, frozen, and

loaded with the antigen of

binding to the pMHC tetramers

staining of low‐affinity T cells

ELISPOT

Tumor tissue: N/A



– ELISPOT plates coated with an



– Does not directly evaluate

Datta et al . [129]



cryopreserved PBMCs

interest are tetramerized

exceeds that required for T cell

and MHC class II specific

Blood: fresh and frozen

anticytokine capture Ab

cell‐mediated cytotoxicity



– T cells are incubated in

activation

T cells

PBMCs

– PBMCs incubated w/ target



– No consensus on how to

dasatinib

antigen, detection Ab added

analyze ELISPOT positive vs



– T cells are stained with MHC

serially to reveal spot formation

negative data

tetramer

ELISA

Tumor tissue: N/A



– Target antigen applied to ELISA – Evaluation of immune response Montgomery et al . [118] – High‐density programmable



– Flow cytometry performed

Blood: fresh and frozen

plates

to only a single antigen at a

protein microarrays (NAPPA)

PBMCs



– Serum added in serial dilutions

time

allow >5000 tumor antigens



Note: TCR = T cell receptor; FFPE = formalin‐fixed, paraffin‐embedded; PBMCs = peripheral blood mononuclear cells; MHC = major histocompatibility complex; HLA = human



– Anti-human 2 o antibody is

leukocyte antigen.

added



– Absorbance is read and control

signal is subtracted from

protein signal





234 Immunotherapy in Translational Cancer Research

PD-1/

Tumor Draining

Immuno- PD-L1

Neo-

Gene Analysis

Flow

TCR

Lymph Node

score

IHC

antigens Immune Signature SNPs Cytometry

Seq

NLR Ratio

(TDLN)

Tumor Tissue

Blood

10

Lymph Node

6

4

Treg

Th2

6

Th2

Th2

Treg 10

DC

Th2

4

Tmem

MDSC

Th2

Th1

MDSC

CD8+

Th1

DC

Th1

DC

Th1

CD8+

g

Tmem

DC

CD8+

2

CD8+

CD8+

g

2

12

Tmem

12

CD8+

Th1

Tmem

CD8+

Th1

Th2

Lymph

Neut

g

2

4

IL-2

IL-4

Th1

CD4+ Th1 T Cell

MDSC Myeloid Der Sup Cell

Cancer Cell

DC

Mature DC

12 IL-12

6

IL-6

Th2

CD4+ Th2 T Cell

Treg

Tmem

T regulatory Cell

T memory Cell

g

IFN-g

10 IL-10

Figure 17.1 Immune monitoring assays and targets:

and other immune cell receptor polymorphisms), flow

(1) Tumor tissue–based assays and targets (blue bar only):

cytometry (immune cell subtypes, cytokines, and immune

immunoscore (tumor‐based T memory cells and CD8+

cell surface receptors), T cell receptor sequencing

T cells), immunohistochemistry (IHC) of PD‐L1/PD‐1

(tumor‐ and blood‐based T cell subtypes). (3) Blood‐

(tumor cells, T cell subtypes, and other immune cell

based assays and targets (red bar only): neutrophil‐to‐

subtypes), neoantigens (tumor cells), genetic analysis

lymphocyte ratio (NLR) (circulating neutrophils and

(tumor cells, immune cell subtypes, immune cell

lymphocytes). (4) Lymph node tissue–based assays and

receptors, and cytokines). (2) Blood and tumor tissue–

targets (green bar): tumor‐draining lymph node

based assays and targets (blue and red bars): single

assessment (tumor cells and lymph node–based immune

nucleotide polymorphisms (SNPs) (CTLA‐4 polymorphisms

cell subtypes).

Another limitation of the immunoscore is that it relapse was shorter among 303 patients with low-cannot be utilized on tumors treated with neoadju- immunoscore colon cancer versus 327 patients vant chemo‐radiation, as such therapies cause with high‐immunoscore colon cancer (HR (95%

significant changes to the tumor histology [6]. An CI), 0.54 (0.34–0.84); p = .006). In both groups, advantage of the immunoscore is its detection of results were independent of patient age, sex, tumor tumor‐infiltrating T cell subtypes, as the presence stage, and location of the cancer in the left or right of certain T cell subtypes may predict which tumors side of the colon [8].

are amenable to enhancement by immunothera-

peutic approaches [7].

Neutrophil‐to‐lymphocyte ratio

Galon et al. recently reported a study evaluating The neutrophil‐to‐lymphocyte ratio (NLR) is a the immunoscore as a prognostic indicator for time generalized measure of systemic inflammation and to relapse in 1300 colon cancer patients. In this has been utilized as a prognostic measure in many study, stage I/II/III colon cancer patients were split noncancer disease states. It has also been used into a training set and an internal validation set. In extensively in various subtypes of cancer as a prog-the internal validation set (630 patients), time to nostic indicator of overall survival. A recent





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 235

meta‐analysis of 100 studies utilizing NLR demon- the number of tumor‐infiltrating PD‐1+ cel s was strated that an NLR greater than the cutoff (defined not correlated with NLR [11].

for each study) was associated with a hazard ratio

for overall survival (OS) of 1.81 (95% CI = 1.67 to Immune predictive biomarkers 1.97; p < .001), an effect observed in all cancer subgroups, disease sites, and stages. In this meta‐anal- PD‐L1 and PD‐1 expression ysis, hazard ratios for NLR greater than the cutoff One of the central drivers in the resurgence of for progression‐free survival (PFS) and DFS were interest in immuno‐oncology has been the clinical 1.63 and 2.27, respectively (all p < .001) [9].

benefit demonstrated by the immune checkpoint

In general, only peripheral blood has been used inhibitors. These therapies targeting cytotoxic T

to calculate NLR. The ratio between absolute neu- lymphocyte associated protein 4 (CTLA‐4) and trophil counts and absolute lymphocyte counts are more recently, programmed cell death protein 1

used to calculate NLR [10]. As the recognition of (PD‐1/PD‐L1) signaling have received United the predictive role of the tumor microenvironment States Food and Drug Administration (FDA) has become increasingly accepted, the use of tumor approval for several indications [12–14]. One tissue has also increased for NLR calculations.

ongoing challenge with this category of therapy has

One limitation in using the NLR is the inconsis- been the validation of reliable predictive biotency of the cutoffs for positive NLRs in different markers of response. PD‐1 is a cell surface receptor disease states. Another limitation of using NLR is expressed on T cel s and pro‐B cel s, initial y found that neutrophil and lymphocyte counts can be to be upregulated on activated mouse T cel s after T

influenced by multiple coexisting conditions such cell receptor engagement [15], and is a member of as infections, inflammation, and medications. A the extended CD28/CTLA‐4 family of T cell regu-benefit of using NLR is the ease of calculation lators [16]. PD‐L1 (B7‐H1, CD274) and PD‐L2

from commonly available labs in the clinical (B7‐DC, CD273) are the ligands for PD‐1 [17]. It is setting.

now recognized that PD‐1 and PD‐L1 are expressed

As an indicator of an inflammatory state, sev- by various cell populations [15], including antigen-eral clinical trials have investigated whether NLR presenting cel s (APCs) [18–20] and tumor cel s could be predictive of the response to immune [21–23]. This signaling axis inhibits antitumor T

checkpoint inhibitor therapy. In a retrospective cell immunity [24] through several potential mech-analysis of three separate studies, Ferruci et al. anisms, including T cell apoptosis, anergy, evaluated the association of NLR with clinical exhaustion, and IL‐10 expression [24]. A correla-outcome in metastatic melanoma patients treated tion has been made between increased expression with ipilimumab. This analysis demonstrated of PD‐L1 by tumor cel s and an increased response that in these studies, patients treated with ipilim- rate to anti‐PD‐L1/PD‐1 therapy in several tumor umab with baseline NLR < 5 had a significantly types, with the largest body of evidence found in improved PFS (HR = 0.38; 95% CI: 0.22–0.66; melanoma trials [13].

p = .0006) and OS (HR = 0.24; 95% CI: 0.13–0.46;

Immunohistochemical analysis for PD‐L1 and

p = .0001) compared with those with a baseline PD‐1 is typical y performed on archival or newly NLR ≥ 5 [10].

obtained formalin‐fixed, paraffin‐embedded

Additional studies have investigated the rela- (FFPE) tumor specimens with the use of the anti-tionship between tumor expression of T cell human PD‐L1 or PD‐1 monoclonal antibodies. The checkpoint receptors, checkpoint ligands, and percentage of tumor cel s exhibiting cell‐surface NLR. A recent analysis evaluated the relationship staining for PD‐L1, for example, is subsequently of NLR and the expression of PD‐L1 and infiltra- scored, with positivity defined a variety of ways but tion of PD‐1+ cel s in primary tumors from 180 most commonly as 5% expression per specimen.

patients who had undergone surgery for gastric Patients with multiple specimens are considered cancer. NLR was significantly increased above PD‐L1 positive if any specimen meets this criterion cutoff in the group of patients with PD‐L1+ tumors [16]. Increased expression of PD‐L1 in tumor‐infil-compared with the PD‐L1 negative group. However, trating immune cel s, such as APCs, has also been





236 Immunotherapy in Translational Cancer Research correlated with increased response to anti‐PD‐L1 not reach statistical significance (NSCLC, p = .920; therapy as demonstrated in non‐small‐cell lung can- all tumors, p = .079) [25].

cer (NSCLC) [25]. It has also been demonstrated in

Final y, a new technology in PD‐L1 detection is

metastatic bladder cancer that PD‐L1 expression on the in vivo imaging of radiolabeled high‐affinity tumor‐infiltrating immune cel s increases the PD‐1 variants to evaluate for PD‐L1 expression in the likelihood of response to anti‐PD‐L1 therapy with entire tumor, thus addressing the challenge of PD-L1

an overall response rate of 43% (95% CI: 26%–63%) expression heterogeneity found in tumors [32].

achieved in patients with PD‐L1 IHC 2/3 tumors

[26]. Additional y, in an analysis of colon cancers Analysis of single nucleotide with microsatellite instability, the majority of PD‐L1 polymorphisms expression was by myeloid cel s while there was no In immuno‐oncology the analysis of single‐nucle-discernable PD‐L1 expression on tumor cel s [27].

otide polymorphisms (SNPs) has focused on poly-

Limitations inherent in utilizing PD‐L1 as a pre- morphisms found in immune‐related molecules.

dictive marker include the fact that PD‐L1 In particular, SNPs in the CTLA‐4 immune check-expression is inducible and that PD‐L1 is not dif- point molecule have been linked to an increased fusely expressed throughout a tumor. Specifical y, risk of multiple cancer types [33] and as a predic-PD‐L1 expression can be induced by cytokines, tive measure for the clinical benefit of immuno-with effector T‐cell‐derived IFN‐γ being the most therapies. SNPs from immune‐related genes have potent inducer of PD‐L1 expression [15]. Increased been used to predict recurrence in patients PD‐L1 expression has also been linked to receiving therapy with bacille Calmette‐Guérin activation of oncogenic pathways including immunotherapy for non‐muscle‐invasive bladder through the loss of PTEN [28] and by the onco- cancer [34]. In predicting response to immunogenic fusion protein NPM/ALK [29]. It has been therapy, studies have evaluated the association demonstrated that PD‐L1 expression is clustered between clinical outcomes and the SNPs of where IFN‐γ + T cel s infiltrate [28, 30]. Due to the CTLA‐4 [35, 36], IRF5 [37], CCR5 [38], and localized nature of PD‐L1 expression, core needle CXCR3 [39].

tumor biopsies may miss areas of PD‐L1 expres-

SNP analysis is performed on isolated genomic

sion. Another limitation of using PD‐L1 expression DNA from collected peripheral blood samples.

analysis by immunohistochemistry (IHC) is that Using software‐designed primer pairs, genotyping many different anti‐PD‐L1 and anti‐PD‐1 anti- of selected SNPs is performed through bidirec-bodies have been used in studies, with various tional resequencing of regions of interest in the levels of validation of these antibodies. Further, selected genes. A sequencer performs the though 5% PD‐L1 staining of the membrane has sequencing reactions using variations under stan-been used for the cutoff of positivity due to the dard sequencing conditions [35]. Sequencing association with clinical response [14], the analysis software is then utilized to determine threshold for PD‐L1 positivity has not been clearly genotype alignment and consistency through both defined [31].

forward and reverse sequencing. Final y, statistical

A key study in the evaluation of PD‐L1 expres- analysis is carried out to correlate SNP(s) with sion in predicting response to anti‐PD‐1 therapy treatment response or outcome of interest [35].

was reported by Herbst et al. In this study, 277

Studies evaluating individual SNPs and their

patients who received the anti‐PD‐L1 therapy relationships to clinical responses after adminis-MPDL3280A had pretreatment tumor tissue speci- tration of immunotherapies is limited by the small mens stained for PD‐L1 expression. The results sample sizes in previously designed trials. Large demonstrated that across multiple tumor types, numbers of patients are needed (due to the number positive clinical responses were observed in of SNPs analyzed) to ful y appreciate the value of patients whose tumor‐infiltrating immune cell SNPs. Another limitation is that the relationships PD‐L1 expression reached statistical significance between individual SNPs and clinical responses to (NSCLC, p = .015; all tumors, p = .007), while the immunotherapies (IL‐2, anti‐CTLA‐4 Abs) have association with tumor cell PD‐L1 expression did been inconsistent among studies, even when





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 237

evaluating the same SNP and therapy pairing [35, load of 10 somatic mutations per megabase of 40, 41]. Last, in the context of Calmette‐Guérin coding DNA results in the formation of a sufficient immunotherapy, SNP evaluations have been retro- number of neoantigens to be recognized by autolo-spective, not prospective [34, 42].

gous T cel s. Tumors with a mutational load of 1 to

In melanoma, three studies were conducted 10 mutations per megabase regularly contain attempting to correlate similar CTLA‐4 SNPs with sufficient neoantigens as wel . But it is felt that can-clinical responses to anti‐CTLA‐4 mAb therapy cers with mutational loads of <1 mutation per (ipilimumab). These studies did not demonstrate a megabase are less likely to carry sufficient neoanti-consistent association between selected SNPs and gens to elicit recognition by T cel s [43].

clinical responses to ipilimumab [35, 36]. Among

The general protocol used to identify the

these three studies was a study by Breunis et al. presence of neoantigens is as follows. Fresh

[35]. In this study, seven common SNPs were tumor is digested and tumor cell lines are gener-selected from the CTLA‐4 gene in 152 Caucasian ated by culture from the resulting cell patients who underwent CTLA‐4 blockade and suspension. Genomic DNA from tumor and were evaluated to determine correlations to normal samples is fragmented and used for treatment responses [35]. The results of this anal- genomic library construction. Exonic regions ysis demonstrated that three of the seven selected are then captured in solution using appropriate SNPs were associated with response to ipilimumab methods. Paired‐end sequencing, sequencing in therapy. These SNPs included the proximal pro- 100 bases from each end of each fragment, is moter SNP rs4553808 ( p = .002), the proximal performed using a HiSeq genome analyzer.

promoter SNP rs11571327 ( p = .02), and the non- Sequence data are then mapped to the reference synonymous SNP rs231775 ( p = .009) [35].

human genome sequence and sequence alter-

New technology has been implemented in a ations are determined by comparison of over recent reanalysis of data from a 2010 study evalu- 50 million bases of tumor and normal DNA.

ating the relationship between CTLA‐4 SNPs and The tags are aligned to the reference human clinical benefit from high‐dose interferon therapy genome sequence using the appropriate soft-in high‐risk melanoma cases. In the original study, ware. A software filter allows for the selection of no statistical y significant difference in relapse‐free sequence reads for subsequent analyses.

survival or OS was demonstrated among the mela- Appropriate software is then applied to identify noma patients with 6 CTLA‐4 SNPs [40]. In the point mutations and small insertions and dele-reanalysis, a new method called network pheno- tions. Known polymorphisms are removed from typing strategy was used for the SNP analysis. analysis. Potential somatic mutations are fil-Network phenotyping strategy is a graph‐theory– tered and visually inspected for the identification based method that captures allele relationship of nonsynonymous single‐nucleotide and patterns for each patient into a six‐partite dinucleotide substitutions (neoantigens).

mathematical graph. Using this method, the inves- Oligonucleotide primers are then designed to tigators were able to relate polymorphic SNP amplify fragments of gene products ranging patterns (distances between PRP and RRP pairs) between ~100 and ~600 nucleotides encompass-differentiating two survival groups (longer and ing the identified mutated epitopes. These shorter than five years), with statistical signifi- primer sets are used to carry out RT‐PCR.

cance for these pairs ranging from p = .002 to Amplified cDNA transcripts are either directly p = .043 [41].

sequenced after purification of the RT‐PCR

products by a DNA purification kit or cloned

Estimation of neoantigenic load

into an appropriate plasmid vector and then

As recent interest has focused on the role of neoan- sequenced [44].

tigens in provoking T‐cell‐mediated antitumor

A limitation to the generalized applicability of

immune responses, studies have investigated neoantigen load evaluation is that a significant methods for detecting neoantigens as well as neo- number of the mutations found in human tumors antigen load. It has been noted that a mutational are not maintained between patients; thus, the





238 Immunotherapy in Translational Cancer Research identification and targeting of neoantigens would Myeloid‐derived suppressor cells have to be patient specific. Further, when present, Myeloid‐derived suppressor cel s (MDSCs) in the neoantigens may not induce an autologous T cell tumor microenvironment suppress T cell activity response and thus would be immunological y irrel- through the inhibition of T cell proliferation and evant [45]. Another limitation is that genomic activation. There is evidence that malignant cel s analysis from core tumor biopsies may not ful y elicit the intratumoral presence of MDSCs represent the mutational and neoantigen load of an through secretion of cytokines that induce the entire tumor [46].

localization of MDCSs into the tumor microenvi-

A recent study by Giannakis et al. evaluated the ronment [49]. It is recognized that there are two relationship between the mutational composition subclasses of MDSC of interest in cancer, mono-of 619 colorectal cancers and tumor immunity, cytic MDSCs (M‐MDSC) and granulocytic MDSCs pathology, and survival data through whole‐exome (Gr‐MDSCs).

sequencing. This study demonstrated a significant

MDSCs are typical y tested for by flow cytom-

association between higher neoantigen load and etry from fresh peripheral blood samples or from the increased presence of tumor‐infiltrating fresh digested tissue samples [50]. As MDSCs are lymphocytes (Spearman’s rank correlation coeffi- a heterogeneous group of cel s, there is no flow cient = 0.36, p = 2.0 × 10−19). The investigators also cytometry standard for testing for their presence.

demonstrated that the neoantigen load signifi- There is evidence that cryopreservation of blood cantly correlated with the density of CD45RO+ T results in significantly reduced numbers of cel s, but not significantly with the density of MDSCs as well as the loss of their immune-CD8+, CD3+, or FOXP3+ T cel s. Last, the investi- suppressive activities [51], thus limiting their ex gators demonstrated that an elevated neoantigen vivo functional analysis. With regard to the gen-load was associated with improved colorectal‐ erally accepted phenotypes of the two subclasses cancer‐specific survival (log rank test, p = .004; of MDSCs listed above, human M‐MDSCs multivariate hazard ratio = 0.57 (95% confidence are phenotypical y CD11b+CD14+CD15−IL‐4Ra+

interval, 0.35–0.93)) [47].

MHC−/low and Gr‐MDSCs are CD11b+CD14−CD15+

A recent study by McGranahan et al. investi- MHC−/low [52].

gated the impact of tumor neoantigen heterogeneity

One of the limitations of utilizing MDSCs in

(ITH) and neoantigen burden on overall survival clinical trial research is that classification and char-in patients with lung carcinoma as well as on acterization of this group of heterogeneous clinical response to checkpoint inhibitor blockade immune cel s remain unresolved, as there is no in both lung carcinoma and melanoma patients. In international consensus on how to define MDSCs patients with lung adenocarcinoma, a high neoan- [53]. Another limitation of utilizing MDSCs in tigen burden, defined as the upper quartile of clinical trial analysis is that studies to date are con-neoantigen load, was associated with significantly tradicting in regard to the clinical correlation longer overall survival ( p = .025). In patients with between circulating/infiltrating MDSC levels and neoantigen homogeneous tumors (neoantigen ITH survival [49].

≤ 1%) there was a trend toward longer overall

Immune monitoring of MDSC has several

survival times compared with heterogeneous potential applications. A recent key study evaluated tumors ( p = .061). In melanoma patients who had baseline circulating MDSCs as well as four other received anti‐CTLA‐4 therapy, the investigators circulating immune cell populations (MDSCs, demonstrated a significantly improved OS in absolute monocytes, absolute eosinophils, lympho-patients whose tumors exhibited a low neoantigen cytes, and Tregs) from patients with metastatic heterogeneity (ITH threshold = 0.01) along with a melanoma who had undergone therapy with high clonal neoantigen burden ( p = .008). But the ipilimumab. The study evaluated a combination relationship between neoantigen burden alone and model of these baseline biomarkers and whether survival outcome with anti‐CTLA‐4 therapy was this model could predict outcome in patients not statistical y significant in this patient population receiving ipilimumab for metastatic melanoma.

( p = .083) [48].

The study demonstrated a 34.5% two‐year survival





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 239

probability after ipilimumab initiation among immunosuppressive cytokines such as IL‐4, IL‐6, patients with Lin—CD14+HLA‐DR−/low MDSC and IL‐10 [60]. Several studies have investigated frequencies <5.1%, while there were no survivors the ratio of Th1/Th2 T cel s in cancer. One such among patients with higher baseline MDSC levels study in colorectal patients demonstrated an ( p = 6.73 × 1011). In this study MDSCs were also the increased CD4+ Th2 T cell population in colo-strongest stand‐alone factor of the entire study to rectal cancer patients when compared to healthy indicate long‐term survival [54].

adults [61].

A study conducted by Gephardt et al. il ustrating

Identification and quantification of Treg and

the potential role of MDSC in immune monitoring Th2 CD4+ T cel s is typical y obtained through during immunotherapy was performed with mela- flow cytometry. No universal y agreed‐upon panel noma patients receiving ipilimumab [55]. This exists for Tregs, but it has been recommended that study evaluated for changes in select myeloid cel s a flow cytometric panel include at minimum (MDSCs and eosinophils) as well as related markers for CD3, CD4, CD25, CD127, and FOXP3

inflammatory factors could serve as predictive bio- markers with Ki67 and CD45RA to identify Treg markers for response to ipilimumab. In this study activation status [2]. However, recent data show myeloid cel s and selected immune biomarkers that FOXP3 is actual y not a reliable marker of were checked at baseline and then at different time human Tregs [62, 63]. A panel that is favored by points during ipilimumab therapy. This study dem- some investigators includes CD4 + CD39 + CD25+

onstrated that before treatment, nonresponders adenosine‐producing Tregs [64]. In regard to Th2

displayed a tendency for an increase in the fre- CD4+ T cel s, identification is typical y obtained quency of monocytic MDSCs (moMDSCs) as through flow cytometry of the cytokines secreted compared with responders ( p > .05). MoMDSCs in by Th2 CD4+ T cel s: IL‐4, IL‐6, and IL‐10 [65].

responders were also strongly reduced after the

The limitation of using Tregs as a biomarker

first ipilimumab infusion as compared with base- is that Tregs make up only a small proportion of line levels, whereas in nonresponders, these values CD4+ T cells (5%). As noted above, there is no showed a pronounced elevation upon the second universally agreed‐upon flow panel for Treg ipilimumab infusion ( p < .05 and p < .01). Final y, identification. This limitation is in part due to ipilimumab nonresponders displayed elevated the plasticity of Tregs and the challenge of dif-serum inflammatory factors S100A8/A9 and ferentiating naïve Tregs from inducible Tregs HMGB1, factors known to attract and activate from peripheral Tregs. In cancer patients, it is MDSCs [55].

felt that inducible Tregs are the predominant

Treg subset in tumors as well as in peripheral

T regulatory and Th2 cells

circulation [2].

CD4+ T cel s differentiate into numerous lineages

One study evaluated changes in Treg levels

that perform distinct biological functions, among other immune biomarkers in patients with including the ability to induce cytotoxic T lympho- advanced and metastatic melanoma treated with cyte (CTL) response (Th1), humoral immunity ipilimumab. Levels of Tregs as well as the other (Th2), immunosuppression (Treg), and proinflam- immune biomarkers were enumerated between matory signaling (Th17) [56]. T regulatory (Treg) baseline and post–12 weeks of therapy with ipilim-cel s and Th2 cel s are CD4+ T cell subpopulations umab in 92 patients. This study demonstrated that recognized to abrogate antitumor immune a decrease or no change in FoxP3/Treg cel s bet-responses [57]. The accumulation of Tregs in ween baseline and week 12 was significantly human tumors and in the peripheral circulation associated with survival, compared with an increase has been extensively reported in cancer patients in FoxP3/Treg cel s ( p = .03). Additional y, patients

[58, 59]. In general, CD4+FOXP3+CD25hi Tregs are with a decrease or no change in FoxP3/Treg cel s thought to correlate with a poor prognosis in between baseline and week 12 had a median OS of oncology [58]. Th2 CD4+ T cel s limit the acute 15.8 months (95% CI: 12.5–19.1), while those inflammatory response and prevent the elabora- patients with an increase in Tregs had a median OS

tion of CTL response through the secretion of of 5.3 months (95% CI: 4.7–5.8) [66].





240 Immunotherapy in Translational Cancer Research We have previously evaluated the relationship samples versus fresh samples, allowing for flexi-between baseline Treg levels (as measured by flow bility in storage and batching of samples for flow cytometry) and clinical response to HER2 vaccine analysis [77].

primed autologous T cell infusions in patients with

A preoperative clinical trial with ipilimumab in

advanced HER2+ cancers. In this study, higher patients with localized urothelial carcinoma of the baseline Treg levels were found in those patients bladder evaluated the changes in ICOS+ T cell fre-who progressed after autologous T cell infusion quency in response to ipilimumab therapy. In this ( p < .001, R2 = −0.989). This study also demon- study, all patients who received ipilimumab had strated no association between clinical response to increased frequency of CD4 + ICOShi T cel s in tumor autologous T‐cell infusion and Treg levels in the tissue and systemic circulation post–ipilimumab infused product or in the peripheral blood after therapy. These same investigators performed a therapy [67].

subsequent retrospective analysis of metastatic mela-

noma patients who had received ipilimumab and

Development of specific T cell

demonstrated that the proportion of patients with a

phenotypes; ICOS+ and polyfunctional

persistent increase in CD4 + ICOShi cell number who

T cells

had clinical benefit after ipilimumab was signifi-

T cell phenotypes associated with antitumor cantly was higher than those without persistent immune effects include ICOS+ and polyfunctional CD4 + ICOShi increase ( p = .03) [77].

T cel s. The ICOS (inducible T cell costimulator)

Wimmers et al. analyzed monofunctional and

molecule is expressed on activated T cel s and has multifunctional (polyfunctional) tumor‐specific functional roles in cell signaling, immune response, CD8+ T cel s in melanoma patients after dendritic and regulation of cell proliferation [68]. The role of cell vaccination. This study demonstrated a ICOS+ T cells in immuno‐oncology has been significant increase in the fraction of multifunc-demonstrated with the increased incidence of tional T cel s among tumor‐specific CD8+ T cell CD4 + ICOS+ T cel s after anti‐CTLA‐4 therapy in responses after one to three cycles of dendritic cell multiple tumor types [69–73]. Polyfunctional vaccination, while the relative contribution of effector CD4+ T cel s are defined by CD40L and by monofunctional CD8+ T cel s to the overall tumor-their ability to produce multiple proinflammatory specific T cell response declined. The investigators cytokines [74]. Importantly, polyfunctional T cel s also demonstrated that they could repeatedly are recognized to mediate more effective antitumor detect the multifunctional T cell responses in these immunity than single cytokine‐secreting T cell patients up to 128 months after vaccination [78].

populations [75].

For the evaluation of ICOS+ T cel s, flow cytom- Immune pharmacodynamic etry of peripheral blood is typical y performed on and pharmacokinetic biomarkers peripheral blood. Cel s are stained with an ICOS

antibody. This is followed by staining with anti- Evaluation of the evolution of the T cell bodies to CD3, CD4, and CD25. For the analysis of receptor (TCR) repertoire polyfunctional T cel s, peripheral blood mononu- The adaptive immune system is able to produce clear cel s (PBMCs) from patients are collected and 1012 unique T cel s per individual, each with a stimulated with the antigen of interest. The unique TCR. Next‐generation sequencing is uti-expanded T cel s are then plated in cytokine (i.e., lized to assess the diversity of an individual’s TCR

IL17 or IFN‐γ) precoated ELISPOT plates. The repertoire, as well as provide greater depth of anal-cel s are restimulated with antigen‐loaded APCs. ysis for TCR clonality than previous technology After 48 hours, for example, IFN‐γ spots are devel- [79]. This method allows for the identification of oped and counted as previously described [76], and important aspects of T cell responsiveness, IL17 spots are developed and counted using a bio- including clonality, diversity, and somatic allelic tinylated IL17 antibody. One benefit of utilizing mutation.

ICOS+ T cel s is that there are not significant dif-

TCR immunosequencing provides TCR seque-

ferences in ICOS expression on T cel s from frozen nces and their frequencies in a particular sample.





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 241

This assay can be performed on fresh, frozen, and vaccine‐primed autologous T cell infusions, we FFPE tissue samples, as well as on peripheral blood also evaluated for the development of TCR clones samples. Selected tumor tissues are minced and after T cell infusion. The median (range) number DNA is extracted using standard DNA extraction of clonal TCRs identified in preinfusion peripheral methods. V and J gene primers are used to amplify blood was 4 (1–14), while postinfusion, the median rearranged V(D)J segments for high throughput number was 10 (3–17). The development of new sequencing at predetermined coverage. Next, TCRVβ species demonstrating clonality post–

sequencing errors in the raw sequence data are autologous T cell infusion was associated with corrected via a clustering algorithm, and the pri- those patients who demonstrated tumor regression mary nucleotide sequence of the amplified regions with therapy ( p < .001, R2 = 0.967) [67].

from the TCR’s unique CDR3 segment is deter-

mined, quantified, and annotated according to the Gene analysis of the tumor International ImMunoGeneTics col aboration and peripheral blood in response

[80], identifying which V, D, and J genes contrib- to treatment uted to each rearrangement [81]. Once TCR Gene expression analysis and high dimensional sequencing is completed, the data are then evalu- data analysis provide tools for comprehensive ated by a number of analytic parameters of the T tumor and systemic immune analysis. This tech-cell population, including diversity, clonality, rich- nology allows evaluation of all key immune com-ness, evenness, and entropy.

ponents simultaneously from a given biologic

The sensitivity of sequence‐based TCR reper- sample [2]. Additional y, this technology provides toire profiling remains limited by sequencing depth a reasonable surrogate for the identification of the and accuracy [82]. It is also reported that activated immune status of the tumor [86–88].

T cel s might not synthesize TCRs, depending on

For genomic expression analyses of an immune

what stage of cell activation the T cell is in [83]. profile, both blood and tumor tissue can be used.

Benefits of this technology allow identification of Fresh blood is the optimal choice for analysis due the presence and tracking of the frequency of a to RNA degradation, which is found with common particular clone or group of clones over time in blood storage methods; alternatively, collection of response to therapy, as well as the identification of blood in RNA preservation tubes such as PAXgene clonal responses to immunotherapies such as can- RNA tubes is preferred. Genomic analyses can be cer vaccines [81]. Another potential benefit of TCR performed on fresh, frozen, or FFPE tumor tissue.

sequencing is that studies have il ustrated that TCR Types of tissue samples that can be used range from sequencing from several biopsies of the same whole tumors to fine‐needle aspirations of tumor tumor demonstrated a highly significant correla- tissues. The challenge with utilizing FFPE tissue for tion and overlap [84].

genomic analysis is the issue of RNA degradation.

Tumeh et al. provided a key example of the use of However, several technologies are capable of TCR sequencing in immunotherapy monitoring addressing this issue. The most frequently used

[85]. In this study of tissue samples pre‐ and post‐ technologies that compensate for RNA degrada-anti‐PD‐1 therapy (pembrolizumab), the tion in preserved tissues include digital PCR, investigators demonstrated that patients with a single‐cell real‐time PCR, and whole‐transcrip-more restricted TCR beta chain usage, reflecting a tome RNA sequencing [89–91]. As the immune T‐cell population that was less diverse in repertoire infiltrate can frequently compose only a small and more clonal in nature, significantly correlated fraction of the overall tumor, the technique of laser with clinical response to pembrolizumab treatment microdissection allows for the isolation of cel s of ( p = .004). In this study, patients who had progres- interest [2].

sive disease were demonstrated to have total T cell

One benefit of gene analysis is in the detection of

number and clonality below the median for the multiple immune cell types and immune molecules trial [85].

within a single experiment. Additional y, compre-

In our previously described study of patients hensive immune gene expression analysis allows with advanced HER2+ cancers infused with HER2 for the evaluation of the complex interplay of both





242 Immunotherapy in Translational Cancer Research the immune stimulatory and immunosuppressive cognate antigen [1]. Additional cytokines com-components of the tumor microenvironment. One monly evaluated by ELISPOT include IL‐10 and limitation of gene expression analysis is in the anal- TNFα [95, 96].

ysis of fluctuating levels of immune cel s and

ELISPOT assays are performed using PBMCs

related immune molecules, such as frequent isolated from whole blood. To reduce interassay changes in the tumor content of macrophages, Th2 variability, patient PBMC samples are cryopre-cel s, and Tregs in response to alterations in the served and batched for ELISPOT analysis.

tumor microenvironment.

ELISPOT plates are coated overnight with an anti‐

A recent study investigated the relationship bet- IFN‐γ capture antibody (if detecting IFN‐γ). The ween the expressions, at the time of diagnosis, of a plates are then blocked, PBMCs are plated, and subnetwork of type I interferon‐stimulated genes then PBMCs are stimulated with peptide pools of (ISGs) as well as subnetworks of T helper/T the antigen or antigens of interest as well as positive regulatory and NK/T cytotoxic cell genes in mela- and negative controls. After antigen(s) stimulation nomas, and correlated expression of these genes overnight, the plates are washed and the PBMCs with patient survival. The investigators observed a are incubated with a secondary biotin‐conjugated graded increase in survival according to ISG anti‐IFN‐γ antibody. The plates are then developed expression, with a median survival of 5106, 2184, to allow identification of spot‐forming cel s. Spots and 813 days for ISG hi, ISG med, and ISG lo, are quantified using automated readers, and the respectively. The overall difference between the frequency of spot‐forming cel s is calculated based survival curves was significant for each ISG expres- on the input cell numbers.

sion group ( p = 5.7 × 10−3) [92].

One limitation of the IFN‐γ ELISPOT assay is

Begdonetti et al. utilized gene expression to that alone it is insufficient for the detection of investigate the role of polymorphisms and overex- antigen‐specific CTLs vs CD4+ T cel s. Additional y, pression of CXCR3/CCR5 chemokine ligands in CTLs with proven lytic activity do not always immune‐mediated tumor rejection in melanoma secrete IFN‐γ [97]. Another limitation of IFN‐γ

and clinical response to adoptive cell therapy. In ELISPOT is that it does not directly evaluate cell-this study, 142 metastatic melanoma patients mediated cytotoxicity. In addition, there is no enrolled in adoptive therapy trials with tumor‐ consensus on how to analyze ELISPOT data to infiltrating lymphocytes were genotyped for determine what constitutes a positive versus a neg-CXCR3 rs2280964 and CCR5‐Δ32 deletion. This ative response [1]. This being said, the ELISPOT

study demonstrated that underexpression of both assay is a very sensitive assay allowing for the CXCR3 and CCR5 according to gene expression detection of cytokines secreted from as few as and polymorphism data (protein prediction 10–100 cel s in a well [94].

model) was associated with response to adoptive

In a recent exploratory analysis of 95 patients

therapy (odds ratio = 6.16 and 2.32, for CR and OR, with HER2+ breast cancer who had completed respectively) [93].

systemic therapy, analysis for HER2‐specific Th1

immunity was performed. Anti‐HER2 Th1

ELISPOT

responses were examined using PBMCs pulsed

Enzyme‐linked immunospot assay (ELISPOT) is with 6 HER2‐derived class II peptides via IFN‐γ

typical y used for its ability to detect cytokines ELISPOT. In this study, Th1‐nonresponsive secreted by T cel s specifical y in response to the in patients, as defined by a negative IFN‐γ ELISPOT, vitro recognition of a particular antigen. ELISPOT demonstrated a worse DFS (median, 47 vs 113

assays can be used for quantification of either anti- months; p < .001) compared with Th1‐responsive body‐secreting B cel s or cel s secreting protein patients ( p < .001) [76].

antigens (e.g., T cel s secreting cytokines or macro-

Although the IFN‐γ ELISPOT is the most com-

phages secreting growth factors) [94]. Currently in monly used ELISPOT for CTL detection in clinical immune‐oncology, ELISPOT is used to evaluate trials, the granzyme B ELISPOT assay and perforin the frequency and function of CD4+ and CTL T ELISPOT assay represent a more direct analysis of cel s through the secretion of IFN‐γ in response to cell‐mediated cytotoxicity, since granzyme B and





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 243

perforin are the key mediators of CTL‐targeted cell study demonstrated by intracellular flow that the death via the granule‐mediated pathway [98]. One amount of CD4+ T lymphocytes positive for IL‐2, caveat to the use of granzyme B and perforin IL‐4, IL‐10, and TGF‐β was significantly lower in ELISPOT assays is that there is rare expression of patients with good clinical response, compared these proteins by CD4+ T cel s [99].

with patients without regression after IFN‐α

therapy [103].

Cytokine flow cytometry

Cytokine flow cytometry is a method that allows MHC tetramers and pentamers for the quantifıcation of selected subsets of T cel s The major histocompatibility complex (MHC)‐tet-based on cytokines produced in response to their ramer assay was original y developed to detect cognate antigen. The most commonly used cyto- antigen‐specific T cel s. The MHC‐tetramer assay kine flow cytometry method for the quantification quantifies the number of T cel s that express a T

of cytokines of interest is intracel ular cytokine cell receptor (TCR) specific for a particular antigen staining (ICS) for flow cytometry.

[104]. MHC peptide tetramers are made of four

Biologic samples utilized for cytokine flow MHC molecules bound to the peptide antigen of cytometry include frozen whole blood, fresh whole interest, each tagged to a biotin molecule [1].

blood, cryopreserved PBMCs, and fresh tissue. To Higher order multimers (pentamers, octamers, perform cytokine flow cytometry, mononuclear etc.) have also been used and general y provide a cel s are isolated from either peripheral blood or longer interaction half‐life with the antigen-tumors. For T cell specific analysis, cel s are fixed, specific T cel s [105].

permeabilized, and subjected to staining for

Biologic samples utilized for MHC tetramer

cytokines of interest using the appropriate anti- analysis include frozen whole blood, fresh whole bodies. Flow cytometry data acquisition is blood, cryopreserved PBMCs, and fresh tissue.

performed with gating, while analysis of this data is Peptide‐MHC (pMHC) multimers are most com-subsequently performed with the appropriate monly linked to fluorochromes and are used to statistical software.

detect T cel s by conventional flow cytometry

Intracel ular cytokine analysis is a more com- [106]. Additional y, pMHC multimers can be prehensive analysis of cell phenotype and cytokine detected via mass spectrometry when linked to production on a single cell level than achieved rare metal ions (typical y lanthanides) [107]. MHC

with ELISPOT or ELISA. Another benefit of this tetramer assays are performed by initial y con-technology is that it allows for single cell cytokine structing biotinylated human leucocyte antigen analysis with a high throughput of up to 103 cel s (HLA) monomers loaded with the antigen of

[100]. One limitation of cytokine flow cytometry interest. The peptide antigens utilized in such is the interassay variability in flow cytometry‐ studies are typical y synthesized. HLA‐loaded pep-based assays, as gating remains highly subjective tide monomers are then tetramerized in the with gate placement largely based on the opera- presence of fluorescent streptavidin. Prior to tet-tor’s visual assessment. To address this limitation, ramer analysis, T cel s are incubated in media there are ongoing efforts to harmonize gating in containing dasatinib (50 nM) to enhance tetramer intracel ular cytokine staining [101]. Another lim- binding, as it is recognized that including a reversitation of intracel ular cytokine staining is that ible protein kinase inhibitor (PKI) during pMHC

peripheral blood collected in heparin versus multimer staining can also increase the range of EDTA tubes yields different levels of particular TCR–pMHC interactions that can be detected with cytokines [102].

pMHC multimers without altering the TCR–

Michelin et al. conducted a prospective study pMHC or pMHC–CD8 interactions [108]. PBMC

of patients with cervical intraepithelial neoplasia cel s are then stained with the MHC tetramer and II‐III using immunotherapy with pegylated flow cytometry is performed [109].

IFN‐α subcutaneously weekly. In this study the

One limitation of the MHC tetramer assay is that

investigators used flow cytometry to evaluate the TCR affinity required for T cell binding to the peripheral CD4+ T lymphocyte populations. This pMHC tetramers exceeds that required for T cel





244 Immunotherapy in Translational Cancer Research activation [110]. Failure to stain T cel s that have a of humoral immunity in oncology has focused on low‐affinity TCR is a significant challenge when determining the presence of autoantibodies to pMHC multimers are used to stain self‐specific T tumor‐associated antigens and in epitope spreading cell populations. This is particularly relevant in the after antitumor therapy. Analyses have demon-setting of cancer where T cel s tend to express lower strated a correlation between humoral immune affinity TCRs [111]. Also, the tetramer assay does response and clinical benefit in breast [114] and not necessarily equate to a cytotoxic T lymphocyte’s colorectal cancer [115]. The traditional method of functional activity [112]. Benefits of MHC‐ tetramer evaluation and assessment of antibody immunity is assays are in the ability to detect T cel s regardless of through an enzyme‐linked immunosorbent assay their effector function and without the requirement (ELISA). More recent methods of antibody for cel ular activation. This feature enables pheno- assessment also include serologic proteome anal-typing of T cel s directly ex vivo using a spectrum of ysis (SERPA), serologic analysis of recombinant fluorochrome‐conjugated antibodies specific for cDNA expression libraries (SEREX), and protein other T cell markers. For higher order MHC multi- microarrays [2].

mers, the advantage of longer multimer (pentamers

To perform ELISA, recombinant protein is

etc.) dwell times is largely irrelevant to the amount applied at set concentrations in appropriate buffer of pMHC multimer binding at physiologic condi- to ELISA plates. Plates are then washed and tions [105].

blocked. Serum is added at predetermined dilu-

Cohen et al. have utilized MHC tetramer assays tions in blocking buffer. After washing, an for the identification of neoantigen‐specific T cel s. anti-human secondary antibody linked to a In this study, the investigators developed a strategy fluorescent probe is added and washed once more to isolate, expand, and study neoantigen‐specific T when the reaction is stopped. Absorbance is read at cel s utilizing neoantigens identified from whole‐ 450 nM, and the control signal is subtracted from exome sequencing of metastatic melanoma tumors. protein signal.

The candidate mutated epitopes were used to gen-

One limitation of ELISAs is that the structure,

erate panels of MHC tetramers that were evaluated quantity, and purity of the recombinant protein for binding to autologous PBMCs. This study dem- used in ELISAs can dramatical y affect the detec-onstrated that by using MHC‐tetramer‐bound tion of autoantibodies; thus, contaminating or neoantigens, it is possible to isolate neoantigen misfolded proteins can lead to false‐positive anti-specific T Cel s from autologous peripheral blood, body detection [116]. Another limitation of this where the T cel s were detected at frequencies rang- assay is that ELISAs allow identification of an ing between 0.4% and 0.002% [109].

immune response to only a single antigen at a

MHC dextramers were developed as a superior time. Additional limitations include providing method to MHC tetramers for the detection of low to moderate throughput and requiring the lower affinity tumor‐specific and MHC class II– expression and purification of every individual specific T cel s due to the greater pMHC density antigen to be tested, highlighting their antitumor and fluorochrome load carried by pMHC dextra- activity [117].

mers. The use of pMHC dextramers in conjunction

In a study that our group previously performed

with 50 nM dasatinib allows robust staining of T in HER2+ breast cancer patients vaccinated with cel s even when the TCR–pMHC affinity is weak HER2 peptides, we demonstrated that vaccination (KD > 250 μM) [112].

successful y induced anti‐HER2 antibodies in a

minority of patients. This was documented by

Assessment of antibody immunity

ELISA analysis of serum from these patients.

In the current immuno‐oncology environment, the These ELISA‐identified anti‐HER2 antibodies field focus has been directed toward eliciting and were subsequently used to effectively suppress maximizing the tumor‐specific cel ular immune downstream HER2 kinase activity and down-responses. Humoral immunity as represented by stream signaling [118].

monoclonal antibodies, such as trastuzumab, also

A developing technology in the area of autoanti-

elicit antitumor response [113]. Clinical investigation body detection is based on microarray technology.





CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 245

One example of this technology is the high‐density ability to detect vaccine‐induced T cel s in the programmable protein microarrays (NAPPA). The DTH biopsy site and favorable clinical outcome NAPPA microarray was recently demonstrated to ( p = .0012) [124].

accommodate the probing of >5000 candidate

It has been demonstrated that significant

tumor antigens using serum from ovarian cancer changes in immune‐cell populations arise within patients. This analysis revealed that from this tumor‐draining lymph nodes (TDLNs), and such extensive group of tumor antigens, 12 potential immune cell population changes strongly corre-autoantigens were identified with sensitivities lated with clinical outcome. TDLNs are recognized ranging from 13% to 22% at >93% specificity [117]. as an early site of interaction between cancer cel s and the immune system. An analysis that evaluated

Correlative and surrogate

the immune content of TDLNs in breast cancer

endpoint biomarkers

patients demonstrated that analysis of TDLNs for

CD4+ T cel s and CD1a + dendritic cel s provided

The identification of immune biomarker surrogates significant risk stratification into favorable and for clinical endpoints is an area of ongoing research unfavorable prognostic groups and was superior to in clinical trial immune monitoring. It has recently risk stratification based on clinicopathologic char-been reported from a retrospective analysis of acteristics including tumor size, tumor extent, or serum samples from the Phase III IMPACT study size of nodal metastasis (CD4, p < .001 and CD1a, of sipuleucel‐T in metastatic castration‐resistant p < .001) [125]. In another study in breast cancer, prostate cancer (mCRPC), that IgG responses to clinical outcome analysis revealed that dendritic PSA and LGALS3 were associated with improved cell clustering in TDLNs correlated with the dura-OS in sipuleucel‐T‐treated patients ( p ≤ .05). These tion of disease‐free survival [126].

IgG responses were subsequently validated in an

Epitope spreading is the concept that anticancer

independent phase II study of sipuleucel‐T therapy induces tumor cell lysis that in turn releases (ProACT) [119]. Additional current candidates for tumor‐specific antigens, inducing additional antitu-correlative endpoints related to immunotherapy are mor immunity, which targets the released best represented by the use of delayed‐type hyper- tumor‐associated antigens. Several clinical trials have sensitivity (DTH) reactions, tumor‐draining lymph demonstrated a correlation between patients who nodes, and epitope spreading.

develop epitope spreading and improved clinical

DTH allows for the evaluation of an immuno- response to immune therapies. Evaluation for epitope therapy’s ability to generate T cell memory spreading in clinical trial analysis has been performed responses following immunotherapy and has been through IFN‐γ ELISPOT analysis of T cell responses shown to be predictive of clinical outcome [120]. to selected tumor antigen peptide mixes not targeted DTH has been used as a measure of antigen recall by the immunotherapy under evaluation (vaccine, or memory and has been shown to directly corre- adoptive therapy, etc.). These additional tumor late with peripheral blood antigen‐specific T cell antigens are typical y selected from known antigens responses [121]. DTH responses have been shown associated with the tumor type being treated. One to correlate with OS in studies of autologous tumor recent study that evaluated the relationship between cell lysate vaccines in melanoma, with both skin epitope spreading and clinical endpoints was a study induration (p < .0001) and erythema ( p = .0004) in Epstein‐Barr virus (EBV)‐associated lymphoma, correlating with survival benefit [122]. In another where patients were reinfused autologous expanded study, stage III and IV melanoma patients injected EBV latent membrane protein–specific CTLs.

with dendritic cell vaccine pulsed with tumor Peripheral blood analysis after this therapy demon-lysate, DTH‐positive patients showed a greater OS strated that both T cel s specific for latent membrane (33 months) when compared with DTH‐negative protein as well as nonviral tumor‐associated antigens patients (11 months, p = .0014) [123]. Last, in mela- could be detected in the peripheral blood. In this noma patients immunized with a vaccine consisting study, more than 50% of patients achieving durable of gp100 and tyrosinase peptide–loaded dendritic clinical responses produced T cel s specific for the cel s, a direct correlation was observed in the nonviral tumor‐associated antigens within two





246 Immunotherapy in Translational Cancer Research months of T cell therapy, in contrast to a lack of 3. Galon J, Costes A, Sanchez‐Cabo F, Kirilovsky A, Mlecnik epitope spreading in the nonresponding patients [127].

B, Lagorce‐Pages C, et al. Type, density, and location of

immune cel s within human colorectal tumors predict

Conclusion

clinical outcome. Science. 2006;313(5795):1960–4.

4. Pages F, Berger A, Camus M, Sanchez‐Cabo F, Costes A,

In summary, as immune therapies are becoming a

Molidor R, et al. Effector memory T cel s, early metas-

standard component of cancer management for

tasis, and survival in colorectal cancer. New England

multiple tumor types, immune biomarkers will be

Journal of Medicine. 2005;353(25):2654–66.

critical in predicting which patients will respond to

5. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, therapy while providing immune monitoring while

Bindea G, et al. In situ cytotoxic and memory T cel s pre-

dict outcome in patients with early‐stage colorectal can-

on treatment for the detection of immune‐

cer. Journal of Clinical Oncology. 2009;27(35):5944–51.

mediated therapeutic resistance. Advances in assay

6. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A,

technology (such as genomic analysis and antibody

Lagorce C, et al. Towards the introduction of the

microarrays) have driven the detection and

’Immunoscore’ in the classification of malignant

tracking of multiple immune biomarkers to new

tumours. Journal of Pathology. 2014;232(2):199–209.

levels. These technologies provide the ability to use

7. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M,

immune biomarkers in an increasingly compre-

Tougeron D, et al. Integrative analyses of colorectal can-

hensive manner to interrogate both the tumor

cer show immunoscore is a stronger predictor of patient

and systemic immune environments for clinical

survival than microsatellite instability. Immunity.

trial use. It will be critical to the success of the

2016;44(3):698–711.

immuno‐oncology field to ful y characterize and 8. Galon J, Marliot F, Ou F‐S, Bifulco CB. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/

statistical y validate each immune biomarker to

III colon cancer: results of a worldwide consortium‐

maximize their use in the ongoing development

based analysis of 1,336 patients. Journal of Clinical

and clinical trial evaluation of current and future

Oncology. 2016;34(suppl; abstr 3500).

immunotherapies.

9. Templeton AJ, McNamara MG, Seruga B, Vera‐Badillo

FE, Aneja P, Ocana A, et al. Prognostic role of neutro-

Acknowledgments

phil‐to‐lymphocyte ratio in solid tumors: a systematic

review and meta‐analysis. Journal of the National

MLD was supported by NCI grant (U01

Cancer Institute. 2014;106(6):dju124.

CA154967), a Komen Leadership Grant, an 10. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di American Cancer Society Clinical Research

Giacomo AM, Giannarelli D, et al. Baseline neutrophil‐

Professorship, and the Athena Distinguished

to‐lymphocyte ratio is associated with outcome of

Professorship for Breast Cancer Research.



ipilimumab‐treated metastatic melanoma patients.

British Journal of Cancer. 2015;112(12):1904–10.

11. Tanaka H TT, Kimura K, Sakurai K, Toyokawa T,et al.

Conflict of interest

Association of the immune checkpoint molecule expres-

sion with neutrophil‐lymphocyte ratio in patients with

MLD is a stockholder in Epithany and VentiRx and

gastric cancer: a retrospective study. Journal of Clinical

receives grant support from Celgene, EMD Serono,

Oncology. 2016;34(suppl 4S; abstr 48).

VentiRx, Jansen, and Seattle Genetics.

12. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman

JA, Haanen JB, et al. Improved survival with ipilimumab

References

in patients with metastatic melanoma. New England

Journal of Medicine. 2010;363(8):711–23.

1. Morse MA, Osada T, Hobeika A, Patel S, Lyerly HK. 13. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian Biomarkers and correlative endpoints for immunother-SL, Hwu P, et al. Safety and activity of anti‐PD‐L1 anti-

apy trials. American Society of Clinical Oncology

body in patients with advanced cancer. New England

Educational Book; American Society of Clinical Oncology

Journal of Medicine. 2012;366(26):2455–65.

Meeting. 2013.

14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN,

2. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen

Smith DC, McDermott DF, et al. Safety, activity, and

TO, et al. Novel technologies and emerging biomarkers

immune correlates of anti‐PD‐1 antibody in cancer.

for personalized cancer immunotherapy. Journal for

New England Journal of Medicine. 2012;366(26):

Immunotherapy of Cancer. 2016;4:3.

2443–54.

CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 247

15. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T,

ronment of microsatellite instable colon cancer is bal-

Yagita H, et al. Expression of the PD‐1 antigen on the

anced by multiple counter‐inhibitory checkpoints.

surface of stimulated mouse T and B lymphocytes.

Cancer Discovery. 2015;5(1):43–51.

International Immunology. 1996;8(5):765–72.

28. Taube JM, Anders RA, Young GD, Xu H, Sharma R,

16. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expres-

McMiller TL, et al. Colocalization of inflammatory

sion of PD‐1, a novel member of the immunoglobulin

response with B7‐h1 expression in human melanocytic

gene superfamily, upon programmed cell death. EMBO

lesions supports an adaptive resistance mechanism of

Journal. 1992;11(11):3887–95.

immune escape. Sci Transl Med. 2012;4(127):127ra37.

17. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, 29. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha et al. Association of PD‐1, PD‐1 ligands, and other fea-TT, et al. Up‐regulation of PD‐L1, IDO, and T(regs) in

tures of the tumor immune microenvironment with

the melanoma tumor microenvironment is driven by

response to anti‐PD‐1 therapy. Clinical Cancer Research.

CD8(+) T cel s. Sci Transl Med. 2013;5(200):200ra116.

2014;20(19):5064–74.

30. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH,

18. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ,

et al. Myeloid‐derived suppressor cel s enhance stem-

Minato N, et al. Differential expression of PD‐L1 and

ness of cancer cel s by inducing microRNA101 and sup-

PD‐L2, ligands for an inhibitory receptor PD‐1, in the

pressing the corepressor CtBP2. Immunity. 2013;39(3):

cel s of lymphohematopoietic tissues. Immunology

611–21.

Letters. 2002;84(1):57–62.

31. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK,

19. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M,

Syrigos KN, Sznol M, et al. Programmed death ligand‐1

Tanno Y, et al. Expression of programmed death 1

expression in non‐small cell lung cancer. Laboratory

ligands by murine T cel s and APC. Journal of

Investigation. 2014;94(1):107–16.

Immunology. 2002;169(10):5538–45.

32. Maute RL, Gordon SR, Mayer AT, McCracken MN,

20. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai

Natarajan A, Ring NG, et al. Engineering high‐affinity

SI, et al. B7‐DC, a new dendritic cell molecule with

PD‐1 variants for optimized immunotherapy and

potent costimulatory properties for T cel s. Journal of

immuno‐PET imaging. Proceedings of the National

Experimental Medicine. 2001;193(7):839–46.

Academy of Sciences of the United States of America.

21. Zou W, Chen L. Inhibitory B7‐family molecules in the

2015;112(47):E6506–14.

tumour microenvironment. Nature Reviews Immunology. 33. Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in 2008;8(6):467–77.

cytotoxic T‐lymphocyte antigen 4 and cancer: the

22. Taube JM, Anders RA, Young GD, Xu H, Sharma R,

dialectical nature of subtle human immune dysregula-

McMiller TL, et al. Colocalization of inflammatory

tion. Cancer Research. 2009;69(15):6011–4.

response with B7‐H1 expression in human melanocytic 34. Lima L, Oliveira D, Ferreira JA, Tavares A, Cruz R, lesions supports an adaptive resistance mechanism of

Medeiros R, et al. The role of functional polymorphisms

immune escape. Science Translational Medicine.

in immune response genes as biomarkers of bacille

2012;4(127):127ra37–ra37.

Calmette‐Guerin (BCG) immunotherapy outcome in

23. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS,

bladder cancer: establishment of a predictive profile in a

Wang H, et al. PD‐L1 expression in the Merkel cell carci-

Southern Europe population. BJU international.

noma microenvironment: association with inflamma-

2015;116(5):753–63.

tion, Merkel cell polyomavirus and overall survival. 35. Breunis WB, Tarazona‐Santos E, Chen R, Kiley M, Cancer Immunology Research. 2013;1(1):54–63.

Rosenberg SA, Chanock SJ. Influence of cytotoxic T lym-

24. Zou W, Wolchok JD, Chen L. PD‐L1 (B7‐H1) and PD‐1

phocyte‐associated antigen 4 (CTLA4) common polymor-

pathway blockade for cancer therapy: mechanisms,

phisms on outcome in treatment of melanoma patients

response biomarkers, and combinations. Sci Transl Med.

with CTLA‐4 blockade. Journal of Immunotherapy

2016;8(328):328rv4.

(Hagerstown, Md: 1997). 2008;31(6):586–90.

25. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, 36. Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli Gordon MS, et al. Predictive correlates of response to the

P, Ascierto PA, et al. Association of CTLA‐4 polymor-

anti‐PD‐L1 antibody MPDL3280A in cancer patients.

phisms with improved overall survival in melanoma

Nature. 2014;515(7528):563–7.

patients treated with CTLA‐4 blockade: a pilot study.

26. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Cancer Investigation. 2013;31(5):336–45.

et al. MPDL3280A (anti‐PD‐L1) treatment leads to 37. Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, clinical activity in metastatic bladder cancer. Nature.

Vymetalkova V, et al. Single nucleotide polymorphisms

2014;515(7528):558–62.

within interferon signaling pathway genes are associated

27. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner

with colorectal cancer susceptibility and survival. PloS

EM, Taube JM, et al. The vigorous immune microenvi-

One. 2014;9(10):e111061.

248 Immunotherapy in Translational Cancer Research 38. Singh V, Jaiswal PK, Kapoor R, Kapoor R, Mittal RD. 49. Khaled YS, Ammori BJ, Elkord E. Myeloid‐derived Impact of chemokines CCR532, CXCL12G801A, and

suppressor cel s in cancer: recent progress and pros-

CXCR2C1208T on bladder cancer susceptibility in

pects. Immunology and Cell Biology. 2013;91(8):

north Indian population. Tumour Biology. 2014;35(5):

493–502.

4765–72.

50. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, et al.

39. Jafarzadeh A, Fooladseresht H, Nemati M, Assadol ahi

Increased frequency and clinical significance of mye-

Z, Sheikhi A, Ghaderi A. Higher circulating levels of

loid‐derived suppressor cel s in human colorectal carci-

chemokine CXCL10 in patients with breast cancer: eval-

noma. World Journal of Gastroenterology. 2012;18(25):

uation of the influences of tumor stage and chemokine

3303–9.

gene polymorphism. Cancer Biomarkers. 2016;16(4): 51. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, 545–54.

Argiris A, Whiteside TL. Myeloid‐derived suppressor

40. Gogas H, Dafni U, Koon H, Spyropoulou‐Vlachou M,

cell measurements in fresh and cryopreserved blood

Metaxas Y, Buchbinder E, et al. Evaluation of six CTLA‐4

samples. Journal of Immunological Methods.

polymorphisms in high‐risk melanoma patients

2012;381(1–2):14–22.

receiving adjuvant interferon therapy in the He13A/98 52. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, multicenter trial. Journal of Translational Medicine.

Mandruzzato S, et al. Myeloid‐derived suppressor cell

2010;8:108.

heterogeneity and subset definition. Current Opinion in

41. Pancoska P, Kirkwood JM, Bouros S, Spyropoulou‐

Immunology. 2010;22(2):238–44.

Vlachou M, Pectasides E, Tsoutsos D, et al. A new 53. Poschke I, Kiessling R. On the armament and appear-mathematical model for the interpretation of transla-

ances of human myeloid‐derived suppressor cel s.

tional research evaluating six CTLA‐4 polymorphisms

Clinical Immunology. 2012;144(3):250–68.

in high‐risk melanoma patients receiving adjuvant inter-

54. Martens A, Wistuba‐Hamprecht K, Foppen MG, Yuan J,

feron. PloS One. 2014;9(1):e86375.

Postow MA, Wong P, et al. Baseline peripheral blood

42. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P,

biomarkers associated with clinical outcome of advanced

Mittal RD. Association of tumour necrosis factor‐alpha

melanoma patients treated with ipilimumab. Clinical

gene (T‐1031C, C‐863A, and C‐857 T) polymorphisms

Cancer Research. 2016;22(12):2908–18.

with bladder cancer susceptibility and outcome after 55. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith bacille Calmette‐Guerin immunotherapy. BJU International.

M, Tarnanidis K, et al. Myeloid cel s and related chronic

2009;104(6):867–73.

inflammatory factors as novel predictive markers in

43. Schumacher TN, Schreiber RD. Neoantigens in cancer

melanoma treatment with ipilimumab. Clinical Cancer

immunotherapy. Science. 2015;348(6230):69–74.

Research. 2015;21(24):5453–9.

44. Robbins PF, Lu YC, El‐Gamil M, Li YF, Gross C, Gartner 56. Zhu J, Paul WE. CD4 T cel s: fates, functions, and faults.

J, et al. Mining exomic sequencing data to identify

Blood. 2008;112(5):1557–69.

mutated antigens recognized by adoptively transferred 57. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka tumor‐reactive T cel s. Nature Medicine. 2013;19(6):

M, et al. Reciprocal developmental pathways for the gen-

747–52.

eration of pathogenic effector TH17 and regulatory

45. Dudley ME, Roopenian DC. Loss of a unique tumor

T cel s. Nature. 2006;441(7090):235–8.

antigen by cytotoxic T lymphocyte immunoselection 58. Whiteside TL. Clinical impact of regulatory T cel s from a 3‐methylcholanthrene‐induced mouse sarcoma

(Treg) in cancer and HIV. Cancer Microenvironment.

reveals secondary unique and shared antigens. Journal

2015;8(3):201–7.

of Experimental Medicine. 1996;184(2):441–7.

59. Whiteside TL. Regulatory T cell subsets in human can-

46. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder cer: are they regulating for or against tumor progres-D, Gronroos E, et al. Intratumor heterogeneity and

sion? Cancer Immunology, Immunotherapy.

branched evolution revealed by multiregion sequencing.

2014;63(1):67–72.

New England Journal of Medicine. 2012;366(10): 60. Disis ML, Stanton SE. Can immunity to breast cancer 883–92.

eliminate residual micrometastases? Clinical Cancer

47. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O,

Research. 2013;19(23):6398–403.

Nishihara R, et al. Genomic correlates of immune‐cell 61. Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe infiltrates in colorectal carcinoma. Cell Reports. 2016.

K, Suzuki S, et al. Effects of PSK on T and dendritic cel s

48. McGranahan N, Furness AJ, Rosenthal R, Ramskov S,

differentiation in gastric or colorectal cancer patients.

Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell

Anticancer Research. 2005;25(1b):443–9.

immunoreactivity and sensitivity to immune checkpoint 62. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prog-blockade. Science. 2016;351(6280):1463–9.

nostic value of FoxP3+ tumor‐infiltrating lymphocytes

CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 249

in cancer: a critical review of the literature. Clinical

essential for eradicating advanced B‐cell lymphoma after

Cancer Research. 2012;18(11):3022–9.

chemotherapy. Blood. 2012;120(11):2229–39.

63. Whiteside TL. Induced regulatory T cel s in inhibitory 75. Phan‐Lai V, Dang Y, Gad E, Childs J, Disis ML. The microenvironments created by cancer. Expert Opinion

antitumor efficacy of IL2/IL21‐cultured polyfunctional

on Biological Therapy. 2014;14(10):1411–25.

neu‐specific T cel s is TNFalpha/IL17 dependent.

64. Whiteside TL, Jackson EK. Adenosine and prosta-

Clinical Cancer Research. 2016;22(9):2207–16.

glandin e2 production by human inducible regulatory T 76. Datta J, Fracol M, McMil an MT, Berk E, Xu S, Goodman cel s in health and disease. Frontiers in Immunology.

N, et al. Association of depressed anti‐HER2 T‐helper

2013;4:212.

type 1 response with recurrence in patients with com-

65. Disis ML. Immune regulation of cancer. Journal of

pletely treated HER2‐positive breast cancer: role for

Clinical Oncology. 2010;28(29):4531–8.

immune monitoring. JAMA Oncology. 2016;2(2):

66. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM,

242–6.

Caraco C, Curvietto M, et al. Immunological and 77. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, biological changes during ipilimumab treatment and

Sun J, et al. Preoperative CTLA‐4 blockade: tolerability

their potential correlation with clinical response and

and immune monitoring in the setting of a presurgical

survival in patients with advanced melanoma. Cancer

clinical trial. Clinical Cancer Research. 2010;

Immunology, Immunotherapy. 2014;63(7):675–83.

16(10):2861–71.

67. Disis ML, Dang Y, Coveler AL, Marzbani E, Kou ZC, 78. Wimmers F, Aarntzen EH, Duiveman‐deBoer T, Figdor Childs JS, et al. HER‐2/neu vaccine‐primed autologous

CG, Jacobs JF, Tel J, et al. Long‐lasting multifunctional

T‐cell infusions for the treatment of advanced stage

CD8 T cell responses in end‐stage melanoma patients

HER‐2/neu expressing cancers. Cancer Immunology,

can be induced by dendritic cell vaccination.

Immunotherapy. 2014;63(2):101–9.

Oncoimmunology. 2016;5(1): e1067745.

68. Ling V, Wu PW, Finnerty HF, Bean KM, Spaulding V, 79. Mori A, Deola S, Xumerle L, Mijatovic V, Malerba G, Fouser LA, et al. Cutting edge: identification of GL50, a

Monsurro V. Next generation sequencing: new tools in

novel B7‐like protein that functional y binds to ICOS

immunology and hematology. Blood Research.

receptor. Journal of Immunology. 2000;164(4):1653–7.

2013;48(4):242–9.

69. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, 80. Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP.

Galbraith S, et al. Ipilimumab increases activated T cel s

IMGT/JunctionAnalysis: the first tool for the analysis of

and enhances humoral immunity in patients with

the immunoglobulin and T cell receptor complex V‐J

advanced melanoma. Journal of Immunotherapy.

and V‐D‐J JUNCTIONs. Bioinformatics. 2004;20(Suppl

2012;35(1):89–97.

1):i379–85.

70. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso 81. Kirsch I, Vignali M, Robins H. T‐cell receptor profiling P, et al. CTLA‐4 blockade increases IFNgamma‐proin cancer. Molecular Oncology. 2015;9(10):2063–70.

ducing CD4 + ICOShi cel s to shift the ratio of effector to 82. Warren RL, Freeman JD, Zeng T, Choe G, Munro S, regulatory T cel s in cancer patients. Proceedings of the

Moore R, et al. Exhaustive T‐cell repertoire sequencing

National Academy of Sciences of the United States of

of human peripheral blood samples reveals signatures of

America. 2008;105(39):14987–92.

antigen selection and a directly measured repertoire size

71. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM,

of at least 1 million clonotypes. Genome Research.

Khaira D, Soulieres D, et al. Tremelimumab in

2011;21(5):790–7.

combination with exemestane in patients with advanced 83. Benichou J, Ben‐Hamo R, Louzoun Y, Efroni S. Rep‐Seq: breast cancer and treatment‐associated modulation of

uncovering the immunological repertoire through next‐

inducible costimulator expression on patient T cel s.

generation sequencing. Immunology. 2012;135(3):183–91.

Clinical Cancer Research. 2010;16(13):3485–94.

84. Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J,

72. Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D,

Williamson DW, Carlson CS, et al. High‐throughput

et al. Biomarkers on melanoma patient T cel s associated

sequencing of T‐cell receptors reveals a homogeneous

with ipilimumab treatment. Journal of Translational

repertoire of tumour‐infiltrating lymphocytes in ovarian

Medicine. 2012;10:146.

cancer. Journal of Pathology. 2013;231(4):433–40.

73. Calabro L, Maio M. Immune checkpoint blockade in 85. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor malignant mesothelioma: a novel therapeutic strategy

EJ, Robert L, et al. PD‐1 blockade induces responses by

against a deadly disease? Oncoimmunology. 2014;3(1):

inhibiting adaptive immune resistance. Nature.

e27482.

2014;515(7528):568–71.

74. Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, 86. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner Munn DH, et al. Polyfunctional CD4(+) T cel s are

M, Obenauf AC, et al. Spatiotemporal dynamics of

250 Immunotherapy in Translational Cancer Research intratumoral immune cel s reveal the immune landscape 100. Seder RA, Darrah PA, Roederer M. T‐cell quality in in human cancer. Immunity. 2013;39(4):782–95.

memory and protection: implications for vaccine

87. Ulloa‐Montoya F, Louahed J, Dizier B, Gruselle O,

design. Nature Reviews Immunology. 2008;

Spiessens B, Lehmann FF, et al. Predictive gene signature

8(4):247–58.

in MAGE‐A3 antigen‐specific cancer immunotherapy. 101. McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Journal of Clinical Oncology. 2013;31(19):2388–95.

Odunsi K, et al. A harmonized approach to intracel-

88. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M,

lular cytokine staining gating: Results from an interna-

Slingluff C, et al. Chemokine expression in melanoma

tional multiconsortia proficiency panel conducted by

metastases associated with CD8+ T‐cell recruitment.

the Cancer Immunotherapy Consortium (CIC/CRI).

Cancer Research. 2009;69(7):3077–85.

Cytometry Part A. 2013;83(8):728–38.

89. Wang C, Gong B, Bushel PR, Thierry‐Mieg J, Thierry‐

102. Keustermans GC, Hoeks SB, Meerding JM, Prakken BJ,

Mieg D, Xu J, et al. The concordance between RNA‐seq

de Jager W. Cytokine assays: an assessment of the prep-

and microarray data depends on chemical treatment and

aration and treatment of blood and tissue samples.

transcript abundance. Nature Biotechnology. 2014;

Methods. 2013;61(1):10–7.

32(9):926–32.

103. Michelin MA, Montes L, Nomelini RS, Trovo MA,

90. Richard AC, Lyons PA, Peters JE, Biasci D, Flint SM, Lee Murta EF. Helper T lymphocyte response in the

JC, et al. Comparison of gene expression microarray data

peripheral blood of patients with intraepithelial neo-

with count‐based RNA measurements informs microar-

plasia submitted to immunotherapy with pegylated

ray interpretation. BMC Genomics. 2014;15:649.

interferon‐alpha. International Journal of Molecular

91. Fan HC, Fu GK, Fodor SP. Expression profiling.

Sciences. 2015;16(3):5497–509.

Combinatorial labeling of single cel s for gene expres-

104. Altman JD, Moss PA, Goulder PJ, Barouch DH,

sion cytometry. Science. 2015;347(6222):1258367.

McHeyzer‐Williams MG, Bell JI, et al. Phenotypic

92. Linsley PS, Speake C, Whalen E, Chaussabel D. Copy

analysis of antigen‐specific T lymphocytes. Science.

number loss of the interferon gene cluster in melanomas

1996;274(5284):94–6.

is linked to reduced T cell infiltrate and poor patient 105. Wooldridge L, Lissina A, Cole DK, van den Berg HA, prognosis. PloS One. 2014;9(10):e109760.

Price DA, Sewell AK. Tricks with tetramers: how to get

93. Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S,

the most from multimeric peptide‐MHC. Immunology.

Dudley ME, et al. CXCR3/CCR5 pathways in metastatic

2009;126(2):147–64.

melanoma patients treated with adoptive therapy and 106. Klenerman P, Cerundolo V, Dunbar PR. Tracking interleukin‐2. British Journal of Cancer. 2013;109(9):

T cel s with tetramers: new tales from new tools.

2412–23.

Nature Reviews Immunology. 2002;2(4):263–72.

94. Kalyuzhny AE. Membrane microplates for one‐ and 107. Newell EW, Sigal N, Nair N, Kidd BA, Greenberg HB, two‐color ELISPOT and FLUOROSPOT assays.

Davis MM. Combinatorial tetramer staining and mass

Methods in Molecular Biology. 2015;1312:435–47.

cytometry analysis facilitate T‐cell epitope mapping and

95. Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs

characterization. Nature Biotechnology. 2013;31(7):

J, et al. Elimination of IL‐10‐inducing T‐helper epitopes

623–9.

from an IGFBP‐2 vaccine ensures potent antitumor 108. Lissina A, Ladell K, Skowera A, Clement M, Edwards activity. Cancer Research. 2014;74(10):2710–8.

E, Seggewiss R, et al. Protein kinase inhibitors substan-

96. Zisakis A, Piperi C, Themistocleous MS, Korkolopoulou

tial y improve the physical detection of T‐cel s with

P, Boviatsis EI, Sakas DE, et al. Comparative analysis of

peptide‐MHC tetramers. Journal of Immunological

peripheral and localised cytokine secretion in glioblas-

Methods. 2009;340(1):11–24.

toma patients. Cytokine. 2007;39(2):99–105.

109. Cohen CJ, Gartner JJ, Horovitz‐Fried M, Shamalov K,

97. Lehmann PV, Zhang W. Unique strengths of ELISPOT

Trebska‐McGowan K, Bliskovsky VV, et al. Isolation of

for T cell diagnostics. Methods in Molecular Biology.

neoantigen‐specific T cel s from tumor and peripheral

2012;792:3–23.

lymphocytes. Journal of Clinical Investigation.

98. Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers

2015;125(10):3981–91.

TJ. ELISPOT assay for monitoring cytotoxic T lympho-

110. Laugel B, van den Berg HA, Gostick E, Cole DK,

cytes (CTL) activity in cancer vaccine clinical trials.

Wooldridge L, Boulter J, et al. Different T cell receptor

Cel s. 2012;1(2):111–26.

affinity thresholds and CD8 coreceptor dependence

99. Brown DM. Cytolytic CD4 cel s: Direct mediators in

govern cytotoxic T lymphocyte activation and tetramer

infectious disease and malignancy. Cel ular Immunology.

binding properties. Journal of Biological Chemistry.

2010;262(2):89–95.

2007;282(33):23799–810.

CHAPTER 17 Immunologic Monitoring in Immuno‐Oncology 251

111. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot 120. Disis ML. Immunologic biomarkers as correlates of A, Chang KM, et al. Different affinity windows for

clinical response to cancer immunotherapy. Cancer

virus and cancer‐specific T‐cell receptors: implications

Immunology, Immunotherapy. 2011;60(3):433–42.

for therapeutic strategies. European Journal of 121. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn Immunology. 2012;42(12):3174–9.

K, Knutson KL. Delayed‐type hypersensitivity response

112. Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K,

is a predictor of peripheral blood T‐cell immunity after

Jones E, et al. Comparison of peptide‐major

HER‐2/neu peptide immunization. Clinical Cancer

histocompatibility complex tetramers and dextramers

Research. 2000;6(4):1347–50.

for the identification of antigen‐specific T cel s. 122. Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Clinical and Experimental Immunology. 2014;177(1):

Stam AG, Meijer S, et al. Skin tests predict survival

47–63.

after autologous tumor cell vaccination in metastatic

113. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G,

melanoma: experience in 81 patients. Annals of

Geyer CE, Jr., et al. Trastuzumab plus adjuvant chemo-

Oncology. 2000;11(8):965–70.

therapy for human epidermal growth factor receptor 2‐

123. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R,

positive breast cancer: planned joint analysis of overal

Gonzalez FE, et al. Prolonged survival of dendritic cell‐

survival from NSABP B‐31 and NCCTG N9831. Journal

vaccinated melanoma patients correlates with tumor‐

of Clinical Oncology. 2014;32(33):3744–52.

specific delayed type IV hypersensitivity response and

114. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen

reduction of tumor growth factor beta‐expressing T

PA, Mick R, et al. Targeting HER‐2/neu in early breast

cel s. Journal of Clinical Oncology. 2009;27(6):945–52.

cancer development using dendritic cel s with staged 124. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg interleukin‐12 burst secretion. Cancer Research.

NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring

2007;67(4):1842–52.

tumor‐specific T cel s in delayed‐type hypersensitivity

115. Ullenhag GJ, Frodin JE, Jeddi‐Tehrani M, Strigard K,

skin biopsies after dendritic cell vaccination correlates

Eriksson E, Samanci A, et al. Durable carcinoembry-

with clinical outcome. Journal of Clinical Oncology.

onic antigen (CEA)‐specific humoral and cel ular

2005;23(24):5779–87.

immune responses in colorectal carcinoma patients 125. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, vaccinated with recombinant CEA and granulocyte/

Lee PP. Profile of immune cel s in axil ary lymph nodes

macrophage colony‐stimulating factor. Clinical Cancer

predicts disease‐free survival in breast cancer. PLoS

Research. 2004;10(10):3273–81.

Medicine. 2005;2(9):e284.

116. Schmetzer O, Moldenhauer G, Riesenberg R, Pires JR, 126. Chang AY, Bhattacharya N, Mu J, Setiadi AF, Carcamo-Schlag P, Pezzutto A. Quality of recombinant protein

Cavazos V, Lee GH, et al. Spatial organization of den-

determines the amount of autoreactivity detected

dritic cel s within tumor draining lymph nodes impacts

against the tumor‐associated epithelial cell adhesion

clinical outcome in breast cancer patients. Journal of

molecule antigen: low frequency of antibodies against

Translational Medicine. 2013;11:242.

the natural protein. Journal of Immunology (Baltimore, 127. Bol ard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Md: 1950). 2005;174(2):942–52.

Hazrat Y, et al. Sustained complete responses in

117. Anderson KS, Cramer DW, Sibani S, Wal strom G,

patients with lymphoma receiving autologous cyto-

Wong J, Park J, et al. Autoantibody signature for the

toxic T lymphocytes targeting Epstein‐Barr virus latent

serologic detection of ovarian cancer. Journal of

membrane proteins. Journal of Clinical Oncology.

Proteome Research. 2015;14(1):578–86.

2014;32(8):798–808.

118. Montgomery RB, Makary E, Schiffman K, Goodell V, 128. Kristensen VN, et al. Integrated molecular profiles of Disis ML. Endogenous anti‐HER2 antibodies block

invasive breast tumors and ductal carcinoma in situ

HER2 phosphorylation and signaling through extra-

(DCIS) reveal differential vascular and interleukin sig-

cel ular signal‐regulated kinase. Cancer Research.

naling. Proceedings of the National Academy of

2005;65(2):650–6.

Sciences of the United States of America.

119. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H,

2012;109:2802–7.

Meagher TC, Hall SJ, et al. Humoral immune response 129. Datta J, et al. Anti‐HER2 CD4(+) T‐helper type 1

against nontargeted tumor antigens after treatment

response is a novel immune correlate to pathologic

with sipuleucel‐T and its association with improved

response following neoadjuvant therapy in HER2‐

clinical outcome. Clinical Cancer Research. 2015;

positive breast cancer. Breast Cancer Research.

21(16):3619–30.

2015;17:71.





CHAPTER 18

18 Cell‐Based Therapies

for Canine Cancer

Nicola J. Mason and M. Kazim Panjwani

School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA Introduction

human cancer patients and the hostile immuno-

suppressive tumor microenvironment (TME) that

Mouse models of cancer serve as the mainstay of poses a formidable barrier to effective immune-studies in tumor biology and in evaluating mediated tumor destruction. Malignancies that response to novel therapies. Studies in tumor arise spontaneously over time are immunological y xenograft and patient‐derived xenograft models edited, resulting in an accumulation of transformed using immune compromised mice have been per- cel s that are increasingly invisible to the existing T

formed to evaluate and prioritize the most prom- cell repertoire [3]. Aberrant T cell signaling and ising therapeutics to advance into human clinical exhaustion contribute to immune therapy failures trials [1]. With the advent of powerful immuno- in the human clinic [4]. Physical and functional logical strategies designed to promote antitumor barriers to cell‐mediated cytotoxicity develop as immune responses capable of inducing remission malignancies evolve, leading to immunological and preventing relapse, more complex models resistance and disease progression. Furthermore, involving genetical y engineered mouse models adverse events seen with potent immune activation and xenografts/patient‐derived xenografts in are dependent upon intact cytokine networks. In humanized mice have been developed. While order to predict more accurately the safety of these models have played an important role in immune therapies and their ability to eliminate early studies of immune‐based therapies, it is tumors and prevent relapse in the clinic, additional becoming increasingly evident that they fall short models are now needed in which malignancies in their ability to accurately predict safety and spontaneously develop in otherwise immunologi-clinical effectiveness in the human clinic [2].

cal y intact hosts.

Unlike cytotoxic agents, immune therapies exert

The domestic dog shares a close phylogenetic

their main influence on the patient’s immune relationship with man and spontaneously develops system rather than the tumor itself. Therefore, it tumors that exhibit similar clinical, biological, and follows that preclinical testing should be performed genetic features as their human counterparts [5–8].

in tumor‐bearing animals that accurately recapitu- Canine tumors develop over a compressed time late the frequently abnormal immune status of span and their natural clinical course is to develop Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

252





CHAPTER 18 Cell‐Based Therapies for Canine Cancer 253

chemoresistance and recur local y or metastasize sequencing of canine B and T cell lymphomas following therapy. Environmental factors that revealed the presence of an average of 18 nonsyn-influence cancer initiation, progression, and onymous mutations per tumor (16 nonsynony-therapeutic response are also shared by humans mous mutations for B cell lymphoma) [23], which and dogs. This is exemplified by the finding that is comparable to that identified by whole‐exome pet dogs share similarities in their microbiome sequencing of human diffuse large B cell lym-with human family members [9]. The microbiome phoma [24, 25]. Complete transcriptome analysis influences host immune responses and therefore using RNA sequencing (RNAseq) in canine inva-pet dogs and humans might be expected to respond sive transitional cell carcinoma and targeted more comparably to immunotherapies than amplification of proto‐oncogenes such as c‐kit in specific pathogen‐free mice [10, 11]. While the canine mast cell tumors have also revealed the spontaneous development of tumors in pet dogs presence of nonsynonymous mutations that may has cemented their role in the drug development serve as neoepitopes and targets for experimental pathway [12], the more recent recognition of immune therapies [23, 26, 27]. Indeed, the hypo-comparable host immune system dysfunction, thesis that canine cancers will harbor nonsynony-immunosuppressive TME, and emerging muta- mous somatic mutations and that mutational load tional burden of tumors between human and will correlate with indices of immune activity is canine patients has invigorated interest in inte- currently being explored through federal y funded grating dogs with cancer into early immunotherapy whole‐exome sequencing and RNAseq studies.

trials.

To predict whether identified, nonsynonymous

mutations are immunogenic, the binding motifs

Relevance of the canine cancer

for canine major histocompatibility complex

patient in evaluating

(MHC) class I molecules (DLA) will need to be

immunotherapies

defined and algorithms for neoepitope prediction

developed and validated. Four canine MHC class I

Tumor immunogenicity

genes that encode functional MHC complexes have

The ultimate goal of immune therapies is to gen- been identified, only one of which is highly poly-erate potent tumor‐specific cytotoxic T cell morphic (DLA‐88). Efforts to identify the binding responses and amplify a self‐propagating cycle of motifs of the commonly utilized DLA‐88 alleles are broadening antitumor immunity that will elimi- underway and have already revealed remarkable nate transformed cel s [13]. Generation of an effec- similarity between the allele‐specific peptide tive polyclonal antitumor immune response is binding motifs of DLA‐88*50101 and HLA‐A*02:01

largely dependent on the tumor harboring non- [28, 29]. These studies pave the way for tetramer synonymous somatic mutations that encode development that will improve interrogation of immunogenic neoepitopes, recognized by CD4+ canine CD8+ T cell responses to different immunoand CD8+ T cel s [14–18]. Advanced next‐genera- therapies and exploration of correlative studies to tion sequencing of multiple human tumor histol- identify predictors of immunological and clinical ogies has revealed that patients with cancers response.

harboring a high mutational burden (“hot” tumors)

are more likely to exhibit baseline tumor‐specific T The immune landscape of canine cell responses that can lead to tumor regression cancer patients and prolonged overall survival if enabled, for One of the main obstacles to achieving clinical example, through checkpoint blockade [19–22]. responses to active and passive cell‐based immu-The number of somatic mutations is a predictor of notherapies is the immunosuppressive TME that neoepitope burden, which is the single most pre- provides physical and functional barriers to effec-dictive indicator of response to immune therapy tive T cell responses in human cancer patients.

[20–22]. Extensive characterization of the muta- These functional barriers include immunosuppres-tional burden of different tumor histologies in dogs sive cell populations such as regulatory T cel s, has yet to be reported. However, whole‐exome myeloid derived suppressor cel s (MDSCs), and





254 Immunotherapy in Translational Cancer Research tumor‐associated macrophages and their inhibi- vaccination strategies that involve administration tory cytokines and enzymes such as IL‐10, TGF‐β, of autologous antigen‐presenting cel s (APCs) arginase I, iNOS2, and IDO. Furthermore, expres- loaded with tumor antigen(s) to generate tumor-sion of checkpoint regulators such as PD‐L1, specific T cel s in vivo.

LAG‐3, and TIM‐3 on tumor‐infiltrating immune

Adoptive transfer of genetical y redirected

cel s and tumor cel s substantial y inhibit the pro- T cel s that target tumor‐associated antigens has liferation and survival of tumor‐specific T cel s that produced unprecedented results in human patients frequently exhibit an exhausted phenotype.

with relapsed, refractory, hematological malig-

Although a comprehensive assessment of the nancies including chronic lymphocytic leukemia TME and immune status of canine cancer patients and acute lymphoblastic leukemia [44–47].

will require a greater arsenal of validated pheno- However, the response of solid tumors to chimeric typic markers and functional assays, reports are antigen receptor (CAR) T cel s in the clinic has beginning to emerge indicating that canine cancer been disappointing [48, 49]. This is in part due to patients exhibit similar immune system aber- the formidable immunosuppressive TME that rancies as human cancer patients and develop presents both physical and functional barriers to immunosuppressive TMEs that exhibit the same CAR T cell efficacy [48]. In addition, CAR T cell physical and functional barriers to effective immu- therapies have been associated with significant notherapy as seen in human oncology patients. morbidity and mortality due to anaphylaxis, Regulatory T cel s (CD4+,CD25+FOXP3+) [30], dramatic cytokine release, neurotoxicity, and on-MDSCs (CD11b+, CD14−, MHCII−) [31, 32], and target, off‐tumor cytotoxicity [50–54]. There are tumor‐associated macrophages have been identi- also significant challenges in making CAR T cell fied in the peripheral blood, draining lymph nodes, products from some human cancer patients and in and tumors of canine patients with lymphoma, ensuring their engraftment and persistence, osteosarcoma, glioblastoma, and mammary carci- necessary to achieve durable remissions [55]. As noma [33–41]. Furthermore, the checkpoint ligand the field advances and efforts to produce the “best PD‐L1 has been identified on the surface of canine in class” autologous or allogeneic T cel s are made, tumor cell lines and is upregulated by IFN‐γ [42, 43]. as combination approaches are explored and stratIn addition, T cell surface makers such as CD28, egies to counter the potential life‐threatening side CTLA4 and PD‐1 are being explored using species‐ effects are developed, the role that immunologi-specific and cross‐reactive antibodies to reveal the cal y intact canine patients with spontaneous presence of exhausted T cell phenotypes in canine tumors may play becomes increasingly obvious. It cancer patients ([40], unpublished data). Defining is therefore not surprising that protocols for the the immune landscape of canine cancer patients is production and use of cell‐based therapies in an active area of research and as more species‐ canine cancer patients and results of early immu-specific antibodies for identifying immune cell notherapy trials in dogs are starting to appear in phenotypes and checkpoint molecules become the literature [56–58].

available, additional comparative barriers to effec-

tive immunotherapies may be revealed.

T cell expansion protocols

The earliest attempts to develop adoptive immuno-

Cell‐based immunotherapies

therapy for dogs using ex vivo expanded lympho-

for passive adoptive transfer

cytes occurred in the early 2000s, with several

groups using solid‐phase anti-canine CD3 plus

Cell‐based therapies designed to promote antitu- recombinant human IL-2 (rhuIL‐2) to generate mor immunity can be broadly divided into two autologous, polyclonal activated lymphocytes from types: (1) passive, adoptive immunotherapy (AI) healthy and tumor‐bearing dogs [59–61].

strategies in which ex vivo expanded native or Peripheral blood mononuclear cel s (PBMCs) cul-genetical y modified lymphocytes such as tumor‐ tured with plate‐bound anti-canine CD3 in the infiltrating lymphocytes, T cel s, and NK cel s are presence of rhuIL‐2 underwent modest expansion administered to eliminate tumor, and (2) active (57‐fold) over two weeks [59]. Increases in CD8+





CHAPTER 18 Cell‐Based Therapies for Canine Cancer 255

and CD4+CD8+ lymphocytes and cytotoxic activity rhuIL‐7 and rhuIL‐15, which aims to avoid the were detected in cultured cel s at the time of harvest detrimental differentiating effects of IL‐2 and

[59]. Following the adoptive transfer of these lym- maintain more “stemlike” canine T cel s that exhibit phokine‐activated killer cel s to healthy or tumor‐ improved engraftment and persistence in vivo bearing dogs, the numbers of peripheral blood (unpublished data). Further development and vali-lymphocytes, total T cel s, and CD8+ T cel s dation of phenotypic markers for canine T cel s will increased [59, 61]. No adverse effects were seen fol- be required to confirm these effects.

lowing adoptive transfer; however, the clinical

Interestingly, while anti‐CD3/CD28 beads and

response of tumor‐bearing dogs to lymphokine‐ anti‐CD3‐loaded aAPCs produce comparable T

activated killer cel s was not reported.

cell growth from most healthy individuals, anti‐

To achieve greater T cell expansion, the K562‐ CD3/CD28 beads fail to expand T cel s from some based, artificial antigen‐presenting cell (aAPC) canine donors and patients with advanced hemato-system original y developed for human T cell logical malignancies [56]. This is consistent with expansion has been used for canine T cel s [56–58, findings of intrinsic defects in T cell activation in 62]. In this system, K562 cells genetically human patients with advanced hematological engineered to express costimulatory molecules are malignancies and results in study dropout when irradiated, loaded with agonistic anti‐CD3 anti- a T cell product cannot be generated [63].

body, and cocultured with PBMCs in the presence Interestingly, T cel s from canine lymphoma of cytokines that promote T cell growth. Using patients that fail to expand with magnetic beads K562 cel s that express huCD32 and canine CD86 can be rescued using aAPCs, although they tend to loaded with an anti-canine CD3 (clone CA17.2A12), expand less compared to T cel s from healthy dogs Panjwani et al. achieved approximately 230‐fold [56, 58]. The ability to “rescue” T cell expansion is expansion of canine CD5+ T cel s over the course of presumably attributable to soluble factors and/or two weeks in the presence of rhuIL‐2 and rhuIL‐21 contact dependent factors afforded by K562

[56]. The addition of rhuIL‐21 heavily skewed the cells, which require further investigation [56].

resulting T cell product toward a CD8 phenotype. Nevertheless, the canine data suggest that revisit-O’Connor et al. employed an agonistic anti‐human ing the use of aAPCs in human T cell product CD3 (clone OKT3) loaded onto K562 cells development might be warranted.

expressing human CD64, CD86, CD137L, and

membrane‐bound human IL‐15 for canine T cell Adoptive T cell immunotherapy expansion [58]. Despite the presence of rhuIL‐2, The efficacy of AI in canine cancer patients is just cel s from healthy dogs failed to expand. However, beginning to be explored. Using the OKT3/aAPC

addition of rhuIL‐21 and restimulation with aAPCs expansion protocol for dogs with B cell lymphoma, every 7 days led to a 399‐fold increase over the doses of up to 3 ×109 cel s/m2 were achieved from course of 36 days with a preferential outgrowth of peripheral blood lymphocytes (approximately 124-CD3+CD8+ cel s. Mata et al. used the lectin PHA in fold expansion over 28 days). Adoptive transfer of place of the anti‐CD3 OKT3 clone, with irradiated these cel s into canine patients in remission follow-K562 cel s expressing human CD80, CD83, CD86, ing induction chemotherapy prolonged tumor‐free and CD137L with rhuIL‐2 and rhuIL‐21, resulting and overall survival times compared to matched in an average 103‐fold expansion of T cel s over the controls and was associated with limited, transient course of two weeks [57].

gastrointestinal side effects [58].

In a comparable approach to human T cell

The mechanisms responsible for improved

expansion protocols currently used in AI clinical survival following adoptive transfer of poly-trials, magnetic beads conjugated to anti-canine clonal activated cells may relate to correction of CD3 (CA17.2A12) and anti-canine CD28 (5B8) altered immune status and overall restoration of have also been used to expand canine T cel s [56]. antitumor immunity [58, 61]. CD8+ T cell counts In these cultures, rhuIL‐2 and rhuIL‐21 were are decreased in both human and canine cancer employed to promote T cell expansion. Comparable patients [37, 64, 65], a situation that might arise expansion is seen when rhuIL‐2 is replaced with in part from an increased sensitivity of CD8+



256 Immunotherapy in Translational Cancer Research

T cells to tumor‐induced apoptosis [65]. have been generated from PBMCs, isolated from Adoptive transfer of expanded cel s led to an whole blood by density centrifugation [57]. In increase in circulating CD8+ T cells and contrast to humans, canine neutrophils exhibit a correction of altered CD4:CD8 ratios. comparable density to lymphocytes and mono-Additionally, tumor‐specific T cells may be cytes, and separation over a 1.077 ficoll gradient expanded in the transferred population and pro- frequently leads to considerable contamination vide temporary antitumor activity. Although of mononuclear cells with neutrophils and other CD40L expression has not been evaluated on granulocytes [68]. This leaves the possibility that expanded canine T cells, it is possible that contaminating myeloid cells might inhibit administration of CD40L+ T cel s may temporarily optimal T cell expansion, particularly in tumor-enhance CD40+ B cell target immunogenicity, bearing dogs with increased numbers of which may account for the improved survival circulating MDSCs that inhibit T cell expansion seen in this study. Indeed, constitutive expres- and function [31]. As such, improved canine T

sion of CD40L by CAR T cells is a strategy that cell expansion may be achieved from leukapher-is currently being explored to enhance the effec- esis products or negatively selected T cells.

tiveness of CD19 CAR T cells [66].

Indeed, purer canine mononuclear cell products

In general, although the techniques described can be obtained under good manufacturing to expand canine T cells provide sufficient cell practice conditions via leukapheresis using either numbers for adoptive therapy, the degree of the Cobe or Optia Spectra [69] (Figure 18.1).

expansion of T cells from healthy or tumor‐ Furthermore, purification of canine T cells by bearing dogs in these systems falls short of that negative selection can be achieved using cross-obtained in similar human culture systems. This reactive antibodies with specificities for canine may be due to suboptimal agonistic antibodies, leukocyte subsets (Figure 18.2).

intrinsic species differences, or the presence of

With established protocols now available for

contaminating immunosuppressive myeloid cells leukapheresis, negative T cell selection and aAPC

in starting cultures [67]. Indeed, unlike the gen- and magnetic bead expansion in the canine system, eration of human T cell products from negatively the stage is set for dogs to play an integral role selected peripheral T cells, canine T cell products in advancing AI strategies.

36%

105

104

CD79a

103

102

0

56%

–102

0

103

104

105

CD5

Figure 18.1 Typical canine leukapheresis product. Cells evaluated for expression of the pan canine T cell marker

were collected from a lightly sedated healthy donor dog

CD5 and the cross‐reactive B cell marker CD79a.

using an Optia Spectra apheresis unit. The product was





CHAPTER 18 Cell‐Based Therapies for Canine Cancer 257

Pre-selection

Post-selection

105

105

104

104

56%

90%

103

103

Anti-mouse lgG

102

102

0

0

–102

–102

0

103

104

105

0

103

104

105

CD5

Figure 18.2 Purification of canine T cells by negative microbeads were incubated with cells, and labeled cells were

selection. Canine peripheral blood mononuclear cells isolated removed using the MACS cell separator system (Miltenyi

by density centrifugation were labeled with antibodies

Biotec Inc., 2303 Lindbergh Street, Auburn, CA, USA 95602).

against CD11b, CD11c, CD14, and CD21. Goat anti‐mouse IgG

Pre‐selection and negatively selected cells are shown.

Genetic modification of lymphocytes

limited time) that is sufficient to evaluate safety

Many of the goals of cell therapy can be achieved or and function in vivo. For example, in the case of advanced through transient or permanent genetic CAR T cel s, transient expression of a novel target modification of the cel ular product. For example, CAR has an important safety implication when T cel s or NK cel s can be modified to redirect their being evaluated in either human or canine patients antigenic specificity via ectopic expression of for the first time.

tumor‐targeting antigen receptors; clustered regu-

Canine CAR T cel s have been generated via

larly interspaced short palindromic repeats electroporation of ex vivo expanded primary (CRISPR) or transcription activator‐like effector canine T cel s with mRNA encoding a first‐genera-nuclease (TALEN) can be used to render them tion CD20‐specific CAR. This approach led to insensitive to inhibitory signals via removal of neg- high‐efficiency, albeit transient, CAR expression ative regulators or to enable the use of allogeneic or and robust antitumor function in vitro [56]. Three even xenogenic products following the removal of infusions of CD20‐RNA CAR T cel s into a canine donor MHC and T cell receptor complexes. As patient with relapsed B cell lymphoma led to strategies to improve cell‐based cancer immuno- transient, modest antitumor effects without adverse therapies via genetic modification become more events, although antibodies developed against the advanced, their safety and efficacy in vivo are likely murine scFv following the second infusion. This to be evaluated in the canine system [70].

proof‐of‐principle study confirmed the feasibility

While most genetic modifications are designed of this platform to assess target safety in the dog to be permanent in nature, short‐term gene expres- prior to the administration of permanently redi-sion in the form of mRNA electroporation can be rected, CD20‐specific CAR T cel s.

appropriate for some aims. mRNA has been used to

An advantage of permanent genetic modifica-

deliver an antigenic payload to APCs or a CAR tion is that the modification is passed on into the to ex vivo expanded T cel s immediately prior to genome of daughter cel s, amplifying its effect over their administration in vivo. This approach pro- time; in the case of modifications that confer vides high‐efficiency gene expression (albeit for a antigen‐specificity, this mimics a quasi‐clonal





258 Immunotherapy in Translational Cancer Research expansion. Much published work in the canine adeno‐associated viruses, and the nonviral Sleeping field has focused on the use of gammaretroviruses Beauty transposon‐transposase system [81].

to permanently transduce cel s of interest. A CAR Combined with the rapid translation of CRISPR

targeting HER2 was introduced into primary technology into cancer immunotherapy in humans canine T cel s by gammaretrovirus and demon- [82], the genetic modification of canine T cel s is a strated in vitro function against osteosarcoma cell rapidly evolving field with many exciting possibil-lines [57]. Additional y, gammaretroviruses have ities and advancements on the horizon.

been used to encode the common gamma chain in

hematopoietic stem cel s (HSC) of dogs that natu- Adoptive NK cell immunotherapy ral y develop X‐linked severe combined Natural killer (NK) cel s are an attractive option for immunodeficiency (XSCID) as a model for human AI due to their natural reactivity against transgene therapy [71]. However, one of the XSCID formed cel s and intrinsic safety mechanism dogs treated with gammaretrovirus‐transduced involving MHC‐activated canonical inhibitory HSCs developed a therapy‐attributed T cell lym- receptors. Without the need for MHC presenta-phoma [72], highlighting the risk of oncogenic tion, antigen specificity, or priming, NK cel s can insertion with gammaretroviral vectors. Lentiviral be an effective monotherapy, and their effects may vectors have an increased safety profile and effi- be enhanced further through expression of a CAR.

ciently modify human T cel s. Lentiviral vectors AI with autologous and allogeneic NK cel s has have been used to modify canine HSCs [73, 74], been evaluated in clinical trials of human patients and primary T cel s (Figure 18.3) and a clinical trial with hematological malignancies, including acute evaluating lentiviral transduced CD20‐specific myeloid leukemia [83], multiple myeloma [84], CAR T cel s in canine B‐NHL (non‐Hodgkin lym- and B‐cell NHL [85], and solid tumors including phoma) patients is ongoing [75].

carcinomas [86] and brain tumors [87]. CAR NK

Additional challenges and risks associated with cel s have been investigated in vitro and in mouse permanent genetic modification of T cel s exist. models [88, 89], and a phase I/II trial targeting Self‐amplification can be a double‐edged sword, as B lymphoid malignancies with CD19‐specific the modification can unexpectedly target critical NK cel s began subject recruitment in 2017

normal host tissues [52, 76, 77]; this can be miti- (NCT3056339).

gated by testing transient mRNA expression first,

While human NK cel s are identified as

or the use of a suicide‐gene system to ablate the CD3−CD56+ with additional phenotypic markers cel s [78]. If the introduced gene is xenogenic in that include the activation receptors NKG2A, origin, it may make the cel s themselves immuno- NKG2C, NKG2D, and NKp46, the identification genic, as in the case of CARs using murine scFvs and definition of canine NK cel s are areas of triggering a host‐anti‐mouse antibody response in ongoing exploration. Due to the limited number both humans and canines [56, 79]; conversion of of specific, validated markers available, canine these genes to match the host species may be an NK cel s have been identified by the absence of important step in overcoming this barrier. Final y, markers that define other, better characterized permanent genetic modification is general y of a immune cell subsets, and by their activity.

lower efficiency than transient modification, Transcriptional profiling is confounded by the though it can take advantage of positive selection limited markers these cel s can be sorted on, and over time. As cell activation and proliferation is drawing exact parallels to human markers may be necessary or advantageous for transduction in the misleading since they may not be shared across case of gammaretroviruses or lentiviruses, respec- species (the presence of CD4 on canine granulo-tively, ongoing improvements in reagents and cytes is an example of this). Furthermore, the protocols for primary canine cell stimulation may existence of innate‐like lymphoid populations increase the efficiency of these methods and the that bridge T and NK cel s in their functions and effectiveness of treatments utilizing them.

expression patterns, such as NK T cel s, means

Other methods being explored for genetic mod- that better tools will be needed to correctly refine ification of canine cel s include foamy viruses [80], these cell populations in dogs.





(A)

250 K

250 K

250 K

10%

35%

85%

200 K

200 K

200 K

150 K

150 K

150 K

FSC

100 K

100 K

100 K

50 K

50 K

50 K

0

0

0

105

0

103

104

105

0

103

104

105

0

103

104

CAR

(B)

1.5 × 106

1.0 × 106

5.0 × 105

CAR T cell no.

0

Baseline

Post-stim1

Post-stim2

Figure 18.3 Functional canine chimeric antigen receptor (CAR) T cells generated by lentiviral transduction. A. Canine T cells expressing a CD20‐CD28‐ζ

CAR prior to antigen stimulation (left panel), one week after stimulation with the CD20‐expressing B cell line CLBL‐1 (middle panel), and one week after a second stimulation with CLBL‐1 (right panel). Plots are gated on 7AAD−CD5+ cells. B. CAR T cell numbers calculated from total cell counts and flow cytometry at baseline and one week after each stimulation with CLBL‐1 cells. FSC = forward scatter.





260 Immunotherapy in Translational Cancer Research Markers most frequently investigated for canine 4‐1BBL and membrane‐bound huIL‐21 in the NK cell identification are CD3, CD5, CD56, and presence of recombinant canine IL‐2 for three NKp46. CD3 is typical y used to identify T cel s, weeks grew ~20,000‐fold [94]. This sets the stage although CD3ε, which the anti-canine antibody for canine NK‐like cel s to be used in AI for canine clone CA17.2A12 binds, is reported to be expressed cancer patients, an endeavor that is already in human NK cel s [90]. CD5 marks a non‐B underway [98].

lineage lymphoid population in healthy canine

PBMCs, with positive cel s splitting into high and Preconditioning regimes for stem low expressers. The CD5low population has been cell transplant and adoptive cell described as CD3+, CD3−, or only expressing intra- transfer

cel ular CD3, a discrepancy that could be attributed Studies to determine the optimal preconditioning to differences in staining technique; however, regime for successful engraftment of bone marrow this subset is uniformly CD8+ [91–94], larger allotransplants were initial y performed in research than CD3+CD5hi cel s and contains prominent dogs and employed intensive myeloablative chemo-cytoplasmic granules consistent with NK cell mor- radiation that was associated with significant morphology [91]. Furthermore, these cel s express high bidity and mortality in dogs and humans.

levels of NK cell–related receptors and demon-

Unfortunately, the toxic effects of high‐dose

strate cytotoxic activity against MHC‐negative chemoradiation for myeloablation prevented canine thyroid adenocarcinoma cel s [91–93]. elderly patients and those in critical condition While a cross‐reactive mouse antihuman CD56 from undergoing allogeneic transplant. Therefore, antibody (clone MOC‐1) has been reported [95, less toxic, nonmyeloablative regimes were devel-96], validation of its specificity is lacking [91–93, oped and tested in dogs for their ability to support 97]. Canine NKp46 has been detected using a successful stem cell engraftment [99]. Clinically cross‐reactive anti-bovine antibody (clone AKS6) applicable preconditioning regimes that involve

[97] or a canine‐specific antibody (clone 48a) [94]; total‐body irradiation (TBI) and/or the cytotoxic in both cases, CD3+NKp46+ and CD3−NKp46+ agents cyclophosphamide, busulfan, and pento-populations were identified. NKp46+CD3− cel s statin promote successful autologous and identified by clone 48a showed cytolytic activity allogeneic hematopoietic stem cell transplant in against osteosarcoma cell lines beyond that of healthy dogs and dogs with lymphoma [100–

donor‐matched CD3+ T cel s. Interestingly, culture 104]. Pentostatin, a purine analog that inhibits of a CD3−NKp46− population showed that these adenosine deaminase in lymphocytes improved can be converted to CD3‐NKp46+ cel s, sugges- allogeneic donor cell engraftment when used in ting that NKp46 may mark only mature canine combination with low dose 100 cGy TBI when NK cel s [94].

compared to 100 cGy TBI alone. This suggests

Although these different NK‐like populations that it might be an agent to consider in the future are still being identified, they can be successful y for reducing the requirement of TBI [101].

expanded ex vivo using a combination of MHC‐ Likewise, another purine analog, fludarabine, negative feeder cel s and cytokines. The canine improved engraftment in human patients under-cytotoxic large granular lymphocytes reported by going HSC transplant when used in combination Shin et al. expanded ~200‐fold from PBMCs with pretransplant TBI (200cGy) and reduced the when cocultured with irradiated K562 feeder cel s need for donor leukocyte infusions to obtain expressing human 4‐1BBL and membrane‐bound graft versus tumor effect [105]. While TBI and huIL‐15 in the presence of rhuIL‐2 and rhuIL‐15 cyclophosphamide preconditioning regimes have over two weeks [93]. Greater than 85% of been widely utilized in dogs undergoing stem cell cel s in the final product were phenotypical y transplants, preconditioning regimes using fluda-CD5loCD3+CD8+TCRαβ−TCRγδ− cel s and dis- rabine either alone or in combination with TBI or played a large granular lymphocyte morphology. cyclophosphamide have not. However, given Similarly, CD3‐NKp46+ cel s cocultured with irra- that fludarabine has been used safely in dogs diated K562 feeder cel s expressing human (http://www.accessdata.fda.gov/drugsatfda_docs/





CHAPTER 18 Cell‐Based Therapies for Canine Cancer 261

nda/2008/022273s000_PharmR.pdf), it is likely Cell‐based therapies for active that combination cyclophosphamide/fludarabine immunization

(Cy/Flu) or chemoradiation (TBI/Flu) precondi-

tioning will soon be explored to promote stem Active immunization with antigen‐loaded den-cell or adoptive T cell engraftment, mimicking dritic cel s that aim to prime tumor‐specific cyto-current protocols in human adoptive T cell toxic T cell responses and establish robust memory transfer. An alternative preconditioning regime responses that will eliminate tumors and prevent that improved engraftment in dogs employed an their recurrence respectively has been an active anti‐CD44 mAb (S5) in combination with 200 area of investigation in many different cancer types.

cGy TBI [106]. The CD44 antibody was reported Similar challenges to the use of dendritic cel s to improve engraftment by eliminating marrow (DCs) in cancer therapy exist between humans and cells that survive irradiation and would otherwise canines and include obtaining sufficient DC pre-mediate rejection.

cursors for vaccine generation, standardization of

Myelosuppressive preconditioning regimes protocols to generate DCs from peripheral blood have also been used in dogs to improve engraft- or bone marrow, and difficulties in and optimal ment of genetically modified, autologous and protocol for clinical use [109, 110]. In addition, a haploidentical stem cell transplants. TBI with 200 key limitation in investigating DC therapies in cGy or 10mg/kg busulfan administered intrave- canine cancer patients is the lack of reliable markers nously as a single agent with or without to identify these cel s and their various subsets.

posttransplant immunosuppression allowed for

Canine peripheral blood and bone marrow–

long‐term engraftment of genetically modified derived DCs activated and loaded with tumor stem cell transplants in dogs [107]. In a head‐to‐ antigens have been investigated for their ability to head comparison of regimes, cyclophosphamide induce antigen‐specific T cell responses in vitro in combination with sublethal TBI led to the and in vivo. Autologous DCs pulsed with tumor greatest engraftment of genetically modified cell lysates were shown to induce CD4+ and CD8+ T

stem cells in dogs [102].

cell responses against tumor antigens when used in

Work in mouse models and in human patients healthy beagle dogs [111]. Autologous DCs fused has shown that optimal preconditioning is with allogeneic tumor cell lines induced cell‐medi-required to promote adoptively transferred T cell ated responses against common antigens shared engraftment and prevent the formation of neu- between allogeneic tumor cell lines in healthy dogs tralizing antibody and cytotoxic T cell responses [112, 113], and promoted tumor regression in dogs against genetically modified T cells that with transmissible venereal tumor [114].

express foreign proteins [108]. The addition of Adenoviral delivery of tumor antigens to ex vivo fludarabine to cyclophosphamide (Cy/Flu) pre- cultured autologous DCs induced tumor‐specific conditioning prior to adoptive transfer of immune responses in dogs with malignant mela-autologous CAR T cells led to higher levels of noma [115]. More recently, the use of CD40

IL‐7 and IL‐15, greater expansion and persis- targeted adenoviral vectors to deliver tumor tence of CD4+ and CD8+ CAR‐T cells in the antigens has also been employed in dogs and acts peripheral blood, and improved outcomes in to induce DC maturation at the time of antigen human patients with NHL compared with those delivery [116]. In each case, no serious adverse receiving Cy alone [108]. Work still continues to events or induction of autoimmunity was observed; identify the most optimal preconditioning however, the effectiveness of this approach in regime for adoptive T and NK cell transfer in canine patients has yet to be confirmed.

humans. As adoptive T and NK cell therapies are

Given the technical challenges of producing

increasingly explored in the dog, it is likely that sufficient numbers of DCs for recurrent immuni-this species will play an important role in zations, CD40‐activated B cel s have been explored performing head‐to‐head comparisons of such as an alternative APC that can be readily activated, non-myeloablative preconditioning regimes and expanded, and loaded with an antigenic payload inform future human clinical trial design.

to induce tumor‐specific immunity [117, 118].





262 Immunotherapy in Translational Cancer Research Protocols to generate CD40‐B cel s from humans an Investigational New Animal Drug file with and dogs have been described, and these cel s have the FDA and submit a Notice of Claimed been shown to stimulate antigen‐specific T cell Investigational Exemption. More information responses following transfection with RNA [117, regarding the regulatory requirements for cell-119]. CD40‐activated B cel s electroporated with based therapies in veterinary species can be found autologous tumor RNA were shown to induce at http://www.fda.gov/downloads/AnimalVeterinary/

tumor‐specific immune responses in dogs in GuidanceComplianceEnforcement/ Guidancefor-remission from B and T cell lymphoma [120]. Industry/UCM405679.pdf.

While this strategy did not prevent relapse in these

canine patients, overall survival was improved

when vaccinated patients were treated with rescue References chemotherapy, suggesting synergism between

vaccine‐induced immune responses and chemo-

1. Richmond A, Su Y. Mouse xenograft models vs GEM

therapy [120].

models for human cancer therapeutics. Dis Model Mech.

2008;1(2–3):78–82.

2. Mak IW, Evaniew N, Ghert M. Lost in translation:

Regulatory guidelines for cell‐

animal models and clinical trials in cancer treatment.

based products for animal use

Am J Transl Res. 2014;6(2):114–8.

3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.

With increasing use of cell‐based therapies in ani-

Cancer immunoediting: from immunosurveil ance to

mals, the FDA has provided guidelines for the

tumor escape. Nat Immunol. 2002;3(11):991–8.

development, manufacture, and marketing of cell‐

4. Zarour HM. Reversing T‐cell Dysfunction and

based products that “intend to diagnose, cure, mit-

Exhaustion in Cancer. Clin Cancer Res. 2016;22(8):

igate, treat, or prevent disease in animals.” The

1856–64.

5. Gordon I, Paoloni M, Mazcko C, Khanna C. The

same statutory and regulatory requirements for

Comparative Oncology Trials Consortium: using spon-

other animal drugs apply to cell‐based products for

taneously occurring cancers in dogs to inform the cancer

animal use. To be legal y marketed, these products

drug development pathway. PLoS Med. 2009;6(10):

will require an approved or conditional y approved

e1000161.

New Animal Drug Application (NADA) that 6. Knapp DW, Waters DJ. Natural y occurring cancer in pet assesses safety, effectiveness, and manufacturing

dogs: important models for developing improved cancer

quality. Genetical y engineered cell‐based products

therapy for humans. Mol Med Today. 1997;3(1):8–11.

such as CAR T cel s, APCs, and animal stem cell 7. Paoloni M, Khanna C. Translation of new cancer treat-products (ASCPs) will likely require additional

ments from pet dogs to humans. Nat Rev Cancer.

risk‐based assessments by the Center for Veterinary

2008;8(2):147–56.

Medicine before development and production. In 8. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and

most current situations, ASCPs are autologous,

humans: man and his best friend share more than com-

more than minimal y manipulated (type I) prod-

panionship. Chromosome Res. 2008;16(1):145–54.

ucts. However, with the advent of CRISPR and 9. Song SJ, Lauber C, Costello EK, Lozupone CA, TALEN technologies, it is likely that canines will be

Humphrey G, Berg‐Lyons D, et al. Cohabiting family

employed to advance the use of allogeneic and even

members share microbiota with one another and with

xenogenic ASCPs in the future.

their dogs. Elife. 2013;2:e00458.

Investigational use of cell‐based products used 10. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-solely for research purposes is allowed by the

Michaels K, Earley ZM, et al. Commensal

FDA, provided the requirements set forth in 21

Bifidobacterium promotes antitumor immunity and

CFR 511 are met. In vivo testing of cell‐based prod-

facilitates anti‐PD‐L1 efficacy. Science. 2015;350(6264):

ucts in laboratory research animals or in

1084–9.

11. Ivanov, II, Honda K. Intestinal commensal microbes as

client‐owned animal clinical trials performed in a

immune modulators. Cell Host Microbe. 2012;12(4):

research setting may, however, be subject to an

496–508.

investigational exemption. Prior to beginning trials 12. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman in client‐owned animals, sponsors should establish

ES, Adamson PC, et al. Toward a drug development path

CHAPTER 18 Cell‐Based Therapies for Canine Cancer 263

that targets metastatic progression in osteosarcoma. Clin 26. Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Cancer Res. 2014;20(16):4200–9.

Davis BW, et al. Homologous mutation to human BRAF

13. Chen DS, Mellman I. Oncology meets immunology: the

V600E Is common in natural y occurring canine bladder

cancer‐immunity cycle. Immunity. 2013;39(1):1–10.

cancer: evidence for a relevant model system and urine‐

14. Castle JC, Kreiter S, Diekmann J, Lower M, van de

based diagnostic test. Mol Cancer Res.

Roemer N, de Graaf J, et al. Exploiting the mutanome for

2015;13(6):993–1002.

tumor vaccination. Cancer Res. 2012;72(5):1081–91.

27. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC,

15. Engelhorn ME, Guevara‐Patino JA, Noffz G, Hooper

Geissler EN. Spontaneous canine mast cell tumors

AT, Lou O, Gold JS, et al. Autoimmunity and tumor

express tandem duplications in the proto‐oncogene c‐

immunity induced by immune responses to mutations

kit. Exp Hematol. 1999;27(4):689–97.

in self. Nat Med. 2006;12(2):198–206.

28. Barth SM, Schreitmuller CM, Proehl F, Oehl K, Lumpp

16. Kreiter S, Vormehr M, van de Roemer N, Diken M,

LM, Kowalewski DJ, et al. Characterization of the canine

Lower M, Diekmann J, et al. Mutant MHC class II epi-

MHC class I DLA‐88*50101 peptide binding motif as a

topes drive therapeutic immune responses to cancer.

prerequisite for canine T cell immunotherapy. PLoS

Nature. 2015;520(7549):692–6.

One. 2016;11(11):e0167017.

17. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, 29. Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F.

Uppaluri R, Magrini VJ, et al. Cancer exome analysis

Canine tumors: a spontaneous animal model of human

reveals a T‐cell‐dependent mechanism of cancer immu-

carcinogenesis. Transl Res. 2012;159(3):165–72.

noediting. Nature. 2012;482(7385):400–4.

30. Mitchell L, Dow SW, Slansky JE, Biller BJ. Induction of

18. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley

remission results in spontaneous enhancement of anti‐

ME, et al. Cancer immunotherapy based on mutation‐

tumor cytotoxic T‐lymphocyte activity in dogs with B

specific CD4+ T cel s in a patient with epithelial cancer.

cell lymphoma. Vet Immunol Immunopathol.

Science. 2014;344(6184):641–5.

2012;145(3–4):597–603.

19. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, 31. Goulart MR, Pluhar GE, Ohlfest JR. Identification of Noguchi T, et al. Checkpoint blockade cancer immuno-myeloid derived suppressor cel s in dogs with natural y

therapy targets tumour‐specific mutant antigens.

occurring cancer. PLoS One. 2012;7(3):e33274.

Nature. 2014;515(7528):577–81.

32. Sherger M, Kisseberth W, London C, Olivo‐Marston S,

20. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P,

Papenfuss TL. Identification of myeloid derived

Makarov V, Havel JJ, et al. Cancer immunology.

suppressor cel s in the peripheral blood of tumor bearing

Mutational landscape determines sensitivity to PD‐1

dogs. BMC Vet Res. 2012;8:209.

blockade in non‐small cell lung cancer. Science. 33. Estrela‐Lima A, Araujo MS, Costa‐Neto JM, Teixeira-2015;348(6230):124–8.

Carvalho A, Barrouin‐Melo SM, Cardoso SV, et al.

21. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM,

Immunophenotypic features of tumor infiltrating lym-

Desrichard A, et al. Genetic basis for clinical response to

phocytes from mammary carcinomas in female dogs

CTLA‐4 blockade in melanoma. New England Journal

associated with prognostic factors and survival rates.

of Medicine. 2014;371(23):2189–99.

BMC Cancer. 2010;10:256.

22. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, 34. Fortuna L, Relf J, Chang YM, Hibbert A, Martineau HM, Zimmer L, et al. Genomic correlates of response to

Garden OA. Prevalence of FoxP3(+) cel s in canine

CTLA‐4 blockade in metastatic melanoma. Science.

tumours and lymph nodes correlates positively with

2015;350(6257):207–11.

glucose transporter 1 expression. J Comp Pathol.

23. Elvers I, Turner‐Maier J, Swofford R, Koltookian M,

2016;155(2–3):171–80.

Johnson J, Stewart C, et al. Exome sequencing of lym-

35. Itoh H, Horiuchi Y, Nagasaki T, Sakonju I, Kakuta T,

phomas from three dog breeds reveals somatic mutation

Fukushima U, et al. Evaluation of immunological status

patterns reflecting genetic background. Genome Res.

in tumor‐bearing dogs. Vet Immunol Immunopathol.

2015;25(11):1634–45.

2009;132(2–4):85–90.

24. de Miranda NF, Georgiou K, Chen L, Wu C, Gao Z, 36. Mucha J, Majchrzak K, Taciak B, Hellmen E, Krol M.

Zaravinos A, et al. Exome sequencing reveals novel muta-

MDSCs mediate angiogenesis and predispose canine

tion targets in diffuse large B‐cell lymphomas derived from

mammary tumor cel s for metastasis via IL‐28/IL‐28RA

Chinese patients. Blood. 2014;124(16):2544–53.

(IFN‐lambda) signaling. PLoS One. 2014;9(7):e103249.

25. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, 37. O’Neill K, Guth A, Biller B, Elmslie R, Dow S. Changes Sougnez C, et al. Discovery and prioritization of somatic

in regulatory T cel s in dogs with cancer and associations

mutations in diffuse large B‐cell lymphoma (DLBCL) by

with tumor type. J Vet Intern Med. 2009;23(4):875–81.

whole‐exome sequencing. Proc Natl Acad Sci U S A. 38. Pinheiro D, Chang YM, Bryant H, Szladovits B, 2012;109(10):3879–84.

Dalessandri T, Davison LJ, et al. Dissecting the regulatory

264 Immunotherapy in Translational Cancer Research microenvironment of a large animal model of non-52. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot

Hodgkin lymphoma: evidence of a negative prognostic

CM, Rosenberg SA. Case report of a serious adverse

impact of FOXP3+ T cel s in canine B cell lymphoma.

event following the administration of T cel s transduced

PLoS One. 2014;9(8):e105027.

with a chimeric antigen receptor recognizing ERBB2.

39. Raposo T, Gregorio H, Pires I, Prada J, Queiroga FL. Prognostic Mol Ther. 2010;18(4):843–51.

value of tumour‐associated macrophages in canine mammary 53. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, tumours. Vet Comp Oncol. 2014;12(1):10–9.

Bunin NJ, et al. Chimeric antigen receptor T cel s for

40. Tagawa M, Maekawa N, Konnai S, Takagi S. Evaluation

sustained remissions in leukemia. N Engl J Med.

of costimulatory molecules in peripheral blood lympho-

2014;371(16):1507–17.

cytes of canine patients with histiocytic sarcoma. PLoS 54. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran One. 2016;11(2):e0150030.

K, et al. Efficacy and toxicity management of 19‐28z

41. Watabe A, Fukumoto S, Komatsu T, Endo Y, Kadosawa

CAR T cell therapy in B cell acute lymphoblastic leu-

T. Alterations of lymphocyte subpopulations in healthy

kemia. Sci Transl Med. 2014;6(224):224ra25.

dogs with aging and in dogs with cancer. Vet Immunol 55. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Immunopathol. 2011;142(3–4):189–200.

Loren AW, et al. Chimeric antigen receptor T cel s per-

42. Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J,

sist and induce sustained remissions in relapsed

Guth A, et al. Immune regulation of canine tumour and

refractory chronic lymphocytic leukemia. Sci Transl

macrophage PD‐L1 expression. Vet Comp Oncol. 2016.

Med. 2015;7(303):303ra139.

43. Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi 56. Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, M, Takagi S, et al. Expression of PD‐L1 on canine tumor

O’Connor CM, Powell DJ, Jr., et al. Feasibility and Safety

cel s and enhancement of IFN‐gamma production from

of RNA‐transfected CD20‐specific Chimeric Antigen

tumor‐infiltrating cel s by PD‐L1 blockade. PLoS One.

Receptor T Cel s in Dogs with Spontaneous B Cell

2014;9(6):e98415.

Lymphoma. Mol Ther. 2016;24(9):1602–14.

44. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg 57. Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent A, et al. T cel s with chimeric antigen receptors have

C, et al. Toward immunotherapy with redirected T cel s

potent antitumor effects and can establish memory in

in a large animal model: ex vivo activation, expansion,

patients with advanced leukemia. Sci Transl Med.

and genetic modification of canine T cel s. J Immunother.

2011;3(95):95ra73.

2014;37(8):407–15.

45. Porter DL, Levine BL, Kalos M, Bagg A, June CH. 58. O’Connor CM, Sheppard S, Hartline CA, Huls H, Chimeric antigen receptor‐modified T cel s in chronic

Johnson M, Pal a SL, et al. Adoptive T‐cell therapy

lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.

improves treatment of canine non‐Hodgkin lymphoma

46. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL,

post chemotherapy. Sci Rep. 2012;2:249.

Rheingold SR, et al. Chimeric antigen receptor‐modified 59. Hoshino Y, Takagi S, Osaki T, Okumura M, Fujinaga T.

T cel s for acute lymphoid leukemia. N Engl J Med.

Phenotypic analysis and effects of sequential

2013;368(16):1509–18.

administration of activated canine lymphocytes on

47. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X,

healthy beagles. J Vet Med Sci. 2008;70(6):581–8.

Cowell LG, et al. CD19‐targeted T cel s rapidly induce 60. Itoh H, Kakuta T, Kudo T, Sakonju I, Hohdatsu T, Ebina molecular remissions in adults with chemotherapy-T, et al. Bulk cultures of canine peripheral blood lym-

refractory acute lymphoblastic leukemia. Sci Transl

phocytes with solid phase anti‐CD3 antibody and

Med. 2013;5(177):177ra38.

recombinant interleukin‐2 for use in immunotherapy. J

48. Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell

Vet Med Sci. 2003;65(3):329–33.

therapy for solid tumors. Annu Rev Med. 2016.

61. Mie K, Shimada T, Akiyoshi H, Hayashi A, Ohashi F.

49. Abken H. Adoptive therapy with CAR redirected T cel s:

Change in peripheral blood lymphocyte count in dogs fol-

the challenges in targeting solid tumors. Immunotherapy.

lowing adoptive immunotherapy using lymphokine‐

2015;7(5):535–44.

activated T killer cel s combined with palliative tumor

50. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M,

resection. Vet Immunol Immunopathol. 2016;177:58–63.

Debets R, et al. Treatment of metastatic renal cell carci-

62. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela‐

noma with autologous T‐lymphocytes genetical y retar-

Rohena A, Milone MC, et al. Engineering artificial

geted against carbonic anhydrase IX: first clinical

antigen‐presenting cel s to express a diverse array of co‐

experience. J Clin Oncol. 2006;24(13):e20–2.

stimulatory molecules. Mol Ther. 2007;15(5):981–8.

51. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, 63. Fraietta JA, Beckwith KA, Patel PR, Ruel a M, Zheng Z, Liu X, et al. T cel s expressing chimeric antigen receptors

Barrett DM, et al. Ibrutinib enhances chimeric antigen

can cause anaphylaxis in humans. Cancer Immunol Res.

receptor T‐cell engraftment and efficacy in leukemia.

2013;1:26–31.

Blood. 2016;127(9):1117–27.

CHAPTER 18 Cell‐Based Therapies for Canine Cancer 265

64. Biller BJ, Guth A, Burton JH, Dow SW. Decreased ratio

clinical evaluation and management of on‐target tox-

of CD8+ T cel s to regulatory T cel s associated with

icity. Mol Ther. 2013;21(4):904–12.

decreased survival in dogs with osteosarcoma. J Vet 77. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Intern Med. 2010;24(5):1118–23.

Levine BL, Emery L, et al. Cardiovascular toxicity and

65. Whiteside TL. Apoptosis of immune cel s in the tumor

titin cross‐reactivity of affinity‐enhanced T cel s in

microenvironment and peripheral circulation of patients

myeloma and melanoma. Blood. 2013;122(6):863–71.

with cancer: implications for immunotherapy. Vaccine. 78. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, 2002;20 Suppl 4:A46–51.

Zhang M, Vera J, et al. Engineering CD19‐specific T

66. Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko

lymphocytes with interleukin‐15 and a suicide gene to

Y, van Leeuwen DG, et al. Enhancing antitumor efficacy

enhance their anti‐lymphoma/leukemia effects and

of chimeric antigen receptor T cel s through constitutive

safety. Leukemia. 2010;24(6):1160–70.

CD40L expression. Mol Ther. 2015;23(4):769–78.

79. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL,

67. Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE,

Liu X, et al. T cel s expressing chimeric antigen receptors

Sabatino M, et al. Myeloid cel s in peripheral blood

can cause anaphylaxis in humans. Cancer Immunol Res.

mononuclear cell concentrates inhibit the expansion of

2013;1(1):26–31.

chimeric antigen receptor T cel s. Cytotherapy. 80. Kiem HP, Allen J, Trobridge G, Olson E, Keyser K, 2016;18(7):893–901.

Peterson L, et al. Foamy‐virus‐mediated gene transfer

68. Wunderli PS, Felsburg PJ. An improved method for the

to canine repopulating cells. Blood. 2007;109(1):

isolation of enriched canine peripheral blood mononu-

65–70.

clear cell and peripheral blood lymphocyte preparations. 81. O’Connor CM. Chimeric antigen receptor T‐cell therapy Vet Immunol Immunopathol. 1989;20(4): 335–44.

for companion canines with spontaneous B‐cell non‐

69. Lupu M, Gooley T, Zellmer E, Graves SS, Storb R.

Hodgkin lymphoma. Mol Ther. 2013;21:S249.

Principles of peripheral blood mononuclear cell apher-

82. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex esis in a preclinical canine model of hematopoietic cell

genome editing to generate universal CAR T cel s resis-

transplantation. J Vet Intern Med. 2008;22(1):74–82.

tant to PD1 inhibition. Clin Cancer Res. 2016.

70. Mata M, Gottschalk S. Man’s best friend: utilizing natu-

83. Miller JS, Soignier Y, Panoskaltsis‐Mortari A,

ral y occurring tumors in dogs to improve chimeric

McNearney SA, Yun GH, Fautsch SK, et al. Successful

antigen receptor T‐cell therapy for human cancers. Mol

adoptive transfer and in vivo expansion of human hap-

Ther. 2016;24(9):1511–2.

loidentical NK cel s in patients with cancer. Blood.

71. Ting‐De Ravin SS, Kennedy DR, Naumann N, Kennedy

2005;105(8):3051–7.

JS, Choi U, Hartnett BJ, et al. Correction of canine 84. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair X‐linked severe combined immunodeficiency by in vivo

B, et al. Ex vivo‐expanded natural killer cel s demon-

retroviral gene therapy. Blood. 2006;107(8):3091–7.

strate robust proliferation in vivo in high‐risk relapsed

72. Kennedy DR, Hartnett BJ, Kennedy JS, Vernau W,

multiple myeloma patients. J Immunother. 2015;38(1):

Moore PF, O’Malley T, et al. Ex vivo gamma‐retroviral

24–36.

gene therapy of dogs with X‐linked severe combined 85. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, immunodeficiency and the development of a thymic T

Panoskaltsis‐Mortari A, Lindgren BR, et al. Allogeneic

cell lymphoma. Vet Immunol Immunopathol.

natural killer cel s for refractory lymphoma. Cancer

2011;142(1–2):36–48.

Immunol Immunother. 2010;59(11):1739–44.

73. Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson 86. Iliopoulou EG, Kountourakis P, Karamouzis MV, BM, Thompson J, et al. Efficient lentiviral gene transfer

Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase

to canine repopulating cel s using an overnight trans-

I trial of adoptive transfer of allogeneic natural killer

duction protocol. Blood. 2004;103(10):3710–6.

cel s in patients with advanced non‐small cell lung

74. Neff T, Gerull S, Peterson LJ, Kiem HP. Improved short‐

cancer. Cancer Immunol Immunother. 2010;59(12):

term engraftment of lentiviral y versus gammaretrovi-

1781–9.

ral y transduced allogeneic canine repopulating cel s. J 87. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz Gene Med. 2007;9(5):357–61.

PM, Sharp SL, et al. Intralesional lymphokine‐activated

75. Panjwani MK. Modeling anti‐CD20 chimeric antigen

killer cel s as adjuvant therapy for primary glioblastoma.

receptor therapy in canine B cell lymphoma patients.

J Immunother. 2009;32(9):914–9.

Seattle, WA: American Association of Immunologists; 88. Chang YH, Connolly J, Shimasaki N, Mimura K, 2016.

Kono K, Campana D. A chimeric receptor with

76. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, NKG2D specificity enhances natural killer cell

van Krimpen B, Groot C, et al. Treatment of metastatic

activation and killing of tumor cells. Cancer Res.

renal cell carcinoma with CAIX CAR‐engineered T cel s:

2013;73(6):1777–86.

266 Immunotherapy in Translational Cancer Research 89. Topfer K, Cartellieri M, Michen S, Wiedemuth R, 101. Panse JP, Storb R, Storer B, Santos EB, Wentzel C, Muller N, Lindemann D, et al. DAP12‐based activating

Sandmaier BM. Prolonged allogeneic marrow engraft-

chimeric antigen receptor for NK cell tumor immuno-

ment following nonmyeloablative conditioning using

therapy. J Immunol. 2015;194(7):3201–12.

100 cGy total body irradiation and pentostatin before

90. Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier

and pharmacological immunosuppression after trans-

LL. Ontogeny of human natural killer (NK) cel s: fetal

plantation. Transplantation. 2005;80(10):1518–21.

NK cel s mediate cytolytic function and express cyto-

102. Barquinero J, Kiem HP, von Kalle C, Darovsky B,

plasmic CD3 epsilon,delta proteins. J Exp Med.

Goehle S, Graham T, et al. Myelosuppressive condi-

1992;175(4):1055–66.

tioning improves autologous engraftment of genetical y

91. Huang YC, Hung SW, Jan TR, Liao KW, Cheng CH,

marked hematopoietic repopulating cel s in dogs.

Wang YS, et al. CD5‐low expression lymphocytes in

Blood. 1995;85(5):1195–201.

canine peripheral blood show characteristics of natural 103. Appelbaum FR, Deeg HJ, Storb R, Graham TC, killer cel s. J Leukoc Biol. 2008;84(6):1501–10.

Charrier K, Bensinger W. Cure of malignant lymphoma

92. Lin YC, Huang YC, Wang YS, Juang RH, Liao KW, Chu

in dogs with peripheral blood stem cell transplantation.

RM. Canine CD8 T cel s showing NK cytotoxic activity

Transplantation. 1986;42(1):19–22.

express mRNAs for NK cell‐associated surface 104. Willcox JL, Pruitt A, Suter SE. Autologous peripheral molecules. Vet Immunol Immunopathol. 2010;

blood hematopoietic cell transplantation in dogs with

133(2–4):144–53.

B‐cell lymphoma. J Vet Intern Med. 2012;26(5):

93. Shin DJ, Park JY, Jang YY, Lee JJ, Lee YK, Shin MG,

1155–63.

et al. Ex vivo expansion of canine cytotoxic large gran-

105. Feinstein L, Sandmaier B, Maloney D, McSweeney PA,

ular lymphocytes exhibiting characteristics of natural

Maris M, Flowers C, et al. Nonmyeloablative hemato-

killer cel s. Vet Immunol Immunopathol. 2013;153

poietic cell transplantation. Replacing high‐dose cyto-

(3–4): 249–59.

toxic therapy by the graft‐versus‐tumor effect. Ann N Y

94. Foltz JA, Somanchi SS, Yang Y, Aquino‐Lopez A,

Acad Sci. 2001;938:328–37; discussion 37–9.

Bishop EE, Lee DA. NCR1 Expression identifies canine 106. Schuening F, Storb R, Goehle S, Meyer J, Graham TC, natural killer cell subsets with phenotypic similarity to

Deeg HJ, et al. Facilitation of engraftment of DLA‐non-

human natural killer cel s. Front Immunol. 2016;7:521.

identical marrow by treatment of recipients with

95. Rutgen BC, Konig R, Hammer SE, Groiss S, Saalmuller

monoclonal antibody directed against marrow cel s

A, Schwendenwein I. Composition of lymphocyte sub-

surviving radiation. Transplantation. 1987; 44(5):

populations in normal canine lymph nodes. Vet Clin

607–13.

Pathol. 2015;44(1):58–69.

107. Bauer TR, Jr., Hai M, Tuschong LM, Burkholder TH,

96. Saalmuller A, Lunney JK, Daubenberger C, Davis W,

Gu YC, Sokolic RA, et al. Correction of the disease phe-

Fischer U, Gobel TW, et al. Summary of the animal

notype in canine leukocyte adhesion deficiency using

homologue section of HLDA8. Cell Immunol.

ex vivo hematopoietic stem cell gene therapy. Blood.

2005;236(1–2):51–8.

2006;108(10):3313–20.

97. Grondahl‐Rosado C, Bonsdorff TB, Brun‐Hansen HC, 108. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Storset AK. NCR1+ cel s in dogs show phenotypic

Robinson E, et al. Immunotherapy of non‐Hodgkin’s

characteristics of natural killer cel s. Vet Res Commun.

lymphoma with a defined ratio of CD8+ and CD4+

2015;39(1):19–30.

CD19‐specific chimeric antigen receptor‐modified T

98. Canter RJ. Combination radioimmunotherapy with

cel s. Sci Transl Med. 2016;8(355):355ra116.

adoptive NK transfer targets cancer stem cel s in canine 109. Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, models of bone and soft tissue sarcoma. J Immunother

Puntel M, et al. Human Flt3L generates dendritic cel s

Cancer. 2015;3(Suppl2):P4.

from canine peripheral blood precursors: implications

99. Mielcarek M, Sandmaier BM, Maloney DG, Maris M,

for a dog glioma clinical trial. PLoS One. 2010;5(6):

McSweeney PA, Woolfrey A, et al. Nonmyeloablative

e11074.

hematopoietic cell transplantation: status quo and 110. Mito K, Sugiura K, Ueda K, Hori T, Akazawa T, Yamate future perspectives. J Clin Immunol. 2002;22(2):70–4.

J, et al. IFN{gamma} markedly cooperates with intratu-

100. Sokolic RA, Bauer TR, Gu YC, Hai M, Tuschong LM,

moral dendritic cell vaccine in dog tumor models.

Burkholder T, et al. Nonmyeloablative conditioning

Cancer Res. 2010;70(18):7093–101.

with busulfan before matched littermate bone marrow 111. Tamura K, Arai H, Ueno E, Saito C, Yagihara H, Isotani transplantation results in reversal of the disease phenoM, et al. Comparison of dendritic cell‐mediated

type in canine leukocyte adhesion deficiency. Biol

immune responses among canine malignant cel s. J Vet

Blood Marrow Transplant. 2005;11(10):755–63.

Med Sci. 2007;69(9):925–30.

CHAPTER 18 Cell‐Based Therapies for Canine Cancer 267

112. Bird RC, Deinnocentes P, Lenz S, Thacker EE, Curiel

specific immune responses in vivo. Vaccine. 2009;

DT, Smith BF. An allogeneic hybrid‐cell fusion vaccine

27(50):7116–24.

against canine mammary cancer. Vet Immunol 117. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH.

Immunopathol. 2008;123(3–4):289–304.

RNA‐transfected CD40‐activated B cel s induce

113. Bird RC, Deinnocentes P, Church Bird AE, van Ginkel

functional T‐cell responses against viral and tumor

FW, Lindquist J, Smith BF. An autologous dendritic cell

antigen targets: implications for pediatric immunother-

canine mammary tumor hybrid‐cell fusion vaccine.

apy. Blood. 2004;103(6):2046–54.

Cancer Immunol Immunother. 2011;60(1):87–97.

118. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K,

114. Pai CC, Kuo TF, Mao SJ, Chuang TF, Lin CS, Chu RM.

Daley J, et al. CD40‐activated human B cel s: an alternative

Immunopathogenic behaviors of canine transmissible

source of highly efficient antigen presenting cel s to gen-

venereal tumor in dogs following an immunotherapy

erate autologous antigen‐specific T cel s for adoptive

using dendritic/tumor cell hybrid. Vet Immunol

immunotherapy. J Clin Invest. 1997;100(11):2757–65.

Immunopathol. 2011;139(2–4):187–99.

119. Mason NJ, Coughlin CM, Overley B, Cohen JN,

115. Gyorffy S, Rodriguez‐Lecompte JC, Woods JP, Foley R,

Mitchell EL, Colligon TA, et al. RNA‐loaded CD40‐

Kruth S, Liaw PC, et al. Bone marrow‐derived dendritic

activated B cel s stimulate antigen‐specific T‐cell

cell vaccination of dogs with natural y occurring mela-

responses in dogs with spontaneous lymphoma. Gene

noma by using human gp100 antigen. J Vet Intern Med.

Ther. 2008;15(13):955–65.

2005;19(1):56–63.

120. Sorenmo KU, Krick E, Coughlin CM, Overley B,

116. Thacker EE, Nakayama M, Smith BF, Bird RC,

Gregor TP, Vonderheide RH, et al. CD40‐activated B

Muminova Z, Strong TV, et al. A genetical y engineered

cell cancer vaccine improves second clinical remission

adenovirus vector targeted to CD40 mediates transduc-

and survival in privately owned dogs with non‐

tion of canine dendritic cel s and promotes antigen‐

Hodgkin’s lymphoma. PLoS One. 2011;6(8):e24167.





CHAPTER 19

19 Interaction between Targeted

Therapy and Immunotherapy

Peter A. Prieto1, Miles C. Andrews2, Alexandria P. Cogdil 2, and Jennifer A. Wargo2,3

1 Department of Surgery, Surgical Oncology, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY, USA

2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Clinical rationale for combining

several different molecularly targeted agents as well

targeted therapy

as immunotherapeutic approaches (Figure 19.1).

and immunotherapy

The basis for these advances hinges on a deeper

understanding of tumor genomics and antitumor

Unprecedented advances in cancer treatment have immune responses. With the advent of next‐generation been made over the last decade and melanoma is a sequencing, significant insights have been made prime example. Before 2011, there were only two into carcinogenesis and potential targets for FDA‐approved regimens for the treatment of meta­ therapy. A prime example of this is the BRAF gene, static melanoma. Neither of these agents— which is mutated in over half of melanomas [5], dacarbazine, an alkylating agent, and aldesleukin, a with a single point mutation present in the vast cytokine‐based immunotherapy—was ever shown majority of cases (V600E/K). This single point to improve overall survival over best supportive mutation leads to constitutive signaling down the care, although treatment with aldesleukin was mitogen‐activated protein kinase (MAPK) sigassociated with durable complete responses in a naling pathway, with several resultant deleterious small subset of treated patients (6%) [1]. Numerous effects, including increased proliferation and resisstrategies were tested in clinical trials during the tance to apoptosis [6]. Therapeutic agents were late 20th century, including newer cytotoxic che­ developed to specifical y target this mutation and motherapy agents and combination regimens, were tested in clinical trials with groundbreaking vaccine strategies, cytokine‐based therapies, results. The first of these agents to be FDA approved combination biochemotherapy, and adoptive cell was vemurafenib in 2011, after a phase III trial transfer; unfortunately, none of these treatment showed a higher response rate (48% vs. 5%) and strategies demonstrated a clear survival advantage improved overall survival (84% vs. 64% at six over then‐standard‐of‐care dacarbazine [2–4]. months) when compared to treatment with dacar­

However, over the past decade, eight new bazine [7]. A second inhibitor of BRAF‐V600

therapeutic regimens have been FDA approved for (dabrafenib) was FDA approved in 2013 after the treatment of metastatic melanoma, including

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

268

CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 269

Sorafenib

Olaparib

Dabrafenib + Trametinib

Cetuximab Sunitinib

Ibrutinib

Bevacizumab Vorinostat

Azacitidine

Dabrafenib

Dacarbazine

Everolimus

Trametinib

Palbociclib

Temozolomide

Vemurafenib + Cobimetinib

Gefitinib

Crizotinib

Trastuzumab Imatinib

Ruxolitinib

Vemurafenib

1980

1990

2000

2005

2010

2013

2016

Ipilimumab

Nivolumab

Interferon-α

Pembrolizumab Atezolizumab

High-dose IL-2

Talimogene laherparepvec

Nivolumab + Ipilimumab

Figure 19.1 Timeline of major initial FDA drug approvals other cancer types (green text) representing classes of

for cytotoxic or targeted therapies (top) and immunother-

agent for which emerging combination targeted + immu-

apies (bottom) focusing on agents with labeled or

notherapy roles are under active clinical investigation.

common off‐label uses in melanoma (black text) or in

demonstrating similar efficacy [8]; however, limi­ tremelimumab and ipilimumab, both of which are tations of this monotherapy approach were monoclonal antibodies directed against cytotoxic apparent with a progression‐free survival (PFS) of T‐lymphocyte antigen 4 (CTLA‐4) [25–27].

less than six months for each of these agents due to CTLA‐4 is a member of the immunoglobulin the development of therapeutic resistance via mul­ superfamily expressed on the T cell surface simitiple mechanisms [9–16]. Many of these resistance larly to the T cell costimulatory protein CD28 that mechanisms involve reactivation of the MAPK regulates T cell activation. CTLA‐4 and CD28

pathway and substantiated the addition of mitogen‐ competitively bind to B7‐1/B7‐2 on antigen-activated protein kinase kinase (MEK) inhibitors to presenting cel s to determine T cell fate, with CD28

a backbone of BRAF inhibitor monotherapy, and providing the key costimulatory signal while this combination was tested in clinical trials dem­ CTLA‐4 contributes an inhibitory signal [28].

onstrating substantial improvements in PFS [17, 18] Work in the late 1990s by multiple groups, including and overall survival (OS) [19, 20]; however, resis­ Allison and colleagues revealed that blockade of tance to therapy remains a significant issue. This CTLA‐4 binding could facilitate and potentiate phenomenon of robust responses with limited effective immune responses against tumor cel s durability in the setting of BRAF/MEK‐targeted [29]. Two large phase III trials showed a survival therapy is reminiscent of those seen with other benefit in patients with metastatic melanoma

molecularly targeted agents [21–24], thus it is an treated with ipilimumab [30, 31]. In a placebo-unfortunate unifying characteristic of this class of controlled trial by Hodi et al., 676 patients were agents in the current state.

randomly assigned to ipilimumab plus a glycopro­

Concurrent with the development of molecu­ tein 100 (gp100) vaccine, ipilimumab alone, or larly targeted therapy for the treatment of gp100 vaccine alone. Overall survival was highest melanoma was the use of a new class of immuno­ in the ipilimumab‐alone cohort at 10.1 months, therapeutic agents termed immune checkpoint with an overall objective response rate of 10.9% and inhibitors, which function by blocking key disease control rate of 28.5%; importantly, 60% of inhibitory molecules acting upon cytotoxic T cel s. patients who responded to ipilimumab alone main­

The first of these checkpoint inhibitors studied tained a significant response at two years. It was in patients with advanced melanoma were based on this first demonstration of a significant

270 Immunotherapy in Translational Cancer Research survival benefit that ipilimumab received FDA in pretreated lung cancer (2015), untreated lung approval in 2011 for the treatment of unresectable cancer (2016), and head and neck squamous cell or metastatic melanoma. In a randomized phase III cancer (2016).

clinical trial of 502 metastatic melanoma patients

Given the nonoverlapping and potential y comtreated with dacarbazine plus ipilimumab or plementary mechanisms of action of CTLA‐4

placebo, the addition of ipilimumab led to a signif­ blockade and PD‐1 blockade [39, 40], their use icantly higher overall survival than placebo together has been explored both preclinical y [41]

(11.2 months vs. 9.1 months) and durable response as well as in clinical trials [42–44], demonstrating (19.3 months vs. 8.3 months) [32].

enhanced antitumor activity in combination com­

The next major group of immune checkpoint pared with either monotherapy. In the phase III blockade agents to demonstrate significant clinical CheckMate 067 trial, over 900 treatment‐naïve benefit was antibodies targeting the programmed metastatic melanoma patients were randomly cell death protein‐1 (PD‐1) axis. PD‐1 interacts assigned to combined nivolumab (1 mg/kg every with two ligands—PD‐L1 and PD‐L2—that are three weeks) plus ipilimumab (3 mg/kg every three members of the B7‐like family of molecules [33, 34]. weeks) for four doses followed by maintenance Anti‐PD‐1 agents have been tested in numerous nivolumab (3 mg/kg every two weeks), nivolumab clinical trials, including in a phase I trial of monotherapy (3 mg/kg every two weeks), or ipili296 patients with either advanced melanoma or mumab monotherapy (3 mg/kg every three weeks other solid tumors, which included non‐small‐cell for four doses). The coprimary endpoints of this lung cancer, prostate cancer, renal cell carcinoma, trial were PFS and OS. At just over 12 months and colorectal cancer. Treatment with the mono­ median follow‐up, the median PFS with either the clonal anti‐PD‐1 antibody nivolumab was combination regimen (nivolumab plus ipilimassociated with a 28% response rate in patients umab) or nivolumab alone was superior to that with metastatic melanoma, with responses lasting with ipilimumab alone (11.5, 6.9, and 2.9 months, longer than one year in 50% of responding patients respectively). The combination of these agents was

[35]. Additional clinical trials of anti‐PD‐1 FDA approved in 2015, based on these results.

agents have been performed (NCT01295827/ However, consistent with clinical experience across NCT01704287) [36, 37], in general finding that reported cohorts, serious toxicities are more anti‐PD‐1 based therapy was associated with a

frequent with combined anti‐PD‐1 and anti‐

lower rate of grade 3 or 4 adverse events than is typ­ CTLA4 therapies than with either monotherapy ical y seen with ipilimumab. In the large phase II [42, 44]. Given these toxicities, additional combi­

KEYNOTE‐002 trial, over 500 patients with ipilim­ nations are being explored, including combinations umab‐refractory metastatic melanoma were with novel checkpoint inhibitors and cross-randomized to treatment with low‐dose pembroli­ modality regimens.

zumab (2 mg/kg every three weeks), high‐dose

Mature data on CTLA‐4 blockade suggests that

pembrolizumab (10 mg/kg every three weeks), or although overall response rates are low, these investigator‐choice chemotherapy (carboplatin responses tend to be durable [30, 32]. This also plus paclitaxel, paclitaxel, carboplatin, dacarbazine, seems to be the case with PD‐1 blockade [35], with or temozolomide) [38]. The primary endpoint of durable responses observed in a high proportion of PFS was significantly improved in both pembroli­ responders leading to a favorable “tail of the survival zumab arms compared with chemotherapy curve.” Mature data for combined CTLA‐4 and (six‐month PFS rates 34%, 38%, and 16% for pem­ PD‐1 blockade is not yet available, though it is anticbrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, ipated that the durability of responses to combination and chemotherapy, respectively) [38]. Toxicity was treatment will at least be additive when compared to limited in this trial, with the most common adverse either monotherapy. This is in stark contrast to the events including fatigue, pruritus, and rash. high response rate and limited durability in the Nivolumab and pembrolizumab received FDA context of treatment with molecularly targeted approval for use in advanced melanoma in 2014, therapy, and for patients eligible to receive either and pembrolizumab is now also approved for use option, many practicing clinicians now chose





CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 271

immunotherapy over targeted therapy in light of characterize these antigenic targets [52]. Large-these differences. Therapeutic strategies targeting scale TIL or autologous lymphocyte culture is labor additional immune checkpoints and immuno‐ and resource intensive, requires specialized facilstimulatory molecules are currently in development ities and expertise, and in the case of TIL, requires and are also being tested in clinical trials (e.g., anti‐ a suitably “resectable” lesion from which to extract LAG3—NCT01968109; anti‐GITR—NCT02697591; starting material. The gene modification of T cel s anti‐OX40—NCT02318394, NCT02315066 ± or fabrication of chimeric antigen receptors mitianti‐4‐1BB).

gates some of these logistical limitations through

Significant advances have also been made the rational design of an army of tumor‐reactive, through other immunotherapy approaches, autologous T cel s without need for surgery or the including the use of agents that can modify the unpredictable success of TIL culture [53].

tumor microenvironment to make it more immu­

Given the high response rates but overall limited

nogenic. An example of this is talimogene durability of responses to targeted therapy coupled laherparepvec (TVEC), a formulation composed of with the lower response rates but more durable a genetical y engineered oncolytic herpes virus responses to immunotherapy, there was interest expressing human granulocyte‐monocyte colony early on in empirical y combining these treatment stimulating factor (GM‐CSF). This agent has been strategies in hopes of maintaining the high response used via intratumoral injection in melanoma and rates of targeted therapy but adding the durability also in other solid tumors and was FDA approved of response observed with immunotherapeutic for the treatment of metastatic melanoma in 2015, approaches. Several trials were designed and initibased on evidence of improvement in durable ated (e.g., vemurafenib plus IL‐2—NCT01754376, responses in the phase III OPTIM trial [45]. NCT01603212, NCT01683188; vemurafenib plus Importantly, responses can be seen in synchronous ipilimumab—NCT01400451), while the scientific metastatic tumors not injected with TVEC, sug­ rationale for combining these approaches was gesting a potential abscopal effect. This and other being deeply studied.

intralesional therapies are currently being tested

across multiple tumor types—both as monother­ Effects of targeted therapy apy and in combination with strategies such as on immune responses checkpoint blockade (e.g., TVEC combinations—

NCT02263508, NCT02978625, NCT02965716; Though the early impetus to combine molecularly PV‐10 (Rose Bengal) vs. TVEC—NCT02288897; targeted approaches with immunotherapy was and CAVATAKTM combinations—NCT02307149, largely empiric, there is now a growing scientific NCT02565992).

rationale for this approach. The immune effects of

A promising form of immunotherapy in clinical molecularly targeted agents are now being elucitrials for melanoma and other cancers is adoptive dated across several cancer types, which in many cell therapy. It involves the in vitro expansion of cases may induce immunotherapy‐favorable cytotoxic T cel s with antitumor reactivity pro­ changes within tumor cel s, the stroma/microenvicured either from the tumor or from circulating ronment, immune cel s, or have overlapping effects lymphocytes, with or without gene modification. on more than one compartment in vivo. This This work in melanoma was pioneered by Steve knowledge is providing valuable insights into the Rosenberg and has been optimized over several appropriateness and potential nuances in decades [46–49], with initial trials in melanoma combining different targeted agents with immunoand recent efforts focusing on other cancer types therapeutic approaches.

[50, 51]. The success of unmodified cel ular ther­

Thus far, this concept has been most thoroughly

apies relies on enrichment of functional y activated studied in the setting of treatment with small‐molantitumor lymphocytes from either bulk tumor‐ ecule kinase inhibitors (KIs), particularly for infiltrating lymphocytes (TIL) or peripheral blood; melanoma. One of the first papers supporting the evidence suggests that these may largely recognize potential application of KIs in modulating antituneoantigens, and research continues to better mor immunity was published in 2006 [54],

272 Immunotherapy in Translational Cancer Research suggesting that oncogenic BRAF mutations were neoplasms, epigenetic modifying agents are of curassociated with immune escape in melanoma. This rently limited use as single‐modality therapies in was complemented by studies published in 2010, solid cancers. However, the use of epigenetic moddemonstrating that MAPK pathway inhibition by ifying agents to increase cancer testis antigen BRAF inhibitors in BRAF‐mutant tumors and by expression has been investigated as a potential MEK inhibitors in BRAF wild‐type tumors were means of augmenting tumor‐cell reactivity to cell-associated with a significant increase in tumor cell based immunotherapy [66, 67]. With the advent of melanoma antigen expression and enhanced immune checkpoint blockade therapies, numerous immune recognition by antigen‐specific CD8+ T combinations of immunotherapies with demethylcel s [55]. Although initial studies were performed ating agents or histone deacetylase inhibitors are in vitro and/or preclinical models, these findings now in progress to determine the potential were also validated in translational studies of

synergies between these treatment modalities

longitudinal tumor samples obtained on clinical (Table 19.1).

trials of MAPK pathway inhibitors [56, 57]. These

VEGF/VEGFR‐targeted agents have a particustudies also revealed other favorable immune larly promising role as adjunctive agents in cancer effects of BRAF ± MEK inhibitor therapy in immunotherapy by virtue of the pleiotropic effects treated patients, with a dense CD8+ T cell infiltrate of VEGF/VEGFR signaling on all cellular observed within two weeks of initiation of therapy,

components of the tumor microenvironment.

and reduced levels of immunosuppressive cyto­ Dysregulated angiogenesis producing immature, kines and VEGF in the tumor microenvironment leaky vasculature and aberrant patterns of endo[57]. Other studies also demonstrated immune‐ thelial cell adhesion molecules such as ICAM‐1, stimulatory effects of BRAF inhibitors on T cel s VCAM‐1, and E‐selectin may lead to a physical themselves [58]. Treatment with BRAF inhibitors microenvironment that is both unfavorable to may also improve immune recognition of tumor immune cell infiltration and favorable to tumor cell cel s by altering antigen processing and presenta­ dissemination [68]. Numerous studies have tion machinery [59]. Immune effects of multiple described adverse changes to regulatory T cel , KIs are now being studied across a range of cancer myeloid‐derived suppressor cel , and dendritic cell types, including both solid and liquid tumors, and populations as a consequence of overactivation of clinical trials are underway combining KI therapy the VEGF‐VEGFR pathway in cancer [69].

with immunotherapy (Table 19.1).

Importantly, inhibitors of VEGF/VEGFR pathway

In addition to KIs, other molecularly targeted signaling have been shown to induce a beneficial agents are being studied to better understand their immune infiltrate, reduce activity of immunosuppotential impact on antitumor immunity, including pressive cell populations, and produce enhanced epigenetic regulators. Diverse molecular mecha­ tumor control in preclinical models [70–73].

nisms conveying tumor cell autonomous growth Limited human clinical data of combination and survival and avoidance of immune recognition antiangiogenic agents with immune checkpoint may be influenced by epigenetic mechanisms blockade in melanoma patients supports the ratio[60, 61]. A prime example of epigenetical y regu­ nale of this combination, demonstrating both lated genes relevant to cancer immunotherapy are tolerability and beneficial immune modulation of the heterogeneous group of cancer testis antigens the tumor microenvironment [74, 75].

found aberrantly expressed across a wide variety of

While it is increasingly evident that targeted

cancer types, including melanoma, non‐small‐cell therapies may have beneficial modulatory effects lung cancer, and prostate cancer [62]. Cancer testis on tumor cel s and the tumor microenvironment, antigens are largely epigenetical y regulated by consideration must be made for the potential delemethylation and are potential y highly immuno­ terious effects of these same agents on admixed genic [63], but they have not yielded significant immune effector and regulatory cell subsets. In clinical improvements when targeted alone by melanoma, diverse effects of MAPK targeted antigen‐specific immunotherapeutic strategies agents on immune cel s have been reported. In gen[64, 65]. Similarly, despite success in hematological eral, the effects of V600‐mutation‐specific BRAF

Table 19.1 Currently recruiting clinical trials of the FDA‐approved immunotherapy agents ipilimumab, nivolumab, pembrolizumab, and atezolizumab in combination with various classes of targeted therapies, excluding combinations of strictly immunotherapeutic agents (e.g., novel checkpoint inhibitors, vaccines, cell therapies, oncolytic viruses), antibody‐drug conjugates, bispecifi c T cell engager molecules, or agents not known to have anticancer effects in addition to potential immunomodulatory synergy. Cytotoxic‐immunotherapy combinations are not included for brevity; however, immunogenic effects of traditional cytotoxic agents are known.

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

Kinase Inhibitors

MAPK pathway inhibitors

Vemurafenib

BRAFi

Pembrolizumab

NCT02818023 (I)

Melanoma

Dabrafenib + trametinib

BRAFi + MEKi

Ipilimumab + nivolumab; pembrolizumab;

NCT02224781 (III); NCT02130466 (I/II); NCT01940809

Melanoma

ipilimumab and/or nivolumab;

(I); NCT02910700 (II); NCT02625337 (II)

nivolumab; pembrolizumab

Vemurafenib + cobimetinib

BRAFi, MEKi

Atezolizumab

NCT02902029 (II); NCT01656642 (Ib)

Melanoma

Encorafenib

RAFi, MEKi

Ipilimumab + nivolumab

NCT02631447 (II)

Melanoma

(LGX818) + binimetinib

(MEK162)

Cobimetinib

MEKi

Atezolizumab

NCT02788279 (III)

Colorectal

ALK inhibitors

Crizotinib

ALK/METi

Pembrolizumab

NCT02511184 (I)

Lung

Ceritinib

ALKi

Nivolumab

NCT02393625 (I)

Lung

Alectinib or erlotinib

ALKi, EGFRi

Atezolizumab

NCT02013219 (Ib)

Lung

BTK inhibitors

Acalabrutinib (ACP196)

BTKi

Pembrolizumab

NCT02362035 (I/II)

Various

Ibrutinib

BTKi

Nivolumab

NCT02420912 (II); NCT02899078 (I/II); NCT02329847

Hematological, renal

(I/II); NCT02940301 (II)

Ibrutinib or idelalisib

BTKi, PI3K δ i

Pembrolizumab

NCT02332980 (II)

Hematological

Other Kinase Inhibitors

Defactinib

FAKi

Pembrolizumab

NCT02546531 (I)

Various

INCB054828

FGFR1/2/3i

Pembrolizumab

NCT02393248 (I/II)

Various

INCB039110 and/or

JAK1i, PI3K δ i

Pembrolizumab

NCT02646748 (I)

Various

INCB050465

Glesatinib or sitravatinib or

METi, multiKi, HDACi

Nivolumab

NCT02954991 (II)

Lung

mocetinostat

(class I/IV)

( Continued)

Table 19.1 ( Continued )

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

nintedanib

multiKi

Pembrolizumab

NCT02856425 (I)

Various

TG02

multiKi of CDKs, JAK2,

Pembrolizumab

NCT02933944 (I)

Rectal

FLT3

Cabozantinib

Multikinase inhibitor,

Nivolumab ± ipilimumab

NCT02496208 (I)

GU

MET inhibitor

TAK‐580 or TAK‐202 or

Pan‐RAFi, anti‐CCR2

Nivolumab ± ipilimumab

NCT02723006 (I)

Melanoma

vedolizumab

mAb, anti‐integrin

α 4 β 7 mAb

Imatinib

PDGFR/cKIT/BCR‐ABLi

Ipilimumab; pembrolizumab

NCT01738139 (I); NCT02812693 (I/II)

Various, melanoma

Dasatinib

SRCi

Nivolumab

NCT02819804 (I); NCT02750514 (II)

Haematological, lung

Napabucasin (BBI608)

STAT3i

Ipilimumab or nivolumab or

NCT02467361 (I/II); NCT02851004 (I/II)

Various, colorectal

pembrolizumab; pembrolizumab

TAK‐659

SYK/FLT3i

Nivolumab

NCT02834247 (I)

Various

Galunisertib

TGFBR1i

Nivolumab

NCT02423343 (I/II)

Various

ERBB Family Inhibitors/Blockers

Cetuximab

Anti‐EGFR mAb

Ipilimumab; pembrolizumab

NCT01860430 (Ib); NCT02713373 (I/II)

HN, colorectal

Necitumumab

Anti‐EGFR mAb

Pembrolizumab

NCT02451930 (I)

Lung

Sym004

Anti‐EGFR mAb

Nivolumab

NCT02924233 (I/II)

Lung

Margetuximab

Anti‐HER2 mAb

Pembrolizumab

NCT02689284 (I/II)

Gastric

Trastuzumab

Anti‐HER2 mAb

Pembrolizumab

NCT02954536 (II); NCT02901301 (I/II)

Gastric

Trastuzumab + pertuzumab

Anti‐HER2 mAb

Atezolizumab

NCT02605915 (I)

Breast

EGF816 or INC280

EGFRi, METi

Nivolumab

NCT02323126 (II)

Lung

Afatinib

ErbB1/2/4i

Pembrolizumab

NCT02364609 (I)

Lung

Antiangiogenic Agents

Vanucizumab (RO5520985)

Angiopoietin2/VEGFA

Atezolizumab

NCT01688206 (I)

Various

mAb

Bevacizumab

Anti‐VEGF mAb

Ipilimumab

NCT01950390 (II)

Melanoma

Bevacizumab

Anti‐VEGF mAb

Pembrolizumab

NCT02313272 (I); NCT02681549 (II)

Brain, lung, melanoma

Bevacizumab

Anti‐VEGF mAb

Atezolizumab

NCT02724878 (II); NCT02420821 (III); NCT02659384 (I);

Renal, ovarian, various

NCT01633970 (I); NCT02715531 (I)

Table 19.1 ( Continued )

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

Bevacizumab, gefitinib,

Anti‐VEGF mAb, EGFRi

Pembrolizumab

NCT02039674 (I/II)

Lung

nintedanib

multiKi

Pembrolizumab

NCT02856425 (I)

Various

erlotinib

TG02

multiKi of CDKs, JAK2,

Pembrolizumab

NCT02933944 (I)

Rectal

Bevacizumab + cobimetinib

Anti‐VEGF mAb, MEKi

Atezolizumab

NCT02876224 (I)

Various

FLT3

Ramucirumab

Anti‐VEGFR2 mAb

Pembrolizumab

NCT02443324 (I)

Various

Cabozantinib

Multikinase inhibitor,

Nivolumab ± ipilimumab

NCT02496208 (I)

GU

Ziv‐aflibercept

VEGF trap

Pembrolizumab

NCT02298959 (I)

Various

MET inhibitor

Axitinib

VEGF/PDGFi

Pembrolizumab

NCT02636725 (II); NCT02853331 (III)

Sarcoma, renal

TAK‐580 or TAK‐202 or

Pan‐RAFi, anti‐CCR2

Nivolumab ± ipilimumab

NCT02723006 (I)

Melanoma

Pazopanib

VEGFR/PDGFR/cKITi

Pembrolizumab

NCT02014636 (I)

Renal

vedolizumab

mAb, anti‐integrin

Lenvatinib

VEGFR1/2/3i

Pembrolizumab

NCT02501096 (Ib/II); NCT02811861 (III)

Various, renal

α 4 β 7 mAb

Sunitinib

VEGFR2/PDGFRB/cKIT/

Nivolumab

NCT02400385 (II)

Melanoma

Imatinib

PDGFR/cKIT/BCR‐ABLi

Ipilimumab; pembrolizumab

NCT01738139 (I); NCT02812693 (I/II)

Various, melanoma

FLT3i

Dasatinib

SRCi

Nivolumab

NCT02819804 (I); NCT02750514 (II)

Haematological, lung

Cancer Stem Cell Inhibitors

Napabucasin (BBI608)

STAT3i

Ipilimumab or nivolumab or

NCT02467361 (I/II); NCT02851004 (I/II)

Various, colorectal

Enoblituzumab

Anticancer stem cell

Ipilimumab; pembrolizumab

NCT02381314 (I); NCT02475213 (I)

Various

pembrolizumab; pembrolizumab

mAb

TAK‐659

SYK/FLT3i

Nivolumab

NCT02834247 (I)

Various

BBI503

Cancer stemness

Nivolumab or pembrolizumab

NCT02483247 (I/II)

Various

Galunisertib

TGFBR1i

Nivolumab

NCT02423343 (I/II)

Various

inhibitor

ERBB Family Inhibitors/Blockers

Tumor Cell Enriched Targets (+immunomodulatory effects)

Cetuximab

Anti‐EGFR mAb

Ipilimumab; pembrolizumab

NCT01860430 (Ib); NCT02713373 (I/II)

HN, colorectal

Rituximab

Anti‐CD20 mAb

Pembrolizumab

NCT02446457 (II)

Hematological

Necitumumab

Anti‐EGFR mAb

Pembrolizumab

NCT02451930 (I)

Lung

ublituximab + TGR‐1202

Anti‐CD20 mAb, PI3K δ i

Pembrolizumab

NCT02535286 (I/II)

Hematological

Sym004

Anti‐EGFR mAb

Nivolumab

NCT02924233 (I/II)

Lung

Varlilumab

Anti‐CD27 mAb

Nivolumab; atezolizumab

NCT02335918 (I/II); NCT02543645 (I/II)

Various

Margetuximab

Anti‐HER2 mAb

Pembrolizumab

NCT02689284 (I/II)

Gastric

Elotuzumab + pomalidomide

Anti‐CS1 mAb,

Nivolumab

NCT02726581 (III)

Hematological

Trastuzumab

Anti‐HER2 mAb

Pembrolizumab

NCT02954536 (II); NCT02901301 (I/II)

Gastric

immunomodulatory/

Trastuzumab + pertuzumab

Anti‐HER2 mAb

Atezolizumab

NCT02605915 (I)

Breast

antiangiogenic

EGF816 or INC280

EGFRi, METi

Nivolumab

NCT02323126 (II)

Lung

GR‐MD‐02

Galectin binding

Pembrolizumab; ipilimumab

NCT02575404 (I); NCT02117362 (I)

Melanoma

Afatinib

ErbB1/2/4i

Pembrolizumab

NCT02364609 (I)

Lung

CB‐839

Glutaminase inhibitor

Nivolumab

NCT02771626 (I/II)

Various

Antiangiogenic Agents

Cell Cycle Targets

Vanucizumab (RO5520985)

Angiopoietin2/VEGFA

Atezolizumab

NCT01688206 (I)

Various

Dinaciclib

CDK1/2/5/9i

Pembrolizumab

NCT02684617 (I)

Hematological

mAb

Abemaciclib

CDK4/6i

Pembrolizumab

NCT02779751 (II); NCT02079636 (I)

Lung, breast

Bevacizumab

Anti‐VEGF mAb

Ipilimumab

NCT01950390 (II)

Melanoma

Palbociclib

CDK4/6i

Pembrolizumab

NCT02778685 (II)

Breast

Bevacizumab

Anti‐VEGF mAb

Pembrolizumab

NCT02313272 (I); NCT02681549 (II)

Brain, lung, melanoma

DNA Repair Targets

Bevacizumab

Anti‐VEGF mAb

Atezolizumab

NCT02724878 (II); NCT02420821 (III); NCT02659384 (I);

Renal, ovarian, various

Niraparib

PARPi

Pembrolizumab

NCT02657889 (I/II)

Breast, ovarian

NCT01633970 (I); NCT02715531 (I)

Olaparib

PARPi

Pembrolizumab

NCT02861573 (I)

Prostate

Veliparib

PARPi

Nivolumab; atezolizumab

NCT02944396 (II); NCT02849496 (II)

Lung, breast

( Continued)

Table 19.1 ( Continued )

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

Epigenetic Modifiers

Azacitidine

DNMTi

Ipilimumab and/or nivolumab;

NCT02530463 (II); NCT02397720 (II); NCT02845297 (II);

Hematological

nivolumab; pembrolizumab;

NCT02508870 (I)

atezolizumab

CC‐486

DNMTi

Pembrolizumab

NCT02900560 (II)

Ovarian

Guadecitabine

DNMTi

Atezolizumab; pembrolizumab

NCT02892318 (I); NCT02901899 (II)

Haematological,

gynecological

SGI‐110

DNMTi

Ipilimumab

NCT02608437 (I)

Melanoma

Azacitidine + entinostat

DNMTi, HDACi

Nivolumab

NCT01928576 (II)

Lung

CC‐486, romidepsin

DNMTi, HDACi

Pembrolizumab

NCT02512172 (I)

Colorectal

ACY‐241

HDAC6i

Ipilimumab + nivolumab

NCT02935790 (I)

Entinostat

HDACi

Ipilimumab + nivolumab; atezolizumab;

NCT02453620 (I); NCT02708680 (II); NCT02909452 (I);

Various, breast, lung,

pembrolizumab; pembrolizumab

NCT02437136 (Ib/II)

melanoma

Epacadostat (INCB024360)

HDACi

Nivolumab; atezolizumab;

NCT02327078 (I/II); NCT02298153 (I); NCT02752074

Various, lung,

pembrolizumab; pembrolizumab;

(III); NCT02862457 (I); NCT02178722 (I/II)

melanoma

pembrolizumab

Panobinostat

HDACi

Ipilimumab

NCT02032810 (I)

Melanoma

Vorinostat

HDACi

Pembrolizumab

NCT02619253 (I/Ib); NCT02538510 (I/II); NCT02638090

Renal, GU, HN, lung,

(I/II); NCT02395627 (II)

breast

HBI‐8000

HDACi (class I)

Nivolumab

NCT02718066 (I/II)

Renal, melanoma, lung

RRx‐001

ROS‐generator, DNMTi

Nivolumab

NCT02518958 (I)

Various

Immunomodulatory Agents (diverse mechanisms)

Daratumumab + lenalidomide

Anti‐CD38 mAb,

Atezolizumab

NCT02431208 (I)

Hematological

or pomalidomide

immunomodulatory/

antiangiogenic

DS‐8273a

Anti‐TRAIL‐DR5 mAb

Nivolumab

NCT02983006 (I); NCT02991196 (I)

Melanoma, colorectal

CB‐1158

Arginase inhibitor

Nivolumab

NCT02903914 (I)

Various

GDC‐0919

IDOi

Atezolizumab

NCT02471846 (I)

Various

Indoximod

IDOi

Ipilimumab or nivolumab or

NCT02073123 (I/II)

Melanoma

pembrolizumab

ALT‐803

IL15 superagonist

Nivolumab

NCT02523469 (I/II)

Lung

Targeted Agent

Targeted Therapy Class

Immunotherapy

NCT Clinical TriaL ID# (Phase)

Tumor Type

Lenalidomide

Immunomodulatory/

Pembrolizumab; pembrolizumab;

NCT02875067 (I/II); NCT02906332 (II); NCT02903381

Hematological

antiangiogenic

nivolumab; pembrolizumab

(II); NCT02579863 (III)

Pomalidomide

Immunomodulatory/

Pembrolizumab

NCT02576977 (III)

Hematological

antiangiogenic

Motolimod + cetuximab

TLR8 agonist, anti‐EGFR mAb

Nivolumab

NCT02124850 (Ib)

HN

IMO‐2125

TLR9 agonist

Ipilimumab or pembrolizumab

NCT02644967 (I/II)

Melanoma

CSF1R Antagonists/Tumor‐Associated Macrophage Inhibitors

AMG820

Anti‐CSF1R mAb

Pembrolizumab

NCT02713529 (I/II)

Various

Cabiralizumab (FPA008)

Anti‐CSF1R mAb

Nivolumab

NCT02526017 (I)

Various

Emactuzumab (RO5509554)

Anti‐CSF1R mAb

Atezolizumab

NCT02323191 (I)

Various

ARRY‐382

CSF1Ri

Pembrolizumab

NCT02880371 (I/II)

Various

PLX3397

CSF1Ri, KITi, FLT3i

Pembrolizumab

NCT02452424 (I/II)

Various

Cytokine/Chemokine Targets

Mogamulizumab (KW‐0761)

Anti‐CCR4 mAb

Nivolumab

NCT02705105 (I/II); NCT02476123 (I); NCT02946671 (I)

Various

Ulocuplumab

Anti‐CXCR4 mAb

Nivolumab

NCT02472977 (I/II)

Various

NKTR‐214

CD122‐biased cytokine

Nivolumab

NCT02983045 (I/II)

Various

X4P‐001

CXCR4 antagonist

Pembrolizumab; nivolumab

NCT02823405 (I); NCT02923531 (I/II)

Melanoma, renal

BL‐8040

Peptide CXCR4

Pembrolizumab

NCT02907099 (II); NCT02826486 (II)

Pancreatic

antagonist

Miscellaneous Agents

CPI‐444

Adenosine A2A receptor

Atezolizumab

NCT02655822 (I/Ib)

Various

antagonist

Demcizumab

Anti‐delta‐like‐4 mAb

Pembrolizumab

NCT02722954 (Ib)

Various

(Notch ligand inhibitor)

B‐701

Anti‐FGFR3 mAb

Pembrolizumab

NCT02925533 (Ib)

GU

BMS‐986012

Anti‐fucosyl‐GM1 mAb

Nivolumab

NCT02247349 (I/II)

Lung

GS‐5745

Anti‐MMP9 mAb

Nivolumab

NCT02864381 (II)

Gastric

ATRA

Differentiation agent

Ipilimumab

NCT02403778 (II)

Melanoma

Vismodegib

Hedgehog antagonist

Pembrolizumab

NCT02690948 (II)

Skin

PT2385

HIF2α antagonist

Nivolumab

NCT02293980 (I)

Renal

CC‐122

Pleiotropic pathway modifier

Nivolumab

NCT02859324 (I/II)

Liver

Selinexor

Selective inhibitor of

Pembrolizumab

NCT02419495 (Ib)

Various

nuclear export (SINE)

Omaveloxolone (RT 408)

Triterpenoid derivative;

Ipilimumab or nivolumab

NCT02259231 (I/II)

Melanoma

modulates ROS, MDSCs





278 Immunotherapy in Translational Cancer Research inhibitors on immune cel s appears smal , while led to a high rate of significant hepatotoxicity, MEK inhibition—which is not specific for tumor apparently reflecting an immune‐potentiation of cell MEK—may have suppressive effects on prolif­ hepatotoxicity seen relatively commonly with eration, cytokine production, and antigen‐specific vemurafenib [79]. In addition to issues of toxicity, expansion of normal T lymphocytes [55, 76–78]. the timing of targeted and immune therapy may Conversely, MAPK activation acts to maintain a have clear implications for the realization of less differentiated state of dendritic cell precursors; biological synergy, in that the kinetics of tumor or thus, MAPK inhibition has been observed to pro­ immune modulation induced by the targeted mote dendritic cell maturation, which could be therapy component may not coincide with those of predicted to improve antigen presentation [76].

the immunotherapy modality applied.

A number of novel or repurposed targeted

agents are under active clinical investigation in Molecular targets multiple cancer types, combined with established of immunotherapy resistance checkpoint inhibitors such as ipilimumab,

nivolumab, pembrolizumab, and atezolizumab. Of Although treatment responses to immunotherathe numerous registered trials on clinicaltrials.gov peutic approaches are typical y long lived, a combining targeted agents with FDA‐approved significant proportion of patients who initial y checkpoint inhibitor agents (Table 19.1), targeted respond to treatment go on to experience disease agent classes include MAPK pathway inhibitors; relapse or progression. Furthermore, the lower epigenetic modifiers such as HDAC inhibitors and objective response rates to immunotherapy up demethylating agents; VEGF‐family ligand, front compared with the dramatical y high receptor, and kinase inhibitors; DNA repair mech­ response rates seen for many targeted therapies anism inhibitors such as PARP inhibitors; used in equivalent clinical settings in appropriately cyclin‐disrupting agents; multiple signaling kinase selected patients implies that a relatively high inhibitors with targets including FAK, PI3K, ALK, proportion of tumors possess mechanisms of resis­

JAK, STAT, BTK, MET, and HIF2a; ErB receptor tance to current immunotherapies even before family antagonists (e.g., EGFR, HER2); inhibitors treatment begins. Significant research efforts to of multiple growth factor ligands and receptors understand the molecular mechanisms underlying (e.g., CSF1R, FGFR3); lineage, EMT, and “stem­ both primary and secondary resistance to immuness” modulators (AXL, NANOG); modulators of notherapy have revealed several highly recurrent apoptotic regulators (SMAC‐mimetic); cytokine intratumoral cel ular adaptations to immune antagonists (TGF‐β); and multitargeted kinase attack. Importantly, many of these offer the promise inhibitors.

of defined, actionable molecular targets for which

Not only do questions remain regarding the the rationale behind combined immunotherapy optimal types of combination targeted and immune and targeted therapy regimens is strong.

therapies, but the most tolerable and efficacious

The potential for tumor cel s to essential y hide

combinations will likely vary between immuno­ from immune surveil ance is well established and therapy modality (e.g., checkpoint blockade versus arguably contributes to the historical y low rates of TIL therapy versus CAR T cell therapy, etc.). Given success with immunotherapy treatments across each targeted therapy’s unique mechanistic basis most cancer types. Poorly immunogenic tumors for potential synergy, clinical evaluation will need may be a simple selective consequence of an inito include methods to assess the optimal sequencing tial y effective—including spontaneous—antitumor of combination treatments. Although to date response, such that the most immunogenic subminimal clinical outcome data are available for clones of a tumor are eliminated first, leaving combination targeted and immune therapy, progressively less immunogenic tumor cel s surimportant lessons have already been learned viving. In this challenging scenario, the antitumor from combination toxicities. For example, the immune reaction may directly contribute to its combination of vemurafenib with ipilimumab in a own ultimate failure; however, more active methods small cohort of patients with metastatic melanoma of immune evasion may prove more amenable to

CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 279

therapeutic intervention (Figure 19.2). Micro­ function, which could be restored by pharmacologenvironmental stimuli within inflamed tumors, ical blockade of the PI3K‐AKT pathway [86].

driven by interferon (IFN) signaling, may lead to

Beyond the traditional focus on effector T cel

altered peptide processing machinery and conse­ functions in intratumoral dynamics, our quent disrupted antigen presentation, or skewed understanding of the roles played by multiple presentation of a less immunogenic epitope reper­ other cel ular subsets in dampening antitutoire (Figure 19.2). Major histocompatibility mor responses is emerging (Figure 19.2).

complex class I loss is a well‐recognized Immunosuppressive regulatory T cell populations phenomenon in preclinical and patient studies are frequently identified, typified by expression of

[80–82]; however, innate immune surveil ance of the key regulatory transcription factor FOXP3, class I–deficient cel s may combat any survival and recruited at least in part by chemokine ligands advantage conferred by this mechanism; further of CCR4 [87]. Cel ular constituents of the innate study of this phenomenon in patient samples is immune system also play immunosuppressive needed to clarify its broader relevance. Defects in roles in the tumor microenvironment, including associated antigen processing and presentation tumor‐associated macrophages and myeloid-machinery, including β‐2 microglobulin (B2M) derived suppressor cel s [88, 89]. By reducing the and TAP (transporter (1/2) ATP binding cassette immunosuppressive skewing of macrophage phesubfamily B member) (Figure 19.2), have also been notypes, blockade of the CSF1R has been shown shown to contribute to immunotherapy resistance to enhance checkpoint inhibitor immunotherapy but are likely uncommon as independent resistance responses in pancreatic adenocarcinoma models mechanisms [83].

[90]. Other potential drivers of the M2‐macrophage

Distinct from immune evasion is the more active phenotype, including eotaxin and oncostatin concept of immune exclusion, producing tumors M [91], particularly in the hypoxic tumor that are often referred to as cold or noninflamed

environment, and moderators of the cancer

due to their lack of lymphocytic infiltration. Several stem cell–macrophage interaction such as key mechanisms of immune exclusion are of gen­ milk‐fat globule–epidermal growth factor VIII eral significance due to their broad potential to (MFG‐E8), STAT3, and IL‐6 [92] may represent contribute to treatment failure across immuno­ additional modifiable molecular targets to therapy modalities (Figure 19.2). Excessive tumor sculpt an immunotherapy‐permissive microenvicell β‐catenin‐Wnt signaling in melanoma [84] and ronment. The metabolic immune checkpoint together with PPAR‐ γ and FGFR3 pathway indoleamine 2,3‐dioxygenase (IDO) may also activation in urothelial cancer [85] induce contribute to immune exclusion and immunoimmune‐unfavorable environments inherently therapy resistance through diverse effects on resistant to the entry and function of cel ular effector T cel s, regulatory T cel s, and other immune elements. Vascular remodeling and disor­ suppressive cell populations in multiple cancer ganized angiogenesis have the potential to impact types [93].

both antigen‐presenting cell efflux to secondary

Of particular relevance to the concept of the

lymphoid organs, and effector cell influx into the non–T cell inflamed tumor microenvironment is tumor. Angiogenic growth factors and their recep­ the role played by interferon signaling in immunotors are increasingly being recognized to have an therapy resistance. Importantly, the effects of even more diverse range of effects on all compo­ IFN‐γ, derived principal y from activated T cel s, nents of the tumor microenvironment, many of depends sensitively on the intensity and duration which may be profitably targeted with molecular of exposure, with an extended IFN‐γ stimulus protherapies to modulate and redirect the immune moting expression of immunosuppressive response. Immune‐unfavorable environments have molecules such as PD‐L1 itself, among more widealso been demonstrated to result from loss of PTEN spread epigenetic changes [94]. Several studies within tumor cel s, mediated by increased expres­ have demonstrated tumor cell resistance to immusion of immunosuppressive cytokines and notherapy resulting from IFN‐signaling defects, consequent reduction in T cell entry and antitumor including JAK1/2 mutations [83, 95]. The IFN

280 Immunotherapy in Translational Cancer Research Restoration of immunogenic

antigen processing

Checkpoint blockade

Vascular normalisation

Disruption of immune

Reversal of epigenetic

exclusion signals

adaptations

Regulatory cell depletion

IMMUNE

IMMUNE

RESOLUTION

RECOGNITION

ATTACK

OF IMMUNE

RESPONSE

β-catenin/Wnt

PPAR-γ

FGFR3

dysangiogenesis

Inflammatory

cytokines

Immune cell

recruitment &

Immunosuppressive

Immunoediting

activation

cell accumulation:

Treg, TAM, MDSC

Defective antigen

Negative regulatory

IFN (–

processing & presentation:

γ, –α/–β)

(checkpoint) molecule

proteasome, β2M, TAP

expression

Metabolic checkpoints

Epigenetic reprogramming

(IDO1, TDO)

Antigen loss

epithelial-mesenchymal (like) transition

Hypoxia

TUMORAL

ADAPTATION

Figure 19.2 Schematic representation of key molecular contribute to multiple resistance‐causing tumoral

resistance mechanisms identified or implicated in

adaptations (yellow shading). β2M = beta‐2‐microglobulin;

resistance to cancer immunotherapy, showing three

FGFR3 = fibroblast growth factor receptor 3; IDO = indole-

principal phases of antitumor immunity modeled on a

amine‐2,3‐dioxygenase; IFN = interferon; MDSC = myeloid‐

basic inflammatory response. Indicated by location are

derived suppressor cell; PPAR‐γ = peroxisome proliferator

classic but nonexclusive points at which resistance

activator gamma; TAM = tumor‐associated macrophage;

mechanisms emerge and/or act. Interferon responses (red

TAP = transporter (1/2) ATP binding cassette subfamily B

shading) effect diverse changes in immune, tumor, and

member; TDO = tryptophan dioxygenase; Treg = regulatory

stromal cells that may drive selection for or directly

T cell.

insensitivity that results from such mutations facil­

Increasing evidence also implicates large‐scale

itates tumor cell avoidance of IFN‐induced rewiring of gene expression, leading to broad but apoptosis and growth suppression, although it is apparently coordinate transcriptomic and phenonot yet clear how frequently such defined muta­ typic alterations contributing to immunotherapy tional resistance mechanisms occur.

resistance (Figure 19.2) [96]. Analysis of gene





CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 281

expression profiles in melanoma samples resistant developed colitis with colon perforation, with one to PD‐1 blockade revealed signatures resembling requiring surgery, and accrual to this cohort was those also seen in melanoma samples resistant to suspended [97], highlighting the complexity as well targeted therapy, and across multiple other tumor as unexpected toxicity observed in combination types within the Cancer Genome Atlas dataset. strategies.

Highly represented elements in such signatures

Another poignant combination approach

include genes involved in epithelial‐to‐mesenchymal involves the use of BRAF‐targeted therapy in (‐like) transition. While such genomic changes are combination with PD‐1 blockade. This stems not by definition multiple and summative, they may be only from the improved tolerability and safety protargetable by similarly broad strategies such as file of PD‐1 blockade compared to CTLA‐4

small‐molecule epigenomic modifiers targeting blockade, but also from evidence regarding the histone acetylation and DNA methylation.

emergence of adaptive immune resistance in the

setting of treatment with BRAF‐targeted therapy

Combining targeted therapy

such that the immunomodulatory molecule PD‐L1

with immunotherapy: Early clinical becomes highly expressed in the tumor microenviresults and caveats ronment within two weeks of initiation of therapy

[57]. Early results from such trials demonstrate

As noted, early interest in empirical y combining encouraging results with a manageable toxicity molecularly targeted therapy and immunotherapy profile and evidence of strong clinical activity [98].

was driven by the desire to unify the high response

Numerous other clinical trials are currently

rates of the former with the enhanced durability of underway combining molecularly targeted therapy responses in the latter. Two of the first clinical trials with immunotherapy for melanoma as well as initiated included vemurafenib (a BRAF inhibitor) other cancers, based on signals of synergy from in combination with ipilimumab (an anti‐CTLA‐4 preclinical studies (Table 19.1). Mature data are not antibody; NCT01400451) and in combination with available, although caveats clearly exist. One major interleukin‐2 (NCT01683188), respectively. In each issue with these types of approaches is the sheer of these trials, immunotherapy was administered number of available therapies that could be used in after a lead‐in with targeted therapy. In the combination, generating both scientific and logistrial combining vemurafenib with ipilimumab, tical difficulties in prioritizing which combinations significant dose‐limiting toxicity was noted with the to study first, and with limited resources.

development of hepatotoxicity in many of the treated Additional y, novel agents in each class are brought patients, substantiating early closure of the trial [79]. forth on a regular basis, each demanding a chance The trial combining vemurafenib with interleukin‐2 to prove their worth in combination trials. It was also closed early due to poor accrual, largely remains unclear if current preclinical models will owing to the emergence of improved therapeutic be useful in predicting the efficacy of various options for patients with metastatic melanoma.

combination strategies, yet given the bottleneck of

Since these initial trials were performed, addi­ translation to human trials, this is exactly what is tional trials have been designed based on insights needed. Another caveat pertains to timing and gained from these trials, from therapeutic advances schedule of different therapeutic agents—should in the field, and from scientific insights in preclin­ treatment be given concurrently or in sequence?

ical models and translational research studies. An And a key nuance to combination strategies (and to example of this is a trial combining the BRAF and these strategies in isolation) is a relative paucity of MEK inhibitors dabrafenib and trametinib with strong predictive biomarkers of response and resisthe immune checkpoint inhibitor ipilimumab tance. Nonetheless, combination strategies are now (NCT01767454) for patients with BRAF‐mutant becoming a standard, and it is paramount for us to metastatic melanoma. Early results reported less of understand the molecular and immune mechaan issue with hepatotoxicity (likely related to the nisms of targeted and immunotherapeutic agents use of dabrafenib rather than vemurafenib). Of alone as well as in combination in order to define note in the triplet cohort, several patients optimal therapeutic strategies.





282 Immunotherapy in Translational Cancer Research References

13. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid

AT, Miller JP, et al. Co‐clinical assessment identifies pat1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, terns of BRAF inhibitor resistance in melanoma. J Clin

Margolin K, et al. High‐dose recombinant interleukin 2

Invest. 2015;125(4):1459–70.

therapy for patients with metastatic melanoma: analysis 14. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng of 270 patients treated between 1985 and 1993. J Clin

C, Moriceau G, et al. RAF inhibitor resistance is medi­

Oncol. 1999;17(7):2105–16.

ated by dimerization of aberrantly spliced BRAF(V600E).

2. Chapman PB, Einhorn LH, Meyers ML, Saxman S,

Nature. 2011;480(7377):387–90.

Destro AN, Panageas KS, et al. Phase III multicenter 15. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, randomized trial of the Dartmouth regimen versus

Li J, Kaadige MR, et al. Response of BRAF‐mutant meladacarbazine in patients with metastatic melanoma.

noma to BRAF inhibition is mediated by a network of

J Clin Oncol. 1999;17(9):2745–51.

transcriptional regulators of glycolysis. Cancer Discov.

3. Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai

2014;4(4):423–33.

C, Testori A, et al. A randomized, controlled phase III 16. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al.

trial of nab‐Paclitaxel versus dacarbazine in chemo­

Non‐genomic and immune evolution of melanoma

therapy‐naive patients with metastatic melanoma. Ann

acquiring MAPKi resistance. Cel . 2015;162(6):1271–85.

Oncol. 2015;26(11):2267–74.

17. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G,

4. Lui P, Cashin R, Machado M, Hemels M, Corey‐Lisle PK,

Maio M, et al. Combined vemurafenib and cobimetinib in

Einarson TR. Treatments for metastatic melanoma: syn­

BRAF‐mutated melanoma. N Engl J Med. 2014;371(20):

thesis of evidence from randomized trials. Cancer Treat

1867–76.

Rev. 2007;33(8):665–80.

18. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de

5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S,

Braud F, Larkin J, et al. Combined BRAF and MEK inhi­

Clegg S, et al. Mutations of the BRAF gene in human

bition versus BRAF inhibition alone in melanoma. N

cancer. Nature. 2002;417(6892):949–54.

Engl J Med. 2014;371(20):1877–88.

6. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, 19. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Tuveson DA. Suppression of BRAF(V599E) in human

Liszkay G, Di Giacomo AM, et al. Cobimetinib

melanoma abrogates transformation. Cancer Res.

combined with vemurafenib in advanced BRAF(V600)‐

2003;63(17):5198–202.

mutant melanoma (coBRIM): updated efficacy results

7. Chapman PB, Hauschild A, Robert C, Haanen JB,

from a randomised, double‐blind, phase 3 trial. Lancet

Ascierto P, Larkin J, et al. Improved survival with vemu­

Oncol. 2016;17(9):1248–60.

rafenib in melanoma with BRAF V600E mutation. N 20. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Engl J Med. 2011;364(26):2507–16.

Braud F, Larkin J, et al. Dabrafenib and trametinib versus

8. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R,

dabrafenib and placebo for Val600 BRAF‐mutant mela­

Mil ward M, et al. Dabrafenib in BRAF‐mutated metastatic

noma: a multicentre, double‐blind, phase 3 randomised

melanoma: a multicentre, open‐label, phase 3 randomised

controlled trial. Lancet. 2015;386(9992):444–51.

controlled trial. Lancet. 2012;380(9839):358–65.

21. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher

9. Corcoran RB, Dias‐Santagata D, Bergethon K, Iafrate AJ,

O, Meyerson M, et al. EGFR mutation and resistance of

Settleman J, Engelman JA. BRAF gene amplification can

non‐small‐cell lung cancer to gefitinib. N Engl J Med.

promote acquired resistance to MEK inhibitors in cancer

2005;352(8):786–92.

cel s harboring the BRAF V600E mutation. Sci Signal. 22. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, 2010;3(149):ra84.

Zakowski MF, et al. Acquired resistance of lung adeno10. Johannessen CM, Johnson LA, Piccioni F, Townes A, carcinomas to gefitinib or erlotinib is associated with a

Frederick DT, Donahue MK, et al. A melanocyte lineage

second mutation in the EGFR kinase domain. PLoS

program confers resistance to MAP kinase pathway

Med. 2005;2(3):e73.

inhibition. Nature. 2013;504(7478):138–42.

23. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al.

11. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H,

A model of acquired autoresistance to a potent ErbB2

et al. Melanomas acquire resistance to B‐RAF(V600E)

tyrosine kinase inhibitor and a therapeutic strategy to

inhibition by RTK or N‐RAS upregulation. Nature.

prevent its onset in breast cancer. Proc Natl Acad Sci U S

2010;468(7326):973–7.

A. 2006;103(20):7795–800.

12. Vil anueva J, Vultur A, Lee JT, Somasundaram R, 24. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Fukunaga‐Kalabis M, Cipol a AK, et al. Acquired resis­

Janne PA, et al. Multiple mutations and bypass mechatance to BRAF inhibitors mediated by a RAF kinase nisms can contribute to development of acquired

switch in melanoma can be overcome by cotargeting

resistance to MET inhibitors. Cancer Res. 2011;71(3):

MEK and IGF‐1R/PI3K. Cancer Cel . 2010;18(6):683–95.

1081–91.

CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 283

25. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL,

anti‐CTLA‐4 treatment (CheckMate 037): a ran­

Schwartzentruber DJ, et al. Cancer regression and autodomised, controlled, open‐label, phase 3 trial. Lancet immunity induced by cytotoxic T lymphocyte‐ associated

Oncol. 2015;16(4):375–84.

antigen 4 blockade in patients with metastatic 38. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid melanoma. Proc Natl Acad Sci U S A. 2003;100(14):

O, Robert C, et al. Pembrolizumab versus investigator‐

8372–7.

choice chemotherapy for ipilimumab‐refractory mela26. Camacho LH, Antonia S, Sosman J, Kirkwood JM, noma (KEYNOTE‐002): a randomised, controlled,

Gajewski TF, Redman B, et al. Phase I/II trial of tremeliphase 2 trial. Lancet Oncol. 2015;16(8):908–18.

mumab in patients with metastatic melanoma. J Clin 39. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Oncol. 2009;27(7):1075–81.

Kluger H, et al. Combination therapy with anti‐CTLA‐4

27. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB,

and anti‐PD‐1 leads to distinct immunologic changes in

Marmol M, et al. Phase III randomized clinical trial

vivo. J Immunol. 2015;194(3):950–9.

comparing tremelimumab with standard‐of‐care che40. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, motherapy in patients with advanced melanoma. J Clin

Noguchi T, et al. Checkpoint blockade cancer immuno­

Oncol. 2013;31(5):616–22.

therapy targets tumour‐specific mutant antigens.

28. Krummel MF, Allison JP. CD28 and CTLA‐4 have

Nature. 2014;515(7528):577–81.

opposing effects on the response of T cel s to stimula41. Curran MA, Montalvo W, Yagita H, Allison JP. PD‐1 and tion. Journal of Experimental Medicine.

CTLA‐4 combination blockade expands infiltrating T

1995;182(2):459–65.

cel s and reduces regulatory T and myeloid cel s within

29. Leach DR, Krummel MF, Allison JP. Enhancement of

B16 melanoma tumors. Proceedings of the National

antitumor immunity by CTLA‐4 blockade. Science.

Academy of Sciences. 2010;107(9):4275–80.

1996;271(5256):1734–6.

42. Wolchok JD, Kluger H, Cal ahan MK, Postow MA, Rizvi

30. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman

NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in

JA, Haanen JB, et al. Improved survival with ipilimumab

advanced melanoma. N Engl J Med. 2013;369(2): 122–33.

in patients with metastatic melanoma. N Engl J Med. 43. Postow MA, Chesney J, Pavlick AC, Robert C, 2010;363(8):711–23.

Grossmann K, McDermott D, et al. Nivolumab and ipili31. Robert C, Long GV, Brady B, Dutriaux C, Maio M, mumab versus ipilimumab in untreated melanoma. N

Mortier L, et al. Nivolumab in previously untreated mel­

Engl J Med. 2015;372(21):2006–17.

anoma without BRAF mutation. N Engl J Med. 44. Larkin J, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Cowey 2015;372(4):320–30.

CL, Lao CD, et al. Combined nivolumab and ipilim32. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, umab or monotherapy in untreated melanoma. N Engl J

Garbe C, et al. Ipilimumab plus dacarbazine for previ­

Med. 2015;373(1):23–34.

ously untreated metastatic melanoma. N Engl J Med. 45. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, 2011;364(26):2517–26.

Senzer N, Chesney J, et al. Talimogene laherparepvec

33. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T,

improves durable response rate in patients with

Nishimura H, et al. Engagement of the PD‐1 immunoinadvanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

hibitory receptor by a novel B7 family member leads to 46. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang negative regulation of lymphocyte activation. Journal of

JC, Topalian SL, et al. Adoptive transfer of cloned

Experimental Medicine. 2000;192(7):1027–34.

melanoma‐reactive T lymphocytes for the treatment of

34. Carreno BM, Collins M. The B7 family of ligands and its

patients with metastatic melanoma. J Immunother.

receptors: new pathways for costimulation and inhibi2001;24(4):363–73.

tion of immune responses. Annu Rev Immunol. 2002; 47. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, 20:29–53.

Schwartzentruber DJ, et al. Cancer regression and auto35. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith immunity in patients after clonal repopulation with anti­

DC, McDermott DF, et al. Safety, activity, and immune

tumor lymphocytes. Science. 2002;298(5594):850–4.

correlates of anti‐PD‐1 antibody in cancer. N Engl J 48. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Med. 2012;366(26):2443–54.

Yang JC, Sherry RM, et al. Cancer regression in patients

36. Robert C, Schachter J, Long GV, Arance A, Grob JJ,

after transfer of genetical y engineered lymphocytes.

Mortier L, et al. Pembrolizumab versus ipilimumab in

Science. 2006;314(5796):126–9.

advanced melanoma. N Engl J Med. 2015; 372(26): 49. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry 2521–32.

RM, Dudley ME, et al. Tumor regression in patients with

37. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R,

metastatic synovial cell sarcoma and melanoma using

Neyns B, et al. Nivolumab versus chemotherapy in

genetical y engineered lymphocytes reactive with NY‐

patients with advanced melanoma who progressed after

ESO‐1. J Clin Oncol. 2011;29(7):917–24.

284 Immunotherapy in Translational Cancer Research 50. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, 63. Sigalotti L, Fratta E, Coral S, Tanzarel a S, Danielli R, et al. T‐cell transfer therapy targeting mutant KRAS in

Colizzi F, et al. Intratumor heterogeneity of cancer/testis

cancer. N Engl J Med. 2016;375(23):2255–62.

antigens expression in human cutaneous melanoma is

51. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP,

methylation‐regulated and functional y reverted by



Carpenter RO, Stetler‐Stevenson M, et al. Chemotherapy‐

5‐aza‐2’‐deoxycytidine. Cancer Res. 2004;64(24):9167–71.

refractory diffuse large B‐cell lymphoma and indolent B‐

64. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T,

cell malignancies can be effectively treated with

Zielinski M, Kim MS, et al. Efficacy of the MAGE‐A3

autologous T cel s expressing an anti‐CD19 chimeric

cancer immunotherapeutic as adjuvant therapy in

antigen receptor. J Clin Oncol. 2015;33(6):540–9.

patients with resected MAGE‐A3‐positive non‐small‐

52. Robbins PF, Lu YC, El‐Gamil M, Li YF, Gross C, Gartner

cell lung cancer (MAGRIT): a randomised, double‐

J, et al. Mining exomic sequencing data to identify

blind, placebo‐controlled, phase 3 trial. Lancet Oncol.

mutated antigens recognized by adoptively transferred

2016;17(6):822–35.

tumor‐reactive T cel s. Nat Med. 2013;19(6):747–52.

65. Andrews MC, Woods K, Cebon J, Behren A. Evolving

53. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C,

role of tumor antigens for future melanoma therapies.

et al. White paper on adoptive cell therapy for cancer

Future Oncol. 2014;10(8):1457–68.

with tumor‐infiltrating lymphocytes: a report of the 66. Wargo JA, Robbins PF, Li Y, Zhao Y, El‐Gamil M, CTEP subcommittee on adoptive cell therapy. Clin

Caragacianu D, et al. Recognition of NY‐ESO‐1+ tumor

Cancer Res. 2011;17(7):1664–73.

cel s by engineered lymphocytes is enhanced by

54. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The

improved vector design and epigenetic modulation of

BRAF‐MAPK signaling pathway is essential for cancer‐

tumor antigen expression. Cancer Immunol

immune evasion in human melanoma cel s. Journal of

Immunother. 2009;58(3):383–94.

Experimental Medicine. 2006;203(7):1651–6.

67. Karpf AR. A potential role for epigenetic modulatory

55. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN,

drugs in the enhancement of cancer/germ‐line antigen

Sloss CM, et al. Selective BRAFV600E inhibition enhances

vaccine efficacy. Epigenetics. 2006;1(3):116–20.

T‐cell recognition of melanoma without affecting lympho68. Hendry SA, Farnsworth RH, Solomon B, Achen MG, cyte function. Cancer Res. 2010;70(13):5213–9.

Stacker SA, Fox SB. The role of the tumor vasculature in

56. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN,

the host immune response: implications for therapeutic

Thompson JF, et al. Selective BRAF inhibitors induce

strategies targeting the tumor microenvironment. Front

marked T‐cell infiltration into human metastatic mela­

Immunol. 2016;7:621.

noma. Clin Cancer Res. 2012;18(5):1386–94.

69. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse

57. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, MA. Vascular endothelial growth factor and immunosup­

Ferrone CR, et al. BRAF inhibition is associated with

pression in cancer: current knowledge and potential for

enhanced melanoma antigen expression and a more

new therapy. Expert Opin Biol Ther. 2007;7(4): 449–60.

favorable tumor microenvironment in patients with met70. Du Four S, Maenhout SK, Niclou SP, Thielemans K, astatic melanoma. Clin Cancer Res. 2013;19(5):1225–31.

Neyns B, Aerts JL. Combined VEGFR and CTLA‐4

58. Cal ahan MK, Masters G, Pratilas CA, Ariyan C, Katz J,

blockade increases the antigen‐presenting function of

Kitano S, et al. Paradoxical activation of T cel s via

intratumoral DCs and reduces the suppressive capacity

augmented ERK signaling mediated by a RAF inhibitor.

of intratumoral MDSCs. Am J Cancer Res.

Cancer Immunol Res. 2014;2(1):70–9.

2016;6(11):2514–31.

59. Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, 71. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo Straten PT, et al. BRAF inhibition improves tumor rec­

NP, Rosenberg SA. Antiangiogenic agents can increase

ognition by the immune system: Potential implications

lymphocyte infiltration into tumor and enhance the

for combinatorial therapies against melanoma involving

effectiveness of adoptive immunotherapy of cancer.

adoptive T‐cell transfer. Oncoimmunology. 2012;1(9):

Cancer Res. 2010;70(15):6171–80.

1476–83.

72. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar

60. Besaratinia A, Tommasi S. Epigenetics of human mela­

R, et al. The effect of anti‐VEGF therapy on immature

noma: promises and challenges. J Mol Cell Biol.

myeloid cell and dendritic cel s in cancer patients.

2014;6(5):356–67.

Cancer Immunol Immunother. 2008;57(8):1115–24.

61. Esteller M. Epigenetics in cancer. N Engl J Med. 73. Dirkx AE, oude Egbrink MG, Castermans K, van der 2008;358(11):1148–59.

Schaft DW, Thijssen VL, Dings RP, et al. Anti‐angiogenesis

62. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis‐

therapy can overcome endothelial cell anergy and proassociated genes: identification, expression profile, and mote leukocyte‐endothelium interactions and infiltraputative function. J Cell Physiol. 2003;194(3):272–88.

tion in tumors. FASEB J. 2006;20(6):621–30.

CHAPTER 19 Interaction between Targeted Therapy and Immunotherapy 285

74. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada 86. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, T, et al. Bevacizumab plus ipilimumab in patients with

et al. Loss of PTEN promotes resistance to T cell‐mediated

metastatic melanoma. Cancer Immunol Res. 2014;2(7):

immunotherapy. Cancer Discov. 2016;6(2):202–16.

632–42.

87. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha

75. Wu X, Giobbie‐Hurder A, Liao X, Lawrence D,

TT, et al. Up‐regulation of PD‐L1, IDO, and T(regs) in

McDermott D, Zhou J, et al. VEGF neutralization plus

the melanoma tumor microenvironment is driven by

CTLA‐4 blockade alters soluble and cel ular factors

CD8(+) T cel s. Sci Transl Med. 2013;5(200):200ra116.

associated with enhancing lymphocyte infiltration and 88. Condeelis J, Pol ard JW. Macrophages: obligate partners humoral recognition in melanoma. Cancer Immunol

for tumor cell migration, invasion, and metastasis. Cel .

Res. 2016;4(10):858–68.

2006;124(2):263–6.

76. Vel a LJ, Pasam A, Dimopoulos N, Andrews M, Knights 89. Gabrilovich DI, Nagaraj S. Myeloid‐derived suppressor A, Puaux AL, et al. MEK inhibition, alone or in

cel s as regulators of the immune system. Nat Rev

combination with BRAF inhibition, affects multiple

Immunol. 2009;9(3):162–74.

functions of isolated normal human lymphocytes and 90. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West dendritic cel s. Cancer Immunol Res. 2014;2(4):351–60.

BL, Luo J, et al. CSF1/CSF1R blockade reprograms

77. Comin‐Anduix B, Chodon T, Sazegar H, Matsunaga

tumor‐infiltrating macrophages and improves response

D, Mock S, Jalil J, et al. The oncogenic BRAF kinase

to T‐cell checkpoint immunotherapy in pancreatic caninhibitor PLX4032/RG7204 does not affect the viacer models. Cancer Res. 2014;74(18):5057–69.

bility or function of human lymphocytes across a wide 91. Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal range of concentrations. Clin Cancer Res. 2010;

N, Shrivastava R, et al. Macrophages are recruited to

16(24):6040–8.

hypoxic tumor areas and acquire a pro‐angiogenic M2‐

78. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C,

polarized phenotype via hypoxic cancer cell derived

Goodman V, et al. BRAF(V600) inhibitor GSK2118436

cytokines Oncostatin M and Eotaxin. Oncotarget.

targeted inhibition of mutant BRAF in cancer patients

2014;5(14):5350–68.

does not impair overall immune competency. Clin 92. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Cancer Res. 2012;18(8):2326–35.

Kinoshita I, Dosaka‐Akita H, et al. Tumor‐associated

79. Ribas A, Hodi FS, Cal ahan M, Konto C, Wolchok J.

macrophages regulate tumorigenicity and anticancer

Hepatotoxicity with combination of vemurafenib and

drug responses of cancer stem/initiating cel s. Proc Natl

ipilimumab. N Engl J Med. 2013;368(14):1365–6.

Acad Sci U S A. 2011;108(30):12425–30.

80. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, 93. Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Yannelli JR, Rosenberg SA. Loss of functional beta

Giles FJ, et al. Molecular pathways: targeting IDO1 and

2‐microglobulin in metastatic melanomas from five

other tryptophan dioxygenases for cancer immunotherpatients receiving immunotherapy. J Natl Cancer Inst.

apy. Clin Cancer Res. 2015;21(24):5427–33.

1996;88(2):100–8.

94. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman‐Saint

81. D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA,

Victor C, et al. Tumor interferon signaling regulates a

Ferrone S. Lack of HLA class I antigen expression by culmultigenic resistance program to immune checkpoint tured melanoma cel s FO‐1 due to a defect in B2m gene

blockade. Cel . 2016;167(6):1540–54 e12.

expression. J Clin Invest. 1991;87(1):284–92.

95. Shin DS, Zaretsky JM, Escuin‐Ordinas H, Garcia‐Diaz A, Hu-82. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Mabetaen Lieskovan S, Kalbasi A, et al. Primary resistance to PD‐1

S, et al. Genetic evolution of T‐cell resistance in the

blockade mediated by JAK1/2 mutations. Cancer Discov. 2016.

course of melanoma progression. Clin Cancer Res. 96. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-2014;20(24):6593–604.

Lieskovan S, et al. Genomic and transcriptomic features

83. Zaretsky JM, Garcia‐Diaz A, Shin DS, Escuin‐Ordinas

of response to anti‐PD‐1 therapy in metastatic mela­

H, Hugo W, Hu‐Lieskovan S, et al. Mutations associated

noma. Cel . 2016;165(1):35–44.

with acquired resistance to PD‐1 blockade in melanoma. 97. Minor DR, Puzanov I, Cal ahan MK, Hug BA, Hoos A.

N Engl J Med. 2016;375(9):819–29.

Severe gastrointestinal toxicity with administration of

84. Spranger S, Bao R, Gajewski TF. Melanoma‐intrinsic

trametinib in combination with dabrafenib and ipilimbeta‐catenin signalling prevents anti‐tumour immunity.

umab. Pigment Cell Melanoma Res. 2015;28(5):611–2.

Nature. 2015;523(7559):231–5.

98. Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C,

85. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM,

Miller W, et al. Phase I study combining anti‐PD‐L1

Steinberg G, et al. Molecular drivers of the non‐T‐cell‐

(MEDI4736) with BRAF (dabrafenib) and/or MEK

inflamed tumor microenvironment in urothelial bladder

(trametinib) inhibitors in advanced melanoma. J Clin

cancer. Cancer Immunol Res. 2016;4(7):563–8.

Oncol. 2015;33(suppl; abstr 3003).





Index

Page locators in bold indicate tables. Page locators in italics indicate figures aAPC see artificial antigen‐presenting cel s

adoptive cel ular therapy (ACT)

absolute lymphocyte counts (ALC), 3

canine cancer, 254–261

ACT see adoptive cel ular therapy

genetical y modified T cel s, 102–104

active immunization, 261–262

immune cell migration, 136, 137

acute lymphoblastic leukemia (ALL)

natural killer cel s, 218–219

genetical y modified T cel s, 106–107

non‐genetical y modified T cel s, 93

natural killer cel s, 218–219

repurposing of drugs, 143, 154

stem cell transplantation, 205, 208

AGS‐003, 80–81

T cell receptor mimic antibodies, 190

ALC see absolute lymphocyte counts

acute myeloid leukemia (AML)

Algenpantucel‐L, 85

genetical y modified T cel s, 104

ALL see acute lymphoblastic leukemia

myeloid leukemia vaccines, 54–59, 61–64

amino acids, 60

natural killer cel s, 217–220

AML see acute myeloid leukemia

stem cell transplantation, 205, 207

angiogenesis, 140

T cell receptor mimic antibodies, 190–192

animal stem cell products (ASCP), 262

ADC see antibody drug conjugates

antibody‐dependent cel ular cytotoxicity (ADCC)

ADCC see antibody‐dependent cel ular cytotoxicity

monoclonal antibody therapy, 14–15, 20

adenoviral vectors, 261

natural killer cel s, 216

adjuvants and cytokines

antibody drug conjugates (ADC), 14

adjuvants, 115

antibody humanization, 189–190

bacille Calmette‐Guérin, 116

antibody libraries, 188–190

carriers, 115–116

anti‐CTLA‐4 therapies

checkpoint inhibitors, 118–119

biomarkers, 2–3

clinical efficacy data for vaccine and cytokine

immune cell migration, 139–140

therapy, 122

immunologic monitoring, 235–237

costimulatory molecules, 119–121

immunomodulation with adjuvants and cytokines,

CpG oligodeoxynucleotides, 118

118–119

cytokines, 121–125

immunomodulation with radiation therapy, 165–167,

imiquimod, 117

169–170

immunomodulation, 115–131

repurposing of drugs, 149

lipopolysaccharide, 116–117

somatic mutations, 24, 28

polyinosinic‐polycytidylic acid, 116

targeted therapy, 269–271, 281

resiquimod, 117–118

T cell receptor mimic antibodies, 187

toll‐like receptors, 116–118, 117

see also checkpoint blockade

Immunotherapy in Translational Cancer Research, First Edition. Edited by Laurence J. N. Cooper, Elizabeth A. Mittendorf, Judy Moyes, and Sabitha Prabhakaran.

© 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc.

286

Index 287

antigen‐binding fragment (Fab), 189–190

pharmacodynamic and pharmacokinetic biomarkers,

antigen‐presenting cel s (APC)

232–233, 240–245

cancer vaccines for solid tumors, 72, 81, 85–86

predictive biomarkers, 230–231, 235–240

canine cancer, 254–258

prognostic biomarkers, 229–235, 230

immune cell migration, 133

bispecific T cell engaging antibodies (BiTE), 195

immunomodulation with adjuvants and cytokines,

bladder cancer, 44

115–116

bortezomib, 221–222

immunomodulation with radiation therapy, 162–165, 167

BRAF gene, 42, 268–269, 272, 278, 281

non‐genetical y modified T cel s, 94–95

breast cancer

somatic mutations, 26–28

checkpoint blockade, 46

T cell receptor mimic antibodies, 186, 194–195

immunomodulation with radiation therapy, 165–166, 168

anti‐idiopathic antibody vaccines, 79, 87

T cell receptor mimic antibodies, 192–193

anti‐PD‐1/PDL‐1 therapies

brentuximab vedotin, 14

biomarkers, 3–7, 7

immunologic monitoring, 228, 235–236

CAIX see carbonic anhydrase IX

immunomodulation with adjuvants and cytokines,

cancer‐associated mucins, 84

118–119

cancer germline (CG) antigens, 24–25

immunomodulation with radiation therapy, 165–167,

cancer vaccines

171–172

carriers, 115–116

repurposing of drugs, 149

checkpoint inhibitors, 118–119

somatic mutations, 24, 28, 32

costimulatory molecules, 119–121

targeted therapy, 270, 279–281

cytokines, 121–125

T cell receptor mimic antibodies, 187

immunomodulation with adjuvants and cytokines,

see also checkpoint blockade

115–125

antitumor immunity cycle, 161–162, 162

myeloid leukemia vaccines, 54–71

APC see antigen‐presenting cel s

non‐genetical y modified T cel s, 97

artificial antigen‐presenting cel s (aAPC), 95, 255–256

solid tumors, 72–90

ASCP see animal stem cell products

somatic mutations, 31–32

atezolizumab, 7, 44, 46

toll‐like receptors, 116–118, 117

autoantibodies, 244–245

canine cancer

autologous stem cell transplantation, 103

active immunization, 261–262

avelumab, 43, 45

adoptive NK cell immunotherapy, 258–260

azacytidine (AZA), 144–147

adoptive T cell immunotherapy, 255–256

background, 252–253

bacille Calmette‐Guérin (BCG), 116

cell‐based therapies, 252–267

4‐1BB, 119–120, 166, 169

genetic modification of lymphocytes, 257–258, 259

BCG see bacille Calmette‐Guérin

immune landscape of patients, 253–254

BCR‐ABL fusion protein, 54, 62–64

immunosuppressive tumor microenvironment, 252–254

Belagenpumatucel‐L, 85–86

passive adoptive transfer, 254–261

biologicals, 139–140

preconditioning regimes for stem cell transplant,

biomarkers, 1–11

260–261

anti‐CTLA‐4, 2–3

purification of canine T cel s by negative selection, 257

anti‐PD‐1/PDL‐1 therapies, 3–7

regulatory guidelines for cell‐based products, 262

approved anti‐PD‐1/PDL‐1 blockade agents and

relevance of the patient in evaluating immunotherapies,

biomarkers, 6–7, 7

253–254

checkpoint blockade, 46–47

T cell expansion protocols, 254–255

correlative and surrogate endpoint biomarkers,

tumor immunogenicity, 253

245–246

typical leukapheresis product, 256

genomic‐related biomarkers, 4–6

CAR see chimeric antigen receptor

historical development, 1–2

carbonic anhydrase IX (CAIX), 110

immune‐related biomarkers, 3–4

carcinogenesis, 144

immunologic monitoring, 228–246

CB see umbilical cord blood

objective response rate, 2

CD3 coreceptors, 186–187, 254–255

288 Index

CD4+ T cel s see helper T cel s

chimeric antigen receptor (CAR)

CD8+ T cel s see cytotoxic T lymphocytes

canine cancer, 254, 256–258, 259

CD19‐CAR T cell therapy, 106–107, 110

clinical translation, 106–107

CD27/CD70, 120–121

clinical trials of CARs for solid tumors, 108

CD28

genetical y modified T cel s, 102, 104–110

canine cancer, 255

Good Manufacturing Practices, 179–180

immune cell migration, 139

historical development, 105

immunomodulation with adjuvants and

immunologic monitoring, 228

cytokines, 119

rationale and structure, 104–105

targeted therapy, 269–270

repurposing of drugs, 154

CD40, 121, 256, 262

solid tumors, 107–109

CD134, 166, 169, 170

T cell receptor mimic antibodies, 194

CD137, 93, 119–120, 166, 169

toxicities from CAR therapies, 109–110

CDC see complement‐dependent cytotoxicity

variability in CD19‐CAR trials, 106

CEA, 25

chronic lymphocytic leukemia (CLL) cel s, 106

celecoxib, 152

chronic myeloid leukemia (CML)

cell culture, 178–179

myeloid leukemia vaccines, 54–59, 61–64

cell lines, 221

natural killer cel s, 219–220

cell transfer immunotherapy, 30–32, 31

stem cell transplantation, 205, 208–209

cell washing, 178

T cell receptor mimic antibodies, 192

cetuximab, 13–15, 20

clustered regularly interspaced short palindromic repeats

CG see cancer germline

(CRISPR), 257–258, 262

checkpoint blockade, 37–53

CML see chronic myeloid leukemia

biomarkers, 2–7, 7, 46–47

colon cancer

bladder cancer, 44

cancer vaccines for solid tumors, 86

breast cancer, 46

checkpoint blockade, 45

cancer vaccines for solid tumors, 72, 81–82, 88

immunologic monitoring, 234

clinical activity of CTLA‐4, PD‐1, and PD‐L1‐blocking

colorectal cancer (CRC)

agents, 38–45, 39, 40–41

checkpoint blockade, 45

colon cancer with mismatch repair deficiency, 45

immune cell migration, 136

combination strategies, 46

immunologic monitoring, 238

cytotoxic T lymphocyte‐associate protein 4, 37, 38

immunomodulation with radiation therapy, 172

historical development, 37

combination therapy

Hodgkin lymphoma, 44–45

cancer vaccines for solid tumors, 81–84

immune cell migration, 139

checkpoint blockade, 46

immunologic monitoring, 228, 235–237

immunomodulation with radiation therapy, 162–167

immunomodulation with adjuvants and cytokines,

non‐genetical y modified T cel s, 97

118–119

repurposing of drugs, 146, 154

melanoma, 39–42

targeted therapy and immunotherapy, 268–285

non‐small‐cell lung cancer, 42–43

complement‐dependent cytotoxicity (CDC), 16, 20

ovarian cancer, 45

complete remission (CR)

preclinical mechanism, 37–38

myeloid leukemia vaccines, 61

preliminary positive clinical data, 45–46

natural killer cel s, 217, 219

programmed cell death receptor‐1 and ligands, 37, 38

stem cell transplantation, 205–210

renal cell carcinoma, 43–44

correlative and surrogate endpoint biomarkers, 245–246

repurposing of drugs, 143

costimulatory molecules

somatic mutations, 24, 28, 32

immune cell migration, 139

targeted therapy, 269–271, 279–281

immunomodulation with adjuvants and cytokines,

T cell receptor activation, 37–38

119–121

T cell receptor mimic antibodies, 187

T cell receptor mimic antibodies, 186–187

chemokines

COX see cyclooxygenase

immune cell migration, 134, 135, 136–140

CpG oligodeoxynucleotides, 118

immunologic monitoring, 242

CPI see checkpoint inhibitors

Index 289

CR see complete remission

cancer vaccines for solid tumors, 72–81, 73

CRC see colorectal cancer

canine cancer, 261–262

C‐reactive protein (CRP), 2

immune cell migration, 132–133, 135

CRISPR see clustered regularly interspaced short

immunomodulation with radiation therapy, 161–165,

palindromic repeats

167–168

CRP see C‐reactive protein

myeloid leukemia vaccines, 59, 61, 64

CRS see cytokine release syndrome

repurposing of drugs, 153–154

cryopreservation, 180

somatic mutations, 32

CTL see cytotoxic T lymphocytes

DFS see disease‐free survival

CTLA‐4 see cytotoxic T lymphocyte‐associated

dinutuximab, 216

protein 4

direct tumor cell killing, 13–14

CTX see cyclophosphamide

disease‐free survival (DFS), 229

cyclooxygenase (COX) inhibitors, 149–152

DLI see donor lymphocyte infusion

cyclophosphamide (CTX), 83–84, 92, 153–154, 203,

DNA methylation (DNMT) inhibitors, 144–146, 144

260–261

donor lymphocyte infusion (DLI), 55

cytokine flow cytometry, 243

DTH see delayed‐type hypersensitivity

cytokine release syndrome (CRS), 94, 109

cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4)

EBV see Epstein‐Barr virus

biomarkers, 1, 2–3

ELANE see neutrophil elastase

immune cell migration, 139–140

electroporation, 179–180

immunologic monitoring, 235–237

ELISA see enzyme‐linked immunosorbent assay

immunomodulation with adjuvants and cytokines,

ELISPOT see enzyme‐linked immunospot

118–119

elpamotide, 82

immunomodulation with radiation therapy, 165–167,

elutriation, 179

169–170

Emepepimut‐S, 82

repurposing of drugs, 149

endogenous T cel s (ETC)

somatic mutations, 24, 28

extending targets, expanding indications, 96–97

targeted therapy, 269–271, 281

generation of T cel s for ETC therapy, 94–95, 95

T cell receptor mimic antibodies, 187

non‐genetical y modified T cel s, 91, 93–98

see also checkpoint blockade

engineered viral vectors, 138

cytotoxic T lymphocytes (CTL)

Enhanzyn, 84

biomarkers, 3–4

environmental monitoring, 182

canine cancer, 253–256, 260–261

enzyme‐linked immunosorbent assay (ELISA), 26–27, 244

genetical y modified T cel s, 101

enzyme‐linked immunospot (ELISPOT), 26–27, 242–243

immune cell migration, 132, 135–136, 140

eosinophils, 238–239

immunologic monitoring, 229, 239–240, 242–244

epidermal growth factor receptor (EGFR), 13, 20

immunomodulation with adjuvants and cytokines,

epitope spreading, 245–246

118–121

Epstein‐Barr virus (EBV)‐associated lymphoma, 245–246

myeloid leukemia vaccines, 55–56, 58–64

E‐selectin, 134, 272

non‐genetical y modified T cel s, 93–98

ETC see endogenous T cel s

repurposing of drugs, 145–146, 148–152

expanded natural killer cel s, 220–221

somatic mutations, 24, 26, 27, 29–32

stem cell transplantation, 205

Fc receptors (FcR), 14–16

targeted therapy, 269–270

Flt‐3 ligand, 165

T cell receptor mimic antibodies, 187

fludarabine, 92, 260–261

DAC see decitabine

GBM see glioblastoma multiforme

dacetuzumab, 121

G‐CSF see granulocyte colony‐stimulating factor

DC see dendritic cel s

gemcitabine, 82

DCVax, 80

gemtuzumab ozogamicin, 14

decitabine (DAC), 144–147

gene expression

delayed‐type hypersensitivity (DTH), 245

immunologic monitoring, 241–242

dendritic cel s (DC)

targeted therapy, 280–281

290 Index

gene therapy, 136–139

physical infrastructure, 182

genetical y modified T cel s, 101–114

standard operating procedures, 177–178, 182

acute lymphoblastic leukemia, 106–107

gp100 see glycoprotein 100

adoptive cel ular immunotherapy, 102–104

graft‐versus‐host disease (GVHD), 202–203, 205, 209–210,

canine cancer, 257–258, 259

217–218

chimeric antigen receptors, 102, 104–110

graft‐versus‐malignancy (GVM) effect, 201, 203–205, 206, chronic lymphocytic leukemia, 106

208–210, 210

clinical development of TCRs, 104

granulocyte colony‐stimulating factor (G‐CSF), 92

clinical experience with TCRs, 103–104

granulocyte‐macrophage colony‐stimulating factor

clinical translation for CARs, 106–107

(GM‐CSF)

clinical trials of CARs for solid tumors, 108

cancer vaccines for solid tumors, 80–84

comparison of TCR versus CAR therapies, 102

immunomodulation with radiation therapy, 165,

future directions, 110

167, 168

immune cell migration, 136, 137

myeloid leukemia vaccines, 59, 61–64

lessons on toxicity from MAGE, 104

GV1001, 82–83

MART‐1, 103

GVAX, 85

methods of T cell modification, 102

GVHD see graft‐versus‐host disease

methods of tumor evasion, 101

GVM see graft‐versus‐malignancy

non‐Hodgkin lymphoma, 106

NY‐ESO‐1 in hematologic and solid tumors, 103

haploidentical donors, 203, 218

solid tumors, 107–109

HDAC see histone deacetylation

specific therapeutic strategies, 102

helper T cel s

T cell activation, 101

canine cancer, 253–256, 258–261

T cell receptors, 101–105, 110

immune cell migration, 133, 136, 140

toxicities from CAR therapies, 109–110

immunologic monitoring, 229, 239–240, 242–243

variability in CD19‐CAR trials, 106

immunomodulation with adjuvants and cytokines, 116,

genomic‐related biomarkers, 4–6

118–119, 121

GITR see glucocorticoid‐induced TNFR‐related protein

myeloid leukemia vaccines, 55–56, 58–64

glioblastoma, 109

non‐genetical y modified T cel s, 94–95

glioblastoma multiforme (GBM), 80, 83

repurposing of drugs, 145–146, 149–152

glucocorticoid‐induced TNFR‐related protein (GITR), 120

somatic mutations, 24, 29–30

glycoprotein 100 (gp100)

stem cell transplantation, 205

cancer vaccines for solid tumors, 81–82

T cell receptor mimic antibodies, 187

immunomodulation with adjuvants and cytokines,

hematologic tumors, 103

118, 122

hematopoietic stem cell transplantation see stem cell repurposing of drugs, 148, 154

transplantation

somatic mutations, 25

hepatotoxicity, 278, 281

glycoproteins, 16

HER2 see human epidermal growth factor

GM‐CSF see granulocyte‐macrophage colony stimulating

HER2/neu (ERBB2), 25

factor

high‐throughput, next‐generation sequencing, 26, 29

Good Manufacturing Practices (GMP), 177–185

histone deacetylation (HDAC) inhibitors, 144, 146–150, concluding remarks, 184

147, 154

criteria for use of cGMP generated cel ular therapies, 180

HLA see human leukocyte antigen

environmental monitoring and cleaning, 182

Hodgkin lymphoma, 5, 6, 44–45

evolution of cGMP immunotherapies, 183–184

HPV see human papilloma viruses

global systems and organizations, 182–183

HSTC see stem cell transplantation

infrastructure considerations, 180–183

human epidermal growth factor (HER2)

introduction to current GMP, 177–178

canine cancer, 258

manufacture of cel ular immunotherapies in cGMP

checkpoint blockade, 46

settings, 178–180

genetical y modified T cel s, 109

modification of cel s for immunotherapy, 179–180

immunologic monitoring, 240–242, 244

organizational infrastructure and quality standards,

monoclonal antibody therapy, 13–14, 19–20

180–182, 181

T cell receptor mimic antibodies, 192–193

Index 291

human leukocyte antigen (HLA)

enzyme‐linked immunospot, 242–243

genetical y modified T cel s, 103, 110

gene analysis of tumor and peripheral blood with

immunologic monitoring, 243

treatment, 241–242

myeloid leukemia vaccines, 54–64, 56

ICOS+ and polyfunctional T cel s, 240

natural killer cel s, 217–218

immunoscore, 229, 234

somatic mutations, 27–29

MHC tetramers and pentamers, 243–244

stem cell transplantation, 202–203, 205

myeloid‐derived suppressor cel s, 238–239

T cell receptor mimic antibodies, 192

neoantigenic load estimation, 237–238

human papilloma viruses (HPV), 25–26

neutrophil‐to‐lymphocyte ratio, 234–235

humoral immunity, 244

PD‐L1 and PD‐1 expression, 228, 235–236

hyaluronan, 61–62

pharmacodynamic and pharmacokinetic biomarkers,

hybridomas, 189–190

232–233, 240–245

predictive biomarkers, 230–231, 235–240

ICAM‐1 see intercel ular adhesion molecule 1

prognostic biomarkers, 229–235, 230

ICOS+, 240

regulatory and helper T cel s, 229, 239–240

ICT‐107, 80

single nucleotide polymorphisms, 236–237

IFA see incomplete Freund’s adjuvant

T cell receptors, 240–241, 243–244

IFN see interferons

immunoscore, 229, 234

IHC see immunohistochemistry

incomplete Freund’s adjuvant (IFA), 115–116, 118

IL see interleukins

indomethacin, 152

IMA901, 83–84

integrins, 134

imiquimod, 117, 118, 165, 168

intercel ular adhesion molecule 1 (ICAM‐1), 145

immune cell migration, 132–142

interferons (IFN)

adoptive cell transfer, 136, 137

immunologic monitoring, 237, 242–243

conclusions and perspectives, 140–141

immunomodulation with adjuvants and cytokines,

current knowledge and open questions, 134–135

115–116, 118, 122

ex vivo modification of immune migration, 135–137

immunomodulation with radiation therapy, 162

immune contexture in cancer, 132

myeloid leukemia vaccines, 54, 63–64

molecular mechanisms of leukocyte migration, 134, 135

repurposing of drugs, 145, 148–149

oncolytic viruses, 137–139

targeted therapy, 279–280

organ‐specific area codes, 133–134

interferon‐stimulated genes (ISG), 242

overview of migratory pathways and immune cell type,

interleukins (IL)

132–133, 133

genetical y modified T cel s, 105, 109

systemic application of drugs and biologicals, 139–140

immunomodulation with adjuvants and cytokines,

targeting leukocyte migration by immunotherapy,

116–125

134–140

IL‐2, 122–123

tumor site enhancement of immune cell migration, 137–139

IL‐10, 123–124

immune‐mediated tumor cell killing, 14–16, 15, 20

IL‐12, 124

immune receptor tyrosine‐based activation motifs

IL‐15, 124–125

(ITAM), 186

IL‐21, 125

immune‐related biomarkers, 3–4

immunomodulation with radiation therapy, 166, 170

immunization, 189–190

natural killer cel s, 219–222, 220, 221

immunoglobulin, 189–190

non‐genetical y modified T cel s, 92–93

immunohistochemistry (IHC), 42–44, 236

repurposing of drugs, 148–149

immunologic monitoring, 228–251

intracel ular antigens, 187

antibody immunity, 244–245

ipilimumab

antigen specific versus tumor microenvironment focus,

biomarkers, 2–3

228–229

cancer vaccines for solid tumors, 81–82

assays and targets, 229, 234

checkpoint blockade, 39, 42, 46–47

biomarkers in immuno‐oncoloy, 228

immunologic monitoring, 237, 239–240

classes of immunologic biomarkers, 229

immunomodulation with adjuvants and cytokines, 119

correlative and surrogate endpoint biomarkers, 245–246

immunomodulation with radiation, 168–169

cytokine flow cytometry, 243

targeted therapy, 269–271, 278

292 Index

ISG see interferon‐stimulated genes

MAPK see mitogen‐activated protein kinase

ITAM see immune receptor tyrosine‐based activation motifs MART‐1

ITH see neoantigen heterogeneity

genetical y modified T cel s, 103

immunomodulation with adjuvants and cytokines,

keyhole limpet hemocyanin (KLH), 83, 84

118, 122

KI see kinase inhibitors

non‐genetical y modified T cel s, 94, 96–97

killer immunoglobulin‐like receptors (KIR), 146, 216–218

somatic mutations, 25

kinase inhibitors (KI), 271–272

T cell receptor mimic antibodies, 193–194

KIR see killer immunoglobulin‐like receptors

mass spectrometry (MS), 28

KLH see keyhole limpet hemocyanin

matched sibling donors (MSD), 203, 208

KRAS mutation

matched unrelated donor (MUD), 203, 208

monoclonal antibody therapy, 13, 20

MDS see myelodysplastic syndrome

non‐genetical y modified T cel s, 93

MDSC see myeloid‐derived suppressor cel s

MEK see mitogen‐activated protein kinase kinase

LAA see leukemia‐associated antigens

melanoma

lactate dehydrogenase (LDH), 2

cancer vaccines for solid tumors, 84–85

lenalidomide, 222

checkpoint blockade, 39–42

lentiviral vectors, 258, 259

immune cell migration, 136, 140

gamma‐lentiviruses, 179

immunologic monitoring, 238, 245

leukapheresis, 256

immunomodulation with adjuvants and cytokines, 118–119

leukemia

immunomodulation with radiation therapy, 166, 169–171

cancer vaccines for solid tumors, 85

somatic mutations, 28–29

natural killer cel s, 218–220

targeted therapy, 270–271, 278, 281

T cell receptor mimic antibodies, 190–192

T cell receptor mimic antibodies, 193–194

see also individual types

melanoma‐associated antigens (MAGE)

leukemia‐associated antigens (LAA), 56–59

cancer vaccines for solid tumors, 84–85

lipopolysaccharide (LPS), 116–117

genetical y modified T cel s, 104

lirilumab, 222

non‐genetical y modified T cel s, 94

LPS see lipopolysaccharide

repurposing of drugs, 145–146

L‐selectin, 134

T cell receptor mimic antibodies, 194

lung cancer

memory T cel s, 101

immune cell migration, 136, 140

mesothelin, 25

immunomodulation with radiation therapy, 165–166, 171

metastatic cancers

see also non‐small‐cell lung cancer

cancer vaccines for solid tumors, 80, 82

lymph nodes, 136, 139

checkpoint blockade, 41–42, 44

lymphoma, 209

immune cell migration, 136, 138

immunomodulation with radiation therapy, 168–172

mAb see monoclonal antibody

somatic mutations, 25–26, 29–32

MAGE see melanoma‐associated antigens

targeted therapy, 270, 278, 281

major histocompatibility complex (MHC)

MHC see major histocompatibility complex

canine cancer, 253, 258–260

microarrays, 244–245

genetical y modified T cel s, 101–103, 105

microsatellite instability (MSI), 6

immunologic monitoring, 243–244

mismatch repair (MMR) deficiency, 5–6, 45

immunomodulation with adjuvants and cytokines, 116–117

mitogen‐activated protein kinase kinase (MEK) inhibitors,

immunomodulation with radiation therapy, 162, 165,

269, 272, 278

167, 171–172

mitogen‐activated protein kinase (MAPK), 268–269, 272, 278

myeloid leukemia vaccines, 57

MMR see mismatch repair

natural killer cel s, 215

monoclonal antibody (mAb) therapy, 12–23

non‐genetical y modified T cel s, 95–96

antibody‐dependent cel ular toxicity, 14–15, 20

repurposing of drugs, 145, 148–149

antibody drug conjugates, 14

somatic mutations, 26–28, 32

cancer vaccines for solid tumors, 87

stem cell transplantation, 202–203

clinical development of mAbs, 16–19

T cell receptor mimic antibodies, 186–190, 194–195

complement‐dependent cytotoxicity, 16, 20

Index 293

direct versus immune‐mediated tumor cell killing,

IL‐2‐activated NK cel s after chemotherapy, 219–220, 220

13–16, 15, 20

IL‐15‐activated donor NK cel s after HSCT, 221

general antibody structure, 13

immune cell migration, 132, 136–138

historical development, 12

immunomodulation with adjuvants and cytokines, 117

immunologic monitoring, 237

leukemia, 219–220

mechanisms of action, 12–16

manipulating anti‐tumor effect of, 217–222

mechanisms of resistance, 19–20

receptors and corresponding ligands, 215–217, 216

T cell receptor mimic antibodies, 192–193

repurposing of drugs, 143, 145–146, 150–152

tumor antigens, 16, 17–18

solid tumors, 220

Montanide ISA, 82, 115–116

stem cell transplantation, 217–219

MS see mass spectrometry

Nelipepimut‐S, 81

MSD see matched sibling donors

neoantigen heterogeneity (ITH), 238

MSI see microsatellite instability

neoantigens

MUD see matched unrelated donor

immunologic monitoring, 237–238

multiple myeloma, 103, 209, 219

myeloid leukemia vaccines, 58–59, 62

myelodysplastic syndrome (MDS), 144–145, 192, 207

somatic mutations, 26–32, 27, 31

myelofibrosis, 208

neoepitopes, 27–29

myeloid‐derived suppressor cel s (MDSC)

neuroblastoma, 218

canine cancer, 253–254, 256

neurotoxicity, 94, 109–110

immune cell migration, 140

neutrophil elastase (ELANE), 62

immunologic monitoring, 238–239

neutrophil‐to‐lymphocyte ratio (NLR), 234–235

immunomodulation with radiation therapy, 166

NHL see non‐Hodgkin lymphoma

repurposing of drugs, 145–146, 152

nivolumab, 4, 6, 42–46, 87, 119, 270

myeloid leukemia vaccines, 54–71

NK see natural killer

amino acids, 60

NLR see neutrophil‐to‐lymphocyte ratio

barriers to successful cancer vaccine strategies, 55–56, 56

non‐genetical y modified T cel s, 91–100

BCR‐ABL fusion protein, 54, 62–64

antigen‐presenting cel s, 94–95

class I and class II antigen presentation, 56

combination therapy, 97

complex/undefined antigen DC vaccine strategies, 64

comparison of TIL versus ETC therapy, 92

dendritic cell vaccines, 59, 61, 64

endogenous T cel s, 91, 93–98

evidence for T‐cell‐mediated killing of myeloid leukemia,

extending targets, expanding indications, 95–97

54–55

generation of T cel s for TIL and ETC therapy,

interferon‐alpha, 54, 63–64

94–95, 95

leukemia‐associated antigens, 56–59

tumor‐infiltrating lymphocytes, 91–93, 97

mechanisms and types of presented cancer antigens, 57

non‐Hodgkin lymphoma (NHL), 106, 121, 258

neoantigens, 58–59, 62

nonself tumor antigens, 25–26

PR1 (PRTN3 and ELANE), 62

non‐small‐cell lung cancer (NSCLC)

RHAMM, 61–62

biomarkers, 5, 7

targets of myeloid vaccines, 56–59

cancer vaccines for solid tumors, 82, 84–86–7

tolerance mechanisms, 57–59, 58

checkpoint blockade, 42–43

trial summary, 65–66

immunologic monitoring, 236

vaccine types, 59

immunomodulation with radiation therapy, 168,

WT1 gene, 59–61

170–172

somatic mutations, 28

NAPPA microarrays, 245

nonsteroidal anti‐inflammatory drugs (NSAID), 150–153,

natural killer (NK) cel s, 215–227

150, 151

adoptive transfer, 218–219

NSCLC see non‐small‐cell lung cancer

agents to augment NK cell efficacy, 221–222

nuclear RNA export factor (NXF2), 145

background and biology, 215–217

NY‐ESO‐1

canine cancer, 258–260

adjuvants and cytokines, 117

cell lines, 221

genetical y modified T cel s, 103

clinical evidence for impact on cancer outcomes, 217

repurposing of drugs, 145

expanded NK cel s, 220–221

somatic mutations, 25

294 Index

obinutuzumab, 15–16

pMHC see peptide/major histocompatibility

objective response rates (ORR), 2, 42–43, 45–46

antigen complex

oncolytic viruses (OV)

polyfunctional T cel s, 240

biomarkers, 6

polyinosinic‐polycytidylic acid (poly‐IC), 116

immune cell migration, 137–139

polymerase chain reaction (PCR), 237

immunologic monitoring, 245–246

PR1 (PRTN3 and ELANE), 62

myeloid leukemia vaccines, 55

PR see partial remission

non‐genetical y modified T cel s, 97

PRAME see preferential y expressed antigen in melanoma somatic mutations, 25–26

predictive biomarkers, 230–231, 235–240

OncoVAX, 86

preferential y expressed antigen in melanoma (PRAME),

on‐target, off‐tumor toxicity, 110

104, 145

ORR see objective response rates

prognostic biomarkers, 229–235, 230

OS see overall survival

programmed cell death receptor/ligand (PD‐1/PDL‐1)

OV see oncolytic viruses

biomarkers, 1, 3–7

ovarian cancer, 45

immunologic monitoring, 228, 235–236

overall survival (OS), 234–235, 238–240

immunomodulation with adjuvants and cytokines, 118–119

overexpressed antigen, 25

immunomodulation with radiation therapy, 165–167,

OX40, 120, 166, 169, 170

171–172

repurposing of drugs, 149

p53, 25

somatic mutations, 24, 28, 32

paclitaxel (PTX), 154

targeted therapy, 270, 279–281

paired‐end sequencing, 237

T cell receptor mimic antibodies, 187

PAMP see pathogen‐associated molecular patterns

see also checkpoint blockade

pancreatic adenocarcinoma, 82, 85, 140

progression‐free survival (PFS), 42, 45–46, 80

pancreatic cancer, 85

prostaglandins (PG), 150–152

panitumumab, 20

prostate cancer, 85–86, 140

panobinostat, 149

prostate‐specific antigen (PSA), 86

partial remission (PR), 219

ProstVac‐VF, 86

passive adoptive transfer, 254–261

proteinase‐3 (PRTN3), 62

pathogen‐associated molecular patterns (PAMP), 116

protein/peptide vaccines

PBMC see peripheral blood mononuclear cel s

cancer vaccines for solid tumors, 74–76, 81–85

PCR see polymerase chain reaction

full protein vaccines, 84–85

PD‐1/PDL‐1 see programmed cell death receptor/ligand

multiple peptide vaccines, 83–84

pembrolizumab, 3–6, 39, 42–46, 171–172

single peptide vaccines, 81–83

pentostatin, 260

PRTN3 see proteinase‐3

peptide/major histocompatibility antigen complex

PSA see prostate‐specific antigen

(pMHC), 186–190, 194–195

P‐selectin, 134

peptide vaccines, 118, 122

PTX see paclitaxel

peripheral blood mononuclear cel s (PBMC), 242–244,

254–256

quality standards, 180–182

pertuzumab, 19

PFS see progression‐free survival

racotumomab, 87

PG see prostaglandins

radiation therapy

pharmacodynamic and pharmacokinetic biomarkers,

antitumor immunity cycle, 161–162, 162

232–233, 240–245

background, 161

platinum‐based chemotherapy

canine cancer, 260–261

biomarkers, 6–7

clinical applications, 167–172

checkpoint blockade, 42–45

CTLA4, 165–167, 169–170

immune cell migration, 140

exogenous DC therapy, 167–168

immunomodulation with radiation, 172

granulocyte‐macrophage colony‐stimulating factor, 165,

monoclonal antibody therapy, 13

167, 168

repurposing drugs, 154

immunomodulation, 161–176

targeted therapy, 270

interleukin‐2, 166, 170

Index 295

OX40, 166, 169, 170

single‐chain variable fragments (scFvs), 105

PD‐1/PDL‐1, 165–167, 171–172

single nucleotide polymorphisms (SNP), 236–237

preclinical studies, 162–167, 163–164

sipuleucel‐T, 80

summary, 172

small molecule inhibitors, 140

T cell‐mediated killing of cancer cel s, 166–167, 171–172

SNP see single nucleotide polymorphisms

T cell priming and activation, 165–166, 168–169

solid tumors

toll‐like receptors, 165, 168

anti‐idiopathic antibody vaccines, 79, 87

transforming growth factor‐beta, 166–167, 170–171

cancer vaccines, 72–90

tumor antigen presentation, 162–165, 167

dendritic cell vaccines, 72–81, 73

RCR see replication‐competent retroviruses

genetical y modified T cel s, 103, 107–109

recurrence‐free survival (RFS), 83

historical development, 72

regulatory T cel s

immune cell migration, 140

immune cell migration, 132, 140

natural killer cel s, 220

immunologic monitoring, 239–240

non‐genetical y modified T cel s, 95, 97

natural killer cel s, 219

protein/peptide vaccines, 74–76, 81–85

repurposing of drugs, 143, 154

stem cell transplantation, 209–210

renal cell carcinoma (RCC)

tumor cell vaccines, 77, 85–86

biomarkers, 4, 6

vaccine strategies, 72, 87–88

cancer vaccines for solid tumors, 80, 87

viral vaccines, 78, 86–87

checkpoint blockade, 43–44

soluble CD25 (sCD25), 2

replication‐competent retroviruses (RCR), 179–180

somatic mutations, 24–36

repurposing of drugs, 143–160

cancer germline antigens, 24–25

adoptive cell therapy, 143, 154

cell transfer immunotherapy, 30–32, 31

background, 143–144

neoantigens, 26–32, 27, 31

chemotherapy agents, 153–154, 153

oncogenic viruses, 25–26

DNA methylation inhibitors, 144–146, 144

overexpressed antigens, 25

histone deacetylation inhibitors, 144, 146–150, 147, 154

PD‐1 and CTLA‐4 immune checkpoint pathways, 24, 28, 32

nonsteroidal anti‐inflammatory drugs, 150–153, 150, 151

self and nonself tumor antigens, 24–26

resiquimod, 117–118

T cell receptor mimic antibodies, 189

resistance

tissue differentiation antigens, 25

molecular targets of immunotherapy resistance,

SOP see standard operating procedures

278–281, 280

SSX see synovial sarcoma X chromosome

monoclonal antibody therapy, 19–20

standard operating procedures (SOP), 177–178, 182

gamma‐retroviruses, 179

stem cell transplantation, 201–214

reverse transcription polymerase chain reaction

acute lymphoid leukemia, 205, 208

(RT‐PCR), 237

acute myeloid leukemia, 205, 207

RHAMM, 61–62

advantages and disadvantages by donor, 204

Rindopepimut, 83

allogenic HSCT process, 201–202, 202

rituximab, 16, 19, 216

background, 201

RL1B, 193

canine cancer, 260–261

RL4B, 193

chronic myeloid leukemia, 205, 208–209

rofecoxib, 152

graft‐versus‐malignancy effect, 201, 203–205, 206,

romidepsin, 149

208–210, 210

RT‐PCR see reverse transcription polymerase chain reaction histocompatibility requirements, 202–203

historical perspective, 203–205

sCD25 see soluble CD25

indications for HSCT, 206–207

scFvs see single‐chain variable fragments

lymphoma, 209

selectins, 134, 135, 272

mechanism of GVM effect, 205, 206

self‐antigens

multiple myeloma, 209

genetical y modified T cel s, 102

myelodysplastic syndrome, 207

myeloid leukemia vaccines, 57–58

myelofibrosis, 208

somatic mutations, 24–25

natural killer cel s, 217–219

Seviprotimut‐L, 84

solid tumors, 209–210

296 Index

sterility testing, 180

TMG see tandem minigene

sunitinib, 83–84

TNBC see triple‐negative breast cancer

synovial sarcoma X chromosome (SSX), 145

TNF‐alpha see tumor necrosis factor alpha

toll‐like receptors (TLR)

TAA see tumor‐associated antigens

immunomodulation with adjuvants and cytokines,

TALEN see transcription activator‐like effector nuclease 116–118, 117

talimogene laherparepvec (TVEC), 271

immunomodulation with radiation therapy, 165, 168

tandem minigenes (TMG), 26–27, 27

total‐body irradiation (TBI), 260–261

TAP see transporter associated with antigen processing TPS see tumor propagation score

targeted therapy, 268–285

transcription activator‐like effector nuclease (TALEN),

clinical rationale for combining with immunotherapy,

257, 262

268–271

transforming growth factor‐beta (TGFbeta), 166–167,

clinical trials, 273–277

170–171

early clinical results and caveats, 281

transgene expression, 102

effects on immune responses, 271–278

transporter associated with antigen processing (TAP), 148

molecular targets of immunotherapy resistance,

trastuzumab, 14, 16, 19, 192–193

278–281, 280

trastuzumab emtansine, 14

timeline of FDA approvals, 268, 269

triple‐negative breast cancer (TNBC), 46

TBI see total‐body irradiation

trogocytosis, 136

T cell receptor mimic (TCRm) antibodies, 186–200

TroVax, 87

advantages and disadvantages, 189–190

TSA see tumor‐specific antigen

antibody library approach, 188–190

tumor‐associated antigens (TAA)

antigen presentation, 186, 194–195

cancer vaccines for solid tumors, 72, 80–81, 86

breast cancer, 192–193

monoclonal antibody therapy, 16, 17–18

chimeric antigen receptor T cel s, 194

non‐genetical y modified T cel s, 96

clinical development, 191

tumor cell vaccines, 77, 85–86

development, 187–190, 188

tumor‐derived lymphocytes, 136, 137

future directions, 195

tumor‐draining lymph nodes (TDLN), 245

hybridomas, 189–190

tumor‐infiltrating lymphocytes (TIL)

immunization approach, 189–190

advances in TIL therapy, 93

leukemia, 190–192

generation of T cel s for TIL therapy, 94–95, 95

mechanisms of action, 190

genetical y modified T cel s, 103

melanoma, 193–194

non‐genetical y modified T cel s, 91–93, 97

TCR interactions with pMHC, coreceptors, and

somatic mutations, 25–26, 28–30

costimulatory molecules, 186–187

targeted therapy, 271

T cell receptors (TCR)

tumor microenvironment (TME), 228–229, 252–254

adoptive cel ular immunotherapy, 102–104

tumor necrosis factor alpha (TNF‐alpha), 118

checkpoint blockade, 37–38

tumor propagation score (TPS), 7

clinical development of TCRs, 104

tumor‐specific antigen (TSA), 148–149

clinical experience, 103–104

TVEC see talimogene laherparepvec

genetical y modified T cel s, 101–105, 110

tyrosine kinase inhibitors (TKI), 208–209

immunologic monitoring, 240–241, 243–244

lessons on toxicity from MAGE, 104

umbilical cord blood (CB), 203

non‐genetical y modified T cel s, 92–94

somatic mutations, 24–26, 30

vaccines see cancer vaccines

TCRm see T cell receptor mimic

vascular endothelial growth factor (VEGF), 2, 82, 272

TDLN see tumor‐draining lymph nodes

vemurafenib, 278

TG4010, 87

viral vaccines, 78, 86–87

TGF‐B2 antisense gene plasmid, 85–86

viral vectors, 179–180

Theratope, 84

Vitespen, 83

TIL see tumor‐infiltrating lymphocytes

tissue differentiation antigens, 25

whole‐exome screening (WES), 29

TLR see toll‐like receptors

Wilms tumor antigen (WT‐1), 25, 190–192

TME see tumor microenvironment

WT1 gene, 59–61





Document Outline


Immunotherapy in Translational Cancer Research

Contents

Editors

Contributors

Introduction

1 Translation in Immunology: The Role of Translational Biomarkers to Guide Clinical Use of Immunotherapy for Cancer Introduction

Biomarkers for anti‐CTLA‐4

Biomarkers for anti‐PD‐1/PDL‐1 therapies Immune‐related biomarkers

Genomic‐related biomarkers

Approved anti‐PD‐1/PDL‐1 blockade agents and biomarkers in clinical use





Conclusion

References





2 Monoclonal Antibody Therapy Introduction

Mechanisms of action

Tumor antigens

Clinical development of monoclonal antibodies

Mechanisms of resistance

Conclusions

References





3 Somatic Mutations and Immunotherapy References





4 Checkpoint Blockade Preclinical mechanism Introduction

T‐cell activation

CTLA‐4

PD‐1 and PD1 ligand 1 and 2





Clinical activity of CTLA‐4, PD‐1, and PD‐L1‐blocking agents Melanoma

Non‐small‐cell lung cancer (NSCLC)

Renal cell carcinoma





Bladder Hodgkin lymphoma





Preliminary positive clinical data Ovarian cancer

Colon cancer with mismatch repair–deficient tumors

Breast cancer

Other malignancies





Combination strategies

Biomarkers

Conclusions

References





5 Myeloid Leukemia Vaccines Evidence for T‐cell‐mediated killing of myeloid leukemia

Barriers to successful cancer vaccine strategies

Myeloid vaccine targets

Vaccine types Leukemia‐associated antigen vaccines





WT1

RHAMM

PR1 (PRTN3 and ELANE)

Leukemia‐specific neoantigens

BCR‐ABL

Complex (undefined) antigen dendritic cell vaccine strategies

Conclusions

Acknowledgement

References





6 Cancer Vaccines for Solid Tumors Introduction

Cancer vaccine strategies

Dendritic cell vaccines Sipuleucel‐T (Provenge®, Dendreon)

DCVax® (Northwest Biotherapeutics)

ICT‐107 (ImmunoCellular)

AGS‐003 (Rocapuldencel-T)





Protein‐based vaccines Single peptide vaccines Glycoprotein 100 (gp100)

Emepepimut‐S (Tecemotide, Cascadian Therapeutics)

Elpamotide

GV1001

Rindopepimut (Rintega®, Celldex Therapeutics)





Multiple peptide vaccines Vitespen® (HSPPC‐96)

IMA901

Seviprotimut‐L (POL‐103A)





Full‐protein vaccines Theratope (STn‐KLH)

MAGE‐A3





Tumor cell vaccines GVAX

Algenpantucel‐L (Hyperacute)

Belagenpumatucel‐L (Lucanix®, NovaRx)

OncoVAX® (Vaccinogen, Inc.)





Viral vaccines ProstVac‐VF (Bavarian Nordic)

TG4010 (Transgene)

TroVax® (MVA‐5T4, Oxford Biomedica)





Anti‐idiotypic antibody vaccine Racotumomab





Summary

References





7 Immunotherapy with Non–Genetically Modified T Cells Introduction

Tumor‐infiltrating lymphocyte therapy Advances in TIL therapy





Endogenous T cell therapy Generating T cells for ETC





Extending targets, expanding indications

Combination therapy

Conclusions

References





8 Immunotherapy with Genetically Modified T Cells Introduction

Methods of tumor immune evasion: Escaping the natural T cells T cell activation





Methods of T cell modification

Specific therapeutic strategies

Genetically modified TCRs for adoptive cellular therapy

Clinical experience MART‐1

NY‐ESO‐1 in hematologic and solid tumors

Lessons on toxicity learned from MAGE

TCRs under clinical development





CARs Rationale and structure

CARs through the generations





Clinical translation Chronic lymphocytic leukemia (CLL), non‐Hodgkin lymphoma (NHL)

Acute lymphoblastic leukemia (ALL)





Solid tumors

CAR toxicities Cytokine release syndrome

Neurotoxicity

On‐target, off‐tumor toxicities





Future directions

References





9 Immunomodulation with Adjuvants and Cytokines Introduction

Carriers

Toll‐like receptors (TLRs)

BCG

Polyinosinic‐polycytidylic acid (poly‐IC)

Lipopolysaccharide (LPS)

Imiquimod

Resiquimod

CpG

Checkpoint inhibitors Ipilimumab (anti‐CTLA‐4)

Nivolumab (anti‐PD‐1)





Costimulatory molecules CD28

4‐1BB

OX40





Glucocorticoid‐induced TNFR-related protein (GITR)

CD27

CD40

Cytokines Interferon‐α

IL‐2

IL‐10

IL‐12

IL‐15

IL‐21





Conclusion

Acknowledgement

References





10 Immune Cell Migration in Cancer and Immunotherapy Introduction The immune contexture in cancer

Immune cell migration

Organ‐specific “area codes”

Molecular mechanisms of leukocyte migration





Targeting leukocyte migration by immunotherapy Immune cell migration in cancer: Current knowledge and open questions

Immunotherapy by ex vivo modification of immune migration

Immunotherapy at the tumor site to enhance immune cell migration

Systemic application of drugs and biologicals





Conclusions and perspectives

References





11 Repurposing of Drugs for Immunotherapy Background

DNMT inhibitors

HDAC inhibitors

Nonsteroidal anti‐inflammatory drugs (NSAIDs)

Repurposing chemotherapy agents towards immunomodulatory functions Cyclophosphamide (CTX)

Paclitaxel (PTX)





Adoptive T cell therapy

References





12 Immunomodulation with Radiation Radiation and the antitumor immunity cycle

Preclinical studies of radiation and immunotherapy Combining radiation with immunotherapy agents that target tumor antigen presentation

Combining radiation with immunotherapy agents that target T‐cell priming and activation

Combining radiation with immunotherapy agents that improve T‐cell‐mediated killing of cancer cells





The next step: Clinical applications Enhancing tumor antigen presentation Exogenous DC therapy

TLR9/TLR7 agonists





Granulocyte‐macrophage colonystimulating factor

T‐cell priming and activation CTLA4

OX40

Interleukin‐2

Transforming growth factor‐beta (TGF β)





Killing cancer cells Anti‐PD1/Anti‐PDL1





Summary

Acknowledgments

References





13 Good Manufacturing Practices Facilities for Cellular Therapy Introduction to current Good Manufacturing Practices

Manufacture of cellular immunotherapies in the cGMP setting Modification of cells for immunotherapy

Criteria for use of cellular therapies generated in a cGMP facility





Infrastructure considerations in cGMP manufacture Organizational infrastructure and quality standards

Physical infrastructure

Environmental monitoring and cleaning

Global systems and organizations for cellular therapy cGMP facilities





Evolution of cGMP immunotherapies

Concluding remarks

Acknowledgments

References





14 T Cell Receptor Mimic Antibodies TCR interactions with pMHC, coreceptors, and costimulatory molecules

TCRm development Antibody library approach to generating TCRm

Immunization approach to generating TCRm

Advantages and disadvantages to antibody display libraries and hybridomas





Leukemia

Breast cancer

Melanoma

TCRm antibodies in the design of chimeric antigen receptor (CAR) T cells

TCRm antibodies as tools for antigen presentation

Future directions

Acknowledgment

References





15 Stem Cell Transplantation for Treatment of Malignancy Introduction

Process of allogeneic hematopoietic stem cell transplant

Histocompatibility requirements

Historical perspective

Mechanism of GVM effect

Indications for HSCT Nonmalignant diseases

Malignant diseases





Acute myeloid leukemia (AML)

Myelodysplastic syndrome (MDS)

Myelofibrosis

Acute lymphoblastic leukemia (ALL)

Chronic myeloid leukemia (CML)

Lymphomas

Multiple myeloma

Solid organ tumors

Conclusions

References





16 Natural Killer Cell–Based Immunotherapy NK cell background and biology

Clinical evidence for NK cell impact on cancer outcomes

Manipulating the anti‐tumor effect of NK cells Hematopoietic stem cell transplantation

Adoptive transfer of NK cells Leukemias

Solid tumors

NK cell lines





Agents to augment NK cell efficacy





Conclusions

References





17 Immunologic Monitoring in Immuno‐Oncology Introduction Biomarkers in immuno‐oncology

The evolution of immune monitoring from an antigen specific to a tumor microenvironment focus





Immune prognostic biomarkers Immunoscore

Neutrophil‐to‐lymphocyte ratio





Immune predictive biomarkers PD‐L1 and PD‐1 expression

Analysis of single nucleotide polymorphisms

Estimation of neoantigenic load

Myeloid‐derived suppressor cells

T regulatory and Th2 cells

Development of specific T cell phenotypes; ICOS+ and polyfunctional T cells





Immune pharmacodynamic and pharmacokinetic biomarkers Evaluation of the evolution of the T cell receptor (TCR) repertoire

Gene analysis of the tumor and peripheral blood in response to treatment

ELISPOT

Cytokine flow cytometry

MHC tetramers and pentamers

Assessment of antibody immunity





Correlative and surrogate endpoint biomarkers

Conclusion

Acknowledgments

Conflict of interest

References





18 Cell‐Based Therapies for Canine Cancer Introduction

Relevance of the canine cancer patient in evaluating immunotherapies Tumor immunogenicity

The immune landscape of canine cancer patients





Cell‐based immunotherapies for passive adoptive transfer T cell expansion protocols

Adoptive T cell immunotherapy

Genetic modification of lymphocytes Adoptive NK cell immunotherapy





Preconditioning regimes for stem cell transplant and adoptive cell transfer





Cell‐based therapies for active immunization

Regulatory guidelines for cell-based products for animal use

References





19 Interaction between Targeted Therapy and Immunotherapy Clinical rationale for combining targeted therapy and immunotherapy

Effects of targeted therapy on immune responses

Molecular targets of immunotherapy resistance

Combining targeted therapy with immunotherapy: Early clinical results and caveats

References





Index





